ID	Gene Name	Species	BBID	BIOCARTA	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	PIR_SUPERFAMILY	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
GBE1	1,4-alpha-glucan branching enzyme 1(GBE1)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0005977~glycogen metabolic process,GO:0005978~glycogen biosynthetic process,GO:0006091~generation of precursor metabolites and energy,GO:0043524~negative regulation of neuron apoptotic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003844~1,4-alpha-glucan branching enzyme activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0043169~cation binding,	IPR004193:Glycoside hydrolase, family 13, N-terminal,IPR006047:Glycosyl hydrolase, family 13, catalytic domain,IPR006048:Alpha-amylase, C-terminal all beta,IPR013780:Glycosyl hydrolase, family 13, all-beta,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR017853:Glycoside hydrolase, superfamily,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,	232500~Glycogen storage disease IV,263570~Polyglucosan body disease, adult form,	PIRSF000463:1,4-alpha-glucan branching enzyme,	SM00642:Aamy,	KW-0320~Glycogen biosynthesis,		KW-0225~Disease variant,KW-0322~Glycogen storage disease,KW-0622~Neuropathy,			KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,DOMAIN:Glycosyl hydrolase family 13 catalytic,
ACCS	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)(ACCS)	Homo sapiens			GO:0006520~cellular amino acid metabolic process,GO:0009058~biosynthetic process,		GO:0003824~catalytic activity,GO:0005515~protein binding,GO:0008483~transaminase activity,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR004839:Aminotransferase, class I/classII,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,									KW-0663~Pyridoxal phosphate,			DOMAIN:Aminotransferase class I/classII,REGION:Disordered,
HPD	4-hydroxyphenylpyruvate dioxygenase(HPD)	Homo sapiens			GO:0006559~L-phenylalanine catabolic process,GO:0006572~tyrosine catabolic process,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003868~4-hydroxyphenylpyruvate dioxygenase activity,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR004360:Glyoxalase/fosfomycin resistance/dioxygenase domain,IPR005956:4-hydroxyphenylpyruvate dioxygenase,	hsa00130:Ubiquinone and other terpenoid-quinone biosynthesis,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	140350~Hawkinsinuria,276710~Tyrosinemia, type III,	PIRSF009283:4-hydroxyphenylpyruvate dioxygenase,		KW-0585~Phenylalanine catabolism,KW-0828~Tyrosine catabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:VOC,DOMAIN:VOC 1,DOMAIN:VOC 2,
NT5E	5'-nucleotidase ecto(NT5E)	Homo sapiens			GO:0006196~AMP catabolic process,GO:0006259~DNA metabolic process,GO:0007159~leukocyte cell-cell adhesion,GO:0009166~nucleotide catabolic process,GO:0010035~response to inorganic substance,GO:0033198~response to ATP,GO:0046032~ADP catabolic process,GO:0046034~ATP metabolic process,GO:0046086~adenosine biosynthetic process,GO:0050728~negative regulation of inflammatory response,GO:0055074~calcium ion homeostasis,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031225~anchored component of membrane,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0002953~5'-deoxynucleotidase activity,GO:0005515~protein binding,GO:0008253~5'-nucleotidase activity,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0050340~thymidylate 5'-phosphatase activity,GO:0050483~IMP 5'-nucleotidase activity,GO:0050484~GMP 5'-nucleotidase activity,	IPR004843:Metallophosphoesterase domain,IPR006146:5'-Nucleotidase, conserved site,IPR006179:5'-Nucleotidase/apyrase,IPR008334:5'-Nucleotidase, C-terminal,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	211800~Calcification of joints and arteries,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:5'-Nucleotidase C-terminal,DOMAIN:Calcineurin-like phosphoesterase,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,SITE:Transition state stabilizer,TRANSMEM:Helical,
NT5C1A	5'-nucleotidase, cytosolic IA(NT5C1A)	Homo sapiens			GO:0000255~allantoin metabolic process,GO:0006196~AMP catabolic process,GO:0006204~IMP catabolic process,GO:0009116~nucleoside metabolic process,GO:0046055~dGMP catabolic process,GO:0046059~dAMP catabolic process,GO:0046085~adenosine metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000166~nucleotide binding,GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0008253~5'-nucleotidase activity,GO:0050483~IMP 5'-nucleotidase activity,	IPR010394:5-nucleotidase,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,				KW-0546~Nucleotide metabolism,	KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,		ACT_SITE:Nucleophile,REGION:Disordered,
HTR1A	5-hydroxytryptamine receptor 1A(HTR1A)	Homo sapiens			GO:0001662~behavioral fear response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007198~adenylate cyclase-inhibiting serotonin receptor signaling pathway,GO:0007210~serotonin receptor signaling pathway,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007268~chemical synaptic transmission,GO:0008284~positive regulation of cell proliferation,GO:0014062~regulation of serotonin secretion,GO:0019229~regulation of vasoconstriction,GO:0035640~exploration behavior,GO:0042053~regulation of dopamine metabolic process,GO:0042428~serotonin metabolic process,GO:0046883~regulation of hormone secretion,GO:0050795~regulation of behavior,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0030425~dendrite,GO:0045202~synapse,	GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0030594~neurotransmitter receptor activity,GO:0051378~serotonin binding,GO:0090722~receptor-receptor interaction,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000610:5-Hydroxytryptamine 1A receptor,IPR002231:5-Hydroxytryptamine receptor family,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04726:Serotonergic synapse,hsa04742:Taste transduction,	614674~Periodic fever, menstrual cycle dependent,		SM01381:SM01381,	KW-0085~Behavior,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MOTIF:DRY motif; important for ligand-induced conformation changes,MOTIF:NPxxY motif; important for ligand-induced conformation changes and signaling,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HTR1B	5-hydroxytryptamine receptor 1B(HTR1B)	Homo sapiens			GO:0002031~G-protein coupled receptor internalization,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007198~adenylate cyclase-inhibiting serotonin receptor signaling pathway,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007610~behavior,GO:0014053~negative regulation of gamma-aminobutyric acid secretion,GO:0014059~regulation of dopamine secretion,GO:0014063~negative regulation of serotonin secretion,GO:0032229~negative regulation of synaptic transmission, GABAergic,GO:0042220~response to cocaine,GO:0042310~vasoconstriction,GO:0042756~drinking behavior,GO:0045471~response to ethanol,GO:0046849~bone remodeling,GO:0050795~regulation of behavior,GO:0051385~response to mineralocorticoid,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0071312~cellular response to alkaloid,GO:0071466~cellular response to xenobiotic stimulus,GO:0071502~cellular response to temperature stimulus,GO:0099509~regulation of presynaptic cytosolic calcium ion concentration,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0030425~dendrite,GO:0042734~presynaptic membrane,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0098666~G-protein coupled serotonin receptor complex,GO:0099056~integral component of presynaptic membrane,	GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0030594~neurotransmitter receptor activity,GO:0051378~serotonin binding,GO:0099626~voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR002147:5-Hydroxytryptamine 1B receptor,IPR002231:5-Hydroxytryptamine receptor family,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04726:Serotonergic synapse,hsa04742:Taste transduction,			SM01381:SM01381,	KW-0085~Behavior,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,MOTIF:DRY motif; important for ligand-induced conformation changes and signaling,MOTIF:NPxxY motif; important for ligand-induced conformation changes and signaling,MUTAGEN:A->S: No effect on agonist binding.,MUTAGEN:C->A: Abolishes agonist binding.,MUTAGEN:D->A: Abolishes agonist binding.,MUTAGEN:D->A: No effect on agonist binding.,MUTAGEN:F->A: Abolishes agonist binding.,MUTAGEN:F->A: No effect on agonist binding.,MUTAGEN:I->A: Abolishes agonist binding.,MUTAGEN:L->A: No effect on agonist binding.,MUTAGEN:M->A: No effect on agonist binding.,MUTAGEN:S->A: No effect on agonist binding.,MUTAGEN:T->A: No effect on agonist binding.,MUTAGEN:T->A: Slightly decreases agonist binding.,MUTAGEN:V->A: No effect on agonist binding.,MUTAGEN:W->A: Abolishes agonist binding.,MUTAGEN:Y->A: No effect on agonist binding.,REGION:Disordered,SITE:Important for species-specific agonist sensitivity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HTR2A	5-hydroxytryptamine receptor 2A(HTR2A)	Homo sapiens			GO:0001659~temperature homeostasis,GO:0006096~glycolytic process,GO:0006874~cellular calcium ion homeostasis,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007208~phospholipase C-activating serotonin receptor signaling pathway,GO:0007210~serotonin receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0007613~memory,GO:0008219~cell death,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0010513~positive regulation of phosphatidylinositol biosynthetic process,GO:0014059~regulation of dopamine secretion,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014824~artery smooth muscle contraction,GO:0014832~urinary bladder smooth muscle contraction,GO:0030431~sleep,GO:0043267~negative regulation of potassium ion transport,GO:0043406~positive regulation of MAP kinase activity,GO:0043491~protein kinase B signaling,GO:0043525~positive regulation of neuron apoptotic process,GO:0044380~protein localization to cytoskeleton,GO:0045600~positive regulation of fat cell differentiation,GO:0045821~positive regulation of glycolytic process,GO:0045907~positive regulation of vasoconstriction,GO:0046718~viral entry into host cell,GO:0048148~behavioral response to cocaine,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0098664~G-protein coupled serotonin receptor signaling pathway,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0030424~axon,GO:0030425~dendrite,GO:0031410~cytoplasmic vesicle,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043198~dendritic shaft,GO:0045211~postsynaptic membrane,GO:0070852~cell body fiber,GO:0098666~G-protein coupled serotonin receptor complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001587~Gq/11-coupled serotonin receptor activity,GO:0001618~virus receptor activity,GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0030296~protein tyrosine kinase activator activity,GO:0030594~neurotransmitter receptor activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0051378~serotonin binding,GO:0071886~1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000455:5-Hydroxytryptamine 2A receptor,IPR002231:5-Hydroxytryptamine receptor family,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04540:Gap junction,hsa04726:Serotonergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,	103780~Alcohol dependence, susceptibility to,164230~Obsessive-compulsive disorder, susceptibility to,181500~Schizophrenia, susceptibility to,606788~Anorexia nervosa, susceptibility to,608516~Major depressive disorder, response to citalopram therapy in,608516~Seasonal affective disorder, susceptibility to,		SM01381:SM01381,	KW-0085~Behavior,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MOTIF:DRY motif; important for ligand-induced conformation changes,MOTIF:NPxxY motif; important for ligand-induced conformation changes and signaling,MOTIF:PDZ-binding,MUTAGEN:C->S: No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-465.,MUTAGEN:G->V: Loss of interaction with PATJ.,MUTAGEN:L->A: Strongly increases dissociation of bound lysergic acid diethylamine, without affecting binding affinity. Reduces signaling via arrestins, but has no effect on signaling via the phosphatidylinositol-calcium second messenger system.,MUTAGEN:N->S: No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-470.,MUTAGEN:S->A: Increased ability of hallucinogens to desensitize the receptor.,MUTAGEN:S->D: Reduced receptor desensitization by nonhallucinogenic agonists.,MUTAGEN:V->A: Loss of interaction with PATJ, CASK, APBA1, DLG1 and DLG4.,REGION:Disordered,SITE:Hydrophobic barrier that decreases the speed of ligand binding and dissociation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HTR3A	5-hydroxytryptamine receptor 3A(HTR3A)	Homo sapiens			GO:0007165~signal transduction,GO:0007210~serotonin receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0060079~excitatory postsynaptic potential,GO:0098662~inorganic cation transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0032154~cleavage furrow,GO:0043005~neuron projection,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:1904602~serotonin-activated cation-selective channel complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005216~ion channel activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0022850~serotonin-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,GO:0051378~serotonin binding,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR008132:5-hydroxytryptamine 3 receptor,IPR008133:5-hydroxytryptamine 3 receptor, A subunit,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04726:Serotonergic synapse,hsa04742:Taste transduction,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Neurotransmitter-gated ion-channel ligand-binding,DOMAIN:Neurotransmitter-gated ion-channel transmembrane,MUTAGEN:R->A: Increased conductance. Massive increase of conductance; when associated with Q-432 and D-436.,MUTAGEN:R->D: Increased conductance. Massive increase of conductance; when associated with Q-432 and A-440.,MUTAGEN:R->Q: Little effect on conductance. Massive increase of conductance; when associated with D-436 and A-440.,MUTAGEN:W->S: Abolished ligand binding to the heteromeric receptor.,REGION:Disordered,REGION:HA-stretch,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
HTR4	5-hydroxytryptamine receptor 4(HTR4)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007198~adenylate cyclase-inhibiting serotonin receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0030277~maintenance of gastrointestinal epithelium,GO:0032098~regulation of appetite,GO:0070254~mucus secretion,GO:0098664~G-protein coupled serotonin receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0045202~synapse,	GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0030594~neurotransmitter receptor activity,GO:0051378~serotonin binding,GO:0099589~serotonin receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001520:5-Hydroxytryptamine 4 receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04726:Serotonergic synapse,			SM01381:SM01381,		KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADAMTS12	ADAM metallopeptidase with thrombospondin type 1 motif 12(ADAMTS12)	Homo sapiens			GO:0002062~chondrocyte differentiation,GO:0006508~proteolysis,GO:0007160~cell-matrix adhesion,GO:0016477~cell migration,GO:0030167~proteoglycan catabolic process,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0032331~negative regulation of chondrocyte differentiation,GO:0043931~ossification involved in bone maturation,GO:0050727~regulation of inflammatory response,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071773~cellular response to BMP stimulus,GO:1901509~regulation of endothelial tube morphogenesis,GO:1902203~negative regulation of hepatocyte growth factor receptor signaling pathway,GO:1902548~negative regulation of cellular response to vascular endothelial growth factor stimulus,GO:2001113~negative regulation of cellular response to hepatocyte growth factor stimulus,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,IPR013273:Peptidase M12B, ADAM-TS,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:PLAC,DOMAIN:Peptidase M12B,DOMAIN:Peptidase M12B propeptide,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,DOMAIN:TSP type-1 5,DOMAIN:TSP type-1 6,DOMAIN:TSP type-1 7,DOMAIN:TSP type-1 8,MOTIF:Cysteine switch,REGION:Disordered,REGION:Spacer 1,REGION:Spacer 2,
ADAMTS16	ADAM metallopeptidase with thrombospondin type 1 motif 16(ADAMTS16)	Homo sapiens			GO:0001658~branching involved in ureteric bud morphogenesis,GO:0003073~regulation of systemic arterial blood pressure,GO:0006508~proteolysis,GO:0030198~extracellular matrix organization,GO:0048232~male gamete generation,GO:1902017~regulation of cilium assembly,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0046872~metal ion binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,IPR013273:Peptidase M12B, ADAM-TS,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:PLAC,DOMAIN:Peptidase M12B,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,DOMAIN:TSP type-1 5,DOMAIN:TSP type-1 6,MOTIF:Cysteine switch,REGION:Disordered,REGION:Spacer,
ADAMTS20	ADAM metallopeptidase with thrombospondin type 1 motif 20(ADAMTS20)	Homo sapiens			GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0009967~positive regulation of signal transduction,GO:0030198~extracellular matrix organization,GO:0030318~melanocyte differentiation,GO:0043066~negative regulation of apoptotic process,GO:0045636~positive regulation of melanocyte differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR010294:ADAM-TS Spacer 1,IPR012314:Peptidase M12B, GON-ADAMTSs,IPR013273:Peptidase M12B, ADAM-TS,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Disintegrin,DOMAIN:GON,DOMAIN:Peptidase M12B,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 10,DOMAIN:TSP type-1 11,DOMAIN:TSP type-1 12,DOMAIN:TSP type-1 13,DOMAIN:TSP type-1 14,DOMAIN:TSP type-1 15,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,DOMAIN:TSP type-1 5,DOMAIN:TSP type-1 6,DOMAIN:TSP type-1 7,DOMAIN:TSP type-1 8,DOMAIN:TSP type-1 9,REGION:Spacer,
ADAMTS3	ADAM metallopeptidase with thrombospondin type 1 motif 3(ADAMTS3)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0006508~proteolysis,GO:0007229~integrin-mediated signaling pathway,GO:0010573~vascular endothelial growth factor production,GO:0016485~protein processing,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030574~collagen catabolic process,GO:0032964~collagen biosynthetic process,GO:0097435~supramolecular fiber organization,GO:1900748~positive regulation of vascular endothelial growth factor signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008270~zinc ion binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,IPR013273:Peptidase M12B, ADAM-TS,IPR024079:Metallopeptidase, catalytic domain,		618154~Hennekam lymphangiectasia-lymphedema syndrome 3,		SM00209:TSP1,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0401~Integrin,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Disintegrin,DOMAIN:PLAC,DOMAIN:Peptidase M12B,DOMAIN:Peptidase M12B propeptide,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,REGION:Disordered,REGION:Spacer,
ADAMTS5	ADAM metallopeptidase with thrombospondin type 1 motif 5(ADAMTS5)	Homo sapiens			GO:0003180~aortic valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0006508~proteolysis,GO:0007520~myoblast fusion,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0042742~defense response to bacterium,GO:0044691~tooth eruption,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008233~peptidase activity,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0050840~extracellular matrix binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR006586:ADAM, cysteine-rich,IPR010294:ADAM-TS Spacer 1,IPR013273:Peptidase M12B, ADAM-TS,IPR013276:Peptidase M12B, ADAM-TS5,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,SM00608:ACR,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:C-linked (Man) tryptophan,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc...) serine,COMPBIAS:Basic and acidic residues,DOMAIN:Disintegrin,DOMAIN:Peptidase M12B,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,MOTIF:Cysteine switch,MUTAGEN:E->A: Complete loss of catalytic activity.,REGION:Disordered,REGION:Spacer,SITE:Cleavage; by furin and PCSK7,
ADAMTS8	ADAM metallopeptidase with thrombospondin type 1 motif 8(ADAMTS8)	Homo sapiens			GO:0006508~proteolysis,GO:0008285~negative regulation of cell proliferation,GO:0030198~extracellular matrix organization,GO:0035435~phosphate ion transmembrane transport,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0005178~integrin binding,GO:0008201~heparin binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0009673~low-affinity phosphate transmembrane transporter activity,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR006586:ADAM, cysteine-rich,IPR010294:ADAM-TS Spacer 1,IPR013273:Peptidase M12B, ADAM-TS,IPR013277:Peptidase M12B, ADAM-TS8,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,SM00608:ACR,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Disintegrin,DOMAIN:Peptidase M12B,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,REGION:Disordered,REGION:Spacer,
ADCYAP1R1	ADCYAP receptor type I(ADCYAP1R1)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007283~spermatogenesis,GO:0009410~response to xenobiotic stimulus,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0019933~cAMP-mediated signaling,GO:0030154~cell differentiation,GO:0032355~response to estradiol,GO:0033555~multicellular organismal response to stress,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0045471~response to ethanol,GO:0046545~development of primary female sexual characteristics,GO:0051057~positive regulation of small GTPase mediated signal transduction,GO:0060548~negative regulation of cell death,GO:0060732~positive regulation of inositol phosphate biosynthetic process,GO:1901032~negative regulation of response to reactive oxygen species,	GO:0005768~endosome,GO:0005791~rough endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0005923~bicellular tight junction,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,	GO:0004930~G-protein coupled receptor activity,GO:0004999~vasoactive intestinal polypeptide receptor activity,GO:0005515~protein binding,GO:0008179~adenylate cyclase binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,GO:0031267~small GTPase binding,GO:0038023~signaling receptor activity,GO:0042923~neuropeptide binding,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR002285:GPCR, family 2, pituitary adenylate cyclase activating polypeptide type 1 receptor,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04911:Insulin secretion,hsa04924:Renin secretion,			SM00008:HormR,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,MUTAGEN:E->R: Reduced affinity for ADCYAP1.,MUTAGEN:P->A: Reduced affinity for ADCYAP1.,MUTAGEN:V->A: Reduced affinity for ADCYAP1.,MUTAGEN:Y->A: Strongly reduced affinity for ADCYAP1.,REGION:Important for ligand binding and specificity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
AFF3	ALF transcription elongation factor 3(AFF3)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0010468~regulation of gene expression,GO:0034612~response to tumor necrosis factor,GO:0035116~embryonic hindlimb morphogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0032783~ELL-EAF complex,	GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR007797:Transcription factor AF4/FMR2,		619297~KINSSHIP syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AF4/FMR2 C-terminal homology,REGION:Disordered,
ALX1	ALX homeobox 1(ALX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001755~neural crest cell migration,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0016604~nuclear body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,		613456~Frontonasal dysplasia 3,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:OAR,MOTIF:OAR,REGION:Transactivation domain,
ALX4	ALX homeobox 4(ALX4)	Homo sapiens			GO:0001501~skeletal system development,GO:0001942~hair follicle development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0009791~post-embryonic development,GO:0009952~anterior/posterior pattern specification,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0042733~embryonic digit morphogenesis,GO:0042981~regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048565~digestive tract development,GO:0048704~embryonic skeletal system morphogenesis,GO:0060021~palate development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,		609597~Parietal foramina 2,613451~Frontonasal dysplasia 2,615529~Craniosynostosis 5, susceptibility to,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0989~Craniosynostosis,	KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:OAR,REGION:Disordered,
APCDD1	APC down-regulated 1(APCDD1)	Homo sapiens			GO:0001942~hair follicle development,GO:0016055~Wnt signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0042487~regulation of odontogenesis of dentin-containing tooth,GO:0043615~astrocyte cell migration,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0017147~Wnt-protein binding,GO:0042802~identical protein binding,		hsa04310:Wnt signaling pathway,	605389~Hypotrichosis 1,		SM01352:SM01352,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1063~Hypotrichosis,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:APCDD1,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ABCA9	ATP binding cassette subfamily A member 9(ABCA9)	Homo sapiens			GO:0006869~lipid transport,GO:0055085~transmembrane transport,	GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005319~lipid transporter activity,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR026082:ABC transporter A, ABCA,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,			SM00382:AAA,	KW-0813~Transport,	KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,TRANSMEM:Helical,
ABCC11	ATP binding cassette subfamily C member 11(ABCC11)	Homo sapiens			GO:0015711~organic anion transport,GO:0015721~bile acid and bile salt transport,GO:0015865~purine nucleotide transport,GO:0042908~xenobiotic transport,GO:0055085~transmembrane transport,GO:0071716~leukotriene transport,GO:0098656~anion transmembrane transport,	GO:0005774~vacuolar membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0070062~extracellular exosome,	GO:0005524~ATP binding,GO:0008514~organic anion transmembrane transporter activity,GO:0008559~xenobiotic-transporting ATPase activity,GO:0015216~purine nucleotide transmembrane transporter activity,GO:0015431~glutathione S-conjugate-exporting ATPase activity,GO:0015432~bile acid-exporting ATPase activity,GO:0016887~ATPase activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0043225~ATPase-coupled anion transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,	117800~Axillary odor, variation in,117800~Colostrum secretion, variation in,117800~Earwax, wet/dry,		SM00382:AAA,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0926~Vacuole,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transmembrane type-1 1,DOMAIN:ABC transmembrane type-1 2,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,MUTAGEN:G->A,P: Does not affect N-glycosylation.,MUTAGEN:G->L,H,D,E: Loss of N-glycosylation.,MUTAGEN:N->Q: Loss of N-glycosylation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
ABCC3	ATP binding cassette subfamily C member 3(ABCC3)	Homo sapiens		h_mrpPathway:Multi-Drug Resistance Factors,h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,	GO:0006805~xenobiotic metabolic process,GO:0006855~drug transmembrane transport,GO:0015721~bile acid and bile salt transport,GO:0015779~glucuronoside transport,GO:0042908~xenobiotic transport,GO:0055085~transmembrane transport,GO:0071716~leukotriene transport,GO:0098656~anion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,	GO:0005524~ATP binding,GO:0008559~xenobiotic-transporting ATPase activity,GO:0015164~glucuronoside transmembrane transporter activity,GO:0015431~glutathione S-conjugate-exporting ATPase activity,GO:0015432~bile acid-exporting ATPase activity,GO:0016887~ATPase activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0042910~xenobiotic transporter activity,GO:0043225~ATPase-coupled anion transmembrane transporter activity,GO:0071714~icosanoid transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR005292:Multi drug resistance-associated protein,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01523:Antifolate resistance,hsa02010:ABC transporters,hsa04976:Bile secretion,			SM00382:AAA,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transmembrane type-1 1,DOMAIN:ABC transmembrane type-1 2,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=13,TRANSMEM:Helical; Name=14,TRANSMEM:Helical; Name=15,TRANSMEM:Helical; Name=16,TRANSMEM:Helical; Name=17,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
ABCG1	ATP binding cassette subfamily G member 1(ABCG1)	Homo sapiens		h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,	GO:0008203~cholesterol metabolic process,GO:0010033~response to organic substance,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010872~regulation of cholesterol esterification,GO:0010875~positive regulation of cholesterol efflux,GO:0010887~negative regulation of cholesterol storage,GO:0032367~intracellular cholesterol transport,GO:0033344~cholesterol efflux,GO:0033700~phospholipid efflux,GO:0033993~response to lipid,GO:0034204~lipid translocation,GO:0034374~low-density lipoprotein particle remodeling,GO:0034375~high-density lipoprotein particle remodeling,GO:0034436~glycoprotein transport,GO:0042632~cholesterol homeostasis,GO:0042987~amyloid precursor protein catabolic process,GO:0043691~reverse cholesterol transport,GO:0045542~positive regulation of cholesterol biosynthetic process,GO:0050714~positive regulation of protein secretion,GO:0055085~transmembrane transport,GO:0055091~phospholipid homeostasis,GO:0071403~cellular response to high density lipoprotein particle stimulus,GO:0090181~regulation of cholesterol metabolic process,GO:1901998~toxin transport,GO:1902004~positive regulation of beta-amyloid formation,	GO:0000139~Golgi membrane,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0055037~recycling endosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005543~phospholipid binding,GO:0015485~cholesterol binding,GO:0016887~ATPase activity,GO:0019534~toxin transporter activity,GO:0034041~sterol-transporting ATPase activity,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0090554~phosphatidylcholine-translocating ATPase activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR005284:Pigment precursor permease,IPR013525:ABC-2 type transporter,IPR017871:ABC transporter, conserved site,IPR020064:ABC transporter, G1-like,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,hsa05417:Lipid and atherosclerosis,			SM00382:AAA,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0449~Lipoprotein,KW-0564~Palmitate,	DOMAIN:ABC transmembrane type-2,DOMAIN:ABC transporter,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A,S: Significantly decreases ABCG1-mediated cholesterol efflux.,MUTAGEN:C->A: No significant effect.,MUTAGEN:K->M: Affects ATP binding. Does not affect efflux of 7beta-hydroxycholesterol. Does not affect localization at plasma membrane. Does not affect homodimerization. Decreases cholesterol and phospholipids efflux. Does not affect heretodimerization with ABCG4.,MUTAGEN:Y->A: Significantly reduces interaction with CAV1; when associated with A-491. Significantly reduces ABCG1-mediated cholesterol efflux; when associated with A-491.,MUTAGEN:Y->A: Significantly reduces interaction with CAV1; when associated with A-493. Significantly reduces ABCG1-mediated cholesterol efflux; when associated with A-493.,MUTAGEN:Y->A: Significantly reduces interaction with CAV1; when associated with A-498. Significantly reduces ABCG1-mediated cholesterol efflux; when associated with A-498. Affects subcellular location at plasma membrane; when associated with A-498. Affects ABCG1 traffincking to the plasma membrane; when associated with A-498.,MUTAGEN:Y->A: Significantly reduces interaction with CAV1; when associated with A-499. Significantly reduces ABCG1-mediated cholesterol efflux; when associated with A-499. Affects subcellular location at plasma membrane; when associated with A-499. Affects ABCG1 traffincking to the plasma membrane; when associated with A-499.,MUTAGEN:Y->F: Does not affect ABCG1-mediated cholesterol efflux; when associated with I-498.,MUTAGEN:Y->F: Does not affect ABCG1-mediated cholesterol efflux; when associated with I-499.,MUTAGEN:Y->I: Dramatically reduces the ability of ABCG1 to mediate cholesterol efflux; when associated with I-498.,MUTAGEN:Y->I: Dramatically reduces the ability of ABCG1 to mediate cholesterol efflux; when associated with I-499.,MUTAGEN:Y->W: Does not affect ABCG1-mediated cholesterol efflux; when associated with I-498.,MUTAGEN:Y->W: Does not affect ABCG1-mediated cholesterol efflux; when associated with I-499.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP6V0A2	ATPase H+ transporting V0 subunit a2(ATP6V0A2)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0006955~immune response,GO:0007035~vacuolar acidification,GO:0016241~regulation of macroautophagy,GO:0036295~cellular response to increased oxygen levels,GO:0061795~Golgi lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0001669~acrosomal vesicle,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030670~phagocytic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,GO:0051117~ATPase binding,	IPR002490:ATPase, V0 complex, subunit 116kDa,IPR026028:ATPase, V0 complex, subunit 116kDa, eukaryotic,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	219200~Cutis laxa, autosomal recessive, type IIA,278250~Wrinkly skin syndrome,	PIRSF001293:V-type proton ATPase 116 kda subunit a isoform 1,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vacuolar,TRANSMEM:Helical,
ATP6V0C	ATPase H+ transporting V0 subunit c(ATP6V0C)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0015986~ATP synthesis coupled proton transport,GO:0016241~regulation of macroautophagy,GO:0030177~positive regulation of Wnt signaling pathway,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0061795~Golgi lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005774~vacuolar membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0031625~ubiquitin protein ligase binding,GO:0046933~proton-transporting ATP synthase activity, rotational mechanism,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000245:V-ATPase proteolipid subunit,IPR002379:V-ATPase proteolipid subunit C-like domain,IPR011555:V-ATPase proteolipid subunit C, eukaryotic,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0770~Synapse,KW-0926~Vacuole,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0832~Ubl conjugation,	DOMAIN:V-ATPase proteolipid subunit C-like,REGION:Disordered,SITE:Essential for proton translocation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ATP6V0D1	ATPase H+ transporting V0 subunit d1(ATP6V0D1)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0007034~vacuolar transport,GO:0007035~vacuolar acidification,GO:0007420~brain development,GO:0016241~regulation of macroautophagy,GO:0036295~cellular response to increased oxygen levels,GO:0060271~cilium assembly,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005813~centrosome,GO:0008021~synaptic vesicle,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030665~clathrin-coated vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0033181~plasma membrane proton-transporting V-type ATPase complex,GO:0043679~axon terminus,GO:0070062~extracellular exosome,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0044877~macromolecular complex binding,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR002843:ATPase, V0 complex,  c/d subunit,IPR016727:ATPase, V0 complex, subunit d,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05203:Viral carcinogenesis,hsa05323:Rheumatoid arthritis,		PIRSF018497:V-type ATPase, subunit d,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0458~Lysosome,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,					KW-0597~Phosphoprotein,	REGION:Disordered,
ATP6V1C1	ATPase H+ transporting V1 subunit C1(ATP6V1C1)	Homo sapiens			GO:0016241~regulation of macroautophagy,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016469~proton-transporting two-sector ATPase complex,GO:0030665~clathrin-coated vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0033180~proton-transporting V-type ATPase, V1 domain,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,GO:0098850~extrinsic component of synaptic vesicle membrane,GO:1902495~transmembrane transporter complex,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR004907:ATPase, V1 complex, subunit C,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,					KW-0007~Acetylation,
ATP4B	ATPase H+/K+ transporting subunit beta(ATP4B)	Homo sapiens			GO:0006883~cellular sodium ion homeostasis,GO:0007155~cell adhesion,GO:0010243~response to organonitrogen compound,GO:0030007~cellular potassium ion homeostasis,GO:0032496~response to lipopolysaccharide,GO:0036376~sodium ion export from cell,GO:0045851~pH reduction,GO:0071805~potassium ion transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005889~hydrogen:potassium-exchanging ATPase complex,GO:0005890~sodium:potassium-exchanging ATPase complex,GO:0016324~apical plasma membrane,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,GO:0008900~hydrogen:potassium-exchanging ATPase activity,GO:1901363~heterocyclic compound binding,	IPR000402:Sodium/potassium-transporting ATPase subunit beta,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04966:Collecting duct acid secretion,hsa04971:Gastric acid secretion,				KW-0130~Cell adhesion,KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:immunoglobulin-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
BTLA	B and T lymphocyte associated(BTLA)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002768~immune response-regulating cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-226 and/or F-257.,MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-226 and/or F-282.,MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-257 and/or F-282.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
BLNK	B cell linker(BLNK)	Homo sapiens		h_bcrPathway:BCR Signaling Pathway,	GO:0006954~inflammatory response,GO:0006959~humoral immune response,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0010628~positive regulation of gene expression,GO:0030183~B cell differentiation,GO:0035556~intracellular signal transduction,GO:0050853~B cell receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043231~intracellular membrane-bounded organelle,	GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0035591~signaling adaptor activity,GO:0042169~SH2 domain binding,GO:0043274~phospholipase binding,GO:1990782~protein tyrosine kinase binding,	IPR000980:SH2 domain,	hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,hsa05169:Epstein-Barr virus infection,hsa05340:Primary immunodeficiency,	613502~Agammaglobulinemia 4,		SM00252:SH2,	KW-0075~B-cell activation,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0727~SH2 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:SH2,MUTAGEN:Y->F: Significant phosphorylation reduction; when associated with F-72; F-84 and F-178.,MUTAGEN:Y->F: Significant phosphorylation reduction; when associated with F-72; F-84 and F-96.,MUTAGEN:Y->F: Significant phosphorylation reduction; when associated with F-72; F-96 and F-178.,MUTAGEN:Y->F: Significant phosphorylation reduction; when associated with F-84; F-96 and F-178.,REGION:Disordered,
BCAR1	BCAR1 scaffold protein, Cas family member(BCAR1)	Homo sapiens		h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_pyk2Pathway:Links between Pyk2 and Map Kinases,	GO:0001558~regulation of cell growth,GO:0007015~actin filament organization,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0008286~insulin receptor signaling pathway,GO:0010595~positive regulation of endothelial cell migration,GO:0016477~cell migration,GO:0030335~positive regulation of cell migration,GO:0035729~cellular response to hepatocyte growth factor stimulus,GO:0042981~regulation of apoptotic process,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0048012~hepatocyte growth factor receptor signaling pathway,GO:0050851~antigen receptor-mediated signaling pathway,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0051301~cell division,GO:0060326~cell chemotaxis,GO:0086100~endothelin receptor signaling pathway,GO:0090527~actin filament reorganization,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030424~axon,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,	IPR001452:Src homology-3 domain,IPR014928:Serine rich protein interaction,IPR021901:CAS family, DUF3513,	hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04935:Growth hormone synthesis, secretion and action,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,			SM00326:SH3,	KW-0130~Cell adhesion,	KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,	KW-0219~Diabetes mellitus,	KW-0728~SH3 domain,KW-0729~SH3-binding,KW-0732~Signal,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CAS family C-terminal,DOMAIN:SH3,DOMAIN:Serine rich protein interaction,MOTIF:SH3-binding,MUTAGEN:D->R: Weakens interaction with SH2D3C.,MUTAGEN:F->R: Weakens interaction with SH2D3C.,MUTAGEN:L->E: Weakens interaction with SH2D3C.,REGION:Disordered,REGION:Divergent helix-loop-helix motif,REGION:Substrate for kinases,
BOK	BCL2 family apoptosis regulator BOK(BOK)	Homo sapiens			GO:0001836~release of cytochrome c from mitochondria,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006921~cellular component disassembly involved in execution phase of apoptosis,GO:0007420~brain development,GO:0008584~male gonad development,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0010506~regulation of autophagy,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0048709~oligodendrocyte differentiation,GO:0051259~protein oligomerization,GO:0051402~neuron apoptotic process,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051902~negative regulation of mitochondrial depolarization,GO:0060546~negative regulation of necroptotic process,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:1900119~positive regulation of execution phase of apoptosis,GO:1901029~negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1901030~positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1901382~regulation of chorionic trophoblast cell proliferation,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903899~positive regulation of PERK-mediated unfolded protein response,GO:1904708~regulation of granulosa cell apoptotic process,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0031966~mitochondrial membrane,GO:0032588~trans-Golgi network membrane,GO:0033106~cis-Golgi network membrane,GO:0055038~recycling endosome membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0046982~protein heterodimerization activity,GO:0051400~BH domain binding,	IPR002475:Bcl2-like,IPR026298:Blc2 family,IPR026309:Bcl-2-related ovarian killer protein,	hsa04215:Apoptosis - multiple species,				KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0999~Mitochondrion inner membrane,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Bcl-2 Bcl-2 homology region 1-3,MOTIF:BH1,MOTIF:BH2,MOTIF:BH3,MOTIF:BH4,MUTAGEN:LRL->AAA: Significantly accumulates in the nucleus. Increases apoptotic activity. Does not interact with XPO1.,REGION:Interactions with ITPR1,REGION:Nuclear export signal,TRANSMEM:Helical,
BNIP3	BCL2 interacting protein 3(BNIP3)	Homo sapiens			GO:0000422~mitophagy,GO:0001666~response to hypoxia,GO:0006915~apoptotic process,GO:0008219~cell death,GO:0009617~response to bacterium,GO:0010508~positive regulation of autophagy,GO:0010637~negative regulation of mitochondrial fusion,GO:0010659~cardiac muscle cell apoptotic process,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0010940~positive regulation of necrotic cell death,GO:0016239~positive regulation of macroautophagy,GO:0021987~cerebral cortex development,GO:0035694~mitochondrial protein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043067~regulation of programmed cell death,GO:0043068~positive regulation of programmed cell death,GO:0043069~negative regulation of programmed cell death,GO:0043243~positive regulation of protein complex disassembly,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045837~negative regulation of membrane potential,GO:0046902~regulation of mitochondrial membrane permeability,GO:0048102~autophagic cell death,GO:0048678~response to axon injury,GO:0048709~oligodendrocyte differentiation,GO:0050873~brown fat cell differentiation,GO:0051402~neuron apoptotic process,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0051607~defense response to virus,GO:0055093~response to hyperoxia,GO:0060548~negative regulation of cell death,GO:0070301~cellular response to hydrogen peroxide,GO:0071260~cellular response to mechanical stimulus,GO:0071279~cellular response to cobalt ion,GO:0071456~cellular response to hypoxia,GO:0072593~reactive oxygen species metabolic process,GO:0090141~positive regulation of mitochondrial fission,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0090649~response to oxygen-glucose deprivation,GO:0097345~mitochondrial outer membrane permeabilization,GO:1901998~toxin transport,GO:1902109~negative regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1903599~positive regulation of mitophagy,GO:1903715~regulation of aerobic respiration,GO:1990144~intrinsic apoptotic signaling pathway in response to hypoxia,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0031307~integral component of mitochondrial outer membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051020~GTPase binding,	IPR010548:BNIP3,	hsa04068:FoxO signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa05131:Shigellosis,hsa05134:Legionellosis,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,TRANSMEM:Helical,
BCL6B	BCL6B transcription repressor(BCL6B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001817~regulation of cytokine production,GO:0002682~regulation of immune system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0042092~type 2 immune response,GO:0042127~regulation of cell proliferation,GO:0045595~regulation of cell differentiation,GO:0050727~regulation of inflammatory response,	GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000210:BTB/POZ-like,IPR011333:BTB/POZ fold,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00225:BTB,SM00355:ZnF_C2H2,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Pro residues,DOMAIN:BTB,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
BUB1B	BUB1 mitotic checkpoint serine/threonine kinase B(BUB1B)	Homo sapiens			GO:0006915~apoptotic process,GO:0007091~metaphase/anaphase transition of mitotic cell cycle,GO:0007094~mitotic spindle assembly checkpoint,GO:0016310~phosphorylation,GO:0051301~cell division,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051754~meiotic sister chromatid cohesion, centromeric,GO:0071459~protein localization to chromosome, centromeric region,	GO:0000776~kinetochore,GO:0000940~condensed chromosome outer kinetochore,GO:0005634~nucleus,GO:0005680~anaphase-promoting complex,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0033597~mitotic checkpoint complex,GO:0043229~intracellular organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR011009:Protein kinase-like domain,IPR013212:Mad3/BUB1 homology region 1,IPR015661:Mitotic checkpoint serine/threonine protein kinase Bub1/Mitotic spindle checkpoint component Mad3,	hsa04110:Cell cycle,hsa05166:Human T-cell leukemia virus 1 infection,	114500~Colorectal cancer, somatic,176430~Premature chromatid separation trait,257300~Mosaic variegated aneuploidy syndrome 1,		SM00777:Mad3_BUB1_I,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0043~Tumor suppressor,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:BUB1 N-terminal,DOMAIN:Protein kinase,MOTIF:D-box,MOTIF:Nuclear localization signal,MUTAGEN:A->W: Loss of interaction with KNL1.,MUTAGEN:D->E: Abolishes the cleavage by caspase-3.,MUTAGEN:F->A: Loss of interaction with KNL1.,MUTAGEN:K->A: Does not abolish the capacity to inhibit APC/CDC20.,MUTAGEN:K->R: Inhibits kinase activity.,MUTAGEN:T->A: Induces chromosome congression defects and mitotic delay.,REGION:Disordered,REGION:Necessary for interaction with KNL1,SITE:Cleavage; by caspase-3,
BMF	Bcl2 modifying factor(BMF)	Homo sapiens			GO:0006915~apoptotic process,GO:0010507~negative regulation of autophagy,GO:0031334~positive regulation of protein complex assembly,GO:0034644~cellular response to UV,GO:0043065~positive regulation of apoptotic process,GO:0043276~anoikis,GO:0090200~positive regulation of release of cytochrome c from mitochondria,	GO:0001669~acrosomal vesicle,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016459~myosin complex,	GO:0005515~protein binding,		hsa05206:MicroRNAs in cancer,				KW-0053~Apoptosis,							COMPBIAS:Acidic residues,MOTIF:BH3,REGION:Disordered,REGION:Interaction with DLC2,
CCL1	C-C motif chemokine ligand 1(CCL1)	Homo sapiens	109.Chemokine_families,33.GProt-coupled_Rec_T_Cell_med_Inflamm,34.Chemokines_in_EAE,		GO:0002548~monocyte chemotaxis,GO:0006874~cellular calcium ion homeostasis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0016032~viral process,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0032740~positive regulation of interleukin-17 production,GO:0043547~positive regulation of GTPase activity,GO:0048245~eosinophil chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0050729~positive regulation of inflammatory response,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090026~positive regulation of monocyte chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0008009~chemokine activity,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,			SM00199:SCY,	KW-0145~Chemotaxis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
CCL11	C-C motif chemokine ligand 11(CCL11)	Homo sapiens	109.Chemokine_families,	h_ccr3Pathway:CCR3 signaling in Eosinophils,h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,h_il5Pathway:IL 5 Signaling Pathway,	GO:0001938~positive regulation of endothelial cell proliferation,GO:0002548~monocyte chemotaxis,GO:0006468~protein phosphorylation,GO:0006874~cellular calcium ion homeostasis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007010~cytoskeleton organization,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007611~learning or memory,GO:0008360~regulation of cell shape,GO:0009314~response to radiation,GO:0009615~response to virus,GO:0030335~positive regulation of cell migration,GO:0030593~neutrophil chemotaxis,GO:0030838~positive regulation of actin filament polymerization,GO:0031640~killing of cells of other organism,GO:0043547~positive regulation of GTPase activity,GO:0045766~positive regulation of angiogenesis,GO:0048245~eosinophil chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0050768~negative regulation of neurogenesis,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0060763~mammary duct terminal end bud growth,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090647~modulation of age-related behavioral decline,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0031728~CCR3 chemokine receptor binding,GO:0046983~protein dimerization activity,GO:0048018~receptor agonist activity,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04657:IL-17 signaling pathway,hsa05310:Asthma,	600807~Asthma, susceptibility to,609423~HIV1, resistance to,		SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) threonine,DOMAIN:Chemokine interleukin-8-like,
CCL2	C-C motif chemokine ligand 2(CCL2)	Homo sapiens	109.Chemokine_families,18.Cytokine_astocytes,19.Cytokine_microglia,33.GProt-coupled_Rec_T_Cell_med_Inflamm,34.Chemokines_in_EAE,35.Chemokines_EAE_Autoreactive_T_Cells,	h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_LDLpathway:Low-density lipoprotein (LDL) pathway during atherogenesis,h_mspPathway:Msp/Ron Receptor Signaling Pathway,	GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0002548~monocyte chemotaxis,GO:0006468~protein phosphorylation,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007010~cytoskeleton organization,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007259~JAK-STAT cascade,GO:0008360~regulation of cell shape,GO:0009617~response to bacterium,GO:0009887~animal organ morphogenesis,GO:0019079~viral genome replication,GO:0019221~cytokine-mediated signaling pathway,GO:0019233~sensory perception of pain,GO:0019725~cellular homeostasis,GO:0030593~neutrophil chemotaxis,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0034351~negative regulation of glial cell apoptotic process,GO:0035684~helper T cell extravasation,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0043615~astrocyte cell migration,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0048245~eosinophil chemotaxis,GO:0048246~macrophage chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0050870~positive regulation of T cell activation,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071407~cellular response to organic cyclic compound,GO:0090280~positive regulation of calcium ion import,GO:1904783~positive regulation of NMDA glutamate receptor activity,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000427~positive regulation of apoptotic cell clearance,GO:2000502~negative regulation of natural killer cell chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0004672~protein kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0031727~CCR2 chemokine receptor binding,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05144:Malaria,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	182940~Spina bifida, susceptibility to,607948~Mycobacterium tuberculosis, susceptibility to,609423~HIV-1, resistance to,Coronary artery disease, modifier of~Coronary artery disease, modifier of,		SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Chemokine interleukin-8-like,MUTAGEN:D->A: Reduction in activity.,MUTAGEN:D->L: 90% reduction in activity.,MUTAGEN:H->A: Strongly reduces heparin binding.,MUTAGEN:I->A: Slight reduction in activity.,MUTAGEN:K->A: No effect on heparin binding.,MUTAGEN:K->A: Strongly reduces heparin binding.,MUTAGEN:Missing: 83% reduction in activity.,MUTAGEN:Missing: 90% reduction in activity.,MUTAGEN:Missing: Loss of activity.,MUTAGEN:Missing: Loss of signaling.,MUTAGEN:Missing: No effect on heparin binding.,MUTAGEN:N->A: 50% reduction in activity.,MUTAGEN:P->A: Loss of dimerization; slight reduction of activity.,MUTAGEN:R->F: 95% reduction in activity; strong reduction of receptor binding.,MUTAGEN:R->L: Loss of activity.,MUTAGEN:RK->AA: Abolishes binding to Link domain of TNFAIP6.,MUTAGEN:S->Q: 40% reduction in activity.,MUTAGEN:T->A: Slight reduction in activity.,MUTAGEN:T->E: Slight reduction in affinity.,MUTAGEN:V->A: Slight reduction in activity.,MUTAGEN:V->E: Slight reduction in affinity.,MUTAGEN:Y->A: Loss of activity.,MUTAGEN:Y->D: Loss of activity.,SITE:Involved in GAG binding,SITE:Involved in GAG binding and receptor binding,SITE:Involved in dimerization,SITE:Involved in dimerization, receptor binding and signaling,
CCL22	C-C motif chemokine ligand 22(CCL22)	Homo sapiens	109.Chemokine_families,		GO:0002548~monocyte chemotaxis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0009615~response to virus,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0043547~positive regulation of GTPase activity,GO:0048245~eosinophil chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04625:C-type lectin receptor signaling pathway,			SM00199:SCY,	KW-0145~Chemotaxis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,
CCR1	C-C motif chemokine receptor 1(CCR1)	Homo sapiens	14.chemokine_receptor-ligand,15.T-cell_polarization-chemokine_receptors,16.Chemokines-rec-T-cells,	h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,	GO:0002407~dendritic cell chemotaxis,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006887~exocytosis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007267~cell-cell signaling,GO:0009611~response to wounding,GO:0010629~negative regulation of gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0019722~calcium-mediated signaling,GO:0030335~positive regulation of cell migration,GO:0030502~negative regulation of bone mineralization,GO:0045672~positive regulation of osteoclast differentiation,GO:0051928~positive regulation of calcium ion transport,GO:0060326~cell chemotaxis,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0090026~positive regulation of monocyte chemotaxis,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0016493~C-C chemokine receptor activity,GO:0019957~C-C chemokine binding,GO:0035717~chemokine (C-C motif) ligand 7 binding,GO:0071791~chemokine (C-C motif) ligand 5 binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000355:Chemokine receptor family,IPR002236:CC chemokine receptor 1,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CXCL1	C-X-C motif chemokine ligand 1(CXCL1)	Homo sapiens			GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007399~nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0030036~actin cytoskeleton organization,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0035556~intracellular signal transduction,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0035580~specific granule lumen,GO:1904724~tertiary granule lumen,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008047~enzyme activator activity,GO:0008083~growth factor activity,GO:0045236~CXCR chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05134:Legionellosis,hsa05146:Amoebiasis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,			SM00199:SCY,	KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-1015~Disulfide bond,
CXCL12	C-X-C motif chemokine ligand 12(CXCL12)	Homo sapiens	109.Chemokine_families,	h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cxcr4Pathway:CXCR4 Signaling Pathway,	GO:0001666~response to hypoxia,GO:0001764~neuron migration,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006874~cellular calcium ion homeostasis,GO:0006935~chemotaxis,GO:0006952~defense response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007411~axon guidance,GO:0008015~blood circulation,GO:0008064~regulation of actin polymerization or depolymerization,GO:0008344~adult locomotory behavior,GO:0009314~response to radiation,GO:0009408~response to heat,GO:0009615~response to virus,GO:0010818~T cell chemotaxis,GO:0022029~telencephalon cell migration,GO:0030335~positive regulation of cell migration,GO:0031100~animal organ regeneration,GO:0031640~killing of cells of other organism,GO:0033603~positive regulation of dopamine secretion,GO:0033622~integrin activation,GO:0038146~chemokine (C-X-C motif) ligand 12 signaling pathway,GO:0043434~response to peptide hormone,GO:0045666~positive regulation of neuron differentiation,GO:0045785~positive regulation of cell adhesion,GO:0048842~positive regulation of axon extension involved in axon guidance,GO:0050930~induction of positive chemotaxis,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0060326~cell chemotaxis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090280~positive regulation of calcium ion import,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:1903237~negative regulation of leukocyte tethering or rolling,GO:1990478~response to ultrasound,GO:1990869~cellular response to chemokine,GO:2000406~positive regulation of T cell migration,GO:2000669~negative regulation of dendritic cell apoptotic process,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008083~growth factor activity,GO:0042379~chemokine receptor binding,GO:0045236~CXCR chemokine receptor binding,	IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04360:Axon guidance,hsa04670:Leukocyte transendothelial migration,hsa04672:Intestinal immune network for IgA production,hsa04810:Regulation of actin cytoskeleton,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05323:Rheumatoid arthritis,	609423~AIDS, resistance to,		SM00199:SCY,	KW-0145~Chemotaxis,KW-0945~Host-virus interaction,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Receptor activation motif,MUTAGEN:A->C: Formation of an intermolecular disulfide bond, leading to a locked dimer; when associated with C-57. No effect on CXCR4 activation, but loss of chemotactic activity; when associated with C-57.,MUTAGEN:E->A: No effect on CXCR4 activation.,MUTAGEN:E->A: No effect on anti-HIV-1 and chemotactic activities.,MUTAGEN:ESH->QSN: Slightly impaired chemotactic activity, no effect on inhibition by heparin.,MUTAGEN:F->A: No effect on anti-HIV-1 and chemotactic activities. Slightly impaired chemotactic activity and no effect on inhibition by heparin; when associated with A-34.,MUTAGEN:F->A: No effect on anti-HIV-1 and chemotactic activities. Slightly impaired chemotactic activity and no effect on inhibition by heparin; when associated with A-35.,MUTAGEN:H->A: No effect on anti-HIV-1 and chemotactic activities.,MUTAGEN:H->A: Reduced dimerization in neutral pH. Eliminates the pH dependence of dimerization.,MUTAGEN:H->L: No significant effect on dimerization in neutral pH. Eliminates the pH dependence of dimerization.,MUTAGEN:H->N: Slightly impaired CXCR4 activation and clear resistance to inhibition by heparin; when associated with Q-48; Q-62; Q-68 and N-69.,MUTAGEN:H->R: No effect on CXCR4 activation. Impaired dimer formation, leading to increased chemotactic activity. Eliminates the pH dependence of dimerization.,MUTAGEN:H->S: 55-fold reduction in binding affinity for Link domain of TNFAIP6; when associated with S-45 and S-48.,MUTAGEN:K->A: Impaired CXCR4 activation.,MUTAGEN:K->A: Loss of chemotactic activity.,MUTAGEN:K->A: No effect on CXCR4 activation.,MUTAGEN:K->E: Impaired CXCR4 activation. Loss of integrin activation; when associated with E-45 or E-64.,MUTAGEN:K->E: Loss of integrin activation; when associated with E-45 or E-48.,MUTAGEN:K->E: Loss of integrin activation; when associated with E-48 or E-64.,MUTAGEN:K->Q: Slightly impaired CXCR4 activation and clear resistance to inhibition by heparin; when associated with N-46; Q-62; Q-68 and N-69.,MUTAGEN:K->R: Abolished CXCR4 activation ability, but only slightly impaired binding to the receptor.,MUTAGEN:K->S: 55-fold reduction in binding affinity for Link domain of TNFAIP6; when associated with S-45 and S-46.,MUTAGEN:K->S: 55-fold reduction in binding affinity for Link domain of TNFAIP6; when associated with S-46 and S-48.,MUTAGEN:KHLK->SSLS: Loss of heparin-binding capacity.,MUTAGEN:L->C: Formation of an intermolecular disulfide bond, leading to a locked dimer; when associated with C-86. No effect on CXCR4 activation, but loss of chemotactic activity; when associated with C-86.,MUTAGEN:Missing: Abolished CXCR4 activation ability, but only slightly impaired binding to the receptor.,MUTAGEN:P->G: Abolished CXCR4 activation ability, but only slightly impaired binding to the receptor.,MUTAGEN:Q->N: Slightly impaired CXCR4 activation and clear resistance to inhibition by heparin; when associated with N-46; Q-48; Q-62 and Q-68.,MUTAGEN:R->A: Impaired CXCR4 activation.,MUTAGEN:R->A: No effect on CXCR4 activation.,MUTAGEN:R->A: Significantly decreased anti-HIV-1 and chemotactic activities.,MUTAGEN:R->E: Greatly impaired CXCR4 activation.,MUTAGEN:R->K: Slightly impaired binding and activation of CXCR4.,MUTAGEN:R->Q: Greatly impaired chemotactic activity and enhanced inhibition by heparin.,MUTAGEN:R->Q: Slightly impaired CXCR4 activation and clear resistance to inhibition by heparin; when associated with N-46; Q-48; Q-62 and N-69.,MUTAGEN:R->Q: Slightly impaired CXCR4 activation and clear resistance to inhibition by heparin; when associated with N-46; Q-48; Q-68 and N-69.,MUTAGEN:R->Q: Slightly impaired chemotactic activity and enhanced inhibition by heparin. Greatly impaired chemotactic activity; when associated with Q-29.,MUTAGEN:RFFESH->AAAAAA: Significantly decreased chemotactic activity.,MUTAGEN:S->A: No effect on anti-HIV-1 and chemotactic activities.,MUTAGEN:SLS->AQA: Significantly impaired CXCR4 activation ability, but only slightly impaired binding to the receptor.,MUTAGEN:TPNCA->GPGCG: Slightly impaired chemotactic activity, no effect on inhibition by heparin.,MUTAGEN:V->A: Impaired CXCR4 activation.,MUTAGEN:Y->A: Impaired CXCR4 activation ability, but only slightly impaired binding to the receptor.,MUTAGEN:Y->H: No significant effect on CXCR4 binding or activation.,REGION:Disordered,REGION:Receptor and heparin binding,REGION:Receptor binding,SITE:Important for dimer formation,SITE:Important for integrin interaction and activation,
CXCL14	C-X-C motif chemokine ligand 14(CXCL14)	Homo sapiens			GO:0006935~chemotaxis,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0031640~killing of cells of other organism,GO:0045662~negative regulation of myoblast differentiation,GO:0048839~inner ear development,GO:0060326~cell chemotaxis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:2000503~positive regulation of natural killer cell chemotaxis,	GO:0005615~extracellular space,GO:0005794~Golgi apparatus,	GO:0005515~protein binding,GO:0008009~chemokine activity,	IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,				KW-0145~Chemotaxis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	DOMAIN:Chemokine interleukin-8-like,MOTIF:D-box,
CXCL17	C-X-C motif chemokine ligand 17(CXCL17)	Homo sapiens			GO:0001525~angiogenesis,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010759~positive regulation of macrophage chemotaxis,GO:0030154~cell differentiation,GO:0048246~macrophage chemotaxis,GO:0050728~negative regulation of inflammatory response,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0090026~positive regulation of monocyte chemotaxis,	GO:0005615~extracellular space,	GO:0005515~protein binding,		hsa04060:Cytokine-cytokine receptor interaction,				KW-0037~Angiogenesis,KW-0145~Chemotaxis,KW-0221~Differentiation,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	COMPBIAS:Basic residues,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-50; S-52; S-75; S-103 and S-110.,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-50; S-52; S-75; S-77 and S-103.,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-50; S-52; S-75; S-77 and S-110.,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-50; S-52; S-77; S-103 and S-110.,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-50; S-75; S-77; S-103 and S-110.,MUTAGEN:C->S: Inhibits migration of nonactivated dendritic cells and monocytes; when associated with S-52; S-75; S-77; S-103 and S-110.,REGION:Disordered,SITE:Cleavage,
CXCL6	C-X-C motif chemokine ligand 6(CXCL6)	Homo sapiens	109.Chemokine_families,		GO:0001776~leukocyte homeostasis,GO:0006935~chemotaxis,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0030593~neutrophil chemotaxis,GO:0032642~regulation of chemokine production,GO:0042119~neutrophil activation,GO:0042742~defense response to bacterium,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0070951~regulation of neutrophil mediated killing of gram-negative bacterium,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008201~heparin binding,GO:0045236~CXCR chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa05133:Pertussis,hsa05323:Rheumatoid arthritis,			SM00199:SCY,	KW-0145~Chemotaxis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0044~Antibiotic,KW-0202~Cytokine,KW-0358~Heparin-binding,KW-0929~Antimicrobial,	KW-1015~Disulfide bond,	DOMAIN:Chemokine interleukin-8-like,
CXCR6	C-X-C motif chemokine receptor 6(CXCR6)	Homo sapiens			GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0019079~viral genome replication,GO:0019722~calcium-mediated signaling,GO:0060326~cell chemotaxis,GO:0070098~chemokine-mediated signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0015026~coreceptor activity,GO:0016493~C-C chemokine receptor activity,GO:0016494~C-X-C chemokine receptor activity,GO:0019957~C-C chemokine binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000355:Chemokine receptor family,IPR002235:CXC chemokine receptor 6,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04062:Chemokine signaling pathway,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CX3CL1	C-X3-C motif chemokine ligand 1(CX3CL1)	Homo sapiens	109.Chemokine_families,		GO:0001774~microglial cell activation,GO:0001954~positive regulation of cell-matrix adhesion,GO:0002052~positive regulation of neuroblast proliferation,GO:0002523~leukocyte migration involved in inflammatory response,GO:0002548~monocyte chemotaxis,GO:0002931~response to ischemia,GO:0006935~chemotaxis,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010976~positive regulation of neuron projection development,GO:0016322~neuron remodeling,GO:0019221~cytokine-mediated signaling pathway,GO:0030336~negative regulation of cell migration,GO:0030593~neutrophil chemotaxis,GO:0030595~leukocyte chemotaxis,GO:0031664~regulation of lipopolysaccharide-mediated signaling pathway,GO:0032233~positive regulation of actin filament bundle assembly,GO:0032690~negative regulation of interleukin-1 alpha production,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032914~positive regulation of transforming growth factor beta1 production,GO:0033622~integrin activation,GO:0035425~autocrine signaling,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043410~positive regulation of MAPK cascade,GO:0043547~positive regulation of GTPase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048167~regulation of synaptic plasticity,GO:0048245~eosinophil chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050767~regulation of neurogenesis,GO:0050902~leukocyte adhesive activation,GO:0050918~positive chemotaxis,GO:0051041~positive regulation of calcium-independent cell-cell adhesion,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051897~positive regulation of protein kinase B signaling,GO:0060055~angiogenesis involved in wound healing,GO:0060326~cell chemotaxis,GO:0061518~microglial cell proliferation,GO:0070050~neuron cellular homeostasis,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0098609~cell-cell adhesion,GO:0098883~synapse disassembly,GO:1900450~negative regulation of glutamate receptor signaling pathway,GO:1903721~positive regulation of I-kappaB phosphorylation,GO:1903979~negative regulation of microglial cell activation,GO:1904141~positive regulation of microglial cell migration,GO:2001223~negative regulation of neuron migration,GO:2001234~negative regulation of apoptotic signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,	GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0031737~CX3C chemokine receptor binding,GO:0042056~chemoattractant activity,GO:0045237~CXCR1 chemokine receptor binding,GO:0048020~CCR chemokine receptor binding,	IPR001811:Chemokine interleukin-8-like domain,IPR008097:CX3C chemokine ligand 1,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04668:TNF signaling pathway,hsa05163:Human cytomegalovirus infection,			SM00199:SCY,	KW-0130~Cell adhesion,KW-0145~Chemotaxis,KW-0395~Inflammatory response,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Chemokine interleukin-8-like,MUTAGEN:K->A: Little or no effect on binding to integrin ITGAV:ITGB3.,MUTAGEN:K->A: Little or no effect on binding to integrin ITGAV:ITGB3; when associated with A-78.,MUTAGEN:K->A: Little or no effect on binding to integrin ITGAV:ITGB3; when associated with A-83.,MUTAGEN:K->A: Reduced binding to integrin ITGAV:ITGB3, but no effect on binding to CX3CR1; when associated with A-61.,MUTAGEN:K->E: Dominant-negative mutant, reduced binding to integrins ITGAV:ITGB3 and ITGA4:ITGB1, no effect on binding to CX3CR1, defective in ternary complex formation, integrin activation and fractalkine signaling and suppression of leukocyte recruitment in the peritonitis model in vivo; when associated with E-61.,MUTAGEN:R->A: Loss of binding to CX3CR1 and ability to induce chemotaxis but no effect on binding to integrins.,MUTAGEN:R->A: Reduced binding to integrin ITGAV:ITGB3, but no effect on binding to CX3CR1; when associated with A-60.,MUTAGEN:R->E: Dominant-negative mutant, reduced binding to integrins ITGAV:ITGB3 and ITGA4:ITGB1, no effect on binding to CX3CR1, defective in ternary complex formation, integrin activation and fractalkine signaling and suppression of leukocyte recruitment in the peritonitis model in vivo; when associated with E-60.,REGION:Chemokine and involved in interaction with ITGAV:ITGB3 and ITGA4:ITGB1,REGION:Disordered,REGION:Mucin-like stalk,SITE:Cleavage; to produce soluble form,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CRP	C-reactive protein(CRP)	Homo sapiens			GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0006958~complement activation, classical pathway,GO:0008228~opsonization,GO:0010628~positive regulation of gene expression,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010888~negative regulation of lipid storage,GO:0032677~regulation of interleukin-8 production,GO:0032930~positive regulation of superoxide anion generation,GO:0032945~negative regulation of mononuclear cell proliferation,GO:0042310~vasoconstriction,GO:0044793~negative regulation by host of viral process,GO:0045087~innate immune response,GO:0050830~defense response to Gram-positive bacterium,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0001849~complement component C1q binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030169~low-density lipoprotein particle binding,GO:0033265~choline binding,GO:0042802~identical protein binding,GO:0050750~low-density lipoprotein particle receptor binding,	IPR001759:Pentaxin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00159:PTX,	KW-0011~Acute phase,	KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	DOMAIN:Pentraxin (PTX),
CLEC11A	C-type lectin domain containing 11A(CLEC11A)	Homo sapiens			GO:0001503~ossification,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,				SM00034:CLECT,	KW-0892~Osteogenesis,	KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,	KW-0430~Lectin,	KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	COMPBIAS:Acidic residues,DOMAIN:C-type lectin,MOTIF:Cell attachment site,REGION:Disordered,
CARTPT	CART prepropeptide(CARTPT)	Homo sapiens			GO:0001678~cellular glucose homeostasis,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0007268~chemical synaptic transmission,GO:0008343~adult feeding behavior,GO:0009267~cellular response to starvation,GO:0032099~negative regulation of appetite,GO:0032812~positive regulation of epinephrine secretion,GO:0032922~circadian regulation of gene expression,GO:0043410~positive regulation of MAPK cascade,GO:0045671~negative regulation of osteoclast differentiation,GO:0045777~positive regulation of blood pressure,GO:0045779~negative regulation of bone resorption,GO:0045860~positive regulation of protein kinase activity,GO:0050796~regulation of insulin secretion,GO:0051971~positive regulation of transmission of nerve impulse,GO:0070093~negative regulation of glucagon secretion,GO:0070253~somatostatin secretion,	GO:0005615~extracellular space,GO:0030141~secretory granule,GO:0045202~synapse,	GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,	IPR009106:CART satiety factor,		601665~Obesity, susceptibility to,				KW-0964~Secreted,	KW-0550~Obesity,	KW-0732~Signal,		KW-0527~Neuropeptide,KW-0529~Neurotransmitter,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	PEPTIDE:CART(1-39),PEPTIDE:CART(42-89),
CD1A	CD1a molecule(CD1A)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0048006~antigen processing and presentation, endogenous lipid antigen via MHC class Ib,GO:0048007~antigen processing and presentation, exogenous lipid antigen via MHC class Ib,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,	GO:0005515~protein binding,GO:0030883~endogenous lipid antigen binding,GO:0030884~exogenous lipid antigen binding,GO:0071723~lipopeptide binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04530:Tight junction,hsa04640:Hematopoietic cell lineage,hsa05146:Amoebiasis,			SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD1B	CD1b molecule(CD1B)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0048006~antigen processing and presentation, endogenous lipid antigen via MHC class Ib,GO:0048007~antigen processing and presentation, exogenous lipid antigen via MHC class Ib,	GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0030883~endogenous lipid antigen binding,GO:0030884~exogenous lipid antigen binding,GO:0071723~lipopeptide binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04530:Tight junction,hsa04640:Hematopoietic cell lineage,hsa05146:Amoebiasis,			SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:MHC class I-like antigen recognition-like,MOTIF:Internalization signal,MUTAGEN:YQ->AA: Strongly reduced internalization and trafficking to endosomes.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD1C	CD1c molecule(CD1C)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002286~T cell activation involved in immune response,GO:0006955~immune response,GO:0048006~antigen processing and presentation, endogenous lipid antigen via MHC class Ib,GO:0048007~antigen processing and presentation, exogenous lipid antigen via MHC class Ib,	GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0030883~endogenous lipid antigen binding,GO:0030884~exogenous lipid antigen binding,GO:0051861~glycolipid binding,GO:0071723~lipopeptide binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04530:Tight junction,hsa04640:Hematopoietic cell lineage,hsa05146:Amoebiasis,			SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,MOTIF:Internalization signal,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD1D	CD1d molecule(CD1D)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0006955~immune response,GO:0016045~detection of bacterium,GO:0034113~heterotypic cell-cell adhesion,GO:0042102~positive regulation of T cell proliferation,GO:0045058~T cell selection,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0048006~antigen processing and presentation, endogenous lipid antigen via MHC class Ib,GO:0048007~antigen processing and presentation, exogenous lipid antigen via MHC class Ib,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,	GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0030882~lipid antigen binding,GO:0030883~endogenous lipid antigen binding,GO:0030884~exogenous lipid antigen binding,GO:0042393~histone binding,GO:0050839~cell adhesion molecule binding,GO:0071723~lipopeptide binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04530:Tight junction,hsa04640:Hematopoietic cell lineage,hsa05146:Amoebiasis,			SM00407:IGc1,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:MHC class I-like antigen recognition-like,MOTIF:Internalization signal,MUTAGEN:V->A: Strongly reduced internalization.,MUTAGEN:Y->A: Strongly reduced internalization.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD207	CD207 molecule(CD207)	Homo sapiens			GO:0044419~interspecies interaction between organisms,GO:0051607~defense response to virus,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0030139~endocytic vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,	GO:0005515~protein binding,GO:0005537~mannose binding,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,		613393~Birbeck granule deficiency,		SM00034:CLECT,		KW-0472~Membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,MUTAGEN:E->A: Loss of binding to 6'-sulfo-LacNAc and invertase.,MUTAGEN:K->A: Loss of binding to 6'-sulfo-LacNAc and 6-sulfo-GlcNAc.,MUTAGEN:K->A: Loss of binding to 6'-sulfo-LacNAc.,MUTAGEN:N->A: Loss of binding to 6'-sulfo-LacNAc and invertase.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CD248	CD248 molecule(CD248)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,		GO:0008284~positive regulation of cell proliferation,GO:0010761~fibroblast migration,GO:0016477~cell migration,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048535~lymph node development,GO:0060033~anatomical structure regression,GO:0072577~endothelial cell apoptotic process,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0050840~extracellular matrix binding,GO:1990430~extracellular matrix protein binding,	IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018097:EGF-like calcium-binding, conserved site,				SM00034:CLECT,SM00179:EGF_CA,SM00181:EGF,		KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:C-type lectin,DOMAIN:EGF-like; calcium-binding,DOMAIN:Sushi,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD40	CD40 molecule(CD40)	Homo sapiens	125.T_Cells_CNS-APCs,15.T-cell_polarization-chemokine_receptors,19.Cytokine_microglia,5.B7_CD40_B-cell_activa,50.Hypothesis_of_bronchial_asthma,55.Allergen_recognition_by_Th2_or_Th0_cell,58.(CD40L)_immnosurveillance,99.NF-kB_activation,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cd40Pathway:CD40L Signaling Pathway,h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_th1th2Pathway:Th1/Th2 Differentiation,	GO:0001934~positive regulation of protein phosphorylation,GO:0002768~immune response-regulating cell surface receptor signaling pathway,GO:0006874~cellular calcium ion homeostasis,GO:0006954~inflammatory response,GO:0019724~B cell mediated immunity,GO:0023035~CD40 signaling pathway,GO:0030168~platelet activation,GO:0030890~positive regulation of B cell proliferation,GO:0032735~positive regulation of interleukin-12 production,GO:0033590~response to cobalamin,GO:0034341~response to interferon-gamma,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0036018~cellular response to erythropoietin,GO:0042100~B cell proliferation,GO:0042113~B cell activation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042832~defense response to protozoan,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043406~positive regulation of MAP kinase activity,GO:0043491~protein kinase B signaling,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043547~positive regulation of GTPase activity,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048304~positive regulation of isotype switching to IgG isotypes,GO:0050776~regulation of immune response,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0065003~macromolecular complex assembly,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090037~positive regulation of protein kinase C signaling,GO:1901652~response to peptide,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0035631~CD40 receptor complex,GO:0043025~neuronal cell body,GO:0043196~varicosity,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0038023~signaling receptor activity,	IPR001368:TNFR/NGFR cysteine-rich region,IPR020435:Tumour necrosis factor receptor 5,	hsa04060:Cytokine-cytokine receptor interaction,hsa04064:NF-kappa B signaling pathway,hsa04514:Cell adhesion molecules,hsa04620:Toll-like receptor signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05202:Transcriptional misregulation in cancer,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05322:Systemic lupus erythematosus,hsa05330:Allograft rejection,hsa05340:Primary immunodeficiency,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,	606843~Immunodeficiency with hyper-IgM, type 3,		SM00208:TNFR,	KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD5L	CD5 molecule like(CD5L)	Homo sapiens			GO:0002376~immune system process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006968~cellular defense response,GO:0030449~regulation of complement activation,GO:0031638~zymogen activation,GO:1903661~positive regulation of complement-dependent cytotoxicity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0072562~blood microparticle,	GO:0004252~serine-type endopeptidase activity,GO:0005044~scavenger receptor activity,	IPR001190:Speract/scavenger receptor,IPR017448:Speract/scavenger receptor-related,				SM00202:SR,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0395~Inflammatory response,	KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,MUTAGEN:S->A: No effect; when associated with 129-A--A-132.,MUTAGEN:SSFS->AAFA: No effect; when associated with A-123.,
CD80	CD80 molecule(CD80)	Homo sapiens	3.T_cell_receptor,97.Immune_injury_MS-lesions_MS_antigen,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,	GO:0002710~negative regulation of T cell mediated immunity,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0009967~positive regulation of signal transduction,GO:0031295~T cell costimulation,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032743~positive regulation of interleukin-2 production,GO:0035556~intracellular signal transduction,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0042130~negative regulation of T cell proliferation,GO:0045627~positive regulation of T-helper 1 cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046718~viral entry into host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0071222~cellular response to lipopolysaccharide,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0098636~protein complex involved in cell adhesion,	GO:0001618~virus receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0048018~receptor agonist activity,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa03267:Virion - Adenovirus,hsa04514:Cell adhesion molecules,hsa04620:Toll-like receptor signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05320:Autoimmune thyroid disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00409:IG,	KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD84	CD84 molecule(CD84)	Homo sapiens			GO:0002250~adaptive immune response,GO:0006914~autophagy,GO:0006952~defense response,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0032685~negative regulation of granulocyte macrophage colony-stimulating factor production,GO:0032701~negative regulation of interleukin-18 production,GO:0032715~negative regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033004~negative regulation of mast cell activation,GO:0042110~T cell activation,GO:0043030~regulation of macrophage activation,GO:0043305~negative regulation of mast cell degranulation,GO:0045087~innate immune response,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:2001256~regulation of store-operated calcium entry,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0072~Autophagy,KW-0130~Cell adhesion,KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,MOTIF:ITSM 1,MOTIF:ITSM 2,MUTAGEN:D->A: Loss of dimerization.,MUTAGEN:H->A: Loss of dimerization.,MUTAGEN:N->A: Loss of dimerization.,MUTAGEN:T->A: Loss of dimerization.,MUTAGEN:Y->A: No effect.,MUTAGEN:Y->D: Loss of dimerization.,MUTAGEN:Y->F: Reduced tyrosine phosphorylation and reduced binding of SH2D1B. Loss of phosphorylation and loss of binding of SH2D1A and SH2D1B; when associated with F-279.,MUTAGEN:Y->F: Reduced tyrosine phosphorylation, reduced binding of SH2D1B and loss of binding of SH2D1A.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD9	CD9 molecule(CD9)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,		GO:0007155~cell adhesion,GO:0007338~single fertilization,GO:0007342~fusion of sperm to egg plasma membrane,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008347~glial cell migration,GO:0014905~myoblast fusion involved in skeletal muscle regeneration,GO:0030168~platelet activation,GO:0030913~paranodal junction assembly,GO:0031623~receptor internalization,GO:0035036~sperm-egg recognition,GO:0051271~negative regulation of cellular component movement,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0090331~negative regulation of platelet aggregation,GO:1905521~regulation of macrophage migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031092~platelet alpha granule membrane,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0005178~integrin binding,GO:0005515~protein binding,	IPR000301:Tetraspanin,IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin, conserved site,	hsa04640:Hematopoietic cell lineage,		PIRSF002419:tetraspanin,		KW-0130~Cell adhesion,KW-0278~Fertilization,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-78; A-79; A-87; A-218 and A-219.,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-9; A-78; A-79; A-218 and A-219.,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-9; A-78; A-79; A-87 and A-218.,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-9; A-78; A-79; A-87 and A-219.,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-9; A-78; A-87; A-218 and A-219.,MUTAGEN:C->A: Loss of palmitoylation; when associated with A-9; A-79; A-87; A-218 and A-219.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CEACAM4	CEA cell adhesion molecule 4(CEACAM4)	Homo sapiens			GO:0002682~regulation of immune system process,GO:0006909~phagocytosis,GO:0007165~signal transduction,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:1990782~protein tyrosine kinase binding,	IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,						KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,MOTIF:ITAM,MUTAGEN:Y->F: No internalization of bacteria; when associated with F-222.,MUTAGEN:Y->F: No internalization of bacteria; when associated with F-233.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CEACAM5	CEA cell adhesion molecule 5(CEACAM5)	Homo sapiens			GO:0006915~apoptotic process,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0010832~negative regulation of myotube differentiation,GO:0034109~homotypic cell-cell adhesion,GO:0043066~negative regulation of apoptotic process,GO:2000811~negative regulation of anoikis,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031225~anchored component of membrane,GO:0070062~extracellular exosome,GO:0071575~integral component of external side of plasma membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,GO:0034235~GPI anchor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0053~Apoptosis,KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0553~Oncogene,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,LIPID:GPI-anchor amidated alanine,MUTAGEN:D->A: No effect on dimerization.,MUTAGEN:D->L,R: Abolishes dimerization.,MUTAGEN:E->A: Abolishes dimerization.,MUTAGEN:F->I: No effect on dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:F->R: Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:I->A: Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:K->A: Abolishes dimerization.,MUTAGEN:L->A,C: No effect on dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:L->S: Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:Q->L,R: Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.,MUTAGEN:S->N: Abolishes dimerization.,MUTAGEN:V->A: Abolishes dimerization.,MUTAGEN:Y->A: Abolishes dimerization.,MUTAGEN:Y->F: No effect on dimerization.,PROPEP:Removed in mature form,REGION:Disordered,
CEACAM8	CEA cell adhesion molecule 8(CEACAM8)	Homo sapiens			GO:0006955~immune response,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031225~anchored component of membrane,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,LIPID:GPI-anchor amidated aspartate,MUTAGEN:AVPSNA->STPFNV: No effect on heterophilic cell adhesion.,MUTAGEN:DPR->NRI: No effect on heterophilic cell adhesion.,MUTAGEN:L->A: Does not affect the monomeric structure. Loss of heterodimerization with CEACAM6.,MUTAGEN:N->G: No effect on heterophilic cell adhesion.,MUTAGEN:N->S: Inhibits heterophilic cell adhesion.,MUTAGEN:Q->A: Does not affect the monomeric structure. Decreases heterodimerization with CEACAM6.,MUTAGEN:R->A: Does not affect the monomeric structure. Loss of heterodimerization with CEACAM6.,MUTAGEN:R->Q: Inhibits heterophilic cell adhesion.,MUTAGEN:SNQQI->GTQQA: No effect on heterophilic cell adhesion.,MUTAGEN:TVDA->RVDG: No effect on heterophilic cell adhesion.,PROPEP:Removed in mature form,
CFTR	CF transmembrane conductance regulator(CFTR)	Homo sapiens		h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,	GO:0006695~cholesterol biosynthetic process,GO:0006821~chloride transport,GO:0006904~vesicle docking involved in exocytosis,GO:0015701~bicarbonate transport,GO:0030301~cholesterol transport,GO:0034976~response to endoplasmic reticulum stress,GO:0035377~transepithelial water transport,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0045921~positive regulation of exocytosis,GO:0048240~sperm capacitation,GO:0050891~multicellular organismal water homeostasis,GO:0051454~intracellular pH elevation,GO:0051649~establishment of localization in cell,GO:0055085~transmembrane transport,GO:0060081~membrane hyperpolarization,GO:0070175~positive regulation of enamel mineralization,GO:0071320~cellular response to cAMP,GO:0097186~amelogenesis,GO:1902161~positive regulation of cyclic nucleotide-gated ion channel activity,GO:1902476~chloride transmembrane transport,GO:1902943~positive regulation of voltage-gated chloride channel activity,GO:1904322~cellular response to forskolin,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030660~Golgi-associated vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0032991~macromolecular complex,GO:0034707~chloride channel complex,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,	GO:0005254~chloride channel activity,GO:0005260~intracellular ATPase-gated chloride channel activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015106~bicarbonate transmembrane transporter activity,GO:0015108~chloride transmembrane transporter activity,GO:0016787~hydrolase activity,GO:0016853~isomerase activity,GO:0016887~ATPase activity,GO:0017081~chloride channel regulator activity,GO:0019869~chloride channel inhibitor activity,GO:0019899~enzyme binding,GO:0030165~PDZ domain binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0043225~ATPase-coupled anion transmembrane transporter activity,GO:0051087~chaperone binding,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR009147:Cystic fibrosis transmembrane conductance regulator,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR025837:CFTR regulator domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,hsa04024:cAMP signaling pathway,hsa04152:AMPK signaling pathway,hsa04530:Tight junction,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04976:Bile secretion,hsa05110:Vibrio cholerae infection,	167800~Pancreatitis, hereditary,211400~Bronchiectasis with or without elevated sweat chloride 1, modifier of,219700~Cystic fibrosis,277180~Congenital bilateral absence of vas deferens,Hypertrypsinemia, neonatal~Hypertrypsinemia, neonatal,Sweat chloride elevation without CF~Sweat chloride elevation without CF,		SM00382:AAA,	KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,KW-0868~Chloride,	KW-0378~Hydrolase,KW-0407~Ion channel,KW-0413~Isomerase,KW-0869~Chloride channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transmembrane type-1 1,DOMAIN:ABC transmembrane type-1 2,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,DOMAIN:CFTR regulator,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MUTAGEN:D->G: Decreases channel activity, no visible effect on protein maturation.,MUTAGEN:F->R: Impaired maturation of glycan chains indicating impaired trafficking from the endoplasmic reticulum to the cell membrane.,MUTAGEN:I->T: Enhances trafficking from the endoplasmic reticulum to the cell membrane.,MUTAGEN:I->V: Decreases channel activity, no visible effect on protein maturation.,MUTAGEN:K->M: Impaired maturation of glycan chains indicating impaired trafficking from the endoplasmic reticulum to the cell membrane.,MUTAGEN:K->M: No effect on maturation of glycans, suggesting that trafficking to the plasma membrane is not altered.,MUTAGEN:M->R: Abolishes channel activity. Impairs protein maturation, suggesting the protein is retained in the endoplasmic reticulum.,MUTAGEN:Missing: Abolishes MARCHF2-mediated degradation.,MUTAGEN:Missing: Reduces interaction with MARCHF2 and abolishes subsequent MARCHF2-mediated degradation. No effect on localization to the Golgi.,MUTAGEN:N->D: Abolishes N-glycosylation, enhances endocytosis and impairs subsequent recycling to the cell surface; when associated with D-894.,MUTAGEN:N->D: Abolishes N-glycosylation, enhances endocytosis and impairs subsequent recycling to the cell surface; when associated with D-900.,REGION:Disordered,REGION:Disordered R region,REGION:Interaction with GORASP2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Discontinuously helical; Name=8,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=9,
CMTM5	CKLF like MARVEL transmembrane domain containing 5(CMTM5)	Homo sapiens			GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0045662~negative regulation of myoblast differentiation,	GO:0005615~extracellular space,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005125~cytokine activity,GO:0005515~protein binding,	IPR008253:Marvel,					KW-0145~Chemotaxis,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,		DOMAIN:MARVEL,TRANSMEM:Helical,
COPS8	COP9 signalosome subunit 8(COPS8)	Homo sapiens			GO:0000338~protein deneddylation,GO:0006468~protein phosphorylation,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0008285~negative regulation of cell proliferation,GO:0010387~COP9 signalosome assembly,GO:0045116~protein neddylation,GO:2000434~regulation of protein neddylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008180~COP9 signalosome,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000717:Proteasome component (PCI) domain,						KW-0539~Nucleus,KW-0736~Signalosome,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	DOMAIN:CSN8/PSMD8/EIF3K,DOMAIN:PCI,
DAB1	DAB adaptor protein 1(DAB1)	Homo sapiens		h_reelinPathway:Reelin Signaling Pathway,	GO:0007162~negative regulation of cell adhesion,GO:0007259~JAK-STAT cascade,GO:0007264~small GTPase mediated signal transduction,GO:0007409~axonogenesis,GO:0007628~adult walking behavior,GO:0016358~dendrite development,GO:0021517~ventral spinal cord development,GO:0021589~cerebellum structural organization,GO:0021766~hippocampus development,GO:0021813~cell-cell adhesion involved in neuronal-glial interactions involved in cerebral cortex radial glia guided migration,GO:0021942~radial glia guided migration of Purkinje cell,GO:0045666~positive regulation of neuron differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046426~negative regulation of JAK-STAT cascade,GO:0048708~astrocyte differentiation,GO:0048712~negative regulation of astrocyte differentiation,GO:0050771~negative regulation of axonogenesis,GO:0051645~Golgi localization,GO:0097477~lateral motor column neuron migration,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,	hsa05017:Spinocerebellar ataxia,	615945~Spinocerebellar ataxia 37,		SM00462:PTB,	KW-0221~Differentiation,KW-0524~Neurogenesis,		KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,			KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PID,REGION:Disordered,
DCC	DCC netrin 1 receptor(DCC)	Homo sapiens			GO:0001764~neuron migration,GO:0006915~apoptotic process,GO:0007409~axonogenesis,GO:0007411~axon guidance,GO:0010977~negative regulation of neuron projection development,GO:0021965~spinal cord ventral commissure morphogenesis,GO:0033563~dorsal/ventral axon guidance,GO:0033564~anterior/posterior axon guidance,GO:0048671~negative regulation of collateral sprouting,GO:0098609~cell-cell adhesion,GO:1901214~regulation of neuron death,GO:2000171~negative regulation of dendrite development,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0044295~axonal growth cone,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0099061~integral component of postsynaptic density membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005042~netrin receptor activity,GO:0005515~protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR010560:Neogenin, C-terminal,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,	hsa04360:Axon guidance,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,	114500~Colorectal cancer, somatic,133239~Esophageal carcinoma, somatic,157600~Mirror movements 1 and/or agenesis of the corpus callosum,617542~Gaze palsy, familial horizontal, with progressive scoliosis, 2,		SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0053~Apoptosis,	KW-0472~Membrane,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,MUTAGEN:L->S: Abolishes interaction with MYO10.,MUTAGEN:LM->SS: Abolishes interaction with MYO10.,REGION:Disordered,REGION:Interaction with MYO10,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DENND2D	DENN domain containing 2D(DENND2D)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR001194:DENN domain,IPR005112:dDENN domain,IPR005113:uDENN domain,				SM00799:DENN,SM00800:uDENN,SM00801:dDENN,		KW-0963~Cytoplasm,				KW-0344~Guanine-nucleotide releasing factor,		DOMAIN:UDENN,DOMAIN:cDENN,DOMAIN:dDENN,DOMAIN:uDENN,REGION:Disordered,
DHX58	DExH-box helicase 58(DHX58)	Homo sapiens			GO:0002753~cytoplasmic pattern recognition receptor signaling pathway,GO:0009615~response to virus,GO:0009617~response to bacterium,GO:0032480~negative regulation of type I interferon production,GO:0032481~positive regulation of type I interferon production,GO:0032728~positive regulation of interferon-beta production,GO:0039534~negative regulation of MDA-5 signaling pathway,GO:0039536~negative regulation of RIG-I signaling pathway,GO:0045087~innate immune response,GO:0045088~regulation of innate immune response,GO:0045824~negative regulation of innate immune response,GO:0051607~defense response to virus,GO:1900245~positive regulation of MDA-5 signaling pathway,GO:1900246~positive regulation of RIG-I signaling pathway,	GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0046872~metal ion binding,	IPR001650:Helicase, C-terminal,IPR006935:Helicase/UvrB domain,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR021673:C-terminal domain of RIG-I,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04622:RIG-I-like receptor signaling pathway,			SM00487:DEXDc,SM00490:HELICc,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,		DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:RLR CTR,MOTIF:DECH box,MUTAGEN:DECH->AACA: Loss of dsRNA-induced ATPase activity.,MUTAGEN:FTRT->ATRA: Loss of dsRNA-induced ATPase activity. No effect on cytoplasmic pattern recognition receptor signaling pathway in response to virus.,MUTAGEN:K->A: Loss of dsRNA-induced ATPase activity. No effect on ds-RNA binding. No effect on cytoplasmic pattern recognition receptor signaling pathway in response to virus.,MUTAGEN:K->E: Abolishes RNA binding.,MUTAGEN:QARGR->AARGA: Loss of dsRNA-induced ATPase activity. No effect on cytoplasmic pattern recognition receptor signaling pathway in response to virus.,MUTAGEN:TAS->AAA: Loss of dsRNA-induced ATPase activity. Loss of ds-RNA binding. No effect on cytoplasmic pattern recognition receptor signaling pathway in response to virus.,MUTAGEN:TSVAE->ASVAA: Loss of dsRNA-induced ATPase activity. No effect on cytoplasmic pattern recognition receptor signaling pathway in response to virus.,REGION:RNA-binding,
DIRAS3	DIRAS family GTPase 3(DIRAS3)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006349~regulation of gene expression by genetic imprinting,GO:0007264~small GTPase mediated signal transduction,	GO:0005886~plasma membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,						KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
DLC1	DLC1 Rho GTPase activating protein(DLC1)	Homo sapiens			GO:0001843~neural tube closure,GO:0003007~heart morphogenesis,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007165~signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0021575~hindbrain morphogenesis,GO:0030036~actin cytoskeleton organization,GO:0030336~negative regulation of cell migration,GO:0030900~forebrain development,GO:0032956~regulation of actin cytoskeleton organization,GO:0035023~regulation of Rho protein signal transduction,GO:0035024~negative regulation of Rho protein signal transduction,GO:0035307~positive regulation of protein dephosphorylation,GO:0048041~focal adhesion assembly,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051497~negative regulation of stress fiber assembly,GO:0051895~negative regulation of focal adhesion assembly,GO:1900119~positive regulation of execution phase of apoptosis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005901~caveola,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030864~cortical actin cytoskeleton,GO:0032587~ruffle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042169~SH2 domain binding,	IPR000198:Rho GTPase-activating protein domain,IPR001660:Sterile alpha motif domain,IPR002913:START domain,IPR008936:Rho GTPase activation protein,IPR013761:Sterile alpha motif/pointed domain,IPR023393:START-like domain,		114500~Colorectal cancer, somatic,		SM00234:START,SM00324:RhoGAP,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,	KW-0043~Tumor suppressor,			KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rho-GAP,DOMAIN:SAM,DOMAIN:START,MUTAGEN:F->G: Abolishes interaction with EF1A1.,MUTAGEN:L->G: Abolishes interaction with EF1A1.,MUTAGEN:R->E: No catalytic activity.,MUTAGEN:S->A: Abolishes interaction with TNS4 and results in diffuse cytoplasmic localization.,MUTAGEN:Y->F: Unable to displace endogenous DLC1 from focal adhesions. Abolishes interaction with TNS4 and results in diffuse cytoplasmic localization.,REGION:Disordered,REGION:Focal adhesion-targeting (FAT),REGION:Polybasic cluster (PBR),
DRAM1	DNA damage regulated autophagy modulator 1(DRAM1)	Homo sapiens			GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0010506~regulation of autophagy,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR019402:Frag1/DRAM/Sfk1,					KW-0053~Apoptosis,KW-0072~Autophagy,	KW-0458~Lysosome,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
LIG1	DNA ligase 1(LIG1)	Homo sapiens			GO:0006260~DNA replication,GO:0006266~DNA ligation,GO:0006273~lagging strand elongation,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0009653~anatomical structure morphogenesis,GO:0051301~cell division,GO:0071897~DNA biosynthetic process,GO:1903461~Okazaki fragment processing involved in mitotic DNA replication,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0043231~intracellular membrane-bounded organelle,	GO:0003677~DNA binding,GO:0003909~DNA ligase activity,GO:0003910~DNA ligase (ATP) activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016874~ligase activity,GO:0046872~metal ion binding,	IPR000977:DNA ligase, ATP-dependent,IPR012308:DNA ligase, ATP-dependent, N-terminal,IPR012309:DNA ligase, ATP-dependent, C-terminal,IPR012310:DNA ligase, ATP-dependent, central,IPR012340:Nucleic acid-binding, OB-fold,IPR016059:DNA ligase, ATP-dependent, conserved site,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,	619774~Immunodeficiency 96,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:N6-AMP-lysine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ATP-dependent DNA ligase family profile,DOMAIN:DNA ligase ATP-dependent N-terminal,MUTAGEN:D->A: Severely reduced DNA ligase activity.,MUTAGEN:K->A: No effect on DNA ligase activity.,MUTAGEN:K->G: Loss of DNA ligase activity.,MUTAGEN:R->A: No effect on DNA ligase activity.,MUTAGEN:R->A: Severely reduced DNA ligase activity.,REGION:Disordered,REGION:Interaction with target DNA,SITE:Interaction with target DNA,
EBF1	EBF transcription factor 1(EBF1)	Homo sapiens	78.B_Cell_Development,		GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0070742~C2H2 zinc finger domain binding,	IPR002909:Cell surface receptor IPT/TIG,IPR003523:Transcription factor COE,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR018350:Transcription factor COE, conserved site,				SM00429:IPT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:IPT/TIG,MUTAGEN:H->A: Impaired EBF1-mediated cell differentiation and gene expression mostly without changing EBF1 occupancy.,REGION:Disordered,REGION:Interaction with DNA,SITE:Interaction with DNA,ZN_FING:C5-type,
EFEMP1	EGF containing fibulin extracellular matrix protein 1(EFEMP1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007601~visual perception,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0032331~negative regulation of chondrocyte differentiation,GO:0043010~camera-type eye development,GO:0048048~embryonic eye morphogenesis,GO:0048050~post-embryonic eye morphogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005006~epidermal growth factor-activated receptor activity,GO:0005154~epidermal growth factor receptor binding,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,		126600~Doyne honeycomb degeneration of retina,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1; atypical,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like calcium-binding,REGION:Disordered,REGION:Mediates interaction with TIMP3,
ELAVL3	ELAV like RNA binding protein 3(ELAVL3)	Homo sapiens			GO:0007399~nervous system development,GO:0030154~cell differentiation,	GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,	IPR000504:RNA recognition motif domain,IPR002343:Paraneoplastic encephalomyelitis antigen,IPR003954:RNA recognition motif domain, eukaryote,IPR006548:Splicing factor ELAV/HuD,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,SM00361:RRM_1,	KW-0221~Differentiation,KW-0524~Neurogenesis,			KW-0677~Repeat,		KW-0217~Developmental protein,KW-0694~RNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:Disordered,
ERC1	ELKS/RAB6-interacting/CAST family member 1(ERC1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0007252~I-kappaB phosphorylation,GO:0007274~neuromuscular synaptic transmission,GO:0015031~protein transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0048167~regulation of synaptic plasticity,GO:0048790~maintenance of presynaptic active zone structure,GO:0051092~positive regulation of NF-kappaB transcription factor activity,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0008385~IkappaB kinase complex,GO:0016020~membrane,GO:0036064~ciliary basal body,GO:0042734~presynaptic membrane,GO:0045202~synapse,GO:0048788~cytoskeleton of presynaptic active zone,	GO:0005515~protein binding,GO:0030165~PDZ domain binding,GO:0031267~small GTPase binding,GO:0045296~cadherin binding,GO:0098882~structural constituent of presynaptic active zone,	IPR019018:Rab-binding domain FIP-RBD,IPR019323:CAZ complex, RIM-binding protein,	hsa04064:NF-kappa B signaling pathway,				KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FIP-RBD,REGION:Disordered,SITE:Breakpoint for translocation to form ERC1-RET oncogene,
EHF	ETS homologous factor(EHF)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0030154~cell differentiation,GO:0030855~epithelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050673~epithelial cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,				SM00251:SAM_PNT,SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		DNA_BIND:ETS,DOMAIN:PNT,REGION:Disordered,
ETV2	ETS variant transcription factor 2(ETV2)	Homo sapiens			GO:0001707~mesoderm formation,GO:0001824~blastocyst development,GO:0001890~placenta development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0030154~cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030509~BMP signaling pathway,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048514~blood vessel morphogenesis,GO:0060803~BMP signaling pathway involved in mesodermal cell fate specification,GO:2000382~positive regulation of mesoderm development,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,				SM00413:ETS,		KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:ETS,REGION:Disordered,
EYA4	EYA transcriptional coactivator and phosphatase 4(EYA4)	Homo sapiens			GO:0006281~DNA repair,GO:0006325~chromatin organization,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0009653~anatomical structure morphogenesis,GO:0016576~histone dephosphorylation,GO:0030154~cell differentiation,GO:0045739~positive regulation of DNA repair,GO:0048839~inner ear development,GO:0048856~anatomical structure development,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR006545:EYA,		601316~Deafness, autosomal dominant 10,605362~Cardiomyopathy, dilated, 1J,			KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0378~Hydrolase,KW-0904~Protein phosphatase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
FBXO39	F-box protein 39(FBXO39)	Homo sapiens			GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,	GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,	IPR001611:Leucine-rich repeat,IPR001810:F-box domain, cyclin-like,					KW-0833~Ubl conjugation pathway,							DOMAIN:F-box,
FBXO47	F-box protein 47(FBXO47)	Homo sapiens						IPR001810:F-box domain, cyclin-like,					KW-0833~Ubl conjugation pathway,							DOMAIN:F-box,
FBXO6	F-box protein 6(FBXO6)	Homo sapiens			GO:0000077~DNA damage checkpoint,GO:0006281~DNA repair,GO:0006508~proteolysis,GO:0006516~glycoprotein catabolic process,GO:0006986~response to unfolded protein,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0044267~cellular protein metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0061630~ubiquitin protein ligase activity,	IPR001810:F-box domain, cyclin-like,IPR007397:F-box associated (FBA) domain,IPR008979:Galactose-binding domain-like,	hsa04141:Protein processing in endoplasmic reticulum,			SM00256:FBOX,SM01198:SM01198,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0834~Unfolded protein response,	KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:F-box,DOMAIN:FBA,MUTAGEN:YW->AA: Abolishes interaction with glycosylated concanavalin-A in vitro.,REGION:Disordered,
F2RL3	F2R like thrombin or trypsin receptor 3(F2RL3)	Homo sapiens		h_par1pathway:Thrombin signaling and protease-activated receptors,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,	GO:0007165~signal transduction,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007596~blood coagulation,GO:0009611~response to wounding,GO:0030168~platelet activation,GO:0035025~positive regulation of Rho protein signal transduction,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0060155~platelet dense granule organization,GO:0070493~thrombin-activated receptor signaling pathway,GO:0070527~platelet aggregation,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0002020~protease binding,GO:0004930~G-protein coupled receptor activity,GO:0015057~thrombin-activated receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR003912:Protease-activated receptor,IPR003944:Protease-activated receptor 4,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04015:Rap1 signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04610:Complement and coagulation cascades,hsa04611:Platelet activation,hsa05200:Pathways in cancer,				KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,MUTAGEN:R->A: No effect on receptor activation.,MUTAGEN:R->A: No proteolytic cleavage (by thrombin or trypsin).,PROPEP:Removed for receptor activation,REGION:Disordered,SITE:Cleavage; by thrombin or trypsin,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FES	FES proto-oncogene, tyrosine kinase(FES)	Homo sapiens			GO:0001578~microtubule bundle formation,GO:0006468~protein phosphorylation,GO:0006935~chemotaxis,GO:0007098~centrosome cycle,GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0008360~regulation of cell shape,GO:0010976~positive regulation of neuron projection development,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030154~cell differentiation,GO:0030155~regulation of cell adhesion,GO:0031116~positive regulation of microtubule polymerization,GO:0042127~regulation of cell proliferation,GO:0043304~regulation of mast cell degranulation,GO:0045087~innate immune response,GO:0045595~regulation of cell differentiation,GO:0045639~positive regulation of myeloid cell differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0046777~protein autophosphorylation,GO:0051450~myoblast proliferation,GO:0060038~cardiac muscle cell proliferation,GO:0060627~regulation of vesicle-mediated transport,GO:0071305~cellular response to vitamin D,GO:2000145~regulation of cell motility,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009898~cytoplasmic side of plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0016021~integral component of membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031410~cytoplasmic vesicle,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008289~lipid binding,GO:0034987~immunoglobulin receptor binding,GO:0035091~phosphatidylinositol binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001060:FCH domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR016250:Tyrosine-protein kinase, non-receptor Fes, subgroup,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa04360:Axon guidance,		PIRSF000632:tyrosine-protein kinase, Fes/Fps type,	SM00055:FCH,SM00219:TyrKc,SM00252:SH2,		KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0727~SH2 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:F-BAR,DOMAIN:FCH,DOMAIN:Protein kinase,DOMAIN:SH2,MUTAGEN:G->V: Abolishes kinase activity.,MUTAGEN:K->E: Abolishes kinase activity. Fails to inhibit proliferation of melanoma cells.,MUTAGEN:L->P: Abolishes autophosphorylation.,MUTAGEN:L->P: Constitutively activated kinase that can act as oncogene. Promotes myeloid cell survival and proliferation.,MUTAGEN:M->V: Reduced autophosphorylation and strongly reduced kinase activity.,MUTAGEN:R->M: Abolishes pTyr binding. Abolishes association with microtubules. Abolishes autophosphorylation. Reduced kinase activity.,MUTAGEN:R->Q: Negligible effect on autophosphorylation and kinase activity.,MUTAGEN:RK->EE: Reduced binding to membranes containing phosphoinositides.,MUTAGEN:RK->QQ: Reduced binding to membranes containing phosphoinositides.,MUTAGEN:S->F: Reduced autophosphorylation and strongly reduced kinase activity.,MUTAGEN:V->M: Strongly reduced autophosphorylation and kinase activity.,MUTAGEN:Y->F: Reduces kinase activity by over 90%.,REGION:Disordered,REGION:Important for interaction with membranes containing phosphoinositides,TRANSMEM:Helical,
FEZF2	FEZ family zinc finger 2(FEZF2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007413~axonal fasciculation,GO:0007626~locomotory behavior,GO:0008285~negative regulation of cell proliferation,GO:0010468~regulation of gene expression,GO:0016358~dendrite development,GO:0021542~dentate gyrus development,GO:0021797~forebrain anterior/posterior pattern specification,GO:0021853~cerebral cortex GABAergic interneuron migration,GO:0021902~commitment of neuronal cell to specific neuron type in forebrain,GO:0043697~cell dedifferentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048664~neuron fate determination,GO:0050767~regulation of neurogenesis,GO:1902667~regulation of axon guidance,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		DOMAIN:C2H2-type,MOTIF:Engrailed homology 1 repressor,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
FKBP1A	FKBP prolyl isomerase 1A(FKBP1A)	Homo sapiens		h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),	GO:0000413~protein peptidyl-prolyl isomerization,GO:0003007~heart morphogenesis,GO:0006457~protein folding,GO:0006458~'de novo' protein folding,GO:0007183~SMAD protein complex assembly,GO:0022417~protein maturation by protein folding,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031398~positive regulation of protein ubiquitination,GO:0032092~positive regulation of protein binding,GO:0032515~negative regulation of phosphoprotein phosphatase activity,GO:0032880~regulation of protein localization,GO:0032925~regulation of activin receptor signaling pathway,GO:0032926~negative regulation of activin receptor signaling pathway,GO:0042026~protein refolding,GO:0042110~T cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0050776~regulation of immune response,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060314~regulation of ryanodine-sensitive calcium-release channel activity,GO:0060347~heart trabecula formation,GO:0061077~chaperone-mediated protein folding,GO:0070588~calcium ion transmembrane transport,GO:0097435~supramolecular fiber organization,GO:1902991~regulation of amyloid precursor protein catabolic process,GO:1990000~amyloid fibril formation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014802~terminal cisterna,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0031312~extrinsic component of organelle membrane,GO:0033017~sarcoplasmic reticulum membrane,GO:0098562~cytoplasmic side of membrane,GO:1990425~ryanodine receptor complex,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0005527~macrolide binding,GO:0005528~FK506 binding,GO:0030547~receptor inhibitor activity,GO:0034713~type I transforming growth factor beta receptor binding,GO:0044325~ion channel binding,GO:0046332~SMAD binding,GO:0048185~activin binding,GO:0070411~I-SMAD binding,GO:0070697~activin receptor binding,	IPR001179:Peptidyl-prolyl cis-trans isomerase, FKBP-type, domain,						KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,	DOMAIN:PPIase FKBP-type,REGION:Disordered,TRANSMEM:Helical,
FASTK	Fas activated serine/threonine kinase(FASTK)	Homo sapiens			GO:0000963~mitochondrial RNA processing,GO:0006468~protein phosphorylation,GO:0043484~regulation of RNA splicing,GO:0044528~regulation of mitochondrial mRNA stability,GO:0097190~apoptotic signaling pathway,	GO:0005759~mitochondrial matrix,GO:0035770~ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0033867~Fas-activated serine/threonine kinase activity,	IPR010622:FAST kinase leucine-rich,IPR013579:FAST kinase-like protein, subdomain 2,IPR013584:RAP domain,IPR015715:Fas activated serine/threonine kinase FAST,				SM00952:SM00952,	KW-0053~Apoptosis,	KW-0496~Mitochondrion,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0694~RNA-binding,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:FAST kinase leucine-rich,DOMAIN:FAST kinase-like protein subdomain 2,DOMAIN:RAP,MUTAGEN:M->G: Abolishes isoform 4 expression.,REGION:Disordered,
FADD	Fas associated via death domain(FADD)	Homo sapiens	150.caspase_and_NFKB_activation,39.Deg_of_Chromosomal_DNA,40.Deg_of_Chrom_DNA_TNF-ind_apoptosis,44.Sig_Trans_TNFR1-DR3-DR4_DR5,46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,86.Apoptosis_Nematode&_Vert,99.NF-kB_activation,	h_ceramidePathway:Ceramide Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_nfkbPathway:NF-kB Signaling Pathway,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_soddPathway:SODD/TNFR1 Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0001822~kidney development,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002821~positive regulation of adaptive immune response,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0032729~positive regulation of interferon-gamma production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033077~T cell differentiation in thymus,GO:0036462~TRAIL-activated apoptotic signaling pathway,GO:0042104~positive regulation of activated T cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043278~response to morphine,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0045651~positive regulation of macrophage differentiation,GO:0045862~positive regulation of proteolysis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048148~behavioral response to cocaine,GO:0048535~lymph node development,GO:0048536~spleen development,GO:0048538~thymus development,GO:0051607~defense response to virus,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:0060546~negative regulation of necroptotic process,GO:0070236~negative regulation of activation-induced cell death of T cells,GO:0071260~cellular response to mechanical stimulus,GO:0071550~death-inducing signaling complex assembly,GO:0097049~motor neuron apoptotic process,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0097527~necroptotic signaling pathway,GO:2000454~positive regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0043005~neuron projection,GO:0044297~cell body,GO:0045121~membrane raft,GO:0097342~ripoptosome,	GO:0002020~protease binding,GO:0005123~death receptor binding,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0032813~tumor necrosis factor receptor superfamily binding,GO:0033612~receptor serine/threonine kinase binding,GO:0035877~death effector domain binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0060090~binding, bridging,GO:0089720~caspase binding,	IPR000488:Death domain,IPR001875:Death effector domain,IPR011029:Death-like domain,IPR016729:FADD,	hsa01524:Platinum drug resistance,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05142:Chagas disease,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	613759~Immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction,	PIRSF018586:FADD protein,	SM00005:DEATH,SM00031:DED,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,		KW-0225~Disease variant,				KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,DOMAIN:DED,DOMAIN:Death,MUTAGEN:D->K: Strongly decreased interaction with FAS.,MUTAGEN:D->R: Loss of interaction with CASP8. Abolishes induction of apoptosis. Decreased interaction with FAS.,MUTAGEN:D->R: Strongly decreased interaction with FAS.,MUTAGEN:E->R: Loss of interaction with CASP8.,MUTAGEN:F->R: Loss of interaction with FAS. Loss of self-association. Abolishes induction of apoptosis.,MUTAGEN:K->E: Loss of self-association.,MUTAGEN:L->A,E: Loss of interaction with FAS.,MUTAGEN:L->E: Decreased interaction with FAS.,MUTAGEN:L->K: Strongly decreased interaction with FAS.,MUTAGEN:R->A: Abolished GlcNAcylation by E.coli NleB1.,MUTAGEN:R->A: Loss of interaction with CASP8.,MUTAGEN:R->E: Decreased interaction with FAS.,MUTAGEN:R->E: Loss of interaction with FAS.,MUTAGEN:R->E: Strongly decreased interaction with FAS.,MUTAGEN:S->R: Loss of interaction with CASP8.,MUTAGEN:V->N: Loss of interaction with FAS.,REGION:Disordered,
FCGRT	Fc gamma receptor and transporter(FCGRT)	Homo sapiens			GO:0002416~IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor,GO:0006955~immune response,	GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0019864~IgG binding,GO:0030881~beta-2-microglobulin binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,		KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC class I-like antigen recognition-like,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCRL1	Fc receptor like 1(FCRL1)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0042113~B cell activation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,	GO:0004888~transmembrane signaling receptor activity,GO:0015026~coreceptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,MOTIF:ITIM motif 4,MOTIF:ITIM motif 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCRL3	Fc receptor like 3(FCRL3)	Homo sapiens			GO:0002638~negative regulation of immunoglobulin production,GO:0007166~cell surface receptor signaling pathway,GO:0007338~single fertilization,GO:0030890~positive regulation of B cell proliferation,GO:0034163~regulation of toll-like receptor 9 signaling pathway,GO:0043410~positive regulation of MAPK cascade,GO:0045577~regulation of B cell differentiation,GO:0050859~negative regulation of B cell receptor signaling pathway,GO:0050864~regulation of B cell activation,GO:0090279~regulation of calcium ion import,GO:1905184~positive regulation of protein serine/threonine phosphatase activity,	GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031528~microvillus membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0019900~kinase binding,GO:0019902~phosphatase binding,GO:0019903~protein phosphatase binding,GO:1990782~protein tyrosine kinase binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0278~Fertilization,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,MOTIF:ITIM motif 4,MUTAGEN:Y->F: No effect on inhibition of cell death. No effect on interaction with INPP5D, PTPN6 and PTPN11. Loss of phosphorylation, calcium influx inhibition and interaction with INPP5D, PTPN6 and PTPN11; when associated with F-650; F-662 and F-692. Alters binding with PTPN6 and PTPN11; when associated with F-692. Decreases calcium influx inhibition; when associated with F-650 and F-662. Decreases calcium influx inhibition; when associated with F-650 and F-692. Decreases calcium influx inhibition; when associated with F-692.,MUTAGEN:Y->F: No effect on inhibition of cell death. No effect on interaction with INPP5D, PTPN6 and PTPN11. Loss of phosphorylation, calcium influx inhibition and interaction with INPP5D, PTPN6 and PTPN11; when associated with F-662; F-692 and F-722. Alters binding with SYK and ZAP70; when associated with F-662. Decreases calcium influx inhibition; when associated with F-662 and F-722. Decreases calcium influx inhibition; when associated with F-692 and F-722.,MUTAGEN:Y->F: Partially reduces inhibition of cell death. Decreases interaction with INPP5D and PTPN11. No effect on interaction with PTPN6. Loss of phosphorylation, calcium influx inhibition and interaction with INPP5D, PTPN6 and PTPN11; when associated with F-650; F-662 and F-722. Alters binding with PTPN6 and PTPN11; when associated with F-772. Decreases calcium influx inhibition; when associated with F-650 and F-722. Increases calcium influx inhibition; when associated with F-650 and F-662. Decreases calcium influx inhibition; when associated with F-722.,MUTAGEN:Y->F: Reduces inhibition of cell death. Decreases interaction with INPP5D and PTPN6. No effect on interaction with PTPN11. Loss of phosphorylation, calcium influx inhibition and interaction with INPP5D, PTPN6 and PTPN11; when associated with F-650; F-692 and F-722. Alters binding with SYK and ZAP70; when associated with F-650. Decreases calcium influx inhibition; when associated with F-650 and F-722. Increases calcium influx inhibition; when associated with F-650 and F-722.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCRL6	Fc receptor like 6(FCRL6)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:0019903~protein phosphatase binding,GO:0042289~MHC class II protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,MOTIF:ITIM motif,MUTAGEN:Y->F: Loss of phosphorylation implicated in interaction with PTPN11. Loss of interaction with PTPN11, PTPN6 and INPPL1.,MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN11. Loss of interaction with INPPD5, INPPL1 and GRB2.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FLI1	Fli-1 proto-oncogene, ETS transcription factor(FLI1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007599~hemostasis,GO:0008015~blood circulation,GO:0009887~animal organ morphogenesis,GO:0030154~cell differentiation,GO:0035855~megakaryocyte development,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,	hsa05202:Transcriptional misregulation in cancer,	617443~Bleeding disorder, platelet-type, 21,		SM00251:SAM_PNT,SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:PNT,REGION:Disordered,
GNA13	G protein subunit alpha 13(GNA13)	Homo sapiens		h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_par1pathway:Thrombin signaling and protease-activated receptors,	GO:0001569~branching involved in blood vessel morphogenesis,GO:0001701~in utero embryonic development,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007266~Rho protein signal transduction,GO:0008217~regulation of blood pressure,GO:0008360~regulation of cell shape,GO:0010259~multicellular organism aging,GO:0010762~regulation of fibroblast migration,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0031584~activation of phospholipase D activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0031526~brush border membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031752~D5 dopamine receptor binding,GO:0046872~metal ion binding,	IPR000469:G-protein alpha subunit, group 12,IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04022:cGMP-PKG signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04611:Platelet activation,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05130:Pathogenic Escherichia coli infection,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,			SM00275:SM00275,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:G-alpha,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Fails to localize to plasma membranes and failed to activate Rho-dependent serum response factor-mediated transcription and actin stress fiber formation.,MUTAGEN:T->A: Abolishes phosphorylation by PKA; disrupts heterotrimer stability.,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNG4	G protein subunit gamma 4(GNG4)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0030308~negative regulation of cell growth,	GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031681~G-protein beta-subunit binding,	IPR001770:G-protein, gamma subunit,IPR015898:G-protein gamma-like domain,	hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,			SM00224:GGL,		KW-0472~Membrane,KW-1003~Cell membrane,				KW-0807~Transducer,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	DOMAIN:G protein gamma,LIPID:S-geranylgeranyl cysteine,PROPEP:Removed in mature form,
GNG7	G protein subunit gamma 7(GNG7)	Homo sapiens			GO:0001662~behavioral fear response,GO:0007168~receptor guanylyl cyclase signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007626~locomotory behavior,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,	GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031681~G-protein beta-subunit binding,	IPR001770:G-protein, gamma subunit,IPR015898:G-protein gamma-like domain,	hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04740:Olfactory transduction,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,			SM00224:GGL,		KW-0472~Membrane,KW-1003~Cell membrane,				KW-0807~Transducer,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	DOMAIN:G protein gamma,LIPID:S-geranylgeranyl cysteine,PROPEP:Removed in mature form,
GPBAR1	G protein-coupled bile acid receptor 1(GPBAR1)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0038184~cell surface bile acid receptor signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1903413~cellular response to bile acid,GO:1904056~positive regulation of cholangiocyte proliferation,GO:2000810~regulation of bicellular tight junction assembly,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0038181~bile acid receptor activity,GO:0038182~G-protein coupled bile acid receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR75	G protein-coupled receptor 75(GPR75)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0070098~chemokine-mediated signaling pathway,GO:1901214~regulation of neuron death,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0004930~G-protein coupled receptor activity,GO:0016493~C-C chemokine receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPRC5C	G protein-coupled receptor class C group 5 member C(GPRC5C)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031982~vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,GO:0070062~extracellular exosome,	GO:0004930~G-protein coupled receptor activity,GO:0030295~protein kinase activator activity,	IPR017978:GPCR, family 3, C-terminal,						KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G-protein coupled receptors family 3 profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GSPT1	G1 to S phase transition 1(GSPT1)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0002184~cytoplasmic translational termination,GO:0006412~translation,GO:0006415~translational termination,GO:0006449~regulation of translational termination,GO:0006479~protein methylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0018444~translation release factor complex,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003747~translation release factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR000795:Elongation factor, GTP-binding domain,IPR004160:Translation elongation factor EFTu/EF1A, C-terminal,IPR004161:Translation elongation factor EFTu/EF1A, domain 2,IPR009000:Translation elongation/initiation factor/Ribosomal, beta-barrel,IPR009001:Translation elongation factor EF1A/initiation factor IF2gamma, C-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03015:mRNA surveillance pathway,				KW-0648~Protein biosynthesis,KW-0866~Nonsense-mediated mRNA decay,				KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Tr-type G,DOMAIN:tr-type G,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
GABARAP	GABA type A receptor-associated protein(GABARAP)	Homo sapiens		h_gabaPathway:Gamma-aminobutyric Acid Receptor Life Cycle,	GO:0000045~autophagosome assembly,GO:0000226~microtubule cytoskeleton organization,GO:0000422~mitophagy,GO:0006605~protein targeting,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0007268~chemical synaptic transmission,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0016236~macroautophagy,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035020~regulation of Rac protein signal transduction,GO:1902524~positive regulation of protein K48-linked ubiquitination,	GO:0000139~Golgi membrane,GO:0000421~autophagosome membrane,GO:0005764~lysosome,GO:0005776~autophagosome,GO:0005790~smooth endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0045202~synapse,GO:0097225~sperm midpiece,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,GO:0048487~beta-tubulin binding,GO:0050811~GABA receptor binding,	IPR004241:Autophagy protein Atg8 ubiquitin-like,	hsa04068:FoxO signaling pathway,hsa04136:Autophagy - other,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04621:NOD-like receptor signaling pathway,hsa04727:GABAergic synapse,				KW-0053~Apoptosis,KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,				KW-0675~Receptor,	KW-0449~Lipoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:D->H: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with Q-24 and H-25.,MUTAGEN:G->A: Impairs localization at the autophagosomal membrane.,MUTAGEN:K->Q: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with H-25 and H-54.,MUTAGEN:R->A: No effect on interaction with TECPR2.,MUTAGEN:Y->H: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with Q-24 and H-54.,MUTAGEN:YL->AA: Inhibits interaction with TECPR2.,PROPEP:Removed in mature form,REGION:Disordered,REGION:Interaction with GABRG2,REGION:Interaction with GPHN,REGION:Interaction with beta-tubulin,SITE:Cleavage; by ATG4B,
GATA4	GATA binding protein 4(GATA4)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_hopPathway:Hop Pathway in Cardiac Development,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001947~heart looping,GO:0003162~atrioventricular node development,GO:0003180~aortic valve morphogenesis,GO:0003190~atrioventricular valve formation,GO:0003197~endocardial cushion development,GO:0003208~cardiac ventricle morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003281~ventricular septum development,GO:0003289~atrial septum primum morphogenesis,GO:0003290~atrial septum secundum morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007267~cell-cell signaling,GO:0007492~endoderm development,GO:0007507~heart development,GO:0007596~blood coagulation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009653~anatomical structure morphogenesis,GO:0010507~negative regulation of autophagy,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0030154~cell differentiation,GO:0030513~positive regulation of BMP signaling pathway,GO:0033189~response to vitamin A,GO:0035054~embryonic heart tube anterior/posterior pattern specification,GO:0036302~atrioventricular canal development,GO:0042060~wound healing,GO:0045165~cell fate commitment,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048513~animal organ development,GO:0048617~embryonic foregut morphogenesis,GO:0051891~positive regulation of cardioblast differentiation,GO:0051896~regulation of protein kinase B signaling,GO:0060290~transdifferentiation,GO:0060413~atrial septum morphogenesis,GO:0060575~intestinal epithelial cell differentiation,GO:0061026~cardiac muscle tissue regeneration,GO:0061049~cell growth involved in cardiac muscle cell development,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071333~cellular response to glucose stimulus,GO:0086004~regulation of cardiac muscle cell contraction,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903202~negative regulation of oxidative stress-induced cell death,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0043565~sequence-specific DNA binding,GO:0051525~NFAT protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070410~co-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Zinc finger, GATA-type,IPR008013:GATA-type transcription activator, N-terminal,IPR013088:Zinc finger, NHR/GATA-type,IPR016375:Transcription factor GATA-4/5/6,	hsa04022:cGMP-PKG signaling pathway,hsa04218:Cellular senescence,hsa04530:Tight junction,hsa04919:Thyroid hormone signaling pathway,	187500~Tetralogy of Fallot,607941~Atrial septal defect 2,614429~Ventricular septal defect 1,614430~Atrioventricular septal defect 4,615542~Testicular anomalies with or without congenital heart disease,	PIRSF003028:transcription factor GATA-4/5/6 types,	SM00401:ZnF_GATA,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0976~Atrial septal defect,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,	COMPBIAS:Polar residues,DOMAIN:GATA-type,DOMAIN:GATA-type transcription activator N-terminal,REGION:Disordered,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GATAD2B	GATA zinc finger domain containing 2B(GATAD2B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0016575~histone deacetylation,GO:0042659~regulation of cell fate specification,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:2000736~regulation of stem cell differentiation,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016581~NuRD complex,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031492~nucleosomal DNA binding,GO:0043565~sequence-specific DNA binding,	IPR000679:Zinc finger, GATA-type,IPR013088:Zinc finger, NHR/GATA-type,	hsa03082:ATP-dependent chromatin remodeling,	615074~GAND syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GATA-type,DOMAIN:Transcriptional repressor p66 coiled-coil MBD2-interaction,REGION:CR1; interaction with MBD2 and MBD3,REGION:CR2; histone tail-binding,REGION:Disordered,ZN_FING:GATA-type,
GIT1	GIT ArfGAP 1(GIT1)	Homo sapiens			GO:0001957~intramembranous ossification,GO:0007420~brain development,GO:0007626~locomotory behavior,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010646~regulation of cell communication,GO:0023051~regulation of signaling,GO:0032012~regulation of ARF protein signal transduction,GO:0032465~regulation of cytokinesis,GO:0032691~negative regulation of interleukin-1 beta production,GO:0036465~synaptic vesicle recycling,GO:0045454~cell redox homeostasis,GO:0045820~negative regulation of glycolytic process,GO:0048013~ephrin receptor signaling pathway,GO:0048666~neuron development,GO:0061743~motor learning,GO:0071222~cellular response to lipopolysaccharide,GO:0090063~positive regulation of microtubule nucleation,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0043005~neuron projection,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0097431~mitotic spindle pole,GO:0098794~postsynapse,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,GO:0043015~gamma-tubulin binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR001164:Arf GTPase activating protein,IPR002110:Ankyrin repeat,IPR013724:Spa2 homology (SHD) of GIT,IPR022018:G protein-coupled receptor kinase-interacting protein 1 C term,	hsa04144:Endocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,			SM00105:ArfGap,SM00248:ANK,SM00555:GIT,		KW-0206~Cytoskeleton,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:ARF GTPase-activating protein GIT1 C-terminal,DOMAIN:Arf-GAP,DOMAIN:GIT Spa2 homology (SHD),MUTAGEN:R->A: When transfected to cells, increased number of multinucleated cells.,REGION:Disordered,REGION:Interaction with ARHGEF7,REGION:Interaction with IKBKG,REGION:Interaction with MAPK1,REGION:Interaction with NCK2 and GRIN3A,REGION:Interaction with PCLO,REGION:Interaction with PTK2/FAK1,REGION:Interaction with PXN and TGFB1I1,REGION:Interaction with gamma-tubulin and localization to the centrosome,REGION:Required for localization at synapses,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,ZN_FING:C4-type,
GLI2	GLI family zinc finger 2(GLI2)	Homo sapiens		h_shhPathway:Sonic Hedgehog (Shh) Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001822~kidney development,GO:0002062~chondrocyte differentiation,GO:0002076~osteoblast development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007389~pattern specification process,GO:0007411~axon guidance,GO:0007418~ventral midline development,GO:0007442~hindgut morphogenesis,GO:0007507~heart development,GO:0009913~epidermal cell differentiation,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0021508~floor plate formation,GO:0021513~spinal cord dorsal/ventral patterning,GO:0021517~ventral spinal cord development,GO:0021696~cerebellar cortex morphogenesis,GO:0021775~smoothened signaling pathway involved in ventral spinal cord interneuron specification,GO:0021776~smoothened signaling pathway involved in spinal cord motor neuron cell fate specification,GO:0021938~smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation,GO:0021965~spinal cord ventral commissure morphogenesis,GO:0021983~pituitary gland development,GO:0030324~lung development,GO:0030879~mammary gland development,GO:0030902~hindbrain development,GO:0031069~hair follicle morphogenesis,GO:0032331~negative regulation of chondrocyte differentiation,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0035295~tube development,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0045666~positive regulation of neuron differentiation,GO:0045740~positive regulation of DNA replication,GO:0045879~negative regulation of smoothened signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048566~embryonic digestive tract development,GO:0048589~developmental growth,GO:0048666~neuron development,GO:0048754~branching morphogenesis of an epithelial tube,GO:0060032~notochord regression,GO:0060513~prostatic bud formation,GO:0060603~mammary gland duct morphogenesis,GO:0060831~smoothened signaling pathway involved in dorsal/ventral neural tube patterning,GO:0071407~cellular response to organic cyclic compound,GO:0090103~cochlea morphogenesis,GO:0098586~cellular response to virus,GO:1901620~regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005929~cilium,GO:0005930~axoneme,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031514~motile cilium,GO:0097542~ciliary tip,GO:0097546~ciliary base,GO:1990788~GLI-SUFU complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa05200:Pathways in cancer,hsa05217:Basal cell carcinoma,	610829~Holoprosencephaly 9,615849~Culler-Jones syndrome,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
GLI3	GLI family zinc finger 3(GLI3)	Homo sapiens		h_shhPathway:Sonic Hedgehog (Shh) Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001701~in utero embryonic development,GO:0002052~positive regulation of neuroblast proliferation,GO:0002062~chondrocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0007224~smoothened signaling pathway,GO:0007405~neuroblast proliferation,GO:0007411~axon guidance,GO:0007442~hindgut morphogenesis,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0009954~proximal/distal pattern formation,GO:0016485~protein processing,GO:0021631~optic nerve morphogenesis,GO:0021766~hippocampus development,GO:0021775~smoothened signaling pathway involved in ventral spinal cord interneuron specification,GO:0021776~smoothened signaling pathway involved in spinal cord motor neuron cell fate specification,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021819~layer formation in cerebral cortex,GO:0021861~forebrain radial glial cell differentiation,GO:0022018~lateral ganglionic eminence cell proliferation,GO:0030318~melanocyte differentiation,GO:0030324~lung development,GO:0030850~prostate gland development,GO:0032331~negative regulation of chondrocyte differentiation,GO:0032332~positive regulation of chondrocyte differentiation,GO:0033077~T cell differentiation in thymus,GO:0035108~limb morphogenesis,GO:0042060~wound healing,GO:0042307~positive regulation of protein import into nucleus,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043585~nose morphogenesis,GO:0043586~tongue development,GO:0043627~response to estrogen,GO:0045060~negative thymic T cell selection,GO:0045665~negative regulation of neuron differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045879~negative regulation of smoothened signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046632~alpha-beta T cell differentiation,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0046639~negative regulation of alpha-beta T cell differentiation,GO:0048557~embryonic digestive tract morphogenesis,GO:0048566~embryonic digestive tract development,GO:0048568~embryonic organ development,GO:0048589~developmental growth,GO:0048593~camera-type eye morphogenesis,GO:0048702~embryonic neurocranium morphogenesis,GO:0048709~oligodendrocyte differentiation,GO:0060021~palate development,GO:0060364~frontal suture morphogenesis,GO:0060366~lambdoid suture morphogenesis,GO:0060367~sagittal suture morphogenesis,GO:0060594~mammary gland specification,GO:0060831~smoothened signaling pathway involved in dorsal/ventral neural tube patterning,GO:0060840~artery development,GO:0060873~anterior semicircular canal development,GO:0060875~lateral semicircular canal development,GO:0061005~cell differentiation involved in kidney development,GO:0070242~thymocyte apoptotic process,GO:0071625~vocalization behavior,GO:0072089~stem cell proliferation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0097421~liver regeneration,GO:1901620~regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning,GO:1903010~regulation of bone development,GO:1990787~negative regulation of hh target transcription factor activity,GO:2000647~negative regulation of stem cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005929~cilium,GO:0005930~axoneme,GO:0016607~nuclear speck,GO:0017053~transcriptional repressor complex,GO:0043231~intracellular membrane-bounded organelle,GO:0097542~ciliary tip,GO:0097546~ciliary base,GO:1990788~GLI-SUFU complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0035035~histone acetyltransferase binding,GO:0036033~mediator complex binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04024:cAMP signaling pathway,hsa04340:Hedgehog signaling pathway,hsa05200:Pathways in cancer,hsa05217:Basal cell carcinoma,	146510~Pallister-Hall syndrome,174200~Polydactyly, postaxial, types A1 and B,174700~Polydactyly, preaxial, type IV,175700~Greig cephalopolysyndactyly syndrome,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:C2H2-type,MUTAGEN:K->R: Loss of proteolytic processing.,MUTAGEN:S->A: Loss of phosphorylation and proteolytic processing.,MUTAGEN:S->A: Loss of proteolytic processing.,REGION:Disordered,REGION:Mediates interaction with DZIP1,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
HLX	H2.0 like homeobox(HLX)	Homo sapiens			GO:0001889~liver development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0007275~multicellular organism development,GO:0007519~skeletal muscle tissue development,GO:0008284~positive regulation of cell proliferation,GO:0030154~cell differentiation,GO:0035265~organ growth,GO:0045063~T-helper 1 cell differentiation,GO:0045064~T-helper 2 cell differentiation,GO:0045627~positive regulation of T-helper 1 cell differentiation,GO:0045629~negative regulation of T-helper 2 cell differentiation,GO:0046622~positive regulation of organ growth,GO:0048484~enteric nervous system development,GO:0048557~embryonic digestive tract morphogenesis,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HCK	HCK proto-oncogene, Src family tyrosine kinase(HCK)	Homo sapiens		h_bArrestin-srcPathway:Roles of -arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_vifPathway:HIV-1 defeats host-mediated resistance by CEM15,	GO:0002522~leukocyte migration involved in immune response,GO:0002758~innate immune response-activating signal transduction,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007498~mesoderm development,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030838~positive regulation of actin filament polymerization,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032956~regulation of actin cytoskeleton organization,GO:0035556~intracellular signal transduction,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0043066~negative regulation of apoptotic process,GO:0043299~leukocyte degranulation,GO:0045087~innate immune response,GO:0045728~respiratory burst after phagocytosis,GO:0046777~protein autophosphorylation,GO:0050727~regulation of inflammatory response,GO:0050764~regulation of phagocytosis,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051179~localization,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0071801~regulation of podosome assembly,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0005925~focal adhesion,GO:0009898~cytoplasmic side of plasma membrane,GO:0030133~transport vesicle,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,	GO:0001784~phosphotyrosine binding,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008289~lipid binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04062:Chemokine signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,	620296~Autoinflammation with pulmonary and cutaneous vasculitis,		SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0268~Exocytosis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0581~Phagocytosis,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Palmitoylation is abolished, some cytoplasmic and no calveolar localization; in isoform 2.,MUTAGEN:D->E: Loss of kinase activity.,MUTAGEN:E->A: Loss of kinase activity.,MUTAGEN:G->A: Myristoylation and palmitoylation are abolished, leading to entirely cytoplasmic localization; in isoform 2.,MUTAGEN:G->C: Slight palmitoylation, cytoplasmic and caveolar localization; in isoform 1;.,MUTAGEN:G->S: Abolishes palmitoylation and localization at the cell membrane.,MUTAGEN:K->E: Loss of kinase activity.,MUTAGEN:Y->A: Reduced catalytic activity and higher affinity for target peptides.,MUTAGEN:Y->F: Constitutively activated kinase, leading to cellular transformation.,REGION:Disordered,
HEATR3	HEAT repeat containing 3(HEATR3)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0042273~ribosomal large subunit biogenesis,GO:0043249~erythrocyte maturation,		GO:0051082~unfolded protein binding,	IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,		620072~Diamond-Blackfan anemia 21,			KW-0265~Erythrocyte maturation,KW-0690~Ribosome biogenesis,		KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,	KW-0677~Repeat,			KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 2,
HNF1A	HNF1 homeobox A(HNF1A)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_ghPathway:Growth Hormone Signaling Pathway,h_hesPathway:Segmentation Clock,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,h_wntPathway:WNT Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001824~blastocyst development,GO:0001889~liver development,GO:0001890~placenta development,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006633~fatty acid biosynthetic process,GO:0006699~bile acid biosynthetic process,GO:0006783~heme biosynthetic process,GO:0006979~response to oxidative stress,GO:0008203~cholesterol metabolic process,GO:0009749~response to glucose,GO:0015721~bile acid and bile salt transport,GO:0015908~fatty acid transport,GO:0016573~histone acetylation,GO:0030073~insulin secretion,GO:0030111~regulation of Wnt signaling pathway,GO:0030326~embryonic limb morphogenesis,GO:0031016~pancreas development,GO:0031018~endocrine pancreas development,GO:0035623~renal glucose absorption,GO:0042593~glucose homeostasis,GO:0043691~reverse cholesterol transport,GO:0045453~bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046323~glucose import,GO:0046883~regulation of hormone secretion,GO:0048341~paraxial mesoderm formation,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0060395~SMAD protein signal transduction,	GO:0000785~chromatin,GO:0001750~photoreceptor outer segment,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,GO:0045120~pronucleus,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,	IPR001356:Homeodomain,IPR006897:Hepatocyte nuclear factor 1, beta isoform, C-terminal,IPR006898:Hepatocyte nuclear factor 1, alpha isoform C-terminal,IPR006899:Hepatocyte nuclear factor 1, N-terminal,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR023219:Hepatocyte nuclear factor 1, dimerisation domain,	hsa04950:Maturity onset diabetes of the young,	125853~Diabetes mellitus, noninsulin-dependent, 2,142330~Hepatic adenoma, somatic,144700~Renal cell carcinoma,222100~Diabetes mellitus, insulin-dependent,600496~MODY, type III,612520~Diabetes mellitus, insulin-dependent, 20,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DNA_BIND:Homeobox; HNF1-type,DOMAIN:HNF-p1,DOMAIN:Hepatocyte nuclear factor 1 alpha isoform C-terminal,DOMAIN:Hepatocyte nuclear factor 1 beta isoform C-terminal,DOMAIN:Homeobox,DOMAIN:POU-specific atypical,MOTIF:Nuclear localization signal,MUTAGEN:E->K: Abolishes transcription activation.,MUTAGEN:F->S: No significant effect on transcription activation.,MUTAGEN:I->Q: No effect on transcription activation.,MUTAGEN:N->D: Reduces transcription activation by 70%.,MUTAGEN:N->W: Abolishes transcription activation.,MUTAGEN:N->W: Reduces transcription activation by 70%.,MUTAGEN:T->Q: No effect on transcription activation.,MUTAGEN:V->D: Reduces transcription activation by 75%.,REGION:Dimerization,REGION:Disordered,REGION:Interaction with DNA,
HSPBP1	HSPA (Hsp70) binding protein 1(HSPBP1)	Homo sapiens			GO:0006457~protein folding,GO:0031398~positive regulation of protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR011989:Armadillo-like helical,IPR013918:Nucleotide exchange factor Fes1,IPR016024:Armadillo-type fold,	hsa04141:Protein processing in endoplasmic reticulum,							KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Nucleotide exchange factor Fes1,REGION:Disordered,REPEAT:ARM 1,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,
INSM1	INSM transcriptional repressor 1(INSM1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001933~negative regulation of protein phosphorylation,GO:0003309~type B pancreatic cell differentiation,GO:0003310~pancreatic A cell differentiation,GO:0003323~type B pancreatic cell development,GO:0003358~noradrenergic neuron development,GO:0007049~cell cycle,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010468~regulation of gene expression,GO:0010564~regulation of cell cycle process,GO:0016477~cell migration,GO:0030182~neuron differentiation,GO:0030335~positive regulation of cell migration,GO:0042421~norepinephrine biosynthetic process,GO:0043254~regulation of protein complex assembly,GO:0045597~positive regulation of cell differentiation,GO:0051726~regulation of cell cycle,GO:0060290~transdifferentiation,GO:0061104~adrenal chromaffin cell differentiation,GO:0061549~sympathetic ganglion development,GO:2000179~positive regulation of neural precursor cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0017053~transcriptional repressor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0030332~cyclin binding,GO:0031490~chromatin DNA binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:0060090~binding, bridging,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0131~Cell cycle,KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Pro residues,MUTAGEN:PPAPSPVPGPLPPPPP->LLALSLVLGLLLLLLL: Inhibits weakly translational repression activity. Inhibits interaction with CCND1 and cell cycle arrest.,REGION:Disordered,REGION:Necessary for interaction with CCND1,REGION:Required and sufficient for interaction with KDM1A,REGION:SNAG domain,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
IQSEC1	IQ motif and Sec7 domain ArfGEF 1(IQSEC1)	Homo sapiens			GO:0030036~actin cytoskeleton organization,GO:0032012~regulation of ARF protein signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0051549~positive regulation of keratinocyte migration,GO:0060996~dendritic spine development,	GO:0005730~nucleolus,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008289~lipid binding,	IPR000048:IQ motif, EF-hand binding site,IPR000904:SEC7-like,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR023394:SEC7-like, alpha orthogonal bundle,	hsa04144:Endocytosis,	618687~Intellectual developmental disorder with short stature and behavioral abnormalities,		SM00222:Sec7,SM00233:PH,		KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0175~Coiled coil,	KW-0446~Lipid-binding,	KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IQ,DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->K: Abolishes guanosine nucleotide exchange factor activity.,REGION:Disordered,
ISL1	ISL LIM homeobox 1(ISL1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001755~neural crest cell migration,GO:0003139~secondary heart field specification,GO:0003148~outflow tract septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003266~regulation of secondary heart field cardioblast proliferation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007409~axonogenesis,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0021520~spinal cord motor neuron cell fate specification,GO:0021522~spinal cord motor neuron differentiation,GO:0021524~visceral motor neuron differentiation,GO:0021559~trigeminal nerve development,GO:0021983~pituitary gland development,GO:0031016~pancreas development,GO:0031103~axon regeneration,GO:0031290~retinal ganglion cell axon guidance,GO:0031333~negative regulation of protein complex assembly,GO:0032024~positive regulation of insulin secretion,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0035066~positive regulation of histone acetylation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043388~positive regulation of DNA binding,GO:0043524~negative regulation of neuron apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048665~neuron fate specification,GO:0048762~mesenchymal cell differentiation,GO:0048880~sensory system development,GO:0048936~peripheral nervous system neuron axonogenesis,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050728~negative regulation of inflammatory response,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060037~pharyngeal system development,GO:0060070~canonical Wnt signaling pathway,GO:0060379~cardiac muscle cell myoblast differentiation,GO:0060384~innervation,GO:0060413~atrial septum morphogenesis,GO:0060913~cardiac cell fate determination,GO:0060931~sinoatrial node cell development,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071657~positive regulation of granulocyte colony-stimulating factor production,GO:0086091~regulation of heart rate by cardiac conduction,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1901258~positive regulation of macrophage colony-stimulating factor production,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0030331~estrogen receptor binding,GO:0043425~bHLH transcription factor binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,	hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00132:LIM,SM00389:HOX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,REGION:LIM-binding domain (LID),
JAK3	Janus kinase 3(JAK3)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il4Pathway:IL 4 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_stat3Pathway:Stat3 Signaling Pathway,	GO:0002250~adaptive immune response,GO:0002731~negative regulation of dendritic cell cytokine production,GO:0006468~protein phosphorylation,GO:0007167~enzyme linked receptor protein signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007259~JAK-STAT cascade,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030183~B cell differentiation,GO:0030218~erythrocyte differentiation,GO:0032693~negative regulation of interleukin-10 production,GO:0032695~negative regulation of interleukin-12 production,GO:0035556~intracellular signal transduction,GO:0035723~interleukin-15-mediated signaling pathway,GO:0035771~interleukin-4-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0042102~positive regulation of T cell proliferation,GO:0042104~positive regulation of activated T cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043029~T cell homeostasis,GO:0045087~innate immune response,GO:0045221~negative regulation of FasL biosynthetic process,GO:0045626~negative regulation of T-helper 1 cell differentiation,GO:0046425~regulation of JAK-STAT cascade,GO:0050868~negative regulation of T cell activation,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0051928~positive regulation of calcium ion transport,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070232~regulation of T cell apoptotic process,GO:0070244~negative regulation of thymocyte apoptotic process,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071104~response to interleukin-9,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0019897~extrinsic component of plasma membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005131~growth hormone receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019903~protein phosphatase binding,	IPR000299:FERM domain,IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR016251:Tyrosine-protein kinase, non-receptor Jak/Tyk2,IPR017441:Protein kinase, ATP binding site,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR020635:Tyrosine-protein kinase, catalytic domain,IPR020775:Tyrosine-protein kinase, non-receptor Jak3,	hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05223:Non-small cell lung cancer,hsa05340:Primary immunodeficiency,	600802~SCID, autosomal recessive, T-negative/B-positive type,	PIRSF000636:tyrosine-protein kinase, Jak/Tyk2 type,	SM00219:TyrKc,SM00252:SH2,SM00295:B41,	KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0705~SCID,	KW-0677~Repeat,KW-0727~SH2 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:FERM,DOMAIN:Protein kinase,DOMAIN:Protein kinase 1,DOMAIN:Protein kinase 2,DOMAIN:SH2; atypical,MUTAGEN:K->A: More than 90% loss of STAT5a activation.,MUTAGEN:Y->F: About 40% loss of STAT5a activation.,MUTAGEN:Y->F: About 80% loss of STAT5a activation.,MUTAGEN:Y->F: Strong decrease of JAK3 phosphorylation.,REGION:Interaction with cytokine/interferon/growth hormone receptors,
LEMD1	LEM domain containing 1(LEMD1)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003887:LEM domain,IPR011015:LEM/LEM-like domain,				SM00540:LEM,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:LEM,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
LHFPL2	LHFPL tetraspan subfamily member 2(LHFPL2)	Homo sapiens			GO:0007338~single fertilization,GO:0046545~development of primary female sexual characteristics,GO:0046546~development of primary male sexual characteristics,GO:1905516~positive regulation of fertilization,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031092~platelet alpha granule membrane,	GO:0005515~protein binding,	IPR019372:Lipoma HMGIC fusion partner-like protein,					KW-0278~Fertilization,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
LHFPL3	LHFPL tetraspan subfamily member 3(LHFPL3)	Homo sapiens			GO:0007605~sensory perception of sound,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR019372:Lipoma HMGIC fusion partner-like protein,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
LIMA1	LIM domain and actin binding 1(LIMA1)	Homo sapiens		h_s1pPathway:SREBP control of lipid synthesis,	GO:0008203~cholesterol metabolic process,GO:0016477~cell migration,GO:0030299~intestinal cholesterol absorption,GO:0030835~negative regulation of actin filament depolymerization,GO:0031529~ruffle organization,GO:0042632~cholesterol homeostasis,GO:0051017~actin filament bundle assembly,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0031526~brush border membrane,GO:0032154~cleavage furrow,	GO:0003785~actin monomer binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001781:Zinc finger, LIM-type,		618079~Low density lipoprotein cholesterol level QTL 8,		SM00132:LIM,	KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,MOTIF:Required for interaction with NPC1L1,REGION:Disordered,REGION:Required for interaction with MYO5B,
LIMD2	LIM domain containing 2(LIMD2)	Homo sapiens			GO:0051017~actin filament bundle assembly,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001781:Zinc finger, LIM-type,				SM00132:LIM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	DOMAIN:LIM zinc-binding,REGION:Disordered,
LPP	LIM domain containing preferred translocation partner in lipoma(LPP)	Homo sapiens			GO:0098609~cell-cell adhesion,	GO:0001725~stress fiber,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,		601626~Leukemia, acute myeloid,Lipoma~Lipoma,		SM00132:LIM,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,MUTAGEN:L->A: Abolishes binding to SCRIB.,MUTAGEN:T->A: Abolishes binding to SCRIB.,REGION:Disordered,SITE:Breakpoint for translocation to form HMGA2-LPP,SITE:Breakpoint for translocation to form HMGA2-LPP and KMT2A/MLL1-LPP,
LIMK1	LIM domain kinase 1(LIMK1)	Homo sapiens		h_ccr3Pathway:CCR3 signaling in Eosinophils,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_rhoPathway:Rho cell motility signaling pathway,	GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007266~Rho protein signal transduction,GO:0007399~nervous system development,GO:0030036~actin cytoskeleton organization,GO:0032233~positive regulation of actin filament bundle assembly,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0043149~stress fiber assembly,GO:0045773~positive regulation of axon extension,GO:0048675~axon extension,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051496~positive regulation of stress fiber assembly,	GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030027~lamellipodium,GO:0043005~neuron projection,GO:0043229~intracellular organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0031072~heat shock protein binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04360:Axon guidance,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05135:Yersinia infection,hsa05170:Human immunodeficiency virus 1 infection,			SM00132:LIM,SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0856~Williams-Beuren syndrome,	KW-0440~LIM domain,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:PDZ,DOMAIN:Protein kinase,MUTAGEN:C->S: Enhances actin aggregation.,MUTAGEN:D->N,A: Abrogates kinase activity.,MUTAGEN:GL->EA: Enhances actin aggregation.,MUTAGEN:Missing: Reduces actin aggregation.,MUTAGEN:RKK->GAA: Abolishes kinase activity.,MUTAGEN:T->A: Abolishes activation by ROCK1.,MUTAGEN:T->E: Phosphomimetic mutant; enhances kinase activity.,MUTAGEN:T->EE: Enhances kinase activity.,MUTAGEN:T->V: Reduces kinase activity.,REGION:Disordered,
LMO2	LIM domain only 2(LMO2)	Homo sapiens			GO:0007275~multicellular organism development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0097067~cellular response to thyroid hormone stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0001221~transcription cofactor binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043425~bHLH transcription factor binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001781:Zinc finger, LIM-type,	hsa05202:Transcriptional misregulation in cancer,	Leukemia, acute T-cell~Leukemia, acute T-cell,		SM00132:LIM,		KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,			DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,
LMO4	LIM domain only 4(LMO4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001843~neural tube closure,GO:0003281~ventricular septum development,GO:0008045~motor neuron axon guidance,GO:0021514~ventral spinal cord interneuron differentiation,GO:0021520~spinal cord motor neuron cell fate specification,GO:0021522~spinal cord motor neuron differentiation,GO:0021527~spinal cord association neuron differentiation,GO:0030334~regulation of cell migration,GO:0031333~negative regulation of protein complex assembly,GO:0033674~positive regulation of kinase activity,GO:0042659~regulation of cell fate specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048538~thymus development,GO:0050865~regulation of cell activation,	GO:0005667~transcription factor complex,GO:0031252~cell leading edge,GO:0090575~RNA polymerase II transcription factor complex,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,				SM00132:LIM,	KW-0804~Transcription,KW-0805~Transcription regulation,			KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,			DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,
LHX1	LIM homeobox 1(LHX1)	Homo sapiens			GO:0001655~urogenital system development,GO:0001657~ureteric bud development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001702~gastrulation with mouth forming second,GO:0001705~ectoderm formation,GO:0001706~endoderm formation,GO:0001822~kidney development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007267~cell-cell signaling,GO:0007389~pattern specification process,GO:0007399~nervous system development,GO:0008045~motor neuron axon guidance,GO:0009653~anatomical structure morphogenesis,GO:0009791~post-embryonic development,GO:0009880~embryonic pattern specification,GO:0009887~animal organ morphogenesis,GO:0009948~anterior/posterior axis specification,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0010468~regulation of gene expression,GO:0010842~retina layer formation,GO:0021517~ventral spinal cord development,GO:0021527~spinal cord association neuron differentiation,GO:0021537~telencephalon development,GO:0021549~cerebellum development,GO:0021702~cerebellar Purkinje cell differentiation,GO:0021871~forebrain regionalization,GO:0021937~cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of granule cell precursor cell proliferation,GO:0030182~neuron differentiation,GO:0032525~somite rostral/caudal axis specification,GO:0035502~metanephric part of ureteric bud development,GO:0035846~oviduct epithelium development,GO:0035847~uterine epithelium development,GO:0035849~nephric duct elongation,GO:0035852~horizontal cell localization,GO:0040019~positive regulation of embryonic development,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048382~mesendoderm development,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0048703~embryonic viscerocranium morphogenesis,GO:0048793~pronephros development,GO:0060059~embryonic retina morphogenesis in camera-type eye,GO:0060065~uterus development,GO:0060066~oviduct development,GO:0060067~cervix development,GO:0060068~vagina development,GO:0060322~head development,GO:0060429~epithelium development,GO:0061205~paramesonephric duct development,GO:0072049~comma-shaped body morphogenesis,GO:0072050~S-shaped body morphogenesis,GO:0072077~renal vesicle morphogenesis,GO:0072177~mesonephric duct development,GO:0072178~nephric duct morphogenesis,GO:0072197~ureter morphogenesis,GO:0072224~metanephric glomerulus development,GO:0072278~metanephric comma-shaped body morphogenesis,GO:0072283~metanephric renal vesicle morphogenesis,GO:0072284~metanephric S-shaped body morphogenesis,GO:0090009~primitive streak formation,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0097379~dorsal spinal cord interneuron posterior axon guidance,GO:0097477~lateral motor column neuron migration,GO:2000543~positive regulation of gastrulation,GO:2000744~positive regulation of anterior head development,GO:2000768~positive regulation of nephron tubule epithelial cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0032991~macromolecular complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00132:LIM,SM00389:HOX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,
LLGL1	LLGL scribble cell polarity complex component 1(LLGL1)	Homo sapiens			GO:0006887~exocytosis,GO:0006893~Golgi to plasma membrane transport,GO:0007409~axonogenesis,GO:0008593~regulation of Notch signaling pathway,GO:0030866~cortical actin cytoskeleton organization,GO:0032878~regulation of establishment or maintenance of cell polarity,GO:0045197~establishment or maintenance of epithelial cell apical/basal polarity,GO:0050708~regulation of protein secretion,GO:0051294~establishment of spindle orientation,GO:0065003~macromolecular complex assembly,	GO:0000137~Golgi cis cisterna,GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0030424~axon,GO:0030864~cortical actin cytoskeleton,GO:0031901~early endosome membrane,GO:0032588~trans-Golgi network membrane,	GO:0005096~GTPase activator activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0045159~myosin II binding,	IPR000664:Lethal(2) giant larvae protein,IPR001680:WD40 repeat,IPR013577:Lethal giant larvae homologue 2,IPR015943:WD40/YVTN repeat-like-containing domain,IPR019775:WD40 repeat, conserved site,	hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa05165:Human papillomavirus infection,			SM00320:WD40,	KW-0268~Exocytosis,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Lethal giant larvae homologue 2,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 10,REPEAT:WD 11,REPEAT:WD 12,REPEAT:WD 13,REPEAT:WD 14,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,REPEAT:WD 9,
LRRFIP1	LRR binding FLII interacting protein 1(LRRFIP1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,	IPR019139:Leucine-rich repeat flightless-interacting protein,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:DNA-binding,REGION:Disordered,
LUC7L3	LUC7 like 3 pre-mRNA splicing factor(LUC7L3)	Homo sapiens			GO:0006376~mRNA splice site selection,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005685~U1 snRNP,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR004882:LUC7-related,					KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
LYPD5	LY6/PLAUR domain containing 5(LYPD5)	Homo sapiens				GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,	IPR016054:Ly-6 antigen / uPA receptor -like,IPR018363:CD59 antigen, conserved site,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:UPAR/Ly6,LIPID:GPI-anchor amidated alanine,PROPEP:Removed in mature form,
LYN	LYN proto-oncogene, Src family tyrosine kinase(LYN)	Homo sapiens	74.CD47-IAP_with_avB3,	h_bcrPathway:BCR Signaling Pathway,h_ephA4Pathway:Eph Kinases and ephrins support platelet aggregation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ptdinsPathway:Phosphoinositides and their downstream targets.,	GO:0001782~B cell homeostasis,GO:0001817~regulation of cytokine production,GO:0001932~regulation of protein phosphorylation,GO:0001933~negative regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002250~adaptive immune response,GO:0002431~Fc receptor mediated stimulatory signaling pathway,GO:0002513~tolerance induction to self antigen,GO:0002553~histamine secretion by mast cell,GO:0002576~platelet degranulation,GO:0002762~negative regulation of myeloid leukocyte differentiation,GO:0002768~immune response-regulating cell surface receptor signaling pathway,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0002902~regulation of B cell apoptotic process,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0006991~response to sterol depletion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0009725~response to hormone,GO:0009743~response to carbohydrate,GO:0010976~positive regulation of neuron projection development,GO:0014003~oligodendrocyte development,GO:0014070~response to organic cyclic compound,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030154~cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030222~eosinophil differentiation,GO:0030335~positive regulation of cell migration,GO:0030889~negative regulation of B cell proliferation,GO:0031175~neuron projection development,GO:0031295~T cell costimulation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0031668~cellular response to extracellular stimulus,GO:0032868~response to insulin,GO:0033003~regulation of mast cell activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0034136~negative regulation of toll-like receptor 2 signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0034605~cellular response to heat,GO:0035556~intracellular signal transduction,GO:0038043~interleukin-5-mediated signaling pathway,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038159~C-X-C chemokine receptor CXCR4 signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043200~response to amino acid,GO:0043304~regulation of mast cell degranulation,GO:0043407~negative regulation of MAP kinase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045087~innate immune response,GO:0045646~regulation of erythrocyte differentiation,GO:0046777~protein autophosphorylation,GO:0048013~ephrin receptor signaling pathway,GO:0048678~response to axon injury,GO:0050777~negative regulation of immune response,GO:0050853~B cell receptor signaling pathway,GO:0050855~regulation of B cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051272~positive regulation of cellular component movement,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0060252~positive regulation of glial cell proliferation,GO:0060369~positive regulation of Fc receptor mediated stimulatory signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070304~positive regulation of stress-activated protein kinase signaling cascade,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070447~positive regulation of oligodendrocyte progenitor proliferation,GO:0070667~negative regulation of mast cell proliferation,GO:0070668~positive regulation of mast cell proliferation,GO:0071300~cellular response to retinoic acid,GO:0090025~regulation of monocyte chemotaxis,GO:0090330~regulation of platelet aggregation,GO:0097028~dendritic cell differentiation,GO:1902532~negative regulation of intracellular signal transduction,GO:1902961~positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:2000670~positive regulation of dendritic cell apoptotic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0030061~mitochondrial crista,GO:0030666~endocytic vesicle membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0034666~integrin alpha2-beta1 complex,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,GO:0099091~postsynaptic specialization, intracellular component,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005161~platelet-derived growth factor receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0017124~SH3 domain binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0043015~gamma-tubulin binding,GO:0043208~glycosphingolipid binding,GO:0044325~ion channel binding,GO:0046875~ephrin receptor binding,GO:0051219~phosphoprotein binding,GO:0097110~scaffold protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04611:Platelet activation,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04730:Long-term depression,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,hsa05417:Lipid and atherosclerosis,	620376~Autoinflammatory disease, systemic, with vasculitis,		SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of localization to the cell membrane; when associated with A-2.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-498.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-499.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-353; A-498 and A-499.,MUTAGEN:E->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-498 and A-499.,MUTAGEN:G->A: Loss of localization to the cell membrane; when associated with A-3.,MUTAGEN:K->A: Loss of activity and no effect on localization to the cell membrane. Abundant localization in the nucleus; when associated with A-2 and A-3.,MUTAGEN:K->L,R: Loss of kinase activity.,MUTAGEN:Y->F: Abolishes autoinhibition and thereby increases kinase activity.,MUTAGEN:Y->F: Strongly reduced kinase activity.,REGION:Disordered,
LARP1	La ribonucleoprotein 1, translational regulator(LARP1)	Homo sapiens			GO:0006413~translational initiation,GO:0008283~cell proliferation,GO:0010608~posttranscriptional regulation of gene expression,GO:0016239~positive regulation of macroautophagy,GO:0017148~negative regulation of translation,GO:0031929~TOR signaling,GO:0038202~TORC1 signaling,GO:0045070~positive regulation of viral genome replication,GO:0045727~positive regulation of translation,GO:0045947~negative regulation of translational initiation,GO:0045948~positive regulation of translational initiation,GO:0048255~mRNA stabilization,GO:0072752~cellular response to rapamycin,GO:1990928~response to amino acid starvation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0042788~polysomal ribosome,	GO:0000339~RNA cap binding,GO:0000340~RNA 7-methylguanosine cap binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0008494~translation activator activity,GO:0031369~translation initiation factor binding,GO:0043024~ribosomal small subunit binding,GO:0045296~cadherin binding,GO:0048027~mRNA 5'-UTR binding,	IPR006607:Protein of unknown function DM15,IPR006630:RNA-binding protein Lupus La,				SM00684:DM15,SM00715:LA,	KW-0648~Protein biosynthesis,KW-0810~Translation regulation,	KW-0963~Cytoplasm,				KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:HTH La-type RNA-binding,MUTAGEN:E->R: Strongly decreased RNA binding.,MUTAGEN:F->A: No effect on interaction with RPTOR.,MUTAGEN:F->A: Strongly reduced interaction with PABPC1.,MUTAGEN:Missing: Loss of interaction with RPTOR.,MUTAGEN:Missing: Strongly reduced interaction with PABPC1.,MUTAGEN:R->E: Abolishes RNA binding. Abolishes inhibition of EIF4G1 binding to mRNA molecules with a 5'TOP motif; when associated with A-960.,MUTAGEN:S->A: Loss of phosphorylation by MTOR; when associated with A-769. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-769; A-847 and A-1058.,MUTAGEN:S->A: Strongly reduced phosphorylation mediated by AKT and RPS6KB1. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-769 and A-847.,MUTAGEN:S->A: Strongly reduced phosphorylation mediated by Akt and RPS6KB1. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-769 and A-1058.,MUTAGEN:T->A: Loss of phosphorylation by MTOR; when associated with A-766. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-847 and A-1058.,MUTAGEN:Y->A: Abolishes RNA binding. Abolishes translational repression of mRNAs with a 5'TOP motif. Abolishes inhibition of EIF4G1 binding to mRNA molecules with a 5'TOP motif; when associated with E-917.,MUTAGEN:Y->A: Strongly decreased RNA binding.,REGION:Disordered,REGION:Interaction with 7-methylguanosine mRNA cap structure,REGION:Interaction with mRNA,REGION:Required for interaction with PABPC1,REGION:Required for interaction with RPTOR and for repression of mRNAs with a 5'TOP motif,
MALT1	MALT1 paracaspase(MALT1)	Homo sapiens			GO:0001923~B-1 B cell differentiation,GO:0002726~positive regulation of T cell cytokine production,GO:0006508~proteolysis,GO:0006952~defense response,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0009620~response to fungus,GO:0031398~positive regulation of protein ubiquitination,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032743~positive regulation of interleukin-2 production,GO:0042098~T cell proliferation,GO:0042113~B cell activation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045087~innate immune response,GO:0050852~T cell receptor signaling pathway,GO:0050856~regulation of T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051168~nuclear export,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:2000321~positive regulation of T-helper 17 cell differentiation,	GO:0001650~fibrillar center,GO:0002096~polkadots,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032449~CBM complex,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0002020~protease binding,GO:0004175~endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0019209~kinase activator activity,GO:0036094~small molecule binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR011029:Death-like domain,IPR013783:Immunoglobulin-like fold,	hsa04064:NF-kappa B signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa05131:Shigellosis,hsa05152:Tuberculosis,	615468~Immunodeficiency 12,		SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:Caspase family p20,DOMAIN:Death,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,MOTIF:Nuclear export signal,MUTAGEN:C->A: Slight decrease in NF-kappa-B activation.,MUTAGEN:E->A: Abolishes binding to TRAF6.,REGION:Caspase-like,REGION:Disordered,SITE:Breakpoint for translocation to form BIRC2-MALT1,
MARVELD1	MARVEL domain containing 1(MARVELD1)	Homo sapiens			GO:0007049~cell cycle,GO:0042552~myelination,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0019911~structural constituent of myelin sheath,	IPR008253:Marvel,					KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	DOMAIN:MARVEL,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MRGPRD	MAS related GPR family member D(MRGPRD)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,IPR026232:Mas-related G protein-coupled receptor D,IPR026234:Mas-related G protein-coupled receptor family,	hsa04614:Renin-angiotensin system,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MRGPRF	MAS related GPR family member F(MRGPRF)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,IPR026228:Mas-related G protein-coupled receptor F,IPR026234:Mas-related G protein-coupled receptor family,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G-protein coupled receptors family 1 profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MRGPRX4	MAS related GPR family member X4(MRGPRX4)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,IPR026234:Mas-related G protein-coupled receptor family,IPR027344:Mas-related G protein-coupled receptor X4,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MAS1	MAS1 proto-oncogene, G protein-coupled receptor(MAS1)	Homo sapiens			GO:0001933~negative regulation of protein phosphorylation,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0007283~spermatogenesis,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0014823~response to activity,GO:0021766~hippocampus development,GO:0034698~response to gonadotropin,GO:0038166~angiotensin-activated signaling pathway,GO:0045740~positive regulation of DNA replication,GO:0050727~regulation of inflammatory response,GO:0060732~positive regulation of inositol phosphate biosynthetic process,GO:0070528~protein kinase C signaling,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0001595~angiotensin receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0004945~angiotensin type II receptor activity,GO:0005515~protein binding,GO:0042277~peptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000820:Proto-oncogene Mas,IPR017452:GPCR, rhodopsin-like, 7TM,IPR026234:Mas-related G protein-coupled receptor family,	hsa04080:Neuroactive ligand-receptor interaction,hsa04614:Renin-angiotensin system,hsa05171:Coronavirus disease - COVID-19,					KW-0472~Membrane,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:I->D: Fails to activate GNA11.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MGA	MAX dimerization protein MGA(MGA)	Homo sapiens			GO:0001708~cell fate specification,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0071339~MLL1 complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046983~protein dimerization activity,	IPR001699:Transcription factor, T-box,IPR008967:p53-like transcription factor, DNA-binding,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR018186:Transcription factor, T-box, conserved site,	hsa03083:Polycomb repressive complex,			SM00353:HLH,SM00425:TBOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:T-box,DOMAIN:BHLH,DOMAIN:MGA conserved,DOMAIN:T-box,DOMAIN:bHLH,REGION:Disordered,
MERTK	MER proto-oncogene, tyrosine kinase(MERTK)	Homo sapiens			GO:0001779~natural killer cell differentiation,GO:0001818~negative regulation of cytokine production,GO:0006468~protein phosphorylation,GO:0006909~phagocytosis,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007267~cell-cell signaling,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007399~nervous system development,GO:0016477~cell migration,GO:0030168~platelet activation,GO:0032940~secretion by cell,GO:0033674~positive regulation of kinase activity,GO:0034446~substrate adhesion-dependent cell spreading,GO:0043491~protein kinase B signaling,GO:0050766~positive regulation of phagocytosis,GO:0051250~negative regulation of lymphocyte activation,GO:0051649~establishment of localization in cell,GO:0060041~retina development in camera-type eye,GO:0060068~vagina development,GO:0097350~neutrophil clearance,GO:2000107~negative regulation of leukocyte apoptotic process,	GO:0001750~photoreceptor outer segment,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016028~rhabdomere,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,		613862~Retinitis pigmentosa 38,		SM00060:FN3,SM00219:TyrKc,SM00409:IG,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0682~Retinitis pigmentosa,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Protein kinase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MNAT1	MNAT1 component of CDK activating kinase(MNAT1)	Homo sapiens		h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0006281~DNA repair,GO:0006289~nucleotide-excision repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007512~adult heart development,GO:0021591~ventricular system development,GO:0043066~negative regulation of apoptotic process,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051592~response to calcium ion,GO:0065003~macromolecular complex assembly,GO:1905775~negative regulation of DNA helicase activity,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000439~core TFIIH complex,GO:0005654~nucleoplasm,GO:0005675~holo TFIIH complex,GO:0005694~chromosome,GO:0019907~cyclin-dependent protein kinase activating kinase holoenzyme complex,GO:0070516~CAK-ERCC2 complex,GO:0070985~TFIIK complex,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR001841:Zinc finger, RING-type,IPR003511:DNA-binding HORMA,IPR003903:Ubiquitin interacting motif,IPR004575:Cdk-activating kinase assembly factor MAT1/Tfb3,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR015877:Cdk-activating kinase assembly factor MAT1, centre,IPR017907:Zinc finger, RING-type, conserved site,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,		PIRSF003338:CDK-activating kinase assembly factor MAT1,	SM00184:RING,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Cdk-activating kinase assembly factor MAT1 centre,DOMAIN:HORMA,DOMAIN:RING-type,DOMAIN:UIM,ZN_FING:RING-type,
MOS	MOS proto-oncogene, serine/threonine kinase(MOS)	Homo sapiens	100.MAPK_signaling_cascades,		GO:0000165~MAPK cascade,GO:0000212~meiotic spindle organization,GO:0006325~chromatin organization,GO:0007165~signal transduction,GO:0040020~regulation of meiotic nuclear division,GO:0043410~positive regulation of MAPK cascade,GO:0046777~protein autophosphorylation,GO:0051296~establishment of meiotic spindle orientation,GO:1902103~negative regulation of metaphase/anaphase transition of meiotic cell cycle,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04114:Oocyte meiosis,hsa04810:Regulation of actin cytoskeleton,hsa04914:Progesterone-mediated oocyte maturation,	620383~Oocyte/zygote/embryo maturation arrest 20,		SM00220:S_TKc,			KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,
MTSS1	MTSS I-BAR domain containing 1(MTSS1)	Homo sapiens			GO:0007009~plasma membrane organization,GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0030035~microspike assembly,GO:0030036~actin cytoskeleton organization,GO:0032233~positive regulation of actin filament bundle assembly,GO:0034334~adherens junction maintenance,GO:0050680~negative regulation of epithelial cell proliferation,GO:0061333~renal tubule morphogenesis,GO:0071498~cellular response to fluid shear stress,GO:0072102~glomerulus morphogenesis,GO:0072160~nephron tubule epithelial cell differentiation,GO:2001013~epithelial cell proliferation involved in renal tubule morphogenesis,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0015629~actin cytoskeleton,GO:0030139~endocytic vesicle,GO:0031235~intrinsic component of the cytoplasmic side of the plasma membrane,	GO:0003779~actin binding,GO:0003785~actin monomer binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0042802~identical protein binding,	IPR003124:WH2 domain,IPR013606:IRSp53/MIM homology domain (IMD),IPR027267:Arfaptin homology (AH) domain/BAR domain,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IMD,DOMAIN:WH2,REGION:Disordered,
NAT8L	N-acetyltransferase 8 like(NAT8L)	Homo sapiens			GO:0009066~aspartate family amino acid metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0030867~rough endoplasmic reticulum membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0008080~N-acetyltransferase activity,GO:0017188~aspartate N-acetyltransferase activity,	IPR000182:GNAT domain,IPR016181:Acyl-CoA N-acyltransferase,	hsa00250:Alanine, aspartate and glutamate metabolism,hsa01100:Metabolic pathways,	614063~N-acetylaspartate deficiency,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,		COMPBIAS:Pro residues,DOMAIN:N-acetyltransferase,REGION:Disordered,TRANSMEM:Helical,
MPG	N-methylpurine DNA glycosylase(MPG)	Homo sapiens			GO:0006284~base-excision repair,GO:0006307~DNA dealkylation involved in DNA repair,GO:0045007~depurination,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0042645~mitochondrial nucleoid,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003905~alkylbase DNA N-glycosylase activity,GO:0005515~protein binding,GO:0008725~DNA-3-methyladenine glycosylase activity,GO:0019104~DNA N-glycosylase activity,GO:0043916~DNA-7-methylguanine glycosylase activity,GO:0052821~DNA-7-methyladenine glycosylase activity,GO:0052822~DNA-3-methylguanine glycosylase activity,	IPR003180:Methylpurine-DNA glycosylase (MPG),IPR011034:Formyl transferase, C-terminal-like,	hsa03410:Base excision repair,				KW-0227~DNA damage,KW-0234~DNA repair,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1135~Mitochondrion nucleoid,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TRANSIT:Mitochondrion,TRANSMEM:Helical,
NBL1	NBL1, DAN family BMP antagonist(NBL1)	Homo sapiens			GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0009887~animal organ morphogenesis,GO:0030514~negative regulation of BMP signaling pathway,GO:0035582~sequestering of BMP in extracellular matrix,GO:0038098~sequestering of BMP from receptor via BMP binding,GO:0045666~positive regulation of neuron differentiation,GO:0048263~determination of dorsal identity,GO:0048812~neuron projection morphogenesis,GO:0090027~negative regulation of monocyte chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0016015~morphogen activity,GO:0036122~BMP binding,GO:0042802~identical protein binding,GO:0048018~receptor agonist activity,	IPR004133:DAN,IPR006207:Cystine knot, C-terminal,IPR016728:Neuroblastoma suppressor of tumorigenicity 1,	hsa04350:TGF-beta signaling pathway,		PIRSF018557:DAN protein,	SM00041:CT,		KW-0964~Secreted,	KW-0043~Tumor suppressor,	KW-0732~Signal,			KW-1015~Disulfide bond,	COMPBIAS:Pro residues,DOMAIN:CTCK,DOMAIN:DAN,REGION:Disordered,
NDRG2	NDRG family member 2(NDRG2)	Homo sapiens			GO:0001818~negative regulation of cytokine production,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0010574~regulation of vascular endothelial growth factor production,GO:0016055~Wnt signaling pathway,GO:0021762~substantia nigra development,GO:0030154~cell differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0090361~regulation of platelet-derived growth factor production,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1990874~vascular smooth muscle cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0030426~growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR004142:Ndr,					KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0043~Tumor suppressor,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:L->D: Decreased interaction with CTNNB1. Abolishes down-regulation of Wnt signaling.,REGION:Disordered,TRANSMEM:Helical,
NKAPL	NFKB activating protein like(NKAPL)	Homo sapiens			GO:0007283~spermatogenesis,GO:0010468~regulation of gene expression,GO:0030154~cell differentiation,	GO:0005634~nucleus,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR009269:Protein of unknown function DUF926,					KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,
NKX2-1	NK2 homeobox 1(NKX2-1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006644~phospholipid metabolic process,GO:0007411~axon guidance,GO:0007420~brain development,GO:0007492~endoderm development,GO:0007626~locomotory behavior,GO:0009725~response to hormone,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0021759~globus pallidus development,GO:0021766~hippocampus development,GO:0021795~cerebral cortex cell migration,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021854~hypothalamus development,GO:0021877~forebrain neuron fate commitment,GO:0021892~cerebral cortex GABAergic interneuron differentiation,GO:0021983~pituitary gland development,GO:0030154~cell differentiation,GO:0030324~lung development,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030878~thyroid gland development,GO:0030900~forebrain development,GO:0031128~developmental induction,GO:0033327~Leydig cell differentiation,GO:0042753~positive regulation of circadian rhythm,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0048709~oligodendrocyte differentiation,GO:0060430~lung saccule development,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060486~Clara cell differentiation,GO:0060510~Type II pneumocyte differentiation,GO:1904936~interneuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001161~intronic transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		118700~Chorea, hereditary benign,188550~Thyroid cancer, nonmedullary, 1,610978~Choreoathetosis, hypothyroidism, and neonatal respiratory distress,		SM00389:HOX,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0984~Congenital hypothyroidism,	KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
NKX6-2	NK6 homeobox 2(NKX6-2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003310~pancreatic A cell differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010454~negative regulation of cell fate commitment,GO:0010455~positive regulation of cell fate commitment,GO:0022010~central nervous system myelination,GO:0030154~cell differentiation,GO:0031018~endocrine pancreas development,GO:0031641~regulation of myelination,GO:0045686~negative regulation of glial cell differentiation,GO:0045687~positive regulation of glial cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048663~neuron fate commitment,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0050885~neuromuscular process controlling balance,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		617560~Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy,		SM00389:HOX,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1026~Leukodystrophy,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,REGION:Disordered,REGION:Repressor domain,
NLRP3	NLR family pyrin domain containing 3(NLRP3)	Homo sapiens			GO:0002221~pattern recognition receptor signaling pathway,GO:0002526~acute inflammatory response,GO:0002674~negative regulation of acute inflammatory response,GO:0002830~positive regulation of type 2 immune response,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007231~osmosensory signaling pathway,GO:0009595~detection of biotic stimulus,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0044546~NLRP3 inflammasome complex assembly,GO:0045087~innate immune response,GO:0045630~positive regulation of T-helper 2 cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050727~regulation of inflammatory response,GO:0050728~negative regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0050830~defense response to Gram-positive bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051260~protein homooligomerization,GO:0051604~protein maturation,GO:0051607~defense response to virus,GO:0070269~pyroptosis,GO:0071222~cellular response to lipopolysaccharide,GO:0071224~cellular response to peptidoglycan,GO:0098586~cellular response to virus,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2000321~positive regulation of T-helper 17 cell differentiation,GO:2000553~positive regulation of T-helper 2 cell cytokine production,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0016020~membrane,GO:0031021~interphase microtubule organizing center,GO:0072559~NLRP3 inflammasome complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042834~peptidoglycan binding,GO:0043531~ADP binding,GO:0043565~sequence-specific DNA binding,GO:0060090~binding, bridging,GO:0070273~phosphatidylinositol-4-phosphate binding,GO:1901981~phosphatidylinositol phosphate binding,	IPR001611:Leucine-rich repeat,IPR004020:DAPIN domain,IPR007111:NACHT nucleoside triphosphatase,IPR011029:Death-like domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05164:Influenza A,hsa05171:Coronavirus disease - COVID-19,hsa05417:Lipid and atherosclerosis,	120100~Familial cold inflammatory syndrome 1,148200~Keratoendothelitis fugax hereditaria,191900~Muckle-Wells syndrome,607115~CINCA syndrome,617772~Deafness, autosomal dominant 34, with or without inflammation,		SM01288:SM01288,SM01289:SM01289,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1271~Inflammasome,	KW-0209~Deafness,KW-0225~Disease variant,KW-1008~Amyloidosis,KW-1010~Non-syndromic deafness,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0378~Hydrolase,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DISULFID:Redox-active,DOMAIN:FISNA,DOMAIN:NACHT,DOMAIN:NACHT LRR and PYD,DOMAIN:Pyrin,LIPID:S-palmitoyl cysteine,MOTIF:KFERQ-like motif 1,MOTIF:KFERQ-like motif 2,MOTIF:KFERQ-like motif 3,MOTIF:KFERQ-like motif 4,MUTAGEN:A->Q: Abolished binding to small-inhibitor MCC950 and ability to activate the NLRP3 inflammasome following stimulation with nigericin.,MUTAGEN:A->V: Induces the formation of short but ordered homopolymers.,MUTAGEN:C->A: Abolished palmitoylation by ZDHHC12, preventing degradation by the chaperone-mediated autophagy pathway.,MUTAGEN:D->R: Abolished ability to activate the NLRP3 inflammasome.,MUTAGEN:D->R: Complete loss of PYCARD/ASC filament nucleation.,MUTAGEN:D->R: Does not affect ability to activate the NLRP3 inflammasome.,MUTAGEN:D->R: Slightly decreased ability to activate the NLRP3 inflammasome; when associated with D-816.,MUTAGEN:D->V: Impaired ability to homooligomerize into ordered polymers. Decreased PYCARD/ASC filament nucleation.,MUTAGEN:DGFDE->AGFAA,AGFNA: In Walker B mutant; abolished ATPase activity. Abolished binding to small-inhibitor MCC950.,MUTAGEN:E->R: Abolished ability to activate the NLRP3 inflammasome.,MUTAGEN:E->R: Complete loss of PYCARD/ASC filament nucleation.,MUTAGEN:E->R: Decreased ability to activate the NLRP3 inflammasome.,MUTAGEN:E->R: Impaired ability to activate the NLRP3 inflammasome.,MUTAGEN:E->R: Impaired ability to homooligomerize into ordered polymers. Complete loss of PYCARD/ASC filament nucleation.,MUTAGEN:F->E: Slightly decreased ability to activate the NLRP3 inflammasome; when associated with E-788.,MUTAGEN:F->E: Slightly decreased ability to activate the NLRP3 inflammasome; when associated with E-813.,MUTAGEN:FD->AR: Slightly impaired autoinhibition of the protein; when associated with A-831.,MUTAGEN:GKT->AAA: In Walker A mutant; abolished ATPase activity. Reduced ATP-binding leading to decreased activation of the NLRP3 inflammasome.,MUTAGEN:H->E: Does not affect ability to activate the NLRP3 inflammasome.,MUTAGEN:H->R: Does not affect ability to homooligomerize into ordered polymers.,MUTAGEN:K->A: Slightly impaired autoinhibition of the protein; when associated with 788-A-R-789.,MUTAGEN:K->E: Complete loss of PYCARD/ASC filament nucleation; when associated with E-23.,MUTAGEN:K->E: Complete loss of PYCARD/ASC filament nucleation; when associated with E-24.,MUTAGEN:K->E: Impaired ability to activate the NLRP3 inflammasome.,MUTAGEN:K->R: Abolished ubiquitination by the SCF(FBXL2) complex.,MUTAGEN:KK->EE: Impaired ability to homooligomerize into ordered polymers. Complete loss of PYCARD/ASC filament nucleation.,MUTAGEN:KKL->EEA: Does not affect autoinhibition of the protein.,MUTAGEN:LK->PA: Loss of PYCARD/ASC-binding. No effect on GBP5-binding.,MUTAGEN:M->E: Impaired ability to homooligomerize into ordered polymers. Complete loss of PYCARD/ASC filament nucleation.,MUTAGEN:Missing: Loss of autoinhibition of the protein.,MUTAGEN:Missing: Strongly decreased interaction with MAVS and localization to mitochondria.,MUTAGEN:N->A: Impaired ability to activate the NLRP3 inflammasome.,MUTAGEN:Q->A,R: Does not affect ability to activate the NLRP3 inflammasome.,MUTAGEN:Q->A: Decreased interaction with HSPA8/HSC70 and NLRP3 degradation by the chaperone-mediated autophagy pathway.,MUTAGEN:Q->A: Impaired ability to activate the NLRP3 inflammasome.,MUTAGEN:QEE->RRR: Strongly decreased ability to activate the NLRP3 inflammasome.,MUTAGEN:R->A: Abolished binding to small-inhibitor MCC950 and ability to activate the NLRP3 inflammasome following stimulation with nigericin.,MUTAGEN:R->D: Slightly decreased ability to activate the NLRP3 inflammasome; when associated with R-789.,MUTAGEN:R->E: Impaired ability to activate the NLRP3 inflammasome.,MUTAGEN:R->E: Impaired ability to homooligomerize into ordered polymers.,MUTAGEN:R->E: Impaired ability to homooligomerize into ordered polymers. Decreased PYCARD/ASC filament nucleation.,MUTAGEN:R->T: Abolished binding to small-inhibitor MCC950 and ability to activate the NLRP3 inflammasome following stimulation with nigericin.,MUTAGEN:R->W: Complete loss of PYCARD/ASC filament nucleation. Decreased PYCARD/ASC filament nucleation.,MUTAGEN:RCKLAR->ACALAA: Abolished formation of the NLRP3 inflammasome.,MUTAGEN:S->A: Abolished phosphorylation by CSNK1A1; increased activation of the NLRP3 inflammasome.,MUTAGEN:S->A: Abolished phosphorylation by MAPK8/JNK1; decreased activation of the NLRP3 inflammasome.,MUTAGEN:S->A: Decreased phosphorylation; increased activation of the NLRP3 inflammasome.,MUTAGEN:S->A: Does not affect activation of the NLRP3 inflammasome.,MUTAGEN:S->D,E: Mimicks phosphorylation state; increased activation of the NLRP3 inflammasome.,MUTAGEN:S->D,E: Mimics phosphorylation state; decreased activation of the NLRP3 inflammasome.,MUTAGEN:V->G: Decreased interaction with MAPK4.,MUTAGEN:V->R: Decreased ability to activate the NLRP3 inflammasome.,MUTAGEN:W->A: Decreased ubiquitination by the SCF(FBXL2) complex.,MUTAGEN:W->A: Does not affect ubiquitination by the SCF(FBXL2) complex.,MUTAGEN:W->G: Does not affect ability to activate the NLRP3 inflammasome.,MUTAGEN:Y->F: Abolished phosphorylation.,MUTAGEN:Y->F: Decreased phosphorylation by BTK; when associated with 136-F--F-143.,MUTAGEN:Y->G: Decreased ability to activate the NLRP3 inflammasome.,MUTAGEN:Y->R: Decreased ability to activate the NLRP3 inflammasome.,MUTAGEN:YRKKYRKY->FRKKFRKF: Decreased phosphorylation by BTK; when associated with F-168.,REGION:Required for binding to phosphatidylinositol 4-phosphate (PtdIns4P),REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
NRARP	NOTCH regulated ankyrin repeat protein(NRARP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002043~blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:0007219~Notch signaling pathway,GO:0030217~T cell differentiation,GO:0032525~somite rostral/caudal axis specification,GO:0045581~negative regulation of T cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0101023~vascular endothelial cell proliferation,GO:1902367~negative regulation of Notch signaling pathway involved in somitogenesis,GO:1905564~positive regulation of vascular endothelial cell proliferation,		GO:0005515~protein binding,	IPR002110:Ankyrin repeat,	hsa04330:Notch signaling pathway,			SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,		REPEAT:ANK 1,REPEAT:ANK 2,
NUAK2	NUAK family kinase 2(NUAK2)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0030036~actin cytoskeleton organization,GO:0032007~negative regulation of TOR signaling,GO:0034504~protein localization to nucleus,GO:0035330~regulation of hippo signaling,GO:0035556~intracellular signal transduction,GO:0042149~cellular response to glucose starvation,GO:0043066~negative regulation of apoptotic process,	GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0031588~nucleotide-activated protein kinase complex,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,		619452~Anencephaly 2,		SM00220:S_TKc,	KW-0053~Apoptosis,		KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:K->R: Loss of autophosphorylation, kinase activity and of anti-apoptotic activity.,MUTAGEN:T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.,REGION:Disordered,
OPA1	OPA1 mitochondrial dynamin like GTPase(OPA1)	Homo sapiens			GO:0000002~mitochondrial genome maintenance,GO:0000266~mitochondrial fission,GO:0001843~neural tube closure,GO:0006915~apoptotic process,GO:0007005~mitochondrion organization,GO:0007007~inner mitochondrial membrane organization,GO:0007601~visual perception,GO:0008053~mitochondrial fusion,GO:0019896~axonal transport of mitochondrion,GO:0043066~negative regulation of apoptotic process,GO:0046039~GTP metabolic process,GO:0051259~protein oligomerization,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0090398~cellular senescence,GO:0097749~membrane tubulation,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030061~mitochondrial crista,GO:0030425~dendrite,GO:0031966~mitochondrial membrane,GO:1904115~axon cytoplasm,	GO:0000287~magnesium ion binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0008289~lipid binding,GO:0070300~phosphatidic acid binding,GO:1901612~cardiolipin binding,	IPR001401:Dynamin, GTPase domain,IPR022812:Dynamin,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa05017:Spinocerebellar ataxia,	125250~Optic atrophy plus syndrome,165500~Optic atrophy 1,210000~Behr syndrome,606657~Glaucoma, normal tension, susceptibility to,616896~Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),		SM00053:DYNc,	KW-0053~Apoptosis,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0122~Cardiomyopathy,KW-0209~Deafness,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1274~Primary mitochondrial disease,	KW-0175~Coiled coil,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,	DOMAIN:Dynamin-like GTPase OPA1 C-terminal,DOMAIN:Dynamin-type G,MOTIF:LQQQIQ motif,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,SITE:Cleavage at site S1,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
PDLIM4	PDZ and LIM domain 4(PDLIM4)	Homo sapiens			GO:0007507~heart development,GO:0030036~actin cytoskeleton organization,GO:0031532~actin cytoskeleton reorganization,GO:0061061~muscle structure development,GO:0098976~excitatory chemical synaptic transmission,	GO:0001725~stress fiber,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005912~adherens junction,GO:0030018~Z disc,GO:0030027~lamellipodium,GO:0031901~early endosome membrane,GO:0031905~early endosome lumen,GO:0031941~filamentous actin,GO:0034777~recycling endosome lumen,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019903~protein phosphatase binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0051371~muscle alpha-actinin binding,GO:0051393~alpha-actinin binding,	IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,		166710~Osteoporosis, susceptibility to,		SM00132:LIM,SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:PDZ,REGION:Disordered,
PLAGL1	PLAG1 like zinc finger 1(PLAGL1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051726~regulation of cell cycle,	GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0016604~nuclear body,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0219~Diabetes mellitus,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,		DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,
POU2F2	POU class 2 homeobox 2(POU2F2)	Homo sapiens	79.B_cell_Activation,		GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006959~humoral immune response,GO:0032755~positive regulation of interleukin-6 production,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0098586~cellular response to virus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000327:POU-specific,IPR000972:Octamer-binding transcription factor,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR017970:Homeobox, conserved site,	hsa05168:Herpes simplex virus 1 infection,hsa05417:Lipid and atherosclerosis,			SM00352:POU,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:POU,DOMAIN:POU-specific,MUTAGEN:VIR->FNP: Suppresses DNA-binding ability.,REGION:Disordered,REGION:Leucine-zipper,
POU3F1	POU class 3 homeobox 1(POU3F1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008366~axon ensheathment,GO:0010628~positive regulation of gene expression,GO:0022011~myelination in peripheral nervous system,GO:0030216~keratinocyte differentiation,GO:0030900~forebrain development,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000327:POU-specific,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR016362:Transcription factor, homeobox/POU,IPR017970:Homeobox, conserved site,			PIRSF002629:POU domain class 3 transcription factor, brain type,	SM00352:POU,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Basic residues,DNA_BIND:Homeobox,DOMAIN:POU-specific,REGION:Disordered,
POU3F3	POU class 3 homeobox 3(POU3F3)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007417~central nervous system development,GO:0007588~excretion,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0021799~cerebral cortex radially oriented cell migration,GO:0021869~forebrain ventricular zone progenitor cell division,GO:0043066~negative regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048878~chemical homeostasis,GO:0071918~urea transmembrane transport,GO:0072218~metanephric ascending thin limb development,GO:0072227~metanephric macula densa development,GO:0072233~metanephric thick ascending limb development,GO:0072236~metanephric loop of Henle development,GO:0072240~metanephric DCT cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0042803~protein homodimerization activity,GO:0043565~sequence-specific DNA binding,GO:0071837~HMG box domain binding,	IPR000327:POU-specific,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR016362:Transcription factor, homeobox/POU,IPR017970:Homeobox, conserved site,		618604~Snijders Blok-Fisher syndrome,	PIRSF002629:POU domain class 3 transcription factor, brain type,	SM00352:POU,SM00389:HOX,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:POU-specific,REGION:Disordered,
POU4F1	POU class 4 homeobox 1(POU4F1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0001967~suckling behavior,GO:0003223~ventricular compact myocardium morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007409~axonogenesis,GO:0007416~synapse assembly,GO:0007498~mesoderm development,GO:0007507~heart development,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0021535~cell migration in hindbrain,GO:0021559~trigeminal nerve development,GO:0021953~central nervous system neuron differentiation,GO:0021986~habenula development,GO:0031175~neuron projection development,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045672~positive regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048665~neuron fate specification,GO:0048880~sensory system development,GO:0048935~peripheral nervous system neuron development,GO:0050767~regulation of neurogenesis,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051355~proprioception involved in equilibrioception,GO:0051402~neuron apoptotic process,GO:0051726~regulation of cell cycle,GO:0060384~innervation,GO:0071345~cellular response to cytokine stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:2000679~positive regulation of transcription regulatory region DNA binding,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0051020~GTPase binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000327:POU-specific,IPR001356:Homeodomain,IPR001387:Helix-turn-helix,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR015584:POU domain-containing protein, class 4-related,IPR017970:Homeobox, conserved site,		619352~Ataxia, intention tremor, and hypotonia syndrome, childhood-onset,		SM00352:POU,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:POU-specific,MOTIF:POU-IV box,REGION:Disordered,
POU4F2	POU class 4 homeobox 2(POU4F2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0007411~axon guidance,GO:0007507~heart development,GO:0007605~sensory perception of sound,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0030182~neuron differentiation,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0031290~retinal ganglion cell axon guidance,GO:0032869~cellular response to insulin stimulus,GO:0043068~positive regulation of programmed cell death,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045596~negative regulation of cell differentiation,GO:0045597~positive regulation of cell differentiation,GO:0045672~positive regulation of osteoclast differentiation,GO:0045773~positive regulation of axon extension,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046326~positive regulation of glucose import,GO:0048675~axon extension,GO:0050885~neuromuscular process controlling balance,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0060041~retina development in camera-type eye,GO:0071345~cellular response to cytokine stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071453~cellular response to oxygen levels,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0090259~regulation of retinal ganglion cell axon guidance,GO:1902870~negative regulation of amacrine cell differentiation,GO:1904178~negative regulation of adipose tissue development,GO:1990791~dorsal root ganglion development,GO:2000679~positive regulation of transcription regulatory region DNA binding,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0002039~p53 binding,GO:0005515~protein binding,GO:1990841~promoter-specific chromatin binding,	IPR000327:POU-specific,IPR001356:Homeodomain,IPR001387:Helix-turn-helix,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR017970:Homeobox, conserved site,				SM00352:POU,SM00389:HOX,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:POU-specific,MOTIF:Nuclear speckle targeting signal,MOTIF:POU-IV box,MUTAGEN:Missing: Absent from nuclear speckle; no change in transcriptional activity.,REGION:Disordered,REGION:Required for DNA-binding and transcriptional repression,REGION:Required for transcriptional activation,
PPFIBP2	PPFIA binding protein 2(PPFIBP2)	Homo sapiens			GO:0007528~neuromuscular junction development,GO:0050808~synapse organization,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0048786~presynaptic active zone,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001660:Sterile alpha motif domain,IPR013761:Sterile alpha motif/pointed domain,				SM00454:SAM,				KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SAM,DOMAIN:SAM 1,DOMAIN:SAM 2,DOMAIN:SAM 3,REGION:Disordered,
PRDM12	PR/SET domain 12(PRDM12)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006479~protein methylation,GO:0010468~regulation of gene expression,GO:0019233~sensory perception of pain,GO:0022008~neurogenesis,GO:0031175~neuron projection development,GO:0032259~methylation,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0051574~positive regulation of histone H3-K9 methylation,GO:1900111~positive regulation of histone H3-K9 dimethylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003677~DNA binding,GO:0008168~methyltransferase activity,GO:0046872~metal ion binding,GO:1990226~histone methyltransferase binding,	IPR001214:SET domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR017126:PR-domain zinc finger protein PRDM12,		616488~Neuropathy, hereditary sensory and autonomic, type VIII,	PIRSF037163:PR-domain zinc finger protein PRDM12,	SM00317:SET,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,DOMAIN:C2H2-type,DOMAIN:SET,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
PRDM13	PR/SET domain 13(PRDM13)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0010468~regulation of gene expression,GO:0021979~hypothalamus cell differentiation,GO:0022008~neurogenesis,GO:0032259~methylation,GO:0097154~GABAergic neuron differentiation,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0042054~histone methyltransferase activity,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001214:SET domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		619761~Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism,619909~Pontocerebellar hypoplasia, type 17,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0991~Intellectual disability,KW-1016~Hypogonadotropic hypogonadism,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,		DOMAIN:SET,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
PRDM14	PR/SET domain 14(PRDM14)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000902~cell morphogenesis,GO:0001708~cell fate specification,GO:0001827~inner cell mass cell fate commitment,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007281~germ cell development,GO:0007566~embryo implantation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009566~fertilization,GO:0010468~regulation of gene expression,GO:0030718~germ-line stem cell population maintenance,GO:0032259~methylation,GO:0034972~histone H3-R26 methylation,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0044030~regulation of DNA methylation,GO:0048873~homeostasis of number of cells within a tissue,GO:0060817~inactivation of paternal X chromosome,GO:1902093~positive regulation of flagellated sperm motility,GO:1902459~positive regulation of stem cell population maintenance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0031490~chromatin DNA binding,GO:0046872~metal ion binding,	IPR001214:SET domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00317:SET,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:SET,REGION:Disordered,REGION:Interaction with CBFA2T2,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
PRDM8	PR/SET domain 8(PRDM8)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0014003~oligodendrocyte development,GO:0021540~corpus callosum morphogenesis,GO:0021957~corticospinal tract morphogenesis,GO:0032259~methylation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0046872~metal ion binding,GO:0046974~histone methyltransferase activity (H3-K9 specific),	IPR001214:SET domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		616640~Epilepsy, progressive myoclonic, 10,		SM00355:ZnF_C2H2,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:SET,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
PRAME	PRAME nuclear receptor transcriptional regulator(PRAME)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006915~apoptotic process,GO:0008284~positive regulation of cell proliferation,GO:0030154~cell differentiation,GO:0040008~regulation of growth,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045596~negative regulation of cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0031462~Cul2-RING ubiquitin ligase complex,	GO:0005515~protein binding,GO:0042974~retinoic acid receptor binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR026271:PRAME family,			PIRSF038286:PRAME family protein,		KW-0053~Apoptosis,KW-0221~Differentiation,KW-0341~Growth regulation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,		KW-0678~Repressor,	KW-0597~Phosphoprotein,	MUTAGEN:LL->VV: Loss of interaction with RARA and defective in repressing RARA signaling.,MUTAGEN:LP->AA: Impaired formation of the CRL2(PRAME) complex.,MUTAGEN:LVELA->PVELF: Impaired formation of the CRL2(PRAME) complex.,REGION:Mediates interaction with RARA,REPEAT:LRR 1; degenerate,REPEAT:LRR 2; degenerate,REPEAT:LRR 3; degenerate,REPEAT:LRR 4; degenerate,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
PYCARD	PYD and CARD domain containing(PYCARD)	Homo sapiens			GO:0001773~myeloid dendritic cell activation,GO:0002218~activation of innate immune response,GO:0002221~pattern recognition receptor signaling pathway,GO:0002230~positive regulation of defense response to virus by host,GO:0002277~myeloid dendritic cell activation involved in immune response,GO:0002588~positive regulation of antigen processing and presentation of peptide antigen via MHC class II,GO:0002821~positive regulation of adaptive immune response,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007231~osmosensory signaling pathway,GO:0010506~regulation of autophagy,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0030838~positive regulation of actin filament polymerization,GO:0031647~regulation of protein stability,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032688~negative regulation of interferon-beta production,GO:0032722~positive regulation of chemokine production,GO:0032729~positive regulation of interferon-gamma production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042104~positive regulation of activated T cell proliferation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043087~regulation of GTPase activity,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0044351~macropinocytosis,GO:0044546~NLRP3 inflammasome complex assembly,GO:0045087~innate immune response,GO:0046330~positive regulation of JNK cascade,GO:0046456~icosanoid biosynthetic process,GO:0050729~positive regulation of inflammatory response,GO:0050766~positive regulation of phagocytosis,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050870~positive regulation of T cell activation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051260~protein homooligomerization,GO:0051607~defense response to virus,GO:0051707~response to other organism,GO:0060907~positive regulation of macrophage cytokine production,GO:0070269~pyroptosis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097202~activation of cysteine-type endopeptidase activity,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2000406~positive regulation of T cell migration,GO:2001056~positive regulation of cysteine-type endopeptidase activity,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,GO:2001242~regulation of intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005874~microtubule,GO:0008385~IkappaB kinase complex,GO:0032991~macromolecular complex,GO:0034774~secretory granule lumen,GO:0035578~azurophil granule lumen,GO:0043025~neuronal cell body,GO:0061702~inflammasome complex,GO:0072558~NLRP1 inflammasome complex,GO:0072559~NLRP3 inflammasome complex,GO:0097169~AIM2 inflammasome complex,	GO:0002020~protease binding,GO:0004197~cysteine-type endopeptidase activity,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0005523~tropomyosin binding,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0017024~myosin I binding,GO:0019899~enzyme binding,GO:0032090~Pyrin domain binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044325~ion channel binding,GO:0046983~protein dimerization activity,GO:0070700~BMP receptor binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,	IPR001315:Caspase Recruitment,IPR002398:Peptidase C14, caspase precursor p45,IPR004020:DAPIN domain,IPR011029:Death-like domain,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05164:Influenza A,hsa05417:Lipid and atherosclerosis,			SM01289:SM01289,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1271~Inflammasome,	KW-0043~Tumor suppressor,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CARD,DOMAIN:Pyrin,MUTAGEN:D->A,K: Abolishes homooligomerization.,MUTAGEN:D->A: Abolishes interaction with PYDC1.,MUTAGEN:E->A: Abolishes homooligomerization.,MUTAGEN:E->A: Abolishes interaction with PYDC1.,MUTAGEN:E->W: Abolishes interaction with NLRP2.,MUTAGEN:F->A: Abolishes homooligomerization.,MUTAGEN:I->A: Abolishes homooligomerization.,MUTAGEN:K->A,E,Q: Abolishes homooligomerization.,MUTAGEN:K->A,Q: Abolishes homooligomerization.,MUTAGEN:K->R: Loss of inflammasome activation activity.,MUTAGEN:L->A,E,G,K,N,Q: Abolishes homooligomerization.,MUTAGEN:L->A: Abolishes homooligomerization.,MUTAGEN:L->Q: Abolishes promotion of apoptosis and NF-kappa-B activation.,MUTAGEN:M->A,N,Q: Abolishes homooligomerization.,MUTAGEN:M->A: Abolishes homooligomerization.,MUTAGEN:P->A: Abolishes homooligomerization.,MUTAGEN:R->A,Q,W: Abolishes homooligomerization.,MUTAGEN:V->A: Abolishes homooligomerization.,MUTAGEN:Y->A: Abolishes interaction with PYDC1.,REGION:Disordered,
RSPO2	R-spondin 2(RSPO2)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0016055~Wnt signaling pathway,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030282~bone mineralization,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0042489~negative regulation of odontogenesis of dentin-containing tooth,GO:0060070~canonical Wnt signaling pathway,GO:0060173~limb development,GO:0060437~lung growth,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060535~trachea cartilage morphogenesis,GO:0071542~dopaminergic neuron differentiation,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005576~extracellular region,GO:0009986~cell surface,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008201~heparin binding,	IPR000884:Thrombospondin, type 1 repeat,IPR006212:Furin-like repeat,IPR009030:Insulin-like growth factor binding protein, N-terminal,	hsa04310:Wnt signaling pathway,	618021~Tetraamelia syndrome 2,618022~Humerofemoral hypoplasia with radiotibial ray deficiency,		SM00209:TSP1,SM00261:FU,	KW-0716~Sensory transduction,KW-0879~Wnt signaling pathway,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0217~Developmental protein,KW-0358~Heparin-binding,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DOMAIN:R-spondin Fu-CRD,DOMAIN:TSP type-1,MUTAGEN:F->A: Loss of LGR5-binding, no effect on interaction with RNF43 and ZNRF3, no effect on WNT3A signaling; when associated with A-105.,MUTAGEN:F->A: Loss of LGR5-binding, no effect on interaction with RNF43 and ZNRF3, no effect on WNT3A signaling; when associated with A-109.,REGION:Disordered,REPEAT:FU,
RAB11FIP4	RAB11 family interacting protein 4(RAB11FIP4)	Homo sapiens			GO:0032456~endocytic recycling,GO:0032465~regulation of cytokinesis,	GO:0005615~extracellular space,GO:0005768~endosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0030139~endocytic vesicle,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0055038~recycling endosome membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042803~protein homodimerization activity,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR019018:Rab-binding domain FIP-RBD,	hsa04144:Endocytosis,				KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,	KW-0106~Calcium,KW-0479~Metal-binding,			COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:FIP-RBD,MUTAGEN:D->A: Abolishes Rab11-binding.,REGION:Disordered,REGION:Necessary for interaction with RAB11A, subcellular location, homo- or heterooligomerization,
RAB17	RAB17, member RAS oncogene family(RAB17)	Homo sapiens			GO:0002415~immunoglobulin transcytosis in epithelial cells mediated by polymeric immunoglobulin receptor,GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0030100~regulation of endocytosis,GO:0032401~establishment of melanosome localization,GO:0032402~melanosome transport,GO:0032456~endocytic recycling,GO:0045056~transcytosis,GO:0046847~filopodium assembly,GO:0050773~regulation of dendrite development,GO:0051489~regulation of filopodium assembly,GO:0051963~regulation of synapse assembly,GO:0060271~cilium assembly,	GO:0005768~endosome,GO:0005769~early endosome,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030139~endocytic vesicle,GO:0030425~dendrite,GO:0042470~melanosome,GO:0043025~neuronal cell body,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,REGION:Disordered,
RAB37	RAB37, member RAS oncogene family(RAB37)	Homo sapiens			GO:0015031~protein transport,	GO:0005768~endosome,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,	KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,REGION:Disordered,
RALYL	RALY RNA binding protein like(RALYL)	Homo sapiens				GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,IPR017347:Heterogeneous nuclear ribonucleoprotein C, Raly,			PIRSF037992:heterogeneous nuclear ribonucleoprotein C, Raly type,	SM00360:RRM,				KW-0175~Coiled coil,		KW-0694~RNA-binding,		COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:RRM,REGION:Disordered,
RORA	RAR related orphan receptor A(RORA)	Homo sapiens			GO:0001525~angiogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006805~xenobiotic metabolic process,GO:0006809~nitric oxide biosynthetic process,GO:0008589~regulation of smoothened signaling pathway,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010906~regulation of glucose metabolic process,GO:0019218~regulation of steroid metabolic process,GO:0021702~cerebellar Purkinje cell differentiation,GO:0021930~cerebellar granule cell precursor proliferation,GO:0030522~intracellular receptor signaling pathway,GO:0032922~circadian regulation of gene expression,GO:0036315~cellular response to sterol,GO:0042632~cholesterol homeostasis,GO:0042692~muscle cell differentiation,GO:0042753~positive regulation of circadian rhythm,GO:0043030~regulation of macrophage activation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045599~negative regulation of fat cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046068~cGMP metabolic process,GO:0050728~negative regulation of inflammatory response,GO:0070328~triglyceride homeostasis,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071456~cellular response to hypoxia,GO:0072539~T-helper 17 cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008142~oxysterol binding,GO:0008270~zinc ion binding,GO:0043565~sequence-specific DNA binding,GO:0098531~transcription factor activity, direct ligand regulated sequence-specific DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR003079:Nuclear receptor ROR,IPR013088:Zinc finger, NHR/GATA-type,	hsa04659:Th17 cell differentiation,hsa04710:Circadian rhythm,hsa05017:Spinocerebellar ataxia,hsa05321:Inflammatory bowel disease,	618060~Intellectual developmental disorder with or without epilepsy or cerebellar ataxia,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MOTIF:AF-2,MUTAGEN:A->L: About 80% loss of transcriptional activity.,MUTAGEN:A->Q: Almost total loss of transcriptional activity.,MUTAGEN:C->L: About 60% loss of transcriptional activity.,MUTAGEN:C->Q: Less effect on transcriptional activity with cholesterol sulfate as substrate as compared to cholesterol as substrate.,MUTAGEN:E->K: Abolishes transcriptional activity. Protects from protein degradation.,MUTAGEN:F->W: Slight loss of transcriptional activity.,MUTAGEN:H->W: Almost total loss of transcriptional activity.,MUTAGEN:K->A: Complete loss of transcriptional activity; when associated with A-507.,MUTAGEN:K->A: Increased transcriptional activity. No effect on protein degradation.,MUTAGEN:K->R: Loss of sumoylation.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:L->F: Small reduction in transcriptional activity. No protein degradation.,MUTAGEN:LF->AA: Decreases interaction with NCOA2. Loss of interaction with FOXP3.,MUTAGEN:T->A: Greatly increased transcriptional activity. Decrease in repression by NR1D1.,MUTAGEN:T->D,E: Some increase in transcriptional activity. No change in repression by NR1D1.,MUTAGEN:T->R: Attenuates transcriptional activity.,MUTAGEN:T->V,I: Some increase in transcriptional activity.,MUTAGEN:V->G: Greatly reduced transcriptional activity. Protects from protein degradation.,MUTAGEN:V->R: Strongly decreases interaction with NCOA2 and MED1.,MUTAGEN:Y->A: Complete loss of transcriptional activity; when associated with A-339.,MUTAGEN:Y->F: About 40% loss of transcriptional activity.,REGION:Disordered,ZN_FING:NR C4-type,
RCBTB2	RCC1 and BTB domain containing protein 2(RCBTB2)	Homo sapiens				GO:0001669~acrosomal vesicle,GO:0005737~cytoplasm,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000210:BTB/POZ-like,IPR000408:Regulator of chromosome condensation, RCC1,IPR009091:Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,				SM00225:BTB,		KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,				DOMAIN:BTB,REPEAT:RCC1,REPEAT:RCC1 1,REPEAT:RCC1 2,REPEAT:RCC1 3,REPEAT:RCC1 4,REPEAT:RCC1 5,REPEAT:RCC1 6,
RBM47	RNA binding motif protein 47(RBM47)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0002244~hematopoietic progenitor cell differentiation,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0016554~cytidine to uridine editing,GO:0032733~positive regulation of interleukin-10 production,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:0070935~3'-UTR-mediated mRNA stabilization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030895~apolipoprotein B mRNA editing enzyme complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR000504:RNA recognition motif domain,IPR006535:HnRNP R/Q splicing factor,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0488~Methylation,	COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:F->A: Decreased function in regulation of alternative splicing. Decreased pre-mRNA binding. No effect on homodimerization.,MUTAGEN:F->A: Decreased function in regulation of alternative splicing. No effect on pre-mRNA binding.,MUTAGEN:F->A: Loss of function in regulation of alternative splicing. Loss of pre-mRNA binding activity. Decreased homodimerization.,REGION:Disordered,
REM1	RRAD and GEM like GTPase 1(REM1)	Homo sapiens			GO:0014722~regulation of skeletal muscle contraction by calcium ion signaling,GO:1901842~negative regulation of high voltage-gated calcium channel activity,GO:1904878~negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,	GO:0005886~plasma membrane,GO:0030315~T-tubule,GO:0031674~I band,	GO:0003924~GTPase activity,GO:0005246~calcium channel regulator activity,GO:0005516~calmodulin binding,GO:0005525~GTP binding,GO:0044325~ion channel binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR017358:Small GTPase superfamily, GEM/REM/Rad,IPR027417:P-loop containing nucleoside triphosphate hydrolase,			PIRSF038017:GTP-binding protein, GEM type,						KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:T->N: No endothelial cell sprouting.,REGION:Calmodulin-binding,REGION:Disordered,
RRAD	RRAD, Ras related glycolysis inhibitor and calcium channel regulator(RRAD)	Homo sapiens			GO:0007264~small GTPase mediated signal transduction,GO:1901841~regulation of high voltage-gated calcium channel activity,GO:1901842~negative regulation of high voltage-gated calcium channel activity,	GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003924~GTPase activity,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005525~GTP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR017358:Small GTPase superfamily, GEM/REM/Rad,IPR027417:P-loop containing nucleoside triphosphate hydrolase,			PIRSF038017:GTP-binding protein, GEM type,			KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	REGION:Calmodulin-binding,REGION:Disordered,
RUNX1	RUNX family transcription factor 1(RUNX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0002062~chondrocyte differentiation,GO:0002573~myeloid leukocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010755~regulation of plasminogen activation,GO:0030097~hemopoiesis,GO:0030099~myeloid cell differentiation,GO:0030182~neuron differentiation,GO:0030853~negative regulation of granulocyte differentiation,GO:0030854~positive regulation of granulocyte differentiation,GO:0032743~positive regulation of interleukin-2 production,GO:0032967~positive regulation of collagen biosynthetic process,GO:0043371~negative regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043378~positive regulation of CD8-positive, alpha-beta T cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048935~peripheral nervous system neuron development,GO:0051094~positive regulation of developmental process,GO:0060043~regulation of cardiac muscle cell proliferation,GO:0061026~cardiac muscle tissue regeneration,GO:0071425~hematopoietic stem cell proliferation,GO:1903055~positive regulation of extracellular matrix organization,GO:1905203~regulation of connective tissue replacement,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016021~integral component of membrane,GO:0016513~core-binding factor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003714~transcription corepressor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000040:Acute myeloid leukemia 1 protein (AML1)/Runt,IPR002893:Zinc finger, MYND-type,IPR008967:p53-like transcription factor, DNA-binding,IPR012346:p53/RUNT-type transcription factor, DNA-binding domain,IPR013289:Eight-Twenty-One,IPR013290:Myeloid transforming gene on chromosome 8 (MTG8),IPR013524:Runt domain,IPR013711:Runx, C-terminal  domain,IPR014896:NHR2-like,IPR016554:Runt-related transcription factor RUNX,IPR027384:Runx, central domain,	hsa04530:Tight junction,hsa04659:Th17 cell differentiation,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,	601399~Platelet disorder, familial, with associated myeloid malignancy,601626~Leukemia, acute myeloid,	PIRSF009374:runt-related transcription factor RUNX,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0812~Transmembrane,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0868~Chloride,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:MYND-type,DOMAIN:NHR2-like,DOMAIN:Runt,MUTAGEN:A->T: Loss of heterodimerization. Disrupts interactionof AML1-MTG8/ETO with CBFB, no effect on AML1-MTG8/ETO-mediated transformation activity.,MUTAGEN:D->A: Strongly reduces DNA-binding.,MUTAGEN:G->R: Loss of heterodimerization and impaired phosphorylation.,MUTAGEN:K->A: Reduces DNA-binding.,MUTAGEN:K->A: Strongly reduces DNA-binding.,MUTAGEN:K->E: Strongly reduces DNA-binding, impaired phosphorylation and reduced EP300 phosphorylation induction.,MUTAGEN:M->V: Disrupts interaction of AML1-MTG8/ETO with CBFB, no effect on AML1-MTG8/ETO-mediated transformation activity.,MUTAGEN:Missing: No DNA-binding.,MUTAGEN:R->A: Strongly reduces DNA-binding.,MUTAGEN:S->A: Reduced phosphorylation.,MUTAGEN:S->A: Reduced phosphorylation; when associated with A-273.,MUTAGEN:S->G: Disrupts AML1-MTG8/ETO DNA-binding, decreases AML1-MTG8/ETO transforming activity.,MUTAGEN:S->R: Loss of heterodimerization and reduced EP300 phosphorylation induction.,MUTAGEN:T->A: No effect on DNA binding.,MUTAGEN:T->A: Reduced phosphorylation; when associated with A-276.,MUTAGEN:T->A: Strongly reduces DNA-binding.,REGION:Disordered,REGION:Interaction with DNA,REGION:Interaction with FOXP3,REGION:Interaction with KAT6A,REGION:Interaction with KAT6B,SITE:Breakpoint for translocation to form AML1-EAP in T-MDS and CML, to form type II MACROD1-RUNX1 fusion protein and to form RUNX1-CBFA2T2 in acute myeloid leukemia,SITE:Breakpoint for translocation to form AML1-EMV-1 (or AML1-EAP) in CML and T-MDS, to form AML1-MTG8 (ETO) in AML-M2, to form AML1-CBFA2T3 in therapy-related myeloid malignancies, to form AML1-MECOM in CML and to form type I MACROD1-RUNX1 fusion protein,
RUNX3	RUNX family transcription factor 3(RUNX3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0002062~chondrocyte differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0030097~hemopoiesis,GO:0030182~neuron differentiation,GO:0043371~negative regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043378~positive regulation of CD8-positive, alpha-beta T cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045786~negative regulation of cell cycle,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048935~peripheral nervous system neuron development,GO:0050680~negative regulation of epithelial cell proliferation,GO:0071559~response to transforming growth factor beta,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016513~core-binding factor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000040:Acute myeloid leukemia 1 protein (AML1)/Runt,IPR008967:p53-like transcription factor, DNA-binding,IPR012346:p53/RUNT-type transcription factor, DNA-binding domain,IPR013524:Runt domain,IPR013711:Runx, C-terminal  domain,IPR016554:Runt-related transcription factor RUNX,	hsa04658:Th1 and Th2 cell differentiation,hsa05169:Epstein-Barr virus infection,		PIRSF009374:runt-related transcription factor RUNX,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Runt,REGION:Disordered,
RASSF1	Ras association domain family member 1(RASSF1)	Homo sapiens			GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0031398~positive regulation of protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0050821~protein stabilization,GO:0051726~regulation of cell cycle,GO:0070507~regulation of microtubule cytoskeleton organization,GO:1902806~regulation of cell cycle G1/S phase transition,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0047485~protein N-terminus binding,	IPR000159:Ras-association,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR011524:SARAH domain,	hsa04014:Ras signaling pathway,hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,			SM00109:C1,SM00314:RA,	KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Ras-associating,DOMAIN:SARAH,REGION:Disordered,REGION:MOAP1-binding,REGION:Mediates interaction with E4F1,ZN_FING:Phorbol-ester/DAG-type,
RASSF2	Ras association domain family member 2(RASSF2)	Homo sapiens			GO:0001501~skeletal system development,GO:0001503~ossification,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0031954~positive regulation of protein autophosphorylation,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0038168~epidermal growth factor receptor signaling pathway via I-kappaB kinase/NF-kappaB cascade,GO:0043065~positive regulation of apoptotic process,GO:0045667~regulation of osteoblast differentiation,GO:0045670~regulation of osteoclast differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046330~positive regulation of JNK cascade,GO:0046849~bone remodeling,GO:0048872~homeostasis of number of cells,GO:0050821~protein stabilization,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1901223~negative regulation of NIK/NF-kappaB signaling,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,	GO:0004672~protein kinase activity,GO:0005515~protein binding,	IPR000159:Ras-association,IPR011524:SARAH domain,	hsa04392:Hippo signaling pathway - multiple species,			SM00314:RA,	KW-0131~Cell cycle,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0043~Tumor suppressor,				KW-0597~Phosphoprotein,	DOMAIN:Ras-associating,DOMAIN:SARAH,REGION:Disordered,
RASSF6	Ras association domain family member 6(RASSF6)	Homo sapiens			GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,		GO:0005515~protein binding,	IPR000159:Ras-association,IPR011524:SARAH domain,	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,			SM00314:RA,	KW-0053~Apoptosis,						KW-0597~Phosphoprotein,	DOMAIN:Ras-associating,DOMAIN:SARAH,
ARHGAP10	Rho GTPase activating protein 10(ARHGAP10)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000198:Rho GTPase-activating protein domain,IPR001452:Src homology-3 domain,IPR001849:Pleckstrin homology domain,IPR008936:Rho GTPase activation protein,IPR011993:Pleckstrin homology-like domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa05100:Bacterial invasion of epithelial cells,			SM00233:PH,SM00324:RhoGAP,SM00326:SH3,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,KW-0732~Signal,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:PH,DOMAIN:Rho-GAP,DOMAIN:SH3,REGION:Disordered,
S100A12	S100 calcium binding protein A12(S100A12)	Homo sapiens			GO:0002548~monocyte chemotaxis,GO:0006805~xenobiotic metabolic process,GO:0006954~inflammatory response,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043406~positive regulation of MAP kinase activity,GO:0043542~endothelial cell migration,GO:0045087~innate immune response,GO:0045576~mast cell activation,GO:0050729~positive regulation of inflammatory response,GO:0050832~defense response to fungus,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0034774~secretory granule lumen,	GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0048306~calcium-dependent protein binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,				SM01394:SM01394,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0186~Copper,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0044~Antibiotic,KW-0295~Fungicide,KW-0929~Antimicrobial,		DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,PEPTIDE:Calcitermin,REGION:Hinge domain,
S100A3	S100 calcium binding protein A3(S100A3)	Homo sapiens				GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,				SM01394:SM01394,		KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0164~Citrullination,KW-1015~Disulfide bond,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:C->A: Abolishes calcium binding; when associated with Ala-30.,MUTAGEN:C->A: Abolishes calcium binding; when associated with Ala-68.,MUTAGEN:C->A: Increases affinity for calcium; when associated with Ala-81.,MUTAGEN:C->A: Increases affinity for calcium; when associated with Ala-99.,
S100A9	S100 calcium binding protein A9(S100A9)	Homo sapiens			GO:0002523~leukocyte migration involved in inflammatory response,GO:0002544~chronic inflammatory response,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006954~inflammatory response,GO:0007267~cell-cell signaling,GO:0010976~positive regulation of neuron projection development,GO:0014002~astrocyte development,GO:0018119~peptidyl-cysteine S-nitrosylation,GO:0030307~positive regulation of cell growth,GO:0030593~neutrophil chemotaxis,GO:0032119~sequestering of zinc ion,GO:0032496~response to lipopolysaccharide,GO:0035425~autocrine signaling,GO:0035606~peptidyl-cysteine S-trans-nitrosylation,GO:0035821~modification of morphology or physiology of other organism,GO:0042742~defense response to bacterium,GO:0043542~endothelial cell migration,GO:0045087~innate immune response,GO:0045113~regulation of integrin biosynthetic process,GO:0050729~positive regulation of inflammatory response,GO:0050832~defense response to fungus,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051493~regulation of cytoskeleton organization,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070488~neutrophil aggregation,GO:0098869~cellular oxidant detoxification,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030054~cell junction,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0016209~antioxidant activity,GO:0035662~Toll-like receptor 4 binding,GO:0048306~calcium-dependent protein binding,GO:0050544~arachidonic acid binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04657:IL-17 signaling pathway,			SM00054:EFh,SM01394:SM01394,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0145~Chemotaxis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0049~Antioxidant,KW-0929~Antimicrobial,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:C->A: Disrupts interaction with NOS2 and inhibits LDL(ox)-induced GAPDH S-nitrosylation; no effect on interaction with S100A8.,MUTAGEN:E->Q: Loss of resistance to bacterial invasion; when associated with Q-36.,MUTAGEN:E->Q: Loss of resistance to bacterial invasion; when associated with Q-78.,MUTAGEN:M->A: Loss of antifungal activity.,MUTAGEN:M->A: No effect on antifungal activity.,REGION:Disordered,
SPDEF	SAM pointed domain containing ETS transcription factor(SPDEF)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002068~glandular epithelial cell development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0010454~negative regulation of cell fate commitment,GO:0010455~positive regulation of cell fate commitment,GO:0030154~cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060480~lung goblet cell differentiation,GO:0060576~intestinal epithelial cell development,GO:0072148~epithelial cell fate commitment,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,				SM00251:SAM_PNT,SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:PNT,REGION:Disordered,
SATB2	SATB homeobox 2(SATB2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0002076~osteoblast development,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009880~embryonic pattern specification,GO:0021902~commitment of neuronal cell to specific neuron type in forebrain,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0051216~cartilage development,GO:0060021~palate development,GO:0071310~cellular response to organic substance,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016363~nuclear matrix,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,	IPR001356:Homeodomain,IPR003350:Homeodomain protein CUT,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,		612313~Glass syndrome,		SM00389:HOX,SM01109:SM01109,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0371~Homeobox,KW-0677~Repeat,		KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:CUT 1,DNA_BIND:CUT 2,DNA_BIND:Homeobox,DOMAIN:CUT,DOMAIN:CUTL,DOMAIN:Homeobox,DOMAIN:ULD,MUTAGEN:K->R: Reduced sumoylation, impaired nuclear localization, but enhanced transcription factor activity.,REGION:Disordered,
SH3BP4	SH3 domain binding protein 4(SH3BP4)	Homo sapiens			GO:0006897~endocytosis,GO:0008285~negative regulation of cell proliferation,GO:0010508~positive regulation of autophagy,GO:0030308~negative regulation of cell growth,GO:0032007~negative regulation of TOR signaling,GO:0034260~negative regulation of GTPase activity,GO:0050790~regulation of catalytic activity,GO:0061462~protein localization to lysosome,GO:0071230~cellular response to amino acid stimulus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005905~clathrin-coated pit,GO:0030136~clathrin-coated vesicle,GO:0070062~extracellular exosome,	GO:0005092~GDP-dissociation inhibitor activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,	IPR000906:ZU5,IPR001452:Src homology-3 domain,				SM00326:SH3,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0472~Membrane,KW-0539~Nucleus,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:ZU5,MUTAGEN:W->A: Loss of function. Loss of targeting to the clathrin-coated pits and vesicles. Loss of interaction with DNM2, RRAGB and RRAGC. No effect on localization to the plasma membrane.,
SIM1	SIM bHLH transcription factor 1(SIM1)	Homo sapiens			GO:0001657~ureteric bud development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0030154~cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR000014:PAS domain,IPR001610:PAC motif,IPR010578:Single-minded, C-terminal,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013655:PAS fold-3,IPR013767:PAS fold,				SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:PAC,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:Single-minded C-terminal,DOMAIN:bHLH,MOTIF:Nuclear localization signal,REGION:Disordered,
SIM2	SIM bHLH transcription factor 2(SIM2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0009880~embryonic pattern specification,GO:0030154~cell differentiation,GO:0030324~lung development,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR000014:PAS domain,IPR001610:PAC motif,IPR010578:Single-minded, C-terminal,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013655:PAS fold-3,IPR013767:PAS fold,				SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic residues,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:Single-minded C-terminal,DOMAIN:bHLH,MOTIF:Nuclear localization signal,MUTAGEN:K->A,G: Reduced nuclear translocation.,MUTAGEN:K->A: No effect on nuclear translocation.,MUTAGEN:K->G: No effect on nuclear translocation.,MUTAGEN:L->A: No effect on nuclear translocation.,MUTAGEN:M->A: No effect on nuclear translocation.,MUTAGEN:P->A: No effect on nuclear translocation.,MUTAGEN:P->A: Reduced nuclear translocation.,MUTAGEN:R->A,G: Reduced nuclear translocation.,MUTAGEN:R->A: No effect on nuclear translocation.,MUTAGEN:T->A: No effect on nuclear translocation.,MUTAGEN:V->A: No effect on nuclear translocation.,MUTAGEN:Y->A: Reduced nuclear translocation.,REGION:Disordered,
SIX6	SIX homeobox 6(SIX6)	Homo sapiens			GO:0001654~eye development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007420~brain development,GO:0007601~visual perception,GO:0009887~animal organ morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,		212550~Optic disc anomalies with retinal and/or macular dystrophy,		SM00389:HOX,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0898~Cataract,KW-1013~Microphthalmia,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:Homeobox protein SIX1 N-terminal SD,REGION:Disordered,
SLITRK3	SLIT and NTRK like family member 3(SLITRK3)	Homo sapiens			GO:0007409~axonogenesis,GO:0051932~synaptic transmission, GABAergic,GO:0051965~positive regulation of synapse assembly,GO:0072553~terminal button organization,GO:0072578~neurotransmitter-gated ion channel clustering,GO:0097116~gephyrin clustering involved in postsynaptic density assembly,GO:0099560~synaptic membrane adhesion,GO:1905606~regulation of presynapse assembly,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0098839~postsynaptic density membrane,GO:0098982~GABA-ergic synapse,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,	GO:0005515~protein binding,	IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,	hsa04514:Cell adhesion molecules,			SM00082:LRRCT,SM00369:LRR_TYP,		KW-0472~Membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:LRRCT 1,DOMAIN:LRRCT 2,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SMOC2	SPARC related modular calcium binding 2(SMOC2)	Homo sapiens			GO:0010595~positive regulation of endothelial cell migration,GO:0030198~extracellular matrix organization,GO:0035470~positive regulation of vascular wound healing,GO:0045743~positive regulation of fibroblast growth factor receptor signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0045931~positive regulation of mitotic cell cycle,GO:1900748~positive regulation of vascular endothelial growth factor signaling pathway,GO:2000573~positive regulation of DNA biosynthetic process,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0071944~cell periphery,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0050840~extracellular matrix binding,	IPR000716:Thyroglobulin type-1,IPR002048:EF-hand domain,IPR002350:Kazal domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR019577:SPARC/Testican, calcium-binding domain,		125400~Dentin dysplasia, type I, with microdontia and misshapen teeth,		SM00211:TY,SM00280:KAZAL,		KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Kazal-like,DOMAIN:Thyroglobulin type-1 1,DOMAIN:Thyroglobulin type-1 2,REGION:Disordered,
SPHKAP	SPHK1 interactor, AKAP domain containing(SPHKAP)	Homo sapiens		h_edg1Pathway:Phospholipids as signalling intermediaries,		GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0005515~protein binding,GO:0051018~protein kinase A binding,	IPR008382:SPHK1-interactor/A-kinase anchor 110kDa,IPR018292:A-kinase anchor 110kDa, C-terminal,						KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:PKA-RII subunit binding domain,
SPTY2D1	SPT2 chromatin protein domain containing 1(SPTY2D1)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0006360~transcription from RNA polymerase I promoter,GO:0010847~regulation of chromatin assembly,GO:0031507~heterochromatin assembly,GO:0043486~histone exchange,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0001042~RNA polymerase I core binding,GO:0003677~DNA binding,GO:0042393~histone binding,	IPR013256:Chromatin SPT2,				SM00784:SPT2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:ED->AA: Strongly reduces affinity for histones.,MUTAGEN:EE->AA: Strongly reduces affinity for histones.,MUTAGEN:LG->AN: Strongly reduces affinity for histones.,MUTAGEN:M->A: Strongly reduces affinity for histones.,REGION:Disordered,REGION:Important for interaction with DNA,REGION:Important for interaction with histones,
SOX1	SRY-box transcription factor 1(SOX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002089~lens morphogenesis in camera-type eye,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0009653~anatomical structure morphogenesis,GO:0021521~ventral spinal cord interneuron specification,GO:0021884~forebrain neuron development,GO:0030154~cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048713~regulation of oligodendrocyte differentiation,GO:1904936~interneuron migration,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR009071:High mobility group (HMG) box domain,IPR022097:Transcription factor SOX,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic residues,DNA_BIND:HMG box,MOTIF:9aaTAD,REGION:Disordered,
SOX14	SRY-box transcription factor 14(SOX14)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0007399~nervous system development,GO:0007601~visual perception,GO:0009649~entrainment of circadian clock,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2001222~regulation of neuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR022097:Transcription factor SOX,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,		DNA_BIND:HMG box,DOMAIN:HMG box,REGION:Disordered,
SOX17	SRY-box transcription factor 17(SOX17)	Homo sapiens			GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001656~metanephros development,GO:0001706~endoderm formation,GO:0001714~endodermal cell fate specification,GO:0001828~inner cell mass cellular morphogenesis,GO:0001947~heart looping,GO:0003142~cardiogenic plate morphogenesis,GO:0003143~embryonic heart tube morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003308~negative regulation of Wnt signaling pathway involved in heart development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0007493~endodermal cell fate determination,GO:0007507~heart development,GO:0009653~anatomical structure morphogenesis,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0021903~rostrocaudal neural tube patterning,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030154~cell differentiation,GO:0030308~negative regulation of cell growth,GO:0031648~protein destabilization,GO:0035050~embryonic heart tube development,GO:0042074~cell migration involved in gastrulation,GO:0045597~positive regulation of cell differentiation,GO:0045732~positive regulation of protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0048617~embryonic foregut morphogenesis,GO:0048866~stem cell fate specification,GO:0050821~protein stabilization,GO:0060214~endocardium formation,GO:0060913~cardiac cell fate determination,GO:0060914~heart formation,GO:0060956~endocardial cell differentiation,GO:0061009~common bile duct development,GO:0061010~gall bladder development,GO:0061031~endodermal digestive tract morphogenesis,GO:0072091~regulation of stem cell proliferation,GO:0072189~ureter development,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1903226~positive regulation of endodermal cell differentiation,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000035~regulation of stem cell division,GO:2000043~regulation of cardiac cell fate specification,GO:2000738~positive regulation of stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR009071:High mobility group (HMG) box domain,IPR021934:Sox C-terminal transactivation domain,	hsa04310:Wnt signaling pathway,	613674~Vesicoureteral reflux 3,		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:HMG box,DOMAIN:HMG box,DOMAIN:Sox C-terminal,MOTIF:9aaTAD,REGION:Disordered,
SOX18	SRY-box transcription factor 18(SOX18)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0001942~hair follicle development,GO:0001944~vasculature development,GO:0001946~lymphangiogenesis,GO:0001947~heart looping,GO:0003151~outflow tract morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0009653~anatomical structure morphogenesis,GO:0022405~hair cycle process,GO:0030154~cell differentiation,GO:0035050~embryonic heart tube development,GO:0043534~blood vessel endothelial cell migration,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0048866~stem cell fate specification,GO:0060214~endocardium formation,GO:0060836~lymphatic endothelial cell differentiation,GO:0060956~endocardial cell differentiation,GO:0061028~establishment of endothelial barrier,GO:0072091~regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR021934:Sox C-terminal transactivation domain,		137940~Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,607823~Hypotrichosis-lymphedema-telangiectasia syndrome,		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1063~Hypotrichosis,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,COMPBIAS:Pro residues,DNA_BIND:HMG box,DOMAIN:Sox C-terminal,MOTIF:9aaTAD,MUTAGEN:YL->QS: Greatly reduced transactivating activity.,REGION:Disordered,REGION:Important for transcriptional activation,REGION:Interaction with DNA,
SOX21	SRY-box transcription factor 21(SOX21)	Homo sapiens			GO:0001942~hair follicle development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048863~stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR022097:Transcription factor SOX,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		DNA_BIND:HMG box,DOMAIN:HMG box,REGION:Disordered,
SOX8	SRY-box transcription factor 8(SOX8)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001755~neural crest cell migration,GO:0002009~morphogenesis of an epithelium,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0007283~spermatogenesis,GO:0007422~peripheral nervous system development,GO:0008584~male gonad development,GO:0010628~positive regulation of gene expression,GO:0010817~regulation of hormone levels,GO:0014015~positive regulation of gliogenesis,GO:0014032~neural crest cell development,GO:0033690~positive regulation of osteoblast proliferation,GO:0035914~skeletal muscle cell differentiation,GO:0043066~negative regulation of apoptotic process,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046533~negative regulation of photoreceptor cell differentiation,GO:0048469~cell maturation,GO:0048484~enteric nervous system development,GO:0048709~oligodendrocyte differentiation,GO:0060009~Sertoli cell development,GO:0060018~astrocyte fate commitment,GO:0060041~retina development in camera-type eye,GO:0060221~retinal rod cell differentiation,GO:0060612~adipose tissue development,GO:0061138~morphogenesis of a branching epithelium,GO:0072034~renal vesicle induction,GO:0072197~ureter morphogenesis,GO:0072289~metanephric nephron tubule formation,GO:0090184~positive regulation of kidney development,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR022151:Sox developmental protein N-terminal,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:HMG box,MOTIF:9aaTAD,REGION:Dimerization (DIM),REGION:Disordered,REGION:Transactivation domain (TAC),REGION:Transactivation domain (TAM),
ST8SIA3	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3(ST8SIA3)	Homo sapiens			GO:0001574~ganglioside biosynthetic process,GO:0006486~protein glycosylation,GO:0006491~N-glycan processing,GO:0006688~glycosphingolipid biosynthetic process,GO:0009100~glycoprotein metabolic process,GO:0009311~oligosaccharide metabolic process,GO:1990743~protein sialylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0003828~alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity,GO:0008373~sialyltransferase activity,GO:0033691~sialic acid binding,GO:0042802~identical protein binding,	IPR001675:Glycosyl transferase, family 29,IPR012163:Sialyltransferase,			PIRSF005557:sialyltransferase,			KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,COMPBIAS:Pro residues,MUTAGEN:H->A: Abolishes enzyme activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
STAG3	STAG3 cohesin complex component(STAG3)	Homo sapiens			GO:0007062~sister chromatid cohesion,GO:0007129~synapsis,GO:0007130~synaptonemal complex assembly,GO:0034089~establishment of meiotic sister chromatid cohesion,GO:0034502~protein localization to chromosome,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0000795~synaptonemal complex,GO:0000800~lateral element,GO:0000802~transverse filament,GO:0001673~male germ cell nucleus,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0008278~cohesin complex,GO:0030893~meiotic cohesin complex,GO:0034991~nuclear meiotic cohesin complex,	GO:0003682~chromatin binding,	IPR013721:STAG,IPR016024:Armadillo-type fold,IPR020839:Stromalin conservative domain,	hsa04114:Oocyte meiosis,	615723~Premature ovarian failure 8,619672~Spermatogenic failure 61,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0469~Meiosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-1066~Premature ovarian failure,				KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:SCD,DOMAIN:STAG,REGION:Disordered,
SMARCB1	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1(SMARCB1)	Homo sapiens		h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,	GO:0001188~RNA polymerase I transcriptional preinitiation complex assembly,GO:0001835~blastocyst hatching,GO:0006337~nucleosome disassembly,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007399~nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0015074~DNA integration,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0030154~cell differentiation,GO:0039692~single stranded viral RNA replication via double stranded DNA intermediate,GO:0043923~positive regulation by host of viral transcription,GO:0045582~positive regulation of T cell differentiation,GO:0045597~positive regulation of cell differentiation,GO:0045663~positive regulation of myoblast differentiation,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0070316~regulation of G0 to G1 transition,GO:0070365~hepatocyte differentiation,GO:0090240~positive regulation of histone H4 acetylation,GO:1900110~negative regulation of histone H3-K9 dimethylation,GO:1900113~negative regulation of histone H3-K9 trimethylation,GO:1900461~positive regulation of pseudohyphal growth by positive regulation of transcription from RNA polymerase II promoter,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:1902459~positive regulation of stem cell population maintenance,GO:1902661~positive regulation of glucose mediated signaling pathway,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000617~positive regulation of histone H3-K9 acetylation,GO:2000781~positive regulation of double-strand break repair,GO:2000819~regulation of nucleotide-excision repair,	GO:0000228~nuclear chromosome,GO:0000776~kinetochore,GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0001741~XY body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016363~nuclear matrix,GO:0016514~SWI/SNF complex,GO:0016586~RSC complex,GO:0032991~macromolecular complex,GO:0035060~brahma complex,GO:0043073~germ cell nucleus,GO:0043231~intracellular membrane-bounded organelle,GO:0070603~SWI/SNF superfamily-type complex,GO:0071564~npBAF complex,GO:0071565~nBAF complex,	GO:0001164~RNA polymerase I CORE element sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0030957~Tat protein binding,GO:0031492~nucleosomal DNA binding,GO:0042802~identical protein binding,	IPR006939:SNF5/SMARCB1/INI1,IPR017393:SWI/SNF chromatin-remodeling complex, component hSNF5/Ini1,	hsa03082:ATP-dependent chromatin remodeling,hsa03250:Viral life cycle - HIV-1,hsa04714:Thermogenesis,hsa05225:Hepatocellular carcinoma,	162091~Schwannomatosis-1, susceptibility to,609322~Rhabdoid tumor predisposition syndrome 1,609322~Rhabdoid tumors, somatic,614608~Coffin-Siris syndrome 3,	PIRSF038126:SWI/SNF chromatin-remodeling complex, component hSNF5/Ini1,		KW-0131~Cell cycle,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1063~Hypotrichosis,	KW-0677~Repeat,		KW-0010~Activator,KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:2 X approximate tandem repeats,REGION:DNA-binding,REGION:Disordered,REGION:HIV-1 integrase-binding,REGION:Interaction with PPP1R15A,REGION:MYC-binding,REPEAT:1,REPEAT:2,
SPI1	Spi-1 proto-oncogene(SPI1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002314~germinal center B cell differentiation,GO:0002316~follicular B cell differentiation,GO:0002327~immature B cell differentiation,GO:0002357~defense response to tumor cell,GO:0002572~pro-T cell differentiation,GO:0002573~myeloid leukocyte differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030154~cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030225~macrophage differentiation,GO:0030851~granulocyte differentiation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0035019~somatic stem cell population maintenance,GO:0036462~TRAIL-activated apoptotic signaling pathway,GO:0043011~myeloid dendritic cell differentiation,GO:0043314~negative regulation of neutrophil degranulation,GO:0043966~histone H3 acetylation,GO:0044027~hypermethylation of CpG island,GO:0045347~negative regulation of MHC class II biosynthetic process,GO:0045579~positive regulation of B cell differentiation,GO:0045646~regulation of erythrocyte differentiation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0060033~anatomical structure regression,GO:0070102~interleukin-6-mediated signaling pathway,GO:0090241~negative regulation of histone H4 acetylation,GO:0090402~oncogene-induced cell senescence,GO:0098508~endothelial to hematopoietic transition,GO:1900745~positive regulation of p38MAPK cascade,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901674~regulation of histone H3-K27 acetylation,GO:1902262~apoptotic process involved in blood vessel morphogenesis,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904151~positive regulation of microglial cell mediated cytotoxicity,GO:1904178~negative regulation of adipose tissue development,GO:1904238~pericyte cell differentiation,GO:1905036~positive regulation of antifungal innate immune response,GO:1905453~regulation of myeloid progenitor cell differentiation,GO:2000529~positive regulation of myeloid dendritic cell chemotaxis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016021~integral component of membrane,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0051525~NFAT protein binding,GO:0060090~binding, bridging,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097677~STAT family protein binding,	IPR000418:Ets domain,	hsa04380:Osteoclast differentiation,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,	619707~Agammaglobulinemia 10, autosomal dominant,		SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	BINDING:contacts bases in the GGAA sequence in the major groove,BINDING:contacts the phosphate backbone of the GGAA sequence in the minor groove upstream,BINDING:forms a salt bridge with the phosphate backbone of the opposite strand downstream of the GGAA core sequence,DNA_BIND:ETS,REGION:Disordered,TRANSMEM:Helical,
TCIRG1	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3(TCIRG1)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0001503~ossification,GO:0002158~osteoclast proliferation,GO:0006874~cellular calcium ion homeostasis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006968~cellular defense response,GO:0007035~vacuolar acidification,GO:0007039~protein catabolic process in the vacuole,GO:0007042~lysosomal lumen acidification,GO:0008284~positive regulation of cell proliferation,GO:0010155~regulation of proton transport,GO:0010272~response to silver ion,GO:0010467~gene expression,GO:0010468~regulation of gene expression,GO:0016064~immunoglobulin mediated immune response,GO:0016236~macroautophagy,GO:0021554~optic nerve development,GO:0030010~establishment of cell polarity,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030316~osteoclast differentiation,GO:0031529~ruffle organization,GO:0033365~protein localization to organelle,GO:0035709~memory T cell activation,GO:0035711~T-helper 1 cell activation,GO:0043029~T cell homeostasis,GO:0044691~tooth eruption,GO:0045453~bone resorption,GO:0045667~regulation of osteoblast differentiation,GO:0045851~pH reduction,GO:0050796~regulation of insulin secretion,GO:0051650~establishment of vesicle localization,GO:0060041~retina development in camera-type eye,GO:0061484~hematopoietic stem cell homeostasis,GO:0070166~enamel mineralization,GO:0071345~cellular response to cytokine stimulus,GO:0090383~phagosome acidification,GO:0097188~dentin mineralization,GO:1902600~hydrogen ion transmembrane transport,	GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005634~nucleus,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0101003~ficolin-1-rich granule membrane,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,GO:0051117~ATPase binding,	IPR002490:ATPase, V0 complex, subunit 116kDa,IPR026028:ATPase, V0 complex, subunit 116kDa, eukaryotic,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	259700~Osteopetrosis, autosomal recessive 1,	PIRSF001293:V-type proton ATPase 116 kda subunit a isoform 1,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0987~Osteopetrosis,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vacuolar,TRANSMEM:Helical,
TLX3	T cell leukemia homeobox 3(TLX3)	Homo sapiens			GO:0001764~neuron migration,GO:0002087~regulation of respiratory gaseous exchange by neurological system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007417~central nervous system development,GO:0007585~respiratory gaseous exchange,GO:0045665~negative regulation of neuron differentiation,GO:0048513~animal organ development,GO:0048665~neuron fate specification,GO:0097154~GABAergic neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,			SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,REGION:Disordered,
TBX18	T-box transcription factor 18(TBX18)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001708~cell fate specification,GO:0001756~somitogenesis,GO:0003163~sinoatrial node development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016331~morphogenesis of embryonic epithelium,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051145~smooth muscle cell differentiation,GO:0060829~negative regulation of canonical Wnt signaling pathway involved in neural plate anterior/posterior pattern formation,GO:0060930~sinoatrial node cell fate commitment,GO:0060931~sinoatrial node cell development,GO:0072189~ureter development,GO:0090103~cochlea morphogenesis,GO:0098907~regulation of SA node cell action potential,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090571~RNA polymerase II transcription repressor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001699:Transcription factor, T-box,IPR008967:p53-like transcription factor, DNA-binding,IPR018186:Transcription factor, T-box, conserved site,		143400~Congenital anomalies of kidney and urinary tract 2,		SM00425:TBOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:T-box,DOMAIN:T-box,MOTIF:Engrailed homology 1 repressor,MOTIF:Nuclear localization signal,REGION:Disordered,
TBX21	T-box transcription factor 21(TBX21)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001708~cell fate specification,GO:0002296~T-helper 1 cell lineage commitment,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009615~response to virus,GO:0032703~negative regulation of interleukin-2 production,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045580~regulation of T cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048304~positive regulation of isotype switching to IgG isotypes,GO:0071310~cellular response to organic substance,GO:0072676~lymphocyte migration,GO:2000320~negative regulation of T-helper 17 cell differentiation,GO:2000329~negative regulation of T-helper 17 cell lineage commitment,GO:2000552~negative regulation of T-helper 2 cell cytokine production,GO:2000556~positive regulation of T-helper 1 cell cytokine production,	GO:0005634~nucleus,GO:0043025~neuronal cell body,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001699:Transcription factor, T-box,IPR008967:p53-like transcription factor, DNA-binding,IPR018186:Transcription factor, T-box, conserved site,	hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05321:Inflammatory bowel disease,	208550~Asthma and nasal polyps,208550~Asthma, aspirin-induced, susceptibility to,619630~Immunodeficiency 88,		SM00425:TBOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1058~Asthma,			KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:T-box,DOMAIN:T-box,REGION:Disordered,SITE:Essential for its interaction with RUNX1 and its ability to inhibit RUNX1 transcriptional activity and suppress TH17 lineage development,
TAL1	TAL bHLH transcription factor 1, erythroid differentiation factor(TAL1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007626~locomotory behavior,GO:0021527~spinal cord association neuron differentiation,GO:0030097~hemopoiesis,GO:0030218~erythrocyte differentiation,GO:0030219~megakaryocyte differentiation,GO:0030220~platelet formation,GO:0030221~basophil differentiation,GO:0031334~positive regulation of protein complex assembly,GO:0035162~embryonic hemopoiesis,GO:0035855~megakaryocyte development,GO:0042127~regulation of cell proliferation,GO:0043249~erythrocyte maturation,GO:0045165~cell fate commitment,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045799~positive regulation of chromatin assembly or disassembly,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051781~positive regulation of cell division,GO:0060018~astrocyte fate commitment,GO:0060216~definitive hemopoiesis,GO:0060217~hemangioblast cell differentiation,GO:0060218~hematopoietic stem cell differentiation,GO:0060375~regulation of mast cell differentiation,GO:1904672~regulation of somatic stem cell population maintenance,GO:1905269~positive regulation of chromatin organization,GO:2000036~regulation of stem cell population maintenance,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0042826~histone deacetylase binding,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,		613065~Leukemia, T-cell acute lymphocytic, somatic,		SM00353:HLH,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,
TARBP1	TAR (HIV-1) RNA binding protein 1(TARBP1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030488~tRNA methylation,	GO:0005634~nucleus,	GO:0003723~RNA binding,GO:0016423~tRNA (guanine) methyltransferase activity,	IPR001537:tRNA/rRNA methyltransferase, SpoU,IPR016024:Armadillo-type fold,IPR025806:Probable methyltransferase TARBP1,									KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
TBL1XR1	TBL1X/Y related 1(TBL1XR1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001835~blastocyst hatching,GO:0002021~response to dietary excess,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016042~lipid catabolic process,GO:0016575~histone deacetylation,GO:0035264~multicellular organism growth,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050872~white fat cell differentiation,GO:0060613~fat pad development,GO:0090207~regulation of triglyceride metabolic process,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016021~integral component of membrane,GO:0017053~transcriptional repressor complex,GO:0072686~mitotic spindle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0042393~histone binding,GO:0047485~protein N-terminus binding,	IPR001680:WD40 repeat,IPR006594:LisH dimerisation motif,IPR015943:WD40/YVTN repeat-like-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,	hsa04310:Wnt signaling pathway,	602342~Pierpont syndrome,616944~Intellectual developmental disorder, autosomal dominant 41,		SM00320:WD40,SM00667:LisH,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:F-box-like,DOMAIN:LisH,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,TRANSMEM:Helical,
TCL1A	TCL1 family AKT coactivator A(TCL1A)	Homo sapiens			GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0031334~positive regulation of protein complex assembly,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0043066~negative regulation of apoptotic process,GO:0071356~cellular response to tumor necrosis factor,GO:0071902~positive regulation of protein serine/threonine kinase activity,	GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0043539~protein serine/threonine kinase activator activity,	IPR004832:TCL1/MTCP1,	hsa04151:PI3K-Akt signaling pathway,	Leukemia/lymphoma, T-cell~Leukemia/lymphoma, T-cell,				KW-0256~Endoplasmic reticulum,KW-0492~Microsome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,					MUTAGEN:D->G: Greatly reduced binding to AKT1, AKT2 and AKT3. Abolishes nuclear transport of AKT1.,MUTAGEN:I->V: Greatly reduced binding to AKT2. Abolishes nuclear transport of AKT1.,MUTAGEN:K->M: Slightly reduced binding to AKT2.,MUTAGEN:M->V: Slightly increased binding to AKT2.,MUTAGEN:PLT->AAA: Unable to homodimerize but has no effect on interaction with AKT1, AKT2 or AKT3.,MUTAGEN:Q->R: Slightly increased binding to AKT2.,
TIMP2	TIMP metallopeptidase inhibitor 2(TIMP2)	Homo sapiens		h_reckPathway:Inhibition of Matrix Metalloproteinases,	GO:0009725~response to hormone,GO:0010033~response to organic substance,GO:0010951~negative regulation of endopeptidase activity,GO:0034097~response to cytokine,GO:0051045~negative regulation of membrane protein ectodomain proteolysis,GO:1905049~negative regulation of metallopeptidase activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0035580~specific granule lumen,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0008270~zinc ion binding,GO:0030414~peptidase inhibitor activity,GO:0046872~metal ion binding,	IPR001134:Netrin domain,IPR001820:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015613:Tissue inhibitor of metalloprotease 2,IPR027465:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase, C-terminal domain,				SM00206:NTR,		KW-0964~Secreted,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0481~Metalloenzyme inhibitor,KW-0483~Metalloprotease inhibitor,KW-0646~Protease inhibitor,	KW-1015~Disulfide bond,	DOMAIN:NTR,REGION:Involved in metalloproteinase-binding,SITE:Involved in metalloproteinase-binding,
TNFAIP1	TNF alpha induced protein 1(TNFAIP1)	Homo sapiens			GO:0006915~apoptotic process,GO:0006955~immune response,GO:0016477~cell migration,GO:0016567~protein ubiquitination,GO:0035024~negative regulation of Rho protein signal transduction,GO:0043149~stress fiber assembly,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045740~positive regulation of DNA replication,GO:0051260~protein homooligomerization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0030332~cyclin binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR011333:BTB/POZ fold,				SM00225:BTB,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,					KW-0597~Phosphoprotein,	DOMAIN:BTB,MUTAGEN:ILI->AAA: Abolishes interaction with CUL3 and induces abnormal actin stress fibers.,MUTAGEN:S->A: Does not affect phosphorylation level.,MUTAGEN:S->A: Does not affect phosphorylation level; when associated with A-237.,MUTAGEN:S->A: Slightly impairs phosphorylation level.,MUTAGEN:S->A: Strongly impairs phosphorylation level.,MUTAGEN:T->A: Does not affect phosphorylation level; when associated with A-142.,REGION:Disordered,
TRAF7	TNF receptor associated factor 7(TRAF7)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0006915~apoptotic process,GO:0007219~Notch signaling pathway,GO:0016567~protein ubiquitination,GO:0043410~positive regulation of MAPK cascade,GO:0043525~positive regulation of neuron apoptotic process,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0000151~ubiquitin ligase complex,GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001293:Zinc finger, TRAF-type,IPR001680:WD40 repeat,IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017907:Zinc finger, RING-type, conserved site,IPR018957:Zinc finger, C3HC4 RING-type,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,IPR027370:RING-type zinc-finger, LisH dimerisation motif,		618164~Cardiac, facial, and digital anomalies with developmental delay,		SM00184:RING,SM00320:WD40,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0853~WD repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:RING-type,DOMAIN:TRAF-type,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,ZN_FING:RING-type,ZN_FING:TRAF-type,
TNFRSF10D	TNF receptor superfamily member 10d(TNFRSF10D)	Homo sapiens			GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0043066~negative regulation of apoptotic process,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0045569~TRAIL binding,	IPR001368:TNFR/NGFR cysteine-rich region,IPR020465:Tumour necrosis factor receptor 10,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,			SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Death; truncated,REGION:Disordered,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF4	TNF receptor superfamily member 4(TNFRSF4)	Homo sapiens		h_ox40Pathway:OX40 Signaling Pathway,	GO:0002639~positive regulation of immunoglobulin production,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0030890~positive regulation of B cell proliferation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042098~T cell proliferation,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046718~viral entry into host cell,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,	GO:0001618~virus receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,	IPR001368:TNFR/NGFR cysteine-rich region,IPR020445:Tumour necrosis factor receptor 4,	hsa04060:Cytokine-cytokine receptor interaction,	615593~Immunodeficiency 16,		SM00208:TNFR,	KW-0945~Host-virus interaction,	KW-0472~Membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3; truncated,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF9	TNF receptor superfamily member 9(TNFRSF9)	Homo sapiens		h_41BBPathway:The 4-1BB-dependent immune response,	GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0033084~regulation of immature T cell proliferation in thymus,GO:0042127~regulation of cell proliferation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0038023~signaling receptor activity,	IPR001368:TNFR/NGFR cysteine-rich region,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR020413:Tumour necrosis factor receptor 9,	hsa04060:Cytokine-cytokine receptor interaction,	620282~Immunodeficiency 109 with lymphoproliferation,		SM00208:TNFR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNFR-Cys,REGION:Disordered,REGION:Interaction with LRR-1,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TOX2	TOX high mobility group box family member 2(TOX2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0031490~chromatin DNA binding,	IPR009071:High mobility group (HMG) box domain,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:HMG box,DOMAIN:HMG box,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Required for transcriptional activation,
TRAIP	TRAF interacting protein(TRAIP)	Homo sapiens			GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007165~signal transduction,GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0016567~protein ubiquitination,GO:0031297~replication fork processing,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032688~negative regulation of interferon-beta production,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0048471~perinuclear region of cytoplasm,GO:0090734~site of DNA damage,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,		616777~Seckel syndrome 9,		SM00184:RING,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RING-type,MOTIF:PIP-box,MUTAGEN:C->A: Abolished ability to regulate nuclear envelope breakdown to anaphase.,MUTAGEN:C->A: Abolished accumulation in nucleolus.,MUTAGEN:F->A: Abolished interaction with PCNA.,MUTAGEN:K->A: Abolished sumoylation and localization to the nucleus; when associated with A-127, A-205, A-247 and A-462.,MUTAGEN:K->A: Abolished sumoylation and localization to the nucleus; when associated with A-80, A-127, A-205 and A-247.,MUTAGEN:K->A: Abolished sumoylation and localization to the nucleus; when associated with A-80, A-127, A-205 and A-462.,MUTAGEN:K->A: Abolished sumoylation and localization to the nucleus; when associated with A-80, A-127, A-247 and A-462.,MUTAGEN:K->A: Abolished sumoylation and localization to the nucleus; when associated with A-80, A-205, A-247 and A-462.,MUTAGEN:QAKL->AAKA: Abolished interaction with PCNA and localization to DNA damage sites.,REGION:Interaction with CYLD,ZN_FING:RING-type,
TSPYL5	TSPY like 5(TSPYL5)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0008284~positive regulation of cell proliferation,GO:0031398~positive regulation of protein ubiquitination,GO:0040008~regulation of growth,GO:0051897~positive regulation of protein kinase B signaling,GO:0071480~cellular response to gamma radiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR002164:Nucleosome assembly protein (NAP),					KW-0341~Growth regulation,							COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,
THY1	Thy-1 cell surface antigen(THY1)	Homo sapiens		h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,	GO:0001525~angiogenesis,GO:0001952~regulation of cell-matrix adhesion,GO:0002693~positive regulation of cellular extravasation,GO:0006469~negative regulation of protein kinase activity,GO:0007010~cytoskeleton organization,GO:0007155~cell adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007267~cell-cell signaling,GO:0030334~regulation of cell migration,GO:0030336~negative regulation of cell migration,GO:0034113~heterotypic cell-cell adhesion,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0043113~receptor clustering,GO:0043547~positive regulation of GTPase activity,GO:0046549~retinal cone cell development,GO:0046777~protein autophosphorylation,GO:0048041~focal adhesion assembly,GO:0050771~negative regulation of axonogenesis,GO:0050852~T cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051894~positive regulation of focal adhesion assembly,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0070571~negative regulation of neuron projection regeneration,GO:0098609~cell-cell adhesion,GO:2000298~regulation of Rho-dependent protein serine/threonine kinase activity,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016324~apical plasma membrane,GO:0030425~dendrite,GO:0030426~growth cone,GO:0030673~axolemma,GO:0031225~anchored component of membrane,GO:0031362~anchored component of external side of plasma membrane,GO:0032590~dendrite membrane,GO:0032809~neuronal cell body membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0005096~GTPase activator activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0034235~GPI anchor binding,	IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,	hsa04670:Leukocyte transendothelial migration,			SM00406:IGv,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Alternate,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,LIPID:GPI-anchor amidated cysteine; alternate,PROPEP:Removed in mature form,REGION:Disordered,
UGT2B7	UDP glucuronosyltransferase family 2 member B7(UGT2B7)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0006805~xenobiotic metabolic process,GO:0008209~androgen metabolic process,GO:0008210~estrogen metabolic process,GO:0052695~cellular glucuronidation,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0008194~UDP-glycosyltransferase activity,GO:0015020~glucuronosyltransferase activity,	IPR002213:UDP-glucuronosyl/UDP-glucosyltransferase,	hsa00040:Pentose and glucuronate interconversions,hsa00053:Ascorbate and aldarate metabolism,hsa00140:Steroid hormone biosynthesis,hsa00830:Retinol metabolism,hsa00860:Porphyrin metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa04976:Bile secretion,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,				KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->A,N: Reduced androsterone, hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:D->A: Reduced androsterone and tetrachlorocatechol glucuronosyltransferase activities; abolished hyodeoxycholic acid glucuronosyltransferase activity.,MUTAGEN:D->N: Abolished androsterone glucuronosyltransferase activity; reduced hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:G->D: Abolished androsterone glucuronosyltransferase activity; reduced hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:G->S: Abolished androsterone glucuronosyltransferase activity; no change in hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:H->A,E: Abolished androsterone glucuronosyltransferase activity; reduced hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:H->A: Reduced androsterone, hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:N->A: Abolished androsterone glucuronosyltransferase activity; reduced hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:Q->A: Abolished androsterone, hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:S->A: Reduced androsterone, hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,MUTAGEN:T->V: Reduced androsterone, hyodeoxycholic acid and tetrachlorocatechol glucuronosyltransferase activities.,TRANSMEM:Helical,
ULBP1	UL16 binding protein 1(ULBP1)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,GO:0030101~natural killer cell activation,GO:0042267~natural killer cell mediated cytotoxicity,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0046658~anchored component of plasma membrane,	GO:0005515~protein binding,GO:0046703~natural killer cell lectin-like receptor binding,	IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,	hsa04650:Natural killer cell mediated cytotoxicity,				KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:GPI-anchor amidated glycine,PROPEP:Removed in mature form,REGION:MHC class I alpha-1 like,REGION:MHC class I alpha-2 like,
VSTM2A	V-set and transmembrane domain containing 2A(VSTM2A)	Homo sapiens			GO:0010628~positive regulation of gene expression,GO:0010884~positive regulation of lipid storage,GO:0030154~cell differentiation,GO:0070352~positive regulation of white fat cell proliferation,GO:0071773~cellular response to BMP stimulus,GO:0090336~positive regulation of brown fat cell differentiation,	GO:0005576~extracellular region,GO:0016021~integral component of membrane,	GO:0042802~identical protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0221~Differentiation,	KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,REGION:Disordered,
VTCN1	V-set domain containing T cell activation inhibitor 1(VTCN1)	Homo sapiens			GO:0001562~response to protozoan,GO:0001817~regulation of cytokine production,GO:0002250~adaptive immune response,GO:0032743~positive regulation of interleukin-2 production,GO:0042102~positive regulation of T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0050852~T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,	GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005102~receptor binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,			SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VPREB1	V-set pre-B cell surrogate light chain 1(VPREB1)	Homo sapiens			GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,		IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,		KW-0256~Endoplasmic reticulum,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,DOMAIN:Ig-like V-type,REGION:Complementarity-determining-1,REGION:Complementarity-determining-2,REGION:Disordered,REGION:Framework-1,REGION:Framework-2,REGION:Framework-3,
VANGL2	VANGL planar cell polarity protein 2(VANGL2)	Homo sapiens			GO:0001736~establishment of planar polarity,GO:0001843~neural tube closure,GO:0001947~heart looping,GO:0035787~cell migration involved in kidney development,GO:0045176~apical protein localization,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:1905515~non-motile cilium assembly,	GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,	GO:0005515~protein binding,	IPR009539:Strabismus,	hsa04310:Wnt signaling pathway,	182940~Neural tube defects,	PIRSF007991:Vang-like protein,			KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
VENTX	VENT homeobox(VENTX)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
VPS18	VPS18 core subunit of CORVET and HOPS complexes(VPS18)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006904~vesicle docking involved in exocytosis,GO:0006914~autophagy,GO:0007032~endosome organization,GO:0007033~vacuole organization,GO:0007040~lysosome organization,GO:0008333~endosome to lysosome transport,GO:0016192~vesicle-mediated transport,GO:0016567~protein ubiquitination,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0034058~endosomal vesicle fusion,GO:0035542~regulation of SNARE complex assembly,GO:0046718~viral entry into host cell,GO:0048284~organelle fusion,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005884~actin filament,GO:0010008~endosome membrane,GO:0030123~AP-3 adaptor complex,GO:0030136~clathrin-coated vesicle,GO:0030897~HOPS complex,GO:0031902~late endosome membrane,GO:0033263~CORVET complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019905~syntaxin binding,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000547:Clathrin, heavy chain/VPS, 7-fold repeat,IPR007810:Pep3/Vps18/deep orange,	hsa04140:Autophagy - animal,hsa05132:Salmonella infection,				KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Pep3/Vps18/deep orange,REGION:Disordered,REPEAT:CHCR,ZN_FING:RING-type,
WIF1	WNT inhibitory factor 1(WIF1)	Homo sapiens		h_wntPathway:WNT Signaling Pathway,	GO:0001568~blood vessel development,GO:0007165~signal transduction,GO:0007368~determination of left/right symmetry,GO:0007507~heart development,GO:0009952~anterior/posterior pattern specification,GO:0016055~Wnt signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0038092~nodal signaling pathway,GO:0045600~positive regulation of fat cell differentiation,GO:0048856~anatomical structure development,	GO:0005576~extracellular region,GO:0009986~cell surface,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0017147~Wnt-protein binding,GO:0038100~nodal binding,GO:0070697~activin receptor binding,	IPR000742:Epidermal growth factor-like domain,IPR003306:WIF domain,IPR013032:EGF-like, conserved site,IPR013111:EGF, extracellular,IPR013309:Wnt inhibitory factor (WIF)-1,	hsa04310:Wnt signaling pathway,			SM00181:EGF,SM00469:WIF,	KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:WIF,REGION:Disordered,
WSCD2	WSC domain containing 2(WSCD2)	Homo sapiens				GO:0000139~Golgi membrane,GO:0016021~integral component of membrane,	GO:0008146~sulfotransferase activity,	IPR002889:Carbohydrate-binding WSC,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00321:WSC,		KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:WSC,DOMAIN:WSC 1,DOMAIN:WSC 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
WWP2	WW domain containing E3 ubiquitin protein ligase 2(WWP2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000209~protein polyubiquitination,GO:0006366~transcription from RNA polymerase II promoter,GO:0006464~cellular protein modification process,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006858~extracellular transport,GO:0010629~negative regulation of gene expression,GO:0016567~protein ubiquitination,GO:0032410~negative regulation of transporter activity,GO:0034765~regulation of ion transmembrane transport,GO:0036211~protein modification process,GO:0042391~regulation of membrane potential,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045732~positive regulation of protein catabolic process,GO:0045746~negative regulation of Notch signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046718~viral entry into host cell,GO:0051224~negative regulation of protein transport,GO:0051865~protein autoubiquitination,GO:0070534~protein K63-linked ubiquitination,GO:1901016~regulation of potassium ion transmembrane transporter activity,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0016874~ligase activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061630~ubiquitin protein ligase activity,	IPR000008:C2 calcium-dependent membrane targeting,IPR000569:HECT,IPR001202:WW domain,IPR024928:E3 ubiquitin-protein ligase, SMURF1 type,	hsa04120:Ubiquitin mediated proteolysis,		PIRSF001569:E3 ubiquitin-protein ligase, SMURF1 type,	SM00119:HECTc,SM00239:C2,SM00456:WW,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0436~Ligase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:HECT,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,DOMAIN:WW 3,DOMAIN:WW 4,MUTAGEN:C->A: Abolishes ubiquitination of POU5F1.,MUTAGEN:H->K: Does not affect FBXL15-mediated ubiquitination.,MUTAGEN:K->R: Does not affect FBXL15-mediated ubiquitination.,REGION:Disordered,
WNT1	Wnt family member 1(WNT1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hesPathway:Segmentation Clock,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,h_wntPathway:WNT Signaling Pathway,	GO:0000578~embryonic axis specification,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0007267~cell-cell signaling,GO:0007520~myoblast fusion,GO:0008284~positive regulation of cell proliferation,GO:0009611~response to wounding,GO:0010592~positive regulation of lamellipodium assembly,GO:0010812~negative regulation of cell-substrate adhesion,GO:0021527~spinal cord association neuron differentiation,GO:0021536~diencephalon development,GO:0021551~central nervous system morphogenesis,GO:0021588~cerebellum formation,GO:0021797~forebrain anterior/posterior pattern specification,GO:0022004~midbrain-hindbrain boundary maturation during brain development,GO:0022408~negative regulation of cell-cell adhesion,GO:0030182~neuron differentiation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030579~ubiquitin-dependent SMAD protein catabolic process,GO:0030901~midbrain development,GO:0031100~animal organ regeneration,GO:0033077~T cell differentiation in thymus,GO:0033278~cell proliferation in midbrain,GO:0036520~astrocyte-dopaminergic neuron signaling,GO:0042472~inner ear morphogenesis,GO:0042770~signal transduction in response to DNA damage,GO:0043066~negative regulation of apoptotic process,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048146~positive regulation of fibroblast proliferation,GO:0048664~neuron fate determination,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060061~Spemann organizer formation,GO:0060070~canonical Wnt signaling pathway,GO:0060348~bone development,GO:0061184~positive regulation of dermatome development,GO:0070365~hepatocyte differentiation,GO:0071375~cellular response to peptide hormone stimulus,GO:0071425~hematopoietic stem cell proliferation,GO:0090344~negative regulation of cell aging,GO:1902035~positive regulation of hematopoietic stem cell proliferation,GO:1903204~negative regulation of oxidative stress-induced neuron death,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1904953~Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation,GO:1904954~canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation,GO:1990403~embryonic brain development,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000773~negative regulation of cellular senescence,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030666~endocytic vesicle membrane,GO:0070062~extracellular exosome,	GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0016015~morphogen activity,GO:0019904~protein domain specific binding,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR009139:Wnt-1 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	615220~Osteogenesis imperfecta, type XV,615221~Osteoporosis, early-onset, susceptibility to, autosomal dominant,		SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-1065~Osteogenesis imperfecta,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,
WNT10A	Wnt family member 10A(WNT10A)	Homo sapiens			GO:0001942~hair follicle development,GO:0010628~positive regulation of gene expression,GO:0014033~neural crest cell differentiation,GO:0016055~Wnt signaling pathway,GO:0030182~neuron differentiation,GO:0031069~hair follicle morphogenesis,GO:0042476~odontogenesis,GO:0042487~regulation of odontogenesis of dentin-containing tooth,GO:0043586~tongue development,GO:0043588~skin development,GO:0045165~cell fate commitment,GO:0048730~epidermis morphogenesis,GO:0048733~sebaceous gland development,GO:0060070~canonical Wnt signaling pathway,GO:0071560~cellular response to transforming growth factor beta stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR013302:Wnt-10 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	150400~Tooth agenesis, selective, 4,224750~Schopf-Schulz-Passarge syndrome,257980~Ectodermal dysplasia 16 (odontoonychodermal dysplasia),		SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-1007~Palmoplantar keratoderma,KW-1063~Hypotrichosis,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,REGION:Disordered,
WNT2	Wnt family member 2(WNT2)	Homo sapiens			GO:0001938~positive regulation of endothelial cell proliferation,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002088~lens development in camera-type eye,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0010463~mesenchymal cell proliferation,GO:0016055~Wnt signaling pathway,GO:0022008~neurogenesis,GO:0030182~neuron differentiation,GO:0030324~lung development,GO:0033278~cell proliferation in midbrain,GO:0045165~cell fate commitment,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048146~positive regulation of fibroblast proliferation,GO:0050769~positive regulation of neurogenesis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0055009~atrial cardiac muscle tissue morphogenesis,GO:0060038~cardiac muscle cell proliferation,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060070~canonical Wnt signaling pathway,GO:0060317~cardiac epithelial to mesenchymal transition,GO:0060492~lung induction,GO:0060501~positive regulation of epithelial cell proliferation involved in lung morphogenesis,GO:0060502~epithelial cell proliferation involved in lung morphogenesis,GO:0060716~labyrinthine layer blood vessel development,GO:0061072~iris morphogenesis,GO:0061180~mammary gland epithelium development,GO:0071300~cellular response to retinoic acid,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1904948~midbrain dopaminergic neuron differentiation,GO:1904954~canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0031232~extrinsic component of external side of plasma membrane,GO:1990909~Wnt signalosome,	GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR009140:Wnt-2 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,
WNT3A	Wnt family member 3A(WNT3A)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001819~positive regulation of cytokine production,GO:0001934~positive regulation of protein phosphorylation,GO:0001947~heart looping,GO:0002092~positive regulation of receptor internalization,GO:0003136~negative regulation of heart induction by canonical Wnt signaling pathway,GO:0006366~transcription from RNA polymerase II promoter,GO:0007411~axon guidance,GO:0008104~protein localization,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0010387~COP9 signalosome assembly,GO:0010628~positive regulation of gene expression,GO:0010977~negative regulation of neuron projection development,GO:0021527~spinal cord association neuron differentiation,GO:0021766~hippocampus development,GO:0021846~cell proliferation in forebrain,GO:0021874~Wnt signaling pathway involved in forebrain neuroblast division,GO:0021904~dorsal/ventral neural tube patterning,GO:0030097~hemopoiesis,GO:0030182~neuron differentiation,GO:0030198~extracellular matrix organization,GO:0030879~mammary gland development,GO:0030890~positive regulation of B cell proliferation,GO:0032092~positive regulation of protein binding,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033278~cell proliferation in midbrain,GO:0034613~cellular protein localization,GO:0035914~skeletal muscle cell differentiation,GO:0036342~post-anal tail morphogenesis,GO:0036465~synaptic vesicle recycling,GO:0042100~B cell proliferation,GO:0042472~inner ear morphogenesis,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045445~myoblast differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048103~somatic stem cell division,GO:0048337~positive regulation of mesodermal cell fate specification,GO:0048343~paraxial mesodermal cell fate commitment,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0048697~positive regulation of collateral sprouting in absence of injury,GO:0048843~negative regulation of axon extension involved in axon guidance,GO:0050768~negative regulation of neurogenesis,GO:0050804~modulation of synaptic transmission,GO:0050807~regulation of synapse organization,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060070~canonical Wnt signaling pathway,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0061184~positive regulation of dermatome development,GO:0061316~canonical Wnt signaling pathway involved in heart development,GO:0061317~canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0070527~platelet aggregation,GO:0071300~cellular response to retinoic acid,GO:0090245~axis elongation involved in somitogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090676~calcium ion transmembrane transport via low voltage-gated calcium channel,GO:0099054~presynapse assembly,GO:0099527~postsynapse to nucleus signaling pathway,GO:1901215~negative regulation of neuron death,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1904339~negative regulation of dopaminergic neuron differentiation,GO:1904953~Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation,GO:1905539~regulation of postsynapse to nucleus signaling pathway,GO:1905606~regulation of presynapse assembly,GO:2000049~positive regulation of cell-cell adhesion mediated by cadherin,GO:2000081~positive regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic cell proliferation,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2000347~positive regulation of hepatocyte proliferation,GO:2000727~positive regulation of cardiac muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030666~endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:1990851~Wnt-Frizzled-LRP5/6 complex,	GO:0003713~transcription coactivator activity,GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0039706~co-receptor binding,GO:0042802~identical protein binding,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR009141:Wnt-3 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,MUTAGEN:C->A: No signaling activity despite the presence of significant amounts of secreted monomeric Wnt3a, exhibits dominant negative properties; when associated with A-334.,MUTAGEN:C->A: No signaling activity despite the presence of significant amounts of secreted monomeric Wnt3a, exhibits dominant negative properties; when associated with A-335.,MUTAGEN:N->Q: Strongly reduced ability to stimulate Wnt-responsive reporters; when associated with Q-298.,MUTAGEN:N->Q: Strongly reduced ability to stimulate Wnt-responsive reporters; when associated with Q-87.,MUTAGEN:S->A: Abrogates WLS binding.,MUTAGEN:S->A: Complete loss of palmitoleoylation.,MUTAGEN:S->T: No effect on palmitoleoylation and secretion; the threonine can functionally replace the serine.,SITE:Cleavage; by TIKI1 and TIKI2,
XAF1	XIAP associated factor 1(XAF1)	Homo sapiens			GO:0006915~apoptotic process,GO:0032480~negative regulation of type I interferon production,GO:0035456~response to interferon-beta,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR001293:Zinc finger, TRAF-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,					KW-0053~Apoptosis,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,DOMAIN:TRAF-type,DOMAIN:XIAP-associated factor 1 C-terminal,REGION:Disordered,ZN_FING:TRAF-type,
ZFP42	ZFP42 zinc finger protein(ZFP42)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008584~male gonad development,GO:0008585~female gonad development,GO:0051321~meiotic cell cycle,	GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0031519~PcG protein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
ZIC1	Zic family member 1(ZIC1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0007417~central nervous system development,GO:0007420~brain development,GO:0007628~adult walking behavior,GO:0008589~regulation of smoothened signaling pathway,GO:0010467~gene expression,GO:0021510~spinal cord development,GO:0021766~hippocampus development,GO:0021772~olfactory bulb development,GO:0030154~cell differentiation,GO:0042307~positive regulation of protein import into nucleus,GO:0042472~inner ear morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0098727~maintenance of cell number,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		616602~Craniosynostosis 6,618736~Structural brain anomalies with impaired intellectual development and craniosynostosis,		SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0989~Craniosynostosis,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2; atypical,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
ZIC5	Zic family member 5(ZIC5)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007417~central nervous system development,GO:0030154~cell differentiation,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
AIM2	absent in melanoma 2(AIM2)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0002221~pattern recognition receptor signaling pathway,GO:0002230~positive regulation of defense response to virus by host,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006974~cellular response to DNA damage stimulus,GO:0007420~brain development,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032731~positive regulation of interleukin-1 beta production,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0035458~cellular response to interferon-beta,GO:0043029~T cell homeostasis,GO:0044546~NLRP3 inflammasome complex assembly,GO:0045087~innate immune response,GO:0050729~positive regulation of inflammatory response,GO:0050795~regulation of behavior,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0051898~negative regulation of protein kinase B signaling,GO:0070050~neuron cellular homeostasis,GO:0070269~pyroptosis,GO:0071466~cellular response to xenobiotic stimulus,GO:1904270~pyroptosome complex assembly,GO:2001056~positive regulation of cysteine-type endopeptidase activity,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0035861~site of double-strand break,GO:0097169~AIM2 inflammasome complex,	GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0035591~signaling adaptor activity,GO:0038187~pattern recognition receptor activity,GO:0042802~identical protein binding,	IPR004020:DAPIN domain,IPR004021:HIN-200/IF120x,IPR011029:Death-like domain,	hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,			SM01289:SM01289,	KW-0227~DNA damage,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1271~Inflammasome,	KW-0043~Tumor suppressor,			KW-0238~DNA-binding,		DOMAIN:HIN-200,DOMAIN:Pyrin,MUTAGEN:A->R,D: Impaired homooligomerization.,MUTAGEN:D->K: Impaired homooligomerization.,MUTAGEN:DEELD->AAALA: In Mut2; abolished interaction with PYCARD/ASC. Abolished ability to bind double-stranded DNA (dsDNA).,MUTAGEN:E->A: Strongly reduced ability to homooligomerize upon double-stranded DNA (dsDNA)-binding.,MUTAGEN:E->K: Impaired ability to nucleate with PYCARD/ASC.,MUTAGEN:F->A: Impairs DNA binding.,MUTAGEN:F->A: Strongly reduced ability to homooligomerize upon double-stranded DNA (dsDNA)-binding.,MUTAGEN:F->G: Abolished ability to homooligomerize.,MUTAGEN:F->L: Strongly impaired ability to homooligomerize.,MUTAGEN:F->W,Y: Impaired ability to homooligomerize.,MUTAGEN:FF->AA: In Mut1; abolished interaction with PYCARD/ASC.,MUTAGEN:I->A: Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204. Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204; A-244; A-251; A-309; A-311; A-355 and A-337.,MUTAGEN:I->D: Impaired homooligomerization.,MUTAGEN:K->A: Impaired double-stranded DNA (dsDNA)-binding, preventing homooligomerization.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204. Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204; A-244; A-251; A-309; A-311; A-355 and A-337.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-160; A-K162; A-163; A-198; A-204. Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204; A-244; A-251; A-309; A-311; A-355 and A-337.,MUTAGEN:K->A: Strongly reduced ability to homooligomerize upon double-stranded DNA (dsDNA)-binding.,MUTAGEN:L->A: Fails to activate interleukin-1 beta production.,MUTAGEN:L->A: Impaired homooligomerization.,MUTAGEN:LL->AA: Impaired double-stranded DNA (dsDNA)-binding, preventing homooligomerization.,MUTAGEN:M->D: Impaired ability to nucleate with PYCARD/ASC.,MUTAGEN:N->L: Impaired ability to form AIM2 inflammasome filaments in response to double-stranded DNA (dsDNA).,MUTAGEN:Q->A: Impaired double-stranded DNA (dsDNA)-binding, preventing homooligomerization.,MUTAGEN:R->A: Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204. Impairs DNA binding; when associated with A-160; A-162; A-163; A-198; A-204; A-244; A-251; A-309; A-311; A-355 and A-337.,MUTAGEN:T->A: Impaired double-stranded DNA (dsDNA)-binding, preventing homooligomerization.,
ACHE	acetylcholinesterase (Cartwright blood group)(ACHE)	Homo sapiens			GO:0001507~acetylcholine catabolic process in synaptic cleft,GO:0001919~regulation of receptor recycling,GO:0002076~osteoblast development,GO:0006581~acetylcholine catabolic process,GO:0007155~cell adhesion,GO:0007399~nervous system development,GO:0007416~synapse assembly,GO:0031623~receptor internalization,GO:0032223~negative regulation of synaptic transmission, cholinergic,GO:0042982~amyloid precursor protein metabolic process,GO:0050714~positive regulation of protein secretion,GO:0060041~retina development in camera-type eye,GO:0095500~acetylcholine receptor signaling pathway,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031225~anchored component of membrane,GO:0031594~neuromuscular junction,GO:0043083~synaptic cleft,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098552~side of membrane,	GO:0001540~beta-amyloid binding,GO:0003990~acetylcholinesterase activity,GO:0004104~cholinesterase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0016787~hydrolase activity,GO:0017171~serine hydrolase activity,GO:0042166~acetylcholine binding,GO:0042803~protein homodimerization activity,GO:0043236~laminin binding,GO:0043621~protein self-association,	IPR000997:Cholinesterase,IPR002018:Carboxylesterase, type B,IPR014788:Acetylcholinesterase, tetramerisation,IPR019819:Carboxylesterase type B, conserved site,IPR019826:Carboxylesterase type B, active site,	hsa00564:Glycerophospholipid metabolism,hsa04725:Cholinergic synapse,	112100~Blood group, Yt system,			KW-0531~Neurotransmitter degradation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,KW-0378~Hydrolase,KW-0719~Serine esterase,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	ACT_SITE:Acyl-ester intermediate,ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Carboxylesterase type B,LIPID:GPI-anchor amidated glycine,MUTAGEN:C->A: Impairment of interchain disulfide bridge formation.,MUTAGEN:D->N: Misfolding, absence of secretion.,MUTAGEN:E->A: Loss of activity.,MUTAGEN:H->A: Loss of activity.,MUTAGEN:S->A: Loss of activity.,REGION:Disordered,TRANSMEM:Helical,
ASCL2	achaete-scute family bHLH transcription factor 2(ASCL2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0001890~placenta development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007423~sensory organ development,GO:0010626~negative regulation of Schwann cell proliferation,GO:0030182~neuron differentiation,GO:0035019~somatic stem cell population maintenance,GO:0045626~negative regulation of T-helper 1 cell differentiation,GO:0045629~negative regulation of T-helper 2 cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050767~regulation of neurogenesis,GO:0060708~spongiotrophoblast differentiation,GO:0060712~spongiotrophoblast layer development,GO:0060719~chorionic trophoblast cell development,GO:0061470~T follicular helper cell differentiation,GO:2000320~negative regulation of T-helper 17 cell differentiation,GO:2000406~positive regulation of T cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0043425~bHLH transcription factor binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR015660:Achaete-scute transcription factor-related,				SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0539~Nucleus,				KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:bHLH,REGION:Disordered,
AFAP1L1	actin filament associated protein 1 like 1(AFAP1L1)	Homo sapiens				GO:0002102~podosome,GO:0005829~cytosol,GO:0030054~cell junction,GO:0042995~cell projection,GO:0070161~anchoring junction,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PH 1,DOMAIN:PH 2,REGION:Disordered,
ACTN2	actinin alpha 2(ACTN2)	Homo sapiens		h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_integrinPathway:Integrin Signaling Pathway,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0006936~muscle contraction,GO:0007155~cell adhesion,GO:0030035~microspike assembly,GO:0030036~actin cytoskeleton organization,GO:0042391~regulation of membrane potential,GO:0042981~regulation of apoptotic process,GO:0043267~negative regulation of potassium ion transport,GO:0043268~positive regulation of potassium ion transport,GO:0045214~sarcomere organization,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048041~focal adhesion assembly,GO:0051695~actin filament uncapping,GO:0055001~muscle cell development,GO:0055013~cardiac muscle cell development,GO:0072659~protein localization to plasma membrane,GO:0086097~phospholipase C-activating angiotensin-activated signaling pathway,GO:1901017~negative regulation of potassium ion transmembrane transporter activity,GO:1901018~positive regulation of potassium ion transmembrane transporter activity,GO:2000009~negative regulation of protein localization to cell surface,GO:2001137~positive regulation of endocytic recycling,GO:2001259~positive regulation of cation channel activity,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0030054~cell junction,GO:0030175~filopodium,GO:0030864~cortical actin cytoskeleton,GO:0031093~platelet alpha granule lumen,GO:0031143~pseudopodium,GO:0042995~cell projection,GO:0043197~dendritic spine,GO:0070062~extracellular exosome,GO:0098839~postsynaptic density membrane,GO:0098871~postsynaptic actin cytoskeleton,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0003779~actin binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0008092~cytoskeletal protein binding,GO:0008307~structural constituent of muscle,GO:0019904~protein domain specific binding,GO:0030274~LIM domain binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0031432~titin binding,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0051015~actin filament binding,GO:0051373~FATZ binding,GO:0070080~titin Z domain binding,	IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002017:Spectrin repeat,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR014837:EF-hand, Ca insensitive,IPR018159:Spectrin/alpha-actinin,	hsa05412:Arrhythmogenic right ventricular cardiomyopathy,	612158~Cardiomyopathy, dilated, 1AA, with or without LVNC,612158~Cardiomyopathy, hypertrophic, 23, with or without LVNC,618654~Congenital myopathy 8,618655~Myopathy, distal, 6, adult onset,		SM00033:CH,SM00054:EFh,SM00150:SPEC,		KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Actin-binding,REPEAT:Spectrin 1,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,
ACVRL1	activin A receptor like type 1(ACVRL1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001936~regulation of endothelial cell proliferation,GO:0001937~negative regulation of endothelial cell proliferation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0001946~lymphangiogenesis,GO:0001955~blood vessel maturation,GO:0001974~blood vessel remodeling,GO:0002043~blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0006275~regulation of DNA replication,GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007507~heart development,GO:0008015~blood circulation,GO:0008217~regulation of blood pressure,GO:0008285~negative regulation of cell proliferation,GO:0009953~dorsal/ventral pattern formation,GO:0010596~negative regulation of endothelial cell migration,GO:0010604~positive regulation of macromolecule metabolic process,GO:0010629~negative regulation of gene expression,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0030509~BMP signaling pathway,GO:0030513~positive regulation of BMP signaling pathway,GO:0032332~positive regulation of chondrocyte differentiation,GO:0032924~activin receptor signaling pathway,GO:0035313~wound healing, spreading of epidermal cells,GO:0035912~dorsal aorta morphogenesis,GO:0043535~regulation of blood vessel endothelial cell migration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045602~negative regulation of endothelial cell differentiation,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051173~positive regulation of nitrogen compound metabolic process,GO:0051239~regulation of multicellular organismal process,GO:0051895~negative regulation of focal adhesion assembly,GO:0060836~lymphatic endothelial cell differentiation,GO:0060840~artery development,GO:0060841~venous blood vessel development,GO:0061154~endothelial tube morphogenesis,GO:0061298~retina vasculature development in camera-type eye,GO:0071363~cellular response to growth factor stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071773~cellular response to BMP stimulus,GO:2000279~negative regulation of DNA biosynthetic process,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0043235~receptor complex,GO:0070724~BMP receptor complex,	GO:0004674~protein serine/threonine kinase activity,GO:0004675~transmembrane receptor protein serine/threonine kinase activity,GO:0005024~transforming growth factor beta-activated receptor activity,GO:0005025~transforming growth factor beta receptor activity, type I,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016361~activin receptor activity, type I,GO:0019901~protein kinase binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048185~activin binding,GO:0050431~transforming growth factor beta binding,GO:0098821~BMP receptor activity,	IPR000333:Activin type II/Transforming growth factor-beta II receptor,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003605:TGF beta receptor, GS motif,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04060:Cytokine-cytokine receptor interaction,	600376~Telangiectasia, hereditary hemorrhagic, type 2,		SM00467:GS,	KW-0037~Angiogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GS,DOMAIN:Protein kinase,MUTAGEN:REL->DFQ: Affinity for BMP9 decreased by 200-fold.,REGION:Mediates specificity for BMP ligand,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ACSL1	acyl-CoA synthetase long chain family member 1(ACSL1)	Homo sapiens			GO:0000038~very long-chain fatty acid metabolic process,GO:0001676~long-chain fatty acid metabolic process,GO:0007584~response to nutrient,GO:0008610~lipid biosynthetic process,GO:0010747~positive regulation of plasma membrane long-chain fatty acid transport,GO:0014070~response to organic cyclic compound,GO:0015908~fatty acid transport,GO:0019432~triglyceride biosynthetic process,GO:0033211~adiponectin-activated signaling pathway,GO:0034201~response to oleic acid,GO:0035338~long-chain fatty-acyl-CoA biosynthetic process,GO:0042178~xenobiotic catabolic process,GO:0044539~long-chain fatty acid import,GO:0071902~positive regulation of protein serine/threonine kinase activity,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005524~ATP binding,GO:0016874~ligase activity,GO:0043539~protein serine/threonine kinase activator activity,GO:0047676~arachidonate-CoA ligase activity,GO:0050197~phytanate-CoA ligase activity,GO:0070251~pristanate-CoA ligase activity,GO:0090434~oleoyl-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020459:AMP-binding,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa00061:Fatty acid biosynthesis,hsa00071:Fatty acid degradation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,hsa04216:Ferroptosis,hsa04714:Thermogenesis,hsa04920:Adipocytokine signaling pathway,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0944~Nitration,	CARBOHYD:O-linked (GlcNAc) serine,DOMAIN:AMP-binding enzyme C-terminal,DOMAIN:AMP-dependent synthetase/ligase,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
ACSL6	acyl-CoA synthetase long chain family member 6(ACSL6)	Homo sapiens			GO:0000038~very long-chain fatty acid metabolic process,GO:0001676~long-chain fatty acid metabolic process,GO:0006637~acyl-CoA metabolic process,GO:0007405~neuroblast proliferation,GO:0008610~lipid biosynthetic process,GO:0035338~long-chain fatty-acyl-CoA biosynthetic process,	GO:0005741~mitochondrial outer membrane,GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005524~ATP binding,GO:0016874~ligase activity,GO:0019899~enzyme binding,GO:0042803~protein homodimerization activity,GO:0047676~arachidonate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa00061:Fatty acid biosynthesis,hsa00071:Fatty acid degradation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,hsa04216:Ferroptosis,hsa04714:Thermogenesis,hsa04920:Adipocytokine signaling pathway,	Myelodysplastic syndrome~Myelodysplastic syndrome,Myelogenous leukemia, acute~Myelogenous leukemia, acute,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0436~Ligase,		DOMAIN:AMP-binding enzyme C-terminal,DOMAIN:AMP-dependent synthetase/ligase,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
ACSS2	acyl-CoA synthetase short chain family member 2(ACSS2)	Homo sapiens		h_cptPathway:Mitochondrial Carnitine Palmitoyltransferase (CPT) System,	GO:0006069~ethanol oxidation,GO:0006085~acetyl-CoA biosynthetic process,GO:0008610~lipid biosynthetic process,GO:0019413~acetate biosynthetic process,GO:0019427~acetyl-CoA biosynthetic process from acetate,GO:0019542~propionate biosynthetic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0003987~acetate-CoA ligase activity,GO:0005524~ATP binding,GO:0016208~AMP binding,GO:0050218~propionate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR011904:Acetate-CoA ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa00010:Glycolysis / Gluconeogenesis,hsa00620:Pyruvate metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,				KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:AMP-binding enzyme C-terminal,DOMAIN:AMP-dependent synthetase/ligase,DOMAIN:Acetyl-coenzyme A synthetase N-terminal,REGION:Disordered,
ACOT11	acyl-CoA thioesterase 11(ACOT11)	Homo sapiens			GO:0006631~fatty acid metabolic process,GO:0006637~acyl-CoA metabolic process,GO:0009266~response to temperature stimulus,GO:0009409~response to cold,GO:0035556~intracellular signal transduction,	GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0008289~lipid binding,GO:0016290~palmitoyl-CoA hydrolase activity,GO:0036042~long-chain fatty acyl-CoA binding,GO:0047617~acyl-CoA hydrolase activity,GO:0052689~carboxylic ester hydrolase activity,GO:0052816~long-chain acyl-CoA hydrolase activity,GO:0102991~myristoyl-CoA hydrolase activity,	IPR002913:START domain,IPR006683:Thioesterase superfamily,IPR023393:START-like domain,				SM00234:START,	KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0809~Transit peptide,		KW-0378~Hydrolase,KW-0719~Serine esterase,	KW-0597~Phosphoprotein,	DOMAIN:HotDog ACOT-type 1,DOMAIN:HotDog ACOT-type 2,DOMAIN:START,TRANSIT:Mitochondrion,
ADORA1	adenosine A1 receptor(ADORA1)	Homo sapiens			GO:0001659~temperature homeostasis,GO:0001666~response to hypoxia,GO:0001973~adenosine receptor signaling pathway,GO:0002087~regulation of respiratory gaseous exchange by neurological system process,GO:0002674~negative regulation of acute inflammatory response,GO:0002686~negative regulation of leukocyte migration,GO:0002793~positive regulation of peptide secretion,GO:0003084~positive regulation of systemic arterial blood pressure,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0003093~regulation of glomerular filtration,GO:0006612~protein targeting to membrane,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007399~nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0010035~response to inorganic substance,GO:0014050~negative regulation of glutamate secretion,GO:0014074~response to purine-containing compound,GO:0016042~lipid catabolic process,GO:0032229~negative regulation of synaptic transmission, GABAergic,GO:0032244~positive regulation of nucleoside transport,GO:0032900~negative regulation of neurotrophin production,GO:0035307~positive regulation of protein dephosphorylation,GO:0035814~negative regulation of renal sodium excretion,GO:0042311~vasodilation,GO:0042323~negative regulation of circadian sleep/wake cycle, non-REM sleep,GO:0043066~negative regulation of apoptotic process,GO:0043268~positive regulation of potassium ion transport,GO:0043410~positive regulation of MAPK cascade,GO:0045741~positive regulation of epidermal growth factor-activated receptor activity,GO:0045822~negative regulation of heart contraction,GO:0046888~negative regulation of hormone secretion,GO:0050890~cognition,GO:0050900~leukocyte migration,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050995~negative regulation of lipid catabolic process,GO:0050996~positive regulation of lipid catabolic process,GO:0051930~regulation of sensory perception of pain,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0055089~fatty acid homeostasis,GO:0060079~excitatory postsynaptic potential,GO:0060087~relaxation of vascular smooth muscle,GO:0060292~long term synaptic depression,GO:0070254~mucus secretion,GO:0070256~negative regulation of mucus secretion,GO:0070328~triglyceride homeostasis,GO:0086004~regulation of cardiac muscle cell contraction,GO:0097190~apoptotic signaling pathway,GO:0099509~regulation of presynaptic cytosolic calcium ion concentration,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1900453~negative regulation of long term synaptic depression,GO:1901216~positive regulation of neuron death,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030425~dendrite,GO:0030673~axolemma,GO:0032279~asymmetric synapse,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043195~terminal bouton,GO:0043197~dendritic spine,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0048786~presynaptic active zone,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001609~G-protein coupled adenosine receptor activity,GO:0001664~G-protein coupled receptor binding,GO:0001883~purine nucleoside binding,GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0032795~heterotrimeric G-protein binding,GO:0046982~protein heterodimerization activity,GO:0099582~neurotransmitter receptor activity involved in regulation of presynaptic cytosolic calcium ion concentration,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001068:Adenosine A1 receptor,IPR001634:Adenosine receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa05032:Morphine addiction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADARB2	adenosine deaminase RNA specific B2 (inactive)(ADARB2)	Homo sapiens			GO:0006382~adenosine to inosine editing,GO:0006396~RNA processing,GO:0006397~mRNA processing,	GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003726~double-stranded RNA adenosine deaminase activity,GO:0003727~single-stranded RNA binding,GO:0004000~adenosine deaminase activity,GO:0008251~tRNA-specific adenosine deaminase activity,GO:0046872~metal ion binding,	IPR002466:Adenosine deaminase/editase,IPR014720:Double-stranded RNA-binding-like domain,				SM00358:DSRM,SM00552:ADEAMc,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0694~RNA-binding,		ACT_SITE:Proton donor,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:A to I editase,DOMAIN:DRBM 1,DOMAIN:DRBM 2,REGION:Disordered,REGION:R-domain (ssRNA-binding),
AMPD3	adenosine monophosphate deaminase 3(AMPD3)	Homo sapiens			GO:0006188~IMP biosynthetic process,GO:0006196~AMP catabolic process,GO:0032264~IMP salvage,GO:0046033~AMP metabolic process,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003876~AMP deaminase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR006329:AMP deaminase,IPR006650:Adenosine/AMP deaminase active site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	612874~AMP deaminase deficiency, erythrocytic,	PIRSF001251:AMP deaminase,		KW-0546~Nucleotide metabolism,		KW-0225~Disease variant,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,
ADCY8	adenylate cyclase 8(ADCY8)	Homo sapiens			GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0003008~system process,GO:0006171~cAMP biosynthetic process,GO:0007165~signal transduction,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007611~learning or memory,GO:0007613~memory,GO:0007616~long-term memory,GO:0007626~locomotory behavior,GO:0009190~cyclic nucleotide biosynthetic process,GO:0010255~glucose mediated signaling pathway,GO:0031915~positive regulation of synaptic plasticity,GO:0032793~positive regulation of CREB transcription factor activity,GO:0034199~activation of protein kinase A activity,GO:0035556~intracellular signal transduction,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0038003~opioid receptor signaling pathway,GO:0042593~glucose homeostasis,GO:0050796~regulation of insulin secretion,GO:0051259~protein oligomerization,GO:0051260~protein homooligomerization,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0065008~regulation of biological quality,GO:0071277~cellular response to calcium ion,GO:0071315~cellular response to morphine,GO:0071333~cellular response to glucose stimulus,GO:0071377~cellular response to glucagon stimulus,GO:0080135~regulation of cellular response to stress,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1900454~positive regulation of long term synaptic depression,GO:1904322~cellular response to forskolin,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0005905~clathrin-coated pit,GO:0014069~postsynaptic density,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030665~clathrin-coated vesicle membrane,GO:0032809~neuronal cell body membrane,GO:0042734~presynaptic membrane,GO:0044853~plasma membrane raft,GO:0045121~membrane raft,GO:0048786~presynaptic active zone,GO:0060076~excitatory synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098978~glutamatergic synapse,GO:0099056~integral component of presynaptic membrane,	GO:0003779~actin binding,GO:0004016~adenylate cyclase activity,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0008294~calcium- and calmodulin-responsive adenylate cyclase activity,GO:0016849~phosphorus-oxygen lyase activity,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051721~protein phosphatase 2A binding,	IPR001054:Adenylyl cyclase class-3/4/guanylyl cyclase,IPR009398:Adenylate cyclase-like,IPR018297:Adenylyl cyclase class-3/4/guanylyl cyclase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01522:Endocrine resistance,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04114:Oocyte meiosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04727:GABAergic synapse,hsa04742:Taste transduction,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04976:Bile secretion,hsa05032:Morphine addiction,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05414:Dilated cardiomyopathy,			SM00044:CYCc,	KW-0115~cAMP biosynthesis,	KW-0168~Coated pit,KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0456~Lyase,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Guanylate cyclase,MOTIF:Essential for CALM1 interaction,REGION:Disordered,REGION:Involved in AKAP5 and PRKAR2A interaction,REGION:Involved in CALM1 interaction,REGION:Involved in ORAI1, STIM1, PPP2CA and PPP2R1A interaction,REGION:Required for both calcium stimulation and maintenance of autoinhibition,SITE:Essential for CALM1 interaction,SITE:Essential for autoinhibition maintenance,SITE:Essential for autoinhibition maintenance by promoting interaction of the N and C termini,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
ADCYAP1	adenylate cyclase activating polypeptide 1(ADCYAP1)	Homo sapiens			GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0007565~female pregnancy,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0019933~cAMP-mediated signaling,GO:0030073~insulin secretion,GO:0031175~neuron projection development,GO:0032880~regulation of protein localization,GO:0043547~positive regulation of GTPase activity,GO:0045786~negative regulation of cell cycle,GO:0045860~positive regulation of protein kinase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060124~positive regulation of growth hormone secretion,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071651~positive regulation of chemokine (C-C motif) ligand 5 production,	GO:0005576~extracellular region,GO:0043005~neuron projection,GO:0043204~perikaryon,	GO:0005102~receptor binding,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0016521~pituitary adenylate cyclase activating polypeptide activity,GO:0031858~pituitary adenylate cyclase-activating polypeptide receptor binding,GO:0051428~peptide hormone receptor binding,	IPR000532:Glucagon/GIP/secretin/VIP,IPR015550:Glucagon-like,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04911:Insulin secretion,hsa04924:Renin secretion,			SM00070:GLUCA,	KW-0524~Neurogenesis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	COMPBIAS:Polar residues,DOMAIN:Glucagon / GIP / secretin / VIP family,MUTAGEN:K->E: Strongly reduced affinity for ADCYAP1R1.,MUTAGEN:L->A: Strongly reduced affinity for ADCYAP1R1.,MUTAGEN:V->A: Strongly reduced affinity for ADCYAP1R1.,MUTAGEN:V->G: Strongly reduced affinity for ADCYAP1R1.,MUTAGEN:Y->A: Strongly reduced affinity for ADCYAP1R1.,PEPTIDE:PACAP-related peptide,PEPTIDE:Pituitary adenylate cyclase-activating polypeptide 27,PEPTIDE:Pituitary adenylate cyclase-activating polypeptide 38,REGION:Disordered,REGION:Important for receptor binding,
AJAP1	adherens junctions associated protein 1(AJAP1)	Homo sapiens			GO:0001953~negative regulation of cell-matrix adhesion,GO:0007155~cell adhesion,GO:0030860~regulation of polarized epithelial cell differentiation,GO:0061045~negative regulation of wound healing,	GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0044214~spanning component of plasma membrane,GO:0044291~cell-cell contact zone,	GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0044877~macromolecular complex binding,						KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:E->A: No effect on membrane localization.,MUTAGEN:K->A: No effect on membrane localization.,MUTAGEN:L->A: Predominantly localized to the apical membrane.,MUTAGEN:LI->HV: Predominantly localized to the apical membrane.,MUTAGEN:Y->A: Predominantly localized to the apical membrane.,REGION:Disordered,REGION:Targeting signals,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ADIPOR1	adiponectin receptor 1(ADIPOR1)	Homo sapiens			GO:0009755~hormone-mediated signaling pathway,GO:0010633~negative regulation of epithelial cell migration,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010906~regulation of glucose metabolic process,GO:0019216~regulation of lipid metabolic process,GO:0019395~fatty acid oxidation,GO:0030308~negative regulation of cell growth,GO:0033210~leptin-mediated signaling pathway,GO:0033211~adiponectin-activated signaling pathway,GO:0042593~glucose homeostasis,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:1901223~negative regulation of NIK/NF-kappaB signaling,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031226~intrinsic component of plasma membrane,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0055100~adiponectin binding,GO:0097003~adipokinetic hormone receptor activity,	IPR004254:Hly-III-related,	hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04920:Adipocytokine signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0675~Receptor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:D->A: Decreases activation of AMPK in response to ADIPOQ binding; when associated with A-191; A-337 and A-341.,MUTAGEN:FVKATTV->SSSGGGS: Decreases activation of AMPK in response to ADIPOQ binding; when associated with 161-S--S-167 and 229-G--G-231.,MUTAGEN:H->A: Decreases activation of AMPK in response to ADIPOQ binding; when associated with A-191; A-208 and A-337.,MUTAGEN:H->A: Decreases activation of AMPK in response to ADIPOQ binding; when associated with A-191; A-208 and A-341.,MUTAGEN:H->A: Decreases activation of AMPK in response to ADIPOQ binding; when associated with A-208; A-337 and A-341.,MUTAGEN:MYFMAPL->SGSSGGS: Decreases activation of AMPK in response to ADIPOQ binding; when associated with 229-G--G-231 and 291-S--S-297.,MUTAGEN:YCS->GGG: Decreases activation of AMPK in response to ADIPOQ binding; when associated with 161-S--S-167 and 291-S--S-297.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ALDH1A3	aldehyde dehydrogenase 1 family member A3(ALDH1A3)	Homo sapiens			GO:0002072~optic cup morphogenesis involved in camera-type eye development,GO:0002138~retinoic acid biosynthetic process,GO:0006915~apoptotic process,GO:0007626~locomotory behavior,GO:0021768~nucleus accumbens development,GO:0031076~embryonic camera-type eye development,GO:0042472~inner ear morphogenesis,GO:0042572~retinol metabolic process,GO:0042573~retinoic acid metabolic process,GO:0042574~retinal metabolic process,GO:0043065~positive regulation of apoptotic process,GO:0048048~embryonic eye morphogenesis,GO:0050885~neuromuscular process controlling balance,GO:0051289~protein homotetramerization,GO:0060013~righting reflex,GO:0060166~olfactory pit development,GO:0060324~face development,GO:0070384~Harderian gland development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0001758~retinal dehydrogenase activity,GO:0004029~aldehyde dehydrogenase (NAD) activity,GO:0004030~aldehyde dehydrogenase [NAD(P)+] activity,GO:0016491~oxidoreductase activity,GO:0016620~oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor,GO:0042803~protein homodimerization activity,GO:0070324~thyroid hormone binding,GO:0070403~NAD+ binding,	IPR015590:Aldehyde dehydrogenase domain,IPR016160:Aldehyde dehydrogenase, conserved site,IPR016161:Aldehyde/histidinol dehydrogenase,IPR016162:Aldehyde dehydrogenase, N-terminal,IPR016163:Aldehyde dehydrogenase, C-terminal,	hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,	615113~Microphthalmia, isolated 8,			KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1013~Microphthalmia,		KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:Aldehyde dehydrogenase,REGION:Disordered,SITE:Transition state stabilizer,
ALDH1L1	aldehyde dehydrogenase 1 family member L1(ALDH1L1)	Homo sapiens			GO:0006730~one-carbon metabolic process,GO:0006740~NADPH regeneration,GO:0009058~biosynthetic process,GO:0009258~10-formyltetrahydrofolate catabolic process,GO:0071704~organic substance metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0004029~aldehyde dehydrogenase (NAD) activity,GO:0016155~formyltetrahydrofolate dehydrogenase activity,GO:0016620~oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor,GO:0016742~hydroxymethyl-, formyl- and related transferase activity,	IPR001555:Phosphoribosylglycinamide formyltransferase, active site,IPR002376:Formyl transferase, N-terminal,IPR005793:Formyl transferase, C-terminal,IPR009081:Acyl carrier protein-like,IPR011034:Formyl transferase, C-terminal-like,IPR011407:10-formyltetrahydrofolate dehydrogenase,IPR015590:Aldehyde dehydrogenase domain,IPR016160:Aldehyde dehydrogenase, conserved site,IPR016161:Aldehyde/histidinol dehydrogenase,IPR016162:Aldehyde dehydrogenase, N-terminal,IPR016163:Aldehyde dehydrogenase, C-terminal,	hsa00670:One carbon pool by folate,hsa01100:Metabolic pathways,		PIRSF036489:10-formyltetrahydrofolate dehydrogenase,		KW-0554~One-carbon metabolism,	KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0596~Phosphopantetheine,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,DOMAIN:Carrier,DOMAIN:Formyl transferase N-terminal,MUTAGEN:S->A: Loss of phosphopantetheinylation by AASDHPPT. Loss of formyltetrahydrofolate dehydrogenase activity.,REGION:Aldehyde dehydrogenase domain,REGION:Disordered,REGION:Hydrolase domain,SITE:Essential for catalytic activity,
AKR1B1	aldo-keto reductase family 1 member B(AKR1B1)	Homo sapiens			GO:0001523~retinoid metabolic process,GO:0002070~epithelial cell maturation,GO:0003091~renal water homeostasis,GO:0005975~carbohydrate metabolic process,GO:0006693~prostaglandin metabolic process,GO:0006700~C21-steroid hormone biosynthetic process,GO:0019853~L-ascorbic acid biosynthetic process,GO:0022900~electron transport chain,GO:0035809~regulation of urine volume,GO:0042572~retinol metabolic process,GO:0043066~negative regulation of apoptotic process,GO:0044597~daunorubicin metabolic process,GO:0044598~doxorubicin metabolic process,GO:0046370~fructose biosynthetic process,GO:0071475~cellular hyperosmotic salinity response,GO:0072205~metanephric collecting duct development,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0001758~retinal dehydrogenase activity,GO:0004032~alditol:NADP+ 1-oxidoreductase activity,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0036130~prostaglandin H2 endoperoxidase reductase activity,GO:0043795~glyceraldehyde oxidoreductase activity,GO:0047655~allyl-alcohol dehydrogenase activity,GO:0047834~D-threo-aldose 1-dehydrogenase activity,GO:0047939~L-glucuronate reductase activity,GO:0047956~glycerol dehydrogenase [NADP+] activity,GO:0052650~NADP-retinol dehydrogenase activity,	IPR018170:Aldo/keto reductase, conserved site,IPR020471:Aldo/keto reductase subgroup,IPR023210:NADP-dependent oxidoreductase domain,	hsa00040:Pentose and glucuronate interconversions,hsa00051:Fructose and mannose metabolism,hsa00052:Galactose metabolism,hsa00561:Glycerolipid metabolism,hsa00790:Folate biosynthesis,hsa01100:Metabolic pathways,		PIRSF000097:aldo-keto reductase,		KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:NADP-dependent oxidoreductase,MUTAGEN:D->N: Reduced glyceraldehyde oxidoreductase activity.,MUTAGEN:H->N: Reduced glyceraldehyde oxidoreductase activity.,MUTAGEN:K->M: Reduced glyceraldehyde oxidoreductase activity.,MUTAGEN:Y->F: Complete loss of glyceraldehyde oxidoreductase activity.,SITE:Lowers pKa of active site Tyr,
ALDOB	aldolase, fructose-bisphosphate B(ALDOB)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,	GO:0006000~fructose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006116~NADH oxidation,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0032781~positive regulation of ATPase activity,GO:0061624~fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate,GO:0070072~vacuolar proton-transporting V-type ATPase complex assembly,GO:1905856~negative regulation of pentose-phosphate shunt,	GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0034451~centriolar satellite,GO:0070062~extracellular exosome,	GO:0004332~fructose-bisphosphate aldolase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0042802~identical protein binding,GO:0051117~ATPase binding,GO:0060090~binding, bridging,GO:0061609~fructose-1-phosphate aldolase activity,GO:0070061~fructose binding,	IPR000741:Fructose-bisphosphate aldolase, class-I,IPR013785:Aldolase-type TIM barrel,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,	229600~Fructose intolerance, hereditary,			KW-0324~Glycolysis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0704~Schiff base,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P,MUTAGEN:K->A: Decreases enzymatic activity. Retains the ability to interact with G6PD.,MUTAGEN:K->A: Loss of enzymatic activity. Impairs the interaction with G6PD.,MUTAGEN:R->A: Decreases enzymatic activity. Impairs the interaction with G6PD.,MUTAGEN:R->A: Decreases enzymatic activity. Retains the ability to interact with G6PD.,MUTAGEN:R->A: Loss of enzymatic activity. Impairs the interaction with G6PD.,MUTAGEN:R->A: Loss of enzymatic activity. Retains the ability to interact with G6PD.,SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate,
AHSG	alpha 2-HS glycoprotein(AHSG)	Homo sapiens			GO:0001501~skeletal system development,GO:0001503~ossification,GO:0006907~pinocytosis,GO:0006953~acute-phase response,GO:0010951~negative regulation of endopeptidase activity,GO:0030500~regulation of bone mineralization,GO:0030502~negative regulation of bone mineralization,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050727~regulation of inflammatory response,GO:0050766~positive regulation of phagocytosis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0004866~endopeptidase inhibitor activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0019210~kinase inhibitor activity,	IPR000010:Proteinase inhibitor I25, cystatin,IPR001363:Proteinase inhibitor I25C, fetuin, conserved site,IPR025760:Fetuin-A-type cystatin domain,		203650~Alopecia-intellectual disability syndrome 1,		SM00043:CY,	KW-0495~Mineral balance,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1063~Hypotrichosis,	KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Pro residues,DISULFID:Interchain (between A and B chains),DOMAIN:Cystatin fetuin-A-type,DOMAIN:Cystatin fetuin-A-type 1,DOMAIN:Cystatin fetuin-A-type 2,PROPEP:Connecting peptide,REGION:Disordered,
AZGP1	alpha-2-glycoprotein 1, zinc-binding(AZGP1)	Homo sapiens			GO:0001580~detection of chemical stimulus involved in sensory perception of bitter taste,GO:0001895~retina homeostasis,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0071806~protein transmembrane transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0009897~external side of plasma membrane,GO:0070062~extracellular exosome,	GO:0004540~ribonuclease activity,GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,	IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,		KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC class I-like antigen recognition-like,REGION:Disordered,
A2M	alpha-2-macroglobulin(A2M)	Homo sapiens			GO:0001553~luteinization,GO:0001869~negative regulation of complement activation, lectin pathway,GO:0002438~acute inflammatory response to antigenic stimulus,GO:0006953~acute-phase response,GO:0007584~response to nutrient,GO:0010037~response to carbon dioxide,GO:0034695~response to prostaglandin E,GO:0048863~stem cell differentiation,GO:0051384~response to glucocorticoid,GO:1990402~embryonic liver development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0002020~protease binding,GO:0004866~endopeptidase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019838~growth factor binding,GO:0019899~enzyme binding,GO:0019959~interleukin-8 binding,GO:0019966~interleukin-1 binding,GO:0042802~identical protein binding,GO:0043120~tumor necrosis factor binding,GO:0048306~calcium-dependent protein binding,GO:0048403~brain-derived neurotrophic factor binding,GO:0048406~nerve growth factor binding,	IPR001599:Alpha-2-macroglobulin,IPR002890:Alpha-2-macroglobulin, N-terminal,IPR008930:Terpenoid cyclases/protein prenyltransferase alpha-alpha toroid,IPR009048:Alpha-macroglobulin, receptor-binding,IPR010916:TonB box, conserved site,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR011626:A-macroglobulin complement component,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR019742:Alpha-2-macroglobulin, conserved site,	hsa04610:Complement and coagulation cascades,			SM01359:SM01359,SM01360:SM01360,SM01361:SM01361,		KW-0964~Secreted,		KW-0082~Bait region,KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0882~Thioester bond,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Isoglutamyl cysteine thioester (Cys-Gln),CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-? in other proteins),DISULFID:Interchain (with C-278),DISULFID:Interchain (with C-431),DOMAIN:Alpha-2-macroglobulin bait region,DOMAIN:Macroglobulin,REGION:Bait region,REGION:Inhibitory,
APCS	amyloid P component, serum(APCS)	Homo sapiens			GO:0002674~negative regulation of acute inflammatory response,GO:0006457~protein folding,GO:0006953~acute-phase response,GO:0006958~complement activation, classical pathway,GO:0044793~negative regulation by host of viral process,GO:0044869~negative regulation by host of viral exo-alpha-sialidase activity,GO:0044871~negative regulation by host of viral glycoprotein metabolic process,GO:0045087~innate immune response,GO:0045656~negative regulation of monocyte differentiation,GO:0046597~negative regulation of viral entry into host cell,GO:0048525~negative regulation of viral process,GO:0051131~chaperone-mediated protein complex assembly,GO:0061045~negative regulation of wound healing,GO:1903016~negative regulation of exo-alpha-sialidase activity,GO:1903019~negative regulation of glycoprotein metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0001849~complement component C1q binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030169~low-density lipoprotein particle binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,GO:0046790~virion binding,GO:0046872~metal ion binding,GO:0051082~unfolded protein binding,	IPR001759:Pentaxin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,		Amyloidosis, secondary, susceptibility to~Amyloidosis, secondary, susceptibility to,		SM00159:PTX,		KW-0034~Amyloid,KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Pentraxin (PTX),
APBA2	amyloid beta precursor protein binding family A member 2(APBA2)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0007268~chemical synaptic transmission,GO:0007399~nervous system development,GO:0007626~locomotory behavior,GO:0010468~regulation of gene expression,GO:0015031~protein transport,GO:0035264~multicellular organism growth,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0043197~dendritic spine,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098793~presynapse,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001478:PDZ domain,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,				SM00228:PDZ,SM00462:PTB,	KW-0653~Protein transport,KW-0813~Transport,			KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PID,REGION:Disordered,REGION:STXBP1-binding,
ANGPTL2	angiopoietin like 2(ANGPTL2)	Homo sapiens			GO:0007267~cell-cell signaling,GO:0007275~multicellular organism development,	GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,IPR020837:Fibrinogen, conserved site,				SM00186:FBG,		KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibrinogen C-terminal,REGION:Disordered,
ANKS1B	ankyrin repeat and sterile alpha motif domain containing 1B(ANKS1B)	Homo sapiens			GO:0048013~ephrin receptor signaling pathway,GO:1900383~regulation of synaptic plasticity by receptor localization to synapse,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0015030~Cajal body,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,	GO:0046875~ephrin receptor binding,	IPR001660:Sterile alpha motif domain,IPR002110:Ankyrin repeat,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,IPR013761:Sterile alpha motif/pointed domain,				SM00248:ANK,SM00454:SAM,SM00462:PTB,		KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PID,DOMAIN:SAM,DOMAIN:SAM 1,DOMAIN:SAM 2,MOTIF:Nuclear localization signal,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
ANKRD22	ankyrin repeat domain 22(ANKRD22)	Homo sapiens						IPR002110:Ankyrin repeat,				SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,				REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
ANKRD9	ankyrin repeat domain 9(ANKRD9)	Homo sapiens			GO:0006878~cellular copper ion homeostasis,GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,GO:0031466~Cul5-RING ubiquitin ligase complex,	GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR002110:Ankyrin repeat,					KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0040~ANK repeat,KW-0677~Repeat,				MOTIF:Important role in both nutrient sensing and binding/regulation of IMPDH2,MUTAGEN:C->S: Inhibits the vesicle-to-rods transition under nutrient-limiting conditions. Inhibits the vesicle-to-rods transition under nutrient-limiting conditions; when associated with C-109. Does not affect the abundance of IMPDH2.,MUTAGEN:C->S: Inhibits the vesicle-to-rods transition under nutrient-limiting conditions. Inhibits the vesicle-to-rods transition under nutrient-limiting conditions; when associated with C-110. Prevents the colocalization of ANKRD9 with IMPDH2 filaments. Increases the abundance of IMPDH2. Increases the abundance of IMPDH2; when associated with C-110.,MUTAGEN:R->A: Loss the vesicle-like pattern and becomes diffuse in the cytosol.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
ANXA9	annexin A9(ANXA9)	Homo sapiens			GO:0007271~synaptic transmission, cholinergic,GO:0070588~calcium ion transmembrane transport,GO:0098609~cell-cell adhesion,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031982~vesicle,GO:0045202~synapse,	GO:0001786~phosphatidylserine binding,GO:0002020~protease binding,GO:0005262~calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0005544~calcium-dependent phospholipid binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0015464~acetylcholine receptor activity,GO:0019834~phospholipase A2 inhibitor activity,GO:0046790~virion binding,	IPR001464:Annexin,IPR009116:Annexin, type XXXI,IPR018252:Annexin repeat, conserved site,IPR018502:Annexin repeat,				SM00335:ANX,				KW-0041~Annexin,KW-0677~Repeat,				REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
AGR2	anterior gradient 2, protein disulphide isomerase family member(AGR2)	Homo sapiens			GO:0006954~inflammatory response,GO:0010628~positive regulation of gene expression,GO:0010811~positive regulation of cell-substrate adhesion,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0048546~digestive tract morphogenesis,GO:0048639~positive regulation of developmental growth,GO:0060480~lung goblet cell differentiation,GO:0060548~negative regulation of cell death,GO:0070254~mucus secretion,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903896~positive regulation of IRE1-mediated unfolded protein response,GO:1903899~positive regulation of PERK-mediated unfolded protein response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,	GO:0002162~dystroglycan binding,GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,GO:0042802~identical protein binding,			620233~Respiratory infections, recurrent, and failure to thrive with or without diarrhea,				KW-0256~Endoplasmic reticulum,KW-0964~Secreted,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0732~Signal,			KW-1015~Disulfide bond,	MOTIF:Homodimer stabilization; interchain,MUTAGEN:C->S: Loss of interaction with MUC2.,MUTAGEN:E->A: Monomer only, and reduced cell adhesion efficiency.,MUTAGEN:K->A: Disrupted dimerization.,MUTAGEN:Y->A: Disrupted dimerization.,REGION:Required to promote cell adhesion,
APLNR	apelin receptor(APLNR)	Homo sapiens			GO:0001525~angiogenesis,GO:0001568~blood vessel development,GO:0001570~vasculogenesis,GO:0001944~vasculature development,GO:0001947~heart looping,GO:0003171~atrioventricular valve development,GO:0003272~endocardial cushion formation,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007369~gastrulation,GO:0007507~heart development,GO:0007512~adult heart development,GO:0010468~regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0031065~positive regulation of histone deacetylation,GO:0035886~vascular smooth muscle cell differentiation,GO:0035904~aorta development,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045766~positive regulation of angiogenesis,GO:0050878~regulation of body fluid levels,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0060183~apelin receptor signaling pathway,GO:0060412~ventricular septum morphogenesis,GO:0060841~venous blood vessel development,GO:0060976~coronary vasculature development,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903596~regulation of gap junction assembly,GO:1904325~positive regulation of inhibitory G-protein coupled receptor phosphorylation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0060182~apelin receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR003904:APJ receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,hsa04371:Apelin signaling pathway,				KW-0037~Angiogenesis,KW-0306~Gastrulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G-protein coupled receptors family 1 profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
APOBEC3A	apolipoprotein B mRNA editing enzyme catalytic subunit 3A(APOBEC3A)	Homo sapiens			GO:0009972~cytidine deamination,GO:0010526~negative regulation of transposition, RNA-mediated,GO:0010529~negative regulation of transposition,GO:0016554~cytidine to uridine editing,GO:0044355~clearance of foreign intracellular DNA,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0051607~defense response to virus,GO:0070383~DNA cytosine deamination,GO:0071466~cellular response to xenobiotic stimulus,GO:0080111~DNA demethylation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0004126~cytidine deaminase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0047844~deoxycytidine deaminase activity,	IPR002125:CMP/dCMP deaminase, zinc-binding,IPR016192:APOBEC/CMP deaminase, zinc-binding,IPR016193:Cytidine deaminase-like,	hsa03250:Viral life cycle - HIV-1,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,	ACT_SITE:Proton donor,DOMAIN:CMP/dCMP-type deaminase,MUTAGEN:C->S: Altered deaminase activity.,MUTAGEN:D->N: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:D->N: No effect on deaminase activity despite an altered restriction activity towards genetic invaders.,MUTAGEN:E->Q: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:H->A: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:H->R: Altered deaminase activity.,MUTAGEN:K->A: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:K->F: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:N->A: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:R->A: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:R->E: No effect on deaminase activity despite an altered restriction activity towards genetic invaders.,MUTAGEN:W->L: Altered deaminase activity and restriction activity towards genetic invaders.,MUTAGEN:Y->A: Altered deaminase activity and restriction activity towards genetic invaders.,REGION:Disordered,
AQP1	aquaporin 1 (Colton blood group)(AQP1)	Homo sapiens			GO:0003091~renal water homeostasis,GO:0003094~glomerular filtration,GO:0003097~renal water transport,GO:0006813~potassium ion transport,GO:0006833~water transport,GO:0006884~cell volume homeostasis,GO:0006972~hyperosmotic response,GO:0009992~cellular water homeostasis,GO:0010761~fibroblast migration,GO:0010763~positive regulation of fibroblast migration,GO:0015670~carbon dioxide transport,GO:0015696~ammonium transport,GO:0015793~glycerol transport,GO:0019233~sensory perception of pain,GO:0019725~cellular homeostasis,GO:0019934~cGMP-mediated signaling,GO:0021670~lateral ventricle development,GO:0030157~pancreatic juice secretion,GO:0030185~nitric oxide transport,GO:0030950~establishment or maintenance of actin cytoskeleton polarity,GO:0033326~cerebrospinal fluid secretion,GO:0033363~secretory granule organization,GO:0034644~cellular response to UV,GO:0035377~transepithelial water transport,GO:0035378~carbon dioxide transmembrane transport,GO:0042060~wound healing,GO:0042476~odontogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0044241~lipid digestion,GO:0045766~positive regulation of angiogenesis,GO:0046878~positive regulation of saliva secretion,GO:0048146~positive regulation of fibroblast proliferation,GO:0048593~camera-type eye morphogenesis,GO:0050829~defense response to Gram-negative bacterium,GO:0050891~multicellular organismal water homeostasis,GO:0051458~corticotropin secretion,GO:0051649~establishment of localization in cell,GO:0070295~renal water absorption,GO:0070301~cellular response to hydrogen peroxide,GO:0071241~cellular response to inorganic substance,GO:0071260~cellular response to mechanical stimulus,GO:0071280~cellular response to copper ion,GO:0071288~cellular response to mercury ion,GO:0071300~cellular response to retinoic acid,GO:0071320~cellular response to cAMP,GO:0071456~cellular response to hypoxia,GO:0071472~cellular response to salt stress,GO:0071474~cellular hyperosmotic response,GO:0071549~cellular response to dexamethasone stimulus,GO:0071732~cellular response to nitric oxide,GO:0071805~potassium ion transmembrane transport,GO:0072220~metanephric descending thin limb development,GO:0072230~metanephric proximal straight tubule development,GO:0072232~metanephric proximal convoluted tubule segment 2 development,GO:0072239~metanephric glomerulus vasculature development,GO:0072488~ammonium transmembrane transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005903~brush border,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030424~axon,GO:0031526~brush border membrane,GO:0031965~nuclear membrane,GO:0042383~sarcolemma,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,	GO:0005223~intracellular cGMP activated cation channel activity,GO:0005267~potassium channel activity,GO:0005372~water transmembrane transporter activity,GO:0005515~protein binding,GO:0008519~ammonium transmembrane transporter activity,GO:0015079~potassium ion transmembrane transporter activity,GO:0015168~glycerol transmembrane transporter activity,GO:0015250~water channel activity,GO:0015267~channel activity,GO:0022857~transmembrane transporter activity,GO:0030184~nitric oxide transmembrane transporter activity,GO:0035379~carbon dioxide transmembrane transporter activity,GO:0042802~identical protein binding,GO:0046875~ephrin receptor binding,	IPR000425:Major intrinsic protein,IPR022357:Major intrinsic protein, conserved site,IPR023271:Aquaporin-like,IPR023274:Aquaporin 1,	hsa04924:Renin secretion,hsa04964:Proximal tubule bicarbonate reclamation,hsa04976:Bile secretion,	110450~Aquaporin-1 deficiency,110450~Blood group, Colton,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,INTRAMEM:Helical; Name=Helix B,INTRAMEM:Helical; Name=Helix E,MOTIF:NPA 1,MOTIF:NPA 2,REGION:Disordered,SITE:Hg(2+)-sensitive residue,SITE:Substrate discrimination,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Helix 1,TRANSMEM:Helical; Name=Helix 2,TRANSMEM:Helical; Name=Helix 3,TRANSMEM:Helical; Name=Helix 4,TRANSMEM:Helical; Name=Helix 5,TRANSMEM:Helical; Name=Helix 6,
ALOX12	arachidonate 12-lipoxygenase, 12S type(ALOX12)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0019369~arachidonic acid metabolic process,GO:0019372~lipoxygenase pathway,GO:0019395~fatty acid oxidation,GO:0033559~unsaturated fatty acid metabolic process,GO:0034440~lipid oxidation,GO:0042554~superoxide anion generation,GO:0043651~linoleic acid metabolic process,GO:0051122~hepoxilin biosynthetic process,GO:0061436~establishment of skin barrier,GO:0090331~negative regulation of platelet aggregation,GO:1901751~leukotriene A4 metabolic process,GO:2001303~lipoxin A4 biosynthetic process,GO:2001306~lipoxin B4 biosynthetic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,	GO:0004052~arachidonate 12-lipoxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0016165~linoleate 13S-lipoxygenase activity,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0047977~hepoxilin-epoxide hydrolase activity,GO:0050473~arachidonate 15-lipoxygenase activity,	IPR000907:Lipoxygenase,IPR001024:Lipoxygenase, LH2,IPR001885:Lipoxygenase, mammalian,IPR013819:Lipoxygenase, C-terminal,IPR020833:Lipoxygenase, iron binding site,IPR020834:Lipoxygenase, conserved site,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,hsa01523:Antifolate resistance,hsa04726:Serotonergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,			SM00308:LH2,	KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0963~Cytoplasm,			KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0378~Hydrolase,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	DOMAIN:Lipoxygenase,DOMAIN:PLAT,MUTAGEN:A->I: Reduced arachidonate 12(S)-lipoxygenase activity. Alters the stereoselectivity of the oxygenation reaction.,MUTAGEN:H->Q,Y: Complete loss of arachidonate 12(S)-lipoxygenase activity.,MUTAGEN:H->Q: Alteredarachidonate 12(S)-lipoxygenase activity and protein expression.,MUTAGEN:H->Q: Complete loss of arachidonate 12(S)-lipoxygenase activity.,MUTAGEN:H->Q: No effect on arachidonate 12(S)-lipoxygenase activity.,MUTAGEN:K->Q: Reduced arachidonate 12(S)-lipoxygenase activity. No effect on the stereoselectivity of the oxygenation reaction.,MUTAGEN:V->M: No effect onarachidonate 12(S)-lipoxygenase activity. No effect on the stereoselectivity of the oxygenation reaction.,SITE:Essential for stabilizing binding to COTL1,
ALOX15	arachidonate 15-lipoxygenase(ALOX15)	Homo sapiens			GO:0001503~ossification,GO:0001676~long-chain fatty acid metabolic process,GO:0002820~negative regulation of adaptive immune response,GO:0006629~lipid metabolic process,GO:0006646~phosphatidylethanolamine biosynthetic process,GO:0006690~icosanoid metabolic process,GO:0006954~inflammatory response,GO:0010811~positive regulation of cell-substrate adhesion,GO:0019369~arachidonic acid metabolic process,GO:0019372~lipoxygenase pathway,GO:0019395~fatty acid oxidation,GO:0030282~bone mineralization,GO:0030838~positive regulation of actin filament polymerization,GO:0032787~monocarboxylic acid metabolic process,GO:0034440~lipid oxidation,GO:0034976~response to endoplasmic reticulum stress,GO:0035358~regulation of peroxisome proliferator activated receptor signaling pathway,GO:0035963~cellular response to interleukin-13,GO:0042060~wound healing,GO:0042759~long-chain fatty acid biosynthetic process,GO:0043277~apoptotic cell clearance,GO:0043651~linoleic acid metabolic process,GO:0050727~regulation of inflammatory response,GO:0051122~hepoxilin biosynthetic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071277~cellular response to calcium ion,GO:1901074~regulation of engulfment of apoptotic cell,GO:2001303~lipoxin A4 biosynthetic process,	GO:0005737~cytoplasm,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0004052~arachidonate 12-lipoxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0016165~linoleate 13S-lipoxygenase activity,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0050473~arachidonate 15-lipoxygenase activity,	IPR000907:Lipoxygenase,IPR001024:Lipoxygenase, LH2,IPR001885:Lipoxygenase, mammalian,IPR013819:Lipoxygenase, C-terminal,IPR020833:Lipoxygenase, iron binding site,IPR020834:Lipoxygenase, conserved site,	hsa00590:Arachidonic acid metabolism,hsa00591:Linoleic acid metabolism,hsa01100:Metabolic pathways,hsa04216:Ferroptosis,hsa04217:Necroptosis,hsa04726:Serotonergic synapse,			SM00308:LH2,	KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0551~Lipid droplet,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0106~Calcium,KW-0408~Iron,KW-0446~Lipid-binding,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,		DOMAIN:Lipoxygenase,DOMAIN:PLAT,MUTAGEN:M->V: Catalyzes 15- and 12-lipoxygenation.,SITE:Essential for stabilizing binding to COTL1,
AHR	aryl hydrocarbon receptor(AHR)	Homo sapiens		h_acrPathway:Ahr Signal Transduction Pathway,	GO:0001568~blood vessel development,GO:0002819~regulation of adaptive immune response,GO:0002841~negative regulation of T cell mediated immune response to tumor cell,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006805~xenobiotic metabolic process,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010468~regulation of gene expression,GO:0019933~cAMP-mediated signaling,GO:0030522~intracellular receptor signaling pathway,GO:0030888~regulation of B cell proliferation,GO:0032922~circadian regulation of gene expression,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0050728~negative regulation of inflammatory response,GO:0071219~cellular response to molecule of bacterial origin,GO:0071320~cellular response to cAMP,GO:1904322~cellular response to forskolin,GO:1904613~cellular response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0034751~aryl hydrocarbon receptor complex,GO:0034752~cytosolic aryl hydrocarbon receptor complex,GO:0034753~nuclear aryl hydrocarbon receptor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001094~TFIID-class transcription factor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051879~Hsp90 protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000014:PAS domain,IPR001610:PAC motif,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013655:PAS fold-3,IPR013767:PAS fold,	hsa04659:Th17 cell differentiation,hsa04934:Cushing syndrome,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,	618345~Retinitis pigmentosa 85,		SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0682~Retinitis pigmentosa,	KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,	COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:A->D: Abolishes transcription factor activity; when associated with D-50 and D-82.,MUTAGEN:F->D: Abolishes transcription factor activity; when associated with D-50 and D-79.,MUTAGEN:F->D: Interfers with transcription factor activity.,MUTAGEN:H->G: Almost abolishes transcription factor activity. No effect on nuclear translocation upon ligand binding.,MUTAGEN:I->D: Interfers with transcription factor activity.,MUTAGEN:L->D: Abolishes transcription factor activity; when associated with D-79 and D-82.,MUTAGEN:L->D: Interfers with transcription factor activity.,MUTAGEN:LLQAL->ELQDE: Strongly reduces transcription factor activity.,MUTAGEN:R->D: Abolishes transcription factor activity. Alters on nuclear translocation upon ligand binding.,MUTAGEN:S->G: Strongly reduces transcription factor activity.,MUTAGEN:V->A: Increases specific ligand binding.,MUTAGEN:V->D: Abolishes specific ligand binding.,MUTAGEN:V->D: Interfers with transcription factor activity.,MUTAGEN:V->L,G: No effect on specific ligand binding.,REGION:DNA-binding,REGION:Disordered,REGION:Required for maintaining the overall integrity of the AHR:ARNT heterodimer and its transcriptional activity,
ASPG	asparaginase(ASPG)	Homo sapiens			GO:0009066~aspartate family amino acid metabolic process,GO:0016042~lipid catabolic process,	GO:0005829~cytosol,	GO:0003847~1-alkyl-2-acetylglycerophosphocholine esterase activity,GO:0004067~asparaginase activity,GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,	IPR002110:Ankyrin repeat,IPR006033:L-asparaginase, type I,IPR006034:Asparaginase/glutaminase,IPR027473:L-asparaginase, C-terminal domain,IPR027474:L-asparaginase, N-terminal,IPR027475:Asparaginase/glutaminase, active site 2,			PIRSF001220:L-asparaginase/Glutamyl-tRNA(Gln) amidotransferase subunit D,	SM00248:ANK,SM00870:SM00870,	KW-0442~Lipid degradation,KW-0443~Lipid metabolism,			KW-0040~ANK repeat,KW-0677~Repeat,		KW-0012~Acyltransferase,KW-0378~Hydrolase,KW-0808~Transferase,		ACT_SITE:Acyl-ester intermediate,DOMAIN:Asparaginase/glutaminase,DOMAIN:Asparaginase/glutaminase C-terminal,DOMAIN:L-asparaginase N-terminal,REGION:Asparaginase,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
ATOH1	atonal bHLH transcription factor 1(ATOH1)	Homo sapiens			GO:0001764~neuron migration,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0007423~sensory organ development,GO:0014014~negative regulation of gliogenesis,GO:0021987~cerebral cortex development,GO:0030182~neuron differentiation,GO:0042472~inner ear morphogenesis,GO:0042491~auditory receptor cell differentiation,GO:0042667~auditory receptor cell fate specification,GO:0042668~auditory receptor cell fate determination,GO:0043066~negative regulation of apoptotic process,GO:0045609~positive regulation of auditory receptor cell differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048663~neuron fate commitment,GO:0061564~axon development,GO:0097402~neuroblast migration,GO:1904019~epithelial cell apoptotic process,GO:1904036~negative regulation of epithelial cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0031490~chromatin DNA binding,GO:0043565~sequence-specific DNA binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,		620284~Deafness, autosomal dominant 89,		SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-1010~Non-syndromic deafness,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,
AXIN2	axin 2(AXIN2)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0001756~somitogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0001957~intramembranous ossification,GO:0003139~secondary heart field specification,GO:0003180~aortic valve morphogenesis,GO:0003183~mitral valve morphogenesis,GO:0003413~chondrocyte differentiation involved in endochondral bone morphogenesis,GO:0008104~protein localization,GO:0008219~cell death,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010942~positive regulation of cell death,GO:0016055~Wnt signaling pathway,GO:0030282~bone mineralization,GO:0032423~regulation of mismatch repair,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033687~osteoblast proliferation,GO:0033689~negative regulation of osteoblast proliferation,GO:0034613~cellular protein localization,GO:0042476~odontogenesis,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043570~maintenance of DNA repeat elements,GO:0045600~positive regulation of fat cell differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0048255~mRNA stabilization,GO:0048468~cell development,GO:0061181~regulation of chondrocyte development,GO:0070602~regulation of centromeric sister chromatid cohesion,GO:0071407~cellular response to organic cyclic compound,GO:0071549~cellular response to dexamethasone stimulus,GO:0072089~stem cell proliferation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1903053~regulation of extracellular matrix organization,GO:2000054~negative regulation of Wnt signaling pathway involved in dorsal/ventral axis specification,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030877~beta-catenin destruction complex,	GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0060090~binding, bridging,GO:0070411~I-SMAD binding,	IPR001158:DIX domain,IPR014936:Axin beta-catenin binding,IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,	hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05213:Endometrial cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	114500~Colorectal cancer, somatic,608615~Oligodontia-colorectal cancer syndrome,		SM00021:DAX,SM00315:RGS,	KW-0879~Wnt signaling pathway,	KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DIX,DOMAIN:RGS,MOTIF:Tankyrase-binding motif,REGION:Disordered,REGION:Interaction with GSK3B,REGION:Interaction with SIAH1 and SIAH2,REGION:Interaction with beta-catenin,
AZU1	azurocidin 1(AZU1)	Homo sapiens			GO:0001774~microglial cell activation,GO:0006508~proteolysis,GO:0006954~inflammatory response,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0008347~glial cell migration,GO:0010628~positive regulation of gene expression,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0019730~antimicrobial humoral response,GO:0019731~antibacterial humoral response,GO:0032724~positive regulation of fractalkine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0042117~monocyte activation,GO:0043066~negative regulation of apoptotic process,GO:0043114~regulation of vascular permeability,GO:0045123~cellular extravasation,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045785~positive regulation of cell adhesion,GO:0045860~positive regulation of protein kinase activity,GO:0048246~macrophage chemotaxis,GO:0050766~positive regulation of phagocytosis,GO:0050829~defense response to Gram-negative bacterium,GO:0050930~induction of positive chemotaxis,GO:0051607~defense response to virus,GO:0060326~cell chemotaxis,GO:0070528~protein kinase C signaling,GO:0070944~neutrophil mediated killing of bacterium,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0019898~extrinsic component of membrane,GO:0035577~azurophil granule membrane,GO:0035578~azurophil granule lumen,GO:0042582~azurophil granule,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008233~peptidase activity,GO:0015643~toxic substance binding,GO:0043395~heparan sulfate proteoglycan binding,	IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,	hsa04613:Neutrophil extracellular trap formation,			SM00020:Tryp_SPc,	KW-0145~Chemotaxis,	KW-0472~Membrane,		KW-0732~Signal,		KW-0044~Antibiotic,KW-0358~Heparin-binding,KW-0721~Serine protease homolog,KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,DOMAIN:Peptidase S1,MUTAGEN:C->S: Loss of antibiotic activity.,PROPEP:Dipeptide found in non-mature form,PROPEP:Removed in mature form,REGION:Possesses antibiotic activity,
BHLHE23	basic helix-loop-helix family member e23(BHLHE23)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007423~sensory organ development,GO:0030182~neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046548~retinal rod cell development,GO:0046671~negative regulation of retinal cell programmed cell death,GO:0048050~post-embryonic eye morphogenesis,GO:0048468~cell development,GO:0048663~neuron fate commitment,GO:0061564~axon development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,				SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,
BATF2	basic leucine zipper ATF-like transcription factor 2(BATF2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0042832~defense response to protozoan,GO:0043011~myeloid dendritic cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,	hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00338:BRLZ,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
BNC1	basonuclin zinc finger protein 1(BNC1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006356~regulation of transcription from RNA polymerase I promoter,GO:0007283~spermatogenesis,GO:0008284~positive regulation of cell proliferation,GO:0008544~epidermis development,GO:0030154~cell differentiation,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:1900195~positive regulation of oocyte maturation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000182~rDNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		618723~Premature ovarian failure 16,		SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1066~Premature ovarian failure,	KW-0677~Repeat,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C2H2-type,MOTIF:Nuclear localization signal,MUTAGEN:S->A: No effect on phosphorylation. Abolishes phosphorylation and induces nuclear restriction; when associated with A-541.,MUTAGEN:S->A: Strongly reduces phosphorylation. Abolishes phosphorylation and induces nuclear restriction; when associated with A-537.,MUTAGEN:S->D: No effect on phosphorylation, no effect on subcellular location.,MUTAGEN:S->D: Reduces phosphorylation and induces partial relocation into the cytoplasm.,MUTAGEN:S->D: Strongly reduces phosphorylation and induces partial relocation into the cytoplasm.,REGION:Disordered,REGION:Hydrophobic,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
BST1	bone marrow stromal cell antigen 1(BST1)	Homo sapiens			GO:0001952~regulation of cell-matrix adhesion,GO:0002691~regulation of cellular extravasation,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0030890~positive regulation of B cell proliferation,GO:0032956~regulation of actin cytoskeleton organization,GO:0050727~regulation of inflammatory response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050848~regulation of calcium-mediated signaling,GO:0090022~regulation of neutrophil chemotaxis,GO:0090322~regulation of superoxide metabolic process,GO:2001044~regulation of integrin-mediated signaling pathway,	GO:0001931~uropod,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0019898~extrinsic component of membrane,GO:0031225~anchored component of membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0003953~NAD+ nucleosidase activity,GO:0016740~transferase activity,GO:0016849~phosphorus-oxygen lyase activity,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,GO:0061811~ADP-ribosyl cyclase activity,GO:0061812~cyclic ADP-ribose hydrolase,	IPR003193:ADP-ribosyl cyclase (CD38/157),	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0520~NAD,	KW-0378~Hydrolase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:GPI-anchor amidated alanine,PROPEP:Removed in mature form,
BST2	bone marrow stromal cell antigen 2(BST2)	Homo sapiens			GO:0002737~negative regulation of plasmacytoid dendritic cell cytokine production,GO:0009615~response to virus,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0042113~B cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0070665~positive regulation of leukocyte proliferation,GO:1901253~negative regulation of intracellular transport of viral material,	GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031225~anchored component of membrane,GO:0035577~azurophil granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR024886:Bone marrow stromal antigen 2,	hsa03250:Viral life cycle - HIV-1,hsa05168:Herpes simplex virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0075~B-cell activation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DISULFID:Interchain,LIPID:GPI-anchor amidated serine,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-63.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-91.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-63 and A-91.,MUTAGEN:K->R: Abolishes redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:K->R: No effect on redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:N->A: Loss of glycosylation site.,MUTAGEN:N->A: Loss of glycosylation site. Impairs anti-viral activity.,MUTAGEN:STS->AAA: Partial resistance to Vpu.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-6.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-8.,PROPEP:Removed in mature form,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
BMP10	bone morphogenetic protein 10(BMP10)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,	GO:0001822~kidney development,GO:0007155~cell adhesion,GO:0007512~adult heart development,GO:0010596~negative regulation of endothelial cell migration,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010628~positive regulation of gene expression,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0030509~BMP signaling pathway,GO:0032924~activin receptor signaling pathway,GO:0045214~sarcomere organization,GO:0045893~positive regulation of transcription, DNA-templated,GO:0055009~atrial cardiac muscle tissue morphogenesis,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0055015~ventricular cardiac muscle cell development,GO:0055117~regulation of cardiac muscle contraction,GO:0060038~cardiac muscle cell proliferation,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060298~positive regulation of sarcomere organization,GO:0060347~heart trabecula formation,GO:0060389~pathway-restricted SMAD protein phosphorylation,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060395~SMAD protein signal transduction,GO:0061036~positive regulation of cartilage development,GO:1903242~regulation of cardiac muscle hypertrophy in response to stress,GO:2000138~positive regulation of cell proliferation involved in heart morphogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009986~cell surface,GO:0030018~Z disc,	GO:0005125~cytokine activity,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0031433~telethonin binding,GO:0033612~receptor serine/threonine kinase binding,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,IPR017948:Transforming growth factor beta, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,			SM00204:TGFB,	KW-0130~Cell adhesion,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,
BMP7	bone morphogenetic protein 7(BMP7)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,	GO:0001501~skeletal system development,GO:0001503~ossification,GO:0001656~metanephros development,GO:0001657~ureteric bud development,GO:0001707~mesoderm formation,GO:0001823~mesonephros development,GO:0001837~epithelial to mesenchymal transition,GO:0003272~endocardial cushion formation,GO:0003344~pericardium morphogenesis,GO:0007411~axon guidance,GO:0008285~negative regulation of cell proliferation,GO:0009880~embryonic pattern specification,GO:0010628~positive regulation of gene expression,GO:0010664~negative regulation of striated muscle cell apoptotic process,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0016358~dendrite development,GO:0021502~neural fold elevation formation,GO:0030326~embryonic limb morphogenesis,GO:0030501~positive regulation of bone mineralization,GO:0030509~BMP signaling pathway,GO:0030855~epithelial cell differentiation,GO:0030858~positive regulation of epithelial cell differentiation,GO:0030902~hindbrain development,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032355~response to estradiol,GO:0033280~response to vitamin D,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0034504~protein localization to nucleus,GO:0036305~ameloblast differentiation,GO:0042325~regulation of phosphorylation,GO:0042326~negative regulation of phosphorylation,GO:0042475~odontogenesis of dentin-containing tooth,GO:0043065~positive regulation of apoptotic process,GO:0043401~steroid hormone mediated signaling pathway,GO:0043407~negative regulation of MAP kinase activity,GO:0043434~response to peptide hormone,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0045786~negative regulation of cell cycle,GO:0045839~negative regulation of mitotic nuclear division,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048596~embryonic camera-type eye morphogenesis,GO:0048738~cardiac muscle tissue development,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048762~mesenchymal cell differentiation,GO:0048812~neuron projection morphogenesis,GO:0050768~negative regulation of neurogenesis,GO:0051216~cartilage development,GO:0060037~pharyngeal system development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060393~regulation of pathway-restricted SMAD protein phosphorylation,GO:0060395~SMAD protein signal transduction,GO:0060411~cardiac septum morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0060485~mesenchyme development,GO:0060548~negative regulation of cell death,GO:0060686~negative regulation of prostatic bud formation,GO:0060687~regulation of branching involved in prostate gland morphogenesis,GO:0060710~chorio-allantoic fusion,GO:0061384~heart trabecula morphogenesis,GO:0070487~monocyte aggregation,GO:0071456~cellular response to hypoxia,GO:0071773~cellular response to BMP stimulus,GO:0072040~negative regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis,GO:0072125~negative regulation of glomerular mesangial cell proliferation,GO:0072133~metanephric mesenchyme morphogenesis,GO:0072134~nephrogenic mesenchyme morphogenesis,GO:0072136~metanephric mesenchymal cell proliferation involved in metanephros development,GO:0090336~positive regulation of brown fat cell differentiation,GO:1900006~positive regulation of dendrite development,GO:1900106~positive regulation of hyaluranon cable assembly,GO:1901145~mesenchymal cell apoptotic process involved in nephron morphogenesis,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1905069~allantois development,GO:1905312~positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:2000121~regulation of removal of superoxide radicals,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031982~vesicle,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0070700~BMP receptor binding,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,IPR017948:Transforming growth factor beta, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04350:TGF-beta signaling pathway,hsa04360:Axon guidance,hsa04390:Hippo signaling pathway,			SM00204:TGFB,	KW-0221~Differentiation,KW-0891~Chondrogenesis,KW-0892~Osteogenesis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:TGF-beta family profile,DOMAIN:TGF-beta propeptide,REGION:Disordered,
BDNF	brain derived neurotrophic factor(BDNF)	Homo sapiens	148.PCAF_GCN5-TFIID-complexes,		GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0007416~synapse assembly,GO:0007422~peripheral nervous system development,GO:0007613~memory,GO:0010832~negative regulation of myotube differentiation,GO:0010976~positive regulation of neuron projection development,GO:0021675~nerve development,GO:0031547~brain-derived neurotrophic factor receptor signaling pathway,GO:0031550~positive regulation of brain-derived neurotrophic factor receptor signaling pathway,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0038180~nerve growth factor signaling pathway,GO:0043524~negative regulation of neuron apoptotic process,GO:0045664~regulation of neuron differentiation,GO:0048668~collateral sprouting,GO:0048672~positive regulation of collateral sprouting,GO:0048812~neuron projection morphogenesis,GO:0050804~modulation of synaptic transmission,GO:0051965~positive regulation of synapse assembly,GO:1900122~positive regulation of receptor binding,GO:2000008~regulation of protein localization to cell surface,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005788~endoplasmic reticulum lumen,GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0016607~nuclear speck,GO:0030424~axon,GO:0030425~dendrite,GO:0048471~perinuclear region of cytoplasm,	GO:0005163~nerve growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR002072:Nerve growth factor-related,IPR019846:Nerve growth factor conserved site,IPR020408:Nerve growth factor-like,IPR020430:Brain-derived neurotrophic factor,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04024:cAMP signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05034:Alcoholism,		PIRSF001789:nerve growth factor, subunit beta,	SM00140:NGF,		KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0339~Growth factor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Nerve growth factor-related,MUTAGEN:R->A: Abolishes processing by MBTPS1.,SITE:Cleavage; by MBTPS1,TRANSMEM:Helical,
BRD4	bromodomain containing 4(BRD4)	Homo sapiens			GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006974~cellular response to DNA damage stimulus,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043922~negative regulation by host of viral transcription,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050727~regulation of inflammatory response,GO:1901407~regulation of phosphorylation of RNA polymerase II C-terminal domain,GO:2000002~negative regulation of DNA damage checkpoint,GO:2001255~positive regulation of histone H3-K36 trimethylation,	GO:0000785~chromatin,GO:0000794~condensed nuclear chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0019899~enzyme binding,GO:0031493~nucleosomal histone binding,GO:0070577~lysine-acetylated histone binding,GO:0099122~RNA polymerase II C-terminal domain binding,	IPR001487:Bromodomain,IPR018359:Bromodomain, conserved site,IPR027353:NET domain,				SM00297:BROMO,	KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0103~Bromodomain,KW-0677~Repeat,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Bromo,DOMAIN:Bromo 1,DOMAIN:Bromo 2,DOMAIN:NET,MUTAGEN:EIE->AIA: Decreases interaction with JMJD6 and NSD3.No effect on interaction with histone 4 acetylated.,MUTAGEN:N->A: Abolishes binding to acetylated histones.,MUTAGEN:S->A: Impaired phosphorylation by CK2 and binding to acetylated histones.,MUTAGEN:SSS->ASA: Impaired phosphorylation by CK2 and binding to acetylated histones.,MUTAGEN:SST->AAA: Impaired phosphorylation by CK2 and binding to acetylated histones.,REGION:BID region,REGION:C-terminal (CTD) region,REGION:Disordered,REGION:NPS region,SITE:Acetylated histone binding,SITE:Breakpoint for translocation to form BDR4-NUTM1 fusion protein,
CREB5	cAMP responsive element binding protein 5(CREB5)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR016378:Transcription factor, cyclic AMP-dependent,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04668:TNF signaling pathway,hsa04714:Thermogenesis,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04918:Thyroid hormone synthesis,hsa04922:Glucagon signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04931:Insulin resistance,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04962:Vasopressin-regulated water reabsorption,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,		PIRSF003153:cyclic AMP-dependent transcription factor, CRE-BP1 type,	SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:C2H2-type,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,ZN_FING:C2H2-type,
CDH17	cadherin 17(CDH17)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0002314~germinal center B cell differentiation,GO:0002315~marginal zone B cell differentiation,GO:0006857~oligopeptide transport,GO:0007043~cell-cell junction assembly,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007229~integrin-mediated signaling pathway,GO:0007275~multicellular organism development,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0033626~positive regulation of integrin activation by cell surface receptor linked signal transduction,GO:0034332~adherens junction organization,GO:0035672~oligopeptide transmembrane transport,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0048536~spleen development,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016342~catenin complex,GO:0030054~cell junction,	GO:0005178~integrin binding,GO:0005215~transporter activity,GO:0005427~proton-dependent oligopeptide secondary active transmembrane transporter activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,	hsa05226:Gastric cancer,			SM00112:CA,	KW-0130~Cell adhesion,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH4	cadherin 4(CDH4)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0007043~cell-cell junction assembly,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007275~multicellular organism development,GO:0007411~axon guidance,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0034332~adherens junction organization,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0045773~positive regulation of axon extension,GO:0048675~axon extension,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005912~adherens junction,GO:0016021~integral component of membrane,GO:0016342~catenin complex,	GO:0005509~calcium ion binding,GO:0045296~cadherin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR014868:Cadherin prodomain,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,	hsa04514:Cell adhesion molecules,			SM00112:CA,SM01055:SM01055,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH5	cadherin 5(CDH5)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0001932~regulation of protein phosphorylation,GO:0001944~vasculature development,GO:0001955~blood vessel maturation,GO:0006874~cellular calcium ion homeostasis,GO:0007043~cell-cell junction assembly,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007275~multicellular organism development,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0030335~positive regulation of cell migration,GO:0030513~positive regulation of BMP signaling pathway,GO:0031115~negative regulation of microtubule polymerization,GO:0031334~positive regulation of protein complex assembly,GO:0034332~adherens junction organization,GO:0035307~positive regulation of protein dephosphorylation,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0043114~regulation of vascular permeability,GO:0043534~blood vessel endothelial cell migration,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0045766~positive regulation of angiogenesis,GO:0050728~negative regulation of inflammatory response,GO:0070830~bicellular tight junction assembly,GO:0098609~cell-cell adhesion,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,GO:1902396~protein localization to bicellular tight junction,GO:1903142~positive regulation of establishment of endothelial barrier,GO:2000114~regulation of establishment of cell polarity,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0005923~bicellular tight junction,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016342~catenin complex,GO:0030054~cell junction,GO:0031965~nuclear membrane,	GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019903~protein phosphatase binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0070051~fibrinogen binding,GO:0070700~BMP receptor binding,GO:1990782~protein tyrosine kinase binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,	hsa04514:Cell adhesion molecules,hsa04520:Adherens junction,hsa04670:Leukocyte transendothelial migration,hsa05418:Fluid shear stress and atherosclerosis,			SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin Y-type LIR-motif,REGION:Disordered,REGION:Required for interaction with PALS1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH7	cadherin 7(CDH7)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0007043~cell-cell junction assembly,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007275~multicellular organism development,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0034332~adherens junction organization,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0098609~cell-cell adhesion,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0016021~integral component of membrane,GO:0016342~catenin complex,	GO:0005509~calcium ion binding,GO:0045296~cadherin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH8	cadherin 8(CDH8)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0007043~cell-cell junction assembly,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007275~multicellular organism development,GO:0009409~response to cold,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0034332~adherens junction organization,GO:0035249~synaptic transmission, glutamatergic,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0050807~regulation of synapse organization,GO:0098609~cell-cell adhesion,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0016021~integral component of membrane,GO:0016342~catenin complex,GO:0043083~synaptic cleft,GO:0043679~axon terminus,GO:0097060~synaptic membrane,GO:0098978~glutamatergic synapse,	GO:0005509~calcium ion binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH23	cadherin related 23(CDH23)	Homo sapiens			GO:0006816~calcium ion transport,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0007626~locomotory behavior,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0045494~photoreceptor cell maintenance,GO:0048563~post-embryonic animal organ morphogenesis,GO:0050896~response to stimulus,GO:0050953~sensory perception of light stimulus,GO:0050957~equilibrioception,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0060088~auditory receptor cell stereocilium organization,GO:0060122~inner ear receptor stereocilium organization,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0001917~photoreceptor inner segment,GO:0005813~centrosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016342~catenin complex,GO:0032420~stereocilium,GO:0032426~stereocilium tip,GO:0060091~kinocilium,GO:0098683~cochlear hair cell ribbon synapse,GO:0098684~photoreceptor ribbon synapse,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,		601067~Usher syndrome, type 1D,601067~Usher syndrome, type 1D/F digenic,601386~Deafness, autosomal recessive 12,617540~Pituitary adenoma 5, multiple types,		SM00112:CA,	KW-0130~Cell adhesion,KW-0716~Sensory transduction,KW-0844~Vision,KW-1009~Hearing,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,KW-0836~Usher syndrome,KW-1010~Non-syndromic deafness,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 10,DOMAIN:Cadherin 11,DOMAIN:Cadherin 12,DOMAIN:Cadherin 13,DOMAIN:Cadherin 14,DOMAIN:Cadherin 15,DOMAIN:Cadherin 16,DOMAIN:Cadherin 17,DOMAIN:Cadherin 18,DOMAIN:Cadherin 19,DOMAIN:Cadherin 2,DOMAIN:Cadherin 20,DOMAIN:Cadherin 21,DOMAIN:Cadherin 22,DOMAIN:Cadherin 23,DOMAIN:Cadherin 24,DOMAIN:Cadherin 25,DOMAIN:Cadherin 26,DOMAIN:Cadherin 27,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin 7,DOMAIN:Cadherin 8,DOMAIN:Cadherin 9,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CALCA	calcitonin related polypeptide alpha(CALCA)	Homo sapiens			GO:0001503~ossification,GO:0001878~response to yeast,GO:0001935~endothelial cell proliferation,GO:0001944~vasculature development,GO:0001976~neurological system process involved in regulation of systemic arterial blood pressure,GO:0001984~artery vasodilation involved in baroreceptor response to increased systemic arterial blood pressure,GO:0002031~G-protein coupled receptor internalization,GO:0002548~monocyte chemotaxis,GO:0006468~protein phosphorylation,GO:0006939~smooth muscle contraction,GO:0006954~inflammatory response,GO:0007159~leukocyte cell-cell adhesion,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0007566~embryo implantation,GO:0007568~aging,GO:0007631~feeding behavior,GO:0008016~regulation of heart contraction,GO:0008217~regulation of blood pressure,GO:0009408~response to heat,GO:0010523~negative regulation of calcium ion transport into cytosol,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0030279~negative regulation of ossification,GO:0031623~receptor internalization,GO:0032147~activation of protein kinase activity,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0032757~positive regulation of interleukin-8 production,GO:0042311~vasodilation,GO:0043542~endothelial cell migration,GO:0045087~innate immune response,GO:0045651~positive regulation of macrophage differentiation,GO:0045671~negative regulation of osteoclast differentiation,GO:0045776~negative regulation of blood pressure,GO:0045779~negative regulation of bone resorption,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045986~negative regulation of smooth muscle contraction,GO:0048265~response to pain,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0071356~cellular response to tumor necrosis factor,GO:0097647~amylin receptor signaling pathway,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990408~calcitonin gene-related peptide receptor signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0043025~neuronal cell body,GO:0043195~terminal bouton,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098992~neuronal dense core vesicle,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0031716~calcitonin receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR001693:Calcitonin peptide-like,IPR015476:Procalcitonin gene-related peptide, proCGRP,IPR018360:Calcitonin, conserved site,IPR021116:Procalcitonin/adrenomedullin,IPR021117:Procalcitonin-like,IPR021118:Procalcitonin, alpha type,	hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,			SM00113:CALCITONIN,		KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,PEPTIDE:Calcitonin,PEPTIDE:Calcitonin gene-related peptide 1,PEPTIDE:Katacalcin,REGION:Disordered,
CACNA1B	calcium voltage-gated channel subunit alpha1 B(CACNA1B)	Homo sapiens			GO:0006816~calcium ion transport,GO:0007268~chemical synaptic transmission,GO:0034765~regulation of ion transmembrane transport,GO:0050804~modulation of synaptic transmission,GO:0070509~calcium ion import,GO:0098703~calcium ion import across plasma membrane,GO:1904645~response to beta-amyloid,	GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0001540~beta-amyloid binding,GO:0005245~voltage-gated calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0008331~high voltage-gated calcium channel activity,	IPR002048:EF-hand domain,IPR002077:Voltage-dependent calcium channel, alpha-1 subunit,IPR005447:Voltage-dependent calcium channel, N-type, alpha-1 subunit,IPR005821:Ion transport domain,IPR014873:Voltage-dependent calcium channel, alpha-1 subunit, IQ domain,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04723:Retrograde endocannabinoid signaling,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04930:Type II diabetes mellitus,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,hsa05207:Chemical carcinogenesis - receptor activation,	618497~Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements,		SM01062:SM01062,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:Ion transport,DOMAIN:Voltage-dependent L-type calcium channel IQ-associated,REGION:Binding to the beta subunit,REGION:Disordered,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=S1 of repeat I,TRANSMEM:Helical; Name=S1 of repeat II,TRANSMEM:Helical; Name=S1 of repeat III,TRANSMEM:Helical; Name=S1 of repeat IV,TRANSMEM:Helical; Name=S2 of repeat I,TRANSMEM:Helical; Name=S2 of repeat II,TRANSMEM:Helical; Name=S2 of repeat III,TRANSMEM:Helical; Name=S2 of repeat IV,TRANSMEM:Helical; Name=S3 of repeat I,TRANSMEM:Helical; Name=S3 of repeat II,TRANSMEM:Helical; Name=S3 of repeat III,TRANSMEM:Helical; Name=S3 of repeat IV,TRANSMEM:Helical; Name=S4 of repeat I,TRANSMEM:Helical; Name=S4 of repeat II,TRANSMEM:Helical; Name=S4 of repeat III,TRANSMEM:Helical; Name=S4 of repeat IV,TRANSMEM:Helical; Name=S5 of repeat I,TRANSMEM:Helical; Name=S5 of repeat II,TRANSMEM:Helical; Name=S5 of repeat III,TRANSMEM:Helical; Name=S5 of repeat IV,TRANSMEM:Helical; Name=S6 of repeat I,TRANSMEM:Helical; Name=S6 of repeat II,TRANSMEM:Helical; Name=S6 of repeat III,TRANSMEM:Helical; Name=S6 of repeat IV,
CACNA1C	calcium voltage-gated channel subunit alpha1 C(CACNA1C)	Homo sapiens			GO:0002520~immune system development,GO:0006816~calcium ion transport,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007507~heart development,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0034765~regulation of ion transmembrane transport,GO:0035115~embryonic forelimb morphogenesis,GO:0035585~calcium-mediated signaling using extracellular calcium source,GO:0043010~camera-type eye development,GO:0045762~positive regulation of adenylate cyclase activity,GO:0060402~calcium ion transport into cytosol,GO:0061337~cardiac conduction,GO:0061577~calcium ion transmembrane transport via high voltage-gated calcium channel,GO:0070509~calcium ion import,GO:0070588~calcium ion transmembrane transport,GO:0086002~cardiac muscle cell action potential involved in contraction,GO:0086012~membrane depolarization during cardiac muscle cell action potential,GO:0086045~membrane depolarization during AV node cell action potential,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098703~calcium ion import across plasma membrane,GO:0098911~regulation of ventricular cardiac muscle cell action potential,GO:0098912~membrane depolarization during atrial cardiac muscle cell action potential,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030018~Z disc,GO:0030315~T-tubule,GO:0030425~dendrite,GO:0043204~perikaryon,GO:0098839~postsynaptic density membrane,GO:1990454~L-type voltage-gated calcium channel complex,	GO:0005216~ion channel activity,GO:0005245~voltage-gated calcium channel activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008331~high voltage-gated calcium channel activity,GO:0046872~metal ion binding,GO:0051393~alpha-actinin binding,GO:0086007~voltage-gated calcium channel activity involved in cardiac muscle cell action potential,GO:0086056~voltage-gated calcium channel activity involved in AV node cell action potential,	IPR002077:Voltage-dependent calcium channel, alpha-1 subunit,IPR005446:Voltage-dependent calcium channel, L-type, alpha-1 subunit,IPR005451:Voltage-dependent calcium channel, L-type, alpha-1C subunit,IPR005821:Ion transport domain,IPR014873:Voltage-dependent calcium channel, alpha-1 subunit, IQ domain,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04742:Taste transduction,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05207:Chemical carcinogenesis - receptor activation,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	601005~Timothy syndrome,611875~Brugada syndrome 3,618447~Long QT syndrome 8,620029~Neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures,		SM01062:SM01062,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0454~Long QT syndrome,KW-0887~Epilepsy,KW-0991~Intellectual disability,KW-0992~Brugada syndrome,KW-1268~Autism spectrum disorder,KW-1269~Autism,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0107~Calcium channel,KW-0112~Calmodulin-binding,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ion transport,DOMAIN:Voltage-dependent calcium channel alpha-1 subunit IQ,INTRAMEM:Pore-forming,MOTIF:Selectivity filter of repeat I,MOTIF:Selectivity filter of repeat II,MOTIF:Selectivity filter of repeat III,MOTIF:Selectivity filter of repeat IV,MUTAGEN:E->K: Loss of selectivity for divalent over monovalent cations.,MUTAGEN:FYATF->AAATA: Mildly decreased channel activity. No effect on channel inactivation. Loss of channel inactivation by Ca(2+) and calmodulin; when associated with A-1672.,MUTAGEN:G->F: Affects voltage-dependent inhibition by dihydropyridines; when associated with I-958.,MUTAGEN:I->A: Loss of channel inactivation by Ca(2+) and calmodulin; when associated with 1666-A--A-1670.,MUTAGEN:L->A: Loss of a low-affinity interaction with CALM1. No effect on channel inactivation by Ca(2+) and calmodulin.,MUTAGEN:Y->I: Affects voltage-dependent inhibition by dihydropyridines; when associated with F-954.,REGION:AID/alpha-interaction domain; mediates interaction with the beta subunit,REGION:Calmodulin-binding,REGION:Calmodulin-binding IQ region,REGION:Dihydropyridine binding,REGION:Disordered,REGION:Important for interaction with STAC1, STAC2 and STAC3,REGION:Important for localization in at the junctional membrane,REGION:Interaction with STAC2,REGION:Phenylalkylamine binding,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,SITE:Calcium ion selectivity and permeability,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=S1 of repeat I,TRANSMEM:Helical; Name=S1 of repeat II,TRANSMEM:Helical; Name=S1 of repeat III,TRANSMEM:Helical; Name=S1 of repeat IV,TRANSMEM:Helical; Name=S2 of repeat I,TRANSMEM:Helical; Name=S2 of repeat II,TRANSMEM:Helical; Name=S2 of repeat III,TRANSMEM:Helical; Name=S2 of repeat IV,TRANSMEM:Helical; Name=S3 of repeat I,TRANSMEM:Helical; Name=S3 of repeat II,TRANSMEM:Helical; Name=S3 of repeat III,TRANSMEM:Helical; Name=S3 of repeat IV,TRANSMEM:Helical; Name=S4 of repeat I,TRANSMEM:Helical; Name=S4 of repeat II,TRANSMEM:Helical; Name=S4 of repeat III,TRANSMEM:Helical; Name=S4 of repeat IV,TRANSMEM:Helical; Name=S5 of repeat I,TRANSMEM:Helical; Name=S5 of repeat II,TRANSMEM:Helical; Name=S5 of repeat III,TRANSMEM:Helical; Name=S5 of repeat IV,TRANSMEM:Helical; Name=S6 of repeat I,TRANSMEM:Helical; Name=S6 of repeat II,TRANSMEM:Helical; Name=S6 of repeat III,TRANSMEM:Helical; Name=S6 of repeat IV,
CACNA1E	calcium voltage-gated channel subunit alpha1 E(CACNA1E)	Homo sapiens			GO:0006816~calcium ion transport,GO:0007268~chemical synaptic transmission,GO:0034765~regulation of ion transmembrane transport,GO:0070509~calcium ion import,GO:0098703~calcium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0005245~voltage-gated calcium channel activity,GO:0005509~calcium ion binding,GO:0008331~high voltage-gated calcium channel activity,GO:0022843~voltage-gated cation channel activity,GO:0046872~metal ion binding,	IPR002048:EF-hand domain,IPR002077:Voltage-dependent calcium channel, alpha-1 subunit,IPR005449:Voltage-dependent calcium channel, R-type, alpha-1 subunit,IPR005821:Ion transport domain,IPR014873:Voltage-dependent calcium channel, alpha-1 subunit, IQ domain,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04930:Type II diabetes mellitus,	618285~Developmental and epileptic encephalopathy 69,		SM01062:SM01062,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:Ion transport,DOMAIN:Voltage-dependent L-type calcium channel IQ-associated,DOMAIN:Voltage-dependent calcium channel alpha-1 subunit IQ,REGION:Binding to the beta subunit,REGION:Disordered,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,SITE:Calcium ion selectivity and permeability,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=S1 of repeat I,TRANSMEM:Helical; Name=S1 of repeat II,TRANSMEM:Helical; Name=S1 of repeat III,TRANSMEM:Helical; Name=S1 of repeat IV,TRANSMEM:Helical; Name=S2 of repeat I,TRANSMEM:Helical; Name=S2 of repeat II,TRANSMEM:Helical; Name=S2 of repeat III,TRANSMEM:Helical; Name=S2 of repeat IV,TRANSMEM:Helical; Name=S3 of repeat I,TRANSMEM:Helical; Name=S3 of repeat II,TRANSMEM:Helical; Name=S3 of repeat III,TRANSMEM:Helical; Name=S3 of repeat IV,TRANSMEM:Helical; Name=S4 of repeat I,TRANSMEM:Helical; Name=S4 of repeat II,TRANSMEM:Helical; Name=S4 of repeat III,TRANSMEM:Helical; Name=S4 of repeat IV,TRANSMEM:Helical; Name=S5 of repeat I,TRANSMEM:Helical; Name=S5 of repeat II,TRANSMEM:Helical; Name=S5 of repeat III,TRANSMEM:Helical; Name=S5 of repeat IV,TRANSMEM:Helical; Name=S6 of repeat I,TRANSMEM:Helical; Name=S6 of repeat II,TRANSMEM:Helical; Name=S6 of repeat III,TRANSMEM:Helical; Name=S6 of repeat IV,
CAMK2A	calcium/calmodulin dependent protein kinase II alpha(CAMK2A)	Homo sapiens		h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_CaCaMPathway:Ca++/ Calmodulin-dependent Protein Kinase Activation,h_crebPathway:Transcription factor CREB and its extracellular signals,h_pgc1aPathway:Regulation of PGC-1a,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0002931~response to ischemia,GO:0006468~protein phosphorylation,GO:0006816~calcium ion transport,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0018105~peptidyl-serine phosphorylation,GO:0035458~cellular response to interferon-beta,GO:0038166~angiotensin-activated signaling pathway,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046777~protein autophosphorylation,GO:0046928~regulation of neurotransmitter secretion,GO:0048168~regulation of neuronal synaptic plasticity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051346~negative regulation of hydrolase activity,GO:0051928~positive regulation of calcium ion transport,GO:0060996~dendritic spine development,GO:0071346~cellular response to interferon-gamma,GO:1902108~regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1990443~peptidyl-threonine autophosphorylation,GO:2000124~regulation of endocannabinoid signaling pathway,GO:2001222~regulation of neuron migration,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005954~calcium- and calmodulin-dependent protein kinase complex,GO:0014069~postsynaptic density,GO:0030666~endocytic vesicle membrane,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0043226~organelle,	GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0035254~glutamate receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013543:Calcium/calmodulin-dependent protein kinase II, association-domain,IPR017441:Protein kinase, ATP binding site,	hsa04012:ErbB signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04114:Oocyte meiosis,hsa04217:Necroptosis,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04740:Olfactory transduction,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04934:Cushing syndrome,hsa04971:Gastric acid secretion,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05152:Tuberculosis,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05214:Glioma,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,	617798~Intellectual developmental disorder, autosomal dominant 53,618095~Intellectual developmental disorder, autosomal recessive 63,		SM00220:S_TKc,		KW-0770~Synapse,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Calcium/calmodulin-dependent protein kinase II association-domain,DOMAIN:Protein kinase,MUTAGEN:K->R: No effect on protein stability or degradation. No effect on neuronal migration; when associated with P-286.,MUTAGEN:Missing: Loss of oligomerization.,MUTAGEN:T->A: No effect on neuronal migration.,MUTAGEN:T->D: Loss of neuronal migration.,MUTAGEN:T->P: No effect on neuronal migration; when associated with R-42.,REGION:Calmodulin-binding,REGION:Disordered,REGION:Interaction with BAALC,
CALN1	calneuron 1(CALN1)	Homo sapiens				GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,			COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
CAPN2	calpain 2(CAPN2)	Homo sapiens		h_mCalpainPathway:mCalpain and friends in Cell motility,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,	GO:0001666~response to hypoxia,GO:0001824~blastocyst development,GO:0006508~proteolysis,GO:0007520~myoblast fusion,GO:0007565~female pregnancy,GO:0009612~response to mechanical stimulus,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0016540~protein autoprocessing,GO:0032675~regulation of interleukin-6 production,GO:0035458~cellular response to interferon-beta,GO:0042542~response to hydrogen peroxide,GO:0048266~behavioral response to pain,GO:0051493~regulation of cytoskeleton organization,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0071222~cellular response to lipopolysaccharide,GO:0071230~cellular response to amino acid stimulus,GO:1901216~positive regulation of neuron death,GO:1901741~positive regulation of myoblast fusion,GO:2001247~positive regulation of phosphatidylcholine biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0030425~dendrite,GO:0030864~cortical actin cytoskeleton,GO:0031143~pseudopodium,GO:0043025~neuronal cell body,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0097038~perinuclear endoplasmic reticulum,	GO:0004198~calcium-dependent cysteine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0008234~cysteine-type peptidase activity,GO:0019899~enzyme binding,GO:0044877~macromolecular complex binding,	IPR000169:Cysteine peptidase, cysteine active site,IPR001300:Peptidase C2, calpain, catalytic domain,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR022682:Peptidase C2, calpain, large subunit, domain III,IPR022683:Peptidase C2, calpain, domain III,IPR022684:Peptidase C2, calpain family,	hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04510:Focal adhesion,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,			SM00230:CysPc,SM00720:calpain_III,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,	DOMAIN:Calpain catalytic,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,PROPEP:Anchors to the small subunit,REGION:Disordered,REGION:Domain III,REGION:Domain IV,REGION:Linker,
CAPN5	calpain 5(CAPN5)	Homo sapiens			GO:0006508~proteolysis,GO:0007165~signal transduction,	GO:0005737~cytoplasm,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0004198~calcium-dependent cysteine-type endopeptidase activity,	IPR000008:C2 calcium-dependent membrane targeting,IPR000169:Cysteine peptidase, cysteine active site,IPR001300:Peptidase C2, calpain, catalytic domain,IPR022682:Peptidase C2, calpain, large subunit, domain III,IPR022683:Peptidase C2, calpain, domain III,IPR022684:Peptidase C2, calpain family,		193235~Vitreoretinopathy, neovascular inflammatory,		SM00230:CysPc,SM00239:C2,SM00720:calpain_III,			KW-0225~Disease variant,			KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,		DOMAIN:C2,DOMAIN:Calpain catalytic,REGION:Disordered,REGION:Domain III,
CNN1	calponin 1(CNN1)	Homo sapiens			GO:0006940~regulation of smooth muscle contraction,GO:0007015~actin filament organization,GO:0031032~actomyosin structure organization,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,	GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0051015~actin filament binding,	IPR000557:Calponin repeat,IPR001715:Calponin homology domain,IPR001997:Calponin,IPR003096:Smooth muscle protein/calponin,				SM00033:CH,				KW-0677~Repeat,		KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),REGION:Disordered,REPEAT:Calponin-like 1,REPEAT:Calponin-like 2,REPEAT:Calponin-like 3,
CNR2	cannabinoid receptor 2(CNR2)	Homo sapiens		h_cb1rPathway:Metabolism of Anandamide, an Endogenous Cannabinoid,	GO:0001975~response to amphetamine,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0019222~regulation of metabolic process,GO:0019233~sensory perception of pain,GO:0030595~leukocyte chemotaxis,GO:0032229~negative regulation of synaptic transmission, GABAergic,GO:0032496~response to lipopolysaccharide,GO:0033004~negative regulation of mast cell activation,GO:0038171~cannabinoid signaling pathway,GO:0045759~negative regulation of action potential,GO:0050728~negative regulation of inflammatory response,GO:0051001~negative regulation of nitric-oxide synthase activity,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0043025~neuronal cell body,GO:0043204~perikaryon,	GO:0004930~G-protein coupled receptor activity,GO:0004949~cannabinoid receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001551:Cannabinoid receptor type 2,IPR002230:Cannabinoid receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,	KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:A->E: Loss of ligand binding. Alters agonist-induced inhibitory effect on adenylate cyclase.,MUTAGEN:D->A: Loss of ligand binding. Alters agonist-induced inhibitory effect on adenylate cyclase.,MUTAGEN:K->A: No effect on agonist binding. Affects cannabinoid agonist binding; when associated with G-112.,MUTAGEN:K->R: No effect on agonist binding.,MUTAGEN:L->P: Abolishes ligand binding and agonist-induced inhibitory effect on adenylate cyclase.,MUTAGEN:R->A: No effect on ligand binding. Alters agonist-induced inhibitory effect on adenylate cyclase.,MUTAGEN:S->G: Affects cannabinoid agonist binding; when associated with A-109.,MUTAGEN:Y->A: Abolishes agonist-induced inhibitory effect on adenylate cyclase. No effect on ligand binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CHST2	carbohydrate sulfotransferase 2(CHST2)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006044~N-acetylglucosamine metabolic process,GO:0006790~sulfur compound metabolic process,GO:0006954~inflammatory response,GO:0007275~multicellular organism development,GO:0018146~keratan sulfate biosynthetic process,GO:1901135~carbohydrate derivative metabolic process,GO:1901564~organonitrogen compound metabolic process,GO:1903238~positive regulation of leukocyte tethering or rolling,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0031228~intrinsic component of Golgi membrane,	GO:0001517~N-acetylglucosamine 6-O-sulfotransferase activity,GO:0008146~sulfotransferase activity,	IPR000863:Sulfotransferase domain,IPR016469:Carbohydrate sulfotransferase,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,		PIRSF005883:carbohydrate sulfotransferase,		KW-0119~Carbohydrate metabolism,KW-0395~Inflammatory response,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Sulfotransferase,MUTAGEN:C->S: Does not affect homodimerization. Abolishes homodimerization but not enzyme activity; when associated with S-39.,MUTAGEN:C->S: Induces migration in both homodimeric and monomeric forms. Abolishes homodimerization but not enzyme activity; when associated with S-12.,MUTAGEN:D->A: Has weak or no effect.,MUTAGEN:K->A: Has weak or no effect.,MUTAGEN:K->A: Loss of function.,MUTAGEN:K->A: No effect.,MUTAGEN:L->A,T: Induces a strong decrease in enzyme activity.,MUTAGEN:L->A: Has weak or no effect.,MUTAGEN:L->A: Induces a strong decrease in enzyme activity.,MUTAGEN:L->T: Has weak or no effect.,MUTAGEN:N->A: Reduced localization in the Golgi.,MUTAGEN:N->A: Unable to sulfate the sialyl Lewis X tetrasaccharide.,MUTAGEN:P->A: Has weak or no effect.,MUTAGEN:R->A: Has weak or no effect.,MUTAGEN:R->A: Induces a strong decrease in enzyme activity.,MUTAGEN:R->A: Loss of function.,MUTAGEN:R->A: No effect.,MUTAGEN:S->A: No effect.,MUTAGEN:T->A: Has weak or no effect.,REGION:Disordered,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CA3	carbonic anhydrase 3(CA3)	Homo sapiens			GO:0006730~one-carbon metabolic process,GO:0006979~response to oxidative stress,GO:0009617~response to bacterium,GO:0045471~response to ethanol,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004089~carbonate dehydratase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016151~nickel cation binding,GO:0016791~phosphatase activity,GO:0016836~hydro-lyase activity,	IPR001148:Alpha carbonic anhydrase,IPR018338:Carbonic anhydrase, alpha-class, conserved site,IPR018441:Carbonic anhydrase, CA-III,IPR023561:Carbonic anhydrase, alpha-class,	hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,			SM01057:SM01057,		KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0318~Glutathionylation,KW-0597~Phosphoprotein,	DOMAIN:Alpha-carbonic anhydrase,MUTAGEN:F->L: Enhanced activity by at least 10-fold.,MUTAGEN:K->H: Enhanced proton transfer in catalysis.,MUTAGEN:R->H: Enhanced proton transfer in catalysis.,REGION:Involved in proton transfer,
CPA1	carboxypeptidase A1(CPA1)	Homo sapiens			GO:0006508~proteolysis,GO:0006691~leukotriene metabolic process,GO:0046686~response to cadmium ion,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0005615~extracellular space,	GO:0004180~carboxypeptidase activity,GO:0004181~metallocarboxypeptidase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000834:Peptidase M14, carboxypeptidase A,IPR003146:Proteinase inhibitor, carboxypeptidase propeptide,	hsa04972:Pancreatic secretion,hsa04974:Protein digestion and absorption,			SM00631:Zn_pept,		KW-0964~Secreted,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,DOMAIN:Carboxypeptidase activation peptide,DOMAIN:Peptidase M14 carboxypeptidase A,PROPEP:Activation peptide,
CPM	carboxypeptidase M(CPM)	Homo sapiens			GO:0006518~peptide metabolic process,GO:0009653~anatomical structure morphogenesis,GO:0016485~protein processing,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031225~anchored component of membrane,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0004180~carboxypeptidase activity,GO:0004181~metallocarboxypeptidase activity,GO:0008270~zinc ion binding,	IPR000834:Peptidase M14, carboxypeptidase A,IPR008969:Carboxypeptidase-like, regulatory domain,				SM00631:Zn_pept,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase M14 carboxypeptidase A,LIPID:GPI-anchor amidated serine,MUTAGEN:E->A: 5-fold decrease in substrate affinity. 22-fold decrease in specific affinity. 104-fold decrease in catalytic efficiency. Greatly reduced heat stability.,MUTAGEN:E->Q: 2-fold decrease in substrate affinity. Small increase in specific affinity. Reduced heat stability by 50%.,MUTAGEN:E->Q: Abolishes enzyme activity.,MUTAGEN:S->A,T: Expressed on cell membrane. Released from membrane by PI-PLC.,MUTAGEN:S->P: Little expression on cell membrane. Perinuclear localization. Not released from membrane by PI-PLC.,PROPEP:Removed in mature form,SITE:Probable structural role,TRANSMEM:Helical,
CPXM1	carboxypeptidase X, M14 family member 1(CPXM1)	Homo sapiens			GO:0006518~peptide metabolic process,GO:0016485~protein processing,	GO:0005615~extracellular space,	GO:0004181~metallocarboxypeptidase activity,GO:0008270~zinc ion binding,	IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000834:Peptidase M14, carboxypeptidase A,IPR008969:Carboxypeptidase-like, regulatory domain,IPR008979:Galactose-binding domain-like,				SM00231:FA58C,SM00631:Zn_pept,		KW-0964~Secreted,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:F5/8 type C,REGION:Disordered,
CPT2	carnitine palmitoyltransferase 2(CPT2)	Homo sapiens		h_cptPathway:Mitochondrial Carnitine Palmitoyltransferase (CPT) System,	GO:0001676~long-chain fatty acid metabolic process,GO:0001701~in utero embryonic development,GO:0006635~fatty acid beta-oxidation,GO:0006853~carnitine shuttle,GO:0009437~carnitine metabolic process,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,	GO:0004095~carnitine O-palmitoyltransferase activity,GO:0005515~protein binding,GO:0008458~carnitine O-octanoyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,	IPR000542:Acyltransferase ChoActase/COT/CPT,IPR023213:Chloramphenicol acetyltransferase-like domain,	hsa00071:Fatty acid degradation,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04714:Thermogenesis,hsa05415:Diabetic cardiomyopathy,	255110~CPT II deficiency, myopathic, stress-induced,600649~CPT II deficiency, infantile,608836~CPT II deficiency, lethal neonatal,614212~Encephalopathy, acute, infection-induced, 4, susceptibility to,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,DOMAIN:Choline/carnitine acyltransferase,INTRAMEM:Note=Mitochondrial inner membrane,REGION:Disordered,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,
CARD11	caspase recruitment domain family member 11(CARD11)	Homo sapiens			GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0030183~B cell differentiation,GO:0030890~positive regulation of B cell proliferation,GO:0031295~T cell costimulation,GO:0032743~positive regulation of interleukin-2 production,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0038202~TORC1 signaling,GO:0042100~B cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045061~thymic T cell selection,GO:0045577~regulation of B cell differentiation,GO:0045580~regulation of T cell differentiation,GO:0046037~GMP metabolic process,GO:0046710~GDP metabolic process,GO:0048872~homeostasis of number of cells,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051260~protein homooligomerization,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032449~CBM complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0004385~guanylate kinase activity,GO:0005515~protein binding,GO:0043621~protein self-association,GO:0050700~CARD domain binding,	IPR001315:Caspase Recruitment,IPR001478:PDZ domain,IPR011029:Death-like domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04064:NF-kappa B signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,	615206~Immunodeficiency 11A,616452~B-cell expansion with NFKB and T-cell anergy,617638~Immunodeficiency 11B with atopic dermatitis,			KW-0391~Immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:CARD,DOMAIN:Guanylate kinase-like,DOMAIN:PDZ,MUTAGEN:C->A: Abolished homodimerization.,REGION:Disordered,REGION:Inhibitory domain (ID),REGION:Linker,
CTSA	cathepsin A(CTSA)	Homo sapiens			GO:0006508~proteolysis,GO:0006886~intracellular protein transport,GO:0031647~regulation of protein stability,GO:1904714~regulation of chaperone-mediated autophagy,GO:1904715~negative regulation of chaperone-mediated autophagy,	GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098575~lumenal side of lysosomal membrane,	GO:0004180~carboxypeptidase activity,GO:0004185~serine-type carboxypeptidase activity,GO:0008047~enzyme activator activity,	IPR001563:Peptidase S10, serine carboxypeptidase,IPR018202:Peptidase S10, serine carboxypeptidase, active site,	hsa04142:Lysosome,hsa04614:Renin-angiotensin system,	256540~Galactosialidosis,				KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,MUTAGEN:H->Q: Inactivates the enzyme.,MUTAGEN:S->A: Inactivates the enzyme.,REGION:Disordered,
CTSK	cathepsin K(CTSK)	Homo sapiens			GO:0000422~mitophagy,GO:0001957~intramembranous ossification,GO:0006508~proteolysis,GO:0006590~thyroid hormone generation,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0010952~positive regulation of peptidase activity,GO:0014070~response to organic cyclic compound,GO:0022617~extracellular matrix disassembly,GO:0030574~collagen catabolic process,GO:0032868~response to insulin,GO:0034224~cellular response to zinc ion starvation,GO:0045453~bone resorption,GO:0045471~response to ethanol,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0061037~negative regulation of cartilage development,GO:0071356~cellular response to tumor necrosis factor,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1903131~mononuclear cell differentiation,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0036021~endolysosome lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,	GO:0001968~fibronectin binding,GO:0004197~cysteine-type endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008234~cysteine-type peptidase activity,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0043394~proteoglycan binding,	IPR000169:Cysteine peptidase, cysteine active site,IPR000668:Peptidase C1A, papain C-terminal,IPR013201:Proteinase inhibitor I29, cathepsin propeptide,IPR015644:Peptidase C1A, cathepsin K,IPR025660:Cysteine peptidase, histidine active site,IPR025661:Cysteine peptidase, asparagine active site,	hsa04142:Lysosome,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa05323:Rheumatoid arthritis,	265800~Pycnodysostosis,		SM00645:Pept_C1,SM00848:SM00848,		KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cathepsin propeptide inhibitor,DOMAIN:Peptidase C1A papain C-terminal,PROPEP:Activation peptide,TRANSMEM:Helical,
CADM3	cell adhesion molecule 3(CADM3)	Homo sapiens			GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,	GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR003585:Neurexin/syndecan/glycophorin C,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,	619519~Charcot-Marie-Tooth disease, axonal, type 2FF,		SM00294:4.1m,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,REGION:Disordered,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDC6	cell division cycle 6(CDC6)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,	h_mcmPathway:CDK Regulation of DNA Replication,	GO:0000076~DNA replication checkpoint,GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000278~mitotic cell cycle,GO:0006270~DNA replication initiation,GO:0007089~traversing start control point of mitotic cell cycle,GO:0008156~negative regulation of DNA replication,GO:0008285~negative regulation of cell proliferation,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0032467~positive regulation of cytokinesis,GO:0033314~mitotic DNA replication checkpoint,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0048146~positive regulation of fibroblast proliferation,GO:0051301~cell division,GO:0051984~positive regulation of chromosome segregation,GO:1904117~cellular response to vasopressin,GO:1904385~cellular response to angiotensin,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0045171~intercellular bridge,GO:0051233~spindle midzone,GO:0072686~mitotic spindle,	GO:0000166~nucleotide binding,GO:0003688~DNA replication origin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019900~kinase binding,	IPR003593:AAA+ ATPase domain,IPR015163:CDC6, C-terminal domain,IPR016314:Cell division protein Cdc6/18,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04110:Cell cycle,hsa05207:Chemical carcinogenesis - receptor activation,	613805~Meier-Gorlin syndrome 5,	PIRSF001767:cell division control protein Cdc6,	SM00382:AAA,SM01074:SM01074,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0235~DNA replication,KW-0498~Mitosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AAA+ ATPase,DOMAIN:Cdc6 C-terminal,MOTIF:Cy,MUTAGEN:Missing: Disrupts the interaction with CCNF. Does not disrupt the interaction with CDH1. Increases protein stability.,MUTAGEN:S->A: Does not change protein stability after CHX addition during mitosis; when associated with A-54 and A-106.,MUTAGEN:S->A: Does not change protein stability after CHX addition during mitosis; when associated with A-54 and A-74.,MUTAGEN:S->A: Does not change protein stability after CHX addition during mitosis; when associated with A-74 and A-106.,MUTAGEN:S->D: Does not change protein stability after CHX addition during mitosis; when associated with D-54 and D-106.,MUTAGEN:S->D: Does not change protein stability after CHX addition during mitosis; when associated with D-54 and D-74.,MUTAGEN:S->D: Does not change protein stability after CHX addition during mitosis; when associated with D-74 and D-106.,REGION:Disordered,
CRABP1	cellular retinoic acid binding protein 1(CRABP1)	Homo sapiens			GO:0007165~signal transduction,GO:0007275~multicellular organism development,GO:0015908~fatty acid transport,GO:0034653~retinoic acid catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0001972~retinoic acid binding,GO:0005501~retinoid binding,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0016918~retinal binding,GO:0019841~retinol binding,	IPR000463:Cytosolic fatty-acid binding,IPR000566:Lipocalin/cytosolic fatty-acid binding protein domain,IPR012674:Calycin,					KW-0813~Transport,	KW-0963~Cytoplasm,			KW-0683~Retinol-binding,KW-0845~Vitamin A,			DOMAIN:Cytosolic fatty-acid binding proteins,DOMAIN:Lipocalin/cytosolic fatty-acid binding,MOTIF:Nuclear localization signal,
CHI3L1	chitinase 3 like 1(CHI3L1)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006032~chitin catabolic process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0009612~response to mechanical stimulus,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0030324~lung development,GO:0032757~positive regulation of interleukin-8 production,GO:0034612~response to tumor necrosis factor,GO:0045766~positive regulation of angiogenesis,GO:0051216~cartilage development,GO:0051897~positive regulation of protein kinase B signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070555~response to interleukin-1,GO:0070741~response to interleukin-6,GO:0071356~cellular response to tumor necrosis factor,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0031012~extracellular matrix,GO:0035580~specific granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008061~chitin binding,GO:0030246~carbohydrate binding,	IPR001223:Glycoside hydrolase, family 18, catalytic domain,IPR011583:Chitinase II,IPR017853:Glycoside hydrolase, superfamily,		181500~Schizophrenia, susceptibility to,611960~Asthma-related traits, susceptibility to, 7,		SM00636:Glyco_18,	KW-0053~Apoptosis,KW-0395~Inflammatory response,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-1058~Asthma,KW-1211~Schizophrenia,	KW-0732~Signal,	KW-0430~Lectin,	KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GH18,REGION:Important for AKT1 activation and IL8 production,
CLCA1	chloride channel accessory 1(CLCA1)	Homo sapiens			GO:0006508~proteolysis,GO:0006816~calcium ion transport,GO:0006821~chloride transport,GO:0034220~ion transmembrane transport,GO:0071456~cellular response to hypoxia,GO:1902476~chloride transmembrane transport,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005902~microvillus,GO:0042589~zymogen granule membrane,	GO:0004222~metalloendopeptidase activity,GO:0005229~intracellular calcium activated chloride channel activity,GO:0005254~chloride channel activity,GO:0046872~metal ion binding,	IPR002035:von Willebrand factor, type A,IPR004727:Calcium-activated chloride channel protein,IPR013642:Chloride channel calcium-activated,IPR013783:Immunoglobulin-like fold,	hsa04924:Renin secretion,hsa04972:Pancreatic secretion,			SM00327:VWA,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,KW-0868~Chloride,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:VWFA,MUTAGEN:D->A: Abolishes proteolytic cleavage.,MUTAGEN:E->A: Abolishes proteolytic cleavage.,MUTAGEN:E->Q: Abolishes proteolytic cleavage.,MUTAGEN:H->A: Abolishes proteolytic cleavage.,MUTAGEN:Q->A: Reduces proteolytic cleavage.,REGION:Metalloprotease domain,SITE:Cleavage; by autolysis,
CCK	cholecystokinin(CCK)	Homo sapiens			GO:0001764~neuron migration,GO:0007165~signal transduction,GO:0007409~axonogenesis,GO:0007586~digestion,GO:0042755~eating behavior,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0030424~axon,	GO:0005179~hormone activity,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0051428~peptide hormone receptor binding,	IPR001651:Gastrin/cholecystokinin peptide hormone,IPR013152:Gastrin/cholecystokinin, conserved site,IPR015499:Cholecystokinin,	hsa04080:Neuroactive ligand-receptor interaction,hsa04911:Insulin secretion,hsa04972:Pancreatic secretion,					KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,	CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,DOMAIN:Gastrin/cholecystokinin peptide hormone,MUTAGEN:Y->F: Reduces the quantity of secreted CCK8 by 50%.,PEPTIDE:Cholecystokinin-12,PEPTIDE:Cholecystokinin-18,PEPTIDE:Cholecystokinin-25,PEPTIDE:Cholecystokinin-33,PEPTIDE:Cholecystokinin-39,PEPTIDE:Cholecystokinin-5,PEPTIDE:Cholecystokinin-58,PEPTIDE:Cholecystokinin-58 desnonopeptide,PEPTIDE:Cholecystokinin-7,PEPTIDE:Cholecystokinin-8,REGION:Disordered,
CHAT	choline O-acetyltransferase(CHAT)	Homo sapiens			GO:0006635~fatty acid beta-oxidation,GO:0006656~phosphatidylcholine biosynthetic process,GO:0006836~neurotransmitter transport,GO:0007274~neuromuscular synaptic transmission,GO:0008292~acetylcholine biosynthetic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043005~neuron projection,GO:0045202~synapse,	GO:0004102~choline O-acetyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,	IPR000542:Acyltransferase ChoActase/COT/CPT,IPR023213:Chloramphenicol acetyltransferase-like domain,	hsa00564:Glycerophospholipid metabolism,hsa04725:Cholinergic synapse,	254210~Myasthenic syndrome, congenital, 6, presynaptic,			KW-0530~Neurotransmitter biosynthesis,		KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,			KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Choline/carnitine acyltransferase,REGION:Disordered,
CHRNA6	cholinergic receptor nicotinic alpha 6 subunit(CHRNA6)	Homo sapiens			GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007271~synaptic transmission, cholinergic,GO:0014059~regulation of dopamine secretion,GO:0034220~ion transmembrane transport,GO:0035094~response to nicotine,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0051899~membrane depolarization,GO:0060079~excitatory postsynaptic potential,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005892~acetylcholine-gated channel complex,GO:0016021~integral component of membrane,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0015464~acetylcholine receptor activity,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04725:Cholinergic synapse,hsa05033:Nicotine addiction,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Associated with receptor activation,DOMAIN:Neurotransmitter-gated ion-channel ligand-binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CSPG4	chondroitin sulfate proteoglycan 4(CSPG4)	Homo sapiens			GO:0001525~angiogenesis,GO:0006929~substrate-dependent cell migration,GO:0008283~cell proliferation,GO:0008347~glial cell migration,GO:0035556~intracellular signal transduction,GO:0043410~positive regulation of MAPK cascade,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048771~tissue remodeling,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0097178~ruffle assembly,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031258~lamellipodium membrane,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0015026~coreceptor activity,GO:0019901~protein kinase binding,	IPR001791:Laminin G domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00282:LamG,	KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0797~Tissue remodeling,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,MOTIF:PDZ-binding,REGION:Cysteine-containing,REGION:Disordered,REGION:Globular or compact configuration stabilized by disulfide bonds,REGION:Interaction with COL5A1,REGION:Interaction with COL6A2,REGION:Neurite growth inhibition,REPEAT:CSPG,REPEAT:CSPG 1,REPEAT:CSPG 10,REPEAT:CSPG 11,REPEAT:CSPG 12,REPEAT:CSPG 13,REPEAT:CSPG 14,REPEAT:CSPG 15,REPEAT:CSPG 2,REPEAT:CSPG 3,REPEAT:CSPG 4,REPEAT:CSPG 5,REPEAT:CSPG 6,REPEAT:CSPG 7,REPEAT:CSPG 8,REPEAT:CSPG 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHODL	chondrolectin(CHODL)	Homo sapiens			GO:0007399~nervous system development,GO:0007517~muscle organ development,GO:0050772~positive regulation of axonogenesis,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,	KW-0524~Neurogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:C-type lectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHD8	chromodomain helicase DNA binding protein 8(CHD8)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006397~mRNA processing,GO:0007420~brain development,GO:0016055~Wnt signaling pathway,GO:0032508~DNA duplex unwinding,GO:0035176~social behavior,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:0048565~digestive tract development,GO:0060134~prepulse inhibition,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:2000270~negative regulation of fibroblast apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032991~macromolecular complex,GO:0071339~MLL1 complex,	GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008013~beta-catenin binding,GO:0016887~ATPase activity,GO:0035064~methylated histone binding,GO:0042393~histone binding,GO:0070016~armadillo repeat domain binding,	IPR000330:SNF2-related,IPR000953:Chromo domain/shadow,IPR001650:Helicase, C-terminal,IPR006576:BRK domain,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR016197:Chromo domain-like,IPR023780:Chromo domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04310:Wnt signaling pathway,	615032~Intellectual developmental disorder with autism and macrocephaly,		SM00298:CHROMO,SM00487:DEXDc,SM00490:HELICc,SM00592:BRK,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1268~Autism spectrum disorder,KW-1269~Autism,	KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRK,DOMAIN:Chromo,DOMAIN:Chromo 1,DOMAIN:Chromo 2,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAH box,MUTAGEN:K->R: Abolishes ATPase activity.,REGION:Disordered,REGION:Interaction with FAM124B,
C1orf52	chromosome 1 open reading frame 52(C1orf52)	Homo sapiens				GO:0005654~nucleoplasm,	GO:0003723~RNA binding,												KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
C1orf87	chromosome 1 open reading frame 87(C1orf87)	Homo sapiens						IPR011992:EF-hand-like domain,												COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
C10orf90	chromosome 10 open reading frame 90(C10orf90)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0016567~protein ubiquitination,GO:0046599~regulation of centriole replication,GO:0050821~protein stabilization,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,	GO:0008017~microtubule binding,GO:0061630~ubiquitin protein ligase activity,						KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,			KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,DOMAIN:ALMS motif,DOMAIN:Centrosomal protein C10orf90 N-terminal,REGION:ALMS motif,REGION:Disordered,REGION:Required for interaction with HDAC1,REGION:Required for interaction with p53/TP53,
CIMIP1	ciliary microtubule inner protein 1(CIMIP1)	Homo sapiens				GO:0005929~cilium,	GO:0005515~protein binding,							KW-0966~Cell projection,
CNTF	ciliary neurotrophic factor(CNTF)	Homo sapiens	121.OligoDiff,		GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043524~negative regulation of neuron apoptotic process,GO:0046533~negative regulation of photoreceptor cell differentiation,GO:0046668~regulation of retinal cell programmed cell death,GO:0048143~astrocyte activation,GO:0048644~muscle organ morphogenesis,GO:0048666~neuron development,GO:0048680~positive regulation of axon regeneration,GO:0060221~retinal rod cell differentiation,GO:0070120~ciliary neurotrophic factor-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0030424~axon,	GO:0005125~cytokine activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0044877~macromolecular complex binding,	IPR000151:Ciliary neurotrophic factor, CNTF,IPR009079:Four-helical cytokine-like, core,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,				KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,
CIITA	class II major histocompatibility complex transactivator(CIITA)	Homo sapiens	18.Cytokine_astocytes,89.CD4_T_Cell_Differentiation,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007568~aging,GO:0016310~phosphorylation,GO:0032966~negative regulation of collagen biosynthetic process,GO:0034341~response to interferon-gamma,GO:0045345~positive regulation of MHC class I biosynthetic process,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046597~negative regulation of viral entry into host cell,GO:0046677~response to antibiotic,GO:0071257~cellular response to electrical stimulus,GO:0071346~cellular response to interferon-gamma,GO:0071360~cellular response to exogenous dsRNA,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0009986~cell surface,GO:0016605~PML body,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003713~transcription coactivator activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0008022~protein C-terminus binding,GO:0016746~transferase activity, transferring acyl groups,GO:0044877~macromolecular complex binding,	IPR001611:Leucine-rich repeat,IPR007111:NACHT nucleoside triphosphatase,IPR008095:MHC class II transactivator,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04612:Antigen processing and presentation,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05340:Primary immunodeficiency,	180300~Rheumatoid arthritis, susceptibility to,209920~Bare lymphocyte syndrome, type II, complementation group A,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0705~SCID,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:NACHT,MUTAGEN:D->A: Strongly reduces GTP-binding and abolishes transactivation at MHC promoters.,MUTAGEN:Missing: Strongly reduces GTP-binding and abolishes transactivation at MHC promoters.,REGION:Disordered,REGION:Required for acetyltransferase activity,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,
CLDN11	claudin 11(CLDN11)	Homo sapiens			GO:0007155~cell adhesion,GO:0007283~spermatogenesis,GO:0008366~axon ensheathment,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0070830~bicellular tight junction assembly,	GO:0005811~lipid particle,GO:0005883~neurofilament,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0030424~axon,GO:0045178~basal part of cell,GO:0070160~occluding junction,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003555:Claudin-11,IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,	619328~Leukodystrophy, hypomyelinating, 22,				KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-1026~Leukodystrophy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN14	claudin 14(CLDN14)	Homo sapiens			GO:0007155~cell adhesion,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0065003~macromolecular complex assembly,GO:0070830~bicellular tight junction assembly,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003556:Claudin-14,IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,	614035~Deafness, autosomal recessive 29,				KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN15	claudin 15(CLDN15)	Homo sapiens			GO:0006811~ion transport,GO:0007155~cell adhesion,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0070830~bicellular tight junction assembly,	GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,GO:0016328~lateral plasma membrane,	GO:0005198~structural molecule activity,GO:0042802~identical protein binding,	IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR008094:Claudin-15,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:D->R: Reverses the charge selectivity for paracellular ion transport, favoring Cl(-) transport.,MUTAGEN:E->K: Impairs the charge selectivity for paracellular ion transport, favoring Cl(-) transport.,MUTAGEN:E->K: No effect on charge selectivity for paracellular ion transport.,REGION:Disordered,REGION:Important for the formation of tight-junction strand-like structures,SITE:Important for Na(+)-selective paracellular ion transport,SITE:Important for the formation of tight-junction strand-like structures,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN16	claudin 16(CLDN16)	Homo sapiens			GO:0006875~cellular metal ion homeostasis,GO:0007155~cell adhesion,GO:0007588~excretion,GO:0010496~intercellular transport,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0030001~metal ion transport,GO:0030003~cellular cation homeostasis,GO:0070830~bicellular tight junction assembly,GO:1903830~magnesium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0015095~magnesium ion transmembrane transporter activity,GO:0042802~identical protein binding,	IPR003927:Claudin-16,IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,	248250~Hypomagnesemia 3, renal,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0982~Primary hypomagnesemia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,			TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN17	claudin 17(CLDN17)	Homo sapiens			GO:0006821~chloride transport,GO:0007155~cell adhesion,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0070830~bicellular tight junction assembly,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0034707~chloride channel complex,	GO:0005198~structural molecule activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0869~Chloride channel,		MUTAGEN:E->A: Decreased transepithelial resistance and anion selectivity.,MUTAGEN:E->K,Q: Decreased transepithelial resistance and anion selectivity. Higher permeability to chloride, sodium and also to larger anions, including pyruvate, nitrate, and thiocyanate.,MUTAGEN:H->A: Loss of anion selectivity. Strongly increased permeabilities not only for chloride, but also for sodium and the larger anions, including pyruvate, nitrate and thiocyanate. No effect on localization to cell-cell junctions.,MUTAGEN:K->A: Reduced channel formation ability. Increased transepithelial resistance. Loss of anion selectivity in favor of cation selectivity.,MUTAGEN:K->E: No effect on channel formation ability. Loss of anion selectivity in favor of cation selectivity. No effect on transepithelial resistance.,MUTAGEN:K->R: Strongly reduced channel formation ability. Increased transepithelial resistance. Loss of anion selectivity in favor of cation selectivity.,MUTAGEN:R->A: Decreased anion selectivity. No effect on transepithelial resistance.,MUTAGEN:R->A: Decreased transepithelial resistance, no effect on anion selectivity.,MUTAGEN:R->A: No effect on transepithelial resistance, nor on anion selectivity. Elevated permeabilities not only for chloride, but also for sodium and the larger anions, including pyruvate, nitrate and thiocyanate.,MUTAGEN:R->A: No effect on transepithelial resistance, nor on anion selectivity. Increased permeability for thiocyanate.,MUTAGEN:R->E: Decreased transepithelial resistance and anion selectivity. Higher permeability to chloride, sodium and also to larger anions, including pyruvate, nitrate, and thiocyanate.,MUTAGEN:R->T: Decreased anion selectivity. Increased permeabilities not only for chloride, but also for sodium and thiocyanate. No effect on transepithelial resistance.,MUTAGEN:S->E: Increased transepithelial resistance. Loss of anion selectivity in favor of cation (sodium) selectivity.,MUTAGEN:Y->A: Increased transepithelial resistance. No effect on localization to cell-cell junctions.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN4	claudin 4(CLDN4)	Homo sapiens			GO:0006821~chloride transport,GO:0007155~cell adhesion,GO:0007565~female pregnancy,GO:0007623~circadian rhythm,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0022604~regulation of cell morphogenesis,GO:0030335~positive regulation of cell migration,GO:0032570~response to progesterone,GO:0061436~establishment of skin barrier,GO:0070293~renal absorption,GO:0070830~bicellular tight junction assembly,GO:0090303~positive regulation of wound healing,GO:1902476~chloride transmembrane transport,GO:1905050~positive regulation of metallopeptidase activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005923~bicellular tight junction,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016327~apicolateral plasma membrane,GO:0016328~lateral plasma membrane,GO:0034707~chloride channel complex,GO:0070160~occluding junction,	GO:0004888~transmembrane signaling receptor activity,GO:0005198~structural molecule activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003550:Claudin-4,IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0856~Williams-Beuren syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0869~Chloride channel,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:F->A: Decreases interaction with Clostridium perfringens CPE.,MUTAGEN:F->D: Abolishes interaction with Clostridium perfringens CPE.,MUTAGEN:I->A: No effect on interaction with Clostridium perfringens CPE.,MUTAGEN:I->D: Strongly decreases interaction with Clostridium perfringens CPE.,MUTAGEN:N->A,D: Decreases interaction with Clostridium perfringens CPE.,MUTAGEN:Y->F: Loss of phosphorylation by EPHA2.,REGION:Interaction with EPHA2,REGION:Interactions with TJP1, TJP2 and TJP3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLDN6	claudin 6(CLDN6)	Homo sapiens			GO:0007155~cell adhesion,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0046718~viral entry into host cell,GO:0070830~bicellular tight junction assembly,	GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,GO:0016327~apicolateral plasma membrane,	GO:0001618~virus receptor activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003925:Claudin-6,IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,				KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0597~Phosphoprotein,	REGION:Interactions with TJP1, TJP2 and TJP3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
F7	coagulation factor VII(F7)	Homo sapiens		h_amiPathway:Acute Myocardial Infarction,h_extrinsicPathway:Extrinsic Prothrombin Activation Pathway,	GO:0001666~response to hypoxia,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0006508~proteolysis,GO:0007596~blood coagulation,GO:0007623~circadian rhythm,GO:0010037~response to carbon dioxide,GO:0010641~positive regulation of platelet-derived growth factor receptor signaling pathway,GO:0016485~protein processing,GO:0030194~positive regulation of blood coagulation,GO:0030335~positive regulation of cell migration,GO:0031100~animal organ regeneration,GO:0032355~response to estradiol,GO:0032571~response to vitamin K,GO:0033595~response to genistein,GO:0043627~response to estrogen,GO:0050927~positive regulation of positive chemotaxis,GO:0051897~positive regulation of protein kinase B signaling,GO:0060416~response to growth hormone,GO:0061476~response to anticoagulant,GO:0070723~response to cholesterol,GO:0097068~response to thyroxine,GO:1904400~response to Thyroid stimulating hormone,GO:1904612~response to 2,3,7,8-tetrachlorodibenzodioxine,GO:1905217~response to astaxanthin,GO:1905225~response to thyrotropin-releasing hormone,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:1905286~serine-type peptidase complex,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000294:Gamma-carboxyglutamic acid-rich (GLA) domain,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR001881:EGF-like calcium-binding,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR012224:Peptidase S1A, coagulation factor VII/IX/X/C/Z,IPR017857:Coagulation factor, subgroup, Gla domain,IPR018097:EGF-like calcium-binding, conserved site,IPR018114:Peptidase S1, trypsin family, active site,	hsa04610:Complement and coagulation cascades,	227500~Factor VII deficiency,608446~Myocardial infarction, decreased susceptibility to,	PIRSF001143:coagulation factor X,	SM00020:Tryp_SPc,SM00069:GLA,SM00179:EGF_CA,SM00181:EGF,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0301~Gamma-carboxyglutamic acid,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc) serine,CARBOHYD:O-linked (Glc...) serine; alternate,CARBOHYD:O-linked (Xyl...) serine; alternate,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:Gla,DOMAIN:Peptidase S1,MUTAGEN:S->A: Complete loss of O-glycosylation and O-xylosylation by POGLUT1.,MUTAGEN:S->A: No effect on O-glycosylation by POGLUT1. Drastic decrease in O-xylosylation.,REGION:Disordered,SITE:Cleavage; by factor Xa, factor XIIa, factor IXa, or thrombin,SITE:Important for S-112 for O-xylosylation,
F11	coagulation factor XI(F11)	Homo sapiens		h_intrinsicPathway:Intrinsic Prothrombin Activation Pathway,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,	GO:0006508~proteolysis,GO:0007596~blood coagulation,GO:0007597~blood coagulation, intrinsic pathway,GO:0031639~plasminogen activation,GO:0051919~positive regulation of fibrinolysis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0042802~identical protein binding,GO:0070009~serine-type aminopeptidase activity,	IPR000177:Apple domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR003609:Apple-like,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,	hsa04610:Complement and coagulation cascades,	612416~Factor XI deficiency, autosomal dominant,612416~Factor XI deficiency, autosomal recessive,		SM00020:Tryp_SPc,SM00223:APPLE,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical,DISULFID:Interchain,DISULFID:Interchain (between heavy and light chains),DOMAIN:Apple,DOMAIN:Apple 1,DOMAIN:Apple 2,DOMAIN:Apple 3,DOMAIN:Apple 4,DOMAIN:Peptidase S1,
F13A1	coagulation factor XIII A chain(F13A1)	Homo sapiens		h_fibrinolysisPathway:Fibrinolysis Pathway,	GO:0007596~blood coagulation,GO:0018149~peptide cross-linking,GO:0072378~blood coagulation, fibrin clot formation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031093~platelet alpha granule lumen,GO:0072562~blood microparticle,GO:1990234~transferase complex,	GO:0003810~protein-glutamine gamma-glutamyltransferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001102:Transglutaminase, N-terminal,IPR002931:Transglutaminase-like,IPR008958:Transglutaminase, C-terminal,IPR013783:Immunoglobulin-like fold,IPR013808:Transglutaminase, conserved site,IPR014756:Immunoglobulin E-set,IPR023608:Protein-glutamine gamma-glutamyltransferase, eukaryota,	hsa04610:Complement and coagulation cascades,hsa05171:Coronavirus disease - COVID-19,	188050~Venous thrombosis, protection against,608446~Myocardial infarction, protection against,613225~Factor XIIIA deficiency,	PIRSF000459:protein-glutamine gamma-glutamyltransferase/erythrocyte membrane protein band 4.2,	SM00460:TGc,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,		KW-0106~Calcium,KW-0479~Metal-binding,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0865~Zymogen,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Transglutaminase N-terminal,DOMAIN:Transglutaminase-like,PROPEP:Activation peptide,REGION:Disordered,SITE:Cleavage; by thrombin; to produce active factor XIII-A,
CCDC8	coiled-coil domain containing 8(CCDC8)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0007088~regulation of mitotic nuclear division,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:1990393~3M complex,	GO:0005515~protein binding,	IPR026523:Paraneoplastic antigen Ma,		614205~3-M syndrome 3,				KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0242~Dwarfism,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MOTIF:PxLPxI/L motif; mediates interaction with ANKRA2,MUTAGEN:P->A: Decreased interaction with ANKRA2.,MUTAGEN:T->A: Decreased interaction with ANKRA2.,REGION:Disordered,
CCDC80	coiled-coil domain containing 80(CCDC80)	Homo sapiens			GO:0009617~response to bacterium,GO:0010811~positive regulation of cell-substrate adhesion,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005614~interstitial matrix,GO:0016021~integral component of membrane,	GO:0001968~fibronectin binding,GO:0008201~heparin binding,	IPR025232:Domain of unknown function DUF4174,						KW-0261~Viral envelope protein,KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0946~Virion,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DUF4174,REGION:Disordered,TRANSMEM:Helical,
CTHRC1	collagen triple helix repeat containing 1(CTHRC1)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0016477~cell migration,GO:0032092~positive regulation of protein binding,GO:0033687~osteoblast proliferation,GO:0033690~positive regulation of osteoblast proliferation,GO:0043932~ossification involved in bone remodeling,GO:0045669~positive regulation of osteoblast differentiation,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060122~inner ear receptor stereocilium organization,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090103~cochlea morphogenesis,GO:0090177~establishment of planar polarity involved in neural tube closure,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016528~sarcoplasm,	GO:0005109~frizzled binding,GO:0005201~extracellular matrix structural constituent,GO:0017147~Wnt-protein binding,	IPR008160:Collagen triple helix repeat,		614266~Barrett esophagus/esophageal adenocarcinoma,				KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0176~Collagen,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Collagen-like,REGION:Disordered,
COL1A2	collagen type I alpha 2 chain(COL1A2)	Homo sapiens			GO:0001501~skeletal system development,GO:0001568~blood vessel development,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007266~Rho protein signal transduction,GO:0008217~regulation of blood pressure,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030282~bone mineralization,GO:0032963~collagen metabolic process,GO:0042476~odontogenesis,GO:0043589~skin morphogenesis,GO:0070208~protein heterotrimerization,GO:0071230~cellular response to amino acid stimulus,GO:0085029~extracellular matrix assembly,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005584~collagen type I trimer,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,	166210~Osteogenesis imperfecta, type II,166220~Osteogenesis imperfecta, type IV,166710~Osteoporosis, postmenopausal,225320~Ehlers-Danlos syndrome, cardiac valvular type,259420~Osteogenesis imperfecta, type III,617821~Ehlers-Danlos syndrome, arthrochalasia type, 2,619120~Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2,		SM00038:COLFI,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0248~Ehlers-Danlos syndrome,KW-1065~Osteogenesis imperfecta,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Pro residues,DOMAIN:Fibrillar collagen NC1,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,
COL5A2	collagen type V alpha 2 chain(COL5A2)	Homo sapiens			GO:0001501~skeletal system development,GO:0001503~ossification,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0043588~skin development,GO:0048592~eye morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:1903225~negative regulation of endodermal cell differentiation,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005588~collagen type V trimer,GO:0005592~collagen type XI trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0046332~SMAD binding,GO:0046872~metal ion binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001007:von Willebrand factor, type C,IPR008160:Collagen triple helix repeat,	hsa04974:Protein digestion and absorption,	130010~Ehlers-Danlos syndrome, classic type, 2,		SM00038:COLFI,SM00214:VWC,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Fibrillar collagen NC1,DOMAIN:VWFC,MOTIF:Cell attachment site,PROPEP:C-terminal propeptide,REGION:Disordered,
COL11A1	collagen type XI alpha 1 chain(COL11A1)	Homo sapiens			GO:0001502~cartilage condensation,GO:0001503~ossification,GO:0002063~chondrocyte development,GO:0006029~proteoglycan metabolic process,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0035987~endodermal cell differentiation,GO:0035989~tendon development,GO:0042472~inner ear morphogenesis,GO:0048704~embryonic skeletal system morphogenesis,GO:0050910~detection of mechanical stimulus involved in sensory perception of sound,GO:0055010~ventricular cardiac muscle tissue morphogenesis,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005592~collagen type XI trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0008201~heparin binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,GO:0050840~extracellular matrix binding,GO:1904399~heparan sulfate binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001791:Laminin G domain,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04974:Protein digestion and absorption,	154780~Marshall syndrome,228520~Fibrochondrogenesis 1,603932~Lumbar disc herniation, susceptibility to,604841~Stickler syndrome, type II,618533~Deafness, autosomal dominant 37,		SM00038:COLFI,SM00210:TSPN,SM00282:LamG,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0038~Ectodermal dysplasia,KW-0209~Deafness,KW-0225~Disease variant,KW-0242~Dwarfism,KW-0757~Stickler syndrome,KW-0898~Cataract,KW-1010~Non-syndromic deafness,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Collagen-like 5,DOMAIN:Collagen-like 6,DOMAIN:Collagen-like 7,DOMAIN:Collagen-like 8,DOMAIN:Fibrillar collagen NC1,DOMAIN:Laminin G,DOMAIN:Laminin G-like,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,REGION:Nonhelical region,REGION:Nonhelical region (C-terminal),REGION:Short nonhelical segment,REGION:Telopeptide,REGION:Triple-helical region,REGION:Triple-helical region (interrupted),
COL11A2	collagen type XI alpha 2 chain(COL11A2)	Homo sapiens			GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0001894~tissue homeostasis,GO:0002062~chondrocyte differentiation,GO:0007605~sensory perception of sound,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0048705~skeletal system morphogenesis,GO:0051216~cartilage development,GO:0060021~palate development,GO:0060023~soft palate development,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005592~collagen type XI trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005840~ribosome,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001791:Laminin G domain,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04974:Protein digestion and absorption,	184840~Otospondylomegaepiphyseal dysplasia, autosomal dominant,215150~Otospondylomegaepiphyseal dysplasia, autosomal recessive,601868~Deafness, autosomal dominant 13,609706~Deafness, autosomal recessive 53,614524~Fibrochondrogenesis 2,		SM00038:COLFI,SM00210:TSPN,SM00282:LamG,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-0242~Dwarfism,KW-0757~Stickler syndrome,KW-1010~Non-syndromic deafness,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Collagen-like 5,DOMAIN:Collagen-like 6,DOMAIN:Collagen-like 7,DOMAIN:Collagen-like 8,DOMAIN:Fibrillar collagen NC1,DOMAIN:Laminin G,DOMAIN:Laminin G-like,PROPEP:C-terminal propeptide,REGION:Disordered,REGION:Nonhelical region,REGION:Triple-helical region,
COL12A1	collagen type XII alpha 1 chain(COL12A1)	Homo sapiens			GO:0007155~cell adhesion,GO:0030199~collagen fibril organization,GO:0035987~endodermal cell differentiation,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005595~collagen type XII trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR001791:Laminin G domain,IPR002035:von Willebrand factor, type A,IPR003961:Fibronectin, type III,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,	hsa04974:Protein digestion and absorption,	616470~Ullrich congenital muscular dystrophy 2,616471~Bethlem myopathy 2,		SM00060:FN3,SM00210:TSPN,SM00327:VWA,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 10,DOMAIN:Fibronectin type-III 11,DOMAIN:Fibronectin type-III 12,DOMAIN:Fibronectin type-III 13,DOMAIN:Fibronectin type-III 14,DOMAIN:Fibronectin type-III 15,DOMAIN:Fibronectin type-III 16,DOMAIN:Fibronectin type-III 17,DOMAIN:Fibronectin type-III 18,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Fibronectin type-III 9,DOMAIN:Laminin G-like,DOMAIN:VWFA,DOMAIN:VWFA 1,DOMAIN:VWFA 2,DOMAIN:VWFA 3,DOMAIN:VWFA 4,MOTIF:Cell attachment site,REGION:Disordered,REGION:Nonhelical region (NC1),REGION:Nonhelical region (NC2),REGION:Nonhelical region (NC3),REGION:Triple-helical region (COL1) with 2 imperfections,REGION:Triple-helical region (COL2) with 1 imperfection,
COL23A1	collagen type XXIII alpha 1 chain(COL23A1)	Homo sapiens			GO:0030198~extracellular matrix organization,	GO:0005581~collagen trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0042802~identical protein binding,	IPR008160:Collagen triple helix repeat,	hsa04974:Protein digestion and absorption,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0176~Collagen,KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Collagen-like 5,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CSF1	colony stimulating factor 1(CSF1)	Homo sapiens	88.Alternatively_Activated_APC,	h_etsPathway:METS affect on Macrophage Differentiation,h_inflamPathway:Cytokines and Inflammatory Response,h_LDLpathway:Low-density lipoprotein (LDL) pathway during atherogenesis,h_mspPathway:Msp/Ron Receptor Signaling Pathway,h_stemPathway:Regulation of hematopoiesis by cytokines,	GO:0001503~ossification,GO:0001780~neutrophil homeostasis,GO:0001954~positive regulation of cell-matrix adhesion,GO:0002158~osteoclast proliferation,GO:0002931~response to ischemia,GO:0003006~developmental process involved in reproduction,GO:0006954~inflammatory response,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007265~Ras protein signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010743~regulation of macrophage derived foam cell differentiation,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0010759~positive regulation of macrophage chemotaxis,GO:0030224~monocyte differentiation,GO:0030225~macrophage differentiation,GO:0030278~regulation of ossification,GO:0030316~osteoclast differentiation,GO:0030335~positive regulation of cell migration,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032946~positive regulation of mononuclear cell proliferation,GO:0035702~monocyte homeostasis,GO:0038145~macrophage colony-stimulating factor signaling pathway,GO:0040018~positive regulation of multicellular organism growth,GO:0042117~monocyte activation,GO:0042476~odontogenesis,GO:0042488~positive regulation of odontogenesis of dentin-containing tooth,GO:0045087~innate immune response,GO:0045651~positive regulation of macrophage differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0045672~positive regulation of osteoclast differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046579~positive regulation of Ras protein signal transduction,GO:0048873~homeostasis of number of cells within a tissue,GO:0051247~positive regulation of protein metabolic process,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0060611~mammary gland fat development,GO:0060763~mammary duct terminal end bud growth,GO:0061518~microglial cell proliferation,GO:0061519~macrophage homeostasis,GO:0097529~myeloid leukocyte migration,GO:1901215~negative regulation of neuron death,GO:1902228~positive regulation of macrophage colony-stimulating factor signaling pathway,GO:1904141~positive regulation of microglial cell migration,GO:1905523~positive regulation of macrophage migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016604~nuclear body,GO:0048471~perinuclear region of cytoplasm,GO:1990682~CSF1-CSF1R complex,	GO:0005125~cytokine activity,GO:0005157~macrophage colony-stimulating factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR008001:Macrophage colony stimulating factor-1,IPR009079:Four-helical cytokine-like, core,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04151:PI3K-Akt signaling pathway,hsa04380:Osteoclast differentiation,hsa04640:Hematopoietic cell lineage,hsa04668:TNF signaling pathway,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05323:Rheumatoid arthritis,		PIRSF001948:macrophage colony-stimulating factor 1,		KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain,MUTAGEN:Missing: Produces biologically active protein which is secreted.,MUTAGEN:R->A: Does not affect production of 150-200 kDa subunit.,MUTAGEN:R->A: Loss of 43 kDa subunit.,MUTAGEN:S->A: Loss of chondroitin sulfate attachment.,REGION:Disordered,REGION:O-glycosylated at one site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CSF2	colony stimulating factor 2(CSF2)	Homo sapiens	88.Alternatively_Activated_APC,	h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,h_erythPathway:Erythrocyte Differentiation Pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_stemPathway:Regulation of hematopoiesis by cytokines,	GO:0001821~histamine secretion,GO:0001892~embryonic placenta development,GO:0006468~protein phosphorylation,GO:0006955~immune response,GO:0007259~JAK-STAT cascade,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0030099~myeloid cell differentiation,GO:0030223~neutrophil differentiation,GO:0030224~monocyte differentiation,GO:0030225~macrophage differentiation,GO:0030335~positive regulation of cell migration,GO:0032747~positive regulation of interleukin-23 production,GO:0034021~response to silicon dioxide,GO:0034405~response to fluid shear stress,GO:0038157~granulocyte-macrophage colony-stimulating factor signaling pathway,GO:0042045~epithelial fluid transport,GO:0042116~macrophage activation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043011~myeloid dendritic cell differentiation,GO:0045187~regulation of circadian sleep/wake cycle, sleep,GO:0045892~negative regulation of transcription, DNA-templated,GO:0070665~positive regulation of leukocyte proliferation,GO:0071222~cellular response to lipopolysaccharide,GO:0071803~positive regulation of podosome assembly,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:0097028~dendritic cell differentiation,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0030526~granulocyte macrophage colony-stimulating factor receptor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005125~cytokine activity,GO:0005129~granulocyte macrophage colony-stimulating factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR000773:Granulocyte-macrophage colony-stimulating factor,IPR009079:Four-helical cytokine-like, core,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04650:Natural killer cell mediated cytotoxicity,hsa04657:IL-17 signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa05131:Shigellosis,hsa05146:Amoebiasis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,hsa05323:Rheumatoid arthritis,			SM00040:CSF2,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine; partial,
C1QL1	complement C1q like 1(C1QL1)	Homo sapiens			GO:0007626~locomotory behavior,GO:0016322~neuron remodeling,GO:0061743~motor learning,GO:0099558~maintenance of synapse structure,GO:1905806~regulation of synapse disassembly,	GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0043083~synaptic cleft,GO:0044301~climbing fiber,GO:0098793~presynapse,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,				SM00110:C1Q,		KW-0964~Secreted,		KW-0176~Collagen,KW-0732~Signal,				COMPBIAS:Pro residues,DOMAIN:C1q,DOMAIN:Collagen-like,REGION:Disordered,
C4BPA	complement component 4 binding protein alpha(C4BPA)	Homo sapiens			GO:0002456~T cell mediated immunity,GO:0006958~complement activation, classical pathway,GO:0009609~response to symbiotic bacterium,GO:0045087~innate immune response,GO:0045732~positive regulation of protein catabolic process,GO:0045959~negative regulation of complement activation, classical pathway,GO:1903027~regulation of opsonization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0072562~blood microparticle,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000436:Sushi/SCR/CCP,	hsa04610:Complement and coagulation cascades,hsa05133:Pertussis,			SM00032:CCP,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with beta chain),DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,DOMAIN:Sushi 4,DOMAIN:Sushi 5,DOMAIN:Sushi 6,DOMAIN:Sushi 7,DOMAIN:Sushi 8,
CNTN2	contactin 2(CNTN2)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0001973~adenosine receptor signaling pathway,GO:0002023~reduction of food intake in response to dietary excess,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007411~axon guidance,GO:0007413~axonal fasciculation,GO:0007612~learning,GO:0007628~adult walking behavior,GO:0010769~regulation of cell morphogenesis involved in differentiation,GO:0010954~positive regulation of protein processing,GO:0016485~protein processing,GO:0021853~cerebral cortex GABAergic interneuron migration,GO:0022010~central nervous system myelination,GO:0022604~regulation of cell morphogenesis,GO:0031133~regulation of axon diameter,GO:0031623~receptor internalization,GO:0045163~clustering of voltage-gated potassium channels,GO:0045444~fat cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0048168~regulation of neuronal synaptic plasticity,GO:0048710~regulation of astrocyte differentiation,GO:0051649~establishment of localization in cell,GO:0060168~positive regulation of adenosine receptor signaling pathway,GO:0070593~dendrite self-avoidance,GO:0071205~protein localization to juxtaparanode region of axon,GO:0071206~establishment of protein localization to juxtaparanode region of axon,GO:0097090~presynaptic membrane organization,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030424~axon,GO:0033268~node of Ranvier,GO:0043025~neuronal cell body,GO:0043194~axon initial segment,GO:0043209~myelin sheath,GO:0044224~juxtaparanode region of axon,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098552~side of membrane,GO:0099025~anchored component of postsynaptic membrane,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0098632~protein binding involved in cell-cell adhesion,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,	615400~Epilepsy, myoclonic, familial adult, 5,		SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0887~Epilepsy,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,LIPID:GPI-anchor amidated asparagine,MOTIF:Cell attachment site,PROPEP:Removed in mature form,REGION:Disordered,
CBFB	core-binding factor subunit beta(CBFB)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000209~protein polyubiquitination,GO:0001649~osteoblast differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0030098~lymphocyte differentiation,GO:0030099~myeloid cell differentiation,GO:0043371~negative regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043378~positive regulation of CD8-positive, alpha-beta T cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0060216~definitive hemopoiesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0016513~core-binding factor complex,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR003417:Core binding factor, beta subunit,		620099~Cleidocranial dysplasia 2,				KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0656~Proto-oncogene,				KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,SITE:Breakpoint for translocation to form CBF-beta-MYH11 oncogene in AML, subtype M4EO,
CRNN	cornulin(CRNN)	Homo sapiens			GO:0009408~response to heat,GO:0010468~regulation of gene expression,GO:0010838~positive regulation of keratinocyte proliferation,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051896~regulation of protein kinase B signaling,GO:0071345~cellular response to cytokine stimulus,GO:0098609~cell-cell adhesion,GO:1902808~positive regulation of cell cycle G1/S phase transition,	GO:0005737~cytoplasm,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,IPR026792:Cornulin,				SM00054:EFh,SM01394:SM01394,		KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0106~Calcium,KW-0479~Metal-binding,			COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,REGION:Disordered,
CRHR2	corticotropin releasing hormone receptor 2(CRHR2)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0060291~long-term synaptic potentiation,GO:0071376~cellular response to corticotropin-releasing hormone stimulus,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0043679~axon terminus,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0015056~corticotrophin-releasing factor receptor activity,GO:0017046~peptide hormone binding,GO:0043404~corticotropin-releasing hormone receptor activity,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR003051:GPCR, family 2, corticotropin releasing factor receptor,IPR003053:GPCR, family 2, corticotropin releasing factor receptor, type 2,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04934:Cushing syndrome,			SM00008:HormR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,REGION:Disordered,SIGNAL:Not cleaved,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CRYAB	crystallin alpha B(CRYAB)	Homo sapiens			GO:0001666~response to hypoxia,GO:0002088~lens development in camera-type eye,GO:0006457~protein folding,GO:0006936~muscle contraction,GO:0007021~tubulin complex assembly,GO:0007517~muscle organ development,GO:0009408~response to heat,GO:0010259~multicellular organism aging,GO:0010629~negative regulation of gene expression,GO:0010941~regulation of cell death,GO:0030308~negative regulation of cell growth,GO:0031109~microtubule polymerization or depolymerization,GO:0031333~negative regulation of protein complex assembly,GO:0032355~response to estradiol,GO:0032387~negative regulation of intracellular transport,GO:0042026~protein refolding,GO:0042542~response to hydrogen peroxide,GO:0043066~negative regulation of apoptotic process,GO:0043067~regulation of programmed cell death,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050821~protein stabilization,GO:0051403~stress-activated MAPK cascade,GO:0060561~apoptotic process involved in morphogenesis,GO:0071480~cellular response to gamma radiation,GO:1905907~negative regulation of amyloid fibril formation,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0015630~microtubule cytoskeleton,GO:0030018~Z disc,GO:0030424~axon,GO:0031430~M band,GO:0032432~actin filament bundle,GO:0032991~macromolecular complex,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0070062~extracellular exosome,GO:0097060~synaptic membrane,GO:0097512~cardiac myofibril,	GO:0001540~beta-amyloid binding,GO:0005198~structural molecule activity,GO:0005212~structural constituent of eye lens,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0051082~unfolded protein binding,	IPR001436:Alpha crystallin/Heat shock protein,IPR002068:Alpha crystallin/Hsp20 domain,IPR003090:Alpha-crystallin, N-terminal,IPR008978:HSP20-like chaperone,	hsa04141:Protein processing in endoplasmic reticulum,hsa04213:Longevity regulating pathway - multiple species,	608810~Myopathy, myofibrillar, 2,613763~Cataract 16, multiple types,613869~Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related,615184~Cardiomyopathy, dilated, 1II,	PIRSF036514:small heat shock protein, beta-1 type,			KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0898~Cataract,KW-1060~Myofibrillar myopathy,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,KW-0273~Eye lens protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,DOMAIN:Alpha-crystallin N-terminal,DOMAIN:SHSP,DOMAIN:sHSP,REGION:Disordered,SITE:Susceptible to oxidation,
CRYBG3	crystallin beta-gamma domain containing 3(CRYBG3)	Homo sapiens			GO:0002088~lens development in camera-type eye,GO:0007601~visual perception,	GO:0032991~macromolecular complex,	GO:0005212~structural constituent of eye lens,GO:0030246~carbohydrate binding,GO:0051018~protein kinase A binding,	IPR000772:Ricin B lectin domain,IPR001064:Beta/gamma crystallin,IPR011024:Gamma-crystallin-related,				SM00247:XTALbg,SM00458:RICIN,				KW-0677~Repeat,	KW-0430~Lectin,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Beta/gamma crystallin 'Greek key',DOMAIN:Beta/gamma crystallin 'Greek key' 1,DOMAIN:Beta/gamma crystallin 'Greek key' 2,DOMAIN:Beta/gamma crystallin 'Greek key' 3,DOMAIN:Beta/gamma crystallin 'Greek key' 4,DOMAIN:Beta/gamma crystallin 'Greek key' 5,DOMAIN:Beta/gamma crystallin 'Greek key' 6,DOMAIN:Beta/gamma crystallin 'Greek key' 7,DOMAIN:Beta/gamma crystallin 'Greek key' 8,DOMAIN:Beta/gamma crystallin 'Greek key' 9,DOMAIN:Ricin B-type lectin,REGION:Disordered,REGION:RII-binding helix,
CUBN	cubilin(CUBN)	Homo sapiens			GO:0001894~tissue homeostasis,GO:0006898~receptor-mediated endocytosis,GO:0008203~cholesterol metabolic process,GO:0009235~cobalamin metabolic process,GO:0009617~response to bacterium,GO:0015031~protein transport,GO:0015889~cobalamin transport,GO:0042953~lipoprotein transport,GO:0051649~establishment of localization in cell,	GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030139~endocytic vesicle,GO:0031232~extrinsic component of external side of plasma membrane,GO:0031526~brush border membrane,GO:0031528~microvillus membrane,GO:0043202~lysosomal lumen,GO:0043235~receptor complex,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0031419~cobalamin binding,GO:0038023~signaling receptor activity,GO:0038024~cargo receptor activity,GO:0042803~protein homodimerization activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000859:CUB domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,	hsa04977:Vitamin digestion and absorption,	261100~Imerslund-Grasbeck syndrome 1,618884~Proteinuria, chronic benign,		SM00042:CUB,SM00179:EGF_CA,SM00181:EGF,	KW-0153~Cholesterol metabolism,KW-0254~Endocytosis,KW-0443~Lipid metabolism,KW-0653~Protein transport,KW-0753~Steroid metabolism,KW-0813~Transport,KW-1207~Sterol metabolism,	KW-0168~Coated pit,KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0170~Cobalt,KW-0479~Metal-binding,KW-0846~Cobalamin,	KW-0675~Receptor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 10,DOMAIN:CUB 11,DOMAIN:CUB 12,DOMAIN:CUB 13,DOMAIN:CUB 14,DOMAIN:CUB 15,DOMAIN:CUB 16,DOMAIN:CUB 17,DOMAIN:CUB 18,DOMAIN:CUB 19,DOMAIN:CUB 2,DOMAIN:CUB 20,DOMAIN:CUB 21,DOMAIN:CUB 22,DOMAIN:CUB 23,DOMAIN:CUB 24,DOMAIN:CUB 25,DOMAIN:CUB 26,DOMAIN:CUB 27,DOMAIN:CUB 3,DOMAIN:CUB 4,DOMAIN:CUB 5,DOMAIN:CUB 6,DOMAIN:CUB 7,DOMAIN:CUB 8,DOMAIN:CUB 9,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,PROPEP:Removed in mature form,REGION:Disordered,REGION:Interaction with AMN,SITE:Cleavage; by furin,
CUL7	cullin 7(CUL7)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0000281~mitotic cytokinesis,GO:0001570~vasculogenesis,GO:0001837~epithelial to mesenchymal transition,GO:0001890~placenta development,GO:0006508~proteolysis,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007030~Golgi organization,GO:0007088~regulation of mitotic nuclear division,GO:0016567~protein ubiquitination,GO:0050775~positive regulation of dendrite morphogenesis,	GO:0005680~anaphase-promoting complex,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0031461~cullin-RING ubiquitin ligase complex,GO:0031467~Cul7-RING ubiquitin ligase complex,GO:0048471~perinuclear region of cytoplasm,GO:1990393~3M complex,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR001373:Cullin, N-terminal,IPR004939:Anaphase-promoting complex, subunit 10/DOC domain,IPR008979:Galactose-binding domain-like,IPR014722:Ribosomal protein L2 domain 2,IPR016024:Armadillo-type fold,IPR016158:Cullin homology,IPR019559:Cullin protein, neddylation domain,IPR021097:CPH domain,	hsa04120:Ubiquitin mediated proteolysis,	273750~3-M syndrome 1,		SM00884:SM00884,SM01337:SM01337,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in NEDD8),DOMAIN:CPH,DOMAIN:Cullin family profile,DOMAIN:DOC,REGION:Disordered,REGION:Interaction with TP53,
CCND2	cyclin D2(CCND2)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0001934~positive regulation of protein phosphorylation,GO:0007616~long-term memory,GO:0008284~positive regulation of cell proliferation,GO:0008344~adult locomotory behavior,GO:0043066~negative regulation of apoptotic process,GO:0044772~mitotic cell cycle phase transition,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0051301~cell division,GO:0071481~cellular response to X-ray,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0097129~cyclin D2-CDK4 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,IPR015451:Cyclin D,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04630:JAK-STAT signaling pathway,hsa04917:Prolactin signaling pathway,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,	615938~Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3,		SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0195~Cyclin,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:Cyclin N-terminal,REGION:Disordered,
CCNJ	cyclin J(CCNJ)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0044772~mitotic cell cycle phase transition,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,	GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,				SM00385:CYCLIN,SM01332:SM01332,						KW-0195~Cyclin,		DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,
CCNP	cyclin P(CCNP)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0044772~mitotic cell cycle phase transition,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0097124~cyclin A2-CDK2 complex,	GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,				SM00385:CYCLIN,SM01332:SM01332,		KW-0539~Nucleus,				KW-0195~Cyclin,		DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,REGION:Disordered,
CDK5R2	cyclin dependent kinase 5 regulatory subunit 2(CDK5R2)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0001764~neuron migration,GO:0007411~axon guidance,GO:0007420~brain development,GO:0021549~cerebellum development,GO:0021722~superior olivary nucleus maturation,GO:0021766~hippocampus development,GO:0021819~layer formation in cerebral cortex,GO:0045956~positive regulation of calcium ion-dependent exocytosis,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016533~cyclin-dependent protein kinase 5 holoenzyme complex,GO:0030426~growth cone,GO:0043005~neuron projection,	GO:0003779~actin binding,GO:0008289~lipid binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004944:Cyclin-dependent kinase 5 activator,			PIRSF009324:cyclin-dependent kinase 5, regulatory subunit (activating),			KW-0472~Membrane,KW-1003~Cell membrane,			KW-0446~Lipid-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Absent from the cell periphery.,REGION:Disordered,
CDKL2	cyclin dependent kinase like 2(CDKL2)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007548~sex differentiation,GO:0016310~phosphorylation,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MOTIF:[NKR]KIAxRE,REGION:Disordered,
CSRNP1	cysteine and serine rich nuclear protein 1(CSRNP1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0009791~post-embryonic development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048705~skeletal system morphogenesis,GO:0060021~palate development,GO:0060325~face morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0016021~integral component of membrane,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR023260:Cysteine/serine-rich nuclear protein family,					KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DOMAIN:Cysteine/serine-rich nuclear protein N-terminal,REGION:Disordered,TRANSMEM:Helical,
CDO1	cysteine dioxygenase type 1(CDO1)	Homo sapiens			GO:0000097~sulfur amino acid biosynthetic process,GO:0006534~cysteine metabolic process,GO:0006954~inflammatory response,GO:0007595~lactation,GO:0019448~L-cysteine catabolic process,GO:0033762~response to glucagon,GO:0042412~taurine biosynthetic process,GO:0043200~response to amino acid,GO:0045471~response to ethanol,GO:0051384~response to glucocorticoid,GO:0051591~response to cAMP,	GO:0005829~cytosol,	GO:0008198~ferrous iron binding,GO:0008270~zinc ion binding,GO:0016151~nickel cation binding,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0017172~cysteine dioxygenase activity,	IPR010300:Cysteine dioxygenase type I,IPR011051:RmlC-like cupin domain,IPR014710:RmlC-like jelly roll fold,	hsa00270:Cysteine and methionine metabolism,hsa00430:Taurine and hypotaurine metabolism,hsa01100:Metabolic pathways,								KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0883~Thioether bond,	CROSSLNK:3'-(S-cysteinyl)-tyrosine (Cys-Tyr),MUTAGEN:C->S: Reduces enzyme activity and iron incorporation by 50%. Zinc incorporation increased by 20%.,MUTAGEN:C->S: Reduces enzyme activity by 20%. Little effect on iron incorporation. No effect on zinc incorporation.,MUTAGEN:R->Q: Reduces enzyme activity by 70%. Reduces iron and zinc incorporation by 50%.,MUTAGEN:Y->F: Almost total loss of enzyme activity and iron incorporation. Reduces zinc incorporation by 20%.,
CRCT1	cysteine rich C-terminal 1(CRCT1)	Homo sapiens					GO:0005515~protein binding,													COMPBIAS:Polar residues,REGION:Disordered,
CRISP2	cysteine rich secretory protein 2(CRISP2)	Homo sapiens				GO:0005576~extracellular region,GO:0005615~extracellular space,		IPR001283:Allergen V5/Tpx-1-related,IPR003582:Metridin-like ShK toxin,IPR013871:Cysteine-rich secretory protein,IPR014044:CAP domain,IPR018244:Allergen V5/Tpx-1-related, conserved site,				SM00198:SCP,		KW-0964~Secreted,		KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:SCP,DOMAIN:ShKT,
CYP1A1	cytochrome P450 family 1 subfamily A member 1(CYP1A1)	Homo sapiens			GO:0001666~response to hypoxia,GO:0001676~long-chain fatty acid metabolic process,GO:0002933~lipid hydroxylation,GO:0006306~DNA methylation,GO:0006631~fatty acid metabolic process,GO:0006694~steroid biosynthetic process,GO:0006778~porphyrin-containing compound metabolic process,GO:0006805~xenobiotic metabolic process,GO:0007568~aging,GO:0008202~steroid metabolic process,GO:0008210~estrogen metabolic process,GO:0008283~cell proliferation,GO:0009308~amine metabolic process,GO:0009611~response to wounding,GO:0009615~response to virus,GO:0009624~response to nematode,GO:0009635~response to herbicide,GO:0009692~ethylene metabolic process,GO:0009804~coumarin metabolic process,GO:0009812~flavonoid metabolic process,GO:0010041~response to iron(III) ion,GO:0014070~response to organic cyclic compound,GO:0017143~insecticide metabolic process,GO:0019341~dibenzo-p-dioxin catabolic process,GO:0019373~epoxygenase P450 pathway,GO:0032094~response to food,GO:0032496~response to lipopolysaccharide,GO:0033189~response to vitamin A,GO:0035902~response to immobilization stress,GO:0042359~vitamin D metabolic process,GO:0042572~retinol metabolic process,GO:0042759~long-chain fatty acid biosynthetic process,GO:0042904~9-cis-retinoic acid biosynthetic process,GO:0043010~camera-type eye development,GO:0046677~response to antibiotic,GO:0046685~response to arsenic-containing substance,GO:0048565~digestive tract development,GO:0050665~hydrogen peroxide biosynthetic process,GO:0055093~response to hyperoxia,GO:0060137~maternal process involved in parturition,GO:0070365~hepatocyte differentiation,GO:0071280~cellular response to copper ion,GO:0071407~cellular response to organic cyclic compound,GO:0097267~omega-hydroxylase P450 pathway,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0005743~mitochondrial inner membrane,GO:0005789~endoplasmic reticulum membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008391~arachidonic acid monooxygenase activity,GO:0008395~steroid hydroxylase activity,GO:0016491~oxidoreductase activity,GO:0016679~oxidoreductase activity, acting on diphenols and related substances as donors,GO:0016711~flavonoid 3'-monooxygenase activity,GO:0019825~oxygen binding,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0030544~Hsp70 protein binding,GO:0032451~demethylase activity,GO:0051879~Hsp90 protein binding,GO:0070330~aromatase activity,GO:0070576~vitamin D 24-hydroxylase activity,GO:0101020~estrogen 16-alpha-hydroxylase activity,GO:0101021~estrogen 2-hydroxylase activity,GO:0102033~cytochrome P450 fatty acid omega-hydroxylase activity,	IPR001128:Cytochrome P450,IPR002401:Cytochrome P450, E-class, group I,IPR008066:Cytochrome P450, E-class, group I, CYP1,IPR017972:Cytochrome P450, conserved site,	hsa00140:Steroid hormone biosynthesis,hsa00380:Tryptophan metabolism,hsa00830:Retinol metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa01100:Metabolic pathways,hsa04913:Ovarian steroidogenesis,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05417:Lipid and atherosclerosis,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,		KW-0732~Signal,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0456~Lyase,KW-0503~Monooxygenase,KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	BINDING:axial binding residue,CARBOHYD:O-linked (GlcNAc) serine,REGION:Mitochondrial targeting signal,
CYP11B2	cytochrome P450 family 11 subfamily B member 2(CYP11B2)	Homo sapiens			GO:0002017~regulation of blood volume by renal aldosterone,GO:0003091~renal water homeostasis,GO:0006700~C21-steroid hormone biosynthetic process,GO:0006704~glucocorticoid biosynthetic process,GO:0006705~mineralocorticoid biosynthetic process,GO:0008202~steroid metabolic process,GO:0008203~cholesterol metabolic process,GO:0016125~sterol metabolic process,GO:0032342~aldosterone biosynthetic process,GO:0032870~cellular response to hormone stimulus,GO:0034650~cortisol metabolic process,GO:0034651~cortisol biosynthetic process,GO:0035865~cellular response to potassium ion,GO:0055075~potassium ion homeostasis,GO:0055078~sodium ion homeostasis,GO:0071375~cellular response to peptide hormone stimulus,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,	GO:0004497~monooxygenase activity,GO:0004507~steroid 11-beta-monooxygenase activity,GO:0005506~iron ion binding,GO:0008395~steroid hydroxylase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,GO:0047783~corticosterone 18-monooxygenase activity,	IPR001128:Cytochrome P450,IPR002399:Cytochrome P450, mitochondrial,IPR017972:Cytochrome P450, conserved site,	hsa00140:Steroid hormone biosynthesis,hsa01100:Metabolic pathways,hsa04925:Aldosterone synthesis and secretion,	203400~Hypoaldosteronism, congenital, due to CMO I deficiency,610600~Hypoaldosteronism, congenital, due to CMO II deficiency,Aldosterone to renin ratio raised~Aldosterone to renin ratio raised,Low renin hypertension, susceptibility to~Low renin hypertension, susceptibility to,			KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-0755~Steroidogenesis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,MUTAGEN:D->E: Increases 11-beta-hydroxylase activity toward 11-deoxycorticosterone and 11-deoxycortisol.,MUTAGEN:I->P: Increases 11-beta- and 18-hydroxylase activities toward 11-deoxycorticosterone; increases 11-beta-hydroxylase activity toward 11-deoxycortisol.,MUTAGEN:K->N: No significant effect on hydroxylase activities toward 11-deoxycorticosterone and 11-deoxycortisol.,TRANSIT:Mitochondrion,
CYP26C1	cytochrome P450 family 26 subfamily C member 1(CYP26C1)	Homo sapiens			GO:0006766~vitamin metabolic process,GO:0007417~central nervous system development,GO:0009952~anterior/posterior pattern specification,GO:0014032~neural crest cell development,GO:0016125~sterol metabolic process,GO:0034653~retinoic acid catabolic process,GO:0048284~organelle fusion,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0001972~retinoic acid binding,GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0008401~retinoic acid 4-hydroxylase activity,GO:0016491~oxidoreductase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,GO:0070330~aromatase activity,	IPR001128:Cytochrome P450,IPR002403:Cytochrome P450, E-class, group IV,IPR017972:Cytochrome P450, conserved site,	hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,	614974~Focal facial dermal dysplasia 4,			KW-0443~Lipid metabolism,	KW-0472~Membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,REGION:Disordered,TRANSMEM:Helical,
CYP3A43	cytochrome P450 family 3 subfamily A member 43(CYP3A43)	Homo sapiens		h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,	GO:0008202~steroid metabolic process,GO:0070989~oxidative demethylation,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0008395~steroid hydroxylase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,GO:0050649~testosterone 6-beta-hydroxylase activity,GO:0070330~aromatase activity,GO:0101020~estrogen 16-alpha-hydroxylase activity,	IPR001128:Cytochrome P450,IPR002401:Cytochrome P450, E-class, group I,IPR002402:Cytochrome P450, E-class, group II,IPR008072:Cytochrome P450, E-class, CYP3A,IPR017972:Cytochrome P450, conserved site,	hsa05204:Chemical carcinogenesis - DNA adducts,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,TRANSMEM:Helical,
CYP4F2	cytochrome P450 family 4 subfamily F member 2(CYP4F2)	Homo sapiens			GO:0000038~very long-chain fatty acid metabolic process,GO:0001676~long-chain fatty acid metabolic process,GO:0003091~renal water homeostasis,GO:0003095~pressure natriuresis,GO:0006690~icosanoid metabolic process,GO:0006691~leukotriene metabolic process,GO:0006805~xenobiotic metabolic process,GO:0007596~blood coagulation,GO:0008217~regulation of blood pressure,GO:0010430~fatty acid omega-oxidation,GO:0019369~arachidonic acid metabolic process,GO:0019373~epoxygenase P450 pathway,GO:0032304~negative regulation of icosanoid secretion,GO:0032305~positive regulation of icosanoid secretion,GO:0036101~leukotriene B4 catabolic process,GO:0042360~vitamin E metabolic process,GO:0042361~menaquinone catabolic process,GO:0042376~phylloquinone catabolic process,GO:0042377~vitamin K catabolic process,GO:0055078~sodium ion homeostasis,GO:0097267~omega-hydroxylase P450 pathway,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008391~arachidonic acid monooxygenase activity,GO:0008392~arachidonic acid epoxygenase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0016709~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen,GO:0018685~alkane 1-monooxygenase activity,GO:0020037~heme binding,GO:0050051~leukotriene-B4 20-monooxygenase activity,GO:0052869~arachidonic acid omega-hydroxylase activity,GO:0052871~alpha-tocopherol omega-hydroxylase activity,GO:0052872~tocotrienol omega-hydroxylase activity,GO:0070330~aromatase activity,GO:0097258~20-hydroxy-leukotriene B4 omega oxidase activity,GO:0097259~20-aldehyde-leukotriene B4 20-monooxygenase activity,GO:0102033~cytochrome P450 fatty acid omega-hydroxylase activity,	IPR001128:Cytochrome P450,IPR002401:Cytochrome P450, E-class, group I,IPR017972:Cytochrome P450, conserved site,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,BINDING:covalent,TRANSMEM:Helical,
CYP7B1	cytochrome P450 family 7 subfamily B member 1(CYP7B1)	Homo sapiens			GO:0006699~bile acid biosynthetic process,GO:0008203~cholesterol metabolic process,GO:0016125~sterol metabolic process,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0035754~B cell chemotaxis,GO:0042632~cholesterol homeostasis,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0060740~prostate gland epithelium morphogenesis,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0008395~steroid hydroxylase activity,GO:0008396~oxysterol 7-alpha-hydroxylase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,GO:0033782~24-hydroxycholesterol 7alpha-hydroxylase activity,GO:0033783~25-hydroxycholesterol 7alpha-hydroxylase activity,GO:0047092~27-hydroxycholesterol 7-alpha-monooxygenase activity,	IPR001128:Cytochrome P450,IPR002403:Cytochrome P450, E-class, group IV,IPR024204:Cytochrome P450, cholesterol 7-alpha-monooxygenase-type,	hsa00120:Primary bile acid biosynthesis,hsa00140:Steroid hormone biosynthesis,	270800~Spastic paraplegia 5A, autosomal recessive,613812~Bile acid synthesis defect, congenital, 3,	PIRSF000047:cytochrome P450, CYP7A1 type,		KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,KW-0988~Intrahepatic cholestasis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,REGION:Disordered,TRANSMEM:Helical,
CYB5R3	cytochrome b5 reductase 3(CYB5R3)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0006809~nitric oxide biosynthetic process,GO:0008015~blood circulation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0005833~hemoglobin complex,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0035578~azurophil granule lumen,GO:1903958~nitric-oxide synthase complex,	GO:0004128~cytochrome-b5 reductase activity, acting on NAD(P)H,GO:0005515~protein binding,GO:0016208~AMP binding,GO:0016491~oxidoreductase activity,GO:0043531~ADP binding,GO:0050421~nitrite reductase (NO-forming) activity,GO:0051287~NAD binding,GO:0071949~FAD binding,	IPR001433:Oxidoreductase FAD/NAD(P)-binding,IPR001709:Flavoprotein pyridine nucleotide cytochrome reductase,IPR001834:NADH:cytochrome b5 reductase (CBR),IPR008333:Oxidoreductase, FAD-binding domain,IPR017927:Ferredoxin reductase-type FAD-binding domain,IPR017938:Riboflavin synthase-like beta-barrel,	hsa00520:Amino sugar and nucleotide sugar metabolism,	250800~Methemoglobinemia, type I,250800~Methemoglobinemia, type II,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:FAD-binding FR-type,LIPID:N-myristoyl glycine,MUTAGEN:C->A: Loss of 30% of NADH-cytochrome b5 reductase activity.,MUTAGEN:C->A: Loss of 80% of NADH-cytochrome b5 reductase activity.,MUTAGEN:C->S: No effect on NADH-cytochrome b5 reductase activity.,MUTAGEN:F->A: Decreases protein stability and slightly decreases NADH-cytochrome b5 reductase activity.,MUTAGEN:F->L: No effect on protein stability and NADH-cytochrome b5 reductase activity.,MUTAGEN:FVF->LVL: No effect on protein stability and NADH-cytochrome b5 reductase activity.,MUTAGEN:S->A: Decreased NADH-cytochrome b5 reductase activity, highly increases Km for NADH and decreases Kcat.,REGION:Disordered,TRANSMEM:Helical,
COX4I2	cytochrome c oxidase subunit 4I2(COX4I2)	Homo sapiens			GO:0006091~generation of precursor metabolites and energy,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005751~mitochondrial respiratory chain complex IV,GO:0016021~integral component of membrane,	GO:0004129~cytochrome-c oxidase activity,	IPR004203:Cytochrome c oxidase subunit IV family,IPR013288:Cytochrome c oxidase subunit IV,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	612714~Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
CYTL1	cytokine like 1(CYTL1)	Homo sapiens			GO:0002062~chondrocyte differentiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,GO:0050650~chondroitin sulfate proteoglycan biosynthetic process,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:1990079~cartilage homeostasis,	GO:0005615~extracellular space,	GO:0005102~receptor binding,							KW-0964~Secreted,		KW-0732~Signal,
CPEB1	cytoplasmic polyadenylation element binding protein 1(CPEB1)	Homo sapiens			GO:0006397~mRNA processing,GO:0006412~translation,GO:0032869~cellular response to insulin stimulus,GO:0071230~cellular response to amino acid stimulus,GO:0071456~cellular response to hypoxia,GO:1900365~positive regulation of mRNA polyadenylation,GO:2000766~negative regulation of cytoplasmic translation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0045202~synapse,GO:1990124~messenger ribonucleoprotein complex,	GO:0000900~translation repressor activity, nucleic acid binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0008135~translation factor activity, RNA binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0043022~ribosome binding,GO:0045182~translation regulator activity,GO:0046872~metal ion binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,				KW-0507~mRNA processing,KW-0810~Translation regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Cytoplasmic polyadenylation element-binding protein 1 N-terminal,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:F->A: Abolishes stress granule assembly and correct localization in dcp1 bodies.,MUTAGEN:H->A: Abolishes stress granule assembly and correct localization in dcp1 bodies.,MUTAGEN:T->A: Does not affect its localization.,MUTAGEN:T->D: Does not affect its localization.,REGION:Disordered,REGION:Necessary for stress granule assembly and correct localization in dcp1 bodies,SITE:Important for the positionning of RRM1 relative to RRM2,
CRTAM	cytotoxic and regulatory T cell molecule(CRTAM)	Homo sapiens			GO:0001768~establishment of T cell polarity,GO:0001819~positive regulation of cytokine production,GO:0002250~adaptive immune response,GO:0002355~detection of tumor cell,GO:0002860~positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0008037~cell recognition,GO:0032729~positive regulation of interferon-gamma production,GO:0045580~regulation of T cell differentiation,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046007~negative regulation of activated T cell proliferation,GO:0050863~regulation of T cell activation,GO:0051606~detection of stimulus,GO:0097021~lymphocyte migration into lymphoid organs,GO:2001185~regulation of CD8-positive, alpha-beta T cell activation,	GO:0001772~immunological synapse,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005102~receptor binding,GO:0042802~identical protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0130~Cell adhesion,KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,MOTIF:PDZ-binding,MUTAGEN:F->A: Reduced binding to CADM1. Severely impairs interaction with CADM1; when associated with A-57, A-67 and A-101.,MUTAGEN:K->A: Reduced binding to CADM1. Severely impairs interaction with CADM1; when associated with A-56, A-57 and A-101.,MUTAGEN:T->A: Reduced binding to CADM1. Severely impairs interaction with CADM1; when associated with A-56, A-67 and A-101.,MUTAGEN:Y->A: Reduced binding to CADM1. Severely impairs interaction with CADM1; when associated with A-56, A-57 and A-67.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DLEU7	deleted in lymphocytic leukemia 7(DLEU7)	Homo sapiens																		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
DLK1	delta like non-canonical Notch ligand 1(DLK1)	Homo sapiens			GO:0030154~cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR013032:EGF-like, conserved site,				SM00179:EGF_CA,SM00181:EGF,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical; partial,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) serine; partial,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (GalNAc...) threonine; partial,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DTX1	deltex E3 ubiquitin ligase 1(DTX1)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0007166~cell surface receptor signaling pathway,GO:0007219~Notch signaling pathway,GO:0008593~regulation of Notch signaling pathway,GO:0010001~glial cell differentiation,GO:0016567~protein ubiquitination,GO:0030217~T cell differentiation,GO:0045581~negative regulation of T cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0003713~transcription coactivator activity,GO:0005112~Notch binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017124~SH3 domain binding,GO:0031625~ubiquitin protein ligase binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR004170:WWE domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR018123:WWE domain, subgroup,IPR018957:Zinc finger, C3HC4 RING-type,	hsa04330:Notch signaling pathway,			SM00184:RING,SM00678:WWE,	KW-0914~Notch signaling pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0729~SH3-binding,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:WWE 1,DOMAIN:WWE 2,MOTIF:SH3-binding,REGION:Disordered,ZN_FING:RING-type,
DSE	dermatan sulfate epimerase(DSE)	Homo sapiens			GO:0015012~heparan sulfate proteoglycan biosynthetic process,GO:0030204~chondroitin sulfate metabolic process,GO:0030205~dermatan sulfate metabolic process,GO:0030206~chondroitin sulfate biosynthetic process,GO:0030208~dermatan sulfate biosynthetic process,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,	GO:0016853~isomerase activity,GO:0046872~metal ion binding,GO:0047757~chondroitin-glucuronate 5-epimerase activity,	IPR008929:Chondroitin AC/alginate lyase,	hsa00532:Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,hsa01100:Metabolic pathways,	615539~Ehlers-Danlos syndrome, musculocontractural type 2,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0492~Microsome,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0413~Isomerase,	KW-0325~Glycoprotein,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) (paucimannose) asparagine,DOMAIN:Heparinase II N-terminal,MUTAGEN:D->A: Impairs catalytic activity.,MUTAGEN:E->A: Abolishes catalytic activity.,MUTAGEN:H->A,N: Abolishes catalytic activity.,MUTAGEN:H->A,N: Severely impairs catalytic activity.,MUTAGEN:H->A: Abolishes catalytic activity.,MUTAGEN:K->A: No significant effect on catalytic activity.,MUTAGEN:P->A: Very low levels of protein expression and no detectable catalytic activity.,MUTAGEN:W->A: Severely impairs catalytic activity.,MUTAGEN:Y->A,F: Abolishes catalytic activity.,MUTAGEN:Y->A: Abolishes catalytic activity.,MUTAGEN:Y->A: Moderately reduced catalytic activity.,SITE:Critical for catalysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
DES	desmin(DES)	Homo sapiens			GO:0006936~muscle contraction,GO:0007010~cytoskeleton organization,GO:0008016~regulation of heart contraction,GO:0045109~intermediate filament organization,GO:0060538~skeletal muscle organ development,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0005911~cell-cell junction,GO:0005916~fascia adherens,GO:0014704~intercalated disc,GO:0030018~Z disc,GO:0031594~neuromuscular junction,GO:0042383~sarcolemma,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,GO:0097512~cardiac myofibril,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0042802~identical protein binding,	IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,	hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	181400~Scapuloperoneal syndrome, neurogenic, Kaeser type,601419~Myopathy, myofibrillar, 1,604765~Cardiomyopathy, dilated, 1I,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0911~Desmin-related myopathy,KW-0947~Limb-girdle muscular dystrophy,KW-1060~Myofibrillar myopathy,	KW-0175~Coiled coil,		KW-0514~Muscle protein,	KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:IF rod,MUTAGEN:A->E,R: Results in impaired filaments formation.,MUTAGEN:A->K,L,V: Does not result in impaired filaments formation.,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Head,REGION:Interaction with CRYAB,REGION:Interaction with NEB,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,
DSC3	desmocollin 3(DSC3)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0048731~system development,GO:0050821~protein stabilization,GO:0098609~cell-cell adhesion,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0030057~desmosome,	GO:0005509~calcium ion binding,GO:0045295~gamma-catenin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR009122:Desmosomal cadherin,IPR014868:Cadherin prodomain,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,		613102~Hypotrichosis and recurrent skin vesicles,		SM00112:CA,SM01055:SM01055,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-1063~Hypotrichosis,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DBX2	developing brain homeobox 2(DBX2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0238~DNA-binding,		DNA_BIND:Homeobox,REGION:Disordered,
DPPA2	developmental pluripotency associated 2(DPPA2)	Homo sapiens			GO:0048731~system development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR003034:SAP domain,IPR025891:Developmental pluripotency-associated protein 2/4, C-terminal domain,IPR025892:Developmental pluripotency-associated protein 2/4, central domain,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,						DOMAIN:SAP,REGION:Disordered,
DRG2	developmentally regulated GTP binding protein 2(DRG2)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0007165~signal transduction,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0046872~metal ion binding,	IPR004095:TGS,IPR005225:Small GTP-binding protein domain,IPR006073:GTP binding domain,IPR006074:GTP1/OBG, conserved site,IPR012675:Beta-grasp domain,IPR012676:TGS-like,IPR027417:P-loop containing nucleoside triphosphate hydrolase,						KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0379~Hydroxylation,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:OBG-type G,DOMAIN:TGS,MUTAGEN:K->A: Impairs JMJD7-mediated hydroxylation and ribonucleic acid binding.,REGION:Disordered,
DGKG	diacylglycerol kinase gamma(DGKG)	Homo sapiens			GO:0006654~phosphatidic acid biosynthetic process,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0030168~platelet activation,GO:0035556~intracellular signal transduction,GO:0046339~diacylglycerol metabolic process,GO:0046486~glycerolipid metabolic process,GO:0046834~lipid phosphorylation,GO:0048666~neuron development,GO:0050773~regulation of dendrite development,GO:0090038~negative regulation of protein kinase C signaling,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003951~NAD+ kinase activity,GO:0004143~diacylglycerol kinase activity,GO:0005509~calcium ion binding,GO:0005524~ATP binding,GO:0008289~lipid binding,	IPR000756:Diacylglycerol kinase, accessory domain,IPR001206:Diacylglycerol kinase, catalytic domain,IPR002048:EF-hand domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR011992:EF-hand-like domain,IPR016064:ATP-NAD kinase-like domain,IPR017438:Inorganic polyphosphate/ATP-NAD kinase, domain 1,IPR018247:EF-Hand 1, calcium-binding site,IPR020454:Diacylglycerol/phorbol-ester binding,	hsa00561:Glycerolipid metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04072:Phospholipase D signaling pathway,hsa05231:Choline metabolism in cancer,			SM00045:DAGKa,SM00046:DAGKc,SM00054:EFh,SM00109:C1,	KW-0443~Lipid metabolism,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:DAGKc,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Phorbol-ester/DAG-type,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
DGKZ	diacylglycerol kinase zeta(DGKZ)	Homo sapiens			GO:0006654~phosphatidic acid biosynthetic process,GO:0007165~signal transduction,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0016477~cell migration,GO:0030168~platelet activation,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0035556~intracellular signal transduction,GO:0045930~negative regulation of mitotic cell cycle,GO:0046339~diacylglycerol metabolic process,GO:0046486~glycerolipid metabolic process,GO:0046834~lipid phosphorylation,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0090216~positive regulation of 1-phosphatidylinositol-4-phosphate 5-kinase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030027~lamellipodium,	GO:0001727~lipid kinase activity,GO:0003951~NAD+ kinase activity,GO:0004143~diacylglycerol kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0016301~kinase activity,GO:0046872~metal ion binding,	IPR000756:Diacylglycerol kinase, accessory domain,IPR001206:Diacylglycerol kinase, catalytic domain,IPR002110:Ankyrin repeat,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR016064:ATP-NAD kinase-like domain,IPR017438:Inorganic polyphosphate/ATP-NAD kinase, domain 1,	hsa00561:Glycerolipid metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04072:Phospholipase D signaling pathway,hsa05231:Choline metabolism in cancer,			SM00045:DAGKa,SM00046:DAGKc,SM00109:C1,SM00248:ANK,	KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:DAGKc,DOMAIN:Diacylglycerol kinase accessory,DOMAIN:Phorbol-ester/DAG-type,MOTIF:Nuclear export signal,MOTIF:PDZ-binding,MUTAGEN:TA->NS: Loss of interaction with SNTG1.,REGION:Disordered,REGION:MARCKS homology,REGION:Mediates interaction with RASGRP1,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
DKK1	dickkopf WNT signaling pathway inhibitor 1(DKK1)	Homo sapiens		h_wnt-Lrp6Pathway:Wnt/LRP6 Signalling,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000902~cell morphogenesis,GO:0000904~cell morphogenesis involved in differentiation,GO:0001706~endoderm formation,GO:0001707~mesoderm formation,GO:0001942~hair follicle development,GO:0002090~regulation of receptor internalization,GO:0003170~heart valve development,GO:0003197~endocardial cushion development,GO:0007611~learning or memory,GO:0010628~positive regulation of gene expression,GO:0010942~positive regulation of cell death,GO:0010977~negative regulation of neuron projection development,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030279~negative regulation of ossification,GO:0030326~embryonic limb morphogenesis,GO:0030514~negative regulation of BMP signaling pathway,GO:0030900~forebrain development,GO:0032091~negative regulation of protein binding,GO:0032526~response to retinoic acid,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0042662~negative regulation of mesodermal cell fate specification,GO:0042663~regulation of endodermal cell fate specification,GO:0043066~negative regulation of apoptotic process,GO:0043507~positive regulation of JUN kinase activity,GO:0043523~regulation of neuron apoptotic process,GO:0045813~positive regulation of Wnt signaling pathway, calcium modulating pathway,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060070~canonical Wnt signaling pathway,GO:0060173~limb development,GO:0060325~face morphogenesis,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0061743~motor learning,GO:0090082~positive regulation of heart induction by negative regulation of canonical Wnt signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090244~Wnt signaling pathway involved in somitogenesis,GO:0090647~modulation of age-related behavioral decline,GO:0098883~synapse disassembly,GO:1901216~positive regulation of neuron death,GO:1901296~negative regulation of canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment,GO:1902949~positive regulation of tau-protein kinase activity,GO:1904338~regulation of dopaminergic neuron differentiation,GO:1904723~negative regulation of Wnt-Frizzled-LRP5/6 complex assembly,GO:1904958~positive regulation of midbrain dopaminergic neuron differentiation,GO:1905607~negative regulation of presynapse assembly,GO:2000096~positive regulation of Wnt signaling pathway, planar cell polarity pathway,GO:2000726~negative regulation of cardiac muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0031901~early endosome membrane,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0039706~co-receptor binding,GO:0048019~receptor antagonist activity,GO:0050750~low-density lipoprotein particle receptor binding,	IPR006796:Dickkopf, N-terminal cysteine-rich,	hsa04310:Wnt signaling pathway,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,DOMAIN:Dickkopf N-terminal cysteine-rich,REGION:DKK-type Cys-1,REGION:DKK-type Cys-2,
DKK2	dickkopf WNT signaling pathway inhibitor 2(DKK2)	Homo sapiens		h_wnt-Lrp6Pathway:Wnt/LRP6 Signalling,	GO:0016055~Wnt signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0039706~co-receptor binding,GO:0048019~receptor antagonist activity,	IPR006796:Dickkopf, N-terminal cysteine-rich,	hsa04310:Wnt signaling pathway,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Dickkopf N-terminal cysteine-rich,REGION:DKK-type Cys-1,REGION:DKK-type Cys-2,
DKK3	dickkopf WNT signaling pathway inhibitor 3(DKK3)	Homo sapiens			GO:0009653~anatomical structure morphogenesis,GO:0016055~Wnt signaling pathway,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030325~adrenal gland development,GO:0032348~negative regulation of aldosterone biosynthetic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1902613~negative regulation of anti-Mullerian hormone signaling pathway,GO:2000065~negative regulation of cortisol biosynthetic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0039706~co-receptor binding,GO:0048019~receptor antagonist activity,	IPR006796:Dickkopf, N-terminal cysteine-rich,					KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Dickkopf N-terminal cysteine-rich,REGION:DKK-type Cys-1,REGION:DKK-type Cys-2,REGION:Disordered,REGION:O-glycosylated at one site,
DPYS	dihydropyrimidinase(DPYS)	Homo sapiens			GO:0006208~pyrimidine nucleobase catabolic process,GO:0006210~thymine catabolic process,GO:0006212~uracil catabolic process,GO:0006248~CMP catabolic process,GO:0006249~dCMP catabolic process,GO:0046050~UMP catabolic process,GO:0046079~dUMP catabolic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004157~dihydropyrimidinase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016810~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds,GO:0042802~identical protein binding,GO:0051219~phosphoprotein binding,	IPR006680:Amidohydrolase 1,IPR011059:Metal-dependent hydrolase, composite domain,IPR011778:Hydantoinase/dihydropyrimidinase,	hsa00240:Pyrimidine metabolism,hsa00410:beta-Alanine metabolism,hsa00770:Pantothenate and CoA biosynthesis,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,	222748~Dihydropyrimidinuria,					KW-0225~Disease variant,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	BINDING:via carbamate group,REGION:Disordered,
DPH1	diphthamide biosynthesis 1(DPH1)	Homo sapiens			GO:0017183~peptidyl-diphthamide biosynthetic process from peptidyl-histidine,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0030054~cell junction,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051539~4 iron, 4 sulfur cluster binding,GO:0090560~2-(3-amino-3-carboxypropyl)histidine synthase activity,	IPR016435:Diphthamide synthesis, eukaryotic DPH1/archaeal DPH2,		616901~Developmental delay with short stature, dysmorphic facial features, and sparse hair,	PIRSF004967:diphthamide biosynthesis protein 1,			KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,KW-1063~Hypotrichosis,	KW-0732~Signal,	KW-0004~4Fe-4S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0949~S-adenosyl-L-methionine,	KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
DDR2	discoidin domain receptor tyrosine kinase 2(DDR2)	Homo sapiens			GO:0001503~ossification,GO:0003416~endochondral bone growth,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0010715~regulation of extracellular matrix disassembly,GO:0010763~positive regulation of fibroblast migration,GO:0010976~positive regulation of neuron projection development,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030199~collagen fibril organization,GO:0030500~regulation of bone mineralization,GO:0031214~biomineral tissue development,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033674~positive regulation of kinase activity,GO:0034103~regulation of tissue remodeling,GO:0035988~chondrocyte proliferation,GO:0035994~response to muscle stretch,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0045669~positive regulation of osteoblast differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046777~protein autophosphorylation,GO:0048146~positive regulation of fibroblast proliferation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0071456~cellular response to hypoxia,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090091~positive regulation of extracellular matrix disassembly,GO:0090303~positive regulation of wound healing,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901299~negative regulation of hydrogen peroxide-mediated programmed cell death,GO:1904385~cellular response to angiotensin,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1904899~positive regulation of hepatic stellate cell proliferation,GO:2000491~positive regulation of hepatic stellate cell activation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016324~apical plasma membrane,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0005524~ATP binding,GO:0038062~protein tyrosine kinase collagen receptor activity,	IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002011:Tyrosine-protein kinase, receptor class II, conserved site,IPR008266:Tyrosine-protein kinase, active site,IPR008979:Galactose-binding domain-like,IPR011009:Protein kinase-like domain,IPR020635:Tyrosine-protein kinase, catalytic domain,		271665~Spondylometaepiphyseal dysplasia, short limb-hand type,618175~Warburg-Cinotti syndrome,		SM00219:TyrKc,SM00231:FA58C,	KW-0892~Osteogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:F5/8 type C,DOMAIN:Protein kinase,MUTAGEN:K->A: Abolishes kinase activity.,MUTAGEN:W->A: Abolishes collagen binding.,MUTAGEN:Y->F: Promotes autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-741.,MUTAGEN:Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-740.,MUTAGEN:Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-740 and F-741.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DLG4	discs large MAGUK scaffold protein 4(DLG4)	Homo sapiens		h_nos1Pathway:Nitric Oxide Signaling Pathway,h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,	GO:0002091~negative regulation of receptor internalization,GO:0007165~signal transduction,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007268~chemical synaptic transmission,GO:0007399~nervous system development,GO:0007612~learning,GO:0009790~embryo development,GO:0016188~synaptic vesicle maturation,GO:0035176~social behavior,GO:0035418~protein localization to synapse,GO:0035641~locomotory exploration behavior,GO:0035865~cellular response to potassium ion,GO:0043113~receptor clustering,GO:0045184~establishment of protein localization,GO:0045197~establishment or maintenance of epithelial cell apical/basal polarity,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0050806~positive regulation of synaptic transmission,GO:0050885~neuromuscular process controlling balance,GO:0060997~dendritic spine morphogenesis,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0065003~macromolecular complex assembly,GO:0071625~vocalization behavior,GO:0097113~AMPA glutamate receptor clustering,GO:0097120~receptor localization to synapse,GO:0098609~cell-cell adhesion,GO:0098970~postsynaptic neurotransmitter receptor diffusion trapping,GO:0099645~neurotransmitter receptor localization to postsynaptic specialization membrane,GO:1904719~positive regulation of AMPA glutamate receptor clustering,GO:2000310~regulation of NMDA receptor activity,GO:2000463~positive regulation of excitatory postsynaptic potential,GO:2000821~regulation of grooming behavior,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0008021~synaptic vesicle,GO:0008076~voltage-gated potassium channel complex,GO:0014069~postsynaptic density,GO:0016323~basolateral plasma membrane,GO:0030054~cell junction,GO:0030666~endocytic vesicle membrane,GO:0030863~cortical cytoskeleton,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031594~neuromuscular junction,GO:0032281~AMPA glutamate receptor complex,GO:0032839~dendrite cytoplasm,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0044224~juxtaparanode region of axon,GO:0044300~cerebellar mossy fiber,GO:0044306~neuron projection terminus,GO:0044309~neuron spine,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0060076~excitatory synapse,GO:0097060~synaptic membrane,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099031~anchored component of postsynaptic density membrane,	GO:0005109~frizzled binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0019865~immunoglobulin binding,GO:0019894~kinesin binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030165~PDZ domain binding,GO:0031697~beta-1 adrenergic receptor binding,GO:0031698~beta-2 adrenergic receptor binding,GO:0031748~D1 dopamine receptor binding,GO:0031812~P2Y1 nucleotide receptor binding,GO:0033130~acetylcholine receptor binding,GO:0035255~ionotropic glutamate receptor binding,GO:0044877~macromolecular complex binding,GO:0097109~neuroligin family protein binding,GO:0097110~scaffold protein binding,GO:0098919~structural constituent of postsynaptic density,	IPR001452:Src homology-3 domain,IPR001478:PDZ domain,IPR008144:Guanylate kinase,IPR008145:Guanylate kinase/L-type calcium channel,IPR016313:Membrane-associated guanylate kinase (MAGUK) scaffold protein,IPR019583:PDZ-associated domain of NMDA receptors,IPR019590:Membrane-associated guanylate kinase (MAGUK), PEST domain, N-terminal,IPR020590:Guanylate kinase, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04390:Hippo signaling pathway,hsa04724:Glutamatergic synapse,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,	618793~Intellectual developmental disorder, autosomal dominant 62,	PIRSF001741:membrane-associated guanylate kinase (MAGUK) scaffold protein,	SM00072:GuKc,SM00228:PDZ,SM00326:SH3,SM01277:SM01277,		KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0728~SH3 domain,KW-0732~Signal,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Disks large homologue 1 N-terminal PEST,DOMAIN:Guanylate kinase-like,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,DOMAIN:SH3,LIPID:S-palmitoyl cysteine,REGION:Disordered,
DLX1	distal-less homeobox 1(DLX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0009790~embryo development,GO:0009954~proximal/distal pattern formation,GO:0014016~neuroblast differentiation,GO:0021544~subpallium development,GO:0021766~hippocampus development,GO:0021879~forebrain neuron differentiation,GO:0021893~cerebral cortex GABAergic interneuron fate commitment,GO:0030154~cell differentiation,GO:0030514~negative regulation of BMP signaling pathway,GO:0042475~odontogenesis of dentin-containing tooth,GO:0043524~negative regulation of neuron apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046533~negative regulation of photoreceptor cell differentiation,GO:0048706~embryonic skeletal system development,GO:0048709~oligodendrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0051402~neuron apoptotic process,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071773~cellular response to BMP stimulus,GO:1902871~positive regulation of amacrine cell differentiation,GO:1903845~negative regulation of cellular response to transforming growth factor beta stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
DLX4	distal-less homeobox 4(DLX4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009790~embryo development,GO:0030154~cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		616788~Orofacial cleft 15,		SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,REGION:Disordered,
DDC	dopa decarboxylase(DDC)	Homo sapiens			GO:0006520~cellular amino acid metabolic process,GO:0006584~catecholamine metabolic process,GO:0007623~circadian rhythm,GO:0009636~response to toxic substance,GO:0010259~multicellular organism aging,GO:0015842~aminergic neurotransmitter loading into synaptic vesicle,GO:0033076~isoquinoline alkaloid metabolic process,GO:0042416~dopamine biosynthetic process,GO:0042423~catecholamine biosynthetic process,GO:0042427~serotonin biosynthetic process,GO:0046684~response to pyrethroid,GO:0052314~phytoalexin metabolic process,GO:0071312~cellular response to alkaloid,GO:0071363~cellular response to growth factor stimulus,GO:0071466~cellular response to xenobiotic stimulus,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,	GO:0004058~aromatic-L-amino-acid decarboxylase activity,GO:0005515~protein binding,GO:0016597~amino acid binding,GO:0016831~carboxy-lyase activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0030170~pyridoxal phosphate binding,GO:0036467~5-hydroxy-L-tryptophan decarboxylase activity,GO:0036468~L-dopa decarboxylase activity,	IPR002129:Pyridoxal phosphate-dependent decarboxylase,IPR010977:Aromatic-L-amino-acid decarboxylase,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,IPR021115:Pyridoxal-phosphate binding site,	hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa00380:Tryptophan metabolism,hsa01100:Metabolic pathways,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,	608643~Aromatic L-amino acid decarboxylase deficiency,			KW-0127~Catecholamine biosynthesis,		KW-0225~Disease variant,	KW-0677~Repeat,	KW-0663~Pyridoxal phosphate,	KW-0210~Decarboxylase,KW-0456~Lyase,	KW-0007~Acetylation,	REGION:2 X approximate tandem repeats,REPEAT:1,REPEAT:2,
DRD2	dopamine receptor D2(DRD2)	Homo sapiens		h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,	GO:0001659~temperature homeostasis,GO:0001666~response to hypoxia,GO:0001933~negative regulation of protein phosphorylation,GO:0001975~response to amphetamine,GO:0001976~neurological system process involved in regulation of systemic arterial blood pressure,GO:0002027~regulation of heart rate,GO:0002028~regulation of sodium ion transport,GO:0002031~G-protein coupled receptor internalization,GO:0002052~positive regulation of neuroblast proliferation,GO:0002092~positive regulation of receptor internalization,GO:0006874~cellular calcium ion homeostasis,GO:0006914~autophagy,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007195~adenylate cyclase-inhibiting dopamine receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007270~neuron-neuron synaptic transmission,GO:0007405~neuroblast proliferation,GO:0007409~axonogenesis,GO:0007416~synapse assembly,GO:0007608~sensory perception of smell,GO:0007616~long-term memory,GO:0007625~grooming behavior,GO:0007626~locomotory behavior,GO:0007628~adult walking behavior,GO:0008104~protein localization,GO:0008285~negative regulation of cell proliferation,GO:0008306~associative learning,GO:0008542~visual learning,GO:0009410~response to xenobiotic stimulus,GO:0009416~response to light stimulus,GO:0009636~response to toxic substance,GO:0010039~response to iron ion,GO:0014059~regulation of dopamine secretion,GO:0014854~response to inactivity,GO:0016055~Wnt signaling pathway,GO:0021756~striatum development,GO:0021769~orbitofrontal cortex development,GO:0021853~cerebral cortex GABAergic interneuron migration,GO:0021984~adenohypophysis development,GO:0030336~negative regulation of cell migration,GO:0030432~peristalsis,GO:0031223~auditory behavior,GO:0032147~activation of protein kinase activity,GO:0032228~regulation of synaptic transmission, GABAergic,GO:0032467~positive regulation of cytokinesis,GO:0032922~circadian regulation of gene expression,GO:0033602~negative regulation of dopamine secretion,GO:0034776~response to histamine,GO:0035094~response to nicotine,GO:0035556~intracellular signal transduction,GO:0035810~positive regulation of urine volume,GO:0035815~positive regulation of renal sodium excretion,GO:0040018~positive regulation of multicellular organism growth,GO:0042220~response to cocaine,GO:0042321~negative regulation of circadian sleep/wake cycle, sleep,GO:0042417~dopamine metabolic process,GO:0042756~drinking behavior,GO:0043266~regulation of potassium ion transport,GO:0043278~response to morphine,GO:0043473~pigmentation,GO:0043491~protein kinase B signaling,GO:0043666~regulation of phosphoprotein phosphatase activity,GO:0045745~positive regulation of G-protein coupled receptor protein signaling pathway,GO:0045776~negative regulation of blood pressure,GO:0045824~negative regulation of innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046676~negative regulation of insulin secretion,GO:0046717~acid secretion,GO:0048148~behavioral response to cocaine,GO:0048149~behavioral response to ethanol,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048678~response to axon injury,GO:0048755~branching morphogenesis of a nerve,GO:0050482~arachidonic acid secretion,GO:0050673~epithelial cell proliferation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050709~negative regulation of protein secretion,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0051583~dopamine uptake involved in synaptic transmission,GO:0051584~regulation of dopamine uptake involved in synaptic transmission,GO:0051586~positive regulation of dopamine uptake involved in synaptic transmission,GO:0051823~regulation of synapse structural plasticity,GO:0051898~negative regulation of protein kinase B signaling,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0060079~excitatory postsynaptic potential,GO:0060124~positive regulation of growth hormone secretion,GO:0060134~prepulse inhibition,GO:0060158~phospholipase C-activating dopamine receptor signaling pathway,GO:0060160~negative regulation of dopamine receptor signaling pathway,GO:0060548~negative regulation of cell death,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071880~adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0090325~regulation of locomotion involved in locomotory behavior,GO:1900038~negative regulation of cellular response to hypoxia,GO:1900168~positive regulation of glial cell-derived neurotrophic factor secretion,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1901386~negative regulation of voltage-gated calcium channel activity,GO:1903530~regulation of secretion by cell,GO:1990384~hyaloid vascular plexus regression,GO:2000300~regulation of synaptic vesicle exocytosis,GO:2001223~negative regulation of neuron migration,	GO:0000139~Golgi membrane,GO:0001669~acrosomal vesicle,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005929~cilium,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0016328~lateral plasma membrane,GO:0030139~endocytic vesicle,GO:0030424~axon,GO:0030425~dendrite,GO:0030672~synaptic vesicle membrane,GO:0036126~sperm flagellum,GO:0042734~presynaptic membrane,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0043679~axon terminus,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0060170~ciliary membrane,GO:0097648~G-protein coupled receptor complex,GO:0097730~non-motile cilium,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001591~dopamine neurotransmitter receptor activity, coupled via Gi/Go,GO:0001965~G-protein alpha-subunit binding,GO:0004930~G-protein coupled receptor activity,GO:0004952~dopamine neurotransmitter receptor activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0032795~heterotrimeric G-protein binding,GO:0035240~dopamine binding,GO:0035255~ionotropic glutamate receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:1901363~heterocyclic compound binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000929:Dopamine receptor family,IPR001922:Dopamine D2 receptor,IPR002110:Ankyrin repeat,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04540:Gap junction,hsa04728:Dopaminergic synapse,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05034:Alcoholism,			SM00248:ANK,SM01381:SM01381,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: No effect on palmitoylation; no effect on localization to the plasma membrane.,MUTAGEN:Missing: Decreased palmitoylation; decreased localization to the plasma membrane; decreased stability.,REGION:Disordered,REGION:Interaction with PPP1R9B,REPEAT:ANK,SITE:Important for receptor activation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
DCLK3	doublecortin like kinase 3(DCLK3)	Homo sapiens			GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:1900181~negative regulation of protein localization to nucleus,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR003533:Doublecortin domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,SM00537:DCX,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Doublecortin,DOMAIN:Protein kinase,REGION:Disordered,
DUOX1	dual oxidase 1(DUOX1)	Homo sapiens			GO:0006590~thyroid hormone generation,GO:0006952~defense response,GO:0006979~response to oxidative stress,GO:0019221~cytokine-mediated signaling pathway,GO:0042335~cuticle development,GO:0042446~hormone biosynthetic process,GO:0042554~superoxide anion generation,GO:0042744~hydrogen peroxide catabolic process,GO:0050665~hydrogen peroxide biosynthetic process,GO:0051591~response to cAMP,GO:0090303~positive regulation of wound healing,GO:0098869~cellular oxidant detoxification,GO:2000147~positive regulation of cell motility,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031252~cell leading edge,GO:0043020~NADPH oxidase complex,	GO:0004601~peroxidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0016174~NAD(P)H oxidase activity,GO:0016175~superoxide-generating NADPH oxidase activity,GO:0020037~heme binding,GO:0050661~NADP binding,	IPR000778:Cytochrome b245, heavy chain,IPR002048:EF-hand domain,IPR010255:Haem peroxidase,IPR011992:EF-hand-like domain,IPR013112:FAD-binding 8,IPR013121:Ferric reductase, NAD binding,IPR013130:Ferric reductase transmembrane component-like domain,IPR017927:Ferredoxin reductase-type FAD-binding domain,IPR017938:Riboflavin synthase-like beta-barrel,IPR018247:EF-Hand 1, calcium-binding site,IPR019791:Haem peroxidase, animal, subgroup,	hsa04918:Thyroid hormone synthesis,			SM00054:EFh,	KW-0376~Hydrogen peroxide,KW-0893~Thyroid hormones biosynthesis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0274~FAD,KW-0285~Flavoprotein,KW-0479~Metal-binding,KW-0521~NADP,	KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:FAD-binding FR-type,DOMAIN:Ferric oxidoreductase,REGION:Disordered,REGION:Interaction with TXNDC11,REGION:Peroxidase-like; mediates peroxidase activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DYRK2	dual specificity tyrosine phosphorylation regulated kinase 2(DYRK2)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0007224~smoothened signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0045725~positive regulation of glycogen biosynthetic process,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016021~integral component of membrane,GO:1990904~ribonucleoprotein complex,	GO:0000287~magnesium ion binding,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0030145~manganese ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,	KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MOTIF:Nuclear localization signal,MUTAGEN:K->R: Abolishes protein serine/threonine kinase activity.,MUTAGEN:KKR->NNN: Impaired nuclear translocation.,MUTAGEN:S->A: Impaired ATM-mediated phosphorylation, reduced affinity with MDM2 and altered MDM2-triggered ubiquitination.,MUTAGEN:T->A: Impaired ATM-mediated phosphorylation, reduced affinity with MDM2 and altered MDM2-triggered ubiquitination.,REGION:Disordered,TRANSMEM:Helical,
DCTN2	dynactin subunit 2(DCTN2)	Homo sapiens			GO:0007017~microtubule-based process,GO:0007052~mitotic spindle organization,GO:0007080~mitotic metaphase plate congression,GO:0032402~melanosome transport,GO:0071539~protein localization to centrosome,	GO:0000776~kinetochore,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0030286~dynein complex,GO:0030426~growth cone,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030507~spectrin binding,GO:0042802~identical protein binding,		hsa04814:Motor proteins,hsa04962:Vasopressin-regulated water reabsorption,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,					KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
DNM3	dynamin 3(DNM3)	Homo sapiens			GO:0006897~endocytosis,GO:0007416~synapse assembly,GO:0031623~receptor internalization,GO:0046847~filopodium assembly,GO:0048488~synaptic vesicle endocytosis,GO:0051491~positive regulation of filopodium assembly,GO:0061002~negative regulation of dendritic spine morphogenesis,GO:0098884~postsynaptic neurotransmitter receptor internalization,GO:1903423~positive regulation of synaptic vesicle recycling,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030424~axon,GO:0043083~synaptic cleft,GO:0043197~dendritic spine,GO:0044327~dendritic spine head,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0061828~apical tubulobulbar complex,GO:0061829~basal tubulobulbar complex,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098844~postsynaptic endocytic zone membrane,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0031798~type 1 metabotropic glutamate receptor binding,GO:0031802~type 5 metabotropic glutamate receptor binding,GO:0042802~identical protein binding,GO:0050998~nitric-oxide synthase binding,	IPR000375:Dynamin central domain,IPR001401:Dynamin, GTPase domain,IPR001849:Pleckstrin homology domain,IPR003130:Dynamin GTPase effector,IPR011993:Pleckstrin homology-like domain,IPR019762:Dynamin, GTPase region, conserved site,IPR020850:GTPase effector domain, GED,IPR022812:Dynamin,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05100:Bacterial invasion of epithelial cells,			SM00053:DYNc,SM00233:PH,SM00302:GED,	KW-0254~Endocytosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:Dynamin-type G,DOMAIN:GED,DOMAIN:PH,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
DNAH5	dynein axonemal heavy chain 5(DNAH5)	Homo sapiens			GO:0003341~cilium movement,GO:0003351~epithelial cilium movement,GO:0007018~microtubule-based movement,GO:0007368~determination of left/right symmetry,GO:0007507~heart development,GO:0021670~lateral ventricle development,GO:0030317~flagellated sperm motility,GO:0036158~outer dynein arm assembly,GO:0051649~establishment of localization in cell,GO:0060271~cilium assembly,GO:0060294~cilium movement involved in cell motility,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005929~cilium,GO:0005930~axoneme,GO:0030286~dynein complex,GO:0031514~motile cilium,GO:0036157~outer dynein arm,GO:0097728~9+0 motile cilium,GO:0097729~9+2 motile cilium,	GO:0005524~ATP binding,GO:0008569~ATP-dependent microtubule motor activity, minus-end-directed,GO:0016887~ATPase activity,GO:0045505~dynein intermediate chain binding,GO:0051959~dynein light intermediate chain binding,	IPR003593:AAA+ ATPase domain,IPR004273:Dynein heavy chain domain,IPR013594:Dynein heavy chain, domain-1,IPR013602:Dynein heavy chain, domain-2,IPR024317:Dynein heavy chain, P-loop containing D4 domain,IPR024743:Dynein heavy chain, coiled coil stalk,IPR026983:Dynein heavy chain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04814:Motor proteins,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	608644~Ciliary dyskinesia, primary, 3, with or without situs inversus,		SM00382:AAA,		KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0990~Primary ciliary dyskinesia,KW-1012~Kartagener syndrome,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,		DOMAIN:AAA+ ATPase,DOMAIN:Dynein heavy chain hydrolytic ATP-binding dynein motor region,REGION:AAA 1,REGION:AAA 2,REGION:AAA 3,REGION:AAA 4,REGION:AAA 5,REGION:AAA 6,REGION:Stalk,REGION:Stem,
EVI5	ecotropic viral integration site 5(EVI5)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0007049~cell cycle,GO:0042147~retrograde transport, endosome to Golgi,GO:0043087~regulation of GTPase activity,GO:0043547~positive regulation of GTPase activity,GO:0051301~cell division,GO:0090630~activation of GTPase activity,	GO:0005634~nucleus,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR000195:Rab-GTPase-TBC domain,				SM00164:TBC,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rab-GAP TBC,REGION:Dimerization,REGION:Disordered,REGION:Interaction with AURKB and INCENP,REGION:Interaction with alpha-tubulin, gamma-tubulin, BIRC5 and FBXO5,REGION:Targeting to the centrosomes,SITE:Breakpoint for translocation to form EVI5-TRNG10 fusion protein,
ENTPD2	ectonucleoside triphosphate diphosphohydrolase 2(ENTPD2)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0009134~nucleoside diphosphate catabolic process,GO:0009181~purine ribonucleoside diphosphate catabolic process,GO:0030168~platelet activation,	GO:0005604~basement membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0004382~guanosine-diphosphatase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0017110~nucleoside-diphosphatase activity,GO:0017111~nucleoside-triphosphatase activity,GO:0045134~uridine-diphosphatase activity,	IPR000407:Nucleoside phosphatase GDA1/CD39,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa04742:Taste transduction,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:C->S: Abolishes ecto-ATPase activity, accumulates intracellularly.,MUTAGEN:N->D: 7% of wild-type ATPase activity, accumulates intracellularly.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ENPP2	ectonucleotide pyrophosphatase/phosphodiesterase 2(ENPP2)	Homo sapiens			GO:0006897~endocytosis,GO:0006935~chemotaxis,GO:0006955~immune response,GO:0009395~phospholipid catabolic process,GO:0010634~positive regulation of epithelial cell migration,GO:0030149~sphingolipid catabolic process,GO:0030334~regulation of cell migration,GO:0034638~phosphatidylcholine catabolic process,GO:0045765~regulation of angiogenesis,GO:0048870~cell motility,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:2000394~positive regulation of lamellipodium morphogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0003676~nucleic acid binding,GO:0004528~phosphodiesterase I activity,GO:0004551~nucleotide diphosphatase activity,GO:0004622~lysophospholipase activity,GO:0005044~scavenger receptor activity,GO:0005509~calcium ion binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0030247~polysaccharide binding,GO:0046872~metal ion binding,GO:0047391~alkylglycerophosphoethanolamine phosphodiesterase activity,	IPR001212:Somatomedin B domain,IPR001604:DNA/RNA non-specific endonuclease,IPR002591:Type I phosphodiesterase/nucleotide pyrophosphatase/phosphate transferase,IPR017850:Alkaline-phosphatase-like, core domain,IPR020436:Somatomedin B, chordata,IPR020821:Extracellular Endonuclease, subunit A,	hsa00565:Ether lipid metabolism,hsa01100:Metabolic pathways,			SM00201:SO,SM00477:NUC,SM00892:SM00892,	KW-0145~Chemotaxis,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0964~Secreted,	KW-0550~Obesity,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:DNA/RNA non-specific endonuclease,DOMAIN:Extracellular Endonuclease subunit A,DOMAIN:SMB,DOMAIN:SMB 1,DOMAIN:SMB 2,MOTIF:Cell attachment site,MUTAGEN:A->V: Reduces lysophospholipase activity by about 50%.,MUTAGEN:F->Y: Reduces lysophospholipase activity by about 70%.,MUTAGEN:H->Q: Loss of ability to hydrolyze sphingosylphosphorylcholine.,MUTAGEN:N->A: Strongly reduced lysophospholipase activity.,MUTAGEN:S->E: Reduces lysophospholipase activity by about 70%.,MUTAGEN:T->A: Loss of lysophospholipase activity and ability to hydrolyze sphingosylphosphorylcholine.,MUTAGEN:Y->Q: Reduces lysophospholipase activity by about 70%.,PROPEP:Removed by furin,REGION:Disordered,REGION:Required for secretion,SITE:Essential for catalytic activity,TRANSMEM:Helical,
EMILIN1	elastin microfibril interfacer 1(EMILIN1)	Homo sapiens			GO:0003180~aortic valve morphogenesis,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0008217~regulation of blood pressure,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010811~positive regulation of cell-substrate adhesion,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030194~positive regulation of blood coagulation,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033627~cell adhesion mediated by integrin,GO:0042127~regulation of cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0048251~elastic fiber assembly,GO:0050866~negative regulation of cell activation,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1900426~positive regulation of defense response to bacterium,GO:1900747~negative regulation of vascular endothelial growth factor signaling pathway,GO:1901203~positive regulation of extracellular matrix assembly,GO:1901731~positive regulation of platelet aggregation,GO:1904027~negative regulation of collagen fibril organization,GO:1905522~negative regulation of macrophage migration,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0034668~integrin alpha4-beta1 complex,GO:0070062~extracellular exosome,GO:1990971~EMILIN complex,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030023~extracellular matrix constituent conferring elasticity,GO:0042802~identical protein binding,GO:0060090~binding, bridging,GO:0098640~integrin binding involved in cell-matrix adhesion,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,IPR011489:EMI domain,		620080~Neuronopathy, distal hereditary motor, type X,		SM00110:C1Q,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0175~Coiled coil,KW-0176~Collagen,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C1q,DOMAIN:Collagen-like,DOMAIN:EMI,REGION:Disordered,
EFS	embryonal Fyn-associated substrate(EFS)	Homo sapiens			GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0016477~cell migration,GO:0035556~intracellular signal transduction,GO:0090527~actin filament reorganization,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005925~focal adhesion,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019904~protein domain specific binding,	IPR001452:Src homology-3 domain,IPR021901:CAS family, DUF3513,				SM00326:SH3,	KW-0130~Cell adhesion,			KW-0728~SH3 domain,KW-0729~SH3-binding,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:SH3,MOTIF:SH3-binding,REGION:Disordered,REGION:Divergent helix-loop-helix motif,
EMX2	empty spiracles homeobox 2(EMX2)	Homo sapiens			GO:0001764~neuron migration,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007417~central nervous system development,GO:0007420~brain development,GO:0009410~response to xenobiotic stimulus,GO:0009952~anterior/posterior pattern specification,GO:0021542~dentate gyrus development,GO:0021796~cerebral cortex regionalization,GO:0021846~cell proliferation in forebrain,GO:0021885~forebrain cell migration,GO:0030182~neuron differentiation,GO:0072197~ureter morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		269160~Schizencephaly,		SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
ERN1	endoplasmic reticulum to nucleus signaling 1(ERN1)	Homo sapiens			GO:0001935~endothelial cell proliferation,GO:0006379~mRNA cleavage,GO:0006402~mRNA catabolic process,GO:0006468~protein phosphorylation,GO:0016241~regulation of macroautophagy,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0033120~positive regulation of RNA splicing,GO:0034620~cellular response to unfolded protein,GO:0034976~response to endoplasmic reticulum stress,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036289~peptidyl-serine autophosphorylation,GO:0036498~IRE1-mediated unfolded protein response,GO:0043507~positive regulation of JUN kinase activity,GO:0046777~protein autophosphorylation,GO:0070054~mRNA splicing, via endonucleolytic cleavage and ligation,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070301~cellular response to hydrogen peroxide,GO:0071333~cellular response to glucose stimulus,GO:0098787~mRNA cleavage involved in mRNA processing,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1901142~insulin metabolic process,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1990579~peptidyl-serine trans-autophosphorylation,	GO:0005637~nuclear inner membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:1990332~Ire1 complex,GO:1990597~AIP1-IRE1 complex,GO:1990604~IRE1-TRAF2-ASK1 complex,GO:1990630~IRE1-RACK1-PP2A complex,	GO:0000287~magnesium ion binding,GO:0004521~endoribonuclease activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0030544~Hsp70 protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0051082~unfolded protein binding,GO:0051879~Hsp90 protein binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR010513:KEN domain,IPR011009:Protein kinase-like domain,IPR011047:Quinonprotein alcohol dehydrogenase-like superfamily,IPR015943:WD40/YVTN repeat-like-containing domain,IPR018391:Pyrrolo-quinoline quinone beta-propeller repeat,	hsa04140:Autophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,SM00564:PQQ,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0418~Kinase,KW-0511~Multifunctional enzyme,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:KEN,DOMAIN:Protein kinase,MUTAGEN:C->S: No effect on dimerization. No effect on interaction with P4HB; when associated with S-148 and S-332.,MUTAGEN:C->S: No effect on dimerization. Weakens dimer; when associated with S-148. No effect on interaction with P4HB; when associated with S-109 and S-148.,MUTAGEN:C->S: No effect on dimerization. Weakens dimer; when associated with S-332. Abolishes interaction with PDIA6. Prolonged splicing of XBP1, probably due to prolonged activation of PDIA6. Inhibits formation of oxidized multimeric forms of ERN1 in response to ER stress. No effect on interaction with P4HB; when associated with S-109 and S-332.,MUTAGEN:D->P: Abolishes ability to homodimerize.,MUTAGEN:K->A: Loss of autophosphorylation and of endoribonuclease activity. Inhibition of growth arrest.,MUTAGEN:Q->E: Impaired ability to homodimerize.,MUTAGEN:W->A: Abolishes ability to homodimerize.,REGION:Disordered,REGION:Interacts with hydroxy-aryl-aldehyde inhibitors,SITE:Interacts with hydroxy-aryl-aldehyde inhibitors,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
EDN3	endothelin 3(EDN3)	Homo sapiens			GO:0001755~neural crest cell migration,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0006874~cellular calcium ion homeostasis,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007275~multicellular organism development,GO:0007411~axon guidance,GO:0008015~blood circulation,GO:0008284~positive regulation of cell proliferation,GO:0010460~positive regulation of heart rate,GO:0010468~regulation of gene expression,GO:0010961~cellular magnesium ion homeostasis,GO:0014826~vein smooth muscle contraction,GO:0019229~regulation of vasoconstriction,GO:0030072~peptide hormone secretion,GO:0030318~melanocyte differentiation,GO:0030593~neutrophil chemotaxis,GO:0042310~vasoconstriction,GO:0043406~positive regulation of MAP kinase activity,GO:0045597~positive regulation of cell differentiation,GO:0045840~positive regulation of mitotic nuclear division,GO:0046887~positive regulation of hormone secretion,GO:0048016~inositol phosphate-mediated signaling,GO:0048070~regulation of developmental pigmentation,GO:0048675~axon extension,GO:0051649~establishment of localization in cell,GO:0060585~positive regulation of prostaglandin-endoperoxide synthase activity,GO:0071805~potassium ion transmembrane transport,GO:1901381~positive regulation of potassium ion transmembrane transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0031708~endothelin B receptor binding,	IPR001928:Endothelin-like toxin,IPR019764:Endothelin-like toxin, conserved site,IPR020475:Bibrotoxin/Sarafotoxin-D,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,hsa04924:Renin secretion,	613265~Waardenburg syndrome, type 4B,613712~Hirschsprung disease, susceptibility to, 4,		SM00272:END,		KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-0367~Hirschsprung disease,KW-0897~Waardenburg syndrome,	KW-0732~Signal,		KW-0838~Vasoactive,KW-0839~Vasoconstrictor,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:Endothelin-like toxin,PEPTIDE:Endothelin-3,REGION:Disordered,REGION:Endothelin-like,SITE:Cleavage; by KEL,
ECEL1	endothelin converting enzyme like 1(ECEL1)	Homo sapiens			GO:0003016~respiratory system process,GO:0007218~neuropeptide signaling pathway,GO:0016485~protein processing,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004222~metalloendopeptidase activity,GO:0008237~metallopeptidase activity,GO:0046872~metal ion binding,	IPR000718:Peptidase M13,IPR008753:Peptidase M13, N-terminal domain,IPR018497:Peptidase M13, C-terminal domain,IPR024079:Metallopeptidase, catalytic domain,		615065~Arthrogryposis, distal, type 5D,				KW-0472~Membrane,	KW-0225~Disease variant,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase M13,DOMAIN:Peptidase M13 C-terminal,DOMAIN:Peptidase M13 N-terminal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
EDNRA	endothelin receptor type A(EDNRA)	Homo sapiens		h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,	GO:0000278~mitotic cell cycle,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001974~blood vessel remodeling,GO:0001975~response to amphetamine,GO:0002027~regulation of heart rate,GO:0003094~glomerular filtration,GO:0003207~cardiac chamber formation,GO:0003220~left ventricular cardiac muscle tissue morphogenesis,GO:0003228~atrial cardiac muscle tissue development,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0003357~noradrenergic neuron differentiation,GO:0006468~protein phosphorylation,GO:0006874~cellular calcium ion homeostasis,GO:0006939~smooth muscle contraction,GO:0007005~mitochondrion organization,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007585~respiratory gaseous exchange,GO:0008217~regulation of blood pressure,GO:0008283~cell proliferation,GO:0009611~response to wounding,GO:0010259~multicellular organism aging,GO:0010467~gene expression,GO:0010737~protein kinase A signaling,GO:0010827~regulation of glucose transport,GO:0014034~neural crest cell fate commitment,GO:0014824~artery smooth muscle contraction,GO:0016322~neuron remodeling,GO:0030202~heparin metabolic process,GO:0030878~thyroid gland development,GO:0034599~cellular response to oxidative stress,GO:0035050~embryonic heart tube development,GO:0035904~aorta development,GO:0042310~vasoconstriction,GO:0042415~norepinephrine metabolic process,GO:0042474~middle ear morphogenesis,GO:0044751~cellular response to human chorionic gonadotropin stimulus,GO:0048066~developmental pigmentation,GO:0048484~enteric nervous system development,GO:0048485~sympathetic nervous system development,GO:0048675~axon extension,GO:0048706~embryonic skeletal system development,GO:0050905~neuromuscular process,GO:0055078~sodium ion homeostasis,GO:0060070~canonical Wnt signaling pathway,GO:0060324~face development,GO:0060385~axonogenesis involved in innervation,GO:0061028~establishment of endothelial barrier,GO:0061626~pharyngeal arch artery morphogenesis,GO:0070294~renal sodium ion absorption,GO:0070588~calcium ion transmembrane transport,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071806~protein transmembrane transport,GO:0072011~glomerular endothelium development,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0086100~endothelin receptor signaling pathway,GO:0086101~endothelin receptor signaling pathway involved in heart process,GO:0097018~renal albumin absorption,GO:0097084~vascular smooth muscle cell development,GO:0097152~mesenchymal cell apoptotic process,GO:0097492~sympathetic neuron axon guidance,GO:1902287~semaphorin-plexin signaling pathway involved in axon guidance,GO:1903210~glomerular visceral epithelial cell apoptotic process,GO:1903537~meiotic cell cycle process involved in oocyte maturation,GO:1904888~cranial skeletal system development,GO:1905144~response to acetylcholine,GO:1905871~regulation of protein localization to cell leading edge,GO:2001259~positive regulation of cation channel activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004962~endothelin receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000499:Endothelin receptor family,IPR002175:Endothelin receptor A,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,hsa04924:Renin secretion,hsa05200:Pathways in cancer,	157300~Migraine, resistance to,616367~Mandibulofacial dysostosis with alopecia,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1063~Hypotrichosis,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
EDNRB	endothelin receptor type B(EDNRB)	Homo sapiens		h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001755~neural crest cell migration,GO:0001934~positive regulation of protein phosphorylation,GO:0002001~renin secretion into blood stream,GO:0002027~regulation of heart rate,GO:0006885~regulation of pH,GO:0007166~cell surface receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0007497~posterior midgut development,GO:0007568~aging,GO:0008217~regulation of blood pressure,GO:0008284~positive regulation of cell proliferation,GO:0010467~gene expression,GO:0014043~negative regulation of neuron maturation,GO:0014070~response to organic cyclic compound,GO:0014826~vein smooth muscle contraction,GO:0019233~sensory perception of pain,GO:0019722~calcium-mediated signaling,GO:0019934~cGMP-mediated signaling,GO:0030202~heparin metabolic process,GO:0030318~melanocyte differentiation,GO:0031620~regulation of fever generation,GO:0032269~negative regulation of cellular protein metabolic process,GO:0032341~aldosterone metabolic process,GO:0035645~enteric smooth muscle cell differentiation,GO:0035810~positive regulation of urine volume,GO:0035812~renal sodium excretion,GO:0035815~positive regulation of renal sodium excretion,GO:0042045~epithelial fluid transport,GO:0042310~vasoconstriction,GO:0042311~vasodilation,GO:0043066~negative regulation of apoptotic process,GO:0048066~developmental pigmentation,GO:0048246~macrophage chemotaxis,GO:0048265~response to pain,GO:0048484~enteric nervous system development,GO:0050678~regulation of epithelial cell proliferation,GO:0051248~negative regulation of protein metabolic process,GO:0051930~regulation of sensory perception of pain,GO:0060070~canonical Wnt signaling pathway,GO:0060406~positive regulation of penile erection,GO:0060465~pharynx development,GO:0061028~establishment of endothelial barrier,GO:0070294~renal sodium ion absorption,GO:0070588~calcium ion transmembrane transport,GO:0071222~cellular response to lipopolysaccharide,GO:0071806~protein transmembrane transport,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0086100~endothelin receptor signaling pathway,GO:0097018~renal albumin absorption,GO:0097402~neuroblast migration,GO:1904383~response to sodium phosphate,GO:1990839~response to endothelin,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,GO:0045121~membrane raft,	GO:0004962~endothelin receptor activity,GO:0005515~protein binding,GO:0017046~peptide hormone binding,GO:0031702~type 1 angiotensin receptor binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000499:Endothelin receptor family,IPR001112:Endothelin receptor B,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04916:Melanogenesis,hsa04926:Relaxin signaling pathway,hsa05200:Pathways in cancer,	277580~Waardenburg syndrome, type 4A,600155~Hirschsprung disease, susceptibility to, 2,600501~ABCD syndrome,		SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0015~Albinism,KW-0209~Deafness,KW-0225~Disease variant,KW-0367~Hirschsprung disease,KW-0897~Waardenburg syndrome,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Abolishes palmitoylation; when associated with S-402 and S-403.,MUTAGEN:C->S: Abolishes palmitoylation; when associated with S-402 and S-405.,MUTAGEN:C->S: Abolishes palmitoylation; when associated with S-403 and S-405.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ELMO3	engulfment and cell motility 3(ELMO3)	Homo sapiens			GO:0006909~phagocytosis,GO:0006915~apoptotic process,GO:0007015~actin filament organization,GO:0048870~cell motility,	GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR001849:Pleckstrin homology domain,IPR006816:Engulfment/cell motility, ELMO,IPR011989:Armadillo-like helical,IPR011993:Pleckstrin homology-like domain,IPR016024:Armadillo-type fold,IPR024574:Domain of unknown function DUF3361,	hsa05100:Bacterial invasion of epithelial cells,				KW-0053~Apoptosis,KW-0581~Phagocytosis,	KW-0963~Cytoplasm,		KW-0729~SH3-binding,				DOMAIN:ELMO,DOMAIN:PH,MOTIF:SH3-binding,
EFNA2	ephrin A2(EFNA2)	Homo sapiens			GO:0007267~cell-cell signaling,GO:0007411~axon guidance,GO:0021772~olfactory bulb development,GO:0030316~osteoclast differentiation,GO:0046849~bone remodeling,GO:0048013~ephrin receptor signaling pathway,	GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0031594~neuromuscular junction,GO:0043204~perikaryon,GO:0098552~side of membrane,	GO:0005515~protein binding,GO:0046875~ephrin receptor binding,	IPR001799:Ephrin,IPR008972:Cupredoxin,IPR019765:Ephrin, conserved site,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04360:Axon guidance,hsa05206:MicroRNAs in cancer,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ephrin RBD,LIPID:GPI-anchor amidated asparagine,PROPEP:Removed in mature form,
EGFR	epidermal growth factor receptor(EGFR)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,h_egfPathway:EGF Signaling Pathway,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_keratinocytePathway:Keratinocyte Differentiation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,	GO:0000165~MAPK cascade,GO:0000902~cell morphogenesis,GO:0001503~ossification,GO:0001892~embryonic placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001942~hair follicle development,GO:0006898~receptor-mediated endocytosis,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007275~multicellular organism development,GO:0007435~salivary gland morphogenesis,GO:0007611~learning or memory,GO:0008284~positive regulation of cell proliferation,GO:0010750~positive regulation of nitric oxide mediated signal transduction,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021795~cerebral cortex cell migration,GO:0022008~neurogenesis,GO:0030154~cell differentiation,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033674~positive regulation of kinase activity,GO:0034614~cellular response to reactive oxygen species,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038134~ERBB2-EGFR signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042177~negative regulation of protein catabolic process,GO:0042327~positive regulation of phosphorylation,GO:0043006~activation of phospholipase A2 activity by calcium-mediated signaling,GO:0043066~negative regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046328~regulation of JNK cascade,GO:0046718~viral entry into host cell,GO:0046777~protein autophosphorylation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048546~digestive tract morphogenesis,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051205~protein insertion into membrane,GO:0051896~regulation of protein kinase B signaling,GO:0051897~positive regulation of protein kinase B signaling,GO:0060571~morphogenesis of an epithelial fold,GO:0061029~eyelid development in camera-type eye,GO:0070141~response to UV-A,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071230~cellular response to amino acid stimulus,GO:0071276~cellular response to cadmium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0098609~cell-cell adhesion,GO:1900020~positive regulation of protein kinase C activity,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1905208~negative regulation of cardiocyte differentiation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030054~cell junction,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031965~nuclear membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070435~Shc-EGFR complex,GO:0097489~multivesicular body, internal vesicle lumen,GO:0097708~intracellular vesicle,GO:0098590~plasma membrane region,	GO:0001618~virus receptor activity,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0004672~protein kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005006~epidermal growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019903~protein phosphatase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030296~protein tyrosine kinase activator activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0048408~epidermal growth factor binding,GO:0051015~actin filament binding,GO:0051117~ATPase binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	211980~Adenocarcinoma of lung, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, susceptibility to,616069~Inflammatory skin and bowel disease, neonatal, 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-1183~Host cell receptor for virus entry,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical; partial,CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Furin-like cysteine-rich,DOMAIN:Growth factor receptor,DOMAIN:Protein kinase,DOMAIN:Receptor L-domain,DOMAIN:Serine-threonine/tyrosine-protein kinase catalytic,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreased palmitoylation.,MUTAGEN:D->A: Increased EGF binding; when associated with A-590 and A-609.,MUTAGEN:D->A: Strongly reduced phosphorylation.,MUTAGEN:DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding.,MUTAGEN:E->A: Reduced phosphorylation.,MUTAGEN:ED->RK: Constitutively activated kinase.,MUTAGEN:F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:I->A: Abolishes phosphorylation.,MUTAGEN:K->A,M: Abolishes kinase activity.,MUTAGEN:K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:L->A,P: Strongly reduced phosphorylation.,MUTAGEN:L->A: Abolishes phosphorylation.,MUTAGEN:L->A: Strongly reduced phosphorylation.,MUTAGEN:Missing: Abolishes palmitoylation.,MUTAGEN:Missing: Increased EGF binding.,MUTAGEN:N->A: Abolishes phosphorylation.,MUTAGEN:P->A: Reduced phosphorylation.,MUTAGEN:P->A: Strongly reduced phosphorylation.,MUTAGEN:Q->G: No effect on interaction with CBLC.,MUTAGEN:R->A: Abolishes phosphorylation.,MUTAGEN:R->A: Reduced phosphorylation.,MUTAGEN:R->E: Abolishes autophosphorylation and activation of downstream kinases.,MUTAGEN:R->G: Strongly decreases interaction with CBLC.,MUTAGEN:R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.,MUTAGEN:T->A: Increased phosphorylation.,MUTAGEN:T->D: Strongly reduced phosphorylation.,MUTAGEN:V->A: Reduced autophosphorylation.,MUTAGEN:V->M: Constitutively activated kinase.,MUTAGEN:Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.,MUTAGEN:Y->F: Abolishes interaction with CBLC.,MUTAGEN:Y->F: No change in interaction with PIK3C2B.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.,REGION:Disordered,REGION:Important for dimerization, phosphorylation and activation,REPEAT:Approximate,SITE:Important for interaction with PIK3C2B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EPN3	epsin 3(EPN3)	Homo sapiens			GO:0006897~endocytosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009898~cytoplasmic side of plasma membrane,GO:0019897~extrinsic component of plasma membrane,GO:0030125~clathrin vesicle coat,GO:0030136~clathrin-coated vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008289~lipid binding,GO:0030276~clathrin binding,GO:1990175~EH domain binding,	IPR003903:Ubiquitin interacting motif,IPR008942:ENTH/VHS,IPR013809:Epsin-like, N-terminal,IPR027318:Epsin-3, metazoa,	hsa04144:Endocytosis,			SM00273:ENTH,SM00726:UIM,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:ENTH,DOMAIN:UIM 1,DOMAIN:UIM 2,REGION:3 X 3 AA repeats of N-P-F,REGION:5 X 3 AA repeats of [DE]-P-W,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,
ERBB3	erb-b2 receptor tyrosine kinase 3(ERBB3)	Homo sapiens		h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,	GO:0003197~endocardial cushion development,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010628~positive regulation of gene expression,GO:0014037~Schwann cell differentiation,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0016310~phosphorylation,GO:0021545~cranial nerve development,GO:0022008~neurogenesis,GO:0033674~positive regulation of kinase activity,GO:0038133~ERBB2-ERBB3 signaling pathway,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0051048~negative regulation of secretion,GO:0051402~neuron apoptotic process,GO:0051897~positive regulation of protein kinase B signaling,GO:0055025~positive regulation of cardiac muscle tissue development,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0097049~motor neuron apoptotic process,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0038143~ERBB3:ERBB2 complex,GO:0043235~receptor complex,GO:0098590~plasma membrane region,	GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019838~growth factor binding,GO:0030296~protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0038131~neuregulin receptor activity,GO:0038132~neuregulin binding,GO:0042802~identical protein binding,GO:0043125~ErbB-3 class receptor binding,GO:0046982~protein heterodimerization activity,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	133180~Erythroleukemia, familial, susceptibility to,243180~Visceral neuropathy, familial, 1, autosomal recessive,607598~Lethal congenital contractural syndrome 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Growth factor receptor,DOMAIN:Protein kinase,DOMAIN:Receptor L-domain,DOMAIN:Serine-threonine/tyrosine-protein kinase catalytic,DOMAIN:Tyrosine-protein kinase catalytic,MUTAGEN:K->M: Strongly reduced autophosphorylation.,MUTAGEN:Y->E: Strongly reduced tyrosine phosphorylation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ESR1	estrogen receptor 1(ESR1)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,h_pelp1Pathway:Pelp1 Modulation of Estrogen Receptor Activity,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001547~antral ovarian follicle growth,GO:0002064~epithelial cell development,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008209~androgen metabolic process,GO:0008584~male gonad development,GO:0010629~negative regulation of gene expression,GO:0010863~positive regulation of phospholipase C activity,GO:0030518~intracellular steroid hormone receptor signaling pathway,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0032355~response to estradiol,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043627~response to estrogen,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045899~positive regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048863~stem cell differentiation,GO:0050727~regulation of inflammatory response,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060065~uterus development,GO:0060068~vagina development,GO:0060523~prostate epithelial cord elongation,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060687~regulation of branching involved in prostate gland morphogenesis,GO:0060745~mammary gland branching involved in pregnancy,GO:0060749~mammary gland alveolus development,GO:0060750~epithelial cell proliferation involved in mammary gland duct elongation,GO:0071168~protein localization to chromatin,GO:0071391~cellular response to estrogen stimulus,GO:0071392~cellular response to estradiol stimulus,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1904035~regulation of epithelial cell apoptotic process,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,GO:0035327~transcriptionally active chromatin,GO:0097550~transcriptional preinitiation complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001093~TFIIB-class transcription factor binding,GO:0001221~transcription cofactor binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003707~steroid hormone receptor activity,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005496~steroid binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008013~beta-catenin binding,GO:0008270~zinc ion binding,GO:0017025~TBP-class protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030284~estrogen receptor activity,GO:0030331~estrogen receptor binding,GO:0034056~estrogen response element binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:0051117~ATPase binding,GO:0071889~14-3-3 protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001292:Oestrogen receptor,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,IPR024178:Oestrogen receptor/oestrogen-related receptor,IPR024736:Oestrogen-type nuclear receptor final C-terminal domain,	hsa01522:Endocrine resistance,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05224:Breast cancer,	114480~Breast cancer, somatic,157300~Migraine, susceptibility to,608446~Myocardial infarction, susceptibility to,615363~Estrogen resistance,	PIRSF002527:estrogen receptor-like nuclear receptor,PIRSF500101:estrogen receptor alpha [Parent=PIRSF002527],	SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-0863~Zinc-finger,	KW-0446~Lipid-binding,KW-0479~Metal-binding,KW-0754~Steroid-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	CARBOHYD:O-linked (GlcNAc) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Nuclear receptor,DOMAIN:Estrogen receptor N-terminal,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of hormone binding capacity and temperature-sensitive loss in DNA-binding.,MUTAGEN:I->C: Loss of transmembrane localization, no effect on peripheral membrane localization. Impairs activation of estrogen-induced activation of NOS3 and production of nitric oxide. No effect on binding to ERES.,MUTAGEN:L->A: Abolishes interaction with NCOA1, NCOA2 and NCOA3.,MUTAGEN:L->P: Impairs AF-1 transactivation.,MUTAGEN:R->A,K: Loss of methylation.,MUTAGEN:S->A: Decreases phosphorylation and transactivation activity. Abolishes AF-1 transactivation. Insensitive to PPP5C inhibition of transactivation activity.,MUTAGEN:S->A: Loss of cyclin A-dependent induction of transcriptional activation.,MUTAGEN:S->E: Enhances transactivation activity. Insensitive to PPP5C inhibition of transactivation activity.,MUTAGEN:V->E: Has higher transcriptional activity in the absence of wild type ER. Inhibits transcriptional activity when coexpressed with the wild type receptor.,MUTAGEN:Y->A: Reduces PELP1-mediated activation of transcriptional activity.,MUTAGEN:Y->P: Impairs AF-1 transactivation.,REGION:Disordered,REGION:Hinge,REGION:Interaction with AKAP13,REGION:Interaction with DDX5; self-association,REGION:Mediates interaction with DNTTIP2,REGION:Modulating (transactivation AF-1); mediates interaction with MACROD1,REGION:Required for interaction with NCOA1,REGION:Self-association,REGION:Transactivation AF-2,ZN_FING:NR C4-type,
EEF1A2	eukaryotic translation elongation factor 1 alpha 2(EEF1A2)	Homo sapiens			GO:0006412~translation,GO:0006414~translational elongation,GO:0043065~positive regulation of apoptotic process,GO:0090218~positive regulation of lipid kinase activity,GO:1904714~regulation of chaperone-mediated autophagy,	GO:0005737~cytoplasm,GO:0005853~eukaryotic translation elongation factor 1 complex,GO:0045202~synapse,GO:0098574~cytoplasmic side of lysosomal membrane,	GO:0003746~translation elongation factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008135~translation factor activity, RNA binding,GO:0019901~protein kinase binding,	IPR000795:Elongation factor, GTP-binding domain,IPR004160:Translation elongation factor EFTu/EF1A, C-terminal,IPR004161:Translation elongation factor EFTu/EF1A, domain 2,IPR004539:Translation elongation factor EF1A, eukaryotic/archaeal,IPR009000:Translation elongation/initiation factor/Ribosomal, beta-barrel,IPR009001:Translation elongation factor EF1A/initiation factor IF2gamma, C-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03013:Nucleocytoplasmic transport,hsa05134:Legionellosis,hsa05140:Leishmaniasis,	616393~Intellectual developmental disorder, autosomal dominant 38,616409~Developmental and epileptic encephalopathy 33,			KW-0648~Protein biosynthesis,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Tr-type G,DOMAIN:tr-type G,MUTAGEN:K->A: Abolishes methylation by EEF1AKMT3.,MUTAGEN:K->R: Abolishes EEF1AKMT4-mediated methylation.,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
EIF2AK2	eukaryotic translation initiation factor 2 alpha kinase 2(EIF2AK2)	Homo sapiens		h_eif2Pathway:Regulation of eIF2,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_ranklPathway:Bone Remodelling,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_tollPathway:Toll-Like Receptor Pathway,	GO:0001819~positive regulation of cytokine production,GO:0006412~translation,GO:0006468~protein phosphorylation,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0017148~negative regulation of translation,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0032722~positive regulation of chemokine production,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0033689~negative regulation of osteoblast proliferation,GO:0034198~cellular response to amino acid starvation,GO:0035455~response to interferon-alpha,GO:0043066~negative regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0046777~protein autophosphorylation,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:1900225~regulation of NLRP3 inflammasome complex assembly,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1901532~regulation of hematopoietic progenitor cell differentiation,GO:1902033~regulation of hematopoietic stem cell proliferation,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004694~eukaryotic translation initiation factor 2alpha kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019888~protein phosphatase regulator activity,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014720:Double-stranded RNA-binding-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04217:Necroptosis,hsa05010:Alzheimer disease,hsa05160:Hepatitis C,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05203:Viral carcinogenesis,	618877~Leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome,619687~Dystonia 33,		SM00220:S_TKc,SM00358:DSRM,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0677~Repeat,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0694~RNA-binding,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ISG15),DOMAIN:DRBM,DOMAIN:DRBM 1,DOMAIN:DRBM 2,DOMAIN:Protein kinase,MUTAGEN:A->E: Significant loss of activity; loss of dsRNA binding and dimerization.,MUTAGEN:D->V: 15-fold decrease in K3L binding affinity and thus resistance of mutated PKR to K3L inhibition.,MUTAGEN:F->S: Loss of PKR inhibition by HCMV protein TRS1.,MUTAGEN:I->T: No effect on PKR inhibition by HCMV protein TRS1.,MUTAGEN:I->V: No effect on PKR inhibition by HCMV protein TRS1.,MUTAGEN:K->A: Impairs dsRNA binding but not dimerization or activity.,MUTAGEN:K->R: Loss of activity.,MUTAGEN:K->R: No effect on PKR inhibition by HCMV protein TRS1.,MUTAGEN:Missing: Loss of activity.,MUTAGEN:Q->E: No effect on PKR inhibition by HCMV protein TRS1.,MUTAGEN:S->A: Moderate loss of activity; when associated with A-255 and A-258.,MUTAGEN:S->A: No effect on enzymatic activity; when associated with A-88; A-89 and A-90.,MUTAGEN:SK->AA: In FL-PKR-2AI; moderate loss of activity but no effect on dsRNA binding.,MUTAGEN:T->A: Loss of activity.,MUTAGEN:T->A: Moderate loss of activity.,MUTAGEN:T->A: Moderate loss of activity; when associated with A-242 and A-255.,MUTAGEN:T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-89.,MUTAGEN:T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-90.,MUTAGEN:T->A: No effect on enzymatic activity; when associated with A-83; A-89 and A-90.,MUTAGEN:T->A: Significant loss of activity and impairs autophosphorylation of T-451.,MUTAGEN:T->K: No effect on PKR inhibition by HCMV protein TRS1.,MUTAGEN:TK->AA: In FL-PKR-2AII; no effect on activity.,REGION:(Microbial infection) Interaction with HCV NS5A,REGION:2 X 13 AA approximate repeats,REGION:Dimerization,REGION:Disordered,REGION:Interaction with EIF2S1/EIF-2ALPHA,REGION:Interaction with TRAF5,REPEAT:1,REPEAT:2,
EIF5A2	eukaryotic translation initiation factor 5A2(EIF5A2)	Homo sapiens			GO:0006414~translational elongation,GO:0007283~spermatogenesis,GO:0010509~polyamine homeostasis,GO:0015031~protein transport,GO:0045901~positive regulation of translational elongation,GO:0045905~positive regulation of translational termination,GO:0051028~mRNA transport,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0043022~ribosome binding,	IPR001884:Translation elongation factor IF5A,IPR008991:Translation protein SH3-like domain,IPR012340:Nucleic acid-binding, OB-fold,IPR014722:Ribosomal protein L2 domain 2,IPR019769:Translation elongation factor, IF5A, hypusine site,IPR020189:Translation elongation factor, IF5A C-terminal,			PIRSF003025:translation initiation factor eIF-5A,	SM01376:SM01376,	KW-0648~Protein biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0251~Elongation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0385~Hypusine,	DOMAIN:Translation elongation factor IF5A C-terminal,
EVX1	even-skipped homeobox 1(EVX1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009792~embryo development ending in birth or egg hatching,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0097377~spinal cord interneuron axon guidance,GO:1904936~interneuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0044297~cell body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
EXTL1	exostosin like glycosyltransferase 1(EXTL1)	Homo sapiens			GO:0001501~skeletal system development,GO:0006486~protein glycosylation,GO:0015012~heparan sulfate proteoglycan biosynthetic process,	GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008375~acetylglucosaminyltransferase activity,GO:0015020~glucuronosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0050508~glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity,	IPR004263:Exostosin-like,IPR015338:EXTL2, alpha-1,4-N-acetylhexosaminyltransferase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,hsa01100:Metabolic pathways,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FAM107B	family with sequence similarity 107 member B(FAM107B)	Homo sapiens						IPR009533:Protein of unknown function DUF1151,								KW-0175~Coiled coil,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
FAM163A	family with sequence similarity 163 member A(FAM163A)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,							KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
FEZ1	fasciculation and elongation protein zeta 1(FEZ1)	Homo sapiens			GO:0007155~cell adhesion,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0010976~positive regulation of neuron projection development,GO:0021766~hippocampus development,GO:0030010~establishment of cell polarity,GO:0045666~positive regulation of neuron differentiation,GO:0051654~establishment of mitochondrion localization,GO:0070584~mitochondrion morphogenesis,GO:0071363~cellular response to growth factor stimulus,GO:1902902~negative regulation of autophagosome assembly,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030426~growth cone,GO:0043025~neuronal cell body,	GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0043015~gamma-tubulin binding,GO:0047485~protein N-terminus binding,	IPR011680:FEZ-like,IPR015642:Fasciculation and elongation protein zeta 1,	hsa03250:Viral life cycle - HIV-1,				KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,MUTAGEN:E->A: No effect on SCOC--binding.,MUTAGEN:K->A: No effect on SCOC-binding.,MUTAGEN:L->P: Loss of SCOC-binding. No effect on ULK1-binding.,REGION:Disordered,
FITM1	fat storage inducing transmembrane protein 1(FITM1)	Homo sapiens			GO:0008654~phospholipid biosynthetic process,GO:0010890~positive regulation of sequestering of triglyceride,GO:0019915~lipid storage,GO:0034389~lipid particle organization,	GO:0005789~endoplasmic reticulum membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0017129~triglyceride binding,GO:0019992~diacylglycerol binding,	IPR019388:Fat storage-inducing transmembrane protein,					KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				SITE:Important for catalytic activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
FABP5	fatty acid binding protein 5(FABP5)	Homo sapiens			GO:0006006~glucose metabolic process,GO:0006629~lipid metabolic process,GO:0006656~phosphatidylcholine biosynthetic process,GO:0008544~epidermis development,GO:0010829~negative regulation of glucose transport,GO:0015908~fatty acid transport,GO:0015909~long-chain fatty acid transport,GO:0031392~regulation of prostaglandin biosynthetic process,GO:0035360~positive regulation of peroxisome proliferator activated receptor signaling pathway,GO:0042593~glucose homeostasis,GO:0051930~regulation of sensory perception of pain,GO:1990379~lipid transport across blood brain barrier,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030667~secretory granule membrane,GO:0035578~azurophil granule lumen,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0001972~retinoic acid binding,GO:0005324~long-chain fatty acid transporter activity,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,	IPR000463:Cytosolic fatty-acid binding,IPR000566:Lipocalin/cytosolic fatty-acid binding protein domain,IPR012674:Calycin,	hsa03320:PPAR signaling pathway,				KW-0445~Lipid transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,			KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:Cytosolic fatty-acid binding proteins,DOMAIN:Lipocalin/cytosolic fatty-acid binding,MOTIF:Nuclear localization signal,MUTAGEN:K->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-33.,MUTAGEN:K->A: Loss of ligand-induced nuclear import; when associated with A-33 and A-34.,MUTAGEN:R->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-34.,
FTMT	ferritin mitochondrial(FTMT)	Homo sapiens			GO:0006826~iron ion transport,GO:0006879~cellular iron ion homeostasis,GO:0006880~intracellular sequestering of iron ion,GO:0008284~positive regulation of cell proliferation,GO:0051349~positive regulation of lyase activity,GO:1904231~positive regulation of succinate dehydrogenase activity,GO:1904234~positive regulation of aconitate hydratase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004322~ferroxidase activity,GO:0005506~iron ion binding,GO:0008198~ferrous iron binding,GO:0008199~ferric iron binding,GO:0046872~metal ion binding,	IPR001519:Ferritin,IPR003019:Metallothionein superfamily, eukaryotic,IPR008331:Ferritin/DPS protein domain,IPR009040:Ferritin- like diiron domain,IPR009078:Ferritin-like superfamily,IPR012347:Ferritin-related,IPR014034:Ferritin, conserved site,IPR017854:Metallothionein domain,IPR023587:Metallothionein domain, vertebrate,	hsa04216:Ferroptosis,				KW-0409~Iron storage,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,		DOMAIN:Ferritin-like diiron,MUTAGEN:S->A: Increases ferroxidase activity and iron binding.,REGION:Disordered,TRANSIT:Mitochondrion,
FBN1	fibrillin 1(FBN1)	Homo sapiens			GO:0001501~skeletal system development,GO:0001656~metanephros development,GO:0006006~glucose metabolic process,GO:0007165~signal transduction,GO:0007507~heart development,GO:0009653~anatomical structure morphogenesis,GO:0010737~protein kinase A signaling,GO:0032100~positive regulation of appetite,GO:0033627~cell adhesion mediated by integrin,GO:0034199~activation of protein kinase A activity,GO:0035582~sequestering of BMP in extracellular matrix,GO:0035583~sequestering of TGFbeta in extracellular matrix,GO:0042593~glucose homeostasis,GO:0043010~camera-type eye development,GO:0045671~negative regulation of osteoclast differentiation,GO:0048048~embryonic eye morphogenesis,GO:0048050~post-embryonic eye morphogenesis,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:2001205~negative regulation of osteoclast development,	GO:0001527~microfibril,GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005178~integrin binding,GO:0005179~hormone activity,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030023~extracellular matrix constituent conferring elasticity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011398:Fibrillin,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,IPR026823:Complement Clr-like EGF domain,	hsa04350:TGF-beta signaling pathway,	102370~Acromicric dysplasia,129600~Ectopia lentis, familial,154700~Marfan syndrome,184900~Stiff skin syndrome,604308~MASS syndrome,608328~Weill-Marchesani syndrome 2, dominant,614185~Geleophysic dysplasia 2,616914~Marfan lipodystrophy syndrome,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0993~Aortic aneurysm,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0358~Heparin-binding,KW-0372~Hormone,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Glc) serine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17; calcium-binding,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 19; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20; calcium-binding,DOMAIN:EGF-like 21; calcium-binding,DOMAIN:EGF-like 22; calcium-binding,DOMAIN:EGF-like 23; calcium-binding,DOMAIN:EGF-like 24; calcium-binding,DOMAIN:EGF-like 25; calcium-binding,DOMAIN:EGF-like 26; calcium-binding,DOMAIN:EGF-like 27; calcium-binding,DOMAIN:EGF-like 28; calcium-binding,DOMAIN:EGF-like 29; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 30; calcium-binding,DOMAIN:EGF-like 31; calcium-binding,DOMAIN:EGF-like 32; calcium-binding,DOMAIN:EGF-like 33; calcium-binding,DOMAIN:EGF-like 34; calcium-binding,DOMAIN:EGF-like 35; calcium-binding,DOMAIN:EGF-like 36; calcium-binding,DOMAIN:EGF-like 37; calcium-binding,DOMAIN:EGF-like 38; calcium-binding,DOMAIN:EGF-like 39; calcium-binding,DOMAIN:EGF-like 40; calcium-binding,DOMAIN:EGF-like 41; calcium-binding,DOMAIN:EGF-like 42; calcium-binding,DOMAIN:EGF-like 43; calcium-binding,DOMAIN:EGF-like 44; calcium-binding,DOMAIN:EGF-like 45; calcium-binding,DOMAIN:EGF-like 46; calcium-binding,DOMAIN:EGF-like 47; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:EGF-like calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,DOMAIN:TB 5,DOMAIN:TB 6,DOMAIN:TB 7,DOMAIN:TB 8,DOMAIN:TB 9,MOTIF:Cell attachment site,MUTAGEN:G->D: Loss of integrin-mediated cell adhesion.,MUTAGEN:R->A: Abolishes furin cleavage site, leading to defects in protein processing at the C-terminus.,MUTAGEN:R->K: Abolishes furin cleavage site, leading to defects in protein processing at the C-terminus.,MUTAGEN:S->T: Defects in protein processing at the C-terminus.,REGION:C-terminal domain,REGION:Disordered,REGION:Fibrillin unique N-terminal (FUN) domain,REGION:Hybrid domain 1,REGION:Hybrid domain 2,REGION:Interaction with MFAP4,REGION:N-terminal domain,SITE:Cleavage; by furin,
FBN2	fibrillin 2(FBN2)	Homo sapiens			GO:0001890~placenta development,GO:0007165~signal transduction,GO:0009653~anatomical structure morphogenesis,GO:0030326~embryonic limb morphogenesis,GO:0030501~positive regulation of bone mineralization,GO:0035583~sequestering of TGFbeta in extracellular matrix,GO:0042593~glucose homeostasis,GO:0043010~camera-type eye development,GO:0045669~positive regulation of osteoblast differentiation,GO:0048048~embryonic eye morphogenesis,GO:0060346~bone trabecula formation,GO:1901163~regulation of trophoblast cell migration,	GO:0001527~microfibril,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,	GO:0005179~hormone activity,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030023~extracellular matrix constituent conferring elasticity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011398:Fibrillin,IPR013032:EGF-like, conserved site,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,IPR026823:Complement Clr-like EGF domain,		121050~Contractural arachnodactyly, congenital,616118~Macular degeneration, early-onset,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0372~Hormone,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Glc) serine,CARBOHYD:O-linked (Glc) threonine,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17; calcium-binding,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 19; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20; calcium-binding,DOMAIN:EGF-like 21; calcium-binding,DOMAIN:EGF-like 22; calcium-binding,DOMAIN:EGF-like 23; calcium-binding,DOMAIN:EGF-like 24; calcium-binding,DOMAIN:EGF-like 25; calcium-binding,DOMAIN:EGF-like 26; calcium-binding,DOMAIN:EGF-like 27; calcium-binding,DOMAIN:EGF-like 28; calcium-binding,DOMAIN:EGF-like 29; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 30; calcium-binding,DOMAIN:EGF-like 31; calcium-binding,DOMAIN:EGF-like 32; calcium-binding,DOMAIN:EGF-like 33; calcium-binding,DOMAIN:EGF-like 34; calcium-binding,DOMAIN:EGF-like 35; calcium-binding,DOMAIN:EGF-like 36; calcium-binding,DOMAIN:EGF-like 37; calcium-binding,DOMAIN:EGF-like 38; calcium-binding,DOMAIN:EGF-like 39; calcium-binding,DOMAIN:EGF-like 40; calcium-binding,DOMAIN:EGF-like 41; calcium-binding,DOMAIN:EGF-like 42; calcium-binding,DOMAIN:EGF-like 43; calcium-binding,DOMAIN:EGF-like 44; calcium-binding,DOMAIN:EGF-like 45; calcium-binding,DOMAIN:EGF-like 46; calcium-binding,DOMAIN:EGF-like 47; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,DOMAIN:TB 5,DOMAIN:TB 6,DOMAIN:TB 7,DOMAIN:TB 8,DOMAIN:TB 9,REGION:Disordered,REGION:Interaction with MFAP4,TRANSMEM:Helical,
FBN3	fibrillin 3(FBN3)	Homo sapiens			GO:0009653~anatomical structure morphogenesis,	GO:0001527~microfibril,GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011398:Fibrillin,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,IPR026823:Complement Clr-like EGF domain,				SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 19; calcium-binding,DOMAIN:EGF-like 20; calcium-binding,DOMAIN:EGF-like 21; calcium-binding,DOMAIN:EGF-like 22; calcium-binding,DOMAIN:EGF-like 23; calcium-binding,DOMAIN:EGF-like 24; calcium-binding,DOMAIN:EGF-like 25; calcium-binding,DOMAIN:EGF-like 26; calcium-binding,DOMAIN:EGF-like 27; calcium-binding,DOMAIN:EGF-like 28,DOMAIN:EGF-like 29; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 30; calcium-binding,DOMAIN:EGF-like 31; calcium-binding,DOMAIN:EGF-like 32; calcium-binding,DOMAIN:EGF-like 33; calcium-binding,DOMAIN:EGF-like 34; calcium-binding,DOMAIN:EGF-like 35; calcium-binding,DOMAIN:EGF-like 36; calcium-binding,DOMAIN:EGF-like 37; calcium-binding,DOMAIN:EGF-like 38; calcium-binding,DOMAIN:EGF-like 39; calcium-binding,DOMAIN:EGF-like 40; calcium-binding,DOMAIN:EGF-like 41; calcium-binding,DOMAIN:EGF-like 42; calcium-binding,DOMAIN:EGF-like 43; calcium-binding,DOMAIN:EGF-like 44; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:EGF-like calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,DOMAIN:TB 5,DOMAIN:TB 6,DOMAIN:TB 7,DOMAIN:TB 8,DOMAIN:TB 9,
FAP	fibroblast activation protein alpha(FAP)	Homo sapiens			GO:0001525~angiogenesis,GO:0006508~proteolysis,GO:0007155~cell adhesion,GO:0010710~regulation of collagen catabolic process,GO:0010716~negative regulation of extracellular matrix disassembly,GO:0043542~endothelial cell migration,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051726~regulation of cell cycle,GO:0051917~regulation of fibrinolysis,GO:0060244~negative regulation of cell proliferation involved in contact inhibition,GO:0097325~melanocyte proliferation,GO:1900119~positive regulation of execution phase of apoptosis,GO:1902362~melanocyte apoptotic process,GO:1903054~negative regulation of extracellular matrix organization,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0031258~lamellipodium membrane,GO:0032587~ruffle membrane,GO:0045177~apical part of cell,GO:0045178~basal part of cell,GO:1905368~peptidase complex,	GO:0002020~protease binding,GO:0004175~endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008236~serine-type peptidase activity,GO:0008239~dipeptidyl-peptidase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR001375:Peptidase S9, prolyl oligopeptidase, catalytic domain,IPR002469:Peptidase S9B, dipeptidylpeptidase IV N-terminal,IPR002471:Peptidase S9, serine active site,					KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Dipeptidylpeptidase IV N-terminal,DOMAIN:Peptidase S9 prolyl oligopeptidase catalytic,MUTAGEN:A->D,N: Inhibits endopeptidase activity. Increases dipeptidyl peptidase activity.,MUTAGEN:A->F,V: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:A->Q: Inhibits endopeptidase activity. No change in dipeptidyl peptidase activity.,MUTAGEN:A->S,T: Strongly reduces endopeptidase activity. No change in dipeptidyl peptidase activity.,MUTAGEN:E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-203.,MUTAGEN:E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-204.,MUTAGEN:N->A: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:R->A,M,E: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:S->A: Reduces dipeptidyl peptidase and gelatinolytic activities. Does not inhibit cell adhesion, migration and invasion.,MUTAGEN:Y->F: Reduces dipeptidyl peptidase and endopeptidase activities.,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FGF11	fibroblast growth factor 11(FGF11)	Homo sapiens			GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0007399~nervous system development,GO:1905150~regulation of voltage-gated sodium channel activity,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0017080~sodium channel regulator activity,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,				SM00442:FGF,						KW-0339~Growth factor,		REGION:Disordered,
FGF12	fibroblast growth factor 12(FGF12)	Homo sapiens			GO:0007165~signal transduction,GO:0007254~JNK cascade,GO:0007267~cell-cell signaling,GO:0007268~chemical synaptic transmission,GO:0007399~nervous system development,GO:0007507~heart development,GO:0008344~adult locomotory behavior,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010765~positive regulation of sodium ion transport,GO:0050905~neuromuscular process,GO:0086002~cardiac muscle cell action potential involved in contraction,GO:0098908~regulation of neuronal action potential,GO:1902305~regulation of sodium ion transmembrane transport,GO:1905150~regulation of voltage-gated sodium channel activity,GO:2000649~regulation of sodium ion transmembrane transporter activity,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0045202~synapse,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0017080~sodium channel regulator activity,GO:0044325~ion channel binding,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,		617166~Developmental and epileptic encephalopathy 47,		SM00442:FGF,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,			KW-0339~Growth factor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Bipartite nuclear localization signal,MUTAGEN:R->A: Gain of function, affects voltage dependence of SCN8A fast inactivation.,MUTAGEN:R->G: Gain of function, affects voltage dependence of SCN8A fast inactivation.,REGION:Disordered,
FGF2	fibroblast growth factor 2(FGF2)	Homo sapiens		h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),	GO:0001649~osteoblast differentiation,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001759~organ induction,GO:0001934~positive regulation of protein phosphorylation,GO:0001935~endothelial cell proliferation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002052~positive regulation of neuroblast proliferation,GO:0006366~transcription from RNA polymerase II promoter,GO:0006661~phosphatidylinositol biosynthetic process,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0007399~nervous system development,GO:0007405~neuroblast proliferation,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009792~embryo development ending in birth or egg hatching,GO:0009887~animal organ morphogenesis,GO:0010001~glial cell differentiation,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010764~negative regulation of fibroblast migration,GO:0010863~positive regulation of phospholipase C activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014843~growth factor dependent regulation of skeletal muscle satellite cell proliferation,GO:0021762~substantia nigra development,GO:0021930~cerebellar granule cell precursor proliferation,GO:0021940~positive regulation of cerebellar granule cell precursor proliferation,GO:0030154~cell differentiation,GO:0030214~hyaluronan catabolic process,GO:0030324~lung development,GO:0030334~regulation of cell migration,GO:0032958~inositol phosphate biosynthetic process,GO:0038001~paracrine signaling,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042491~auditory receptor cell differentiation,GO:0042660~positive regulation of cell fate specification,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043491~protein kinase B signaling,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045609~positive regulation of auditory receptor cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046668~regulation of retinal cell programmed cell death,GO:0048513~animal organ development,GO:0048598~embryonic morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048678~response to axon injury,GO:0048864~stem cell development,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050918~positive chemotaxis,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051726~regulation of cell cycle,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060070~canonical Wnt signaling pathway,GO:0060128~corticotropin hormone secreting cell differentiation,GO:0060129~thyroid-stimulating hormone-secreting cell differentiation,GO:0060548~negative regulation of cell death,GO:0060591~chondroblast differentiation,GO:0060644~mammary gland epithelial cell differentiation,GO:0060978~angiogenesis involved in coronary vascular morphogenesis,GO:0061045~negative regulation of wound healing,GO:0070371~ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071260~cellular response to mechanical stimulus,GO:0072089~stem cell proliferation,GO:0090049~regulation of cell migration involved in sprouting angiogenesis,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902748~positive regulation of lens fiber cell differentiation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902913~positive regulation of neuroepithelial cell differentiation,GO:1903587~regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903672~positive regulation of sprouting angiogenesis,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904977~lymphatic endothelial cell migration,GO:1905278~positive regulation of epithelial tube formation,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:2000544~regulation of endothelial cell chemotaxis to fibroblast growth factor,GO:2000546~positive regulation of endothelial cell chemotaxis to fibroblast growth factor,GO:2000573~positive regulation of DNA biosynthetic process,GO:2000647~negative regulation of stem cell proliferation,GO:2000648~positive regulation of stem cell proliferation,GO:2000738~positive regulation of stem cell differentiation,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005104~fibroblast growth factor receptor binding,GO:0005125~cytokine activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0019956~chemokine binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0042056~chemoattractant activity,GO:0042802~identical protein binding,GO:0090722~receptor-receptor interaction,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04810:Regulation of actin cytoskeleton,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,			SM00442:FGF,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0539~Nucleus,KW-0964~Secreted,				KW-0217~Developmental protein,KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),MOTIF:Cell attachment site; atypical,MUTAGEN:K->E: No effect on integrin binding.,MUTAGEN:K->E: Reduces binding to integrin ITGAV:ITGB3 and suppresses FGF2 signaling with reduced ERK1/2 activation and reduced ability to induce DNA synthesis, cell migration and angiogenesis. Acts as a potent antagonist of FGF2-mediated angiogenesis.,MUTAGEN:KR->EE: Abolishes binding to integrin ITGAV:ITGB3 and suppresses FGF2 signaling with loss of ERK1/2 activation and reduced ability to induce DNA synthesis, cell migration and angiogenesis. Acts as a potent antagonist of FGF2-mediated angiogenesis.,MUTAGEN:R->E: No effect on integrin binding.,PROPEP:Or 93, or 124, or 125, or 131, or 161,REGION:Disordered,REGION:Heparin-binding,SITE:Important for interaction with integrin,
FGF23	fibroblast growth factor 23(FGF23)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0006796~phosphate-containing compound metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009887~animal organ morphogenesis,GO:0010628~positive regulation of gene expression,GO:0010966~regulation of phosphate transport,GO:0010980~positive regulation of vitamin D 24-hydroxylase activity,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0030502~negative regulation of bone mineralization,GO:0030643~cellular phosphate ion homeostasis,GO:0032026~response to magnesium ion,GO:0042369~vitamin D catabolic process,GO:0044320~cellular response to leptin stimulus,GO:0045668~negative regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046888~negative regulation of hormone secretion,GO:0055062~phosphate ion homeostasis,GO:0055074~calcium ion homeostasis,GO:0070371~ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071305~cellular response to vitamin D,GO:0071354~cellular response to interleukin-6,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0090080~positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway,GO:1904383~response to sodium phosphate,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,	GO:0005104~fibroblast growth factor receptor binding,GO:0005105~type 1 fibroblast growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05200:Pathways in cancer,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,	193100~Hypophosphatemic rickets, autosomal dominant,617993~Tumoral calcinosis, hyperphosphatemic, familial, 2,		SM00442:FGF,	KW-0221~Differentiation,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc) threonine,COMPBIAS:Basic and acidic residues,MUTAGEN:T->A: Loss of glycosylation.,REGION:Disordered,SITE:Cleavage; by proprotein convertases,
FGF3	fibroblast growth factor 3(FGF3)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009653~anatomical structure morphogenesis,GO:0009887~animal organ morphogenesis,GO:0010628~positive regulation of gene expression,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0051781~positive regulation of cell division,GO:0055026~negative regulation of cardiac muscle tissue development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005104~fibroblast growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,	610706~Deafness, congenital with inner ear agenesis, microtia, and microdontia,		SM00442:FGF,	KW-0221~Differentiation,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,
FGF4	fibroblast growth factor 4(FGF4)	Homo sapiens			GO:0001502~cartilage condensation,GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009887~animal organ morphogenesis,GO:0010463~mesenchymal cell proliferation,GO:0010628~positive regulation of gene expression,GO:0019827~stem cell population maintenance,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0035019~somatic stem cell population maintenance,GO:0035116~embryonic hindlimb morphogenesis,GO:0042475~odontogenesis of dentin-containing tooth,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051781~positive regulation of cell division,GO:0060363~cranial suture morphogenesis,GO:0060561~apoptotic process involved in morphogenesis,GO:0060591~chondroblast differentiation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0072089~stem cell proliferation,GO:1904019~epithelial cell apoptotic process,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000544~regulation of endothelial cell chemotaxis to fibroblast growth factor,GO:2000648~positive regulation of stem cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005104~fibroblast growth factor receptor binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,			SM00442:FGF,	KW-0221~Differentiation,	KW-0964~Secreted,	KW-0656~Proto-oncogene,	KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,KW-9996~Developmental protein,
FGF6	fibroblast growth factor 6(FGF6)	Homo sapiens			GO:0001502~cartilage condensation,GO:0001525~angiogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009887~animal organ morphogenesis,GO:0010628~positive regulation of gene expression,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0045445~myoblast differentiation,GO:0051781~positive regulation of cell division,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016021~integral component of membrane,GO:0042383~sarcolemma,	GO:0005104~fibroblast growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,			SM00442:FGF,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0472~Membrane,KW-0964~Secreted,	KW-0656~Proto-oncogene,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
FGF8	fibroblast growth factor 8(FGF8)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001759~organ induction,GO:0001823~mesonephros development,GO:0001839~neural plate morphogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0001947~heart looping,GO:0001974~blood vessel remodeling,GO:0003007~heart morphogenesis,GO:0003148~outflow tract septum morphogenesis,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0006979~response to oxidative stress,GO:0007369~gastrulation,GO:0008045~motor neuron axon guidance,GO:0008078~mesodermal cell migration,GO:0008284~positive regulation of cell proliferation,GO:0008406~gonad development,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0009653~anatomical structure morphogenesis,GO:0009887~animal organ morphogenesis,GO:0009953~dorsal/ventral pattern formation,GO:0010628~positive regulation of gene expression,GO:0014070~response to organic cyclic compound,GO:0021543~pallium development,GO:0021544~subpallium development,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021846~cell proliferation in forebrain,GO:0021884~forebrain neuron development,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0030334~regulation of cell migration,GO:0030539~male genitalia development,GO:0030878~thyroid gland development,GO:0030916~otic vesicle formation,GO:0030917~midbrain-hindbrain boundary development,GO:0033563~dorsal/ventral axon guidance,GO:0035050~embryonic heart tube development,GO:0035108~limb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035265~organ growth,GO:0035909~aorta morphogenesis,GO:0042476~odontogenesis,GO:0042487~regulation of odontogenesis of dentin-containing tooth,GO:0043524~negative regulation of neuron apoptotic process,GO:0045165~cell fate commitment,GO:0045597~positive regulation of cell differentiation,GO:0045745~positive regulation of G-protein coupled receptor protein signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0046622~positive regulation of organ growth,GO:0048702~embryonic neurocranium morphogenesis,GO:0048853~forebrain morphogenesis,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050918~positive chemotaxis,GO:0051402~neuron apoptotic process,GO:0051781~positive regulation of cell division,GO:0055026~negative regulation of cardiac muscle tissue development,GO:0060037~pharyngeal system development,GO:0060128~corticotropin hormone secreting cell differentiation,GO:0060129~thyroid-stimulating hormone-secreting cell differentiation,GO:0060348~bone development,GO:0060425~lung morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0060563~neuroepithelial cell differentiation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071542~dopaminergic neuron differentiation,GO:0072089~stem cell proliferation,GO:0090134~cell migration involved in mesendoderm migration,GO:2000648~positive regulation of stem cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,	GO:0005104~fibroblast growth factor receptor binding,GO:0005105~type 1 fibroblast growth factor receptor binding,GO:0005111~type 2 fibroblast growth factor receptor binding,GO:0008083~growth factor activity,GO:0042056~chemoattractant activity,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,	612702~Hypogonadotropic hypogonadism 6 with or without anosmia,		SM00442:FGF,	KW-0221~Differentiation,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1016~Hypogonadotropic hypogonadism,	KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,
FGF9	fibroblast growth factor 9(FGF9)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001649~osteoblast differentiation,GO:0001654~eye development,GO:0001934~positive regulation of protein phosphorylation,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002062~chondrocyte differentiation,GO:0006606~protein import into nucleus,GO:0007165~signal transduction,GO:0007224~smoothened signaling pathway,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0008584~male gonad development,GO:0009887~animal organ morphogenesis,GO:0010463~mesenchymal cell proliferation,GO:0010628~positive regulation of gene expression,GO:0021762~substantia nigra development,GO:0030154~cell differentiation,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030238~male sex determination,GO:0030324~lung development,GO:0030326~embryonic limb morphogenesis,GO:0030334~regulation of cell migration,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032924~activin receptor signaling pathway,GO:0032927~positive regulation of activin receptor signaling pathway,GO:0042472~inner ear morphogenesis,GO:0045880~positive regulation of smoothened signaling pathway,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048505~regulation of timing of cell differentiation,GO:0048566~embryonic digestive tract development,GO:0048706~embryonic skeletal system development,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051781~positive regulation of cell division,GO:0060011~Sertoli cell proliferation,GO:0060038~cardiac muscle cell proliferation,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060070~canonical Wnt signaling pathway,GO:0060484~lung-associated mesenchyme development,GO:0072089~stem cell proliferation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1905931~negative regulation of vascular smooth muscle cell differentiation involved in phenotypic switching,GO:2000243~positive regulation of reproductive process,GO:2000648~positive regulation of stem cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005104~fibroblast growth factor receptor binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,	IPR002209:Heparin-binding growth factor/Fibroblast growth factor,IPR008996:Cytokine, IL-1-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05226:Gastric cancer,	612961~Multiple synostoses syndrome 3,		SM00442:FGF,	KW-0221~Differentiation,	KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,
FGFBP1	fibroblast growth factor binding protein 1(FGFBP1)	Homo sapiens			GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008285~negative regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0045743~positive regulation of fibroblast growth factor receptor signaling pathway,GO:0051450~myoblast proliferation,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:2000288~positive regulation of myoblast proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,	GO:0005515~protein binding,GO:0008201~heparin binding,GO:0017134~fibroblast growth factor binding,GO:0019838~growth factor binding,	IPR010510:FGF binding 1,						KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) serine,COMPBIAS:Basic and acidic residues,MUTAGEN:C->A: Strongly reduces interaction with FGF2.,REGION:Disordered,REGION:Sufficient for interaction with FGF2 and FGF2-induced effects,
FGFR1	fibroblast growth factor receptor 1(FGFR1)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001501~skeletal system development,GO:0001764~neuron migration,GO:0001837~epithelial to mesenchymal transition,GO:0006468~protein phosphorylation,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010518~positive regulation of phospholipase activity,GO:0010863~positive regulation of phospholipase C activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0016477~cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0033674~positive regulation of kinase activity,GO:0043009~chordate embryonic development,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045595~regulation of cell differentiation,GO:0045597~positive regulation of cell differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0046777~protein autophosphorylation,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048513~animal organ development,GO:0048705~skeletal system morphogenesis,GO:0051897~positive regulation of protein kinase B signaling,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:2000546~positive regulation of endothelial cell chemotaxis to fibroblast growth factor,GO:2001239~regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031410~cytoplasmic vesicle,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005007~fibroblast growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008201~heparin binding,GO:0017134~fibroblast growth factor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0090722~receptor-receptor interaction,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016248:Tyrosine-protein kinase, fibroblast growth factor receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04520:Adherens junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04714:Thermogenesis,hsa04810:Regulation of actin cytoskeleton,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05230:Central carbon metabolism in cancer,	101600~Pfeiffer syndrome,123150~Jackson-Weiss syndrome,147950~Hypogonadotropic hypogonadism 2 with or without anosmia,166250~Osteoglophonic dysplasia,190440~Trigonocephaly 1,613001~Encephalocraniocutaneous lipomatosis, somatic mosaic,615465~Hartsfield syndrome,	PIRSF000628:fibroblast growth factor receptor,	SM00219:TyrKc,SM00408:IGc2,SM00409:IG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0370~Holoprosencephaly,KW-0956~Kallmann syndrome,KW-0989~Craniosynostosis,KW-0991~Intellectual disability,KW-1016~Hypogonadotropic hypogonadism,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0358~Heparin-binding,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity.,MUTAGEN:D->V: Abolishes interaction with PLCG1.,MUTAGEN:K->A: Loss of kinase activity.,MUTAGEN:R->E: Strongly reduced autophosphorylation in response to FGF signaling. No effect on in vitro kinase activity.,MUTAGEN:R->V: Abolishes interaction with PLCG1.,MUTAGEN:Y->F: Abolishes interaction with PLCG1 and SHB. Decreases phosphorylation of FRS2, activation of RAS and MAP kinase signaling and stimulation of cell proliferation.,MUTAGEN:Y->F: No effect on kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-654.,MUTAGEN:Y->F: Reduced kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-653.,REGION:Disordered,REGION:Heparin-binding,SITE:Breakpoint for translocation to form CEP43-FGFR1 or FGFR1-CEP43 fusion proteins,SITE:Breakpoint for translocation to form CNTRL-FGFR1 OR FGFR1-CNTRL fusion proteins,SITE:Breakpoint for translocation to form FGFR1OP2-FGFR1,SITE:Mediates interaction with PLCG1 and SHB,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FLRT2	fibronectin leucine rich transmembrane protein 2(FLRT2)	Homo sapiens			GO:0003007~heart morphogenesis,GO:0007411~axon guidance,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0050919~negative chemotaxis,GO:0051965~positive regulation of synapse assembly,GO:0061343~cell adhesion involved in heart morphogenesis,GO:0071711~basement membrane organization,GO:2001222~regulation of neuron migration,	GO:0005615~extracellular space,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0043005~neuron projection,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005104~fibroblast growth factor receptor binding,GO:0030674~protein binding, bridging,GO:0045499~chemorepellent activity,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,				SM00013:LRRNT,SM00082:LRRCT,SM00369:LRR_TYP,	KW-0130~Cell adhesion,	KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0492~Microsome,KW-0770~Synapse,KW-0771~Synaptosome,KW-0964~Secreted,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:LRRCT,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FLG	filaggrin(FLG)	Homo sapiens			GO:0018149~peptide cross-linking,GO:0030216~keratinocyte differentiation,GO:0061436~establishment of skin barrier,	GO:0001533~cornified envelope,GO:0005634~nucleus,GO:0005829~cytosol,GO:0036457~keratohyalin granule,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0005198~structural molecule activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,GO:0046914~transition metal ion binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR003303:Filaggrin,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,		146700~Ichthyosis vulgaris,605803~Dermatitis, atopic, susceptibility to, 2,		SM01394:SM01394,			KW-0977~Ichthyosis,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0164~Citrullination,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,REPEAT:Filaggrin 1,REPEAT:Filaggrin 10,REPEAT:Filaggrin 11,REPEAT:Filaggrin 12,REPEAT:Filaggrin 13,REPEAT:Filaggrin 14,REPEAT:Filaggrin 15,REPEAT:Filaggrin 16,REPEAT:Filaggrin 17,REPEAT:Filaggrin 18,REPEAT:Filaggrin 19,REPEAT:Filaggrin 2,REPEAT:Filaggrin 20,REPEAT:Filaggrin 21,REPEAT:Filaggrin 22,REPEAT:Filaggrin 23,REPEAT:Filaggrin 3,REPEAT:Filaggrin 4,REPEAT:Filaggrin 5,REPEAT:Filaggrin 6,REPEAT:Filaggrin 7,REPEAT:Filaggrin 8,REPEAT:Filaggrin 9,
FSHB	follicle stimulating hormone subunit beta(FSHB)	Homo sapiens		h_cremPathway:Regulation of Spermatogenesis by CREM,	GO:0006701~progesterone biosynthetic process,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007283~spermatogenesis,GO:0007292~female gamete generation,GO:0007565~female pregnancy,GO:0008284~positive regulation of cell proliferation,GO:0010469~regulation of receptor activity,GO:0010628~positive regulation of gene expression,GO:0010893~positive regulation of steroid biosynthetic process,GO:0030335~positive regulation of cell migration,GO:0042699~follicle-stimulating hormone signaling pathway,GO:0045670~regulation of osteoclast differentiation,GO:0045780~positive regulation of bone resorption,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060011~Sertoli cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016914~follicle-stimulating hormone complex,	GO:0005179~hormone activity,GO:0005515~protein binding,GO:0016913~follicle-stimulating hormone activity,	IPR001545:Gonadotropin, beta subunit,IPR006208:Cystine knot,IPR018245:Gonadotropin, beta subunit, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,	229070~Hypogonadotropic hypogonadism 24 without anosmia,		SM00068:GHB,		KW-0964~Secreted,	KW-0225~Disease variant,KW-1016~Hypogonadotropic hypogonadism,	KW-0732~Signal,		KW-0372~Hormone,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glycoprotein hormone subunit beta,MUTAGEN:T->E: Increased activation of the follicle-stimulating hormone signaling pathway.,
FSTL1	follistatin like 1(FSTL1)	Homo sapiens			GO:0007275~multicellular organism development,GO:0030154~cell differentiation,GO:0030510~regulation of BMP signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043542~endothelial cell migration,GO:0045446~endothelial cell differentiation,GO:0061484~hematopoietic stem cell homeostasis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,	IPR002048:EF-hand domain,IPR002350:Kazal domain,IPR003645:Follistatin-like, N-terminal,IPR011992:EF-hand-like domain,IPR015369:Follistatin/Osteonectin EGF domain,				SM00274:FOLN,SM00280:KAZAL,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Follistatin-like,DOMAIN:Kazal-like,DOMAIN:VWFC,
FOXA2	forkhead box A2(FOXA2)	Homo sapiens			GO:0000432~positive regulation of transcription from RNA polymerase II promoter by glucose,GO:0001708~cell fate specification,GO:0006325~chromatin organization,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008344~adult locomotory behavior,GO:0009653~anatomical structure morphogenesis,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0030154~cell differentiation,GO:0030193~regulation of blood coagulation,GO:0031018~endocrine pancreas development,GO:0033132~negative regulation of glucokinase activity,GO:0040019~positive regulation of embryonic development,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061178~regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070741~response to interleukin-6,GO:0071542~dopaminergic neuron differentiation,GO:0090009~primitive streak formation,GO:2000049~positive regulation of cell-cell adhesion mediated by cadherin,GO:2000543~positive regulation of gastrulation,GO:2000971~negative regulation of detection of glucose,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0030054~cell junction,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0019904~protein domain specific binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR013638:Fork-head N-terminal,IPR018122:Transcription factor, fork head, conserved site,IPR018533:Forkhead box protein, C-terminal,	hsa04213:Longevity regulating pathway - multiple species,hsa04950:Maturity onset diabetes of the young,			SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DNA_BIND:Fork-head,DOMAIN:Fork-head,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Transactivation domain 1,REGION:Transactivation domain 2,
FOXB2	forkhead box B2(FOXB2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,				SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic residues,COMPBIAS:Pro residues,DNA_BIND:Fork-head,REGION:Disordered,
FOXC2	forkhead box C2(FOXC2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001656~metanephros development,GO:0001657~ureteric bud development,GO:0001756~somitogenesis,GO:0001946~lymphangiogenesis,GO:0001974~blood vessel remodeling,GO:0003275~apoptotic process involved in outflow tract morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0007498~mesoderm development,GO:0007507~heart development,GO:0008286~insulin receptor signaling pathway,GO:0009653~anatomical structure morphogenesis,GO:0009725~response to hormone,GO:0010595~positive regulation of endothelial cell migration,GO:0014032~neural crest cell development,GO:0030154~cell differentiation,GO:0030199~collagen fibril organization,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035050~embryonic heart tube development,GO:0035470~positive regulation of vascular wound healing,GO:0043010~camera-type eye development,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046620~regulation of organ growth,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048343~paraxial mesodermal cell fate commitment,GO:0048703~embryonic viscerocranium morphogenesis,GO:0048844~artery morphogenesis,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060038~cardiac muscle cell proliferation,GO:0072011~glomerular endothelium development,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0072144~glomerular mesangial cell development,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0097746~regulation of blood vessel diameter,GO:1902257~negative regulation of apoptotic process involved in outflow tract morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,		153400~Lymphedema-distichiasis syndrome,153400~Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus,		SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Fork-head,DOMAIN:Fork-head,REGION:Disordered,
FOXE1	forkhead box E1(FOXE1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006590~thyroid hormone generation,GO:0009653~anatomical structure morphogenesis,GO:0016477~cell migration,GO:0030154~cell differentiation,GO:0030878~thyroid gland development,GO:0031069~hair follicle morphogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048538~thymus development,GO:0048562~embryonic organ morphogenesis,GO:0060022~hard palate development,GO:0060023~soft palate development,GO:0060465~pharynx development,GO:1904888~cranial skeletal system development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,		241850~Bamforth-Lazarus syndrome,616534~Thyroid cancer, nonmedullary, 4,		SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0984~Congenital hypothyroidism,			KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DNA_BIND:Fork-head,REGION:Disordered,
FOXF2	forkhead box F2(FOXF2)	Homo sapiens			GO:0001837~epithelial to mesenchymal transition,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009887~animal organ morphogenesis,GO:0030198~extracellular matrix organization,GO:0032434~regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0042249~establishment of planar polarity of embryonic epithelium,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048566~embryonic digestive tract development,GO:0048596~embryonic camera-type eye morphogenesis,GO:0048806~genitalia development,GO:0060021~palate development,GO:1902914~regulation of protein polyubiquitination,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016604~nuclear body,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001093~TFIIB-class transcription factor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,				SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:Fork-head,REGION:Disordered,
FOXG1	forkhead box G1(FOXG1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002052~positive regulation of neuroblast proliferation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007346~regulation of mitotic cell cycle,GO:0007405~neuroblast proliferation,GO:0007420~brain development,GO:0007568~aging,GO:0009953~dorsal/ventral pattern formation,GO:0016199~axon midline choice point recognition,GO:0021852~pyramidal neuron migration,GO:0042472~inner ear morphogenesis,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045787~positive regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048664~neuron fate determination,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,	hsa04068:FoxO signaling pathway,	613454~Rett syndrome, congenital variant,		SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Pro residues,DNA_BIND:Fork-head,MUTAGEN:P->A: Abolishes interaction with KDM5B.,MUTAGEN:VP->AA: Abolishes interaction with KDM5B.,REGION:Disordered,REGION:Interaction with KDM5B,REGION:Required for interaction with TLE6,
FOXL2	forkhead box L2(FOXL2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001541~ovarian follicle development,GO:0001555~oocyte growth,GO:0002074~extraocular skeletal muscle development,GO:0006309~apoptotic DNA fragmentation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007338~single fertilization,GO:0009653~anatomical structure morphogenesis,GO:0019101~female somatic sex determination,GO:0030154~cell differentiation,GO:0033686~positive regulation of luteinizing hormone secretion,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046881~positive regulation of follicle-stimulating hormone secretion,GO:0048048~embryonic eye morphogenesis,GO:0060014~granulosa cell differentiation,GO:0060065~uterus development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090543~Flemming body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0030331~estrogen receptor binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0043028~cysteine-type endopeptidase regulator activity involved in apoptotic process,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,		110100~Blepharophimosis, epicanthus inversus, and ptosis, type 1,110100~Blepharophimosis, epicanthus inversus, and ptosis, type 2,608996~Premature ovarian failure 3,		SM00339:FH,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1066~Premature ovarian failure,			KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:Fork-head,DOMAIN:Fork-head,MUTAGEN:K->R: Results in reduced sumoylation. Loss of transcriptional repression activity.,REGION:Disordered,
FOXS1	forkhead box S1(FOXS1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001568~blood vessel development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,GO:0040018~positive regulation of multicellular organism growth,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050885~neuromuscular process controlling balance,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,				SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,		DNA_BIND:Fork-head,REGION:Disordered,
FMN2	formin 2(FMN2)	Homo sapiens			GO:0006974~cellular response to DNA damage stimulus,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0016477~cell migration,GO:0030036~actin cytoskeleton organization,GO:0035556~intracellular signal transduction,GO:0040038~polar body extrusion after meiotic divisions,GO:0042177~negative regulation of protein catabolic process,GO:0043066~negative regulation of apoptotic process,GO:0045010~actin nucleation,GO:0046907~intracellular transport,GO:0048477~oogenesis,GO:0051295~establishment of meiotic spindle localization,GO:0051758~homologous chromosome movement towards spindle pole involved in homologous chromosome segregation,GO:0070649~formin-nucleated actin cable assembly,GO:0071456~cellular response to hypoxia,GO:2000781~positive regulation of double-strand break repair,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005819~spindle,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0030659~cytoplasmic vesicle membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0003779~actin binding,GO:0008017~microtubule binding,	IPR000591:DEP domain,IPR001265:Formin,IPR015425:Actin-binding FH2,		616193~Intellectual developmental disorder, autosomal recessive 47,		SM00498:FH2,	KW-0227~DNA damage,KW-0346~Stress response,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,		KW-0009~Actin-binding,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FH1,DOMAIN:FH2,MUTAGEN:K->A,E: Abolishes interaction with SPIRE1.,MUTAGEN:K->A,E: Strongly reduces interaction with SPIRE1.,MUTAGEN:K->A: Strongly reduces interaction with SPIRE1.,MUTAGEN:KRR->AAA: Blocks accumulation in the nucleus in response to DNA damage.,REGION:Disordered,REGION:Important for interaction with SPIRE1,
FXN	frataxin(FXN)	Homo sapiens			GO:0006119~oxidative phosphorylation,GO:0006783~heme biosynthetic process,GO:0006811~ion transport,GO:0006879~cellular iron ion homeostasis,GO:0007005~mitochondrion organization,GO:0007628~adult walking behavior,GO:0008284~positive regulation of cell proliferation,GO:0009792~embryo development ending in birth or egg hatching,GO:0010039~response to iron ion,GO:0010722~regulation of ferrochelatase activity,GO:0016226~iron-sulfur cluster assembly,GO:0016540~protein autoprocessing,GO:0018283~iron incorporation into metallo-sulfur cluster,GO:0019230~proprioception,GO:0030307~positive regulation of cell growth,GO:0034755~iron ion transmembrane transport,GO:0035265~organ growth,GO:0040015~negative regulation of multicellular organism growth,GO:0043066~negative regulation of apoptotic process,GO:0043085~positive regulation of catalytic activity,GO:0044571~[2Fe-2S] cluster assembly,GO:0044572~[4Fe-4S] cluster assembly,GO:0046621~negative regulation of organ growth,GO:0046716~muscle cell cellular homeostasis,GO:0051349~positive regulation of lyase activity,GO:0055072~iron ion homeostasis,GO:0070301~cellular response to hydrogen peroxide,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:1904231~positive regulation of succinate dehydrogenase activity,GO:1904234~positive regulation of aconitate hydratase activity,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0099128~mitochondrial iron-sulfur cluster assembly complex,GO:1990221~L-cysteine desulfurase complex,GO:1990229~iron-sulfur cluster assembly complex,	GO:0004322~ferroxidase activity,GO:0005515~protein binding,GO:0008198~ferrous iron binding,GO:0008199~ferric iron binding,GO:0034986~iron chaperone activity,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR002908:Frataxin/CyaY,IPR017789:Frataxin,IPR020895:Frataxin conserved site,	hsa00860:Porphyrin metabolism,	229300~Friedreich ataxia,229300~Friedreich ataxia with retained reflexes,		SM01219:SM01219,	KW-0350~Heme biosynthesis,KW-0406~Ion transport,KW-0409~Iron storage,KW-0410~Iron transport,KW-0813~Transport,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,		MUTAGEN:D->G: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:D->K: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:D->K: Drasticly reduces interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:D->Y: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:E->K: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:E->K: Significantly reduces interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:G->V: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:I->F: Reduces interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:LR->GG: Abolishes cleavage to yield frataxin mature form and allows accumulation of frataxin(56-210) and frataxin(78-210).,MUTAGEN:N->A: Does not affect interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,MUTAGEN:RK->GG: Abolishes cleavage to yield frataxin mature form and allows the accumulation of frataxin(56-210).,MUTAGEN:RR->GG: Abolishes cleavage to yield frataxin intermediate form and allows accumulation of frataxin(56-210) and frataxin(78-210).,MUTAGEN:RR->GG: No effect on processing of wild-type FXN.,MUTAGEN:W->G: Loss of interaction with the core iron-sulfur cluster assembly complex. Does not affect mitochondrial localization. Does not affect proteolytic processing.,TRANSIT:Mitochondrion,
FFAR2	free fatty acid receptor 2(FFAR2)	Homo sapiens			GO:0002232~leukocyte chemotaxis involved in inflammatory response,GO:0002385~mucosal immune response,GO:0002673~regulation of acute inflammatory response,GO:0002720~positive regulation of cytokine production involved in immune response,GO:0002752~cell surface pattern recognition receptor signaling pathway,GO:0002879~positive regulation of acute inflammatory response to non-antigenic stimulus,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0019915~lipid storage,GO:0032024~positive regulation of insulin secretion,GO:0032722~positive regulation of chemokine production,GO:0032757~positive regulation of interleukin-8 production,GO:0042593~glucose homeostasis,GO:0045444~fat cell differentiation,GO:0046676~negative regulation of insulin secretion,GO:0071398~cellular response to fatty acid,GO:0090276~regulation of peptide hormone secretion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0042995~cell projection,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR013312:G protein-coupled receptor 40-related receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,				KW-0391~Immunity,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:E->A: Partial loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:G->E: Partial loss of SCFA-independent constitutive G protein-coupled receptor activity.,MUTAGEN:H->A,F: Complete loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:H->A: Partial loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:N->A: Complete loss of acetate-induced G protein-coupled receptor activity.,MUTAGEN:Q->A: No effect on SCFA-induced G protein-coupled receptor activity.,MUTAGEN:Q->E: Partial loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:R->A,K,L,S: Complete loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:R->A: Complete loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:Y->A: Complete loss of SCFA-induced G protein-coupled receptor activity.,MUTAGEN:Y->A: Partial loss of propionate-induced G protein-coupled receptor activity.,MUTAGEN:Y->W: Complete loss of acetate-induced G protein-coupled receptor activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FZD10	frizzled class receptor 10(FZD10)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0030182~neuron differentiation,GO:0032956~regulation of actin cytoskeleton organization,GO:0034260~negative regulation of GTPase activity,GO:0035567~non-canonical Wnt signaling pathway,GO:0038031~non-canonical Wnt signaling pathway via JNK cascade,GO:0043507~positive regulation of JUN kinase activity,GO:0043547~positive regulation of GTPase activity,GO:0060070~canonical Wnt signaling pathway,GO:0071300~cellular response to retinoic acid,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0017147~Wnt-protein binding,GO:0042813~Wnt-activated receptor activity,	IPR000539:Frizzled protein,IPR015526:Frizzled/secreted frizzled-related protein,IPR017981:GPCR, family 2-like,IPR020067:Frizzled domain,IPR026549:Frizzled-10,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00063:FRI,SM01330:SM01330,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:FZ,DOMAIN:G-protein coupled receptors family 2 profile 2,MOTIF:Lys-Thr-X-X-X-Trp motif, mediates interaction with the PDZ domain of Dvl family members,MOTIF:PDZ-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FBP1	fructose-bisphosphatase 1(FBP1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0005975~carbohydrate metabolic process,GO:0005986~sucrose biosynthetic process,GO:0006000~fructose metabolic process,GO:0006002~fructose 6-phosphate metabolic process,GO:0006094~gluconeogenesis,GO:0006111~regulation of gluconeogenesis,GO:0016311~dephosphorylation,GO:0030308~negative regulation of cell growth,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0031667~response to nutrient levels,GO:0032869~cellular response to insulin stimulus,GO:0045820~negative regulation of glycolytic process,GO:0046580~negative regulation of Ras protein signal transduction,GO:0071286~cellular response to magnesium ion,GO:0071320~cellular response to cAMP,GO:0071466~cellular response to xenobiotic stimulus,GO:0071475~cellular hyperosmotic salinity response,GO:0071477~cellular hypotonic salinity response,GO:0097403~cellular response to raffinose,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0016208~AMP binding,GO:0042132~fructose 1,6-bisphosphate 1-phosphatase activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0048029~monosaccharide binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000146:Fructose-1,6-bisphosphatase class 1/Sedoheputulose-1,7-bisphosphatase,IPR020548:Fructose-1,6-bisphosphatase, active site,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04152:AMPK signaling pathway,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,	229700~Fructose-1,6-bisphosphatase deficiency,	PIRSF000904:fructose-1,6-bisphosphatase/sedoheptulose-1,7-bisphosphatase,PIRSF500210:fructose-1,6-bisphosphatase [Parent=PIRSF000904],		KW-0119~Carbohydrate metabolism,KW-0312~Gluconeogenesis,		KW-0225~Disease variant,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0021~Allosteric enzyme,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Fructose-1-6-bisphosphatase class 1 C-terminal,DOMAIN:Fructose-1-6-bisphosphatase class I N-terminal,MUTAGEN:D->A: Reduced activity.,MUTAGEN:Q->E: Increased affinity towards Ca(2+) and Mg(2+).,REGION:Disordered,
FUT2	fucosyltransferase 2(FUT2)	Homo sapiens			GO:0001936~regulation of endothelial cell proliferation,GO:0005975~carbohydrate metabolic process,GO:0006486~protein glycosylation,GO:0006664~glycolipid metabolic process,GO:0009312~oligosaccharide biosynthetic process,GO:0030155~regulation of cell adhesion,GO:0036065~fucosylation,GO:0042355~L-fucose catabolic process,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0032580~Golgi cisterna membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008107~galactoside 2-alpha-L-fucosyltransferase activity,GO:0008417~fucosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0031127~alpha-(1,2)-fucosyltransferase activity,	IPR002516:Glycosyl transferase, family 11,	hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa00603:Glycosphingolipid biosynthesis - globo and isoglobo series,hsa01100:Metabolic pathways,	612542~Vitamin B12 plasma level QTL1,616754~Bombay phenotype, digenic,Norwalk virus infection, resistance to~Norwalk virus infection, resistance to,			KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0934~Plastid,		KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,UNSURE:D or N,
FURIN	furin, paired basic amino acid cleaving enzyme(FURIN)	Homo sapiens		h_notchPathway:Proteolysis and Signaling Pathway of Notch ,	GO:0001825~blastocyst formation,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006465~signal peptide processing,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0009966~regulation of signal transduction,GO:0016485~protein processing,GO:0016486~peptide hormone processing,GO:0019058~viral life cycle,GO:0019081~viral translation,GO:0019082~viral protein processing,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030574~collagen catabolic process,GO:0031638~zymogen activation,GO:0032374~regulation of cholesterol transport,GO:0032804~negative regulation of low-density lipoprotein particle receptor catabolic process,GO:0032902~nerve growth factor production,GO:0032911~negative regulation of transforming growth factor beta1 production,GO:0032940~secretion by cell,GO:0034369~plasma lipoprotein particle remodeling,GO:0042176~regulation of protein catabolic process,GO:0043043~peptide biosynthetic process,GO:0046598~positive regulation of viral entry into host cell,GO:0051004~regulation of lipoprotein lipase activity,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051604~protein maturation,GO:0052548~regulation of endopeptidase activity,GO:0090472~dibasic protein processing,GO:0097341~zymogen inhibition,GO:1901394~positive regulation of transforming growth factor beta1 activation,GO:1990000~amyloid fibril formation,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005796~Golgi lumen,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030140~trans-Golgi network transport vesicle,GO:0030173~integral component of Golgi membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0004175~endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008233~peptidase activity,GO:0008236~serine-type peptidase activity,GO:0042277~peptide binding,GO:0046872~metal ion binding,GO:0048406~nerve growth factor binding,GO:1904399~heparan sulfate binding,	IPR000209:Peptidase S8/S53 domain,IPR002884:Proprotein convertase, P,IPR006212:Furin-like repeat,IPR008979:Galactose-binding domain-like,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR015500:Peptidase S8, subtilisin-related,IPR022398:Peptidase S8, subtilisin, His-active site,IPR023827:Peptidase S8, subtilisin,  Asp-active site,IPR023828:Peptidase S8, subtilisin, Ser-active site,	hsa03250:Viral life cycle - HIV-1,			SM00261:FU,	KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:P/Homo B,DOMAIN:Peptidase S8,DOMAIN:Peptidase S8 pro-domain,DOMAIN:Peptidase S8/S53,MOTIF:Cell attachment site,MOTIF:Trans Golgi network signal,MUTAGEN:D->N: Loss of catalytic activity and propeptide first cleavage. Abnormal accumulation in the early secretory pathway.,MUTAGEN:R->A: Loss of catalytic activity and, propeptide second cleavage and removal. Normal trafficking to the Golgi.,MUTAGEN:S->A: Slight reduction in phosphorylation. Loss of phosphorylation and abnormal accumulation in the early secretory pathway; when associated with A-773.,MUTAGEN:S->A: Slight reduction in phosphorylation. Loss of phosphorylation and abnormal accumulation in the early secretory pathway; when associated with A-775.,MUTAGEN:SDS->DDD: Phosphomimetic mutant. Localization in early endosome is increased.,MUTAGEN:V->R: Loss of catalytic activity and propeptide second cleavage and removal. Abnormal accumulation in the early secretory pathway.,PROPEP:Inhibition peptide,REGION:Cell surface signal,REGION:Disordered,REPEAT:FU 1,REPEAT:FU 2,SITE:Cleavage, first; by autolysis,SITE:Cleavage, second; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
GAL	galanin and GMAP prepropeptide(GAL)	Homo sapiens			GO:0006954~inflammatory response,GO:0007218~neuropeptide signaling pathway,GO:0007631~feeding behavior,GO:0009410~response to xenobiotic stimulus,GO:0010737~protein kinase A signaling,GO:0019933~cAMP-mediated signaling,GO:0030073~insulin secretion,GO:0031943~regulation of glucocorticoid metabolic process,GO:0032868~response to insulin,GO:0035902~response to immobilization stress,GO:0043065~positive regulation of apoptotic process,GO:0043627~response to estrogen,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050672~negative regulation of lymphocyte proliferation,GO:0051464~positive regulation of cortisol secretion,GO:0051795~positive regulation of timing of catagen,GO:1902608~positive regulation of large conductance calcium-activated potassium channel activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0030141~secretory granule,GO:0043025~neuronal cell body,	GO:0004966~galanin receptor activity,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0031763~galanin receptor binding,GO:0031764~type 1 galanin receptor binding,GO:0031765~type 2 galanin receptor binding,GO:0031766~type 3 galanin receptor binding,	IPR008174:Galanin,IPR008175:Galanin precursor,IPR013068:Galanin message associated peptide (GMAP),	hsa04080:Neuroactive ligand-receptor interaction,	616461~Epilepsy, familial temporal lobe, 8,		SM00071:Galanin,		KW-0964~Secreted,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,		KW-0372~Hormone,KW-0527~Neuropeptide,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,PEPTIDE:Galanin,PEPTIDE:Galanin message-associated peptide,REGION:Disordered,
GALR1	galanin receptor 1(GALR1)	Homo sapiens			GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051464~positive regulation of cortisol secretion,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004966~galanin receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000405:Galanin receptor family,IPR003906:Galanin receptor 1,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GALR2	galanin receptor 2(GALR2)	Homo sapiens			GO:0006936~muscle contraction,GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007275~multicellular organism development,GO:0007611~learning or memory,GO:0007631~feeding behavior,GO:0031175~neuron projection development,GO:0043647~inositol phosphate metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046488~phosphatidylinositol metabolic process,GO:0090663~galanin-activated signaling pathway,GO:1902608~positive regulation of large conductance calcium-activated potassium channel activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005929~cilium,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004966~galanin receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000405:Galanin receptor family,IPR003907:Galanin receptor 2,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
LGALS2	galectin 2(LGALS2)	Homo sapiens			GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0050729~positive regulation of inflammatory response,GO:0098609~cell-cell adhesion,	GO:0005737~cytoplasm,GO:1990724~galectin complex,	GO:0005515~protein binding,GO:0016936~galactoside binding,GO:0030246~carbohydrate binding,	IPR001079:Galectin, carbohydrate recognition domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,		608446~Myocardial infarction, susceptibility to,		SM00276:GLECT,SM00908:SM00908,					KW-0430~Lectin,			DOMAIN:Galectin,REGION:Disordered,
LGALS3BP	galectin 3 binding protein(LGALS3BP)	Homo sapiens			GO:0006897~endocytosis,GO:0006968~cellular defense response,GO:0007155~cell adhesion,GO:0007165~signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016020~membrane,GO:0031089~platelet dense granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0005044~scavenger receptor activity,GO:0005515~protein binding,	IPR000210:BTB/POZ-like,IPR001190:Speract/scavenger receptor,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR017448:Speract/scavenger receptor-related,				SM00202:SR,SM00875:SM00875,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:BACK,DOMAIN:BTB,DOMAIN:SRCR,REGION:Disordered,
LGALS7B	galectin 7B(LGALS7B)	Homo sapiens			GO:0006915~apoptotic process,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0010628~positive regulation of gene expression,GO:0032689~negative regulation of interferon-gamma production,GO:2000562~negative regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0016936~galactoside binding,GO:0030246~carbohydrate binding,	IPR001079:Galectin, carbohydrate recognition domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00276:GLECT,SM00908:SM00908,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,			KW-0430~Lectin,			DOMAIN:Galectin,REGION:Disordered,
LGALS8	galectin 8(LGALS8)	Homo sapiens			GO:0098586~cellular response to virus,GO:0098792~xenophagy,GO:1904977~lymphatic endothelial cell migration,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,	GO:0005178~integrin binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,	IPR001079:Galectin, carbohydrate recognition domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00276:GLECT,SM00908:SM00908,	KW-0072~Autophagy,	KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0430~Lectin,			COMPBIAS:Polar residues,DOMAIN:Galectin,DOMAIN:Galectin 1,DOMAIN:Galectin 2,MUTAGEN:R->H: Abolishes localization to cytoplasmic vesicles in case of infection by S.typhimurium.,MUTAGEN:R->H: Does not affect localization to cytoplasmic vesicles in case of infection by S.typhimurium.,REGION:Disordered,SITE:Critical for binding to sialylated and sulfated oligosaccharides,
GJA4	gap junction protein alpha 4(GJA4)	Homo sapiens			GO:0001568~blood vessel development,GO:0003158~endothelium development,GO:0006816~calcium ion transport,GO:0007043~cell-cell junction assembly,GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0048265~response to pain,GO:0055085~transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005921~gap junction,GO:0005922~connexin complex,GO:0016021~integral component of membrane,	GO:0005243~gap junction channel activity,GO:0005515~protein binding,	IPR000500:Connexin,IPR002263:Gap junction alpha-4 protein (Cx37),IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,				SM00037:CNX,SM01089:SM01089,		KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Connexin N-terminal,DOMAIN:Gap junction protein cysteine-rich,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GJA5	gap junction protein alpha 5(GJA5)	Homo sapiens			GO:0001525~angiogenesis,GO:0003105~negative regulation of glomerular filtration,GO:0003151~outflow tract morphogenesis,GO:0003158~endothelium development,GO:0003161~cardiac conduction system development,GO:0003174~mitral valve development,GO:0003193~pulmonary valve formation,GO:0003281~ventricular septum development,GO:0003283~atrial septum development,GO:0006813~potassium ion transport,GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0007507~heart development,GO:0010643~cell communication by chemical coupling,GO:0010644~cell communication by electrical coupling,GO:0010649~regulation of cell communication by electrical coupling,GO:0010652~positive regulation of cell communication by chemical coupling,GO:0016264~gap junction assembly,GO:0042311~vasodilation,GO:0045776~negative regulation of blood pressure,GO:0045907~positive regulation of vasoconstriction,GO:0048844~artery morphogenesis,GO:0055085~transmembrane transport,GO:0055117~regulation of cardiac muscle contraction,GO:0060307~regulation of ventricular cardiac muscle cell membrane repolarization,GO:0060371~regulation of atrial cardiac muscle cell membrane depolarization,GO:0060373~regulation of ventricular cardiac muscle cell membrane depolarization,GO:0086021~SA node cell to atrial cardiac muscle cell communication by electrical coupling,GO:0086044~atrial cardiac muscle cell to AV node cell communication by electrical coupling,GO:0086053~AV node cell to bundle of His cell communication by electrical coupling,GO:0086054~bundle of His cell to Purkinje myocyte communication by electrical coupling,GO:0086055~Purkinje myocyte to ventricular cardiac muscle cell communication by electrical coupling,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0098904~regulation of AV node cell action potential,GO:0098905~regulation of bundle of His cell action potential,GO:0098906~regulation of Purkinje myocyte action potential,GO:0098910~regulation of atrial cardiac muscle cell action potential,GO:1990029~vasomotion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005921~gap junction,GO:0005922~connexin complex,GO:0014704~intercalated disc,GO:0016021~integral component of membrane,GO:0042995~cell projection,	GO:0005243~gap junction channel activity,GO:0005515~protein binding,GO:0055077~gap junction hemi-channel activity,GO:0071253~connexin binding,GO:0086020~gap junction channel activity involved in SA node cell-atrial cardiac muscle cell electrical coupling,GO:0086075~gap junction channel activity involved in cardiac conduction electrical coupling,GO:0086076~gap junction channel activity involved in atrial cardiac muscle cell-AV node cell electrical coupling,GO:0086077~gap junction channel activity involved in AV node cell-bundle of His cell electrical coupling,GO:0086078~gap junction channel activity involved in bundle of His cell-Purkinje myocyte electrical coupling,GO:0086079~gap junction channel activity involved in Purkinje myocyte-ventricular cardiac muscle cell electrical coupling,GO:0097718~disordered domain specific binding,	IPR000500:Connexin,IPR002264:Gap junction alpha-5 protein (Cx40),IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,		108770~Atrial standstill, digenic (GJA5/SCN5A),614049~Atrial fibrillation, familial, 11,		SM00037:CNX,SM01089:SM01089,		KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1020~Atrial fibrillation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Connexin N-terminal,DOMAIN:Gap junction protein cysteine-rich,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GJB2	gap junction protein beta 2(GJB2)	Homo sapiens			GO:0002931~response to ischemia,GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0007568~aging,GO:0007605~sensory perception of sound,GO:0010644~cell communication by electrical coupling,GO:0016264~gap junction assembly,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0032526~response to retinoic acid,GO:0032570~response to progesterone,GO:0034599~cellular response to oxidative stress,GO:0044752~response to human chorionic gonadotropin,GO:0046677~response to antibiotic,GO:0046697~decidualization,GO:0048839~inner ear development,GO:0055085~transmembrane transport,GO:0071377~cellular response to glucagon stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:1905867~epididymis development,GO:1990349~gap junction-mediated intercellular transport,	GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005921~gap junction,GO:0005922~connexin complex,GO:0016021~integral component of membrane,GO:0016328~lateral plasma membrane,GO:0044297~cell body,GO:0048471~perinuclear region of cytoplasm,GO:0097449~astrocyte projection,	GO:0005243~gap junction channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:1903763~gap junction channel activity involved in cell communication by electrical coupling,	IPR000500:Connexin,IPR002268:Gap junction beta-2 protein (Cx26),IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,		124500~Vohwinkel syndrome,148210~Keratitis-ichthyosis-deafness syndrome,148350~Keratoderma, palmoplantar, with deafness,149200~Bart-Pumphrey syndrome,220290~Deafness, autosomal recessive 1A,601544~Deafness, autosomal dominant 3A,602540~Hystrix-like ichthyosis with deafness,		SM00037:CNX,SM01089:SM01089,	KW-1009~Hearing,	KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0209~Deafness,KW-0225~Disease variant,KW-0977~Ichthyosis,KW-1007~Palmoplantar keratoderma,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-1015~Disulfide bond,	BINDING:in other chain,COMPBIAS:Polar residues,DOMAIN:Connexin N-terminal,DOMAIN:Gap junction protein cysteine-rich,MUTAGEN:M->A: Loss of gap junction ion conductance, probably due to very low open probability of the channels. Can form functional channels with wild-type, but with strongly reduced channel conductance. No visible effect on channel assembly and membrane insertion.,MUTAGEN:Missing: Loss of gap junction ion conductance.,MUTAGEN:Missing: Strongly reduced insertion into the cell membrane and strongly reduced gap junction plaque assembly.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GJB5	gap junction protein beta 5(GJB5)	Homo sapiens			GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0008544~epidermis development,GO:0055085~transmembrane transport,GO:0060707~trophoblast giant cell differentiation,GO:0060708~spongiotrophoblast differentiation,GO:0060713~labyrinthine layer morphogenesis,GO:1905867~epididymis development,	GO:0005922~connexin complex,GO:0016021~integral component of membrane,	GO:0005243~gap junction channel activity,GO:0005515~protein binding,	IPR000500:Connexin,IPR002271:Gap junction beta-5 protein (Cx30.3),IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,				SM00037:CNX,SM01089:SM01089,		KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Connexin N-terminal,DOMAIN:Gap junction protein cysteine-rich,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GRP	gastrin releasing peptide(GRP)	Homo sapiens			GO:0007165~signal transduction,GO:0007218~neuropeptide signaling pathway,GO:0035176~social behavior,GO:0036343~psychomotor behavior,GO:0043207~response to external biotic stimulus,GO:0043303~mast cell degranulation,GO:0090277~positive regulation of peptide hormone secretion,GO:1900738~positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway,GO:1903817~negative regulation of voltage-gated potassium channel activity,GO:1903942~positive regulation of respiratory gaseous exchange,GO:1905151~negative regulation of voltage-gated sodium channel activity,GO:2000987~positive regulation of behavioral fear response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0034774~secretory granule lumen,GO:0043005~neuron projection,GO:0098992~neuronal dense core vesicle,	GO:0005102~receptor binding,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,	IPR000874:Bombesin/neuromedin-B/ranatensin peptide family,IPR015674:Gastrin releasing peptide,	hsa04080:Neuroactive ligand-receptor interaction,				KW-0467~Mast cell degranulation,	KW-0964~Secreted,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,			KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	COMPBIAS:Polar residues,PEPTIDE:Gastrin-releasing peptide,PEPTIDE:Neuromedin-C,REGION:Disordered,
GBX2	gastrulation brain homeobox 2(GBX2)	Homo sapiens			GO:0001569~branching involved in blood vessel morphogenesis,GO:0001755~neural crest cell migration,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0021549~cerebellum development,GO:0021555~midbrain-hindbrain boundary morphogenesis,GO:0021568~rhombomere 2 development,GO:0021794~thalamus development,GO:0021884~forebrain neuron development,GO:0021930~cerebellar granule cell precursor proliferation,GO:0042472~inner ear morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048483~autonomic nervous system development,GO:0051960~regulation of nervous system development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
GDNF	glial cell derived neurotrophic factor(GDNF)	Homo sapiens			GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001755~neural crest cell migration,GO:0001759~organ induction,GO:0001941~postsynaptic membrane organization,GO:0003337~mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0008344~adult locomotory behavior,GO:0010468~regulation of gene expression,GO:0021516~dorsal spinal cord development,GO:0021784~postganglionic parasympathetic fiber development,GO:0030432~peristalsis,GO:0031175~neuron projection development,GO:0032770~positive regulation of monooxygenase activity,GO:0033603~positive regulation of dopamine secretion,GO:0043066~negative regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048255~mRNA stabilization,GO:0048484~enteric nervous system development,GO:0048485~sympathetic nervous system development,GO:0048568~embryonic organ development,GO:0048731~system development,GO:0051584~regulation of dopamine uptake involved in synaptic transmission,GO:0060676~ureteric bud formation,GO:0060688~regulation of morphogenesis of a branching structure,GO:0061642~chemoattraction of axon,GO:0071679~commissural neuron axon guidance,GO:0072107~positive regulation of ureteric bud formation,GO:0072108~positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:2000736~regulation of stem cell differentiation,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,GO:2001260~regulation of semaphorin-plexin signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0030116~glial cell-derived neurotrophic factor receptor binding,GO:0030971~receptor tyrosine kinase binding,GO:0042803~protein homodimerization activity,GO:1902379~chemoattractant activity involved in axon guidance,	IPR001839:Transforming growth factor-beta, C-terminal,IPR016649:Glial cell line-derived neurotrophic factor,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,	613711~Hirschsprung disease, susceptibility to, 3,	PIRSF016238:glial cell line-derived neurotrophic factor [Parent=PIRSF800009],	SM00204:TGFB,		KW-0964~Secreted,	KW-0225~Disease variant,KW-0367~Hirschsprung disease,	KW-0732~Signal,		KW-0339~Growth factor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:TGF-beta family profile,REGION:Disordered,
GCM2	glial cells missing transcription factor 2(GCM2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006874~cellular calcium ion homeostasis,GO:0030643~cellular phosphate ion homeostasis,GO:0042063~gliogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048856~anatomical structure development,GO:0060017~parathyroid gland development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003902:Transcription regulator, GCM-like,	hsa04928:Parathyroid hormone synthesis, secretion and action,	617343~Hyperparathyroidism 4,618883~Hypoparathyroidism, familial isolated 2,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:GCM,DOMAIN:GCM,REGION:C-terminal conserved inhibitory domain (CCID),REGION:Disordered,
GFAP	glial fibrillary acidic protein(GFAP)	Homo sapiens		h_prionPathway:Prion Pathway,	GO:0006886~intracellular protein transport,GO:0009611~response to wounding,GO:0010467~gene expression,GO:0010625~positive regulation of Schwann cell proliferation,GO:0010977~negative regulation of neuron projection development,GO:0014002~astrocyte development,GO:0014010~Schwann cell proliferation,GO:0030198~extracellular matrix organization,GO:0031102~neuron projection regeneration,GO:0043254~regulation of protein complex assembly,GO:0045109~intermediate filament organization,GO:0051580~regulation of neurotransmitter uptake,GO:0060020~Bergmann glial cell differentiation,GO:0060291~long-term synaptic potentiation,GO:0070779~D-aspartate import,GO:1904714~regulation of chaperone-mediated autophagy,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0042995~cell projection,GO:0044297~cell body,GO:0045111~intermediate filament cytoskeleton,GO:0097450~astrocyte end-foot,GO:0098574~cytoplasmic side of lysosomal membrane,	GO:0005178~integrin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,	IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,	hsa04630:JAK-STAT signaling pathway,	203450~Alexander disease,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1026~Leukodystrophy,	KW-0175~Coiled coil,			KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,
GLDN	gliomedin(GLDN)	Homo sapiens			GO:0007165~signal transduction,GO:0032528~microvillus organization,GO:0034113~heterotypic cell-cell adhesion,GO:0045162~clustering of voltage-gated sodium channels,	GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030424~axon,	GO:0086080~protein binding involved in heterotypic cell-cell adhesion,	IPR003112:Olfactomedin-like,IPR008160:Collagen triple helix repeat,		617194~Lethal congenital contracture syndrome 11,		SM00284:OLF,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Olfactomedin-like,REGION:Disordered,SITE:Cleavage; by BMP1,SITE:Cleavage; by furin-like protease,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GLP1R	glucagon like peptide 1 receptor(GLP1R)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007611~learning or memory,GO:0008016~regulation of heart contraction,GO:0019933~cAMP-mediated signaling,GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0045776~negative regulation of blood pressure,GO:0045777~positive regulation of blood pressure,GO:0046879~hormone secretion,GO:0071377~cellular response to glucagon stimulus,GO:1990911~response to psychosocial stress,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0004967~glucagon receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,GO:0044508~glucagon-like peptide 1 receptor activity,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR003290:GPCR, family 2, glucagon-like peptide-1/glucagon receptor,IPR003292:GPCR, family 2, glucagon-like peptide-1 receptor,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04911:Insulin secretion,			SM00008:HormR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,MUTAGEN:E->A: No effect on stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:E->A: Slightly decreases stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:E->Q: No effect on stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:G->C: Causes the formation of an artifactual disulfide bond that abolishes signaling in response to GLP-1 binding; when associated with C-317.,MUTAGEN:I->C: Causes the formation of an artifactual disulfide bond that abolishes signaling in response to GLP-1 binding; when associated with C-361.,MUTAGEN:L->A: Abolishes stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:L->A: No effect on stimulation of cAMP accumulation and on GLP-1 binding.,MUTAGEN:P->A: Strongly decreased stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:R->A: Strongly decreased stimulation of cAMP accumulation in response to GLP-1.,MUTAGEN:R->Q: Decreases sensitivity to GLP-1.,MUTAGEN:S->A: Abolishes inhibition by negative allosteric modulators.,MUTAGEN:T->A: Abolishes inhibition by the negative allosteric modulators NNC0640 and PF-06372222, but does not abolish inhibition by MK-0893.,MUTAGEN:Y->A: Abolishes stimulation of cAMP accumulation in response to GLP-1.,REGION:Important for allosteric inhibitor binding,SITE:Interaction with the endogenous ligand GLP-1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GCNT2	glucosaminyl (N-acetyl) transferase 2 (I blood group)(GCNT2)	Homo sapiens			GO:0006024~glycosaminoglycan biosynthetic process,GO:0006486~protein glycosylation,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0010608~posttranscriptional regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010812~negative regulation of cell-substrate adhesion,GO:0030335~positive regulation of cell migration,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0036438~maintenance of lens transparency,GO:0051897~positive regulation of protein kinase B signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0008109~N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity,GO:0008375~acetylglucosaminyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,	IPR003406:Glycosyl transferase, family 14,	hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa01100:Metabolic pathways,	110800~Adult i phenotype without cataract,110800~Blood group, Ii,116700~Cataract 13 with adult i phenotype,				KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0898~Cataract,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GBA3	glucosylceramidase beta 3 (gene/pseudogene)(GBA3)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006680~glucosylceramide catabolic process,GO:0006683~galactosylceramide catabolic process,GO:0006687~glycosphingolipid metabolic process,GO:0009313~oligosaccharide catabolic process,GO:0016139~glycoside catabolic process,GO:0046477~glycosylceramide catabolic process,GO:0050821~protein stabilization,GO:0051692~cellular oligosaccharide catabolic process,GO:1901805~beta-glucoside catabolic process,GO:1903017~positive regulation of exo-alpha-sialidase activity,	GO:0005829~cytosol,GO:1902494~catalytic complex,	GO:0004336~galactosylceramidase activity,GO:0004348~glucosylceramidase activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004565~beta-galactosidase activity,GO:0005515~protein binding,GO:0008422~beta-glucosidase activity,GO:0017042~glycosylceramidase activity,GO:0102483~scopolin beta-glucosidase activity,	IPR001360:Glycoside hydrolase, family 1,IPR017853:Glycoside hydrolase, superfamily,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,				KW-0326~Glycosidase,KW-0378~Hydrolase,		ACT_SITE:Nucleophile,ACT_SITE:Proton donor,MUTAGEN:E->D: 2-fold decreased glucosylceramidase activity.,MUTAGEN:E->Q: Loss of glucosylceramidase activity.,MUTAGEN:F->S: Decreased glucosidase activity.,MUTAGEN:V->Y: No change in temperature or pH dependence. Decreased glucosidase activity.,MUTAGEN:Y->F,A: Decreased glucosidase activity.,
GAD1	glutamate decarboxylase 1(GAD1)	Homo sapiens			GO:0006538~glutamate catabolic process,GO:0006540~glutamate decarboxylation to succinate,GO:0007268~chemical synaptic transmission,GO:0009449~gamma-aminobutyric acid biosynthetic process,GO:0018352~protein-pyridoxal-5-phosphate linkage,GO:0019752~carboxylic acid metabolic process,GO:0035176~social behavior,GO:0035641~locomotory exploration behavior,GO:0042136~neurotransmitter biosynthetic process,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0012506~vesicle membrane,GO:0043679~axon terminus,GO:0048786~presynaptic active zone,GO:0060077~inhibitory synapse,GO:0061202~clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane,GO:0098982~GABA-ergic synapse,	GO:0004351~glutamate decarboxylase activity,GO:0005515~protein binding,GO:0016830~carbon-carbon lyase activity,GO:0016831~carboxy-lyase activity,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR002129:Pyridoxal phosphate-dependent decarboxylase,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015424:Pyridoxal phosphate-dependent transferase,IPR021115:Pyridoxal-phosphate binding site,	hsa00250:Alanine, aspartate and glutamate metabolism,hsa00410:beta-Alanine metabolism,hsa00430:Taurine and hypotaurine metabolism,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,hsa04727:GABAergic synapse,hsa04940:Type I diabetes mellitus,	619124~Developmental and epileptic encephalopathy 89,			KW-0530~Neurotransmitter biosynthesis,		KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,		KW-0663~Pyridoxal phosphate,	KW-0210~Decarboxylase,KW-0456~Lyase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
GRIA1	glutamate ionotropic receptor AMPA type subunit 1(GRIA1)	Homo sapiens			GO:0001919~regulation of receptor recycling,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007416~synapse assembly,GO:0007616~long-term memory,GO:0009410~response to xenobiotic stimulus,GO:0010226~response to lithium ion,GO:0010628~positive regulation of gene expression,GO:0019228~neuronal action potential,GO:0021510~spinal cord development,GO:0021987~cerebral cortex development,GO:0031623~receptor internalization,GO:0032355~response to estradiol,GO:0034220~ion transmembrane transport,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0035249~synaptic transmission, glutamatergic,GO:0042220~response to cocaine,GO:0045838~positive regulation of membrane potential,GO:0046685~response to arsenic-containing substance,GO:0050804~modulation of synaptic transmission,GO:0050806~positive regulation of synaptic transmission,GO:0051602~response to electrical stimulus,GO:0060078~regulation of postsynaptic membrane potential,GO:0060292~long term synaptic depression,GO:0060992~response to fungicide,GO:0071230~cellular response to amino acid stimulus,GO:0071242~cellular response to ammonium ion,GO:0071359~cellular response to dsRNA,GO:0071375~cellular response to peptide hormone stimulus,GO:0071418~cellular response to amine stimulus,GO:0099505~regulation of presynaptic membrane potential,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,GO:1990416~cellular response to brain-derived neurotrophic factor stimulus,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0030666~endocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,GO:0031901~early endosome membrane,GO:0032281~AMPA glutamate receptor complex,GO:0032591~dendritic spine membrane,GO:0032809~neuronal cell body membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0044308~axonal spine,GO:0044309~neuron spine,GO:0045211~postsynaptic membrane,GO:0048787~presynaptic active zone membrane,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0060076~excitatory synapse,GO:0097060~synaptic membrane,GO:0098793~presynapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099061~integral component of postsynaptic density membrane,GO:0099544~perisynaptic space,	GO:0001540~beta-amyloid binding,GO:0001965~G-protein alpha-subunit binding,GO:0004970~ionotropic glutamate receptor activity,GO:0004971~AMPA glutamate receptor activity,GO:0005515~protein binding,GO:0008066~glutamate receptor activity,GO:0008179~adenylate cyclase binding,GO:0015276~ligand-gated ion channel activity,GO:0019865~immunoglobulin binding,GO:0019901~protein kinase binding,GO:0030165~PDZ domain binding,GO:0031267~small GTPase binding,GO:0031489~myosin V binding,GO:0031681~G-protein beta-subunit binding,GO:0031698~beta-2 adrenergic receptor binding,GO:0035254~glutamate receptor binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0051018~protein kinase A binding,GO:0097110~scaffold protein binding,GO:0099507~ligand-gated ion channel activity involved in regulation of presynaptic membrane potential,GO:0099583~neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001320:Ionotropic glutamate receptor,IPR001508:NMDA receptor,IPR001828:Extracellular ligand-binding receptor,IPR019594:Glutamate receptor, L-glutamate/glycine-binding,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05033:Nicotine addiction,	619927~Intellectual developmental disorder, autosomal dominant 67,619931~Intellectual developmental disorder, autosomal recessive 76,		SM00079:PBPe,SM00918:SM00918,	KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ionotropic glutamate receptor C-terminal,DOMAIN:Ionotropic glutamate receptor L-glutamate and glycine-binding,INTRAMEM:Helical; Pore-forming,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=M4,
GRIA4	glutamate ionotropic receptor AMPA type subunit 4(GRIA4)	Homo sapiens			GO:0007215~glutamate receptor signaling pathway,GO:0034220~ion transmembrane transport,GO:0034392~negative regulation of smooth muscle cell apoptotic process,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0035249~synaptic transmission, glutamatergic,GO:0050804~modulation of synaptic transmission,GO:0060078~regulation of postsynaptic membrane potential,GO:0099505~regulation of presynaptic membrane potential,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,GO:0032281~AMPA glutamate receptor complex,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0098839~postsynaptic density membrane,GO:1903561~extracellular vesicle,	GO:0001540~beta-amyloid binding,GO:0004970~ionotropic glutamate receptor activity,GO:0004971~AMPA glutamate receptor activity,GO:0015276~ligand-gated ion channel activity,GO:0038023~signaling receptor activity,GO:0099507~ligand-gated ion channel activity involved in regulation of presynaptic membrane potential,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001320:Ionotropic glutamate receptor,IPR001508:NMDA receptor,IPR001638:Extracellular solute-binding protein, family 3,IPR001828:Extracellular ligand-binding receptor,IPR019594:Glutamate receptor, L-glutamate/glycine-binding,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04728:Dopaminergic synapse,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05033:Nicotine addiction,	617864~Neurodevelopmental disorder with or without seizures and gait abnormalities,		SM00079:PBPe,SM00918:SM00918,	KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ionotropic glutamate receptor C-terminal,DOMAIN:Ionotropic glutamate receptor L-glutamate and glycine-binding,DOMAIN:Receptor ligand binding region,DOMAIN:Solute-binding protein family 3/N-terminal,INTRAMEM:Helical; Pore-forming,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=M4,
GRM6	glutamate metabotropic receptor 6(GRM6)	Homo sapiens			GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007626~locomotory behavior,GO:0009584~detection of visible light,GO:0050908~detection of light stimulus involved in visual perception,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060041~retina development in camera-type eye,GO:0090280~positive regulation of calcium ion import,GO:1905665~positive regulation of calcium ion import across plasma membrane,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0030425~dendrite,GO:0035841~new growing cell tip,GO:0045202~synapse,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008066~glutamate receptor activity,GO:0042803~protein homodimerization activity,	IPR000112:GPCR, family 3, metabotropic glutamate receptor 6,IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000337:GPCR, family 3,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04724:Glutamatergic synapse,	257270~Night blindness, congenital stationary (complete), 1B, autosomal recessive,			KW-0716~Sensory transduction,KW-0844~Vision,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1014~Congenital stationary night blindness,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GRM8	glutamate metabotropic receptor 8(GRM8)	Homo sapiens			GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007601~visual perception,GO:0051966~regulation of synaptic transmission, glutamatergic,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0001642~group III metabotropic glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0008066~glutamate receptor activity,	IPR000144:GPCR, family 3, metabotropic glutamate receptor 8,IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000337:GPCR, family 3,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04724:Glutamatergic synapse,				KW-0716~Sensory transduction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:G-protein coupled receptors family 3 profile,DOMAIN:Receptor ligand binding region,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPT	glutamic--pyruvic transaminase(GPT)	Homo sapiens		h_SARSpathway:SARS Coronavirus Protease,	GO:0009058~biosynthetic process,GO:0032869~cellular response to insulin stimulus,GO:0042594~response to starvation,GO:0042853~L-alanine catabolic process,GO:0045722~positive regulation of gluconeogenesis,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004021~L-alanine:2-oxoglutarate aminotransferase activity,GO:0030170~pyridoxal phosphate binding,	IPR004839:Aminotransferase, class I/classII,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,	hsa00220:Arginine biosynthesis,hsa00250:Alanine, aspartate and glutamate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,					KW-0963~Cytoplasm,			KW-0663~Pyridoxal phosphate,	KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
GSTO2	glutathione S-transferase omega 2(GSTO2)	Homo sapiens			GO:0006749~glutathione metabolic process,GO:0006805~xenobiotic metabolic process,GO:0019852~L-ascorbic acid metabolic process,GO:0071243~cellular response to arsenic-containing substance,GO:0098869~cellular oxidant detoxification,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004364~glutathione transferase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016740~transferase activity,GO:0042802~identical protein binding,GO:0045174~glutathione dehydrogenase (ascorbate) activity,GO:0050610~methylarsonate reductase activity,	IPR004045:Glutathione S-transferase, N-terminal,IPR005442:Glutathione S-transferase, omega-class,IPR010987:Glutathione S-transferase, C-terminal-like,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,									KW-0560~Oxidoreductase,KW-0808~Transferase,		ACT_SITE:Nucleophile,DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,MUTAGEN:Y->A: Abolishes DHAR activity.,
GPX3	glutathione peroxidase 3(GPX3)	Homo sapiens			GO:0006979~response to oxidative stress,GO:0006982~response to lipid hydroperoxide,GO:0042744~hydrogen peroxide catabolic process,GO:0098869~cellular oxidant detoxification,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0004601~peroxidase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0008430~selenium binding,GO:0042802~identical protein binding,	IPR000889:Glutathione peroxidase,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa04918:Thyroid hormone synthesis,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,		PIRSF000303:glutathione peroxidase,			KW-0964~Secreted,		KW-0732~Signal,		KW-0560~Oxidoreductase,KW-0575~Peroxidase,		COMPBIAS:Polar residues,NON_STD:Selenocysteine,REGION:Disordered,
GPC1	glypican 1(GPC1)	Homo sapiens			GO:0001523~retinoid metabolic process,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006027~glycosaminoglycan catabolic process,GO:0009966~regulation of signal transduction,GO:0014037~Schwann cell differentiation,GO:0016477~cell migration,GO:0030200~heparan sulfate proteoglycan catabolic process,GO:0032288~myelin assembly,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:1905475~regulation of protein localization to membrane,GO:2001016~positive regulation of skeletal muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005796~Golgi lumen,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031012~extracellular matrix,GO:0031226~intrinsic component of plasma membrane,GO:0043202~lysosomal lumen,GO:0045121~membrane raft,GO:0045202~synapse,GO:0046658~anchored component of plasma membrane,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0017134~fibroblast growth factor binding,GO:0043236~laminin binding,	IPR001863:Glypican,IPR015502:Glypican-1,IPR019803:Glypican, conserved site,	hsa05205:Proteoglycans in cancer,hsa05418:Fluid shear stress and atherosclerosis,					KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0186~Copper,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0357~Heparan sulfate,KW-0449~Lipoprotein,KW-0654~Proteoglycan,KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:GPI-anchor amidated serine,MUTAGEN:N->Q: No effect on protein yield. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-79.,MUTAGEN:N->Q: Protein yield reduced by half. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-116.,PROPEP:Removed in mature form,REGION:Disordered,
GOSR1	golgi SNAP receptor complex member 1(GOSR1)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0006906~vesicle fusion,GO:0015031~protein transport,GO:0042147~retrograde transport, endosome to Golgi,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005797~Golgi medial cisterna,GO:0005801~cis-Golgi network,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0031201~SNARE complex,	GO:0005484~SNAP receptor activity,	IPR023601:Golgi SNAP receptor complex, subunit 1,	hsa04130:SNARE interactions in vesicular transport,		PIRSF027109:Golgi SNARE protein,		KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
GRHL2	grainyhead like transcription factor 2(GRHL2)	Homo sapiens			GO:0001843~neural tube closure,GO:0003208~cardiac ventricle morphogenesis,GO:0003382~epithelial cell morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007155~cell adhesion,GO:0007420~brain development,GO:0008283~cell proliferation,GO:0008544~epidermis development,GO:0021915~neural tube development,GO:0034329~cell junction assembly,GO:0035264~multicellular organism growth,GO:0042733~embryonic digit morphogenesis,GO:0043010~camera-type eye development,GO:0044030~regulation of DNA methylation,GO:0045617~negative regulation of keratinocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0051973~positive regulation of telomerase activity,GO:0060324~face development,GO:0060463~lung lobe morphogenesis,GO:0060487~lung epithelial cell differentiation,GO:0060672~epithelial cell morphogenesis involved in placental branching,GO:0061713~anterior neural tube closure,GO:0070830~bicellular tight junction assembly,GO:0090132~epithelium migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005911~cell-cell junction,GO:0016020~membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001161~intronic transcription regulatory region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,	IPR007604:CP2 transcription factor,		608641~Deafness, autosomal dominant 28,616029~Ectodermal dysplasia/short stature syndrome,618031~Corneal dystrophy, posterior polymorphous, 4,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0038~Ectodermal dysplasia,KW-0209~Deafness,KW-0225~Disease variant,KW-0242~Dwarfism,KW-1010~Non-syndromic deafness,KW-1212~Corneal dystrophy,			KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Grh/CP2 DB,MUTAGEN:R->A,Q: Loss of activity as transcriptional activator.,REGION:Disordered,REGION:Transcription activation,SITE:Important for activation of transcription,
GRHL3	grainyhead like transcription factor 3(GRHL3)	Homo sapiens			GO:0001736~establishment of planar polarity,GO:0001843~neural tube closure,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0007398~ectoderm development,GO:0007417~central nervous system development,GO:0008544~epidermis development,GO:0010628~positive regulation of gene expression,GO:0032956~regulation of actin cytoskeleton organization,GO:0042060~wound healing,GO:0043547~positive regulation of GTPase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061029~eyelid development in camera-type eye,GO:0061436~establishment of skin barrier,GO:0090103~cochlea morphogenesis,GO:0090179~planar cell polarity pathway involved in neural tube closure,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,GO:0043565~sequence-specific DNA binding,	IPR007604:CP2 transcription factor,		606713~van der Woude syndrome 2,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		DOMAIN:Grh/CP2 DB,REGION:Transcription activation,
GREM1	gremlin 1, DAN family BMP antagonist(GREM1)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002092~positive regulation of receptor internalization,GO:0003257~positive regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation,GO:0003337~mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0009887~animal organ morphogenesis,GO:0009954~proximal/distal pattern formation,GO:0010717~regulation of epithelial to mesenchymal transition,GO:0030199~collagen fibril organization,GO:0030308~negative regulation of cell growth,GO:0030326~embryonic limb morphogenesis,GO:0030502~negative regulation of bone mineralization,GO:0030514~negative regulation of BMP signaling pathway,GO:0032331~negative regulation of chondrocyte differentiation,GO:0033689~negative regulation of osteoblast proliferation,GO:0038098~sequestering of BMP from receptor via BMP binding,GO:0043066~negative regulation of apoptotic process,GO:0045668~negative regulation of osteoblast differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046851~negative regulation of bone remodeling,GO:0048263~determination of dorsal identity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051893~regulation of focal adhesion assembly,GO:0051973~positive regulation of telomerase activity,GO:0055007~cardiac muscle cell differentiation,GO:0060173~limb development,GO:0060379~cardiac muscle cell myoblast differentiation,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0060676~ureteric bud formation,GO:0090027~negative regulation of monocyte chemotaxis,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0090291~negative regulation of osteoclast proliferation,GO:1900086~positive regulation of peptidyl-tyrosine autophosphorylation,GO:1900155~negative regulation of bone trabecula formation,GO:1900158~negative regulation of bone mineralization involved in bone maturation,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2000273~positive regulation of receptor activity,GO:2000727~positive regulation of cardiac muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009986~cell surface,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0016015~morphogen activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0036122~BMP binding,GO:0042803~protein homodimerization activity,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0048018~receptor agonist activity,	IPR004133:DAN,IPR006207:Cystine knot, C-terminal,IPR017159:Gremlin precursor,	hsa04350:TGF-beta signaling pathway,		PIRSF037254:gremlin precursor,	SM00041:CT,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:CTCK,REGION:Disordered,
GAS7	growth arrest specific 7(GAS7)	Homo sapiens			GO:0030041~actin filament polymerization,GO:0048812~neuron projection morphogenesis,	GO:0005737~cytoplasm,GO:0005884~actin filament,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0051015~actin filament binding,	IPR001060:FCH domain,IPR001202:WW domain,IPR001452:Src homology-3 domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,				SM00055:FCH,SM00326:SH3,SM00456:WW,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0728~SH3 domain,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:F-BAR,DOMAIN:SH3,DOMAIN:WW,REGION:Disordered,
GAP43	growth associated protein 43(GAP43)	Homo sapiens			GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0009611~response to wounding,GO:0010001~glial cell differentiation,GO:0016198~axon choice point recognition,GO:0031103~axon regeneration,GO:0040008~regulation of growth,GO:0042246~tissue regeneration,GO:0045165~cell fate commitment,GO:0048708~astrocyte differentiation,GO:0051489~regulation of filopodium assembly,GO:0060019~radial glial cell differentiation,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030425~dendrite,GO:0031527~filopodium membrane,GO:0032584~growth cone membrane,GO:0043204~perikaryon,GO:0098793~presynapse,GO:0098982~GABA-ergic synapse,	GO:0001786~phosphatidylserine binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0035727~lysophosphatidic acid binding,GO:1901981~phosphatidylinositol phosphate binding,	IPR000048:IQ motif, EF-hand binding site,IPR001422:Neuromodulin (GAP-43),IPR017454:Neuromodulin (GAP-43), C-terminal,IPR018243:Neuromodulin, palmitoylation/phosphorylation site,IPR018947:Neuromodulin gap junction N-terminal,				SM00015:IQ,	KW-0221~Differentiation,KW-0341~Growth regulation,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,				KW-0112~Calmodulin-binding,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IQ,DOMAIN:Neuromodulin (GAP-43) C-terminal,DOMAIN:Neuromodulin gap junction N-terminal,LIPID:S-palmitoyl cysteine,MUTAGEN:CC->SS: Inhibits axonal and dendritic filopodia formation and reduces dendritic and axonal branching.,REGION:Disordered,
GDF10	growth differentiation factor 10(GDF10)	Homo sapiens			GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0021549~cerebellum development,GO:0030278~regulation of ossification,GO:0042698~ovulation cycle,GO:0045444~fat cell differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0060395~SMAD protein signal transduction,GO:1904373~response to kainic acid,	GO:0005615~extracellular space,	GO:0005125~cytokine activity,GO:0008083~growth factor activity,	IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,IPR017197:Bone morphogenetic protein 3/growth differentiation factor 10,IPR017948:Transforming growth factor beta, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,		PIRSF037403:bone morphogenetic protein 3/GDF10 [Parent=PIRSF800009],	SM00204:TGFB,	KW-0892~Osteogenesis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,REGION:Disordered,
GHRHR	growth hormone releasing hormone receptor(GHRHR)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007595~lactation,GO:0008284~positive regulation of cell proliferation,GO:0008340~determination of adult lifespan,GO:0019933~cAMP-mediated signaling,GO:0030104~water homeostasis,GO:0030252~growth hormone secretion,GO:0032868~response to insulin,GO:0032869~cellular response to insulin stimulus,GO:0033143~regulation of intracellular steroid hormone receptor signaling pathway,GO:0040018~positive regulation of multicellular organism growth,GO:0042445~hormone metabolic process,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0043627~response to estrogen,GO:0046010~positive regulation of circadian sleep/wake cycle, non-REM sleep,GO:0048469~cell maturation,GO:0048609~multicellular organismal reproductive process,GO:0051246~regulation of protein metabolic process,GO:0051384~response to glucocorticoid,GO:0051649~establishment of localization in cell,GO:0060124~positive regulation of growth hormone secretion,GO:0060133~somatotropin secreting cell development,GO:0071333~cellular response to glucose stimulus,	GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016363~nuclear matrix,GO:0030141~secretory granule,GO:0042383~sarcolemma,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0016520~growth hormone-releasing hormone receptor activity,GO:0017046~peptide hormone binding,GO:0019838~growth factor binding,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR003288:GPCR, family 2, growth hormone-releasing hormone receptor,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04935:Growth hormone synthesis, secretion and action,	618157~Growth hormone deficiency, isolated, type IV,		SM00008:HormR,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GHRH	growth hormone releasing hormone(GHRH)	Homo sapiens		h_ghrelinPathway:Ghrelin: Regulation of Food Intake and Energy Homeostasis,	GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0021984~adenohypophysis development,GO:0030252~growth hormone secretion,GO:0032094~response to food,GO:0035264~multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0046005~positive regulation of circadian sleep/wake cycle, REM sleep,GO:0060124~positive regulation of growth hormone secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0043195~terminal bouton,GO:0043204~perikaryon,	GO:0005184~neuropeptide hormone activity,GO:0016608~growth hormone-releasing hormone activity,GO:0031770~growth hormone-releasing hormone receptor binding,GO:0051428~peptide hormone receptor binding,	IPR000532:Glucagon/GIP/secretin/VIP,IPR015550:Glucagon-like,	hsa04080:Neuroactive ligand-receptor interaction,hsa04935:Growth hormone synthesis, secretion and action,	Gigantism due to GHRF hypersecretion~Gigantism due to GHRF hypersecretion,Isolated growth hormone deficiency due to defect in GHRF~Isolated growth hormone deficiency due to defect in GHRF,		SM00070:GLUCA,		KW-0964~Secreted,		KW-0732~Signal,			KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	PEPTIDE:Somatoliberin,
GHSR	growth hormone secretagogue receptor(GHSR)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007283~spermatogenesis,GO:0007611~learning or memory,GO:0008154~actin polymerization or depolymerization,GO:0008343~adult feeding behavior,GO:0009725~response to hormone,GO:0009755~hormone-mediated signaling pathway,GO:0010700~negative regulation of norepinephrine secretion,GO:0030252~growth hormone secretion,GO:0032094~response to food,GO:0032099~negative regulation of appetite,GO:0032100~positive regulation of appetite,GO:0032354~response to follicle-stimulating hormone,GO:0032355~response to estradiol,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032869~cellular response to insulin stimulus,GO:0036321~ghrelin secretion,GO:0040018~positive regulation of multicellular organism growth,GO:0043134~regulation of hindgut contraction,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0045923~positive regulation of fatty acid metabolic process,GO:0046676~negative regulation of insulin secretion,GO:0046697~decidualization,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0050728~negative regulation of inflammatory response,GO:0051963~regulation of synapse assembly,GO:0051969~regulation of transmission of nerve impulse,GO:0060123~regulation of growth hormone secretion,GO:0060416~response to growth hormone,GO:0071222~cellular response to lipopolysaccharide,GO:0071548~response to dexamethasone,GO:0090327~negative regulation of locomotion involved in locomotory behavior,GO:0097067~cellular response to thyroid hormone stimulus,GO:1902065~response to L-glutamate,GO:1903672~positive regulation of sprouting angiogenesis,GO:1904000~positive regulation of eating behavior,GO:1904008~response to monosodium glutamate,GO:1904349~positive regulation of small intestine smooth muscle contraction,GO:1905333~regulation of gastric motility,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:2000110~negative regulation of macrophage apoptotic process,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0045121~membrane raft,GO:0097060~synaptic membrane,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0001616~growth hormone secretagogue receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0016520~growth hormone-releasing hormone receptor activity,GO:0017046~peptide hormone binding,GO:0042802~identical protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR003905:Growth hormone secretagogue receptor type 1,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04935:Growth hormone synthesis, secretion and action,	615925~Growth hormone deficiency, isolated partial,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GREB1	growth regulating estrogen receptor binding 1(GREB1)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,	GO:0007275~multicellular organism development,	GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:GREB1 N-terminal,REGION:Disordered,TRANSMEM:Helical,
GUCY2D	guanylate cyclase 2D, retinal(GUCY2D)	Homo sapiens			GO:0006182~cGMP biosynthetic process,GO:0007165~signal transduction,GO:0007168~receptor guanylyl cyclase signaling pathway,GO:0007601~visual perception,GO:0019934~cGMP-mediated signaling,GO:0022400~regulation of rhodopsin mediated signaling pathway,	GO:0001750~photoreceptor outer segment,GO:0005640~nuclear outer membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0042622~photoreceptor outer segment membrane,GO:0097381~photoreceptor disc membrane,	GO:0001653~peptide receptor activity,GO:0004016~adenylate cyclase activity,GO:0004383~guanylate cyclase activity,GO:0004672~protein kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0038023~signaling receptor activity,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,	IPR000719:Protein kinase, catalytic domain,IPR001054:Adenylyl cyclase class-3/4/guanylyl cyclase,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001828:Extracellular ligand-binding receptor,IPR011009:Protein kinase-like domain,IPR011645:Haem NO binding associated,IPR018297:Adenylyl cyclase class-3/4/guanylyl cyclase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04740:Olfactory transduction,hsa04744:Phototransduction,	204000~Leber congenital amaurosis 1,215500~Choroidal dystrophy, central areolar 1,601777~Cone-rod dystrophy 6,618555~Night blindness, congenital stationary, type 1I,		SM00044:CYCc,	KW-0141~cGMP biosynthesis,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0966~Cell projection,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,KW-0901~Leber congenital amaurosis,KW-1014~Congenital stationary night blindness,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0456~Lyase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:Guanylate cyclase,DOMAIN:Protein kinase,MUTAGEN:C->D: Changes the substrate specificity from GTP to ATP.,MUTAGEN:E->K: Changes the substrate specificity from GTP to ATP.,MUTAGEN:M->R: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.,MUTAGEN:R->P: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GUCA2A	guanylate cyclase activator 2A(GUCA2A)	Homo sapiens			GO:0007165~signal transduction,	GO:0005576~extracellular region,	GO:0005179~hormone activity,GO:0005515~protein binding,GO:0030250~guanylate cyclase activator activity,	IPR000879:Guanylin,			PIRSF001849:guanylin,			KW-0964~Secreted,		KW-0732~Signal,			KW-1015~Disulfide bond,	PEPTIDE:Guanylin,
HHAT	hedgehog acyltransferase(HHAT)	Homo sapiens			GO:0007224~smoothened signaling pathway,GO:0018009~N-terminal peptidyl-L-cysteine N-palmitoylation,GO:0018345~protein palmitoylation,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008374~O-acyltransferase activity,GO:0016409~palmitoyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,	IPR004299:Membrane bound O-acyl transferase, MBOAT,	hsa04340:Hedgehog signaling pathway,	600092~Nivelon-Nivelon-Mabille syndrome,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0012~Acyltransferase,KW-0217~Developmental protein,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0564~Palmitate,	LIPID:S-palmitoyl cysteine,MUTAGEN:H->A: Reduced catalytic activity. Defective HHAT-mediated palmitoyl-CoA uptake into microsomal membranes.,MUTAGEN:Y->A: No significant effect on catalytic activity. Defective HHAT-mediated palmitoyl-CoA uptake into microsomal membranes.,REGION:Essential for palmitoylation of SHH,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HHIP	hedgehog interacting protein(HHIP)	Homo sapiens			GO:0007165~signal transduction,GO:0007405~neuroblast proliferation,GO:0009953~dorsal/ventral pattern formation,GO:0009968~negative regulation of signal transduction,GO:0040036~regulation of fibroblast growth factor receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0045879~negative regulation of smoothened signaling pathway,GO:0048705~skeletal system morphogenesis,GO:0060441~epithelial tube branching involved in lung morphogenesis,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0060170~ciliary membrane,	GO:0003824~catalytic activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0097108~hedgehog family protein binding,	IPR000742:Epidermal growth factor-like domain,IPR011041:Soluble quinoprotein glucose/sorbosone dehydrogenase,IPR011042:Six-bladed beta-propeller, TolB-like,IPR012938:Glucose/Sorbosone dehydrogenase,IPR018143:Folate receptor-like,	hsa04024:cAMP signaling pathway,hsa04340:Hedgehog signaling pathway,hsa05200:Pathways in cancer,hsa05217:Basal cell carcinoma,			SM00181:EGF,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,MUTAGEN:D->A,R: Abolishes SHH binding.,MUTAGEN:D->A: Abolishes SHH binding.,MUTAGEN:E->A: Abolishes SHH binding.,MUTAGEN:M->A: Abolishes SHH binding.,REGION:Interaction with SHH zinc binding site,
HCST	hematopoietic cell signal transducer(HCST)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0050776~regulation of immune response,GO:0051897~positive regulation of protein kinase B signaling,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0043548~phosphatidylinositol 3-kinase binding,	IPR009861:DAP10 membrane,	hsa04650:Natural killer cell mediated cytotoxicity,					KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:D->A: Abolishes stable interaction with KLRK1.,MUTAGEN:M->Q: Abrogates cell killing and interaction with PIK3R1. No effect on interaction with GRB2.,MUTAGEN:N->Q: Abrogates cell killing and interaction with GRB2. No effect on interaction with PIK3R1.,REGION:GRB2 binding site,REGION:PIK3R1 binding site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HPX	hemopexin(HPX)	Homo sapiens			GO:0002639~positive regulation of immunoglobulin production,GO:0002925~positive regulation of humoral immune response mediated by circulating immunoglobulin,GO:0006879~cellular iron ion homeostasis,GO:0015886~heme transport,GO:0020027~hemoglobin metabolic process,GO:0042168~heme metabolic process,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060335~positive regulation of interferon-gamma-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,GO:0072562~blood microparticle,	GO:0005515~protein binding,GO:0015232~heme transporter activity,GO:0046872~metal ion binding,	IPR000585:Hemopexin-like domain,IPR016358:Hemopexin, chordata,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,			PIRSF002551:hemopexin,	SM00120:HX,	KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:axial binding residue,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,REGION:Disordered,REGION:O-glycosylated at one site,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,REPEAT:Hemopexin 5,REPEAT:Hemopexin 6,REPEAT:Hemopexin 7,REPEAT:Hemopexin 8,
HS6ST1	heparan sulfate 6-O-sulfotransferase 1(HS6ST1)	Homo sapiens			GO:0001525~angiogenesis,GO:0006024~glycosaminoglycan biosynthetic process,GO:0015015~heparan sulfate proteoglycan biosynthetic process, enzymatic modification,GO:0048286~lung alveolus development,GO:0048666~neuron development,GO:0060716~labyrinthine layer blood vessel development,GO:1901137~carbohydrate derivative biosynthetic process,	GO:0000139~Golgi membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0098791~Golgi subcompartment,	GO:0005515~protein binding,GO:0008146~sulfotransferase activity,GO:0017095~heparan sulfate 6-O-sulfotransferase activity,	IPR005331:Sulfotransferase,IPR010635:Heparan sulphate 6-sulfotransferase,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,	614880~Hypogonadotropic hypogonadism 15 with or without anosmia,				KW-0472~Membrane,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1016~Hypogonadotropic hypogonadism,	KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
HSPG2	heparan sulfate proteoglycan 2(HSPG2)	Homo sapiens			GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006027~glycosaminoglycan catabolic process,GO:0006629~lipid metabolic process,GO:0006898~receptor-mediated endocytosis,GO:0006954~inflammatory response,GO:0007162~negative regulation of cell adhesion,GO:0007224~smoothened signaling pathway,GO:0007420~brain development,GO:0007566~embryo implantation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0016525~negative regulation of angiogenesis,GO:0030154~cell differentiation,GO:0031100~animal organ regeneration,GO:0060548~negative regulation of cell death,GO:0072359~circulatory system development,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0001540~beta-amyloid binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0030021~extracellular matrix structural constituent conferring compression resistance,GO:0050750~low-density lipoprotein particle receptor binding,GO:0070052~collagen V binding,	IPR000034:Laminin B type IV,IPR000082:SEA domain,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013106:Immunoglobulin V-set,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa04512:ECM-receptor interaction,hsa05161:Hepatitis B,hsa05205:Proteoglycans in cancer,	224410~Dyssegmental dysplasia, Silverman-Handmaker type,255800~Schwartz-Jampel syndrome, type 1,		SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00192:LDLa,SM00200:SEA,SM00281:LamB,SM00282:LamG,SM00406:IGv,SM00408:IGc2,SM00409:IG,	KW-0037~Angiogenesis,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0393~Immunoglobulin domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 13,DOMAIN:Ig-like C2-type 14,DOMAIN:Ig-like C2-type 15,DOMAIN:Ig-like C2-type 16,DOMAIN:Ig-like C2-type 17,DOMAIN:Ig-like C2-type 18,DOMAIN:Ig-like C2-type 19,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 20,DOMAIN:Ig-like C2-type 21,DOMAIN:Ig-like C2-type 22,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:LDL-receptor class A 4,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 1; first part,DOMAIN:Laminin EGF-like 1; second part,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4; truncated,DOMAIN:Laminin EGF-like 5; first part,DOMAIN:Laminin EGF-like 5; second part,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9; first part,DOMAIN:Laminin EGF-like 9; second part,DOMAIN:Laminin G,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin IV type A,DOMAIN:Laminin IV type A 1,DOMAIN:Laminin IV type A 2,DOMAIN:Laminin IV type A 3,DOMAIN:SEA,MUTAGEN:D->A: Retains proper folding. Reduced calcium ion binding.,MUTAGEN:D->I: Abolishes BMP1-mediated cleavage of endorepellin.,MUTAGEN:N->A: Retains proper folding. Reduced calcium ion binding.,REGION:Disordered,REGION:Mediates motor neuron attachment,SITE:Cleavage; by BMP1,
HS3ST2	heparan sulfate-glucosamine 3-sulfotransferase 2(HS3ST2)	Homo sapiens			GO:0006024~glycosaminoglycan biosynthetic process,GO:0015015~heparan sulfate proteoglycan biosynthetic process, enzymatic modification,GO:1901135~carbohydrate derivative metabolic process,GO:1901564~organonitrogen compound metabolic process,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0008146~sulfotransferase activity,GO:0008467~[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity,GO:0033871~[heparan sulfate]-glucosamine 3-sulfotransferase 2 activity,	IPR000863:Sulfotransferase domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:For sulfotransferase activity,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Sulfotransferase,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
HPSE2	heparanase 2 (inactive)(HPSE2)	Homo sapiens			GO:0006027~glycosaminoglycan catabolic process,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031012~extracellular matrix,	GO:0016798~hydrolase activity, acting on glycosyl bonds,GO:0030305~heparanase activity,GO:0043395~heparan sulfate proteoglycan binding,	IPR005199:Glycoside hydrolase, family 79,IPR017853:Glycoside hydrolase, superfamily,	hsa00531:Glycosaminoglycan degradation,hsa01100:Metabolic pathways,hsa05205:Proteoglycans in cancer,	236730~Urofacial syndrome 1,				KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
HEPACAM	hepatic and glial cell adhesion molecule(HEPACAM)	Homo sapiens			GO:0007049~cell cycle,GO:0007155~cell adhesion,GO:0008104~protein localization,GO:0034613~cellular protein localization,GO:0040008~regulation of growth,GO:0051726~regulation of cell cycle,	GO:0005737~cytoplasm,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,		IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,		613925~Megalencephalic leukoencephalopathy with subcortical cysts 2A,613926~Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without impaired intellectual development,		SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,KW-0131~Cell cycle,KW-0338~Growth arrest,KW-0341~Growth regulation,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HAMP	hepcidin antimicrobial peptide(HAMP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002092~positive regulation of receptor internalization,GO:0002262~myeloid cell homeostasis,GO:0006366~transcription from RNA polymerase II promoter,GO:0006879~cellular iron ion homeostasis,GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007259~JAK-STAT cascade,GO:0007568~aging,GO:0010039~response to iron ion,GO:0010043~response to zinc ion,GO:0030163~protein catabolic process,GO:0031640~killing of cells of other organism,GO:0032413~negative regulation of ion transmembrane transporter activity,GO:0033189~response to vitamin A,GO:0034755~iron ion transmembrane transport,GO:0034760~negative regulation of iron ion transmembrane transport,GO:0036017~response to erythropoietin,GO:0042116~macrophage activation,GO:0042742~defense response to bacterium,GO:0043032~positive regulation of macrophage activation,GO:0045471~response to ethanol,GO:0045732~positive regulation of protein catabolic process,GO:0045779~negative regulation of bone resorption,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050728~negative regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050832~defense response to fungus,GO:0051649~establishment of localization in cell,GO:0060586~multicellular organismal iron ion homeostasis,GO:0061051~positive regulation of cell growth involved in cardiac muscle cell development,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0071222~cellular response to lipopolysaccharide,GO:0071354~cellular response to interleukin-6,GO:0071356~cellular response to tumor necrosis factor,GO:0071481~cellular response to X-ray,GO:0097421~liver regeneration,GO:1902916~positive regulation of protein polyubiquitination,GO:1903364~positive regulation of cellular protein catabolic process,GO:1903413~cellular response to bile acid,GO:1904039~negative regulation of ferrous iron export,GO:1904255~negative regulation of iron channel activity,GO:1904479~negative regulation of intestinal absorption,GO:1990641~response to iron ion starvation,GO:2000646~positive regulation of receptor catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0014704~intercalated disc,GO:0045179~apical cortex,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0005507~copper ion binding,GO:0097690~iron channel inhibitor activity,	IPR010500:Hepcidin,	hsa04350:TGF-beta signaling pathway,	613313~Hemochromatosis, type 2B,				KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0044~Antibiotic,KW-0295~Fungicide,KW-0372~Hormone,KW-0929~Antimicrobial,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,PEPTIDE:Hepcidin-20,PEPTIDE:Hepcidin-25,REGION:Disordered,
HES5	hes family bHLH transcription factor 5(HES5)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007155~cell adhesion,GO:0007219~Notch signaling pathway,GO:0007224~smoothened signaling pathway,GO:0007420~brain development,GO:0008284~positive regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0014003~oligodendrocyte development,GO:0021537~telencephalon development,GO:0021781~glial cell fate commitment,GO:0021861~forebrain radial glial cell differentiation,GO:0021915~neural tube development,GO:0022010~central nervous system myelination,GO:0030509~BMP signaling pathway,GO:0030513~positive regulation of BMP signaling pathway,GO:0031641~regulation of myelination,GO:0042491~auditory receptor cell differentiation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043010~camera-type eye development,GO:0045595~regulation of cell differentiation,GO:0045608~negative regulation of auditory receptor cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048469~cell maturation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048708~astrocyte differentiation,GO:0048712~negative regulation of astrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0050678~regulation of epithelial cell proliferation,GO:0050767~regulation of neurogenesis,GO:0051216~cartilage development,GO:0060122~inner ear receptor stereocilium organization,GO:0065003~macromolecular complex assembly,GO:0072049~comma-shaped body morphogenesis,GO:0072050~S-shaped body morphogenesis,GO:0072086~specification of loop of Henle identity,GO:0072282~metanephric nephron tubule morphogenesis,GO:0090162~establishment of epithelial cell polarity,GO:0097150~neuronal stem cell population maintenance,GO:2000737~negative regulation of stem cell differentiation,GO:2000974~negative regulation of pro-B cell differentiation,GO:2000978~negative regulation of forebrain neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003650:Orange,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,	hsa04330:Notch signaling pathway,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05224:Breast cancer,			SM00353:HLH,SM00511:ORANGE,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DOMAIN:BHLH,DOMAIN:Orange,DOMAIN:bHLH,MOTIF:WRPW motif,REGION:Disordered,
HMGB1	high mobility group box 1(HMGB1)	Homo sapiens		h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001773~myeloid dendritic cell activation,GO:0002218~activation of innate immune response,GO:0002407~dendritic cell chemotaxis,GO:0002437~inflammatory response to antigenic stimulus,GO:0002643~regulation of tolerance induction,GO:0002840~regulation of T cell mediated immune response to tumor cell,GO:0006265~DNA topological change,GO:0006281~DNA repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006310~DNA recombination,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006914~autophagy,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0010508~positive regulation of autophagy,GO:0016458~gene silencing,GO:0017055~negative regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0031175~neuron projection development,GO:0031507~heterochromatin assembly,GO:0032072~regulation of restriction endodeoxyribonuclease activity,GO:0032392~DNA geometric change,GO:0032425~positive regulation of mismatch repair,GO:0032689~negative regulation of interferon-gamma production,GO:0032732~positive regulation of interleukin-1 production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033151~V(D)J recombination,GO:0034165~positive regulation of toll-like receptor 9 signaling pathway,GO:0035711~T-helper 1 cell activation,GO:0042104~positive regulation of activated T cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0043277~apoptotic cell clearance,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043371~negative regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043388~positive regulation of DNA binding,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045063~T-helper 1 cell differentiation,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0046598~positive regulation of viral entry into host cell,GO:0048584~positive regulation of response to stimulus,GO:0050918~positive chemotaxis,GO:0051106~positive regulation of DNA ligation,GO:0051276~chromosome organization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0090026~positive regulation of monocyte chemotaxis,GO:0097350~neutrophil clearance,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,GO:2000426~negative regulation of apoptotic cell clearance,GO:2001200~positive regulation of dendritic cell differentiation,	GO:0000793~condensed chromosome,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0017053~transcriptional repressor complex,GO:0034774~secretory granule lumen,GO:0035868~alphav-beta3 integrin-HMGB1 complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0000400~four-way junction DNA binding,GO:0000405~bubble DNA binding,GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0001530~lipopolysaccharide binding,GO:0001786~phosphatidylserine binding,GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005125~cytokine activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008301~DNA binding, bending,GO:0016829~lyase activity,GO:0019958~C-X-C chemokine binding,GO:0042056~chemoattractant activity,GO:0048018~receptor agonist activity,GO:0050786~RAGE receptor binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070182~DNA polymerase binding,GO:0097100~supercoiled DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR017967:HMG box A DNA-binding domain, conserved site,	hsa03410:Base excision repair,hsa04140:Autophagy - animal,hsa04217:Necroptosis,hsa04613:Neutrophil extracellular trap formation,			SM00398:HMG,	KW-0072~Autophagy,KW-0145~Chemotaxis,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0158~Chromosome,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?),DISULFID:In disulfide HMGB1; alternate,DNA_BIND:HMG box,DNA_BIND:HMG box 1,DNA_BIND:HMG box 2,DOMAIN:HMG box,MOTIF:Nuclear localization signal (NLS) 1,MOTIF:Nuclear localization signal (NLS) 2,MUTAGEN:C->S: Inhibits oxidation-dependent inactivation of immunostimmulatory activity in apoptotic cells.,MUTAGEN:D->A: Abolishes cleavage by CASP1 and impairs ability to antagonize apoptosis-induced immune tolerance.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-35; A-39; A-42; A-46 and A-181.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-35; A-39; A-42; A-46 and A-53.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-35; A-39; A-42; A-53 and A-181.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-35; A-39; A-46; A-53 and A-181.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-35; A-42; A-46; A-53 and A-181.,MUTAGEN:S->A: Greatly reduces phosphorylation, nuclear localization; when associated with A-39; A-42; A-46; A-53 and A-181.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-35; E-39; E-42; E-46 and E-181.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-35; E-39; E-42; E-46 and E-53.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-35; E-39; E-42; E-53 and E-181.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-35; E-39; E-46; E-53 and E-181.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-35; E-42; E-46; E-53 and E-181.,MUTAGEN:S->E: Cytoplasmic localization (phosphorylation mimicking); when associated with E-39; E-42; E-46; E-53 and E-181.,REGION:Binding to AGER/RAGE,REGION:Cytokine-stimulating activity,REGION:Disordered,REGION:LPS binding (Lipid A),REGION:LPS binding (delipidated),REGION:Sufficient for interaction with HAVCR2,SITE:Cleavage; by CASP1,SITE:Cleavage; by thrombin:thrombomodulin,
HPCA	hippocalcin(HPCA)	Homo sapiens			GO:0007420~brain development,GO:0019722~calcium-mediated signaling,GO:0031283~negative regulation of guanylate cyclase activity,GO:0031584~activation of phospholipase D activity,GO:0045762~positive regulation of adenylate cyclase activity,GO:0048839~inner ear development,GO:0060041~retina development in camera-type eye,GO:0071257~cellular response to electrical stimulus,GO:0071277~cellular response to calcium ion,GO:0090314~positive regulation of protein targeting to membrane,GO:1901385~regulation of voltage-gated calcium channel activity,GO:1901986~response to ketamine,GO:1902065~response to L-glutamate,GO:1904009~cellular response to monosodium glutamate,GO:1904010~response to Aroclor 1254,GO:1905232~cellular response to L-glutamate,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0019898~extrinsic component of membrane,GO:0030424~axon,GO:0032590~dendrite membrane,GO:0032809~neuronal cell body membrane,GO:0032839~dendrite cytoplasm,GO:0043204~perikaryon,GO:0044327~dendritic spine head,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,		224500~Dystonia 2, torsion, autosomal recessive,		SM00054:EFh,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:N-myristoyl glycine,
HRH1	histamine receptor H1(HRH1)	Homo sapiens			GO:0006954~inflammatory response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007613~memory,GO:0008542~visual learning,GO:0032962~positive regulation of inositol trisphosphate biosynthetic process,GO:0043114~regulation of vascular permeability,GO:0045907~positive regulation of vasoconstriction,GO:0048016~inositol phosphate-mediated signaling,GO:0048167~regulation of synaptic plasticity,GO:0048245~eosinophil chemotaxis,GO:0071420~cellular response to histamine,GO:0098664~G-protein coupled serotonin receptor signaling pathway,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0045202~synapse,	GO:0004930~G-protein coupled receptor activity,GO:0004969~histamine receptor activity,GO:0004993~G-protein coupled serotonin receptor activity,GO:0030594~neurotransmitter receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000921:Histamine H1 receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04750:Inflammatory mediator regulation of TRP channels,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:G-protein coupled receptors family 1 profile,REGION:Disordered,REGION:Important for agonist binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HAL	histidine ammonia-lyase(HAL)	Homo sapiens			GO:0006548~histidine catabolic process,GO:0019556~histidine catabolic process to glutamate and formamide,GO:0019557~histidine catabolic process to glutamate and formate,	GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004397~histidine ammonia-lyase activity,GO:0016841~ammonia-lyase activity,	IPR001106:Aromatic amino acid lyase,IPR005921:Histidine ammonia-lyase,IPR008948:L-Aspartase-like,IPR021922:Protein of unknown function DUF3534,IPR022313:Phenylalanine/histidine ammonia-lyases, active site,IPR024083:Fumarase/histidase, N-terminal,	hsa00340:Histidine metabolism,hsa01100:Metabolic pathways,	235800~Histidinemia,			KW-0369~Histidine metabolism,		KW-0225~Disease variant,			KW-0456~Lyase,	KW-0597~Phosphoprotein,	CROSSLNK:5-imidazolinone (Ala-Gly),DOMAIN:Par3/HAL N-terminal,
HDAC9	histone deacetylase 9(HDAC9)	Homo sapiens		h_mitrPathway:Signal Dependent Regulation of Myogenesis by Corepressor MITR,h_ranbp2Pathway:Sumoylation by RanBP2 Regulates Transcriptional Repression,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001818~negative regulation of cytokine production,GO:0001975~response to amphetamine,GO:0006325~chromatin organization,GO:0006954~inflammatory response,GO:0007507~heart development,GO:0016575~histone deacetylation,GO:0030182~neuron differentiation,GO:0030183~B cell differentiation,GO:0032869~cellular response to insulin stimulus,GO:0034983~peptidyl-lysine deacetylation,GO:0042113~B cell activation,GO:0042632~cholesterol homeostasis,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048742~regulation of skeletal muscle fiber development,GO:0051005~negative regulation of lipoprotein lipase activity,GO:0051153~regulation of striated muscle cell differentiation,GO:0070932~histone H3 deacetylation,GO:0070933~histone H4 deacetylation,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:1990678~histone H4-K16 deacetylation,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0035097~histone methyltransferase complex,	GO:0003714~transcription corepressor activity,GO:0004407~histone deacetylase activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0031078~histone deacetylase activity (H3-K14 specific),GO:0032041~NAD-dependent histone deacetylase activity (H3-K14 specific),GO:0032129~histone deacetylase activity (H3-K9 specific),GO:0033558~protein deacetylase activity,GO:0034739~histone deacetylase activity (H4-K16 specific),GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000286:Histone deacetylase superfamily,IPR017320:Histone deacetylase class II, eukaryotic,IPR023696:Ureohydrolase domain,IPR023801:Histone deacetylase domain,IPR024643:Histone deacetylase, glutamine rich N-terminal domain,	hsa04613:Neutrophil extracellular trap formation,hsa05034:Alcoholism,hsa05203:Viral carcinogenesis,		PIRSF037911:histone deacetylase class II, eukaryotic type,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Histone deacetylase,DOMAIN:Histone deacetylase glutamine rich N-terminal,REGION:Disordered,REGION:Histone deacetylase,REGION:Interaction with CTBP1,REGION:Interaction with ETV6,REGION:Interaction with MAPK10,REGION:Interaction with MEF2,
HOXA1	homeobox A1(HOXA1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007605~sensory perception of sound,GO:0007634~optokinetic behavior,GO:0009653~anatomical structure morphogenesis,GO:0021599~abducens nerve formation,GO:0042473~outer ear morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048702~embryonic neurocranium morphogenesis,GO:0048839~inner ear development,GO:0048844~artery morphogenesis,GO:0050795~regulation of behavior,GO:0050890~cognition,GO:0050905~neuromuscular process,GO:0060840~artery development,GO:0060876~semicircular canal formation,GO:0090102~cochlea development,GO:0090103~cochlea morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa04550:Signaling pathways regulating pluripotency of stem cells,	601536~Athabaskan brainstem dysgenesis syndrome,601536~Bosley-Salih-Alorainy syndrome,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-1268~Autism spectrum disorder,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,REGION:Interaction with OGT,
HOXA10	homeobox A10(HOXA10)	Homo sapiens			GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030326~embryonic limb morphogenesis,GO:0030850~prostate gland development,GO:0033574~response to testosterone,GO:0043627~response to estrogen,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060065~uterus development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,			SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXA2	homeobox A2(HOXA2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001709~cell fate determination,GO:0002076~osteoblast development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007379~segment specification,GO:0008045~motor neuron axon guidance,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0021568~rhombomere 2 development,GO:0021658~rhombomere 3 morphogenesis,GO:0035284~brain segmentation,GO:0042474~middle ear morphogenesis,GO:0045665~negative regulation of neuron differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048703~embryonic viscerocranium morphogenesis,GO:0060037~pharyngeal system development,GO:0061061~muscle structure development,GO:0071300~cellular response to retinoic acid,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		612290~Microtia with or without hearing impairment (AD),612290~Microtia, hearing impairment, and cleft palate (AR),		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA4	homeobox A4(HOXA4)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0009952~anterior/posterior pattern specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA5	homeobox A5(HOXA5)	Homo sapiens			GO:0003016~respiratory system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0010628~positive regulation of gene expression,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030878~thyroid gland development,GO:0033599~regulation of mammary gland epithelial cell proliferation,GO:0035264~multicellular organism growth,GO:0043065~positive regulation of apoptotic process,GO:0045639~positive regulation of myeloid cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048286~lung alveolus development,GO:0048704~embryonic skeletal system morphogenesis,GO:0060435~bronchiole development,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060480~lung goblet cell differentiation,GO:0060484~lung-associated mesenchyme development,GO:0060535~trachea cartilage morphogenesis,GO:0060574~intestinal epithelial cell maturation,GO:0060638~mesenchymal-epithelial cell signaling,GO:0060644~mammary gland epithelial cell differentiation,GO:0060749~mammary gland alveolus development,GO:0060764~cell-cell signaling involved in mammary gland development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA6	homeobox A6(HOXA6)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0048704~embryonic skeletal system morphogenesis,GO:0048706~embryonic skeletal system development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA7	homeobox A7(HOXA7)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001953~negative regulation of cell-matrix adhesion,GO:0002686~negative regulation of leukocyte migration,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0045617~negative regulation of keratinocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048863~stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031965~nuclear membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA9	homeobox A9(HOXA9)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030850~prostate gland development,GO:0030879~mammary gland development,GO:0033574~response to testosterone,GO:0035115~embryonic forelimb morphogenesis,GO:0042118~endothelial cell activation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0060065~uterus development,GO:0060216~definitive hemopoiesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR006711:Hox9, N-terminal activation domain,IPR009057:Homeodomain-like,IPR017112:Homeobox protein Hox9,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,		PIRSF037109:homeobox protein, Hox9 type,	SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0488~Methylation,	DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:Hox9 N-terminal activation,MUTAGEN:R->A: Results in loss of methylation.,REGION:Disordered,SITE:Breakpoint for translocation to form MSI2/HOXA9 fusion protein,SITE:Breakpoint for translocation to form the NUP98-HOXA9 fusion protein,
HOXB1	homeobox B1(HOXB1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0009952~anterior/posterior pattern specification,GO:0021570~rhombomere 4 development,GO:0021571~rhombomere 5 development,GO:0021612~facial nerve structural organization,GO:0021754~facial nucleus development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0019904~protein domain specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa04550:Signaling pathways regulating pluripotency of stem cells,	614744~Facial paresis, hereditary congenital, 3,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXB13	homeobox B13(HOXB13)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008544~epidermis development,GO:0009611~response to wounding,GO:0033574~response to testosterone,GO:0040008~regulation of growth,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060743~epithelial cell maturation involved in prostate gland development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		610997~Prostate cancer, hereditary, 9,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Interaction with 5-mCpG DNA,REGION:Interaction with DNA,
HOXD10	homeobox D10(HOXD10)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007338~single fertilization,GO:0007519~skeletal muscle tissue development,GO:0008344~adult locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0021520~spinal cord motor neuron cell fate specification,GO:0030326~embryonic limb morphogenesis,GO:0035136~forelimb morphogenesis,GO:0035137~hindlimb morphogenesis,GO:0045786~negative regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048935~peripheral nervous system neuron development,GO:0050905~neuromuscular process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	192950~Charcot-Marie-Tooth disease, foot deformity of,192950~Vertical talus, congenital,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DNA_BIND:Homeobox,REGION:Disordered,
HOXD11	homeobox D11(HOXD11)	Homo sapiens			GO:0001658~branching involved in ureteric bud morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009953~dorsal/ventral pattern formation,GO:0048856~anatomical structure development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR021918:Domain of unknown function DUF3528, homeobox protein, eukaryotic,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXD13	homeobox D13(HOXD13)	Homo sapiens			GO:0001501~skeletal system development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0009952~anterior/posterior pattern specification,GO:0030539~male genitalia development,GO:0033574~response to testosterone,GO:0042127~regulation of cell proliferation,GO:0042733~embryonic digit morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048619~embryonic hindgut morphogenesis,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060571~morphogenesis of an epithelial fold,GO:0060602~branch elongation of an epithelium,GO:0060687~regulation of branching involved in prostate gland morphogenesis,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		113200~Brachydactyly, type D,113300~Brachydactyly, type E,186000~Synpolydactyly 1,186300~Syndactyly, type V,610713~Brachydactyly-syndactyly syndrome,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,REGION:Disordered,
HOXD8	homeobox D8(HOXD8)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008595~anterior/posterior axis specification, embryo,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048705~skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXD9	homeobox D9(HOXD9)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007338~single fertilization,GO:0007519~skeletal muscle tissue development,GO:0008344~adult locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030879~mammary gland development,GO:0035115~embryonic forelimb morphogenesis,GO:0035137~hindlimb morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048935~peripheral nervous system neuron development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR006711:Hox9, N-terminal activation domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
HRNR	hornerin(HRNR)	Homo sapiens			GO:0031424~keratinization,GO:0043163~cell envelope organization,GO:0061436~establishment of skin barrier,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0035578~azurophil granule lumen,GO:0036457~keratohyalin granule,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0046914~transition metal ion binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,				SM01394:SM01394,	KW-0417~Keratinization,			KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,REGION:S-100-like,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
HAPLN4	hyaluronan and proteoglycan link protein 4(HAPLN4)	Homo sapiens			GO:0001501~skeletal system development,GO:0002052~positive regulation of neuroblast proliferation,GO:0007155~cell adhesion,GO:0007417~central nervous system development,GO:0010001~glial cell differentiation,GO:0051932~synaptic transmission, GABAergic,GO:1904862~inhibitory synapse assembly,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0045202~synapse,GO:0072534~perineuronal net,	GO:0005540~hyaluronic acid binding,	IPR000538:Link,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00406:IGv,SM00408:IGc2,SM00409:IG,SM00445:LINK,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,	KW-0373~Hyaluronic acid,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:Link 1,DOMAIN:Link 2,
HAS1	hyaluronan synthase 1(HAS1)	Homo sapiens			GO:0006024~glycosaminoglycan biosynthetic process,GO:0007155~cell adhesion,GO:0010764~negative regulation of fibroblast migration,GO:0030213~hyaluronan biosynthetic process,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0045226~extracellular polysaccharide biosynthetic process,GO:0085029~extracellular matrix assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0050501~hyaluronan synthase activity,							KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HYAL1	hyaluronidase 1(HYAL1)	Homo sapiens			GO:0000302~response to reactive oxygen species,GO:0005975~carbohydrate metabolic process,GO:0006027~glycosaminoglycan catabolic process,GO:0006954~inflammatory response,GO:0009615~response to virus,GO:0010634~positive regulation of epithelial cell migration,GO:0030207~chondroitin sulfate catabolic process,GO:0030212~hyaluronan metabolic process,GO:0030213~hyaluronan biosynthetic process,GO:0030214~hyaluronan catabolic process,GO:0030307~positive regulation of cell growth,GO:0030308~negative regulation of cell growth,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045766~positive regulation of angiogenesis,GO:0045785~positive regulation of cell adhesion,GO:0045927~positive regulation of growth,GO:0046677~response to antibiotic,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051216~cartilage development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071467~cellular response to pH,GO:0071493~cellular response to UV-B,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900106~positive regulation of hyaluranon cable assembly,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0031410~cytoplasmic vesicle,GO:0036117~hyaluranon cable,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0004415~hyalurononglucosaminidase activity,GO:0050501~hyaluronan synthase activity,GO:0052757~chondroitin hydrolase activity,	IPR013785:Aldolase-type TIM barrel,IPR017853:Glycoside hydrolase, superfamily,IPR018155:Hyaluronidase,	hsa00531:Glycosaminoglycan degradation,hsa01100:Metabolic pathways,hsa04142:Lysosome,	601492~Mucopolysaccharidosis type IX,	PIRSF038193:hyaluronidase,			KW-0458~Lysosome,KW-0964~Secreted,	KW-0225~Disease variant,KW-0510~Mucopolysaccharidosis,	KW-0245~EGF-like domain,KW-0732~Signal,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,
HCRTR1	hypocretin receptor 1(HCRTR1)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007631~feeding behavior,GO:0032870~cellular response to hormone stimulus,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0070374~positive regulation of ERK1 and ERK2 cascade,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0045202~synapse,	GO:0004930~G-protein coupled receptor activity,GO:0016499~orexin receptor activity,GO:0017046~peptide hormone binding,GO:0042277~peptide binding,	IPR000204:Orexin receptor family,IPR000276:G protein-coupled receptor, rhodopsin-like,IPR004059:Orexin receptor 1,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:Missing: Abolishes response to orexin-A.,MUTAGEN:N->A: Strongly impairs response to orexin-A.,MUTAGEN:W->A: Strongly impairs response to orexin-A.,REGION:Disordered,REGION:Required for response to orexin-A,SITE:Important for responses to orexin,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
IER5	immediate early response 5(IER5)	Homo sapiens			GO:0034605~cellular response to heat,GO:0042127~regulation of cell proliferation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1900036~positive regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR008653:Immediate early response,					KW-0346~Stress response,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0678~Repressor,		COMPBIAS:Pro residues,REGION:Disordered,
ID4	inhibitor of DNA binding 4(ID4)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0002052~positive regulation of neuroblast proliferation,GO:0007405~neuroblast proliferation,GO:0008104~protein localization,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0021766~hippocampus development,GO:0021895~cerebral cortex neuron differentiation,GO:0022010~central nervous system myelination,GO:0030154~cell differentiation,GO:0032922~circadian regulation of gene expression,GO:0034613~cellular protein localization,GO:0045444~fat cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048708~astrocyte differentiation,GO:0048712~negative regulation of astrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0060740~prostate gland epithelium morphogenesis,GO:0060741~prostate gland stromal morphogenesis,GO:0061682~seminal vesicle morphogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR026052:DNA-binding protein inhibitor,	hsa04350:TGF-beta signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0678~Repressor,		COMPBIAS:Pro residues,DOMAIN:bHLH,REGION:Disordered,
IKBKE	inhibitor of nuclear factor kappa B kinase subunit epsilon(IKBKE)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006955~immune response,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010467~gene expression,GO:0010884~positive regulation of lipid storage,GO:0018105~peptidyl-serine phosphorylation,GO:0032481~positive regulation of type I interferon production,GO:0034340~response to type I interferon,GO:0035456~response to interferon-beta,GO:0038061~NIK/NF-kappaB signaling,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043254~regulation of protein complex assembly,GO:0048255~mRNA stabilization,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:0097400~interleukin-17-mediated signaling pathway,GO:0098586~cellular response to virus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016605~PML body,GO:0031966~mitochondrial membrane,GO:1902554~serine/threonine protein kinase complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004704~NF-kappaB-inducing kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008384~IkappaB kinase activity,GO:0019903~protein phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0036435~K48-linked polyubiquitin binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04936:Alcoholic liver disease,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05207:Chemical carcinogenesis - receptor activation,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,	KW-0227~DNA damage,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,MUTAGEN:E->A: Slight decrease of kinase activity.,MUTAGEN:K->A: Loss of kinase activity and loss of nuclear import.,MUTAGEN:K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.,MUTAGEN:K->A: No effect on ubiquitination.,MUTAGEN:K->R: Loss of sumoylation and loss of targeting to nuclear bodies.,MUTAGEN:K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.,MUTAGEN:K->R: No effect on ubiquitination.,MUTAGEN:S->A: Loss of autophosphorylation and of kinase activity.,MUTAGEN:S->E: Decrease in kinase activity.,REGION:Interaction with DDX3X,REGION:Leucine-zipper,
IRAG1	inositol 1,4,5-triphosphate receptor associated 1(IRAG1)	Homo sapiens			GO:0019934~cGMP-mediated signaling,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0031095~platelet dense tubular network membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR008677:MRVI1,	hsa04022:cGMP-PKG signaling pathway,hsa04270:Vascular smooth muscle contraction,					KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Interaction with ITPR1,REGION:Interaction with PRKG1,TRANSMEM:Helical,
INPP1	inositol polyphosphate-1-phosphatase(INPP1)	Homo sapiens			GO:0006796~phosphate-containing compound metabolic process,GO:0007165~signal transduction,GO:0046854~phosphatidylinositol phosphorylation,GO:0046855~inositol phosphate dephosphorylation,	GO:0005829~cytosol,	GO:0004441~inositol-1,4-bisphosphate 1-phosphatase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,GO:0052829~inositol-1,3,4-trisphosphate 1-phosphatase activity,	IPR000760:Inositol monophosphatase,IPR020550:Inositol monophosphatase, conserved site,IPR020583:Inositol monophosphatase, metal-binding site,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,								KW-0452~Lithium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,
IGF2BP1	insulin like growth factor 2 mRNA binding protein 1(IGF2BP1)	Homo sapiens			GO:0001817~regulation of cytokine production,GO:0007399~nervous system development,GO:0010468~regulation of gene expression,GO:0010610~regulation of mRNA stability involved in response to stress,GO:0017148~negative regulation of translation,GO:0022013~pallium cell proliferation in forebrain,GO:0051028~mRNA transport,GO:0051252~regulation of RNA metabolic process,GO:0070934~CRD-mediated mRNA stabilization,GO:0097150~neuronal stem cell population maintenance,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:2000767~positive regulation of cytoplasmic translation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030426~growth cone,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0048471~perinuclear region of cytoplasm,GO:0070937~CRD-mediated mRNA stability complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0045182~translation regulator activity,GO:0048027~mRNA 5'-UTR binding,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR000504:RNA recognition motif domain,IPR004087:K Homology domain,IPR004088:K Homology domain, type 1,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa05206:MicroRNAs in cancer,			SM00322:KH,SM00360:RRM,	KW-0509~mRNA transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:K Homology,DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,DOMAIN:KH 4,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:K->E: Partial reduction in interaction with m6A-modified mRNA; when associated with E-213.,MUTAGEN:K->E: Partial reduction in interaction with m6A-modified mRNA; when associated with E-294.,MUTAGEN:KE->EL: 50-fold decrease in RNA-binding affinity, decreased location in cytoplasmic RNP, increased nuclear location; when associated with 213-E-L-214 and 423-E-L-424.,MUTAGEN:KE->EL: 50-fold decrease in RNA-binding affinity, decreased location in cytoplasmic RNP, increased nuclear location; when associated with 294-E-L-295 and 423-E-L-424.,MUTAGEN:KG->EE: Loss of binding to RBPR and loss of interaction with m6A-modified mRNA; when associated with 423-E-E-424.,MUTAGEN:KK->EE: Loss of binding to RBPR and loss of interaction with m6A-modified mRNA; when associated with 505-E-E-506.,MUTAGEN:KK->EL: 50-fold decrease in RNA-binding affinity, decreased location in cytoplasmic RNP, increased nuclear location; when associated with 213-E-L-214 and 294-E-L-295.,REGION:Disordered,REGION:Necessary for interaction with ELAVL4 and binding to TAU mRNA,REGION:Sufficient for nuclear export,
IGF2BP3	insulin like growth factor 2 mRNA binding protein 3(IGF2BP3)	Homo sapiens			GO:0001817~regulation of cytokine production,GO:0006412~translation,GO:0007399~nervous system development,GO:0009653~anatomical structure morphogenesis,GO:0010468~regulation of gene expression,GO:0017148~negative regulation of translation,GO:0051028~mRNA transport,GO:0051252~regulation of RNA metabolic process,GO:0070934~CRD-mediated mRNA stabilization,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0045182~translation regulator activity,GO:0048027~mRNA 5'-UTR binding,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR000504:RNA recognition motif domain,IPR004087:K Homology domain,IPR004088:K Homology domain, type 1,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00322:KH,SM00360:RRM,	KW-0509~mRNA transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,DOMAIN:KH 4,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:K->E: Partial reduction in interaction with m6A-modified mRNA; when associated with E-213. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, modestly impaired binding to ACTB and MYC transcripts and almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on subcellular location; when associated with E-213; 422-E-E-423 and 505-E-E-506.,MUTAGEN:K->E: Partial reduction in interaction with m6A-modified mRNA; when associated with E-294. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, modestly impaired binding to ACTB and MYC transcripts and almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on subcellular location; when associated with E-294; 422-E-E-423 and 505-E-E-506.,MUTAGEN:KG->EE: Loss of interaction with m6A-modified mRNA; when associated with 422-E-E-423. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, modestly impaired binding to ACTB and MYC transcripts and almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on subcellular location; when associated with E-213; E-294 and 422-E-E-423.,MUTAGEN:KQ->EE: Loss of interaction with m6A-modified mRNA; when associated with 505-E-E-506. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, modestly impaired binding to ACTB and MYC transcripts and almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on subcellular location; when associated with E-213; E-294 and 505-E-E-506.,REGION:Disordered,
IGFBP6	insulin like growth factor binding protein 6(IGFBP6)	Homo sapiens		h_ghrelinPathway:Ghrelin: Regulation of Food Intake and Energy Homeostasis,	GO:0007165~signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0016477~cell migration,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0043410~positive regulation of MAPK cascade,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0042568~insulin-like growth factor binary complex,	GO:0001968~fibronectin binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0031994~insulin-like growth factor I binding,GO:0031995~insulin-like growth factor II binding,GO:0042802~identical protein binding,	IPR000716:Thyroglobulin type-1,IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR022321:Insulin-like growth factor-binding protein family 1-6, chordata,IPR022326:Insulin-like growth factor-binding protein 6,				SM00121:IB,SM00211:TY,		KW-0964~Secreted,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (HexNAc...) serine,CARBOHYD:O-linked (HexNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:IGFBP N-terminal,DOMAIN:Thyroglobulin type-1,REGION:Disordered,
INS	insulin(INS)	Homo sapiens			GO:0001819~positive regulation of cytokine production,GO:0002674~negative regulation of acute inflammatory response,GO:0006006~glucose metabolic process,GO:0006355~regulation of transcription, DNA-templated,GO:0006521~regulation of cellular amino acid metabolic process,GO:0006953~acute-phase response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010750~positive regulation of nitric oxide mediated signal transduction,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0022898~regulation of transmembrane transporter activity,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0031954~positive regulation of protein autophosphorylation,GO:0032148~activation of protein kinase B activity,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032880~regulation of protein localization,GO:0033861~negative regulation of NAD(P)H oxidase activity,GO:0038060~nitric oxide-cGMP-mediated signaling pathway,GO:0042060~wound healing,GO:0042177~negative regulation of protein catabolic process,GO:0042311~vasodilation,GO:0042593~glucose homeostasis,GO:0043410~positive regulation of MAPK cascade,GO:0045597~positive regulation of cell differentiation,GO:0045721~negative regulation of gluconeogenesis,GO:0045725~positive regulation of glycogen biosynthetic process,GO:0045818~negative regulation of glycogen catabolic process,GO:0045821~positive regulation of glycolytic process,GO:0045840~positive regulation of mitotic nuclear division,GO:0045861~negative regulation of proteolysis,GO:0045922~negative regulation of fatty acid metabolic process,GO:0046326~positive regulation of glucose import,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0046631~alpha-beta T cell activation,GO:0046889~positive regulation of lipid biosynthetic process,GO:0048167~regulation of synaptic plasticity,GO:0050708~regulation of protein secretion,GO:0050709~negative regulation of protein secretion,GO:0050714~positive regulation of protein secretion,GO:0050890~cognition,GO:0050995~negative regulation of lipid catabolic process,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051247~positive regulation of protein metabolic process,GO:0051897~positive regulation of protein kinase B signaling,GO:0055089~fatty acid homeostasis,GO:0060266~negative regulation of respiratory burst involved in inflammatory response,GO:0060267~positive regulation of respiratory burst,GO:0090277~positive regulation of peptide hormone secretion,GO:0090336~positive regulation of brown fat cell differentiation,GO:1900182~positive regulation of protein localization to nucleus,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1902952~positive regulation of dendritic spine maintenance,GO:1903076~regulation of protein localization to plasma membrane,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903576~response to L-arginine,GO:1990535~neuron projection maintenance,GO:2000252~negative regulation of feeding behavior,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0030133~transport vesicle,GO:0031904~endosome lumen,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0034774~secretory granule lumen,	GO:0002020~protease binding,GO:0005158~insulin receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004825:Insulin,IPR016179:Insulin-like,IPR022352:Insulin family,IPR022353:Insulin, conserved site,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04114:Oocyte meiosis,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04911:Insulin secretion,hsa04913:Ovarian steroidogenesis,hsa04914:Progesterone-mediated oocyte maturation,hsa04917:Prolactin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04940:Type I diabetes mellitus,hsa04950:Maturity onset diabetes of the young,hsa04960:Aldosterone-regulated sodium reabsorption,hsa05010:Alzheimer disease,hsa05215:Prostate cancer,hsa05415:Diabetic cardiomyopathy,	125852~Diabetes mellitus, insulin-dependent, 2,613370~Maturity-onset diabetes of the young, type 10,616214~Hyperproinsulinemia,618858~Diabetes mellitus, permanent neonatal 4,		SM00078:IlGF,	KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,	KW-0964~Secreted,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0732~Signal,		KW-0372~Hormone,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	DISULFID:Interchain (between B and A chains),DOMAIN:Insulin-like,PEPTIDE:Insulin A chain,PEPTIDE:Insulin B chain,PROPEP:C peptide,
ITGB3	integrin subunit beta 3(ITGB3)	Homo sapiens		h_edg1Pathway:Phospholipids as signalling intermediaries,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0001934~positive regulation of protein phosphorylation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0001954~positive regulation of cell-matrix adhesion,GO:0007044~cell-substrate junction assembly,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007566~embryo implantation,GO:0007596~blood coagulation,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010763~positive regulation of fibroblast migration,GO:0010888~negative regulation of lipid storage,GO:0014823~response to activity,GO:0014909~smooth muscle cell migration,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016477~cell migration,GO:0030168~platelet activation,GO:0030198~extracellular matrix organization,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0031589~cell-substrate adhesion,GO:0032147~activation of protein kinase activity,GO:0032369~negative regulation of lipid transport,GO:0032880~regulation of protein localization,GO:0032956~regulation of actin cytoskeleton organization,GO:0033627~cell adhesion mediated by integrin,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0033690~positive regulation of osteoblast proliferation,GO:0034113~heterotypic cell-cell adhesion,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035295~tube development,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0038027~apolipoprotein A-I-mediated signaling pathway,GO:0042060~wound healing,GO:0043277~apoptotic cell clearance,GO:0045124~regulation of bone resorption,GO:0045766~positive regulation of angiogenesis,GO:0045780~positive regulation of bone resorption,GO:0046718~viral entry into host cell,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048146~positive regulation of fibroblast proliferation,GO:0048333~mesodermal cell differentiation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050748~negative regulation of lipoprotein metabolic process,GO:0050919~negative chemotaxis,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0051611~regulation of serotonin uptake,GO:0060055~angiogenesis involved in wound healing,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070527~platelet aggregation,GO:0071260~cellular response to mechanical stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:0072126~positive regulation of glomerular mesangial cell proliferation,GO:0072378~blood coagulation, fibrin clot formation,GO:0098880~maintenance of postsynaptic specialization structure,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1900731~positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway,GO:1901163~regulation of trophoblast cell migration,GO:1903053~regulation of extracellular matrix organization,GO:1905598~negative regulation of low-density lipoprotein receptor activity,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000406~positive regulation of T cell migration,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0031092~platelet alpha granule membrane,GO:0031258~lamellipodium membrane,GO:0031527~filopodium membrane,GO:0031528~microvillus membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0034683~integrin alphav-beta3 complex,GO:0035866~alphav-beta3 integrin-PKCalpha complex,GO:0035867~alphav-beta3 integrin-IGF-1-IGF1R complex,GO:0035868~alphav-beta3 integrin-HMGB1 complex,GO:0042470~melanosome,GO:0043235~receptor complex,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0070062~extracellular exosome,GO:0071062~alphav-beta3 integrin-vitronectin complex,GO:0071133~alpha9-beta1 integrin-ADAM8 complex,GO:0098978~glutamatergic synapse,	GO:0001618~virus receptor activity,GO:0001968~fibronectin binding,GO:0002020~protease binding,GO:0003756~protein disulfide isomerase activity,GO:0005080~protein kinase C binding,GO:0005161~platelet-derived growth factor receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0017134~fibroblast growth factor binding,GO:0019899~enzyme binding,GO:0019960~C-X3-C chemokine binding,GO:0031994~insulin-like growth factor I binding,GO:0038132~neuregulin binding,GO:0042802~identical protein binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,GO:0050840~extracellular matrix binding,GO:0070051~fibrinogen binding,	IPR002369:Integrin beta subunit, N-terminal,IPR012896:Integrin beta subunit, tail,IPR013111:EGF, extracellular,IPR014836:Integrin beta subunit, cytoplasmic domain,IPR015812:Integrin beta subunit,IPR016201:Plexin-like fold,IPR027068:Integrin beta-3 subunit,	hsa03266:Virion - Herpesvirus,hsa04015:Rap1 signaling pathway,hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04640:Hematopoietic cell lineage,hsa04810:Regulation of actin cytoskeleton,hsa04919:Thyroid hormone signaling pathway,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05418:Fluid shear stress and atherosclerosis,	608446~Myocardial infarction, susceptibility to,619267~Glanzmann thrombasthenia 2,619271~Bleeding disorder, platelet-type, 24, autosomal dominant,Purpura, posttransfusion~Purpura, posttransfusion,Thrombocytopenia, neonatal alloimmune~Thrombocytopenia, neonatal alloimmune,	PIRSF002512:integrin, beta subunit,	SM00187:INB,SM00423:PSI,SM01241:SM01241,SM01242:SM01242,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	BINDING:in ADMIDAS binding site,BINDING:in ADMIDAS binding site and liganded-open conformation,BINDING:in ADMIDAS binding site and unliganded-closed conformation,BINDING:in LIMBS binding site,BINDING:in MIDAS binding site,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:Integrin beta epidermal growth factor-like,DOMAIN:Integrin beta subunit VWA,DOMAIN:Integrin beta subunit cytoplasmic,DOMAIN:Integrin beta subunit tail,DOMAIN:PSI,DOMAIN:VWFA,MOTIF:LIR,MUTAGEN:Missing: Increases ligand-binding activity.,MUTAGEN:Missing: Slight increase in ligand-binding activity; when associated with A-659.,MUTAGEN:R->A: Slight increase in ligand-binding activity; when associated with 698-D--K-702 del.,MUTAGEN:Y->A: No effect on cell surface location but impairs interaction with TNS3 and PEAK1.,REGION:CX3CL1-binding,REGION:Disordered,REGION:Involved in CX3CL1-, NRG1-, FGF1- and IGF1-binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITIH5	inter-alpha-trypsin inhibitor heavy chain 5(ITIH5)	Homo sapiens			GO:0030212~hyaluronan metabolic process,	GO:0005576~extracellular region,	GO:0004867~serine-type endopeptidase inhibitor activity,	IPR002035:von Willebrand factor, type A,IPR010600:Inter-alpha-trypsin inhibitor heavy chain, C-terminal,IPR013694:VIT domain,				SM00327:VWA,SM00609:VIT,		KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:VIT,DOMAIN:VWFA,REGION:Disordered,
ICAM2	intercellular adhesion molecule 2(ICAM2)	Homo sapiens		h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_lymPathway:Adhesion and Diapedesis of Lymphocytes,	GO:0007155~cell adhesion,GO:0098609~cell-cell adhesion,	GO:0001931~uropod,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005902~microvillus,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032154~cleavage furrow,GO:0071944~cell periphery,	GO:0005178~integrin binding,	IPR003987:Intercellular adhesion molecule/vascular cell adhesion molecule, N-terminal,IPR003988:Intercellular adhesion molecule,IPR013768:Intercellular adhesion molecule, N-terminal,IPR013783:Immunoglobulin-like fold,IPR015653:Intercellular adhesion molecule 2,	hsa04514:Cell adhesion molecules,hsa04650:Natural killer cell mediated cytotoxicity,				KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0966~Cell projection,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Intercellular adhesion molecule N-terminal,REGION:Disordered,REGION:Required for interaction with EZR, MSN and RDX and co-localization to microvilli,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFI16	interferon gamma inducible protein 16(IFI16)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001819~positive regulation of cytokine production,GO:0002218~activation of innate immune response,GO:0006914~autophagy,GO:0006954~inflammatory response,GO:0010506~regulation of autophagy,GO:0030099~myeloid cell differentiation,GO:0030224~monocyte differentiation,GO:0032731~positive regulation of interleukin-1 beta production,GO:0035458~cellular response to interferon-beta,GO:0040029~regulation of gene expression, epigenetic,GO:0042149~cellular response to glucose starvation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043392~negative regulation of DNA binding,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045824~negative regulation of innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,GO:0071479~cellular response to ionizing radiation,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0097202~activation of cysteine-type endopeptidase activity,GO:2000117~negative regulation of cysteine-type endopeptidase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,	IPR004020:DAPIN domain,IPR004021:HIN-200/IF120x,IPR011029:Death-like domain,	hsa04621:NOD-like receptor signaling pathway,			SM01289:SM01289,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HIN-200,DOMAIN:HIN-200 1,DOMAIN:HIN-200 2,DOMAIN:Pyrin,MOTIF:Nuclear localization signal,MUTAGEN:E->A: Abolishes TP53-mediated transcriptional activation; when associated with A-222.,MUTAGEN:E->A: Abolishes TP53-mediated transcriptional activation; when associated with A-272.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-732 and A-734.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-732 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A-732; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-667; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-663; A-667; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:K->Q: Predominant cytoplasmic, reduces nuclear localization (mimics non-acetylated state).,MUTAGEN:K->R: Minor effect on nuclear localization (mimics acetylated state).,MUTAGEN:Missing: Mostly nuclear, minor cytoplasmic localization.,MUTAGEN:Missing: Predominant cytoplasmic localization.,MUTAGEN:Missing: Predominant nuclear, some cytoplasmic localization.,MUTAGEN:R->A: Impairs DNA binding; when associated with A-627; A-663; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:S->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-674; A-732; A-734 and A-759.,MUTAGEN:Y->A: Abolishes TP53-mediated transcriptional activation; when associated with A-218.,MUTAGEN:Y->A: Abolishes TP53-mediated transcriptional activation; when associated with A-267.,REGION:Disordered,REGION:Interaction with TP53 C-terminus,REGION:Interaction with TP53 core domain,
IFNGR2	interferon gamma receptor 2(IFNGR2)	Homo sapiens		h_ifngPathway:IFN gamma signaling pathway ,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_th1th2Pathway:Th1/Th2 Differentiation,h_tidPathway:Chaperones modulate interferon Signaling Pathway,	GO:0001774~microglial cell activation,GO:0007166~cell surface receptor signaling pathway,GO:0009615~response to virus,GO:0019221~cytokine-mediated signaling pathway,GO:0038196~type III interferon signaling pathway,GO:0051607~defense response to virus,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0098586~cellular response to virus,GO:1904783~positive regulation of NMDA glutamate receptor activity,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,	GO:0004896~cytokine receptor activity,GO:0004906~interferon-gamma receptor activity,GO:0005515~protein binding,	IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015373:Interferon alpha/beta receptor, beta chain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04066:HIF-1 signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,	614889~Immunodeficiency 28, mycobacteriosis,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,MOTIF:Dileucine internalization motif,MUTAGEN:I->A: Does not affect accumulation on the cell membrane.,MUTAGEN:L->A: Leads to small increase in accumulation on the cell membrane.,MUTAGEN:LI->AA: Leads to overaccumulation on the cell membrane. Enhances function.,MUTAGEN:Missing: Does not affect accumulation on the cell membrane.,MUTAGEN:Missing: Leads to overaccumulation on the cell membrane.,MUTAGEN:Missing: Leads to overaccumulation on the cell membrane. Enhances function.,MUTAGEN:N->Q: Complete inhibition of transport to the cell membrane.,MUTAGEN:T->A,Q: Does not affect function.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFITM3	interferon induced transmembrane protein 3(IFITM3)	Homo sapiens			GO:0006955~immune response,GO:0009615~response to virus,GO:0032897~negative regulation of viral transcription,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0045071~negative regulation of viral genome replication,GO:0046597~negative regulation of viral entry into host cell,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR007593:Interferon-induced transmembrane protein,		614680~Influenza, severe, susceptibility to,			KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),INTRAMEM:Helical,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of anti-HCV activity. Only localizes at the lysosome. No effect on SARS-CoV-2 infection; when associated with 71-A-A-72. Loss of anti-influenza A virus activity; when associated with 71-A-A-72.,MUTAGEN:CC->AA: Loss of anti-HCV activity. Only localizes at the lysosome. No effect on SARS-CoV-2 infection; when associated with A-105. Loss of anti-influenza A virus activity; when associated with A-105.,MUTAGEN:L->Q: Accumulates at the plasma membrane. Loss of anti-SARS-CoV-2 activity by enhancing Spike-mediated cell-to-cell fusion.,MUTAGEN:Missing: Slightly enhances infection by SARS-CoV-2.,MUTAGEN:SLFNT->ALFAA: Decreases anti-SARS-CoV-2 activity.,MUTAGEN:Y->A: Loss of phosphorylation. Accumulates at the plasma membrane. Increases anti-HCV properties. Loss of anti-SARS-CoV-2 activity by enhancing Spike-mediated cell-to-cell fusion.,REGION:Disordered,REGION:Interaction with SPP1,REGION:Interaction with VAPA,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IRF4	interferon regulatory factor 4(IRF4)	Homo sapiens	79.B_cell_Activation,	h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,	GO:0002376~immune system process,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0032733~positive regulation of interleukin-10 production,GO:0032736~positive regulation of interleukin-13 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0034122~negative regulation of toll-like receptor signaling pathway,GO:0042110~T cell activation,GO:0042832~defense response to protozoan,GO:0043011~myeloid dendritic cell differentiation,GO:0043388~positive regulation of DNA binding,GO:0043966~histone H3 acetylation,GO:0043967~histone H4 acetylation,GO:0045622~regulation of T-helper cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:0072540~T-helper 17 cell lineage commitment,	GO:0000785~chromatin,GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001346:Interferon regulatory factor DNA-binding domain,IPR008984:SMAD/FHA domain,IPR017855:SMAD domain-like,IPR019471:Interferon regulatory factor-3,IPR019817:Interferon regulatory factor, conserved site,	hsa04659:Th17 cell differentiation,	611724~Skin/hair/eye pigmentation, variation in, 8,		SM00348:IRF,SM01243:SM01243,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DNA_BIND:IRF tryptophan pentad repeat,DOMAIN:IRF tryptophan pentad repeat,DOMAIN:Interferon regulatory factor-3,
IRF6	interferon regulatory factor 6(IRF6)	Homo sapiens			GO:0002376~immune system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008285~negative regulation of cell proliferation,GO:0010839~negative regulation of keratinocyte proliferation,GO:0030216~keratinocyte differentiation,GO:0043616~keratinocyte proliferation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048468~cell development,GO:0060021~palate development,GO:0060173~limb development,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:0060644~mammary gland epithelial cell differentiation,GO:0072089~stem cell proliferation,GO:1904888~cranial skeletal system development,GO:2000647~negative regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030054~cell junction,GO:0070062~extracellular exosome,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001346:Interferon regulatory factor DNA-binding domain,IPR008984:SMAD/FHA domain,IPR017855:SMAD domain-like,IPR019471:Interferon regulatory factor-3,IPR019817:Interferon regulatory factor, conserved site,		119300~van der Woude syndrome 1,119500~Popliteal pterygium syndrome 1,608864~Orofacial cleft 6,		SM00348:IRF,SM01243:SM01243,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0238~DNA-binding,	KW-0832~Ubl conjugation,	DNA_BIND:IRF tryptophan pentad repeat,DOMAIN:IRF tryptophan pentad repeat,REGION:Disordered,
IL13	interleukin 13(IL13)	Homo sapiens	113.Th1andTh2cells,35.Chemokines_EAE_Autoreactive_T_Cells,50.Hypothesis_of_bronchial_asthma,80.T_cell_Activation,88.Alternatively_Activated_APC,89.CD4_T_Cell_Differentiation,97.Immune_injury_MS-lesions_MS_antigen,	h_cytokinePathway:Cytokine Network,h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,h_inflamPathway:Cytokines and Inflammatory Response,	GO:0001774~microglial cell activation,GO:0002639~positive regulation of immunoglobulin production,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0010155~regulation of proton transport,GO:0010628~positive regulation of gene expression,GO:0030890~positive regulation of B cell proliferation,GO:0032496~response to lipopolysaccharide,GO:0032723~positive regulation of connective tissue growth factor production,GO:0032733~positive regulation of interleukin-10 production,GO:0033861~negative regulation of NAD(P)H oxidase activity,GO:0035094~response to nicotine,GO:0042116~macrophage activation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043032~positive regulation of macrophage activation,GO:0043306~positive regulation of mast cell degranulation,GO:0045471~response to ethanol,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050714~positive regulation of protein secretion,GO:0050728~negative regulation of inflammatory response,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0071260~cellular response to mechanical stimulus,GO:0071345~cellular response to cytokine stimulus,GO:0071635~negative regulation of transforming growth factor beta production,GO:1901215~negative regulation of neuron death,GO:1901247~negative regulation of lung ciliated cell differentiation,GO:1901251~positive regulation of lung goblet cell differentiation,GO:1903660~negative regulation of complement-dependent cytotoxicity,GO:2000231~positive regulation of pancreatic stellate cell proliferation,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,	GO:0005125~cytokine activity,GO:0005126~cytokine receptor binding,GO:0005144~interleukin-13 receptor binding,GO:0005515~protein binding,	IPR001325:Interleukin-4/interleukin-13,IPR009079:Four-helical cytokine-like, core,IPR018096:Interleukin-4/interleukin-13, conserved site,IPR020470:Interleukin-13,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04664:Fc epsilon RI signaling pathway,hsa05200:Pathways in cancer,hsa05310:Asthma,hsa05321:Inflammatory bowel disease,	600807~Asthma, susceptibility to,607154~Allergic rhinitis, susceptibility to,		SM00190:IL4_13,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
IL17RA	interleukin 17 receptor A(IL17RA)	Homo sapiens			GO:0006954~inflammatory response,GO:0007166~cell surface receptor signaling pathway,GO:0009615~response to virus,GO:0030163~protein catabolic process,GO:0032736~positive regulation of interleukin-13 production,GO:0032747~positive regulation of interleukin-23 production,GO:0032754~positive regulation of interleukin-5 production,GO:0032755~positive regulation of interleukin-6 production,GO:0038173~interleukin-17A-mediated signaling pathway,GO:0045087~innate immune response,GO:0050729~positive regulation of inflammatory response,GO:0050832~defense response to fungus,GO:0071621~granulocyte chemotaxis,GO:0072537~fibroblast activation,GO:0072538~T-helper 17 type immune response,GO:0097400~interleukin-17-mediated signaling pathway,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:2000340~positive regulation of chemokine (C-X-C motif) ligand 1 production,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030368~interleukin-17 receptor activity,	IPR013568:SEFIR,	hsa04060:Cytokine-cytokine receptor interaction,hsa04657:IL-17 signaling pathway,hsa04936:Alcoholic liver disease,	613953~Immunodeficiency 51,			KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:SEFIR,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL17F	interleukin 17F(IL17F)	Homo sapiens			GO:0001819~positive regulation of cytokine production,GO:0002225~positive regulation of antimicrobial peptide production,GO:0002250~adaptive immune response,GO:0006954~inflammatory response,GO:0016525~negative regulation of angiogenesis,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0032645~regulation of granulocyte macrophage colony-stimulating factor production,GO:0032663~regulation of interleukin-2 production,GO:0032675~regulation of interleukin-6 production,GO:0032677~regulation of interleukin-8 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032761~positive regulation of lymphotoxin A production,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0051216~cartilage development,GO:0097400~interleukin-17-mediated signaling pathway,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:2000340~positive regulation of chemokine (C-X-C motif) ligand 1 production,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005125~cytokine activity,GO:0005126~cytokine receptor binding,GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,	IPR010345:Interleukin-17,IPR020440:Interleukin-17, chordata,	hsa04060:Cytokine-cytokine receptor interaction,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa05321:Inflammatory bowel disease,	613956~Candidiasis, familial, 6, autosomal dominant,			KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-137),DISULFID:Interchain (with C-47),MUTAGEN:R->A: Significantly decreases the affinity for IL17RA and IL17RC by nearly 5-fold and 200-fold, respectively.,
IL23A	interleukin 23 subunit alpha(IL23A)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002230~positive regulation of defense response to virus by host,GO:0002827~positive regulation of T-helper 1 type immune response,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0010536~positive regulation of activation of Janus kinase activity,GO:0032693~negative regulation of interleukin-10 production,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032740~positive regulation of interleukin-17 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032816~positive regulation of natural killer cell activation,GO:0032819~positive regulation of natural killer cell proliferation,GO:0034105~positive regulation of tissue remodeling,GO:0042098~T cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042104~positive regulation of activated T cell proliferation,GO:0042509~regulation of tyrosine phosphorylation of STAT protein,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043382~positive regulation of memory T cell differentiation,GO:0045087~innate immune response,GO:0045672~positive regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048771~tissue remodeling,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0051135~positive regulation of NK T cell activation,GO:0051142~positive regulation of NK T cell proliferation,GO:0051607~defense response to virus,GO:0090023~positive regulation of neutrophil chemotaxis,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2000318~positive regulation of T-helper 17 type immune response,GO:2000330~positive regulation of T-helper 17 cell lineage commitment,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0070743~interleukin-23 complex,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0045519~interleukin-23 receptor binding,	IPR009079:Four-helical cytokine-like, core,IPR010831:Interleukin 23 alpha subunit p19,	hsa04060:Cytokine-cytokine receptor interaction,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,hsa05133:Pertussis,hsa05152:Tuberculosis,hsa05200:Pathways in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0797~Tissue remodeling,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,	DISULFID:Interchain (with C-119 in IL12A),
IL6R	interleukin 6 receptor(IL6R)	Homo sapiens		h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_il6Pathway:IL 6 signaling pathway,	GO:0002384~hepatic immune response,GO:0002446~neutrophil mediated immunity,GO:0002548~monocyte chemotaxis,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0006953~acute-phase response,GO:0008284~positive regulation of cell proliferation,GO:0010536~positive regulation of activation of Janus kinase activity,GO:0010573~vascular endothelial growth factor production,GO:0019221~cytokine-mediated signaling pathway,GO:0031018~endocrine pancreas development,GO:0032717~negative regulation of interleukin-8 production,GO:0032722~positive regulation of chemokine production,GO:0032755~positive regulation of interleukin-6 production,GO:0032966~negative regulation of collagen biosynthetic process,GO:0034097~response to cytokine,GO:0038154~interleukin-11-mediated signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043410~positive regulation of MAPK cascade,GO:0045669~positive regulation of osteoblast differentiation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070120~ciliary neurotrophic factor-mediated signaling pathway,GO:0072126~positive regulation of glomerular mesangial cell proliferation,GO:0072540~T-helper 17 cell lineage commitment,GO:0097191~extrinsic apoptotic signaling pathway,GO:1901731~positive regulation of platelet aggregation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005896~interleukin-6 receptor complex,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0043235~receptor complex,GO:0070110~ciliary neurotrophic factor receptor complex,	GO:0004896~cytokine receptor activity,GO:0004897~ciliary neurotrophic factor receptor activity,GO:0004915~interleukin-6 receptor activity,GO:0004921~interleukin-11 receptor activity,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019955~cytokine binding,GO:0019970~interleukin-11 binding,GO:0019981~interleukin-6 binding,GO:0042803~protein homodimerization activity,GO:0070119~ciliary neurotrophic factor binding,	IPR003530:Long hematopoietin receptor, soluble alpha chain, conserved site,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR015321:Interleukin-6 receptor alpha chain, binding,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04066:HIF-1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04659:Th17 cell differentiation,hsa04932:Non-alcoholic fatty liver disease,hsa05163:Human cytomegalovirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,	614689~Interleukin-6 receptor, soluble, serum level of, QTL,614752~Interleukin 6, serum level of, QTL,618944~Hyper-IgE recurrent infection syndrome 5, autosomal recessive,		SM00060:FN3,SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,MOTIF:WSXWS motif,MUTAGEN:C->A: Complete loss of ligand-binding.,MUTAGEN:C->A: No change of ligand-binding and IL6 signaling.,MUTAGEN:C->D: 30% increase of ligand-binding and 100% increase in IL6 signaling.,MUTAGEN:C->D: Complete loss of ligand-binding.,MUTAGEN:C->L: Complete loss of ligand-binding.,MUTAGEN:C->S: Complete loss of ligand-binding.,MUTAGEN:D->G: 70% decrease of ligand-binding and no IL6 signaling.,MUTAGEN:D->T: 30% decrease of ligand-binding and IL6 signaling.,MUTAGEN:D->V: Complete loss of ligand-binding.,MUTAGEN:E->A: 50% decrease of ligand-binding and IL6 signaling.,MUTAGEN:F->A: No change of ligand-binding and IL6 signaling.,MUTAGEN:F->L: No change of ligand-binding and IL6 signaling.,MUTAGEN:G->D: 80% decrease of ligand-binding and no IL6 signaling.,MUTAGEN:H->I: No change of ligand-binding and no IL6 signaling.,MUTAGEN:I->D: Complete loss of ligand-binding.,MUTAGEN:N->A: No effect on IL6R signaling; when associated with A-55, A-93, A-221 and A-245. Loss of cleavage by ADAM17; when associated with A-55, A-93, A-221 and A-245.,MUTAGEN:N->A: No effect on cleavage or sIL6R levels. No effect on IL6R signaling; when associated with A-55, A-221, A-245 and A-350. Loss of cleavage by ADAM17; when associated with A-55, A-221, A-245 and A-350.,MUTAGEN:N->A: No effect on cleavage or sIL6R levels. No effect on IL6R signaling; when associated with A-55, A-93, A-245 and A-350. Loss of cleavage by ADAM17; when associated with A-55, A-93, A-245 and A-350.,MUTAGEN:N->A: Slightly induces cleavage and sIL6R levels.No effect on IL6R signaling; when associated with A-55, A-93, A-221 and A-350. Loss of cleavage by ADAM17; when associated with A-55, A-93, A-221 and A-350.,MUTAGEN:N->A: Strongly induces cleavage and sIL6R levels. No effect on IL6R signaling; when associated with A-93, A-221, A-245 and A-350. Loss of cleavage by ADAM17; when associated with A-93, A-221, A-245 and A-350.,MUTAGEN:P->G: No change of ligand-binding and IL6 signaling.,MUTAGEN:P->I,D: Reduces cleavage by ADAM17.,MUTAGEN:PV->IE: Abolishes cleavage by ADAM17.,MUTAGEN:Q->K: Complete loss of ligand-binding.,MUTAGEN:R->G: Complete loss of ligand-binding.,MUTAGEN:R->S: 30% decrease of ligand-binding and IL6 signaling.,MUTAGEN:T->A: No effect on IL6R signaling.,MUTAGEN:T->A: Strongly induces cleavage and sIL6R levels.,MUTAGEN:V->E,G: Abolishes cleavage by ADAM17.,MUTAGEN:V->G: 80% decrease of ligand-binding and no IL6 signaling.,MUTAGEN:V->N: 50% Decrease of ligand-binding and 50% increase in IL6 signaling.,MUTAGEN:W->L: Complete loss of ligand-binding.,MUTAGEN:W->Q: 30% decrease of ligand-binding and increase of IL6 signaling.,REGION:Disordered,SITE:Cleavage; by ADAM10 and ADAM17,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL6	interleukin 6(IL6)	Homo sapiens	11.IL-6_gp130-Jak-STAT,110.CRHandLC-NA,114.Genomic_reformatting_Brain_Ischemia,12.IL-6_type_cytok-signal-transduct,15.T-cell_polarization-chemokine_receptors,18.Cytokine_astocytes,19.Cytokine_microglia,20.Cytokine_oligodendrocytes,21.Cytokine_neurons,22.Cytokine-chemokine_CNS,56.Macrophage_regulation_of_CD4+T_cells,58.(CD40L)_immnosurveillance,7.IL17_hematopoesis,80.T_cell_Activation,97.Immune_injury_MS-lesions_MS_antigen,	h_cytokinePathway:Cytokine Network,h_erythPathway:Erythrocyte Differentiation Pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il17Pathway:IL 17 Signaling Pathway,h_il1rPathway:Signal transduction through IL1R,h_il5Pathway:IL 5 Signaling Pathway,h_il6Pathway:IL 6 signaling pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,h_LDLpathway:Low-density lipoprotein (LDL) pathway during atherogenesis,h_stemPathway:Regulation of hematopoiesis by cytokines,	GO:0001781~neutrophil apoptotic process,GO:0002314~germinal center B cell differentiation,GO:0002384~hepatic immune response,GO:0002446~neutrophil mediated immunity,GO:0002548~monocyte chemotaxis,GO:0002639~positive regulation of immunoglobulin production,GO:0002675~positive regulation of acute inflammatory response,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0006959~humoral immune response,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010573~vascular endothelial growth factor production,GO:0010574~regulation of vascular endothelial growth factor production,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010888~negative regulation of lipid storage,GO:0014823~response to activity,GO:0019221~cytokine-mediated signaling pathway,GO:0030168~platelet activation,GO:0031018~endocrine pancreas development,GO:0031175~neuron projection development,GO:0032494~response to peptidoglycan,GO:0032682~negative regulation of chemokine production,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032740~positive regulation of interleukin-17 production,GO:0032745~positive regulation of interleukin-21 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042102~positive regulation of T cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045599~negative regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045727~positive regulation of translation,GO:0045765~regulation of angiogenesis,GO:0045779~negative regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050768~negative regulation of neurogenesis,GO:0050796~regulation of insulin secretion,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050871~positive regulation of B cell activation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051384~response to glucocorticoid,GO:0051607~defense response to virus,GO:0060252~positive regulation of glial cell proliferation,GO:0061470~T follicular helper cell differentiation,GO:0070050~neuron cellular homeostasis,GO:0070091~glucagon secretion,GO:0070092~regulation of glucagon secretion,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070301~cellular response to hydrogen peroxide,GO:0071222~cellular response to lipopolysaccharide,GO:0072540~T-helper 17 cell lineage commitment,GO:0072574~hepatocyte proliferation,GO:0090091~positive regulation of extracellular matrix disassembly,GO:0090594~inflammatory response to wounding,GO:0097421~liver regeneration,GO:0098586~cellular response to virus,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1901731~positive regulation of platelet aggregation,GO:1902512~positive regulation of apoptotic DNA fragmentation,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1903978~regulation of microglial cell activation,GO:1904894~positive regulation of STAT cascade,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:2000553~positive regulation of T-helper 2 cell cytokine production,GO:2000635~negative regulation of primary miRNA processing,GO:2000660~negative regulation of interleukin-1-mediated signaling pathway,GO:2000676~positive regulation of type B pancreatic cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005896~interleukin-6 receptor complex,	GO:0005125~cytokine activity,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR003574:Interleukin-6,IPR009079:Four-helical cytokine-like, core,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01523:Antifolate resistance,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa04668:TNF signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05332:Graft-versus-host disease,hsa05410:Hypertrophic cardiomyopathy,hsa05417:Lipid and atherosclerosis,	108010~Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to,125853~Type 2 diabetes mellitus,148000~Kaposi sarcoma, susceptibility to,222100~Type 1 diabetes mellitus,266600~Crohn disease-associated growth failure,604302~Rheumatoid arthritis, systemic juvenile,	PIRSF001935:interleukin-6,	SM00126:IL6,	KW-0011~Acute phase,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:A->V: Almost no loss of activity.,MUTAGEN:M->T,N,S,R: Loss of activity.,MUTAGEN:R->K,E,Q,T,A,P: Loss of activity.,MUTAGEN:S->P: 87% loss of activity.,MUTAGEN:W->R: No loss of activity.,REGION:Disordered,
INA	internexin neuronal intermediate filament protein alpha(INA)	Homo sapiens			GO:0021762~substantia nigra development,GO:0030154~cell differentiation,GO:0045109~intermediate filament organization,GO:0060052~neurofilament cytoskeleton organization,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005882~intermediate filament,GO:0005883~neurofilament,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098794~postsynapse,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0098973~structural constituent of postsynaptic actin cytoskeleton,	IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,				SM01391:SM01391,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0403~Intermediate filament,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 2,REGION:Tail,
IVL	involucrin(IVL)	Homo sapiens			GO:0010224~response to UV-B,GO:0018149~peptide cross-linking,GO:0018153~isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine,GO:0030216~keratinocyte differentiation,GO:0031424~keratinization,	GO:0001533~cornified envelope,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000354:Involucrin repeat,IPR002360:Involucrin,IPR019571:Involucrin, N-terminal,IPR019743:Involucrin, conserved site,					KW-0417~Keratinization,	KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0449~Lipoprotein,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-? in other proteins),LIPID:Omega-hydroxyceramide glutamate ester,REGION:39 X 10 AA approximate tandem repeats of [LP]-[EKG]-[LHVYQEK]-[PLSQE]-[EQDV]-[QHEKRGA]-Q-[EMVQLP]-[GKLE]-[QHVNLD],REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24; approximate,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:34,REPEAT:35,REPEAT:36; approximate,REPEAT:37,REPEAT:38,REPEAT:39; approximate,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
DIO1	iodothyronine deiodinase 1(DIO1)	Homo sapiens			GO:0006520~cellular amino acid metabolic process,GO:0006590~thyroid hormone generation,GO:0042403~thyroid hormone metabolic process,GO:0042446~hormone biosynthetic process,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004800~thyroxine 5'-deiodinase activity,GO:0008430~selenium binding,	IPR000643:Iodothyronine deiodinase,IPR008261:Iodothyronine deiodinase, active site,IPR027252:Iodothyronine deiodinase I/III,	hsa04919:Thyroid hormone signaling pathway,	619855~Thyroid hormone metabolism, abnormal, 2,	PIRSF001330:iodothyronine deiodinase,PIRSF500144:types I/III iodothyronine deiodinase [Parent=PIRSF001330],		KW-0893~Thyroid hormones biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0560~Oxidoreductase,		NON_STD:Selenocysteine,TRANSMEM:Helical,
DIO3	iodothyronine deiodinase 3(DIO3)	Homo sapiens			GO:0001666~response to hypoxia,GO:0040018~positive regulation of multicellular organism growth,GO:0042403~thyroid hormone metabolic process,GO:0042404~thyroid hormone catabolic process,GO:0042446~hormone biosynthetic process,GO:0046549~retinal cone cell development,GO:0070342~brown fat cell proliferation,GO:0097474~retinal cone cell apoptotic process,	GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004800~thyroxine 5'-deiodinase activity,GO:0033798~thyroxine 5-deiodinase activity,	IPR000643:Iodothyronine deiodinase,IPR008261:Iodothyronine deiodinase, active site,IPR027252:Iodothyronine deiodinase I/III,	hsa04919:Thyroid hormone signaling pathway,		PIRSF001330:iodothyronine deiodinase,PIRSF500144:types I/III iodothyronine deiodinase [Parent=PIRSF001330],		KW-0893~Thyroid hormones biosynthesis,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0560~Oxidoreductase,		MUTAGEN:U->A: Complete loss of activity.,NON_STD:Selenocysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
IRX1	iroquois homeobox 1(IRX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030182~neuron differentiation,GO:0048468~cell development,GO:0072086~specification of loop of Henle identity,GO:0072272~proximal/distal pattern formation involved in metanephric nephron development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003893:Iroquois-class homeodomain protein,IPR008422:Homeobox KN domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,SM00548:IRO,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox; TALE-type,REGION:Disordered,
ICA1	islet cell autoantigen 1(ICA1)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0050796~regulation of insulin secretion,GO:0051049~regulation of transport,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0030672~synaptic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,	IPR006723:Islet cell autoantigen Ica1, C-terminal,IPR010504:Arfaptin homology (AH) domain,IPR024114:Islet cell autoantigen 1/Ica1-like,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa04940:Type I diabetes mellitus,			SM01015:SM01015,SM01237:SM01237,	KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AH,DOMAIN:Islet cell autoantigen Ica1 C-terminal,REGION:Disordered,TRANSMEM:Helical,
JTB	jumping translocation breakpoint(JTB)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0000281~mitotic cytokinesis,GO:0006915~apoptotic process,GO:0008637~apoptotic mitochondrial changes,GO:0042127~regulation of cell proliferation,GO:0045860~positive regulation of protein kinase activity,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0030496~midbody,	GO:0019901~protein kinase binding,	IPR008657:Jumping translocation breakpoint,					KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
KALRN	kalirin RhoGEF kinase(KALRN)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0016192~vesicle-mediated transport,GO:0035556~intracellular signal transduction,GO:0048013~ephrin receptor signaling pathway,GO:0051056~regulation of small GTPase mediated signal transduction,GO:1902531~regulation of intracellular signal transduction,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0015629~actin cytoskeleton,GO:0019898~extrinsic component of membrane,GO:0070062~extracellular exosome,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000219:Dbl homology (DH) domain,IPR000719:Protein kinase, catalytic domain,IPR001251:CRAL-TRIO domain,IPR001452:Src homology-3 domain,IPR001849:Pleckstrin homology domain,IPR002017:Spectrin repeat,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR018159:Spectrin/alpha-actinin,				SM00060:FN3,SM00150:SPEC,SM00220:S_TKc,SM00233:PH,SM00325:RhoGEF,SM00326:SH3,SM00408:IGc2,SM00409:IG,SM00516:SEC14,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0344~Guanine-nucleotide releasing factor,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CRAL-TRIO,DOMAIN:DH,DOMAIN:DH 1,DOMAIN:DH 2,DOMAIN:Fibronectin type-III,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:Protein kinase,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,MUTAGEN:K->A: Loss of autophosphorylation.,REGION:Disordered,REPEAT:Spectrin 1,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,
KLK1	kallikrein 1(KLK1)	Homo sapiens			GO:0003073~regulation of systemic arterial blood pressure,GO:0031638~zymogen activation,	GO:0005634~nucleus,GO:0030141~secretory granule,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,	IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,	hsa04614:Renin-angiotensin system,hsa04961:Endocrine and other factor-regulated calcium reabsorption,	615953~Kallikrein, decreased urinary activity of,		SM00020:Tryp_SPc,				KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,CARBOHYD:O-linked (GalNAc...) serine,DOMAIN:Peptidase S1,PROPEP:Activation peptide,
KLK2	kallikrein related peptidase 2(KLK2)	Homo sapiens		h_cdk5Pathway:Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_ngfPathway:Nerve growth factor pathway (NGF),h_trkaPathway:Trka Receptor Signaling Pathway,	GO:0003073~regulation of systemic arterial blood pressure,GO:0006508~proteolysis,GO:0031638~zymogen activation,	GO:0005576~extracellular region,GO:0030141~secretory granule,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,	IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,	hsa04614:Renin-angiotensin system,hsa04961:Endocrine and other factor-regulated calcium reabsorption,			SM00020:Tryp_SPc,				KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Peptidase S1,PROPEP:Activation peptide,REGION:Disordered,
KLK9	kallikrein related peptidase 9(KLK9)	Homo sapiens			GO:0006508~proteolysis,	GO:0005576~extracellular region,GO:0030141~secretory granule,	GO:0004252~serine-type endopeptidase activity,	IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,				SM00020:Tryp_SPc,		KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Peptidase S1,REGION:Disordered,
KLHDC7B	kelch domain containing 7B(KLHDC7B)	Homo sapiens					GO:0005515~protein binding,	IPR006652:Kelch repeat type 1,IPR015915:Kelch-type beta propeller,				SM00612:Kelch,				KW-0677~Repeat,KW-0880~Kelch repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,
KLHL1	kelch like family member 1(KLHL1)	Homo sapiens			GO:0007628~adult walking behavior,GO:0016358~dendrite development,GO:0021680~cerebellar Purkinje cell layer development,GO:0030036~actin cytoskeleton organization,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0030425~dendrite,GO:0043025~neuronal cell body,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,			PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,		KW-0009~Actin-binding,		COMPBIAS:Polar residues,DOMAIN:BTB,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KLHL21	kelch like family member 21(KLHL21)	Homo sapiens			GO:0007049~cell cycle,GO:0016567~protein ubiquitination,GO:0032465~regulation of cytokinesis,GO:0035853~chromosome passenger complex localization to spindle midzone,GO:0051301~cell division,	GO:0005827~polar microtubule,GO:0005829~cytosol,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0097602~cullin family protein binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,			PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,				COMPBIAS:Basic and acidic residues,DOMAIN:BACK,DOMAIN:BTB,MUTAGEN:DLLQ->AALA: Abolishes interaction with CUL3.,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KRT1	keratin 1(KRT1)	Homo sapiens			GO:0001867~complement activation, lectin pathway,GO:0001895~retina homeostasis,GO:0006979~response to oxidative stress,GO:0018149~peptide cross-linking,GO:0031424~keratinization,GO:0042730~fibrinolysis,GO:0045109~intermediate filament organization,GO:0045765~regulation of angiogenesis,GO:0050728~negative regulation of inflammatory response,GO:0051290~protein heterotetramerization,GO:0061436~establishment of skin barrier,GO:0070268~cornification,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0045095~keratin filament,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0030280~structural constituent of epidermis,GO:0038023~signaling receptor activity,GO:0046982~protein heterodimerization activity,	IPR003054:Type II keratin,IPR018039:Intermediate filament protein, conserved site,		113800~Epidermolytic hyperkeratosis 1,146590~Ichthyosis histrix, Curth-Macklin type,600962~Palmoplantar keratoderma, nonepidermolytic,607654~Keratosis palmoplantaris striata III,620148~Ichthyosis, annular epidermolytic 2,620411~Palmoplantar keratoderma, epidermolytic, 2,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0977~Ichthyosis,KW-1007~Palmoplantar keratoderma,	KW-0175~Coiled coil,			KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KRT18	keratin 18(KRT18)	Homo sapiens			GO:0007049~cell cycle,GO:0009653~anatomical structure morphogenesis,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0043000~Golgi to plasma membrane CFTR protein transport,GO:0043001~Golgi to plasma membrane protein transport,GO:0043066~negative regulation of apoptotic process,GO:0045104~intermediate filament cytoskeleton organization,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097284~hepatocyte apoptotic process,GO:0098609~cell-cell adhesion,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005882~intermediate filament,GO:0005912~adherens junction,GO:0016363~nuclear matrix,GO:0034451~centriolar satellite,GO:0045095~keratin filament,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,	GO:0003723~RNA binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0097110~scaffold protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR002957:Keratin, type I,IPR018039:Intermediate filament protein, conserved site,	hsa04915:Estrogen signaling pathway,hsa05150:Staphylococcus aureus infection,	215600~Cirrhosis, cryptogenic,215600~Cirrhosis, noncryptogenic, susceptibility to,		SM01391:SM01391,	KW-0131~Cell cycle,KW-0945~Host-virus interaction,	KW-0403~Intermediate filament,KW-0416~Keratin,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine; alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:IF rod,MUTAGEN:D->E: Prevents cleavage by caspase-6 during apoptosis. Induces aggregates of keratin filaments in an altered organization.,MUTAGEN:R->C,H: In transgenic mice, induces marked disruption of liver and pancreas keratin filament network. Increases phosphorylation and glycosylation.,MUTAGEN:S->A: Abolishes phosphorylation; when associated with A-47; A-49 and A-51, or with A-15; A-18; A-34; A-47; A-49 and A-51. Abolishes binding to YWHAE and YWHAZ; when associated with A-34. No effect on caspase cleavage during apoptosis.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-15 and A-18.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-15 and A-23. Abolishes phosphorylation; when associated with A-15; A-34; A-47; A-49; A-51 and A-53.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-18 and A-23. Abolishes phosphorylation; when associated with A-18; A-34; A-47; A-49; A-51 and A-53.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-2 and A-10.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-2 and A-7.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-30 and A-31. Abolishes phosphorylation; when associated with A-15; A-18; A-47; A-49; A-51 and A-53. Abolishes binding to YWHAE and YWHAZ; and when associated with A-53.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-30 and A-34, or with A-30; A-44 and A-51. Abolishes glycosylation but does not affect binding to YWHAE and YWHAZ; when associated with A-30 and A-49.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-30; A-31 and A-47. Abolishes phosphorylation; when associated with A-47; A-49 and A-53, or with A-15; A-18; A-34; A-47; A-49 and A-53.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-31 and A-34, or with A-31; A-44 and A-51. Abolishes glycosylation but does not affect binding to YWHAE and YWHAZ; when associated with A-31 and A-49.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-42, or with A-30; A-31 and A-51.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-44.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-47. Abolishes phosphorylation; when associated with A-47; A-51 and A-53, or with A-15; A-18; A-34; A-47; A-51 and A-53. Abolishes glycosylation but does not affect binding to YWHAE and YWHAZ; when associated with A-30 and A-31.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-49. Abolishes phosphorylation; when associated with A-49; A-51 and A-53, or with A-15; A-18; A-34; A-49; A-51 and A-53.,MUTAGEN:S->A: No effect on phosphorylation; when associated with A-7 and A-10.,MUTAGEN:S->D,E: Abolishes binding to YWHAE and YWHAZ.,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Head,REGION:Interaction with DNAJB6,REGION:Interaction with TRADD,REGION:Linker 1,REGION:Linker 12,REGION:Necessary for interaction with PNN,REGION:Tail,SITE:Cleavage; by caspase-3, caspase-6 or caspase-7,SITE:Stutter,
KRT19	keratin 19(KRT19)	Homo sapiens			GO:0007219~Notch signaling pathway,GO:0030855~epithelial cell differentiation,GO:0043627~response to estrogen,GO:0045109~intermediate filament organization,GO:0045214~sarcomere organization,GO:0060706~cell differentiation involved in embryonic placenta development,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0016327~apicolateral plasma membrane,GO:0030018~Z disc,GO:0042383~sarcolemma,GO:0043034~costamere,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:1990357~terminal web,	GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008307~structural constituent of muscle,	IPR002957:Keratin, type I,IPR018039:Intermediate filament protein, conserved site,	hsa04915:Estrogen signaling pathway,hsa05150:Staphylococcus aureus infection,			SM01391:SM01391,	KW-0945~Host-virus interaction,	KW-0403~Intermediate filament,KW-0416~Keratin,		KW-0175~Coiled coil,			KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:IF rod,MUTAGEN:S->A: Abolishes phosphorylation; induces perinuclear collapse or short cytoplasmic filaments.,MUTAGEN:S->A: No effect on phosphorylation; no functional effect.,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Necessary for interaction with PNN,REGION:Rod-like helical tail,SITE:Stutter,
KRT4	keratin 4(KRT4)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0030855~epithelial cell differentiation,GO:0031424~keratinization,GO:0045109~intermediate filament organization,GO:0050680~negative regulation of epithelial cell proliferation,GO:0070268~cornification,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0009986~cell surface,GO:0045095~keratin filament,GO:0045111~intermediate filament cytoskeleton,	GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,	IPR003054:Type II keratin,IPR018039:Intermediate filament protein, conserved site,		193900~White sponge nevus 1,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0488~Methylation,	DOMAIN:IF rod,DOMAIN:Keratin type II head,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KRT6A	keratin 6A(KRT6A)	Homo sapiens			GO:0001899~negative regulation of cytolysis by symbiont of host cells,GO:0002009~morphogenesis of an epithelium,GO:0008284~positive regulation of cell proliferation,GO:0030154~cell differentiation,GO:0031424~keratinization,GO:0031640~killing of cells of other organism,GO:0042060~wound healing,GO:0045109~intermediate filament organization,GO:0050830~defense response to Gram-positive bacterium,GO:0051838~cytolysis by host of symbiont cells,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070268~cornification,GO:2000536~negative regulation of entry of bacterium into host cell,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0016020~membrane,GO:0045095~keratin filament,GO:0070062~extracellular exosome,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,	IPR003054:Type II keratin,IPR018039:Intermediate filament protein, conserved site,		615726~Pachyonychia congenita 3,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,	KW-0020~Allergen,KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-1007~Palmoplantar keratoderma,	KW-0175~Coiled coil,			KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:IF rod,DOMAIN:Keratin type II head,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KRT80	keratin 80(KRT80)	Homo sapiens			GO:0031424~keratinization,GO:0045109~intermediate filament organization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0045095~keratin filament,GO:0045111~intermediate filament cytoskeleton,	GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,	IPR003054:Type II keratin,				SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KIF21A	kinesin family member 21A(KIF21A)	Homo sapiens			GO:0007018~microtubule-based movement,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:0071532~ankyrin repeat binding,	IPR001680:WD40 repeat,IPR001752:Kinesin, motor domain,IPR015943:WD40/YVTN repeat-like-containing domain,IPR019775:WD40 repeat, conserved site,IPR019821:Kinesin, motor region, conserved site,IPR020472:G-protein beta WD-40 repeat,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04814:Motor proteins,	135700~Fibrosis of extraocular muscles, congenital, 1,135700~Fibrosis of extraocular muscles, congenital, 3B,		SM00129:KISc,SM00320:WD40,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Kinesin motor,MUTAGEN:L->A: Does not bind to KANK1 or KANK2.,MUTAGEN:R->A: Very weak binding affinity for KANK1 and KANK2.,REGION:Disordered,REGION:Interaction with KANK1 and KANK2,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
KIF2A	kinesin family member 2A(KIF2A)	Homo sapiens	28.KLFs_cytoplas_dynein_cargo_nerve_axons,30.Kinesin_superfamily_proteins,		GO:0000226~microtubule cytoskeleton organization,GO:0007018~microtubule-based movement,GO:0007019~microtubule depolymerization,GO:0007052~mitotic spindle organization,GO:0007399~nervous system development,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0051301~cell division,GO:0090307~mitotic spindle assembly,	GO:0000922~spindle pole,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005876~spindle microtubule,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0003774~motor activity,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04814:Motor proteins,	615411~Cortical dysplasia, complex, with other brain malformations 3,		SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0505~Motor protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Kinesin motor,REGION:Disordered,REGION:Globular,
KIF5B	kinesin family member 5B(KIF5B)	Homo sapiens			GO:0007018~microtubule-based movement,GO:0007028~cytoplasm organization,GO:0007411~axon guidance,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0032230~positive regulation of synaptic transmission, GABAergic,GO:0032418~lysosome localization,GO:0035617~stress granule disassembly,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042391~regulation of membrane potential,GO:0043268~positive regulation of potassium ion transport,GO:0047496~vesicle transport along microtubule,GO:0047497~mitochondrion transport along microtubule,GO:0048489~synaptic vesicle transport,GO:0051642~centrosome localization,GO:0071346~cellular response to interferon-gamma,GO:0072383~plus-end-directed vesicle transport along microtubule,GO:0098971~anterograde dendritic transport of neurotransmitter receptor complex,GO:0099641~anterograde axonal protein transport,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1990048~anterograde neuronal dense core vesicle transport,GO:1990049~retrograde neuronal dense core vesicle transport,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0031982~vesicle,GO:0032839~dendrite cytoplasm,GO:0034451~centriolar satellite,GO:0035253~ciliary rootlet,GO:0043005~neuron projection,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:1904115~axon cytoplasm,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,hsa04728:Dopaminergic synapse,hsa04814:Motor proteins,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,hsa05223:Non-small cell lung cancer,			SM00129:KISc,		KW-0206~Cytoskeleton,KW-0458~Lysosome,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Kinesin motor,REGION:Disordered,REGION:Globular,
KL	klotho(KL)	Homo sapiens			GO:0002526~acute inflammatory response,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0005975~carbohydrate metabolic process,GO:0006112~energy reserve metabolic process,GO:0007568~aging,GO:0008286~insulin receptor signaling pathway,GO:0008340~determination of adult lifespan,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0014823~response to activity,GO:0030501~positive regulation of bone mineralization,GO:0033280~response to vitamin D,GO:0042421~norepinephrine biosynthetic process,GO:0055074~calcium ion homeostasis,GO:0090080~positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway,GO:1990776~response to angiotensin,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0070062~extracellular exosome,	GO:0004566~beta-glucuronidase activity,GO:0005104~fibroblast growth factor receptor binding,GO:0005179~hormone activity,GO:0005499~vitamin D binding,GO:0008422~beta-glucosidase activity,GO:0017134~fibroblast growth factor binding,	IPR001360:Glycoside hydrolase, family 1,IPR017853:Glycoside hydrolase, superfamily,	hsa00040:Pentose and glucuronate interconversions,hsa00053:Ascorbate and aldarate metabolism,hsa01100:Metabolic pathways,hsa04211:Longevity regulating pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04961:Endocrine and other factor-regulated calcium reabsorption,	617994~Tumoral calcinosis, hyperphosphatemic, familial, 3,				KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0848~Vitamin D,	KW-0326~Glycosidase,KW-0372~Hormone,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Glycosyl hydrolase-1 1,REGION:Glycosyl hydrolase-1 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LACTB	lactamase beta(LACTB)	Homo sapiens			GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0019216~regulation of lipid metabolic process,	GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0008233~peptidase activity,GO:0042802~identical protein binding,	IPR001466:Beta-lactamase-related,IPR012338:Beta-lactamase/transpeptidase-like,					KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,	KW-0043~Tumor suppressor,	KW-0809~Transit peptide,		KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,	ACT_SITE:Acyl-ester intermediate,COMPBIAS:Basic and acidic residues,DOMAIN:Beta-lactamase-related,REGION:Disordered,TRANSIT:Mitochondrion,
LAMA1	laminin subunit alpha 1(LAMA1)	Homo sapiens		h_prionPathway:Prion Pathway,	GO:0002011~morphogenesis of an epithelial sheet,GO:0006468~protein phosphorylation,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007411~axon guidance,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0031175~neuron projection development,GO:0043010~camera-type eye development,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045785~positive regulation of cell adhesion,GO:0045995~regulation of embryonic development,GO:0048514~blood vessel morphogenesis,GO:0051149~positive regulation of muscle cell differentiation,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0061304~retinal blood vessel morphogenesis,GO:2001046~positive regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005606~laminin-1 complex,GO:0005608~laminin-3 complex,GO:0005615~extracellular space,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0098637~protein complex involved in cell-matrix adhesion,	GO:0005102~receptor binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0043208~glycosphingolipid binding,	IPR000034:Laminin B type IV,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002049:EGF-like, laminin,IPR008211:Laminin, N-terminal,IPR009254:Laminin I,IPR010307:Laminin II,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,	615960~Poretti-Boltshauser syndrome,		SM00136:LamNT,SM00180:EGF_Lam,SM00181:EGF,SM00281:LamB,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 12,DOMAIN:Laminin EGF-like 13,DOMAIN:Laminin EGF-like 14; first part,DOMAIN:Laminin EGF-like 14; second part,DOMAIN:Laminin EGF-like 15,DOMAIN:Laminin EGF-like 16,DOMAIN:Laminin EGF-like 17,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4,DOMAIN:Laminin EGF-like 5; first part,DOMAIN:Laminin EGF-like 5; second part,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9,DOMAIN:Laminin G,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,DOMAIN:Laminin G-like 5,DOMAIN:Laminin IV type A 1,DOMAIN:Laminin IV type A 2,DOMAIN:Laminin N-terminal,MOTIF:Cell attachment site,REGION:Domain II and I,
LAMA2	laminin subunit alpha 2(LAMA2)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,	GO:0007155~cell adhesion,GO:0007411~axon guidance,GO:0007517~muscle organ development,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0014037~Schwann cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0032224~positive regulation of synaptic transmission, cholinergic,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0045785~positive regulation of cell adhesion,GO:0045995~regulation of embryonic development,GO:0051149~positive regulation of muscle cell differentiation,GO:2001046~positive regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0016020~membrane,GO:0031594~neuromuscular junction,GO:0042383~sarcolemma,GO:0043083~synaptic cleft,GO:0043197~dendritic spine,GO:0098637~protein complex involved in cell-matrix adhesion,	GO:0005102~receptor binding,GO:0005198~structural molecule activity,GO:0005201~extracellular matrix structural constituent,	IPR000034:Laminin B type IV,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002049:EGF-like, laminin,IPR008211:Laminin, N-terminal,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR009254:Laminin I,IPR010307:Laminin II,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,	607855~Muscular dystrophy, congenital, merosin deficient or partially deficient,618138~Muscular dystrophy, limb-girdle, autosomal recessive 23,		SM00136:LamNT,SM00180:EGF_Lam,SM00181:EGF,SM00281:LamB,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,	KW-0175~Coiled coil,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 12,DOMAIN:Laminin EGF-like 13,DOMAIN:Laminin EGF-like 14; first part,DOMAIN:Laminin EGF-like 14; second part,DOMAIN:Laminin EGF-like 15,DOMAIN:Laminin EGF-like 16,DOMAIN:Laminin EGF-like 17,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4,DOMAIN:Laminin EGF-like 5; first part,DOMAIN:Laminin EGF-like 5; second part,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9,DOMAIN:Laminin G,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,DOMAIN:Laminin G-like 5,DOMAIN:Laminin IV type A,DOMAIN:Laminin IV type A 1,DOMAIN:Laminin IV type A 2,DOMAIN:Laminin N-terminal,REGION:Disordered,REGION:Domain II and I,
LAMA4	laminin subunit alpha 4(LAMA4)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,	GO:0001568~blood vessel development,GO:0007155~cell adhesion,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0045995~regulation of embryonic development,GO:0050873~brown fat cell differentiation,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0016020~membrane,GO:0031594~neuromuscular junction,GO:0043083~synaptic cleft,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005201~extracellular matrix structural constituent,	IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002049:EGF-like, laminin,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR009254:Laminin I,IPR010307:Laminin II,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05143:African trypanosomiasis,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	615235~Cardiomyopathy, dilated, 1JJ,		SM00180:EGF_Lam,SM00181:EGF,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DISULFID:Interchain,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4; truncated,DOMAIN:Laminin G,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,DOMAIN:Laminin G-like 5,MOTIF:Cell attachment site,REGION:Disordered,REGION:Domain II and I,
LTBP1	latent transforming growth factor beta binding protein 1(LTBP1)	Homo sapiens			GO:0007178~transmembrane receptor protein serine/threonine kinase signaling pathway,GO:0035583~sequestering of TGFbeta in extracellular matrix,GO:1901388~regulation of transforming growth factor beta activation,	GO:0001527~microfibril,GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0032991~macromolecular complex,	GO:0005024~transforming growth factor beta-activated receptor activity,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0050431~transforming growth factor beta binding,GO:0050436~microfibril binding,GO:0060090~binding, bridging,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011398:Fibrillin,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,	hsa04350:TGF-beta signaling pathway,	619451~Cutis laxa, autosomal recessive, type IIE,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Glc) serine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (with C-33 in TGFB1); in linked form,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,MOTIF:Cell attachment site,MUTAGEN:DNCE->ANCA: Abolishes interaction with the Latency-associated peptide chain (LAP) regulatory chain of TGFB1; when associated with A-1348.,MUTAGEN:E->A: Abolishes interaction with the Latency-associated peptide chain (LAP) regulatory chain of TGFB1; when associated with 1382-A--A-1385.,MUTAGEN:EIFP->DL: Loss of binding to TGFB1.,MUTAGEN:N->A,Q: Abolishes N-glycosylation at this site without affecting ability to interact with the Latency-associated peptide chain (LAP) regulatory chain of TGFB1.,REGION:8-Cys3 region,REGION:C-terminal domain,REGION:Disordered,
LTBP3	latent transforming growth factor beta binding protein 3(LTBP3)	Homo sapiens			GO:0002062~chondrocyte differentiation,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0030282~bone mineralization,GO:0030502~negative regulation of bone mineralization,GO:0032331~negative regulation of chondrocyte differentiation,GO:0036363~transforming growth factor beta activation,GO:0045780~positive regulation of bone resorption,GO:0046849~bone remodeling,GO:0048251~elastic fiber assembly,GO:0060349~bone morphogenesis,GO:0060430~lung saccule development,GO:1902462~positive regulation of mesenchymal stem cell proliferation,GO:2000741~positive regulation of mesenchymal stem cell differentiation,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0050431~transforming growth factor beta binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013032:EGF-like, conserved site,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,		601216~Dental anomalies and short stature,617809~Geleophysic dysplasia 3,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0986~Amelogenesis imperfecta,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (with C-33 in TGFB1); in linked form,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,REGION:Disordered,
LAYN	layilin(LAYN)	Homo sapiens				GO:0001726~ruffle,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005540~hyaluronic acid binding,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,		KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,REGION:2 X 4 AA repeats of N-X-I-Y,REGION:3 X 5 AA repeats of E-S-G-X-V,REGION:Disordered,REGION:Interaction with NF2,REGION:Interaction with TLN1,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:2-1,REPEAT:2-2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRAT	lecithin retinol acyltransferase(LRAT)	Homo sapiens			GO:0001523~retinoid metabolic process,GO:0006776~vitamin A metabolic process,GO:0007601~visual perception,GO:0009617~response to bacterium,GO:0032370~positive regulation of lipid transport,GO:0032526~response to retinoic acid,GO:0033189~response to vitamin A,GO:0042572~retinol metabolic process,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005771~multivesicular body,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005791~rough endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0001972~retinoic acid binding,GO:0005515~protein binding,GO:0016416~O-palmitoyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0019841~retinol binding,GO:0047173~phosphatidylcholine-retinol O-acyltransferase activity,GO:0102279~lecithin:11-cis retinol acyltransferase activity,	IPR007053:LRAT-like domain,	hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,hsa04977:Vitamin digestion and absorption,	613341~Leber congenital amaurosis 14,613341~Retinal dystrophy, early-onset severe,613341~Retinitis pigmentosa, juvenile,			KW-0443~Lipid metabolism,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,KW-0901~Leber congenital amaurosis,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,		ACT_SITE:Acyl-thioester intermediate,DOMAIN:LRAT,MUTAGEN:C->A,S: Loss of activity.,MUTAGEN:C->A: Does not affect activity.,MUTAGEN:C->A: Loss of activity.,MUTAGEN:C->S: Does not affect activity.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LEFTY2	left-right determination factor 2(LEFTY2)	Homo sapiens			GO:0007165~signal transduction,GO:0009948~anterior/posterior axis specification,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030509~BMP signaling pathway,GO:0060395~SMAD protein signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031093~platelet alpha granule lumen,	GO:0005125~cytokine activity,GO:0005160~transforming growth factor beta receptor binding,GO:0008083~growth factor activity,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR003942:Left- Right determination factor,IPR015615:Transforming growth factor-beta-related,IPR017948:Transforming growth factor beta, conserved site,	hsa04350:TGF-beta signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,		PIRSF037402:lefty protein [Parent=PIRSF800009],	SM00204:TGFB,		KW-0964~Secreted,	KW-0225~Disease variant,KW-1056~Heterotaxy,	KW-0732~Signal,		KW-0202~Cytokine,KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TGF-beta family profile,PROPEP:Or 135,
LEP	leptin(LEP)	Homo sapiens		h_leptinPathway:Reversal of Insulin Resistance by Leptin,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001542~ovulation from ovarian follicle,GO:0001666~response to hypoxia,GO:0001890~placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001936~regulation of endothelial cell proliferation,GO:0002021~response to dietary excess,GO:0003300~cardiac muscle hypertrophy,GO:0006006~glucose metabolic process,GO:0006111~regulation of gluconeogenesis,GO:0006112~energy reserve metabolic process,GO:0006114~glycerol biosynthetic process,GO:0006629~lipid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0006909~phagocytosis,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0007565~female pregnancy,GO:0007623~circadian rhythm,GO:0008203~cholesterol metabolic process,GO:0008206~bile acid metabolic process,GO:0008217~regulation of blood pressure,GO:0008284~positive regulation of cell proliferation,GO:0008340~determination of adult lifespan,GO:0008343~adult feeding behavior,GO:0010507~negative regulation of autophagy,GO:0010888~negative regulation of lipid storage,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014823~response to activity,GO:0019953~sexual reproduction,GO:0021954~central nervous system neuron development,GO:0030073~insulin secretion,GO:0030217~T cell differentiation,GO:0030300~regulation of intestinal cholesterol absorption,GO:0032008~positive regulation of TOR signaling,GO:0032099~negative regulation of appetite,GO:0032310~prostaglandin secretion,GO:0032355~response to estradiol,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032814~regulation of natural killer cell activation,GO:0032817~regulation of natural killer cell proliferation,GO:0032868~response to insulin,GO:0032869~cellular response to insulin stimulus,GO:0033197~response to vitamin E,GO:0033210~leptin-mediated signaling pathway,GO:0033686~positive regulation of luteinizing hormone secretion,GO:0035360~positive regulation of peroxisome proliferator activated receptor signaling pathway,GO:0035556~intracellular signal transduction,GO:0035630~bone mineralization involved in bone maturation,GO:0035904~aorta development,GO:0038108~negative regulation of appetite by leptin-mediated signaling pathway,GO:0042102~positive regulation of T cell proliferation,GO:0042269~regulation of natural killer cell mediated cytotoxicity,GO:0042307~positive regulation of protein import into nucleus,GO:0042445~hormone metabolic process,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042593~glucose homeostasis,GO:0042755~eating behavior,GO:0043066~negative regulation of apoptotic process,GO:0043270~positive regulation of ion transport,GO:0043410~positive regulation of MAPK cascade,GO:0044320~cellular response to leptin stimulus,GO:0045471~response to ethanol,GO:0045765~regulation of angiogenesis,GO:0045906~negative regulation of vasoconstriction,GO:0046325~negative regulation of glucose import,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0046850~regulation of bone remodeling,GO:0046881~positive regulation of follicle-stimulating hormone secretion,GO:0048639~positive regulation of developmental growth,GO:0050796~regulation of insulin secretion,GO:0050810~regulation of steroid biosynthetic process,GO:0050892~intestinal absorption,GO:0050901~leukocyte tethering or rolling,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051541~elastin metabolic process,GO:0051726~regulation of cell cycle,GO:0051897~positive regulation of protein kinase B signaling,GO:0060587~regulation of lipoprotein lipid oxidation,GO:0060612~adipose tissue development,GO:0061037~negative regulation of cartilage development,GO:0070093~negative regulation of glucagon secretion,GO:0071298~cellular response to L-ascorbic acid,GO:0071300~cellular response to retinoic acid,GO:0090335~regulation of brown fat cell differentiation,GO:0098868~bone growth,GO:1900015~regulation of cytokine production involved in inflammatory response,GO:1900745~positive regulation of p38MAPK cascade,GO:1904651~positive regulation of fat cell apoptotic process,GO:1990051~activation of protein kinase C activity,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000486~negative regulation of glutamine transport,GO:2000491~positive regulation of hepatic stellate cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0051428~peptide hormone receptor binding,GO:1990460~leptin receptor binding,	IPR000065:Obesity factor,IPR009079:Four-helical cytokine-like, core,	hsa04060:Cytokine-cytokine receptor interaction,hsa04080:Neuroactive ligand-receptor interaction,hsa04152:AMPK signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04932:Non-alcoholic fatty liver disease,	614962~Obesity, morbid, due to leptin deficiency,	PIRSF001837:leptin,			KW-0964~Secreted,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0550~Obesity,	KW-0732~Signal,			KW-1015~Disulfide bond,
LRRC4	leucine rich repeat containing 4(LRRC4)	Homo sapiens			GO:0050804~modulation of synaptic transmission,GO:0097119~postsynaptic density protein 95 clustering,GO:0099560~synaptic membrane adhesion,GO:1904861~excitatory synapse assembly,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043197~dendritic spine,GO:0060076~excitatory synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099061~integral component of postsynaptic density membrane,	GO:0005515~protein binding,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR026882:Leucine-rich repeat-containing protein 4,	hsa04360:Axon guidance,hsa04514:Cell adhesion molecules,			SM00013:LRRNT,SM00082:LRRCT,SM00369:LRR_TYP,SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:LRRCT,DOMAIN:LRRNT,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRIT1	leucine rich repeat, Ig-like and transmembrane domains 1(LRIT1)	Homo sapiens				GO:0005789~endoplasmic reticulum membrane,GO:0030176~integral component of endoplasmic reticulum membrane,		IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00082:LRRCT,SM00369:LRR_TYP,SM00408:IGc2,SM00409:IG,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Ig-like C2-type,DOMAIN:LRRCT,DOMAIN:LRRNT,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LILRA2	leukocyte immunoglobulin like receptor A2(LILRA2)	Homo sapiens			GO:0002220~innate immune response activating cell surface receptor signaling pathway,GO:0002283~neutrophil activation involved in immune response,GO:0006952~defense response,GO:0007165~signal transduction,GO:0019221~cytokine-mediated signaling pathway,GO:0031665~negative regulation of lipopolysaccharide-mediated signaling pathway,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0045087~innate immune response,GO:0050867~positive regulation of cell activation,GO:0051928~positive regulation of calcium ion transport,GO:0071657~positive regulation of granulocyte colony-stimulating factor production,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0001791~IgM binding,GO:0003823~antigen binding,GO:0032396~inhibitory MHC class I receptor activity,GO:0038023~signaling receptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0944~Nitration,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRB1	leukocyte immunoglobulin like receptor B1(LILRB1)	Homo sapiens			GO:0001915~negative regulation of T cell mediated cytotoxicity,GO:0002230~positive regulation of defense response to virus by host,GO:0002250~adaptive immune response,GO:0002309~T cell proliferation involved in immune response,GO:0002719~negative regulation of cytokine production involved in immune response,GO:0002767~immune response-inhibiting cell surface receptor signaling pathway,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0007165~signal transduction,GO:0009615~response to virus,GO:0010628~positive regulation of gene expression,GO:0014063~negative regulation of serotonin secretion,GO:0019221~cytokine-mediated signaling pathway,GO:0031623~receptor internalization,GO:0032688~negative regulation of interferon-beta production,GO:0032689~negative regulation of interferon-gamma production,GO:0032693~negative regulation of interleukin-10 production,GO:0032695~negative regulation of interleukin-12 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032945~negative regulation of mononuclear cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045786~negative regulation of cell cycle,GO:0045806~negative regulation of endocytosis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0046636~negative regulation of alpha-beta T cell activation,GO:0051607~defense response to virus,GO:0051926~negative regulation of calcium ion transport,GO:0060907~positive regulation of macrophage cytokine production,GO:0071222~cellular response to lipopolysaccharide,GO:0071635~negative regulation of transforming growth factor beta production,GO:0097028~dendritic cell differentiation,GO:2000669~negative regulation of dendritic cell apoptotic process,GO:2001186~negative regulation of CD8-positive, alpha-beta T cell activation,GO:2001189~negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:2001193~positive regulation of gamma-delta T cell activation involved in immune response,GO:2001199~negative regulation of dendritic cell differentiation,GO:2001205~negative regulation of osteoclast development,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0023025~MHC class Ib protein complex binding,GO:0023029~MHC class Ib protein binding,GO:0030107~HLA-A specific inhibitory MHC class I receptor activity,GO:0030109~HLA-B specific inhibitory MHC class I receptor activity,GO:0032393~MHC class I receptor activity,GO:0032394~MHC class Ib receptor activity,GO:0032396~inhibitory MHC class I receptor activity,GO:0042169~SH2 domain binding,GO:0042288~MHC class I protein binding,GO:0042803~protein homodimerization activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,MOTIF:ITIM motif 4,MUTAGEN:Y->F: Impairs receptor phosphorylation and abolishes inhibition of serotonin release. No effect on PTPN6 binding; when associated with F-562.,MUTAGEN:Y->F: No effect on PTPN6 binding. Abolishes PTPN6 binding; when associated with F-644.,MUTAGEN:Y->F: No effect on PTPN6 binding; when associated with F-533.,MUTAGEN:Y->F: Reduces PTPN6 binding. Abolishes PTPN6 binding; when associated with F-614.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LCOR	ligand dependent nuclear receptor corepressor(LCOR)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0071392~cellular response to estradiol stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0001222~transcription corepressor binding,GO:0003677~DNA binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0030331~estrogen receptor binding,GO:0042826~histone deacetylase binding,GO:1990226~histone methyltransferase binding,GO:1990381~ubiquitin-specific protease binding,	IPR007889:DNA binding HTH domain, Psq-type,IPR009057:Homeodomain-like,	hsa03083:Polycomb repressive complex,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:H-T-H motif,DOMAIN:HTH psq-type,MOTIF:Interaction with nuclear receptors,MOTIF:Nuclear localization signal,MUTAGEN:LL->AA: Loss of estradiol-dependent interaction with ESR1 and ESR2.,REGION:Disordered,
LNX1	ligand of numb-protein X 1(LNX1)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,	GO:0005737~cytoplasm,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0016874~ligase activity,GO:0030165~PDZ domain binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR001478:PDZ domain,IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,				SM00184:RING,SM00228:PDZ,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0436~Ligase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,DOMAIN:PDZ 4,DOMAIN:RING-type,MOTIF:NPXY motif,REGION:Disordered,REGION:Interaction with MAGEB18,ZN_FING:RING-type,
LPA	lipoprotein(a)(LPA)	Homo sapiens			GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0006869~lipid transport,GO:0008015~blood circulation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0019897~extrinsic component of plasma membrane,GO:0034358~plasma lipoprotein particle,	GO:0001968~fibronectin binding,GO:0004175~endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0004866~endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0034185~apolipoprotein binding,	IPR000001:Kringle,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR018114:Peptidase S1, trypsin family, active site,	hsa04979:Cholesterol metabolism,	618807~Coronary artery disease, susceptibility to,618807~LPA deficiency, congenital,		SM00020:Tryp_SPc,SM00130:KR,	KW-0445~Lipid transport,KW-0813~Transport,		KW-0065~Atherosclerosis,	KW-0420~Kringle,KW-0677~Repeat,KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Kringle,DOMAIN:Kringle 1,DOMAIN:Kringle 10,DOMAIN:Kringle 11,DOMAIN:Kringle 12,DOMAIN:Kringle 13,DOMAIN:Kringle 14,DOMAIN:Kringle 15,DOMAIN:Kringle 16,DOMAIN:Kringle 2,DOMAIN:Kringle 3,DOMAIN:Kringle 4,DOMAIN:Kringle 5,DOMAIN:Kringle 6,DOMAIN:Kringle 7,DOMAIN:Kringle 8,DOMAIN:Kringle 9,DOMAIN:Peptidase S1,REGION:Disordered,
LY6K	lymphocyte antigen 6 family member K(LY6K)	Homo sapiens			GO:0007339~binding of sperm to zona pellucida,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0045121~membrane raft,GO:0098552~side of membrane,								KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:UPAR/Ly6,LIPID:GPI-anchor amidated glycine,PROPEP:Removed in mature form,REGION:Disordered,
LOXL2	lysyl oxidase like 2(LOXL2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0001837~epithelial to mesenchymal transition,GO:0001935~endothelial cell proliferation,GO:0002040~sprouting angiogenesis,GO:0006464~cellular protein modification process,GO:0007155~cell adhesion,GO:0007568~aging,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0018057~peptidyl-lysine oxidation,GO:0030199~collagen fibril organization,GO:0032332~positive regulation of chondrocyte differentiation,GO:0036211~protein modification process,GO:0043542~endothelial cell migration,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046688~response to copper ion,GO:0070828~heterochromatin organization,GO:1902455~negative regulation of stem cell population maintenance,	GO:0000785~chromatin,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005044~scavenger receptor activity,GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0070492~oligosaccharide binding,	IPR001190:Speract/scavenger receptor,IPR001695:Lysyl oxidase,IPR017448:Speract/scavenger receptor-related,IPR019828:Lysyl oxidase, conserved site,				SM00202:SR,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0084~Basement membrane,KW-0158~Chromosome,KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0539~Nucleus,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0186~Copper,KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0560~Oxidoreductase,KW-0678~Repressor,	KW-0325~Glycoprotein,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr),DOMAIN:SRCR,DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,DOMAIN:SRCR 4,MUTAGEN:H->A: Loss of enzyme activity.,MUTAGEN:HRH->ARA: Abolishes oxidase activity and oxidation of trimethylated 'Lys-4' of histone H3 but does not affect secretion, interaction with SNAI1, binding to the CDH1 promoter, repression of CDH1 transcription or ability to induce EMT.,MUTAGEN:K->A: Loss of enzyme activity.,MUTAGEN:N->Q: Inhibits secretion.,MUTAGEN:Y->A: Loss of enzyme activity.,MUTAGEN:Y->F: Does not affect ability to inhibit keratinocyte differentiation.,REGION:Disordered,REGION:Lysyl-oxidase like,
HLA-DMA	major histocompatibility complex, class II, DM alpha(HLA-DMA)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,	GO:0005765~lysosomal membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II alpha chain N-terminal,MUTAGEN:F->A: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:I->N: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:N->A,R: Abrogates the interaction with MHCII and peptide exchange.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-124.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-220.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HLA-DOA	major histocompatibility complex, class II, DO alpha(HLA-DOA)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002587~negative regulation of antigen processing and presentation of peptide antigen via MHC class II,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0045580~regulation of T cell differentiation,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0042613~MHC class II protein complex,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DPB1	major histocompatibility complex, class II, DP beta 1(HLA-DPB1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002480~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032729~positive regulation of interferon-gamma production,GO:0042102~positive regulation of T cell proliferation,GO:0045321~leukocyte activation,GO:0050778~positive regulation of immune response,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0060333~interferon-gamma-mediated signaling pathway,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001003:MHC class II, alpha chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	Beryllium disease, chronic, susceptibility to~Beryllium disease, chronic, susceptibility to,		SM00407:IGc1,SM00920:SM00920,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC class II beta chain N-terminal,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ME3	malic enzyme 3(ME3)	Homo sapiens			GO:0006090~pyruvate metabolic process,GO:0006108~malate metabolic process,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0009060~aerobic respiration,GO:0072592~oxygen metabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005886~plasma membrane,	GO:0004470~malic enzyme activity,GO:0004471~malate dehydrogenase (decarboxylating) (NAD+) activity,GO:0004473~malate dehydrogenase (decarboxylating) (NADP+) activity,GO:0005509~calcium ion binding,GO:0008948~oxaloacetate decarboxylase activity,GO:0046872~metal ion binding,GO:0051287~NAD binding,GO:0070401~NADP+ binding,	IPR001891:Malic oxidoreductase,IPR002126:Cadherin,IPR012301:Malic enzyme, N-terminal,IPR012302:Malic enzyme, NAD-binding,IPR015884:Malic enzyme, conserved site,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,	hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa03320:PPAR signaling pathway,		PIRSF000106:malic enzyme,	SM00112:CA,SM00919:SM00919,SM01274:SM01274,		KW-0496~Mitochondrion,		KW-0677~Repeat,KW-0809~Transit peptide,	KW-0479~Metal-binding,KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,DOMAIN:Cadherin,DOMAIN:Malic enzyme N-terminal,DOMAIN:Malic enzyme NAD-binding,REGION:Disordered,SITE:Important for activity,TRANSIT:Mitochondrion,
MMP14	matrix metallopeptidase 14(MMP14)	Homo sapiens		h_reckPathway:Inhibition of Matrix Metalloproteinases,	GO:0001501~skeletal system development,GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001666~response to hypoxia,GO:0001935~endothelial cell proliferation,GO:0001958~endochondral ossification,GO:0006508~proteolysis,GO:0006979~response to oxidative stress,GO:0008584~male gonad development,GO:0009612~response to mechanical stimulus,GO:0010831~positive regulation of myotube differentiation,GO:0010954~positive regulation of protein processing,GO:0014070~response to organic cyclic compound,GO:0016485~protein processing,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0030574~collagen catabolic process,GO:0031638~zymogen activation,GO:0035987~endodermal cell differentiation,GO:0035988~chondrocyte proliferation,GO:0043615~astrocyte cell migration,GO:0043627~response to estrogen,GO:0045579~positive regulation of B cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048771~tissue remodeling,GO:0048870~cell motility,GO:0051895~negative regulation of focal adhesion assembly,GO:0060322~head development,GO:0097094~craniofacial suture morphogenesis,GO:1903076~regulation of protein localization to plasma membrane,GO:1905523~positive regulation of macrophage migration,GO:1990834~response to odorant,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005796~Golgi lumen,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0031410~cytoplasmic vesicle,GO:0042470~melanosome,GO:0044354~macropinosome,GO:0045111~intermediate filament cytoskeleton,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR021805:Peptidase M10A, matrix metallopeptidase, C-terminal,IPR024079:Metallopeptidase, catalytic domain,	hsa04668:TNF signaling pathway,hsa04912:GnRH signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,	277950~Winchester syndrome,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,DOMAIN:Peptidase metallopeptidase,DOMAIN:Peptidoglycan binding-like,MOTIF:Cysteine switch,PROPEP:Activation peptide,REGION:Disordered,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MMP21	matrix metallopeptidase 21(MMP21)	Homo sapiens			GO:0002244~hematopoietic progenitor cell differentiation,GO:0006508~proteolysis,GO:0007368~determination of left/right symmetry,GO:0030198~extracellular matrix organization,GO:0030574~collagen catabolic process,GO:0060976~coronary vasculature development,GO:0061371~determination of heart left/right asymmetry,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0008270~zinc ion binding,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018487:Hemopexin-like repeats,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,		616749~Heterotaxy, visceral, 7, autosomal,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,		KW-0964~Secreted,	KW-1056~Heterotaxy,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Peptidase M10 metallopeptidase,MOTIF:Cysteine switch,REGION:Disordered,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,
MMP26	matrix metallopeptidase 26(MMP26)	Homo sapiens			GO:0006508~proteolysis,GO:0030198~extracellular matrix organization,GO:0030574~collagen catabolic process,GO:0050728~negative regulation of inflammatory response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0008270~zinc ion binding,	IPR001818:Peptidase M10, metallopeptidase,IPR006026:Peptidase, metallopeptidase,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,				SM00235:ZnMc,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase metallopeptidase,MOTIF:Cysteine switch,
MED25	mediator complex subunit 25(MED25)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0035563~positive regulation of chromatin binding,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048147~negative regulation of fibroblast proliferation,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:2001178~positive regulation of mediator complex assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0001223~transcription coactivator binding,GO:0005515~protein binding,GO:0042974~retinoic acid receptor binding,GO:0046965~retinoid X receptor binding,	IPR021394:Mediator complex, subunit Med25, PTOV activation and synapsin 2,IPR021397:Mediator complex, subunit Med25, synapsin 1,IPR021406:Mediator complex, subunit Med25, NR box,IPR021419:Mediator complex, subunit Med25, von Willebrand factor type A,		616449~Basel-Vanagait-Smirin-Yosef syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0991~Intellectual disability,			KW-0010~Activator,	KW-0488~Methylation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Mediator complex subunit Med25 NR box,DOMAIN:Mediator complex subunit Med25 PTOV,DOMAIN:Mediator complex subunit Med25 synapsin 1,DOMAIN:Mediator of RNA polymerase II transcription subunit 25 von Willebrand factor type A,DOMAIN:SPIN-DOC-like zinc-finger,MOTIF:LXXLL motif,MUTAGEN:L->A: Abrogates interaction with RARA.,MUTAGEN:LL->AA: Abrogates interaction with RARA.,REGION:Disordered,REGION:Interaction with CREBBP,REGION:Interaction with RARA,REGION:Interaction with VP16,REGION:Interaction with the Mediator complex,
MC2R	melanocortin 2 receptor(MC2R)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0019222~regulation of metabolic process,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004977~melanocortin receptor activity,GO:0004978~corticotropin receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001168:Adrenocorticotrophin (ACTH) receptor,IPR001671:Melanocortin/ACTH receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04934:Cushing syndrome,	202200~Glucocorticoid deficiency, due to ACTH unresponsiveness,		SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MITF	melanocyte inducing transcription factor(MITF)	Homo sapiens	53.Early-response_Tr_Fac_mast_cells,	h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0030316~osteoclast differentiation,GO:0030318~melanocyte differentiation,GO:0030336~negative regulation of cell migration,GO:0042127~regulation of cell proliferation,GO:0043010~camera-type eye development,GO:0043066~negative regulation of apoptotic process,GO:0044336~canonical Wnt signaling pathway involved in negative regulation of apoptotic process,GO:0045165~cell fate commitment,GO:0045670~regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046849~bone remodeling,GO:0065003~macromolecular complex assembly,GO:1902362~melanocyte apoptotic process,GO:2000144~positive regulation of DNA-templated transcription, initiation,GO:2001141~regulation of RNA biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR021802:Basic helix-loop-helix leucine zipper transcrition factor MiT/TFE,	hsa04137:Mitophagy - animal,hsa04380:Osteoclast differentiation,hsa04916:Melanogenesis,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05218:Melanoma,	103500~Tietz albinism-deafness syndrome,193510~Waardenburg syndrome, type 2A,614456~Melanoma, cutaneous malignant, susceptibility to, 8,617306~COMMAD syndrome,		SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0015~Albinism,KW-0209~Deafness,KW-0225~Disease variant,KW-0897~Waardenburg syndrome,KW-0987~Osteopetrosis,KW-1013~Microphthalmia,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:BHLH,DOMAIN:MiT/TFE transcription factors N-terminal,DOMAIN:bHLH,MUTAGEN:K->R: Loss of sumoylation; when associated with R-289.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-423.,MUTAGEN:S->A,P: Loss of phosphorylation and function.,MUTAGEN:S->A: Abolishes both transcription factor activity and ubiquitination, leading to an inert and stable protein; when associated with A-180.,MUTAGEN:S->A: Abolishes both transcription factor activity and ubiquitination, leading to an inert and stable protein; when associated with A-516.,REGION:DNA-binding regulation,REGION:Disordered,REGION:Leucine-zipper,REGION:Transactivation,
MCAM	melanoma cell adhesion molecule(MCAM)	Homo sapiens			GO:0001525~angiogenesis,GO:0003094~glomerular filtration,GO:0007155~cell adhesion,GO:0009653~anatomical structure morphogenesis,GO:0030335~positive regulation of cell migration,GO:0061042~vascular wound healing,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,		IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013151:Immunoglobulin,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MTNR1B	melatonin receptor 1B(MTNR1B)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007268~chemical synaptic transmission,GO:0010754~negative regulation of cGMP-mediated signaling,GO:0042593~glucose homeostasis,GO:0043010~camera-type eye development,GO:0043524~negative regulation of neuron apoptotic process,GO:0045906~negative regulation of vasoconstriction,GO:0046010~positive regulation of circadian sleep/wake cycle, non-REM sleep,GO:0046676~negative regulation of insulin secretion,GO:0050796~regulation of insulin secretion,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0051970~negative regulation of transmission of nerve impulse,GO:0051971~positive regulation of transmission of nerve impulse,GO:0098908~regulation of neuronal action potential,GO:1902260~negative regulation of delayed rectifier potassium channel activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0045202~synapse,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008502~melatonin receptor activity,	IPR000025:Melatonin receptor family,IPR000276:G protein-coupled receptor, rhodopsin-like,IPR002278:Melatonin receptor 1A,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,	125853~Diabetes mellitus, type 2, susceptibility to,		SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
MAGI2	membrane associated guanylate kinase, WW and PDZ domain containing 2(MAGI2)	Homo sapiens			GO:0002092~positive regulation of receptor internalization,GO:0003402~planar cell polarity pathway involved in axis elongation,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0010976~positive regulation of neuron projection development,GO:0030336~negative regulation of cell migration,GO:0032516~positive regulation of phosphoprotein phosphatase activity,GO:0032926~negative regulation of activin receptor signaling pathway,GO:0038180~nerve growth factor signaling pathway,GO:0043113~receptor clustering,GO:0051898~negative regulation of protein kinase B signaling,GO:0060395~SMAD protein signal transduction,GO:0072015~glomerular visceral epithelial cell development,GO:0072583~clathrin-dependent endocytosis,GO:1990090~cellular response to nerve growth factor stimulus,	GO:0001750~photoreceptor outer segment,GO:0001917~photoreceptor inner segment,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005770~late endosome,GO:0005814~centriole,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005923~bicellular tight junction,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030425~dendrite,GO:0032991~macromolecular complex,GO:0036057~slit diaphragm,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0097546~ciliary base,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019902~phosphatase binding,GO:0030159~receptor signaling complex scaffold activity,GO:0031697~beta-1 adrenergic receptor binding,GO:0046332~SMAD binding,GO:0060090~binding, bridging,GO:0070699~type II activin receptor binding,	IPR001202:WW domain,IPR001478:PDZ domain,IPR008144:Guanylate kinase,IPR008145:Guanylate kinase/L-type calcium channel,IPR020590:Guanylate kinase, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04015:Rap1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,	617609~Nephrotic syndrome, type 15,		SM00072:GuKc,SM00228:PDZ,SM00456:WW,	KW-0254~Endocytosis,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,		KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Guanylate kinase-like,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,DOMAIN:PDZ 4,DOMAIN:PDZ 5,DOMAIN:PDZ 6,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,REGION:Disordered,REGION:Interaction with DDN,
MME	membrane metalloendopeptidase(MME)	Homo sapiens			GO:0001822~kidney development,GO:0001890~placenta development,GO:0006508~proteolysis,GO:0006518~peptide metabolic process,GO:0007568~aging,GO:0007611~learning or memory,GO:0010814~substance P catabolic process,GO:0010815~bradykinin catabolic process,GO:0016485~protein processing,GO:0019233~sensory perception of pain,GO:0030163~protein catabolic process,GO:0030324~lung development,GO:0042447~hormone catabolic process,GO:0043627~response to estrogen,GO:0046449~creatinine metabolic process,GO:0050435~beta-amyloid metabolic process,GO:0050769~positive regulation of neurogenesis,GO:0061837~neuropeptide processing,GO:0071345~cellular response to cytokine stimulus,GO:0071492~cellular response to UV-A,GO:0071493~cellular response to UV-B,GO:0090399~replicative senescence,GO:0097242~beta-amyloid clearance,GO:1900273~positive regulation of long-term synaptic potentiation,	GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005903~brush border,GO:0005925~focal adhesion,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030667~secretory granule membrane,GO:0031410~cytoplasmic vesicle,GO:0043025~neuronal cell body,GO:0044306~neuron projection terminus,GO:0045121~membrane raft,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098793~presynapse,	GO:0001786~phosphatidylserine binding,GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0008238~exopeptidase activity,GO:0008270~zinc ion binding,GO:0042277~peptide binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0070012~oligopeptidase activity,GO:1901612~cardiolipin binding,	IPR000718:Peptidase M13,IPR008753:Peptidase M13, N-terminal domain,IPR018497:Peptidase M13, C-terminal domain,IPR024079:Metallopeptidase, catalytic domain,	hsa04614:Renin-angiotensin system,hsa04640:Hematopoietic cell lineage,hsa04974:Protein digestion and absorption,hsa05010:Alzheimer disease,	617017~Charcot-Marie-Tooth disease, axonal, type 2T,617018~Spinocerebellar ataxia 43,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0950~Spinocerebellar ataxia,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase M13,DOMAIN:Peptidase M13 C-terminal,DOMAIN:Peptidase M13 N-terminal,LIPID:N-myristoyl glycine,MOTIF:Stop-transfer sequence,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MEOX2	mesenchyme homeobox 2(MEOX2)	Homo sapiens			GO:0001525~angiogenesis,GO:0001757~somite specification,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007519~skeletal muscle tissue development,GO:0008015~blood circulation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060021~palate development,GO:0060173~limb development,GO:0061053~somite development,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MUTAGEN:Q->E: Abolishes DNA-binding. Does not affect ability to activate expression of CDKN2A.,REGION:Disordered,
MSLN	mesothelin(MSLN)	Homo sapiens			GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0031016~pancreas development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0031225~anchored component of membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,	IPR010335:Mesothelin,IPR026664:Stereocilin related,					KW-0130~Cell adhesion,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,REGION:Disordered,REGION:Required for megakaryocyte-potentiating factor activity,
MT3	metallothionein 3(MT3)	Homo sapiens			GO:0001666~response to hypoxia,GO:0001934~positive regulation of protein phosphorylation,GO:0006112~energy reserve metabolic process,GO:0006707~cholesterol catabolic process,GO:0006829~zinc II ion transport,GO:0006875~cellular metal ion homeostasis,GO:0006882~cellular zinc ion homeostasis,GO:0007420~brain development,GO:0010273~detoxification of copper ion,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0010940~positive regulation of necrotic cell death,GO:0010942~positive regulation of cell death,GO:0010977~negative regulation of neuron projection development,GO:0014002~astrocyte development,GO:0016570~histone modification,GO:0019430~removal of superoxide radicals,GO:0030003~cellular cation homeostasis,GO:0030308~negative regulation of cell growth,GO:0030517~negative regulation of axon extension,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032095~regulation of response to food,GO:0032148~activation of protein kinase B activity,GO:0033210~leptin-mediated signaling pathway,GO:0034599~cellular response to oxidative stress,GO:0034614~cellular response to reactive oxygen species,GO:0036091~positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0043066~negative regulation of apoptotic process,GO:0043085~positive regulation of catalytic activity,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0044242~cellular lipid catabolic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050821~protein stabilization,GO:0051354~negative regulation of oxidoreductase activity,GO:0055069~zinc ion homeostasis,GO:0055073~cadmium ion homeostasis,GO:0060049~regulation of protein glycosylation,GO:0060547~negative regulation of necrotic cell death,GO:0070371~ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071248~cellular response to metal ion,GO:0071276~cellular response to cadmium ion,GO:0071280~cellular response to copper ion,GO:0071294~cellular response to zinc ion,GO:0071456~cellular response to hypoxia,GO:0071732~cellular response to nitric oxide,GO:0097214~positive regulation of lysosomal membrane permeability,GO:1901215~negative regulation of neuron death,GO:1990748~cellular detoxification,GO:2000117~negative regulation of cysteine-type endopeptidase activity,GO:2000296~negative regulation of hydrogen peroxide catabolic process,GO:2000376~positive regulation of oxygen metabolic process,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0016234~inclusion body,GO:0030424~axon,GO:0043197~dendritic spine,GO:0048471~perinuclear region of cytoplasm,GO:0097450~astrocyte end-foot,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016209~antioxidant activity,GO:0030295~protein kinase activator activity,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0046870~cadmium ion binding,GO:0046872~metal ion binding,	IPR000006:Metallothionein, vertebrate,IPR003019:Metallothionein superfamily, eukaryotic,IPR017854:Metallothionein domain,IPR018064:Metallothionein, vertebrate, metal binding site,IPR023587:Metallothionein domain, vertebrate,									KW-0186~Copper,KW-0479~Metal-binding,KW-0480~Metal-thiolate cluster,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Alpha,REGION:Beta,
MAT1A	methionine adenosyltransferase 1A(MAT1A)	Homo sapiens			GO:0006556~S-adenosylmethionine biosynthetic process,GO:0006730~one-carbon metabolic process,GO:0009087~methionine catabolic process,GO:0051289~protein homotetramerization,	GO:0005829~cytosol,GO:0048269~methionine adenosyltransferase complex,	GO:0004478~methionine adenosyltransferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR002133:S-adenosylmethionine synthetase,IPR022628:S-adenosylmethionine synthetase, N-terminal,IPR022629:S-adenosylmethionine synthetase, central domain,IPR022630:S-adenosylmethionine synthetase, C-terminal,IPR022631:S-adenosylmethionine synthetase, conserved site,IPR022636:S-adenosylmethionine synthetase superfamily,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,hsa01240:Biosynthesis of cofactors,	250850~Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency,250850~Methionine adenosyltransferase deficiency, autosomal recessive,	PIRSF000497:methionine adenosyltransferase,		KW-0554~One-carbon metabolism,		KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,	KW-0808~Transferase,	KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	BINDING:in other chain,DOMAIN:S-adenosylmethionine synthetase C-terminal,DOMAIN:S-adenosylmethionine synthetase N-terminal,DOMAIN:S-adenosylmethionine synthetase central,REGION:Flexible loop,
MIR1-1	microRNA 1-1(MIR1-1)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0010455~positive regulation of cell fate commitment,GO:0010460~positive regulation of heart rate,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010831~positive regulation of myotube differentiation,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0030336~negative regulation of cell migration,GO:0032410~negative regulation of transporter activity,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043569~negative regulation of insulin-like growth factor receptor signaling pathway,GO:0045602~negative regulation of endothelial cell differentiation,GO:0051055~negative regulation of lipid biosynthetic process,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:0060298~positive regulation of sarcomere organization,GO:0060373~regulation of ventricular cardiac muscle cell membrane depolarization,GO:0060412~ventricular septum morphogenesis,GO:0060452~positive regulation of cardiac muscle contraction,GO:0060980~cell migration involved in coronary vasculogenesis,GO:0086094~positive regulation of ryanodine-sensitive calcium-release channel activity by adrenergic receptor signaling pathway involved in positive regulation of cardiac muscle contraction,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090677~reversible differentiation,GO:1902260~negative regulation of delayed rectifier potassium channel activity,GO:1903672~positive regulation of sprouting angiogenesis,GO:1903762~positive regulation of voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization,GO:1903780~negative regulation of cardiac conduction,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904879~positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,GO:1905032~negative regulation of membrane repolarization during cardiac muscle cell action potential,GO:1905461~positive regulation of vascular associated smooth muscle cell apoptotic process,GO:1905700~negative regulation of drug transmembrane export,GO:1905904~positive regulation of mesoderm formation,GO:1905913~negative regulation of calcium ion export from cell,GO:2000724~positive regulation of cardiac vascular smooth muscle cell differentiation,GO:2000727~positive regulation of cardiac muscle cell differentiation,GO:2000818~negative regulation of myoblast proliferation,GO:2001016~positive regulation of skeletal muscle cell differentiation,	GO:0005615~extracellular space,GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR1197	microRNA 1197(MIR1197)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,
MIR122	microRNA 122(MIR122)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0005615~extracellular space,GO:0016442~RISC complex,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,			hsa05206:MicroRNAs in cancer,
MIR124-2	microRNA 124-2(MIR124-2)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,			hsa05206:MicroRNAs in cancer,
MIR124-3	microRNA 124-3(MIR124-3)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,			hsa05206:MicroRNAs in cancer,
MIR129-1	microRNA 129-1(MIR129-1)	Homo sapiens			GO:0032410~negative regulation of transporter activity,GO:0032717~negative regulation of interleukin-8 production,GO:0035195~gene silencing by miRNA,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:1905700~negative regulation of drug transmembrane export,	GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR129-2	microRNA 129-2(MIR129-2)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,			hsa05206:MicroRNAs in cancer,
MIR134	microRNA 134(MIR134)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0045930~negative regulation of mitotic cell cycle,GO:1904046~negative regulation of vascular endothelial growth factor production,	GO:0005615~extracellular space,GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR145	microRNA 145(MIR145)	Homo sapiens			GO:0006940~regulation of smooth muscle contraction,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010668~ectodermal cell differentiation,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010763~positive regulation of fibroblast migration,GO:0016525~negative regulation of angiogenesis,GO:0030036~actin cytoskeleton organization,GO:0030336~negative regulation of cell migration,GO:0032699~negative regulation of interleukin-16 production,GO:0032733~positive regulation of interleukin-10 production,GO:0032965~regulation of collagen biosynthetic process,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0035886~vascular smooth muscle cell differentiation,GO:0036446~myofibroblast differentiation,GO:0038166~angiotensin-activated signaling pathway,GO:0043032~positive regulation of macrophage activation,GO:0044663~establishment or maintenance of cell type involved in phenotypic switching,GO:0045651~positive regulation of macrophage differentiation,GO:0048333~mesodermal cell differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050728~negative regulation of inflammatory response,GO:0051898~negative regulation of protein kinase B signaling,GO:0060414~aorta smooth muscle tissue morphogenesis,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090370~negative regulation of cholesterol efflux,GO:1900039~positive regulation of cellular response to hypoxia,GO:1900239~regulation of phenotypic switching,GO:1904673~negative regulation of somatic stem cell population maintenance,GO:1904676~negative regulation of somatic stem cell division,GO:1905175~negative regulation of vascular smooth muscle cell dedifferentiation,GO:2000724~positive regulation of cardiac vascular smooth muscle cell differentiation,	GO:0016442~RISC complex,GO:0070062~extracellular exosome,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR146B	microRNA 146b(MIR146B)	Homo sapiens			GO:0032700~negative regulation of interleukin-17 production,GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR154	microRNA 154(MIR154)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR184	microRNA 184(MIR184)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,				614303~EDICT syndrome,
MIR190B	microRNA 190b(MIR190B)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR196A1	microRNA 196a-1(MIR196A1)	Homo sapiens			GO:0010593~negative regulation of lamellipodium assembly,GO:0035195~gene silencing by miRNA,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR206	microRNA 206(MIR206)	Homo sapiens			GO:0010455~positive regulation of cell fate commitment,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010831~positive regulation of myotube differentiation,GO:0010875~positive regulation of cholesterol efflux,GO:0032715~negative regulation of interleukin-6 production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035195~gene silencing by miRNA,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0051055~negative regulation of lipid biosynthetic process,GO:0051898~negative regulation of protein kinase B signaling,GO:0060354~negative regulation of cell adhesion molecule production,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090370~negative regulation of cholesterol efflux,GO:1902004~positive regulation of beta-amyloid formation,	GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR211	microRNA 211(MIR211)	Homo sapiens				GO:0016442~RISC complex,
MIR25	microRNA 25(MIR25)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0055022~negative regulation of cardiac muscle tissue growth,GO:1903243~negative regulation of cardiac muscle hypertrophy in response to stress,	GO:0005615~extracellular space,GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR300	microRNA 300(MIR300)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,
MIR34A	microRNA 34a(MIR34A)	Homo sapiens			GO:0006974~cellular response to DNA damage stimulus,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0010884~positive regulation of lipid storage,GO:0016525~negative regulation of angiogenesis,GO:0032682~negative regulation of chemokine production,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034763~negative regulation of transmembrane transport,GO:0035195~gene silencing by miRNA,GO:0035359~negative regulation of peroxisome proliferator activated receptor signaling pathway,GO:0042632~cholesterol homeostasis,GO:0048678~response to axon injury,GO:0050859~negative regulation of B cell receptor signaling pathway,GO:0051152~positive regulation of smooth muscle cell differentiation,GO:0051726~regulation of cell cycle,GO:0051898~negative regulation of protein kinase B signaling,GO:0061044~negative regulation of vascular wound healing,GO:0070328~triglyceride homeostasis,GO:0071456~cellular response to hypoxia,GO:0071659~negative regulation of IP-10 production,GO:0071672~negative regulation of smooth muscle cell chemotaxis,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0090281~negative regulation of calcium ion import,GO:0097468~programmed cell death in response to reactive oxygen species,GO:1900222~negative regulation of beta-amyloid clearance,GO:1901985~positive regulation of protein acetylation,GO:1902532~negative regulation of intracellular signal transduction,GO:1903671~negative regulation of sprouting angiogenesis,GO:1904046~negative regulation of vascular endothelial growth factor production,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,GO:1905205~positive regulation of connective tissue replacement,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:2000108~positive regulation of leukocyte apoptotic process,GO:2000774~positive regulation of cellular senescence,	GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR369	microRNA 369(MIR369)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,
MIR377	microRNA 377(MIR377)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:1903671~negative regulation of sprouting angiogenesis,	GO:0016442~RISC complex,
MIR379	microRNA 379(MIR379)	Homo sapiens			GO:0010633~negative regulation of epithelial cell migration,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0032868~response to insulin,GO:0035278~miRNA mediated inhibition of translation,GO:0051898~negative regulation of protein kinase B signaling,GO:0070328~triglyceride homeostasis,		GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR410	microRNA 410(MIR410)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,	GO:0005615~extracellular space,GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR411	microRNA 411(MIR411)	Homo sapiens			GO:0032701~negative regulation of interleukin-18 production,GO:0035195~gene silencing by miRNA,	GO:0005615~extracellular space,GO:0016442~RISC complex,GO:1903561~extracellular vesicle,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR412	microRNA 412(MIR412)	Homo sapiens			GO:0035195~gene silencing by miRNA,
MIR485	microRNA 485(MIR485)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0060546~negative regulation of necroptotic process,	GO:0005615~extracellular space,GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,GO:1990715~mRNA CDS binding,
MIR488	microRNA 488(MIR488)	Homo sapiens			GO:0032691~negative regulation of interleukin-1 beta production,GO:0032717~negative regulation of interleukin-8 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0035195~gene silencing by miRNA,GO:0050728~negative regulation of inflammatory response,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR495	microRNA 495(MIR495)	Homo sapiens			GO:0032410~negative regulation of transporter activity,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0045602~negative regulation of endothelial cell differentiation,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903671~negative regulation of sprouting angiogenesis,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:1905652~negative regulation of artery morphogenesis,GO:1905700~negative regulation of drug transmembrane export,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR496	microRNA 496(MIR496)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,
MIR497	microRNA 497(MIR497)	Homo sapiens			GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0035195~gene silencing by miRNA,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,	GO:0016442~RISC complex,	GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR519C	microRNA 519c(MIR519C)	Homo sapiens			GO:0035195~gene silencing by miRNA,
MIR520C	microRNA 520c(MIR520C)	Homo sapiens			GO:0001960~negative regulation of cytokine-mediated signaling pathway,GO:0010561~negative regulation of glycoprotein biosynthetic process,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031327~negative regulation of cellular biosynthetic process,GO:0032717~negative regulation of interleukin-8 production,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,GO:0060355~positive regulation of cell adhesion molecule production,		GO:0003730~mRNA 3'-UTR binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR525	microRNA 525(MIR525)	Homo sapiens			GO:0035195~gene silencing by miRNA,
MIR557	microRNA 557(MIR557)	Homo sapiens			GO:0035195~gene silencing by miRNA,
MIR572	microRNA 572(MIR572)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,	GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR589	microRNA 589(MIR589)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0005615~extracellular space,GO:0016442~RISC complex,
MIR758	microRNA 758(MIR758)	Homo sapiens			GO:0035195~gene silencing by miRNA,GO:0045087~innate immune response,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0090370~negative regulation of cholesterol efflux,GO:0098586~cellular response to virus,		GO:1903231~mRNA binding involved in posttranscriptional gene silencing,
MIR762	microRNA 762(MIR762)	Homo sapiens			GO:0007605~sensory perception of sound,GO:0014850~response to muscle activity,GO:0070482~response to oxygen levels,GO:0071230~cellular response to amino acid stimulus,
MIR770	microRNA 770(MIR770)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,
MIR9-1	microRNA 9-1(MIR9-1)	Homo sapiens			GO:0007162~negative regulation of cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0010629~negative regulation of gene expression,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031047~gene silencing by RNA,GO:0032410~negative regulation of transporter activity,GO:0033689~negative regulation of osteoblast proliferation,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0035279~mRNA cleavage involved in gene silencing by miRNA,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045668~negative regulation of osteoblast differentiation,GO:0046426~negative regulation of JAK-STAT cascade,GO:0051055~negative regulation of lipid biosynthetic process,GO:0090370~negative regulation of cholesterol efflux,GO:1901202~negative regulation of extracellular matrix assembly,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901492~positive regulation of lymphangiogenesis,GO:1904761~negative regulation of myofibroblast differentiation,GO:1905700~negative regulation of drug transmembrane export,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016442~RISC complex,GO:0070062~extracellular exosome,	GO:0003727~single-stranded RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0008035~high-density lipoprotein particle binding,GO:1903231~mRNA binding involved in posttranscriptional gene silencing,		hsa05206:MicroRNAs in cancer,
MIR9-3	microRNA 9-3(MIR9-3)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,			hsa05206:MicroRNAs in cancer,
MIRLET7A3	microRNA let-7a-3(MIRLET7A3)	Homo sapiens			GO:0035195~gene silencing by miRNA,	GO:0016442~RISC complex,			hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,
MSMP	microseminoprotein, prostate associated(MSMP)	Homo sapiens			GO:0002548~monocyte chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0048247~lymphocyte chemotaxis,	GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005125~cytokine activity,GO:0031727~CCR2 chemokine receptor binding,	IPR008735:Beta-microseminoprotein,					KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,	REGION:Disordered,
MACF1	microtubule actin crosslinking factor 1(MACF1)	Homo sapiens			GO:0010632~regulation of epithelial cell migration,GO:0016055~Wnt signaling pathway,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030334~regulation of cell migration,GO:0032886~regulation of microtubule-based process,GO:0042060~wound healing,GO:0043001~Golgi to plasma membrane protein transport,GO:0045104~intermediate filament cytoskeleton organization,GO:0045773~positive regulation of axon extension,GO:0051893~regulation of focal adhesion assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0032587~ruffle membrane,GO:0042995~cell projection,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005198~structural molecule activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008092~cytoskeletal protein binding,GO:0045296~cadherin binding,GO:0051011~microtubule minus-end binding,GO:0051015~actin filament binding,	IPR001101:Plectin repeat,IPR001452:Src homology-3 domain,IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002017:Spectrin repeat,IPR002048:EF-hand domain,IPR003108:Growth-arrest-specific protein 2 domain,IPR011992:EF-hand-like domain,IPR018159:Spectrin/alpha-actinin,IPR018247:EF-Hand 1, calcium-binding site,		618325~Lissencephaly 9 with complex brainstem malformation,		SM00033:CH,SM00054:EFh,SM00150:SPEC,SM00243:GAS2,SM00250:PLEC,	KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0728~SH3 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:GAR,DOMAIN:SH3,REGION:13 X 13 AA approximate tandem repeat of P-T-S-P-A-A-A-V-P-T-P-E-E,REGION:4 X 4 AA tandem repeats of [GS]-S-R-[AR],REGION:Actin-binding,REGION:C-terminal tail,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 21,REPEAT:LRR 22,REPEAT:LRR 23,REPEAT:LRR 24,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,REPEAT:Plectin 1,REPEAT:Plectin 10,REPEAT:Plectin 11,REPEAT:Plectin 2,REPEAT:Plectin 3,REPEAT:Plectin 4,REPEAT:Plectin 5,REPEAT:Plectin 6,REPEAT:Plectin 7,REPEAT:Plectin 8,REPEAT:Plectin 9,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TRANSMEM:Helical,
MARK1	microtubule affinity regulating kinase 1(MARK1)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0001764~neuron migration,GO:0006468~protein phosphorylation,GO:0007010~cytoskeleton organization,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010975~regulation of neuron projection development,GO:0016055~Wnt signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:0050773~regulation of dendrite development,GO:0051654~establishment of mitochondrion localization,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0030425~dendrite,	GO:0000287~magnesium ion binding,GO:0001786~phosphatidylserine binding,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0016301~kinase activity,GO:0048156~tau protein binding,GO:0050321~tau-protein kinase activity,GO:0070300~phosphatidic acid binding,	IPR000719:Protein kinase, catalytic domain,IPR001772:Kinase associated domain 1 (KA1),IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR017441:Protein kinase, ATP binding site,				SM00165:UBA,SM00220:S_TKc,	KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-1268~Autism spectrum disorder,KW-1269~Autism,		KW-0067~ATP-binding,KW-0446~Lipid-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:KA1,DOMAIN:Protein kinase,DOMAIN:UBA,MUTAGEN:R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-698.,MUTAGEN:R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-701.,MUTAGEN:RFK->AFA: Impairs phospholipid-binding.,MUTAGEN:T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.,MUTAGEN:T->E: Constitutively active.,REGION:Disordered,
MARK2	microtubule affinity regulating kinase 2(MARK2)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0000422~mitophagy,GO:0001764~neuron migration,GO:0006468~protein phosphorylation,GO:0010976~positive regulation of neuron projection development,GO:0016055~Wnt signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030010~establishment of cell polarity,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0045197~establishment or maintenance of epithelial cell apical/basal polarity,GO:0046777~protein autophosphorylation,GO:0050770~regulation of axonogenesis,GO:0051493~regulation of cytoskeleton organization,GO:0051646~mitochondrion localization,GO:0061564~axon development,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0071963~establishment or maintenance of cell polarity regulating cell shape,GO:1904526~regulation of microtubule binding,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016328~lateral plasma membrane,GO:0030425~dendrite,GO:0097427~microtubule bundle,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008289~lipid binding,GO:0030295~protein kinase activator activity,GO:0045296~cadherin binding,GO:0048156~tau protein binding,GO:0050321~tau-protein kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR001772:Kinase associated domain 1 (KA1),IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR017441:Protein kinase, ATP binding site,				SM00165:UBA,SM00220:S_TKc,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0446~Lipid-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:KA1,DOMAIN:Protein kinase,DOMAIN:UBA,MUTAGEN:T->A: Loss of membrane dissociation and binding to YWHAZ.,MUTAGEN:T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.,REGION:Disordered,
MAP1LC3C	microtubule associated protein 1 light chain 3 gamma(MAP1LC3C)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006995~cellular response to nitrogen starvation,GO:0009267~cellular response to starvation,GO:0016236~macroautophagy,GO:0032527~protein exit from endoplasmic reticulum,GO:0035973~aggrephagy,GO:0097352~autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0012505~endomembrane system,GO:0031090~organelle membrane,GO:0031410~cytoplasmic vesicle,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,	IPR004241:Autophagy protein Atg8 ubiquitin-like,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04216:Ferroptosis,hsa04371:Apelin signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,					KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:G->A: No processing of precursor.,MUTAGEN:SLVS->ALVA: Impaired phosphorylation by TBK1.,MUTAGEN:SLVS->DLVD: Phospho-mimetic mutant; impaired interaction with ATG4 proteins, preventing cleavage at the C-terminus, conjugation to phosphatidylethanolamine and localization to autophagosomes.,PROPEP:Removed in mature form,SITE:Cleavage; by ATG4B,
MAPK10	mitogen-activated protein kinase 10(MAPK10)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,	GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007254~JNK cascade,GO:0009416~response to light stimulus,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042752~regulation of circadian rhythm,GO:0048511~rhythmic process,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0090398~cellular senescence,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004705~JUN kinase activity,GO:0004707~MAP kinase activity,GO:0004708~MAP kinase kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR003527:Mitogen-activated protein (MAP) kinase, conserved site,IPR008271:Serine/threonine-protein kinase, active site,IPR008351:Mitogen-activated protein (MAP) kinase, JNK,IPR011009:Protein kinase-like domain,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04024:cAMP signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04723:Retrograde endocannabinoid signaling,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04926:Relaxin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00220:S_TKc,	KW-0090~Biological rhythms,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0887~Epilepsy,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,LIPID:S-palmitoyl cysteine,MOTIF:TXY,MUTAGEN:C->S: Loss of palmitoylation.,REGION:Disordered,
MAP2K4	mitogen-activated protein kinase kinase 4(MAP2K4)	Homo sapiens	100.MAPK_signaling_cascades,77.IkBa_Kinase_JNK_MEKK1,	h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_ceramidePathway:Ceramide Signaling Pathway,h_egfPathway:EGF Signaling Pathway,h_fasPathway:FAS signaling pathway ( CD95 ),h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pdgfPathway:PDGF Signaling Pathway,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_stressPathway:TNF/Stress Related Signaling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,	GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007254~JNK cascade,GO:0009611~response to wounding,GO:0016310~phosphorylation,GO:0034390~smooth muscle cell apoptotic process,GO:0034393~positive regulation of smooth muscle cell apoptotic process,GO:0036481~intrinsic apoptotic signaling pathway in response to hydrogen peroxide,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043525~positive regulation of neuron apoptotic process,GO:0045740~positive regulation of DNA replication,GO:0046330~positive regulation of JNK cascade,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0061049~cell growth involved in cardiac muscle cell development,GO:0071260~cellular response to mechanical stimulus,GO:0072709~cellular response to sorbitol,GO:0090398~cellular senescence,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0030424~axon,GO:0032839~dendrite cytoplasm,GO:0043204~perikaryon,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004708~MAP kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008545~JUN kinase kinase activity,GO:0060090~binding, bridging,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa04912:GnRH signaling pathway,hsa04926:Relaxin signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,REGION:D domain,REGION:DVD domain,REGION:Disordered,SITE:Cleavage; by anthrax lethal factor,
MAP4K1	mitogen-activated protein kinase kinase kinase kinase 1(MAP4K1)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,	GO:0006468~protein phosphorylation,GO:0007254~JNK cascade,GO:0008283~cell proliferation,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:0043410~positive regulation of MAPK cascade,GO:0046777~protein autophosphorylation,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,	GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008349~MAP kinase kinase kinase kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR001180:Citron-like,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR021160:Mitogen-activated protein (MAP) kinase kinase kinase kinase,	hsa04010:MAPK signaling pathway,		PIRSF038172:mitogen-activated protein kinase kinase kinase kinase,	SM00036:CNH,SM00220:S_TKc,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:CNH,DOMAIN:Protein kinase,MUTAGEN:T->A: Retains kinase activity. Not degraded by the Cul7-RING ubiquitin-protein ligase complex containing FBXW8.,REGION:Disordered,
MAD2L2	mitotic arrest deficient 2 like 2(MAD2L2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001558~regulation of cell growth,GO:0002208~somatic diversification of immunoglobulins involved in immune response,GO:0006302~double-strand break repair,GO:0007015~actin filament organization,GO:0007094~mitotic spindle assembly checkpoint,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0042177~negative regulation of protein catabolic process,GO:0042276~error-prone translesion synthesis,GO:0042772~DNA damage response, signal transduction resulting in transcription,GO:0043247~telomere maintenance in response to DNA damage,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045830~positive regulation of isotype switching,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051301~cell division,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1901203~positive regulation of extracellular matrix assembly,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:2000042~negative regulation of double-strand break repair via homologous recombination,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,GO:2000678~negative regulation of transcription regulatory region DNA binding,GO:2001034~positive regulation of double-strand break repair via nonhomologous end joining,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0016035~zeta DNA polymerase complex,GO:0035861~site of double-strand break,	GO:0005515~protein binding,GO:0008432~JUN kinase binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR003511:DNA-binding HORMA,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,hsa05100:Bacterial invasion of epithelial cells,	617243~Fanconi anemia, complementation group V,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0923~Fanconi anemia,					DOMAIN:HORMA,MUTAGEN:L->A: Significantly prevents interaction with REV1; no effect on interaction with REV3L.,MUTAGEN:Q->A: Significantly prevents interaction with REV1; no effect on interaction with REV3L.,MUTAGEN:R->A: Induces structural changes that increase affinity for REV3L and REV1. No effect on interaction with REV1; when associated with A-171.,MUTAGEN:W->A: Alters interaction with REV3L and REV1. Loss of interaction with REV3L; when associated with A-63. No effect on interaction with REV1; when associated with A-124.,MUTAGEN:Y->A: Alters interaction with REV3L. Loss of interaction with REV3L; when associated with A-171.,MUTAGEN:Y->A: Significantly prevents interaction with REV1; no effect on interaction with REV3L.,REGION:Disordered,REGION:Mediates interaction with REV1 and REV3L and homodimerization,REGION:Mediates interaction with ipaB,
MUC1	mucin 1, cell surface associated(MUC1)	Homo sapiens			GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0043618~regulation of transcription from RNA polymerase II promoter in response to stress,GO:0051179~localization,GO:0090240~positive regulation of histone H4 acetylation,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,	IPR000082:SEA domain,		174000~Tubulointerstitial kidney disease, autosomal dominant, 2,		SM00200:SEA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SEA,LIPID:S-palmitoyl cysteine,MOTIF:Interaction with GRB2,MOTIF:Interaction with SRC and ESR1,MOTIF:Required for interaction with AP1S2,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited and AP1S1 binding reduced by 30%; when associated with C-1186. Accumulates in intracellular compartments; when associated with C-1186 and N-1203.,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited, and AP1S1 binding reduced by 30%; when associated with C-1184. Accumulates in intracellular compartments; when associated with C-1184 and N-1203.,MUTAGEN:D->A: Greatly reduced formation of isoform 5/isoform Y complex.,MUTAGEN:D->E: No effect on formation of isoform 5/isoform Y complex.,MUTAGEN:RRK->AAA: No nuclear targeting of HRG-stimulated MUC1 C-terminal nor JUP/gamma-catenin. No effect on interaction with JUP/gamma-catenin.,MUTAGEN:RRK->QQQ: No effect on palmitoylation.,MUTAGEN:S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y: Completely abrogates cleavage.,MUTAGEN:S->A: No change in PRKCD- nor GSK3B-mediated phosphorylation.,MUTAGEN:S->A: No change in PRKCD-mediated phosphorylation. Loss of GSK3B-mediated phosphorylation. CTNNB1.,MUTAGEN:S->C,T: Almost complete cleavage.,MUTAGEN:T->A: Loss of PRKCD-mediated phosphorylation. Decreased PRKCD binding. No increased binding to CTNNB1 in the presence of autophosphorylated PRKCD. Increases formation of E-cadherin/beta-catenin complex.,MUTAGEN:Y->E: No effect on nuclear colocalization of MUC1CT and CTNNB1. No effect on in vitro PDFGR-induced cell invasiveness.,MUTAGEN:Y->F: Greatly reduced EGFR- and Src-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-mediated phosphorylation. Decreased Src-binding.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear colocalization of MUC1CT and CTNNB1.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-induced cell invasiveness.,MUTAGEN:Y->F: Some reduction in EGFR-mediated phosphorylation.,MUTAGEN:Y->N: No effect on endocytosis.,MUTAGEN:Y->N: Reduced endocytosis by 30%. Greatly reduced binding to AP1S2 and GRB2. Binding AP1S1 reduced by 25%. Reduced endocytosis by 77%; when associated with N-1243. Accumulates in intracellular compartments; when associated with C-1184 and C-1186.,MUTAGEN:Y->N: Reduces binding to AP1S2 by 33%. Greatly reduced binding to GRB2. Reduced endocytosis by 50%. Reduced endocytosis by 77%; when associated with N-1203.,REGION:42 X 20 AA approximate tandem repeats of P-A-P-G-S-T-A-P-P-A-H-G-V-T-S-A-P-D-T-R,REGION:Disordered,REGION:Interaction with P53,REGION:Required for interaction with GSK3B,REGION:Required for interaction with beta- and gamma-catenins,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:1; approximate,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:2; approximate,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:34,REPEAT:35,REPEAT:36,REPEAT:37,REPEAT:38,REPEAT:39,REPEAT:4,REPEAT:40,REPEAT:41,REPEAT:42,REPEAT:43,REPEAT:44,REPEAT:45,REPEAT:46; approximate,REPEAT:47; approximate,REPEAT:48; approximate,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MUC6	mucin 6, oligomeric mucus/gel-forming(MUC6)	Homo sapiens			GO:0030277~maintenance of gastrointestinal epithelium,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,	IPR001007:von Willebrand factor, type C,IPR001846:von Willebrand factor, type D domain,IPR002919:Trypsin Inhibitor-like, cysteine rich domain,IPR006207:Cystine knot, C-terminal,IPR014853:Uncharacterised domain, cysteine-rich,				SM00041:CT,SM00215:VWC_out,SM00216:VWD,SM00832:SM00832,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CTCK,DOMAIN:TIL,DOMAIN:VWFD,DOMAIN:VWFD 1,DOMAIN:VWFD 2,DOMAIN:VWFD 3,REGION:Approximate repeats,REGION:Disordered,REPEAT:1; truncated,REPEAT:2,
MCOLN2	mucolipin TRP cation channel 2(MCOLN2)	Homo sapiens			GO:0002250~adaptive immune response,GO:0015031~protein transport,GO:0045087~innate immune response,GO:0051209~release of sequestered calcium ion into cytosol,GO:0070588~calcium ion transmembrane transport,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:0071642~positive regulation of macrophage inflammatory protein 1 alpha production,GO:0071651~positive regulation of chemokine (C-C motif) ligand 5 production,GO:1905517~macrophage migration,GO:1990266~neutrophil migration,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,	GO:0005764~lysosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0055038~recycling endosome membrane,	GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0042802~identical protein binding,GO:0072345~NAADP-sensitive calcium-release channel activity,	IPR013122:Polycystin cation channel, PKD1/PKD2,	hsa04020:Calcium signaling pathway,				KW-0109~Calcium transport,KW-0391~Immunity,KW-0399~Innate immunity,KW-0406~Ion transport,KW-0653~Protein transport,KW-0813~Transport,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,	KW-1015~Disulfide bond,	INTRAMEM:Pore-forming,MOTIF:Selectivity filter,MUTAGEN:A->P: Constitutive active Ca(2+) permeable and inward rectifying channel.,MUTAGEN:DD->KK: Blocks channel activity. Decreases recycling of internalized CD59 to the cell surface.,MUTAGEN:F->L: Does not effect current amplitude; possible effect on regulation.,REGION:Extracellular/lumenal pore loop,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MADCAM1	mucosal vascular addressin cell adhesion molecule 1(MADCAM1)	Homo sapiens		h_lymPathway:Adhesion and Diapedesis of Lymphocytes,	GO:0002687~positive regulation of leukocyte migration,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007165~signal transduction,GO:0007229~integrin-mediated signaling pathway,GO:0034113~heterotypic cell-cell adhesion,GO:0043113~receptor clustering,GO:0050901~leukocyte tethering or rolling,GO:2000403~positive regulation of lymphocyte migration,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0098640~integrin binding involved in cell-matrix adhesion,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,IPR015169:Adhesion molecule, immunoglobulin-like,	hsa04514:Cell adhesion molecules,hsa04672:Intestinal immune network for IgA production,			SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,REGION:5.5 X 8 AA tandem repeats of [PS]-P-D-T-T-S-[QP]-E,REGION:Disordered,REGION:Mucin-like,REPEAT:1; truncated,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MMRN2	multimerin 2(MMRN2)	Homo sapiens			GO:0002042~cell migration involved in sprouting angiogenesis,GO:0007155~cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0030336~negative regulation of cell migration,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:1900426~positive regulation of defense response to bacterium,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1905278~positive regulation of epithelial tube formation,GO:1905332~positive regulation of morphogenesis of an epithelium,	GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0070062~extracellular exosome,GO:1990972~multimerin complex,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,	IPR001073:Complement C1q protein,IPR008983:Tumour necrosis factor-like domain,IPR011489:EMI domain,				SM00110:C1Q,	KW-0037~Angiogenesis,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:C1q,DOMAIN:EMI,REGION:Disordered,
MRAS	muscle RAS oncogene homolog(MRAS)	Homo sapiens			GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0030036~actin cytoskeleton organization,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0030742~GTP-dependent protein binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04218:Cellular senescence,hsa04371:Apelin signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05205:Proteoglycans in cancer,	618499~Noonan syndrome 11,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
MSC	musculin(MSC)	Homo sapiens	79.B_cell_Activation,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003161~cardiac conduction system development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007519~skeletal muscle tissue development,GO:0014707~branchiomeric skeletal muscle development,GO:0032502~developmental process,GO:0060021~palate development,GO:0060539~diaphragm development,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,				SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,		DOMAIN:bHLH,MOTIF:Nuclear localization signal,REGION:Disordered,
MAG	myelin associated glycoprotein(MAG)	Homo sapiens			GO:0007155~cell adhesion,GO:0010977~negative regulation of neuron projection development,GO:0019226~transmission of nerve impulse,GO:0021762~substantia nigra development,GO:0030517~negative regulation of axon extension,GO:0031103~axon regeneration,GO:0031643~positive regulation of myelination,GO:0032289~central nervous system myelin formation,GO:0043524~negative regulation of neuron apoptotic process,GO:0045665~negative regulation of neuron differentiation,GO:0048711~positive regulation of astrocyte differentiation,GO:0071260~cellular response to mechanical stimulus,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0033270~paranode region of axon,GO:0035749~myelin sheath adaxonal region,GO:0043209~myelin sheath,GO:0043218~compact myelin,GO:0043220~Schmidt-Lanterman incisure,GO:0045121~membrane raft,GO:0097453~mesaxon,	GO:0005102~receptor binding,GO:0019901~protein kinase binding,GO:0030246~carbohydrate binding,GO:0033691~sialic acid binding,GO:0042803~protein homodimerization activity,GO:1905576~ganglioside GT1b binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,	616680~Spastic paraplegia 75, autosomal recessive,		SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0446~Lipid-binding,		KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like V-type,LIPID:S-palmitoyl cysteine,REGION:Disordered,REGION:Interaction with RTN4R and RTN4RL2,REGION:Required for normal axon myelination in the central nervous system,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MYT1	myelin transcription factor 1(MYT1)	Homo sapiens		H_cdc25Pathway:cdc25 and chk1 Regulatory Pathway in response to DNA damage,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0030154~cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0008270~zinc ion binding,	IPR002515:Zinc finger, C2HC-type,IPR013681:Myelin transcription factor 1,					KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Myelin transcription factor 1,REGION:Disordered,ZN_FING:CCHHC-type 1,ZN_FING:CCHHC-type 2,ZN_FING:CCHHC-type 3,ZN_FING:CCHHC-type 4,ZN_FING:CCHHC-type 5,ZN_FING:CCHHC-type 6,ZN_FING:CCHHC-type 7,
MNDA	myeloid cell nuclear differentiation antigen(MNDA)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0006968~cellular defense response,GO:0006974~cellular response to DNA damage stimulus,GO:0030889~negative regulation of B cell proliferation,GO:0032731~positive regulation of interleukin-1 beta production,GO:0035458~cellular response to interferon-beta,GO:0043065~positive regulation of apoptotic process,GO:0050853~B cell receptor signaling pathway,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0034399~nuclear periphery,GO:0035578~azurophil granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,	IPR004020:DAPIN domain,IPR004021:HIN-200/IF120x,IPR011029:Death-like domain,				SM01289:SM01289,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HIN-200,DOMAIN:Pyrin,MOTIF:Nuclear localization signal,REGION:Disordered,
MIAT	myocardial infarction associated transcript(MIAT)	Homo sapiens			GO:0001708~cell fate specification,GO:0042742~defense response to bacterium,GO:2000111~positive regulation of macrophage apoptotic process,	GO:0005634~nucleus,	GO:0035198~miRNA binding,			608446~Myocardial infarction, susceptibility to,
MYF6	myogenic factor 6(MYF6)	Homo sapiens			GO:0001756~somitogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007519~skeletal muscle tissue development,GO:0035914~skeletal muscle cell differentiation,GO:0042693~muscle cell fate commitment,GO:0045663~positive regulation of myoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048743~positive regulation of skeletal muscle fiber development,GO:0060415~muscle tissue morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0072686~mitotic spindle,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002546:Myogenic basic muscle-specific protein,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,				SM00353:HLH,SM00520:BASIC,	KW-0221~Differentiation,KW-0517~Myogenesis,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:bHLH,REGION:Disordered,
MB	myoglobin(MB)	Homo sapiens			GO:0001666~response to hypoxia,GO:0007507~heart development,GO:0015671~oxygen transport,GO:0043353~enucleate erythrocyte differentiation,GO:0050873~brown fat cell differentiation,GO:0071588~hydrogen peroxide mediated signaling pathway,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005344~oxygen transporter activity,GO:0019825~oxygen binding,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR000971:Globin,IPR002335:Myoglobin,IPR009050:Globin-like,		620286~Myopathy, sarcoplasmic body,			KW-0561~Oxygen transport,KW-0813~Transport,				KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0514~Muscle protein,	KW-0597~Phosphoprotein,	BINDING:distal binding residue,BINDING:proximal binding residue,DOMAIN:Globin family profile,
MYO15A	myosin XVA(MYO15A)	Homo sapiens			GO:0007015~actin filament organization,GO:0007605~sensory perception of sound,GO:0007626~locomotory behavior,GO:0009416~response to light stimulus,GO:0030050~vesicle transport along actin filament,GO:0042472~inner ear morphogenesis,	GO:0005737~cytoplasm,GO:0015629~actin cytoskeleton,GO:0016459~myosin complex,GO:0031982~vesicle,GO:0032420~stereocilium,GO:0070062~extracellular exosome,GO:0098858~actin-based cell projection,	GO:0000146~microfilament motor activity,GO:0003779~actin binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0051015~actin filament binding,	IPR000048:IQ motif, EF-hand binding site,IPR000299:FERM domain,IPR000857:MyTH4 domain,IPR001452:Src homology-3 domain,IPR001609:Myosin head, motor domain,IPR011993:Pleckstrin homology-like domain,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04814:Motor proteins,	600316~Deafness, autosomal recessive 3,		SM00015:IQ,SM00139:MyTH4,SM00242:MYSc,SM00295:B41,SM00326:SH3,	KW-1009~Hearing,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0505~Motor protein,KW-0518~Myosin,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FERM,DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:MyTH4,DOMAIN:MyTH4 1,DOMAIN:MyTH4 2,DOMAIN:Myosin motor,DOMAIN:SH3,REGION:Actin-binding,REGION:Disordered,REGION:Neck or regulatory domain,REGION:Tail,
MYH11	myosin heavy chain 11(MYH11)	Homo sapiens			GO:0006939~smooth muscle contraction,GO:0030241~skeletal muscle myosin thick filament assembly,GO:0031032~actomyosin structure organization,GO:0048251~elastic fiber assembly,GO:0055013~cardiac muscle cell development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005859~muscle myosin complex,GO:0016459~myosin complex,GO:0016460~myosin II complex,GO:0032982~myosin filament,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0000146~microfilament motor activity,GO:0003774~motor activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0008307~structural constituent of muscle,GO:0051015~actin filament binding,	IPR000048:IQ motif, EF-hand binding site,IPR001609:Myosin head, motor domain,IPR002928:Myosin tail,IPR004009:Myosin, N-terminal, SH3-like,IPR008989:Myosin S1 fragment, N-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04270:Vascular smooth muscle contraction,hsa04530:Tight junction,hsa04810:Regulation of actin cytoskeleton,hsa04814:Motor proteins,hsa05130:Pathogenic Escherichia coli infection,	132900~Aortic aneurysm, familial thoracic 4,619350~Visceral myopathy 2,619351~Megacystis-microcolon-intestinal hypoperistalsis syndrome 2,		SM00015:IQ,SM00242:MYSc,		KW-0787~Thick filament,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0993~Aortic aneurysm,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IQ,DOMAIN:Myosin N-terminal SH3-like,DOMAIN:Myosin motor,DOMAIN:Myosin tail,REGION:Actin-binding,REGION:C-terminal,REGION:Disordered,
MYH7B	myosin heavy chain 7B(MYH7B)	Homo sapiens			GO:0051480~regulation of cytosolic calcium ion concentration,GO:1905289~regulation of CAMKK-AMPK signaling cascade,	GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016459~myosin complex,GO:0016460~myosin II complex,GO:0032982~myosin filament,GO:0097512~cardiac myofibril,	GO:0000146~microfilament motor activity,GO:0003774~motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0051015~actin filament binding,	IPR000048:IQ motif, EF-hand binding site,IPR001609:Myosin head, motor domain,IPR002928:Myosin tail,IPR004009:Myosin, N-terminal, SH3-like,IPR008989:Myosin S1 fragment, N-terminal,IPR014751:DNA repair protein XRCC4, C-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04814:Motor proteins,			SM00242:MYSc,		KW-0472~Membrane,KW-0787~Thick filament,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,		COMPBIAS:Basic and acidic residues,DOMAIN:IQ,DOMAIN:Myosin N-terminal SH3-like,DOMAIN:Myosin motor,DOMAIN:Myosin tail,REGION:Actin-binding,REGION:Disordered,
MYL9	myosin light chain 9(MYL9)	Homo sapiens			GO:0006937~regulation of muscle contraction,GO:0030239~myofibril assembly,GO:0070527~platelet aggregation,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005859~muscle myosin complex,GO:0005938~cell cortex,GO:0016460~myosin II complex,GO:0030016~myofibril,GO:0030018~Z disc,	GO:0005509~calcium ion binding,GO:0008307~structural constituent of muscle,GO:0032036~myosin heavy chain binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04814:Motor proteins,hsa04921:Oxytocin signaling pathway,hsa05131:Shigellosis,hsa05132:Salmonella infection,	619365~Megacystis-microcolon-intestinal hypoperistalsis syndrome 4,		SM00054:EFh,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,REGION:Disordered,
MYLK	myosin light chain kinase(MYLK)	Homo sapiens	68.Mitogen_signaling_in_growth_control,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_mCalpainPathway:mCalpain and friends in Cell motility,h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_rhoPathway:Rho cell motility signaling pathway,	GO:0006468~protein phosphorylation,GO:0006939~smooth muscle contraction,GO:0014820~tonic smooth muscle contraction,GO:0030335~positive regulation of cell migration,GO:0032060~bleb assembly,GO:0051928~positive regulation of calcium ion transport,GO:0060414~aorta smooth muscle tissue morphogenesis,GO:0071476~cellular hypotonic response,GO:0090303~positive regulation of wound healing,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0032154~cleavage furrow,	GO:0003779~actin binding,GO:0004672~protein kinase activity,GO:0004687~myosin light chain kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa04971:Gastric acid secretion,	249210~Megacystis-microcolon-intestinal hypoperistalsis syndrome 1,613780~Aortic aneurysm, familial thoracic 7,		SM00060:FN3,SM00220:S_TKc,SM00408:IGc2,SM00409:IG,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0993~Aortic aneurysm,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of acetylation and no kinase activity repression by NAA10/ARD1.,REGION:5 X 28 AA approximate tandem repeats,REGION:6 X 12 AA approximate tandem repeats,REGION:Actin-binding (calcium/calmodulin-insensitive),REGION:Actin-binding (calcium/calmodulin-sensitive),REGION:Calmodulin-binding,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5; truncated,REPEAT:2-1; truncated,REPEAT:2-2,REPEAT:2-3,REPEAT:2-4,REPEAT:2-5,REPEAT:2-6,
MARCKS	myristoylated alanine rich protein kinase C substrate(MARCKS)	Homo sapiens		h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,	GO:0006915~apoptotic process,GO:0007005~mitochondrion organization,GO:0007015~actin filament organization,GO:0007417~central nervous system development,GO:0021915~neural tube development,GO:0022008~neurogenesis,GO:0034976~response to endoplasmic reticulum stress,GO:0051017~actin filament bundle assembly,GO:0051764~actin crosslink formation,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0032432~actin filament bundle,GO:0042585~germinal vesicle,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005080~protein kinase C binding,GO:0005516~calmodulin binding,GO:0042802~identical protein binding,GO:0051015~actin filament binding,	IPR002101:Myristoylated alanine-rich C-kinase substrate MARCKS,	hsa04666:Fc gamma R-mediated phagocytosis,hsa05206:MicroRNAs in cancer,					KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:N-myristoyl glycine,REGION:Calmodulin-binding (PSD),REGION:Disordered,
NEBL	nebulette(NEBL)	Homo sapiens			GO:0071691~cardiac muscle thin filament assembly,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0030018~Z disc,GO:0031674~I band,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005523~tropomyosin binding,GO:0008092~cytoskeletal protein binding,GO:0008307~structural constituent of muscle,GO:0031005~filamin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR000900:Nebulin 35 residue motif,IPR001452:Src homology-3 domain,IPR001781:Zinc finger, LIM-type,				SM00132:LIM,SM00227:NEBU,SM00326:SH3,		KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0728~SH3 domain,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,	KW-0488~Methylation,	COMPBIAS:Pro residues,DOMAIN:LIM zinc-binding,DOMAIN:SH3,REGION:Disordered,REGION:Linker,REPEAT:Nebulin 1,REPEAT:Nebulin 10,REPEAT:Nebulin 11,REPEAT:Nebulin 12,REPEAT:Nebulin 13,REPEAT:Nebulin 14,REPEAT:Nebulin 15,REPEAT:Nebulin 16,REPEAT:Nebulin 17,REPEAT:Nebulin 18,REPEAT:Nebulin 19,REPEAT:Nebulin 2,REPEAT:Nebulin 20,REPEAT:Nebulin 21,REPEAT:Nebulin 22,REPEAT:Nebulin 23,REPEAT:Nebulin 3,REPEAT:Nebulin 4,REPEAT:Nebulin 5,REPEAT:Nebulin 6,REPEAT:Nebulin 7,REPEAT:Nebulin 8,REPEAT:Nebulin 9,
NDN	necdin, MAGE family member(NDN)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0003016~respiratory system process,GO:0007413~axonal fasciculation,GO:0007417~central nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0008347~glial cell migration,GO:0009791~post-embryonic development,GO:0019233~sensory perception of pain,GO:0040008~regulation of growth,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0048666~neuron development,GO:0048675~axon extension,GO:0048871~multicellular organismal homeostasis,GO:0071514~genetic imprinting,GO:0090312~positive regulation of protein deacetylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0042995~cell projection,GO:0043204~perikaryon,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043015~gamma-tubulin binding,GO:1990841~promoter-specific chromatin binding,	IPR002190:MAGE protein,				SM01373:SM01373,	KW-0341~Growth regulation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:MAGE,REGION:Disordered,
NTNG2	netrin G2(NTNG2)	Homo sapiens			GO:0007409~axonogenesis,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0010975~regulation of neuron projection development,GO:0016477~cell migration,GO:0034446~substrate adhesion-dependent cell spreading,GO:0050804~modulation of synaptic transmission,GO:0070831~basement membrane assembly,GO:0099560~synaptic membrane adhesion,GO:1905606~regulation of presynapse assembly,GO:2001222~regulation of neuron migration,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0030424~axon,GO:0043256~laminin complex,GO:0045171~intercellular bridge,GO:0046658~anchored component of plasma membrane,GO:0048787~presynaptic active zone membrane,GO:0090543~Flemming body,GO:0098552~side of membrane,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:0099029~anchored component of presynaptic active zone membrane,	GO:0005515~protein binding,	IPR000742:Epidermal growth factor-like domain,IPR002049:EGF-like, laminin,IPR008211:Laminin, N-terminal,	hsa04360:Axon guidance,hsa04514:Cell adhesion molecules,	618718~Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia,		SM00136:LamNT,SM00180:EGF_Lam,SM00181:EGF,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,	KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin N-terminal,LIPID:GPI-anchor amidated glycine,PROPEP:Removed in mature form,REGION:NGL discriminant loop I,REGION:NGL discriminant loop II,REGION:NGL discriminant loop III,
NELL1	neural EGFL like 1(NELL1)	Homo sapiens			GO:0007399~nervous system development,GO:0010468~regulation of gene expression,GO:0030154~cell differentiation,GO:0030501~positive regulation of bone mineralization,GO:0033689~negative regulation of osteoblast proliferation,GO:0042177~negative regulation of protein catabolic process,GO:0045667~regulation of osteoblast differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045778~positive regulation of ossification,GO:1903363~negative regulation of cellular protein catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0005080~protein kinase C binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0016301~kinase activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001007:von Willebrand factor, type C,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,				SM00179:EGF_CA,SM00181:EGF,SM00210:TSPN,SM00214:VWC,SM00215:VWC_out,SM00282:LamG,	KW-0221~Differentiation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0418~Kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:Laminin G-like,DOMAIN:VWFC,DOMAIN:VWFC 1,DOMAIN:VWFC 2,
NRN1	neuritin 1(NRN1)	Homo sapiens			GO:0007399~nervous system development,GO:1990138~neuron projection extension,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0045202~synapse,GO:0046658~anchored component of plasma membrane,GO:0098552~side of membrane,		IPR026144:Neuritin family,						KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,	COMPBIAS:Polar residues,LIPID:GPI-anchor amidated glycine,PROPEP:Removed in mature form,REGION:Disordered,
NEFH	neurofilament heavy chain(NEFH)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0007409~axonogenesis,GO:0030031~cell projection assembly,GO:0033693~neurofilament bundle assembly,GO:0045110~intermediate filament bundle assembly,GO:0048936~peripheral nervous system neuron axonogenesis,GO:0060052~neurofilament cytoskeleton organization,GO:0061564~axon development,GO:1902513~regulation of organelle transport along microtubule,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005883~neurofilament,GO:0014069~postsynaptic density,GO:0030424~axon,GO:0097418~neurofibrillary tangle,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019894~kinesin binding,GO:0019901~protein kinase binding,GO:0030674~protein binding, bridging,GO:0070840~dynein complex binding,	IPR010790:Protein of unknown function DUF1388,IPR018039:Intermediate filament protein, conserved site,	hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,	105400~Amyotrophic lateral sclerosis, susceptibility to,616924~Charcot-Marie-Tooth disease, axonal, type 2CC,		SM01391:SM01391,		KW-0206~Cytoskeleton,KW-0403~Intermediate filament,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0036~Amyotrophic lateral sclerosis,KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IF rod,REGION:30 X 6 AA repeats of K-S-P-[AEPV]-[EAK]-[AEVK],REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
NEFM	neurofilament medium chain(NEFM)	Homo sapiens			GO:0033693~neurofilament bundle assembly,	GO:0005737~cytoplasm,GO:0005882~intermediate filament,GO:0005883~neurofilament,GO:0030424~axon,GO:0045111~intermediate filament cytoskeleton,GO:0097418~neurofibrillary tangle,	GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR002957:Keratin, type I,IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,	hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM01391:SM01391,		KW-0206~Cytoskeleton,KW-0403~Intermediate filament,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:IF rod,REGION:6 X 13 AA approximate tandem repeats of K-S-P-V-[PS]-K-S-P-V-E-E-[KA]-[GAK],REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,
NGB	neuroglobin(NGB)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006915~apoptotic process,GO:0015671~oxygen transport,	GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0043204~perikaryon,	GO:0005344~oxygen transporter activity,GO:0005515~protein binding,GO:0019825~oxygen binding,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR000971:Globin,IPR009050:Globin-like,IPR012292:Globin, structural domain,					KW-0053~Apoptosis,KW-0561~Oxygen transport,KW-0813~Transport,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,			KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	BINDING:distal binding residue,BINDING:proximal binding residue,DISULFID:Redox-active,DOMAIN:Globin family profile,REGION:Globin,
NEUROD1	neuronal differentiation 1(NEUROD1)	Homo sapiens			GO:0003326~pancreatic A cell fate commitment,GO:0003329~pancreatic PP cell fate commitment,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006913~nucleocytoplasmic transport,GO:0007259~JAK-STAT cascade,GO:0007263~nitric oxide mediated signal transduction,GO:0007423~sensory organ development,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0009952~anterior/posterior pattern specification,GO:0021542~dentate gyrus development,GO:0021549~cerebellum development,GO:0022008~neurogenesis,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030073~insulin secretion,GO:0030182~neuron differentiation,GO:0031018~endocrine pancreas development,GO:0035881~amacrine cell differentiation,GO:0035883~enteroendocrine cell differentiation,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046426~negative regulation of JAK-STAT cascade,GO:0048562~embryonic organ morphogenesis,GO:0048666~neuron development,GO:0048839~inner ear development,GO:0050796~regulation of insulin secretion,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060730~regulation of intestinal epithelial structure maintenance,GO:0061564~axon development,GO:0071333~cellular response to glucose stimulus,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,GO:2000679~positive regulation of transcription regulatory region DNA binding,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR016637:Transcription factor, basic helix-loop-helix, NeuroD,IPR022575:Neurogenic differentiation factor, domain of unknown function,	hsa04950:Maturity onset diabetes of the young,	125853~Type 2 diabetes mellitus, susceptibility to,606394~Maturity-onset diabetes of the young 6,	PIRSF015618:basic helix-loop-helix transcription factor NeuroD,	SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:BHLH,DOMAIN:Neurogenic differentiation factor,DOMAIN:bHLH,MOTIF:Nuclear localization signal,REGION:Disordered,
NPTX2	neuronal pentraxin 2(NPTX2)	Homo sapiens			GO:0007268~chemical synaptic transmission,GO:0008306~associative learning,GO:0098962~regulation of postsynaptic neurotransmitter receptor activity,	GO:0005576~extracellular region,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR001759:Pentaxin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00159:PTX,		KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Pentraxin (PTX),
NPY	neuropeptide Y(NPY)	Homo sapiens			GO:0001878~response to yeast,GO:0002865~negative regulation of acute inflammatory response to antigenic stimulus,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007218~neuropeptide signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0007631~feeding behavior,GO:0008217~regulation of blood pressure,GO:0008284~positive regulation of cell proliferation,GO:0008343~adult feeding behavior,GO:0010811~positive regulation of cell-substrate adhesion,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0021954~central nervous system neuron development,GO:0021987~cerebral cortex development,GO:0031175~neuron projection development,GO:0032100~positive regulation of appetite,GO:0032903~regulation of nerve growth factor production,GO:0042117~monocyte activation,GO:0045087~innate immune response,GO:0045776~negative regulation of blood pressure,GO:0045964~positive regulation of dopamine metabolic process,GO:0048572~short-day photoperiodism,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050909~sensory perception of taste,GO:0060575~intestinal epithelial cell differentiation,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0099538~synaptic signaling via neuropeptide,GO:1901215~negative regulation of neuron death,GO:1904000~positive regulation of eating behavior,GO:1904407~positive regulation of nitric oxide metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0043195~terminal bouton,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,GO:0098982~GABA-ergic synapse,GO:0098992~neuronal dense core vesicle,	GO:0001664~G-protein coupled receptor binding,GO:0004930~G-protein coupled receptor activity,GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0005184~neuropeptide hormone activity,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0031841~neuropeptide Y receptor binding,	IPR001955:Pancreatic hormone-like,IPR020392:Pancreatic hormone-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04920:Adipocytokine signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa05034:Alcoholism,			SM00309:PAH,		KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0527~Neuropeptide,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,	PEPTIDE:C-flanking peptide of NPY,PEPTIDE:Neuropeptide Y,SITE:Cleavage; by FAP,
NTM	neurotrimin(NTM)	Homo sapiens			GO:0007155~cell adhesion,GO:0008038~neuron recognition,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,LIPID:GPI-anchor amidated asparagine,PROPEP:Removed in mature form,REGION:Disordered,
NTF3	neurotrophin 3(NTF3)	Homo sapiens			GO:0002092~positive regulation of receptor internalization,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007267~cell-cell signaling,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0007613~memory,GO:0008284~positive regulation of cell proliferation,GO:0021675~nerve development,GO:0030335~positive regulation of cell migration,GO:0032148~activation of protein kinase B activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0038180~nerve growth factor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0045664~regulation of neuron differentiation,GO:0048812~neuron projection morphogenesis,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050804~modulation of synaptic transmission,GO:0050918~positive chemotaxis,GO:0050930~induction of positive chemotaxis,GO:0090630~activation of GTPase activity,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0008021~synaptic vesicle,GO:0030424~axon,GO:0030425~dendrite,	GO:0005102~receptor binding,GO:0005163~nerve growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0042056~chemoattractant activity,	IPR002072:Nerve growth factor-related,IPR015578:Neurotrophin-3,IPR019846:Nerve growth factor conserved site,IPR020408:Nerve growth factor-like,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04722:Neurotrophin signaling pathway,		PIRSF001789:nerve growth factor, subunit beta,	SM00140:NGF,		KW-0964~Secreted,		KW-0732~Signal,		KW-0339~Growth factor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
NRTN	neurturin(NRTN)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001755~neural crest cell migration,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007399~nervous system development,GO:0021675~nerve development,GO:0031175~neuron projection development,	GO:0005576~extracellular region,GO:0030424~axon,	GO:0005102~receptor binding,GO:0008083~growth factor activity,GO:0030116~glial cell-derived neurotrophic factor receptor binding,GO:0030971~receptor tyrosine kinase binding,	IPR001839:Transforming growth factor-beta, C-terminal,	hsa04010:MAPK signaling pathway,hsa04151:PI3K-Akt signaling pathway,					KW-0964~Secreted,	KW-0225~Disease variant,KW-0367~Hirschsprung disease,	KW-0732~Signal,		KW-0339~Growth factor,	KW-1015~Disulfide bond,	DISULFID:Interchain,REGION:Disordered,
NEXN	nexilin F-actin binding protein(NEXN)	Homo sapiens			GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007411~axon guidance,GO:0030334~regulation of cell migration,GO:0051493~regulation of cytoskeleton organization,GO:0070593~dendrite self-avoidance,	GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030018~Z disc,GO:0030424~axon,	GO:0008307~structural constituent of muscle,GO:0051015~actin filament binding,GO:0098632~protein binding involved in cell-cell adhesion,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,		613122~Cardiomyopathy, dilated, 1CC,613876~Cardiomyopathy, hypertrophic, 20,		SM00409:IG,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0965~Cell junction,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0393~Immunoglobulin domain,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,REGION:Disordered,
NNMT	nicotinamide N-methyltransferase(NNMT)	Homo sapiens			GO:0006769~nicotinamide metabolic process,GO:0009410~response to xenobiotic stimulus,GO:0010243~response to organonitrogen compound,GO:0010967~regulation of polyamine biosynthetic process,GO:0031060~regulation of histone methylation,GO:0031100~animal organ regeneration,GO:0032259~methylation,GO:0034356~NAD biosynthesis via nicotinamide riboside salvage pathway,GO:0045722~positive regulation of gluconeogenesis,GO:0051569~regulation of histone H3-K4 methylation,GO:0090312~positive regulation of protein deacetylation,	GO:0005829~cytosol,	GO:0008112~nicotinamide N-methyltransferase activity,GO:0008170~N-methyltransferase activity,GO:0030760~pyridine N-methyltransferase activity,	IPR000940:Methyltransferase, NNMT/PNMT/TEMT,IPR025820:Methyltransferase NNMT/PNMT/TEMT, conserved site,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,	Homocysteine plasma level~Homocysteine plasma level,	PIRSF000384:phenylethanolamine N-methyltransferase,			KW-0963~Cytoplasm,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0164~Citrullination,	MUTAGEN:D->A: Loss of N-methyltransferase activity.,MUTAGEN:R->K: Has no effect on N-methyltransferase activity.,MUTAGEN:R->K: Loss of N-methyltransferase activity like its citrullinated counterpart.,MUTAGEN:S->A: Has no effect on N-methyltransferase activity.,MUTAGEN:Y->A: Loss of N-methyltransferase activity.,MUTAGEN:Y->F: Decreases N-methyltransferase activity.,
NID2	nidogen 2(NID2)	Homo sapiens			GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0071711~basement membrane organization,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005518~collagen binding,	IPR000033:LDLR class B repeat,IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000716:Thyroglobulin type-1,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR003886:Nidogen, extracellular domain,IPR006605:G2 nidogen/fibulin G2F,IPR009017:Green fluorescent protein,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011042:Six-bladed beta-propeller, TolB-like,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,IPR026823:Complement Clr-like EGF domain,				SM00135:LY,SM00179:EGF_CA,SM00181:EGF,SM00211:TY,SM00539:NIDO,SM00682:G2F,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0488~Methylation,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:NIDO,DOMAIN:Nidogen G2 beta-barrel,DOMAIN:Thyroglobulin type-1,DOMAIN:Thyroglobulin type-1 1,DOMAIN:Thyroglobulin type-1 2,REGION:Disordered,REPEAT:LDL-receptor class B,REPEAT:LDL-receptor class B 1,REPEAT:LDL-receptor class B 2,REPEAT:LDL-receptor class B 3,REPEAT:LDL-receptor class B 4,REPEAT:LDL-receptor class B 5,
NOTCH3	notch receptor 3(NOTCH3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0007411~axon guidance,GO:0014016~neuroblast differentiation,GO:0030900~forebrain development,GO:0045665~negative regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048663~neuron fate commitment,GO:0048844~artery morphogenesis,GO:0072104~glomerular capillary formation,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0015629~actin cytoskeleton,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0045296~cadherin binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000800:Notch domain,IPR001881:EGF-like calcium-binding,IPR002110:Ankyrin repeat,IPR008297:Notch,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR010660:Notch, NOD domain,IPR011656:Notch, NODP domain,IPR013032:EGF-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,IPR022331:Neurogenic locus Notch 3,IPR024600:Domain of unknown function DUF3454, notch,	hsa01522:Endocrine resistance,hsa04330:Notch signaling pathway,hsa04371:Apelin signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04919:Thyroid hormone signaling pathway,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05224:Breast cancer,	125310~Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,130720~Lateral meningocele syndrome,615293~Myofibromatosis, infantile 2,	PIRSF002279:notch protein,	SM00004:NL,SM00179:EGF_CA,SM00181:EGF,SM00248:ANK,SM01334:SM01334,SM01338:SM01338,SM01339:SM01339,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17; calcium-binding,DOMAIN:EGF-like 18,DOMAIN:EGF-like 19,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20,DOMAIN:EGF-like 21; calcium-binding,DOMAIN:EGF-like 22; calcium-binding,DOMAIN:EGF-like 23; calcium-binding,DOMAIN:EGF-like 24,DOMAIN:EGF-like 25,DOMAIN:EGF-like 26,DOMAIN:EGF-like 27,DOMAIN:EGF-like 28,DOMAIN:EGF-like 29; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 30; calcium-binding,DOMAIN:EGF-like 31,DOMAIN:EGF-like 32,DOMAIN:EGF-like 33,DOMAIN:EGF-like 34,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:LNR 1,REPEAT:LNR 2,REPEAT:LNR 3,SITE:Cleavage; by furin-like protease,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NOTCH4	notch receptor 4(NOTCH4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001709~cell fate determination,GO:0001763~morphogenesis of a branching structure,GO:0001837~epithelial to mesenchymal transition,GO:0001886~endothelial cell morphogenesis,GO:0001944~vasculature development,GO:0006355~regulation of transcription, DNA-templated,GO:0007219~Notch signaling pathway,GO:0007221~positive regulation of transcription of Notch receptor target,GO:0030097~hemopoiesis,GO:0030154~cell differentiation,GO:0030879~mammary gland development,GO:0042060~wound healing,GO:0045596~negative regulation of cell differentiation,GO:0045602~negative regulation of endothelial cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050793~regulation of developmental process,GO:0060354~negative regulation of cell adhesion molecule production,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0098791~Golgi subcompartment,	GO:0005112~Notch binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000800:Notch domain,IPR001881:EGF-like calcium-binding,IPR002110:Ankyrin repeat,IPR008297:Notch,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR010660:Notch, NOD domain,IPR011656:Notch, NODP domain,IPR013032:EGF-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,IPR022355:Neurogenic locus Notch 4,	hsa01522:Endocrine resistance,hsa04330:Notch signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05224:Breast cancer,		PIRSF002279:notch protein,	SM00004:NL,SM00179:EGF_CA,SM00181:EGF,SM00248:ANK,SM01338:SM01338,SM01339:SM01339,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0010~Activator,KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16,DOMAIN:EGF-like 17,DOMAIN:EGF-like 18,DOMAIN:EGF-like 19,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20,DOMAIN:EGF-like 21,DOMAIN:EGF-like 22,DOMAIN:EGF-like 23,DOMAIN:EGF-like 24,DOMAIN:EGF-like 25,DOMAIN:EGF-like 26,DOMAIN:EGF-like 27,DOMAIN:EGF-like 28,DOMAIN:EGF-like 29,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:LNR,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:LNR 1,REPEAT:LNR 2,REPEAT:LNR 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NSD1	nuclear receptor binding SET domain protein 1(NSD1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000414~regulation of histone H3-K36 methylation,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0016571~histone methylation,GO:0032259~methylation,GO:0033135~regulation of peptidyl-serine phosphorylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:1903025~regulation of RNA polymerase II regulatory region sequence-specific DNA binding,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0031981~nuclear lumen,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008270~zinc ion binding,GO:0018024~histone-lysine N-methyltransferase activity,GO:0030331~estrogen receptor binding,GO:0042799~histone methyltransferase activity (H4-K20 specific),GO:0042974~retinoic acid receptor binding,GO:0046872~metal ion binding,GO:0046965~retinoid X receptor binding,GO:0046966~thyroid hormone receptor binding,GO:0046975~histone methyltransferase activity (H3-K36 specific),GO:0050681~androgen receptor binding,	IPR000313:PWWP,IPR001214:SET domain,IPR001965:Zinc finger, PHD-type,IPR003616:Post-SET domain,IPR006560:AWS,IPR011011:Zinc finger, FYVE/PHD-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR019786:Zinc finger, PHD-type, conserved site,IPR019787:Zinc finger, PHD-finger,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	117550~Sotos syndrome,		SM00249:PHD,SM00293:PWWP,SM00317:SET,SM00508:PostSET,SM00570:AWS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0675~Receptor,KW-0678~Repressor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:AWS,DOMAIN:NSD Cys-His rich,DOMAIN:PHD-type,DOMAIN:PWWP,DOMAIN:PWWP 1,DOMAIN:PWWP 2,DOMAIN:Post-SET,DOMAIN:SET,MUTAGEN:R->C: Reduced enzyme activity.,MUTAGEN:R->W: Nearly abolished enzyme activity.,REGION:Disordered,REGION:Inhibits enzyme activity in the absence of bound histone,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,ZN_FING:PHD-type 3,ZN_FING:PHD-type 4; atypical,
NCOR2	nuclear receptor corepressor 2(NCOR2)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_etsPathway:METS affect on Macrophage Differentiation,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007595~lactation,GO:0010243~response to organonitrogen compound,GO:0010565~regulation of cellular ketone metabolic process,GO:0021549~cerebellum development,GO:0032355~response to estradiol,GO:0044849~estrous cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060766~negative regulation of androgen receptor signaling pathway,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0017053~transcriptional repressor complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005112~Notch binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042826~histone deacetylase binding,GO:0044877~macromolecular complex binding,GO:0046965~retinoid X receptor binding,GO:0047485~protein N-terminus binding,	IPR001005:SANT/Myb domain,IPR009057:Homeodomain-like,IPR017884:SANT domain,IPR017930:Myb domain,	hsa04330:Notch signaling pathway,hsa05169:Epstein-Barr virus infection,			SM00717:SANT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:HTH myb-type,DOMAIN:Myb-like,DOMAIN:N-CoR GPS2-interacting,DOMAIN:SANT,DOMAIN:SANT 1,DOMAIN:SANT 2,MOTIF:CORNR box of ID1,MOTIF:CORNR box of ID2,MUTAGEN:HRIL->AEIA: Abolishes interaction with TBL1X.,MUTAGEN:R->A: Abolishes interaction with the apo LBD of RARA. Restores some interaction on the addition of inverse agonist BMS493.,MUTAGEN:T->G: Abolishes interaction with the apo LBD of RARA. Restores some interaction on the addition of inverse agonist BMS493.,MUTAGEN:V->P: Abolishes interaction with the apo LBD of RARA. No change on interaction on the addition of inverse agonist BMS493.,REGION:Disordered,REGION:Interaction with SIN3A/B,REGION:Required for interaction with RARA in the absence of its ligand,
NR0B2	nuclear receptor subfamily 0 group B member 2(NR0B2)	Homo sapiens		h_fxrPathway:FXR and LXR Regulation of Cholesterol Metabolism,h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0007623~circadian rhythm,GO:0008203~cholesterol metabolic process,GO:0009749~response to glucose,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0014070~response to organic cyclic compound,GO:0015721~bile acid and bile salt transport,GO:0031100~animal organ regeneration,GO:0032024~positive regulation of insulin secretion,GO:0032922~circadian regulation of gene expression,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045471~response to ethanol,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019904~protein domain specific binding,GO:0042803~protein homodimerization activity,GO:0042975~peroxisome proliferator activated receptor binding,GO:0044877~macromolecular complex binding,GO:0046965~retinoid X receptor binding,GO:0046966~thyroid hormone receptor binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001723:Steroid hormone receptor,	hsa04976:Bile secretion,	601665~Obesity, mild, early-onset,		SM00430:HOLI,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0550~Obesity,			KW-0675~Receptor,KW-0678~Repressor,	KW-0488~Methylation,	DOMAIN:NR LBD,
NR2E1	nuclear receptor subfamily 2 group E member 1(NR2E1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001662~behavioral fear response,GO:0002052~positive regulation of neuroblast proliferation,GO:0002118~aggressive behavior,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007399~nervous system development,GO:0007405~neuroblast proliferation,GO:0007601~visual perception,GO:0021542~dentate gyrus development,GO:0021764~amygdala development,GO:0021772~olfactory bulb development,GO:0021819~layer formation in cerebral cortex,GO:0021872~forebrain generation of neurons,GO:0021895~cerebral cortex neuron differentiation,GO:0021960~anterior commissure morphogenesis,GO:0030154~cell differentiation,GO:0030198~extracellular matrix organization,GO:0030522~intracellular receptor signaling pathway,GO:0035019~somatic stem cell population maintenance,GO:0035176~social behavior,GO:0043066~negative regulation of apoptotic process,GO:0043401~steroid hormone mediated signaling pathway,GO:0043615~astrocyte cell migration,GO:0045165~cell fate commitment,GO:0045665~negative regulation of neuron differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045787~positive regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048708~astrocyte differentiation,GO:0048712~negative regulation of astrocyte differentiation,GO:0048814~regulation of dendrite morphogenesis,GO:0048856~anatomical structure development,GO:0060041~retina development in camera-type eye,GO:0060164~regulation of timing of neuron differentiation,GO:0060291~long-term synaptic potentiation,GO:0090049~regulation of cell migration involved in sprouting angiogenesis,GO:2000178~negative regulation of neural precursor cell proliferation,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2000648~positive regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003707~steroid hormone receptor activity,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042826~histone deacetylase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,				SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,KW-9996~Developmental protein,		DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,REGION:Required for transcriptional repression,ZN_FING:NR C4-type,
NR2F2	nuclear receptor subfamily 2 group F member 2(NR2F2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0001893~maternal placenta development,GO:0001937~negative regulation of endothelial cell proliferation,GO:0001945~lymph vessel development,GO:0003084~positive regulation of systemic arterial blood pressure,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007519~skeletal muscle tissue development,GO:0008585~female gonad development,GO:0009566~fertilization,GO:0009952~anterior/posterior pattern specification,GO:0009956~radial pattern formation,GO:0010596~negative regulation of endothelial cell migration,GO:0030154~cell differentiation,GO:0030522~intracellular receptor signaling pathway,GO:0030900~forebrain development,GO:0032355~response to estradiol,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048514~blood vessel morphogenesis,GO:0048856~anatomical structure development,GO:0060173~limb development,GO:0060674~placenta blood vessel development,GO:0060707~trophoblast giant cell differentiation,GO:0060838~lymphatic endothelial cell fate commitment,GO:1904936~interneuron migration,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001972~retinoic acid binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042803~protein homodimerization activity,GO:0043565~sequence-specific DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,		615779~Congenital heart defects, multiple types, 4,618901~46XX sex reversal 5,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:D->R: Reduces transcription activation by 40%; when associated with E-228.,MUTAGEN:FV->AA: Reduces transcription activation by 50%.,MUTAGEN:LL->AA: Reduces transcription activation by 50%.,MUTAGEN:LL->AA: Reduces transcription activation by 80%.,MUTAGEN:R->E: Reduces transcription activation by 40%; when associated with R-398.,MUTAGEN:S->A: Reduces transcription activation by 50%; when associated with A-249.,MUTAGEN:S->W: Reduces transcription activation by 50%.,MUTAGEN:W->A: Reduces transcription activation by 50%; when associated with A-250.,REGION:Disordered,REGION:Important for dimerization,REGION:Interaction with ZFPM2,ZN_FING:NR C4-type,
NOL4	nucleolar protein 4(NOL4)	Homo sapiens				GO:0005730~nucleolus,	GO:0003723~RNA binding,	IPR026747:Nucleolar protein 4,						KW-0539~Nucleus,						COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
NUP62	nucleoporin 62(NUP62)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,	GO:0006405~RNA export from nucleus,GO:0006606~protein import into nucleus,GO:0006913~nucleocytoplasmic transport,GO:0007080~mitotic metaphase plate congression,GO:0007098~centrosome cycle,GO:0007100~mitotic centrosome separation,GO:0007166~cell surface receptor signaling pathway,GO:0007569~cell aging,GO:0008219~cell death,GO:0008285~negative regulation of cell proliferation,GO:0009966~regulation of signal transduction,GO:0015031~protein transport,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043407~negative regulation of MAP kinase activity,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046578~regulation of Ras protein signal transduction,GO:0046580~negative regulation of Ras protein signal transduction,GO:0046601~positive regulation of centriole replication,GO:0051028~mRNA transport,GO:0060236~regulation of mitotic spindle organization,GO:0090398~cellular senescence,GO:0098534~centriole assembly,GO:1903438~positive regulation of mitotic cytokinetic process,GO:1904781~positive regulation of protein localization to centrosome,	GO:0000922~spindle pole,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0031965~nuclear membrane,GO:0044613~nuclear pore central transport channel,GO:0072686~mitotic spindle,GO:0090543~Flemming body,GO:1990904~ribonucleoprotein complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0017056~structural constituent of nuclear pore,GO:0030159~receptor signaling complex scaffold activity,GO:0030544~Hsp70 protein binding,GO:0042169~SH2 domain binding,GO:0043130~ubiquitin binding,GO:0051425~PTB domain binding,GO:0051879~Hsp90 protein binding,	IPR007758:Nucleoporin, NSP1-like, C-terminal,IPR026010:Nucleoporin NSP1/NUP62,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	271930~Striatonigral degeneration, infantile,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,DISULFID:Interchain (with NUP155),DOMAIN:Nucleoporin NSP1-like C-terminal,REGION:5 X 2 AA repeats of F-G,REGION:Disordered,REGION:Required for centrosome localization,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,
OLIG2	oligodendrocyte transcription factor 2(OLIG2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007423~sensory organ development,GO:0021522~spinal cord motor neuron differentiation,GO:0021530~spinal cord oligodendrocyte cell fate specification,GO:0021778~oligodendrocyte cell fate specification,GO:0021794~thalamus development,GO:0030182~neuron differentiation,GO:0042552~myelination,GO:0045665~negative regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048663~neuron fate commitment,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0061564~axon development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,				SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:bHLH,REGION:Disordered,
ONECUT1	one cut homeobox 1(ONECUT1)	Homo sapiens			GO:0001889~liver development,GO:0001952~regulation of cell-matrix adhesion,GO:0002064~epithelial cell development,GO:0003309~type B pancreatic cell differentiation,GO:0003310~pancreatic A cell differentiation,GO:0003311~pancreatic D cell differentiation,GO:0006006~glucose metabolic process,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007219~Notch signaling pathway,GO:0007492~endoderm development,GO:0009653~anatomical structure morphogenesis,GO:0016477~cell migration,GO:0030183~B cell differentiation,GO:0030335~positive regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031018~endocrine pancreas development,GO:0045165~cell fate commitment,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048536~spleen development,GO:0060271~cilium assembly,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003350:Homeodomain protein CUT,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,	hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04950:Maturity onset diabetes of the young,			SM00389:HOX,SM01109:SM01109,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:CUT,DNA_BIND:Homeobox,DOMAIN:CUT,DOMAIN:Homeobox,REGION:Disordered,
OPCML	opioid binding protein/cell adhesion molecule like(OPCML)	Homo sapiens			GO:0007155~cell adhesion,GO:0008038~neuron recognition,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,		167000~Ovarian cancer, somatic,		SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,LIPID:GPI-anchor amidated asparagine,PROPEP:Removed in mature form,
OPRM1	opioid receptor mu 1(OPRM1)	Homo sapiens			GO:0002438~acute inflammatory response to antigenic stimulus,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007197~adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007600~sensory perception,GO:0008285~negative regulation of cell proliferation,GO:0009314~response to radiation,GO:0019233~sensory perception of pain,GO:0031635~adenylate cyclase-inhibiting opioid receptor signaling pathway,GO:0032094~response to food,GO:0032100~positive regulation of appetite,GO:0032496~response to lipopolysaccharide,GO:0038003~opioid receptor signaling pathway,GO:0042060~wound healing,GO:0042220~response to cocaine,GO:0042755~eating behavior,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0044849~estrous cycle,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0048149~behavioral response to ethanol,GO:0050769~positive regulation of neurogenesis,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0051930~regulation of sensory perception of pain,GO:0060079~excitatory postsynaptic potential,GO:0061358~negative regulation of Wnt protein secretion,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070588~calcium ion transmembrane transport,GO:0070848~response to growth factor,GO:0071315~cellular response to morphine,GO:0080135~regulation of cellular response to stress,GO:2000310~regulation of NMDA receptor activity,	GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0032590~dendrite membrane,GO:0032839~dendrite cytoplasm,GO:0042383~sarcolemma,GO:0043005~neuron projection,GO:0043204~perikaryon,GO:0045121~membrane raft,GO:0045202~synapse,GO:0097444~spine apparatus,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001965~G-protein alpha-subunit binding,GO:0004930~G-protein coupled receptor activity,GO:0004979~beta-endorphin receptor activity,GO:0004985~opioid receptor activity,GO:0005245~voltage-gated calcium channel activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0019904~protein domain specific binding,GO:0031005~filamin binding,GO:0031681~G-protein beta-subunit binding,GO:0038047~morphine receptor activity,GO:0042277~peptide binding,GO:0042923~neuropeptide binding,	IPR000105:Mu opioid receptor,IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001418:Opioid receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,hsa04915:Estrogen signaling pathway,hsa05032:Morphine addiction,					KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,MOTIF:NPxxY; plays a role in stabilizing the activated conformation of the receptor,MUTAGEN:C->A,S: Abolishes ligand binding; when associated with A-142 or S-142.,MUTAGEN:C->A,S: Abolishes ligand binding; when associated with A-219 or S-219.,MUTAGEN:K->A: Impairs interaction with calmodulin.,MUTAGEN:R->A: Impairs interaction with calmodulin.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
OTX2	orthodenticle homeobox 2(OTX2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007411~axon guidance,GO:0008589~regulation of smoothened signaling pathway,GO:0030900~forebrain development,GO:0030901~midbrain development,GO:0040019~positive regulation of embryonic development,GO:0040036~regulation of fibroblast growth factor receptor signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0065003~macromolecular complex assembly,GO:0071542~dopaminergic neuron differentiation,GO:0090009~primitive streak formation,GO:2000543~positive regulation of gastrulation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0030426~growth cone,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003022:Transcription factor Otx2,IPR003025:Transcription factor Otx,IPR009057:Homeodomain-like,IPR013851:Transcription factor Otx, C-terminal,IPR017970:Homeobox, conserved site,		610125~Microphthalmia, syndromic 5,610125~Retinal dystrophy, early-onset, with or without pituitary dysfunction,613986~Pituitary hormone deficiency, combined, 6,		SM00389:HOX,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-1013~Microphthalmia,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:Transcription factor Otx C-terminal,REGION:Disordered,
OTP	orthopedia homeobox(OTP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002052~positive regulation of neuroblast proliferation,GO:0007405~neuroblast proliferation,GO:0021879~forebrain neuron differentiation,GO:0021979~hypothalamus cell differentiation,GO:0021985~neurohypophysis development,GO:0030182~neuron differentiation,GO:0061101~neuroendocrine cell differentiation,GO:0071542~dopaminergic neuron differentiation,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:OAR,REGION:Disordered,
OLR1	oxidized low density lipoprotein receptor 1(OLR1)	Homo sapiens			GO:0002376~immune system process,GO:0006508~proteolysis,GO:0006897~endocytosis,GO:0006954~inflammatory response,GO:0007159~leukocyte cell-cell adhesion,GO:0008015~blood circulation,GO:0008219~cell death,GO:0042157~lipoprotein metabolic process,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0035579~specific granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0070821~tertiary granule membrane,	GO:0005041~low-density lipoprotein receptor activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,	IPR001304:C-type lectin,IPR013600:Ly49-like N-terminal,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,	hsa03320:PPAR signaling pathway,hsa04145:Phagosome,hsa05417:Lipid and atherosclerosis,	608446~Myocardial infarction, susceptibility to,		SM00034:CLECT,	KW-0130~Cell adhesion,KW-0391~Immunity,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:C-type lectin,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Abolishes homodimerization.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-144; S-155; S-172; S-243 and S-256.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-144; S-155; S-172; S-243 and S-264.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-144; S-155; S-172; S-256 and S-264.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-144; S-155; S-243; S-256 and S-264.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-144; S-172; S-243; S-256 and S-264.,MUTAGEN:C->S: Abolishes sorting into the cell surface and binding to acetylated LDL (AcLDL) while increasing N-glycosylation; when associated with S-155; S-172; S-243; S-256 and S-264.,MUTAGEN:E->K: Abolishes sorting into the cell surface; when associated with 22-E--E-25.,MUTAGEN:H->A: No effect.,MUTAGEN:H->Q: Abolishes binding to acetylated LDL (AcLDL); when associated with N-229 and N-231.,MUTAGEN:KKAK->EEAE: Impairs sorting into the cell surface but retains ability to bind oxLDL. Abolishes sorting into the cell surface; when associated with K-69.,MUTAGEN:Missing: Impairs protein folding and transport.,MUTAGEN:N->Q: Does not affect glycosylation state.,MUTAGEN:Q->L: Impairs binding to acetylated LDL (AcLDL); when associated with 198-AA-199.,MUTAGEN:R->N: Abolishes binding to acetylated LDL (AcLDL). Abolishes binding to AcLDL; when associated with Q-226 and N-229.,MUTAGEN:R->N: Does not affect binding to acetylated LDL (AcLDL).,MUTAGEN:R->N: Does not affect subcellular location but displays a reduced affinity for acetylated LDL (AcLDL).,MUTAGEN:R->N: Does not affect subcellular location but displays a reduced affinity for acetylated LDL (AcLDL). Abolishes binding to acetylated LDL (AcLDL); when associated with Q-226 and N-231.,MUTAGEN:R->N: Does not affect subcellular location but displays a strongly reduced affinity for acetylated LDL (AcLDL).,MUTAGEN:RN->LL: Abolishes binding to acetylated LDL (AcLDL).,MUTAGEN:S->A: Impairs binding to acetylated LDL (AcLDL); when associated with 235-AL-236.,MUTAGEN:SQ->AL: Impairs binding to acetylated LDL (AcLDL); when associated with A-240.,MUTAGEN:SS->AA: Impairs binding to acetylated LDL (AcLDL); when associated with L-193.,MUTAGEN:W->A: Abolishes binding to acetylated LDL (AcLDL), probably due to inappropriate homodimerization.,REGION:Disordered,REGION:Neck,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
OSBPL7	oxysterol binding protein like 7(OSBPL7)	Homo sapiens			GO:0006699~bile acid biosynthetic process,GO:0006869~lipid transport,GO:0010506~regulation of autophagy,GO:0015918~sterol transport,GO:0071397~cellular response to cholesterol,GO:1901800~positive regulation of proteasomal protein catabolic process,	GO:0005654~nucleoplasm,GO:0005776~autophagosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0097038~perinuclear endoplasmic reticulum,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0015248~sterol transporter activity,GO:0015485~cholesterol binding,GO:0032934~sterol binding,	IPR000648:Oxysterol-binding protein,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR018494:Oxysterol-binding protein, conserved site,				SM00233:PH,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PH,REGION:Disordered,
PAX1	paired box 1(PAX1)	Homo sapiens			GO:0001501~skeletal system development,GO:0001756~somitogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0008283~cell proliferation,GO:0043367~CD4-positive, alpha-beta T cell differentiation,GO:0043374~CD8-positive, alpha-beta T cell differentiation,GO:0048538~thymus development,GO:0048856~anatomical structure development,GO:0060017~parathyroid gland development,GO:0060349~bone morphogenesis,GO:0061056~sclerotome development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001523:Paired domain,IPR009057:Homeodomain-like,		615560~Otofaciocervical syndrome 2,		SM00351:PAX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0563~Paired box,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Paired,DOMAIN:Paired,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,
PAX3	paired box 3(PAX3)	Homo sapiens		h_pmlPathway:Regulation of transcriptional activity by PML,	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007399~nervous system development,GO:0007517~muscle organ development,GO:0007605~sensory perception of sound,GO:0009887~animal organ morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048856~anatomical structure development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022106:Paired box protein 7,	hsa05202:Transcriptional misregulation in cancer,	122880~Craniofacial-deafness-hand syndrome,148820~Waardenburg syndrome, type 3,193500~Waardenburg syndrome, type 1,268220~Rhabdomyosarcoma 2, alveolar,		SM00351:PAX,SM00389:HOX,	KW-0517~Myogenesis,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0897~Waardenburg syndrome,	KW-0371~Homeobox,KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DNA_BIND:Paired,DOMAIN:Homeobox,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,SITE:Breakpoint for translocation to form PAX3-NCOA1 oncogene,
PAX4	paired box 4(PAX4)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0009410~response to xenobiotic stimulus,GO:0009887~animal organ morphogenesis,GO:0030154~cell differentiation,GO:0031016~pancreas development,GO:0043066~negative regulation of apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0048856~anatomical structure development,GO:0051591~response to cAMP,GO:0060041~retina development in camera-type eye,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,	hsa04950:Maturity onset diabetes of the young,	125853~Diabetes mellitus, type 2,612225~Maturity-onset diabetes of the young, type IX,612227~Diabetes mellitus, ketosis-prone, susceptibility to,		SM00351:PAX,SM00389:HOX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0371~Homeobox,KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DNA_BIND:Paired,DOMAIN:Homeobox,DOMAIN:Paired,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,REGION:Transcription repression,
PAX5	paired box 5(PAX5)	Homo sapiens	152.altered_synaptic_signalling-neurodegenerative_disorders,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006959~humoral immune response,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007568~aging,GO:0009887~animal organ morphogenesis,GO:0021670~lateral ventricle development,GO:0021987~cerebral cortex development,GO:0030183~B cell differentiation,GO:0030534~adult behavior,GO:0035914~skeletal muscle cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048856~anatomical structure development,GO:0051573~negative regulation of histone H3-K9 methylation,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR022130:Paired-box protein 2 C-terminal,	hsa05202:Transcriptional misregulation in cancer,	615545~Leukemia, acute lymphoblastic, susceptibility to, 3,		SM00351:PAX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Paired,DOMAIN:Paired,DOMAIN:Paired-box protein 2 C-terminal,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,SITE:Breakpoint for translocation to form PAX5-ETV6,SITE:Breakpoint for translocation to form PAX5-FOXP1,SITE:Breakpoint for translocation to form PAX5-ZNF521,
PAX6	paired box 6(PAX6)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000132~establishment of mitotic spindle orientation,GO:0001568~blood vessel development,GO:0001654~eye development,GO:0001709~cell fate determination,GO:0001755~neural crest cell migration,GO:0001764~neuron migration,GO:0001933~negative regulation of protein phosphorylation,GO:0002052~positive regulation of neuroblast proliferation,GO:0002088~lens development in camera-type eye,GO:0003309~type B pancreatic cell differentiation,GO:0003322~pancreatic A cell development,GO:0006306~DNA methylation,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007405~neuroblast proliferation,GO:0007406~negative regulation of neuroblast proliferation,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0007435~salivary gland morphogenesis,GO:0007601~visual perception,GO:0009611~response to wounding,GO:0009786~regulation of asymmetric cell division,GO:0009887~animal organ morphogenesis,GO:0009950~dorsal/ventral axis specification,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0010975~regulation of neuron projection development,GO:0021517~ventral spinal cord development,GO:0021549~cerebellum development,GO:0021593~rhombomere morphogenesis,GO:0021778~oligodendrocyte cell fate specification,GO:0021796~cerebral cortex regionalization,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021902~commitment of neuronal cell to specific neuron type in forebrain,GO:0021905~forebrain-midbrain boundary formation,GO:0021983~pituitary gland development,GO:0021986~habenula development,GO:0022027~interkinetic nuclear migration,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030216~keratinocyte differentiation,GO:0030334~regulation of cell migration,GO:0030858~positive regulation of epithelial cell differentiation,GO:0032808~lacrimal gland development,GO:0032869~cellular response to insulin stimulus,GO:0033365~protein localization to organelle,GO:0042462~eye photoreceptor cell development,GO:0042593~glucose homeostasis,GO:0042660~positive regulation of cell fate specification,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045471~response to ethanol,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048505~regulation of timing of cell differentiation,GO:0048596~embryonic camera-type eye morphogenesis,GO:0048663~neuron fate commitment,GO:0048708~astrocyte differentiation,GO:0048856~anatomical structure development,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050768~negative regulation of neurogenesis,GO:0060041~retina development in camera-type eye,GO:0061034~olfactory bulb mitral cell layer development,GO:0061072~iris morphogenesis,GO:0061303~cornea development in camera-type eye,GO:0071333~cellular response to glucose stimulus,GO:0071380~cellular response to prostaglandin E stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:0080111~DNA demethylation,GO:0098598~learned vocalization behavior or vocal learning,GO:1901142~insulin metabolic process,GO:1904798~positive regulation of core promoter binding,GO:1904937~sensory neuron migration,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000178~negative regulation of neural precursor cell proliferation,GO:2001224~positive regulation of neuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003680~AT DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031490~chromatin DNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0035035~histone acetyltransferase binding,GO:0070410~co-SMAD binding,GO:0070412~R-SMAD binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,	hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04950:Maturity onset diabetes of the young,	106210~Aniridia,106210~Cataract with late-onset corneal dystrophy,120200~Coloboma, ocular,120430~Coloboma of optic nerve,120430~Morning glory disc anomaly,136520~Foveal hypoplasia 1,148190~Keratitis,165550~Optic nerve hypoplasia,604229~Anterior segment dysgenesis 5, multiple subtypes,		SM00351:PAX,SM00389:HOX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,KW-1059~Peters anomaly,	KW-0371~Homeobox,KW-0563~Paired box,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,DNA_BIND:Paired,DOMAIN:Homeobox,DOMAIN:Paired,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,REGION:Required for suppression of NFATC1-mediated transcription,TRANSMEM:Helical,
PAX7	paired box 7(PAX7)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0009653~anatomical structure morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0048856~anatomical structure development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001523:Paired domain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022106:Paired box protein 7,	hsa05202:Transcriptional misregulation in cancer,	268220~Rhabdomyosarcoma 2, alveolar,618578~Congenital myopathy 19,		SM00351:PAX,SM00389:HOX,	KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0371~Homeobox,KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DNA_BIND:Paired,MOTIF:OAR,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,REGION:Sufficient to mediate interaction with PAXBP1,
PAX9	paired box 9(PAX9)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007492~endoderm development,GO:0009887~animal organ morphogenesis,GO:0042476~odontogenesis,GO:0042481~regulation of odontogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048856~anatomical structure development,GO:0060325~face morphogenesis,GO:0071363~cellular response to growth factor stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001523:Paired domain,IPR009057:Homeodomain-like,		604625~Tooth agenesis, selective, 3,		SM00351:PAX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Paired,DOMAIN:Paired,MUTAGEN:P->A: Abolishes interaction with KDM5B.,MUTAGEN:VP->AA: Abolishes interaction with KDM5B.,REGION:Disordered,REGION:Interaction with KDM5B,REGION:PAI subdomain,REGION:RED subdomain,
PHOX2A	paired like homeobox 2A(PHOX2A)	Homo sapiens			GO:0003357~noradrenergic neuron differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0021523~somatic motor neuron differentiation,GO:0021623~oculomotor nerve formation,GO:0021642~trochlear nerve formation,GO:0021703~locus ceruleus development,GO:0030901~midbrain development,GO:0043576~regulation of respiratory gaseous exchange,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048484~enteric nervous system development,GO:0048485~sympathetic nervous system development,GO:0071542~dopaminergic neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,		602078~Fibrosis of extraocular muscles, congenital, 2,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,REGION:Disordered,
PITX2	paired like homeodomain 2(PITX2)	Homo sapiens		h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007368~determination of left/right symmetry,GO:0009653~anatomical structure morphogenesis,GO:0035315~hair cell differentiation,GO:0035993~deltoid tuberosity development,GO:0042476~odontogenesis,GO:0043010~camera-type eye development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048536~spleen development,GO:0060126~somatotropin secreting cell differentiation,GO:0060127~prolactin secreting cell differentiation,GO:0060971~embryonic heart tube left/right pattern formation,GO:0061072~iris morphogenesis,GO:0061325~cell proliferation involved in outflow tract morphogenesis,GO:0070986~left/right axis specification,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043021~ribonucleoprotein complex binding,GO:0051219~phosphoprotein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR016233:Homeobox protein Pitx/unc30,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa04350:TGF-beta signaling pathway,	137600~Anterior segment dysgenesis 4,180500~Axenfeld-Rieger syndrome, type 1,180550~Ring dermoid of cornea,	PIRSF000563:homeobox protein, Pitx/Unc30 types,	SM00389:HOX,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-1059~Peters anomaly,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:OAR,MOTIF:Nuclear localization signal,MOTIF:OAR,REGION:Disordered,
PPT2	palmitoyl-protein thioesterase 2(PPT2)	Homo sapiens			GO:0046949~fatty-acyl-CoA biosynthetic process,GO:0098734~macromolecule depalmitoylation,	GO:0005764~lysosome,GO:0016021~integral component of membrane,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016790~thiolester hydrolase activity,GO:0098599~palmitoyl hydrolase activity,	IPR002472:Palmitoyl protein thioesterase,	hsa00062:Fatty acid elongation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa04142:Lysosome,					KW-0458~Lysosome,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,MUTAGEN:D->A: Abolishes enzymatic activity.,MUTAGEN:H->A: Abolishes enzymatic activity.,MUTAGEN:H->A: No effect on enzymatic activity.,MUTAGEN:S->A: Abolishes enzymatic activity.,REGION:Disordered,TRANSMEM:Helical,
PTF1A	pancreas associated transcription factor 1a(PTF1A)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0009888~tissue development,GO:0010842~retina layer formation,GO:0021549~cerebellum development,GO:0031016~pancreas development,GO:0031017~exocrine pancreas development,GO:0032502~developmental process,GO:0035881~amacrine cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048384~retinoic acid receptor signaling pathway,GO:0048663~neuron fate commitment,GO:0061074~regulation of neural retina development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,		609069~Pancreatic and cerebellar agenesis,615935~Pancreatic agenesis 2,		SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:bHLH,REGION:Disordered,
PDX1	pancreatic and duodenal homeobox 1(PDX1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001889~liver development,GO:0003309~type B pancreatic cell differentiation,GO:0006006~glucose metabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007263~nitric oxide mediated signal transduction,GO:0007417~central nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009887~animal organ morphogenesis,GO:0010040~response to iron(II) ion,GO:0010157~response to chlorate,GO:0010255~glucose mediated signaling pathway,GO:0010260~animal organ senescence,GO:0010942~positive regulation of cell death,GO:0016331~morphogenesis of embryonic epithelium,GO:0030073~insulin secretion,GO:0031017~exocrine pancreas development,GO:0031100~animal organ regeneration,GO:0032024~positive regulation of insulin secretion,GO:0033273~response to vitamin,GO:0034097~response to cytokine,GO:0035094~response to nicotine,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042593~glucose homeostasis,GO:0043201~response to leucine,GO:0043279~response to alkaloid,GO:0043388~positive regulation of DNA binding,GO:0044342~type B pancreatic cell proliferation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048565~digestive tract development,GO:0048863~stem cell differentiation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0051384~response to glucocorticoid,GO:0051594~detection of glucose,GO:0060290~transdifferentiation,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070542~response to fatty acid,GO:0097050~type B pancreatic cell apoptotic process,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1904692~positive regulation of type B pancreatic cell proliferation,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0044877~macromolecular complex binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,	hsa04911:Insulin secretion,hsa04930:Type II diabetes mellitus,hsa04950:Maturity onset diabetes of the young,	125853~Diabetes mellitus, type II, susceptibility to,260370~Pancreatic agenesis 1,606392~MODY, type IV,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Transactivation domain,
PPY	pancreatic polypeptide(PPY)	Homo sapiens			GO:0007218~neuropeptide signaling pathway,GO:0007631~feeding behavior,GO:0009306~protein secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0001664~G-protein coupled receptor binding,GO:0005179~hormone activity,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0031841~neuropeptide Y receptor binding,	IPR001955:Pancreatic hormone-like,IPR015480:Pancreatic hormone,IPR020392:Pancreatic hormone-like, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,			SM00309:PAH,		KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	PEPTIDE:Pancreatic icosapeptide,PEPTIDE:Pancreatic polypeptide,REGION:Disordered,
PVALB	parvalbumin(PVALB)	Homo sapiens			GO:0010467~gene expression,GO:0090102~cochlea development,GO:0098976~excitatory chemical synaptic transmission,GO:0098977~inhibitory chemical synaptic transmission,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030424~axon,GO:0032420~stereocilium,GO:0032437~cuticular plate,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0005509~calcium ion binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR002048:EF-hand domain,IPR008080:Parvalbumin,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,				KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:D->A: Inactivation.,MUTAGEN:E->V: Inactivation.,
PEG3	paternally expressed 3(PEG3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0010468~regulation of gene expression,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005776~autophagosome,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR003309:Transcription regulator SCAN,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,SM00431:SCAN,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:SCAN box,REGION:3 X 7 AA repeat of P-E-V-E-A-A-E,REGION:4 X 5 AA repeat of P-X-G-E-A,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
PAMR1	peptidase domain containing associated with muscle regeneration 1(PAMR1)	Homo sapiens			GO:0002252~immune effector process,GO:0006955~immune response,	GO:0005576~extracellular region,	GO:0004252~serine-type endopeptidase activity,GO:0005509~calcium ion binding,	IPR000436:Sushi/SCR/CCP,IPR000742:Epidermal growth factor-like domain,IPR000859:CUB domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR001881:EGF-like calcium-binding,IPR009003:Trypsin-like cysteine/serine peptidase domain,				SM00020:Tryp_SPc,SM00032:CCP,SM00042:CUB,SM00179:EGF_CA,SM00181:EGF,		KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,		KW-0378~Hydrolase,KW-0645~Protease,KW-0721~Serine protease homolog,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:EGF-like,DOMAIN:Peptidase S1,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,
PER1	period circadian regulator 1(PER1)	Homo sapiens		h_circadianPathway:Circadian Rhythms,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002028~regulation of sodium ion transport,GO:0006338~chromatin remodeling,GO:0007623~circadian rhythm,GO:0009649~entrainment of circadian clock,GO:0010608~posttranscriptional regulation of gene expression,GO:0032922~circadian regulation of gene expression,GO:0042634~regulation of hair cycle,GO:0042752~regulation of circadian rhythm,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043966~histone H3 acetylation,GO:0043967~histone H4 acetylation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046329~negative regulation of JNK cascade,GO:0048511~rhythmic process,GO:0051591~response to cAMP,GO:0070932~histone H3 deacetylation,GO:0097167~circadian regulation of translation,GO:1900015~regulation of cytokine production involved in inflammatory response,GO:1900744~regulation of p38MAPK cascade,GO:2000323~negative regulation of glucocorticoid receptor signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0031490~chromatin DNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0070888~E-box binding,	IPR000014:PAS domain,IPR013655:PAS fold-3,IPR022728:Period circadian-like, C-terminal,	hsa04710:Circadian rhythm,hsa04713:Circadian entrainment,			SM00091:PAS,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,MOTIF:LXXLL,MOTIF:Nuclear export signal 1,MOTIF:Nuclear export signal 2,MOTIF:Nuclear export signal 3,MOTIF:Nuclear localization signal,MUTAGEN:FLSRF->ALSRA: Strongly decreases interaction with BTRC and FBXW11.,MUTAGEN:SEYT->AEYA: No effect on interaction with BTRC and FBXW11.,MUTAGEN:SVVSVTSQCSFSS->AVVAVTAQCAFAA: No effect on interaction with BTRC and FBXW11.,MUTAGEN:TSGCSS->AAGCSA: Strongly decreases interaction with BTRC and FBXW11 and inhibits degradation promoted by CSNK1E.,REGION:CRY binding domain,REGION:Disordered,REGION:Interaction with BTRC,REGION:Required for phosphorylation by CSNK1E,
PRDX5	peroxiredoxin 5(PRDX5)	Homo sapiens			GO:0006954~inflammatory response,GO:0006979~response to oxidative stress,GO:0016480~negative regulation of transcription from RNA polymerase III promoter,GO:0032967~positive regulation of collagen biosynthetic process,GO:0034599~cellular response to oxidative stress,GO:0034614~cellular response to reactive oxygen species,GO:0042744~hydrogen peroxide catabolic process,GO:0043066~negative regulation of apoptotic process,GO:0045454~cell redox homeostasis,GO:0051354~negative regulation of oxidoreductase activity,GO:0060785~regulation of apoptosis involved in tissue homeostasis,GO:0070995~NADPH oxidation,GO:0098869~cellular oxidant detoxification,GO:2001057~reactive nitrogen species metabolic process,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0001016~RNA polymerase III regulatory region DNA binding,GO:0004601~peroxidase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008379~thioredoxin peroxidase activity,GO:0016209~antioxidant activity,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0051920~peroxiredoxin activity,GO:0072541~peroxynitrite reductase activity,	IPR013740:Redoxin,IPR013766:Thioredoxin domain,	hsa04146:Peroxisome,					KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-0963~Cytoplasm,		KW-0676~Redox-active center,KW-0809~Transit peptide,		KW-0049~Antioxidant,KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate,DISULFID:Redox-active,DOMAIN:Thioredoxin,LIPID:S-palmitoyl cysteine,MOTIF:Microbody targeting signal,MUTAGEN:C->S: Loss of antioxidant activity. Loss of S-palmitoylation.,MUTAGEN:C->S: Loss of antioxidant activity. No change in S-palmitoylation levels.,MUTAGEN:C->S: No change in antioxidant activity. No change in S-palmitoylation levels.,TRANSIT:Mitochondrion,
PSPN	persephin(PSPN)	Homo sapiens			GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0007417~central nervous system development,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005102~receptor binding,GO:0008083~growth factor activity,GO:0030116~glial cell-derived neurotrophic factor receptor binding,GO:0030971~receptor tyrosine kinase binding,	IPR001839:Transforming growth factor-beta, C-terminal,	hsa04010:MAPK signaling pathway,hsa04151:PI3K-Akt signaling pathway,			SM00204:TGFB,		KW-0964~Secreted,		KW-0732~Signal,		KW-0339~Growth factor,	KW-1015~Disulfide bond,	DISULFID:Interchain,REGION:Disordered,
PCYT2	phosphate cytidylyltransferase 2, ethanolamine(PCYT2)	Homo sapiens			GO:0006646~phosphatidylethanolamine biosynthetic process,GO:0008654~phospholipid biosynthetic process,GO:0009058~biosynthetic process,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,	GO:0003824~catalytic activity,GO:0004306~ethanolamine-phosphate cytidylyltransferase activity,GO:0005515~protein binding,	IPR004821:Cytidyltransferase-like domain,IPR014729:Rossmann-like alpha/beta/alpha sandwich fold,	hsa00440:Phosphonate and phosphinate metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,	618770~Spastic paraplegia 82, autosomal recessive,			KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,		KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,			KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:Cytidyltransferase-like,REGION:Disordered,
PREX2	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2(PREX2)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0008344~adult locomotory behavior,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0023051~regulation of signaling,GO:0035556~intracellular signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0048813~dendrite morphogenesis,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,	IPR000219:Dbl homology (DH) domain,IPR000591:DEP domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001478:PDZ domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00049:DEP,SM00228:PDZ,SM00233:PH,SM00325:RhoGEF,				KW-0677~Repeat,		KW-0344~Guanine-nucleotide releasing factor,		DOMAIN:DEP,DOMAIN:DEP 1,DOMAIN:DEP 2,DOMAIN:DH,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PH,REGION:Disordered,
PIP5K1A	phosphatidylinositol-4-phosphate 5-kinase type 1 alpha(PIP5K1A)	Homo sapiens		h_rhoPathway:Rho cell motility signaling pathway,	GO:0006650~glycerophospholipid metabolic process,GO:0006661~phosphatidylinositol biosynthetic process,GO:0006909~phagocytosis,GO:0007165~signal transduction,GO:0008654~phospholipid biosynthetic process,GO:0010761~fibroblast migration,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0030036~actin cytoskeleton organization,GO:0030216~keratinocyte differentiation,GO:0031532~actin cytoskeleton reorganization,GO:0046854~phosphatidylinositol phosphorylation,GO:0048041~focal adhesion assembly,GO:0060326~cell chemotaxis,GO:0072659~protein localization to plasma membrane,GO:0090630~activation of GTPase activity,GO:0097178~ruffle assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016607~nuclear speck,GO:0030027~lamellipodium,GO:0032587~ruffle membrane,	GO:0000285~1-phosphatidylinositol-3-phosphate 5-kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016307~phosphatidylinositol phosphate kinase activity,GO:0016308~1-phosphatidylinositol-4-phosphate 5-kinase activity,GO:0019900~kinase binding,GO:0052742~phosphatidylinositol kinase activity,GO:0052810~1-phosphatidylinositol-5-kinase activity,GO:0052812~phosphatidylinositol-3,4-bisphosphate 5-kinase activity,	IPR002498:Phosphatidylinositol-4-phosphate 5-kinase, core,IPR023610:Phosphatidylinositol-4-phosphate 5-kinase,IPR027484:Phosphatidylinositol-4-phosphate 5-kinase, N-terminal domain,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04510:Focal adhesion,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05135:Yersinia infection,hsa05231:Choline metabolism in cancer,			SM00330:PIPKc,	KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:PIPK,MUTAGEN:D->A: Increased enzyme activation by diarachidonoyl phosphatidic acid (DAPA).,MUTAGEN:D->N: Does not affect targeting of RAC1 to the plasma membrane; when associated with Q-440.,MUTAGEN:L->I: Decreased 1-phosphatidylinositol-4-phosphate 5-kinase activity with 1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phospho-1D-myo-inositol 4-phosphate (arachidonate-PtdIns4P) as substrate. Increased enzyme activation by diarachidonoyl phosphatidic acid (DAPA). No change in enzyme activation by 1-stearoyl-2-oleoyl phosphatidic acid (SOPA) or 1-stearoyl-2-arachidonoyl phosphatidic acid (SAPA).,MUTAGEN:R->Q: Does not affect targeting of RAC1 to the plasma membrane; when associated with N-322.,REGION:Disordered,
PDE4B	phosphodiesterase 4B(PDE4B)	Homo sapiens			GO:0001780~neutrophil homeostasis,GO:0006198~cAMP catabolic process,GO:0007165~signal transduction,GO:0030593~neutrophil chemotaxis,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0050852~T cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0071222~cellular response to lipopolysaccharide,GO:0071466~cellular response to xenobiotic stimulus,GO:0071872~cellular response to epinephrine stimulus,GO:0086004~regulation of cardiac muscle cell contraction,GO:1901841~regulation of high voltage-gated calcium channel activity,GO:1901898~negative regulation of relaxation of cardiac muscle,	GO:0000930~gamma-tubulin complex,GO:0005634~nucleus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005891~voltage-gated calcium channel complex,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0030018~Z disc,GO:0043197~dendritic spine,GO:0048471~perinuclear region of cytoplasm,GO:0060076~excitatory synapse,	GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004115~3',5'-cyclic-AMP phosphodiesterase activity,GO:0030552~cAMP binding,GO:0043015~gamma-tubulin binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,	IPR002073:3'5'-cyclic nucleotide phosphodiesterase, catalytic domain,IPR003607:HD/PDEase domain,IPR023088:3'5'-cyclic nucleotide phosphodiesterase,IPR023174:3'5'-cyclic nucleotide phosphodiesterase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04024:cAMP signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05032:Morphine addiction,			SM00471:HDc,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0114~cAMP,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PDEase,DOMAIN:Phosphodiesterase 4 upstream conserved regions (UCR),MUTAGEN:N->A: Changes substrate selectivity from cAMP-specific to dual cAMP and cGMP binding and hydrolysis; when associated with Q-575 and W-652.,MUTAGEN:NPTKSLELY->HPTKSLELH: Increases substrate selectivity for cGMP.,MUTAGEN:Y->Q: Changes substrate selectivity from cAMP-specific to dual cAMP and cGMP binding and hydrolysis; when associated with A-567 and W-652.,MUTAGEN:Y->W: Changes substrate selectivity from cAMP-specific to dual cAMP and cGMP binding and hydrolysis; when associated with A-567 and Q-575.,REGION:Disordered,
PDE4C	phosphodiesterase 4C(PDE4C)	Homo sapiens			GO:0006198~cAMP catabolic process,GO:0007165~signal transduction,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005929~cilium,GO:0048471~perinuclear region of cytoplasm,	GO:0004112~cyclic-nucleotide phosphodiesterase activity,GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004115~3',5'-cyclic-AMP phosphodiesterase activity,GO:0046872~metal ion binding,	IPR002073:3'5'-cyclic nucleotide phosphodiesterase, catalytic domain,IPR003607:HD/PDEase domain,IPR023088:3'5'-cyclic nucleotide phosphodiesterase,IPR023174:3'5'-cyclic nucleotide phosphodiesterase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04024:cAMP signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05032:Morphine addiction,			SM00471:HDc,		KW-0966~Cell projection,KW-0969~Cilium,			KW-0114~cAMP,KW-0464~Manganese,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PDEase,DOMAIN:Phosphodiesterase 4 upstream conserved regions (UCR),REGION:Disordered,
PACS1	phosphofurin acidic cluster sorting protein 1(PACS1)	Homo sapiens			GO:0002260~lymphocyte homeostasis,GO:0034067~protein localization to Golgi apparatus,GO:0072659~protein localization to plasma membrane,	GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030137~COPI-coated vesicle,	GO:0005515~protein binding,GO:0044325~ion channel binding,	IPR019381:Phosphofurin acidic cluster sorting protein 1,		615009~Schuurs-Hoeijmakers syndrome,			KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Involved in binding to AP-1,
PACS2	phosphofurin acidic cluster sorting protein 2(PACS2)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0006915~apoptotic process,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0034497~protein localization to pre-autophagosomal structure,GO:0072659~protein localization to plasma membrane,GO:1990456~mitochondrion-ER tethering,	GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,GO:0044325~ion channel binding,	IPR019381:Phosphofurin acidic cluster sorting protein 1,		618067~Developmental and epileptic encephalopathy 66,			KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0887~Epilepsy,				KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PHPT1	phosphohistidine phosphatase 1(PHPT1)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0030036~actin cytoskeleton organization,GO:0035971~peptidyl-histidine dephosphorylation,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0051350~negative regulation of lyase activity,GO:0097581~lamellipodium organization,GO:2000147~positive regulation of cell motility,GO:2000249~regulation of actin cytoskeleton reorganization,GO:2000984~negative regulation of ATP citrate synthase activity,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016604~nuclear body,GO:0061851~leading edge of lamellipodium,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019855~calcium channel inhibitor activity,GO:0044325~ion channel binding,GO:0051015~actin filament binding,GO:0101006~protein histidine phosphatase activity,	IPR007702:Janus/Ocnus,						KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,MUTAGEN:H->A: Decreased affinity for substrate and slightly reduced catalytic activity.,MUTAGEN:H->A: Loss of activity.,MUTAGEN:K->A: Decreased affinity for substrate and strongly reduced catalytic activity.,MUTAGEN:R->A: Decreased affinity for substrate and reduced catalytic activity.,MUTAGEN:R->A: Slightly decreased affinity for substrate, but no effect on catalytic activity.,MUTAGEN:S->A: Decreased affinity for substrate and strongly reduced catalytic activity.,
PIK3R1	phosphoinositide-3-kinase regulatory subunit 1(PIK3R1)	Homo sapiens	104.Insulin_signaling,105.Signaling_glucose_uptake,106.Glycogen_synthase-synthesis,107.mRNA_translation-protein_synthesis,2.Cytokine_Receptors,37.Akt-PKB_Effector_of_P13K_in_Vivo,63.LAT_couples_T-cell_receptor,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_badPathway:Regulation of BAD phosphorylation,h_bcellsurvivalPathway:B Cell Survival Pathway,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_crebPathway:Transcription factor CREB and its extracellular signals,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_egfPathway:EGF Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gcrpathway:Corticosteroids and cardioprotection,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il7Pathway:IL-7 Signal Transduction,h_insulinPathway:Insulin Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_ngfPathway:Nerve growth factor pathway (NGF),h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_par1pathway:Thrombin signaling and protease-activated receptors,h_pdgfPathway:PDGF Signaling Pathway,h_plcPathway:Phospholipase C Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0001678~cellular glucose homeostasis,GO:0001953~negative regulation of cell-matrix adhesion,GO:0002687~positive regulation of leukocyte migration,GO:0006366~transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0006606~protein import into nucleus,GO:0006955~immune response,GO:0007165~signal transduction,GO:0008286~insulin receptor signaling pathway,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010592~positive regulation of lamellipodium assembly,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030316~osteoclast differentiation,GO:0030335~positive regulation of cell migration,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032869~cellular response to insulin stimulus,GO:0033120~positive regulation of RNA splicing,GO:0034143~regulation of toll-like receptor 4 signaling pathway,GO:0034446~substrate adhesion-dependent cell spreading,GO:0034644~cellular response to UV,GO:0034976~response to endoplasmic reticulum stress,GO:0042307~positive regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0045671~negative regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046326~positive regulation of glucose import,GO:0046626~regulation of insulin receptor signaling pathway,GO:0046854~phosphatidylinositol phosphorylation,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0050821~protein stabilization,GO:0051491~positive regulation of filopodium assembly,GO:0051497~negative regulation of stress fiber assembly,GO:0060396~growth hormone receptor signaling pathway,GO:0097529~myeloid leukocyte migration,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1903076~regulation of protein localization to plasma membrane,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005801~cis-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0005943~phosphatidylinositol 3-kinase complex, class IA,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:1990578~perinuclear endoplasmic reticulum membrane,	GO:0001784~phosphotyrosine binding,GO:0003677~DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005158~insulin receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005168~neurotrophin TRKA receptor binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019209~kinase activator activity,GO:0019903~protein phosphatase binding,GO:0035014~phosphatidylinositol 3-kinase regulator activity,GO:0036312~phosphatidylinositol 3-kinase regulatory subunit binding,GO:0043125~ErbB-3 class receptor binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0043559~insulin binding,GO:0043560~insulin receptor substrate binding,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,GO:0046982~protein heterodimerization activity,GO:0052742~phosphatidylinositol kinase activity,	IPR000198:Rho GTPase-activating protein domain,IPR000980:SH2 domain,IPR001452:Src homology-3 domain,IPR003070:Orphan nuclear receptor,IPR008936:Rho GTPase activation protein,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	269880~SHORT syndrome,615214~Agammaglobulinemia 7, autosomal recessive,616005~Immunodeficiency 36,		SM00252:SH2,SM00324:RhoGAP,SM00326:SH3,	KW-0346~Stress response,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,		KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,		KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:Rho-GAP,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,DOMAIN:SH3,REGION:Disordered,
PLA2G1B	phospholipase A2 group IB(PLA2G1B)	Homo sapiens			GO:0002227~innate immune response in mucosa,GO:0002446~neutrophil mediated immunity,GO:0006633~fatty acid biosynthetic process,GO:0006644~phospholipid metabolic process,GO:0006654~phosphatidic acid biosynthetic process,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0016042~lipid catabolic process,GO:0019370~leukotriene biosynthetic process,GO:0019731~antibacterial humoral response,GO:0030593~neutrophil chemotaxis,GO:0032431~activation of phospholipase A2 activity,GO:0032757~positive regulation of interleukin-8 production,GO:0032869~cellular response to insulin stimulus,GO:0035556~intracellular signal transduction,GO:0036148~phosphatidylglycerol acyl-chain remodeling,GO:0036149~phosphatidylinositol acyl-chain remodeling,GO:0036150~phosphatidylserine acyl-chain remodeling,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0036152~phosphatidylethanolamine acyl-chain remodeling,GO:0043406~positive regulation of MAP kinase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046324~regulation of glucose import,GO:0046470~phosphatidylcholine metabolic process,GO:0046471~phosphatidylglycerol metabolic process,GO:0048146~positive regulation of fibroblast proliferation,GO:0050482~arachidonic acid secretion,GO:0050714~positive regulation of protein secretion,GO:0050778~positive regulation of immune response,GO:0050830~defense response to Gram-positive bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:1904635~positive regulation of glomerular visceral epithelial cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009986~cell surface,GO:0030141~secretory granule,	GO:0004623~phospholipase A2 activity,GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005543~phospholipid binding,GO:0032052~bile acid binding,GO:0047498~calcium-dependent phospholipase A2 activity,	IPR001211:Phospholipase A2,IPR016090:Phospholipase A2 domain,	hsa00564:Glycerophospholipid metabolism,hsa00565:Ether lipid metabolism,hsa00590:Arachidonic acid metabolism,hsa00591:Linoleic acid metabolism,hsa00592:alpha-Linolenic acid metabolism,hsa01100:Metabolic pathways,hsa04014:Ras signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04972:Pancreatic secretion,hsa04975:Fat digestion and absorption,			SM00085:PA2c,	KW-0443~Lipid metabolism,KW-1208~Phospholipid metabolism,	KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0068~Autocatalytic cleavage,KW-0865~Zymogen,KW-1015~Disulfide bond,	DOMAIN:Phospholipase A2,PROPEP:Activation peptide,
PLA2G5	phospholipase A2 group V(PLA2G5)	Homo sapiens			GO:0006631~fatty acid metabolic process,GO:0006644~phospholipid metabolic process,GO:0006654~phosphatidic acid biosynthetic process,GO:0010518~positive regulation of phospholipase activity,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0016042~lipid catabolic process,GO:0019370~leukotriene biosynthetic process,GO:0034374~low-density lipoprotein particle remodeling,GO:0034638~phosphatidylcholine catabolic process,GO:0035965~cardiolipin acyl-chain remodeling,GO:0036149~phosphatidylinositol acyl-chain remodeling,GO:0036150~phosphatidylserine acyl-chain remodeling,GO:0042130~negative regulation of T cell proliferation,GO:0050482~arachidonic acid secretion,GO:0050766~positive regulation of phagocytosis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0090265~positive regulation of immune complex clearance by monocytes and macrophages,GO:0090385~phagosome-lysosome fusion,GO:1903028~positive regulation of opsonization,GO:1905036~positive regulation of antifungal innate immune response,GO:1905164~positive regulation of phagosome maturation,	GO:0005576~extracellular region,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0032009~early phagosome,GO:0032010~phagolysosome,GO:0055037~recycling endosome,	GO:0004623~phospholipase A2 activity,GO:0005509~calcium ion binding,GO:0005543~phospholipid binding,GO:0047498~calcium-dependent phospholipase A2 activity,GO:0047499~calcium-independent phospholipase A2 activity,	IPR001211:Phospholipase A2,IPR016090:Phospholipase A2 domain,	hsa00564:Glycerophospholipid metabolism,hsa00565:Ether lipid metabolism,hsa00590:Arachidonic acid metabolism,hsa00591:Linoleic acid metabolism,hsa00592:alpha-Linolenic acid metabolism,hsa01100:Metabolic pathways,hsa04014:Ras signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04972:Pancreatic secretion,hsa04975:Fat digestion and absorption,	228980~Fleck retina, familial benign,		SM00085:PA2c,	KW-0276~Fatty acid metabolism,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,KW-0581~Phagocytosis,KW-0595~Phospholipid degradation,KW-1208~Phospholipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-1015~Disulfide bond,	DOMAIN:Phospholipase A2,MUTAGEN:K->E: Decreases arachidonate release from cell membranes; when associated with E-112.,MUTAGEN:R->E: Decreases arachidonate release from cell membranes; when associated with E-113.,MUTAGEN:W->A: Impairs arachidonate release from cell membranes.,
PLCE1	phospholipase C epsilon 1(PLCE1)	Homo sapiens		h_plcePathway:Phospholipase C-epsilon pathway,	GO:0001558~regulation of cell growth,GO:0006651~diacylglycerol biosynthetic process,GO:0006940~regulation of smooth muscle contraction,GO:0007010~cytoskeleton organization,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007264~small GTPase mediated signal transduction,GO:0007265~Ras protein signal transduction,GO:0007507~heart development,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010592~positive regulation of lamellipodium assembly,GO:0016042~lipid catabolic process,GO:0019722~calcium-mediated signaling,GO:0032835~glomerulus development,GO:0043410~positive regulation of MAPK cascade,GO:0045859~regulation of protein kinase activity,GO:0046578~regulation of Ras protein signal transduction,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048016~inositol phosphate-mediated signaling,GO:0051209~release of sequestered calcium ion into cytosol,	GO:0000139~Golgi membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030027~lamellipodium,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004629~phospholipase C activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031267~small GTPase binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000159:Ras-association,IPR000909:Phospholipase C, phosphatidylinositol-specific , X domain,IPR001192:Phosphoinositide phospholipase C,IPR001711:Phospholipase C, phosphatidylinositol-specific, Y domain,IPR001895:Guanine-nucleotide dissociation stimulator CDC25,IPR011992:EF-hand-like domain,IPR015359:Phospholipase C, phosphoinositol-specific, EF-hand-like,IPR017946:PLC-like phosphodiesterase, TIM beta/alpha-barrel domain,IPR023578:Ras guanine nucleotide exchange factor, domain,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04919:Thyroid hormone signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05131:Shigellosis,hsa05205:Proteoglycans in cancer,	610725~Nephrotic syndrome, type 3,		SM00147:RasGEF,SM00148:PLCXc,SM00149:PLCYc,SM00239:C2,SM00314:RA,	KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0344~Guanine-nucleotide releasing factor,KW-0378~Hydrolase,KW-0807~Transducer,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:PI-PLC X-box,DOMAIN:PI-PLC Y-box,DOMAIN:Ras-GEF,DOMAIN:Ras-associating,DOMAIN:Ras-associating 1,DOMAIN:Ras-associating 2,MUTAGEN:H->L: Loss of the phospholipase C enzymatic activity. Still activates HRAS and the MAP kinase pathway.,MUTAGEN:K->L: No effect on HRAS-binding.,MUTAGEN:Q->E: Decreases 17.5-fold the affinity for HRAS.,MUTAGEN:Q->E: Increases 2.8-fold the affinity for HRAS.,MUTAGEN:Q->K: Increases 1.4-fold the affinity for HRAS.,MUTAGEN:R->L: Abolishes interaction with HRAS.,MUTAGEN:Y->L: Reduces HRAS-binding.,REGION:Disordered,REGION:Required for activation by RHOA, RHOB, GNA12, GNA13 and G-beta gamma,
PLD5	phospholipase D family member 5(PLD5)	Homo sapiens				GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043229~intracellular organelle,	GO:0003824~catalytic activity,	IPR001736:Phospholipase D/Transphosphatidylase,				SM00155:PLDc,		KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:PLD phosphodiesterase,DOMAIN:PLD phosphodiesterase 1,DOMAIN:PLD phosphodiesterase 2,REGION:Disordered,TRANSMEM:Helical,
PLTP	phospholipid transfer protein(PLTP)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0006869~lipid transport,GO:0010189~vitamin E biosynthetic process,GO:0010875~positive regulation of cholesterol efflux,GO:0015914~phospholipid transport,GO:0015918~sterol transport,GO:0030317~flagellated sperm motility,GO:0034375~high-density lipoprotein particle remodeling,GO:0035627~ceramide transport,GO:0046836~glycolipid transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0034364~high-density lipoprotein particle,	GO:0008035~high-density lipoprotein particle binding,GO:0008289~lipid binding,GO:0008429~phosphatidylethanolamine binding,GO:0008525~phosphatidylcholine transporter activity,GO:0008526~phosphatidylinositol transporter activity,GO:0019992~diacylglycerol binding,GO:0030169~low-density lipoprotein particle binding,GO:0031210~phosphatidylcholine binding,GO:0034189~very-low-density lipoprotein particle binding,GO:0070300~phosphatidic acid binding,GO:0097001~ceramide binding,GO:1901611~phosphatidylglycerol binding,GO:1904121~phosphatidylethanolamine transporter activity,GO:1990050~phosphatidic acid transporter activity,	IPR001124:Lipid-binding serum glycoprotein, C-terminal,IPR017942:Lipid-binding serum glycoprotein, N-terminal,IPR017943:Bactericidal permeability-increasing protein, alpha/beta domain,IPR017954:Lipid-binding serum glycoprotein, conserved site,	hsa03320:PPAR signaling pathway,hsa04979:Cholesterol metabolism,		PIRSF002417:lipid-binding protein, LBP type,	SM00328:BPI1,SM00329:BPI2,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Lipid-binding serum glycoprotein C-terminal,DOMAIN:Lipid-binding serum glycoprotein N-terminal,MUTAGEN:M->E: Significant reduction in HDL-binding and absence of lipid transfer activity.,MUTAGEN:N->A: Increased nuclear localization; when associated with A-64; A-117 and A-143.,MUTAGEN:N->A: Increased nuclear localization; when associated with A-64; A-94 and A-117.,MUTAGEN:N->A: Increased nuclear localization; when associated with A-64; A-94 and A-143.,MUTAGEN:N->A: Increased nuclear localization; when associated with A-94; A-117 and A-143.,MUTAGEN:S->A: Significant reduction in phospholipid transfer activity. Increased secretion.,MUTAGEN:S->A: Significant reduction in phospholipid transfer activity. No effect on secretion.,MUTAGEN:S->A: Significant reduction in phospholipid transfer activity. Reduced secretion.,
PKP1	plakophilin 1(PKP1)	Homo sapiens			GO:0007043~cell-cell junction assembly,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0010628~positive regulation of gene expression,GO:0045110~intermediate filament bundle assembly,GO:0098609~cell-cell adhesion,GO:1902373~negative regulation of mRNA catabolic process,	GO:0001533~cornified envelope,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0030057~desmosome,GO:0101003~ficolin-1-rich granule membrane,GO:1990124~messenger ribonucleoprotein complex,	GO:0005515~protein binding,GO:0005521~lamin binding,GO:0019215~intermediate filament binding,GO:0030280~structural constituent of epidermis,GO:0045296~cadherin binding,	IPR000225:Armadillo,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,		604536~Ectodermal dysplasia/skin fragility syndrome,		SM00185:ARM,	KW-0130~Cell adhesion,	KW-0539~Nucleus,KW-0965~Cell junction,	KW-0038~Ectodermal dysplasia,	KW-0677~Repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:ARM,REPEAT:ARM 1,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,
PLAT	plasminogen activator, tissue type(PLAT)	Homo sapiens		h_amiPathway:Acute Myocardial Infarction,h_fibrinolysisPathway:Fibrinolysis Pathway,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,	GO:0001666~response to hypoxia,GO:0006464~cellular protein modification process,GO:0006508~proteolysis,GO:0007596~blood coagulation,GO:0010757~negative regulation of plasminogen activation,GO:0014909~smooth muscle cell migration,GO:0031639~plasminogen activation,GO:0035249~synaptic transmission, glutamatergic,GO:0036211~protein modification process,GO:0042730~fibrinolysis,GO:0045861~negative regulation of proteolysis,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048167~regulation of synaptic plasticity,GO:0051591~response to cAMP,GO:0051918~negative regulation of fibrinolysis,GO:0060279~positive regulation of ovulation,GO:0060468~prevention of polyspermy,GO:0070542~response to fatty acid,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071549~cellular response to dexamethasone stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009986~cell surface,GO:0030141~secretory granule,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,GO:0097180~serine protease inhibitor complex,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0098992~neuronal dense core vesicle,GO:0099544~perisynaptic space,	GO:0004252~serine-type endopeptidase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0051219~phosphoprotein binding,	IPR000001:Kringle,IPR000083:Fibronectin, type I,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR018114:Peptidase S1, trypsin family, active site,IPR026280:Tissue plasminogen activator,	hsa04371:Apelin signaling pathway,hsa04610:Complement and coagulation cascades,hsa05202:Transcriptional misregulation in cancer,hsa05215:Prostate cancer,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF001145:tissue plasminogen activator,	SM00020:Tryp_SPc,SM00058:FN1,SM00130:KR,	KW-0617~Plasminogen activation,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0420~Kringle,KW-0677~Repeat,KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,CARBOHYD:O-linked (Fuc) threonine,DISULFID:Interchain (between A and B chains),DOMAIN:EGF-like,DOMAIN:Fibronectin type-I,DOMAIN:Kringle,DOMAIN:Kringle 1,DOMAIN:Kringle 2,DOMAIN:Peptidase S1,PROPEP:Removed by plasmin,REGION:Important for binding to annexin A2,SITE:Important for binding to LRP1,SITE:Important for single-chain activity,SITE:Not glycosylated,
PLAU	plasminogen activator, urokinase(PLAU)	Homo sapiens		h_fibrinolysisPathway:Fibrinolysis Pathway,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,	GO:0001666~response to hypoxia,GO:0006508~proteolysis,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007596~blood coagulation,GO:0010469~regulation of receptor activity,GO:0010755~regulation of plasminogen activation,GO:0010757~negative regulation of plasminogen activation,GO:0014909~smooth muscle cell migration,GO:0014910~regulation of smooth muscle cell migration,GO:0030155~regulation of cell adhesion,GO:0030335~positive regulation of cell migration,GO:0031639~plasminogen activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0038195~urokinase plasminogen activator signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042730~fibrinolysis,GO:0051917~regulation of fibrinolysis,GO:0051918~negative regulation of fibrinolysis,GO:0061041~regulation of wound healing,GO:2000097~regulation of smooth muscle cell-matrix adhesion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0097180~serine protease inhibitor complex,GO:0098637~protein complex involved in cell-matrix adhesion,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR000001:Kringle,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR018114:Peptidase S1, trypsin family, active site,	hsa04064:NF-kappa B signaling pathway,hsa04610:Complement and coagulation cascades,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,	104300~Alzheimer disease, late-onset, susceptibility to,601709~Quebec platelet disorder,		SM00020:Tryp_SPc,SM00130:KR,	KW-0094~Blood coagulation,KW-0280~Fibrinolysis,KW-0356~Hemostasis,KW-0617~Plasminogen activation,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0420~Kringle,KW-0732~Signal,		KW-0378~Hydrolase,KW-0418~Kinase,KW-0645~Protease,KW-0720~Serine protease,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc) threonine,DISULFID:Interchain (between A and B chains),DOMAIN:EGF-like,DOMAIN:Kringle,DOMAIN:Peptidase S1,MUTAGEN:S->E: Abolishes phosphorylation, proadhesive function and ability to induce chemotactic response; when associated with E-158.,MUTAGEN:S->E: Abolishes phosphorylation, proadhesive function and ability to induce chemotactic response; when associated with E-323.,REGION:Binds urokinase plasminogen activator surface receptor,REGION:Connecting peptide,SITE:Cleavage; during zymogen activation,
PDGFRB	platelet derived growth factor receptor beta(PDGFRB)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,		GO:0001525~angiogenesis,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007275~multicellular organism development,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009636~response to toxic substance,GO:0010863~positive regulation of phospholipase C activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016477~cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030335~positive regulation of cell migration,GO:0031401~positive regulation of protein modification process,GO:0032355~response to estradiol,GO:0032516~positive regulation of phosphoprotein phosphatase activity,GO:0032526~response to retinoic acid,GO:0032956~regulation of actin cytoskeleton organization,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033674~positive regulation of kinase activity,GO:0034405~response to fluid shear stress,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035441~cell migration involved in vasculogenesis,GO:0035789~metanephric mesenchymal cell migration,GO:0035791~platelet-derived growth factor receptor-beta signaling pathway,GO:0035793~positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway,GO:0035909~aorta morphogenesis,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0038084~vascular endothelial growth factor signaling pathway,GO:0038091~positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0042327~positive regulation of phosphorylation,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0043627~response to estrogen,GO:0045840~positive regulation of mitotic nuclear division,GO:0046488~phosphatidylinositol metabolic process,GO:0046777~protein autophosphorylation,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048146~positive regulation of fibroblast proliferation,GO:0048584~positive regulation of response to stimulus,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048839~inner ear development,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050921~positive regulation of chemotaxis,GO:0051897~positive regulation of protein kinase B signaling,GO:0055003~cardiac myofibril assembly,GO:0055093~response to hyperoxia,GO:0060326~cell chemotaxis,GO:0060437~lung growth,GO:0060981~cell migration involved in coronary angiogenesis,GO:0061298~retina vasculature development in camera-type eye,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071670~smooth muscle cell chemotaxis,GO:0072075~metanephric mesenchyme development,GO:0072262~metanephric glomerular mesangial cell proliferation involved in metanephros development,GO:0072277~metanephric glomerular capillary formation,GO:0072278~metanephric comma-shaped body morphogenesis,GO:0072284~metanephric S-shaped body morphogenesis,GO:0090280~positive regulation of calcium ion import,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000491~positive regulation of hepatic stellate cell activation,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031226~intrinsic component of plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004992~platelet activating factor receptor activity,GO:0005017~platelet-derived growth factor-activated receptor activity,GO:0005019~platelet-derived growth factor beta-receptor activity,GO:0005102~receptor binding,GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019838~growth factor binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0038085~vascular endothelial growth factor binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0048407~platelet-derived growth factor binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001824:Tyrosine-protein kinase, receptor class III, conserved site,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,IPR027288:Platelet-derived growth factor receptor beta,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,	131440~Myeloproliferative disorder with eosinophilia,228550~Myofibromatosis, infantile, 1,601812~Premature aging syndrome, Penttinen type,615007~Basal ganglia calcification, idiopathic, 4,616592~Kosaki overgrowth syndrome,	PIRSF500948:beta-type platelet-derived growth factor receptor [Parent=PIRSF000615],	SM00219:TyrKc,SM00408:IGc2,SM00409:IG,	KW-0145~Chemotaxis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Protein kinase,MUTAGEN:K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.,MUTAGEN:Y->F: Loss of interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.,MUTAGEN:Y->F: Loss of kinase activity; when associated with F-579. No effect on interaction with GRB10.,MUTAGEN:Y->F: Loss of kinase activity; when associated with F-581. Strongly reduces interaction with SRC family kinases. No effect on interaction with GRB10.,MUTAGEN:Y->F: No effect neither on interaction with GRB10 and RASA1 nor on phosphatidylinositol 3-kinase activity.,MUTAGEN:Y->F: No effect on interaction with GRB10. Abolishes interaction with PLCG1; when associated with F-1021.,MUTAGEN:Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity.,MUTAGEN:Y->F: Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.,MUTAGEN:Y->F: Strongly reduces expression levels.,MUTAGEN:Y->F: Strongly reduces up-regulation of cell proliferation. Abolishes interaction with PLCG1; when associated with F-1009. No effect on interaction with GRB10.,MUTAGEN:Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-740. Abolishes phosphatidylinositol 3-kinase activity and interaction with NCK1, and slightly reduces interaction with RASA1. No effect on interaction with GRB10.,MUTAGEN:Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-751. Strongly decreases phosphatidylinositol 3-kinase activity. No effect on interaction with GRB10 and RASA1.,REGION:Disordered,SITE:Breakpoint for insertion to form PDE4DIP-PDGFRB fusion protein,SITE:Breakpoint for translocation to form TRIP11-PDGFRB,SITE:Breakpoint for translocation to form the CEP85L-PDGFRB fusion protein,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PDGFA	platelet derived growth factor subunit A(PDGFA)	Homo sapiens	18.Cytokine_astocytes,88.Alternatively_Activated_APC,	h_edg1Pathway:Phospholipids as signalling intermediaries,h_inflamPathway:Cytokines and Inflammatory Response,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),	GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001775~cell activation,GO:0001942~hair follicle development,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009887~animal organ morphogenesis,GO:0010035~response to inorganic substance,GO:0010512~negative regulation of phosphatidylinositol biosynthetic process,GO:0010544~negative regulation of platelet activation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014910~regulation of smooth muscle cell migration,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0030335~positive regulation of cell migration,GO:0031954~positive regulation of protein autophosphorylation,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032956~regulation of actin cytoskeleton organization,GO:0035790~platelet-derived growth factor receptor-alpha signaling pathway,GO:0035793~positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway,GO:0042060~wound healing,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043588~skin development,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048146~positive regulation of fibroblast proliferation,GO:0048286~lung alveolus development,GO:0048839~inner ear development,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050919~negative chemotaxis,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0060683~regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1990401~embryonic lung development,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005902~microvillus,GO:0009986~cell surface,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:1990265~platelet-derived growth factor complex,	GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008083~growth factor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0048407~platelet-derived growth factor binding,GO:0070851~growth factor receptor binding,	IPR000072:Platelet-derived growth factor (PDGF),IPR006782:Platelet-derived growth factor, N-terminal,IPR023581:Platelet-derived growth factor, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05206:MicroRNAs in cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05231:Choline metabolism in cancer,hsa05418:Fluid shear stress and atherosclerosis,			SM00141:PDGF,		KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Platelet-derived growth factor (PDGF) family profile,DOMAIN:Platelet-derived growth factor N-terminal,PROPEP:Removed in mature form,REGION:Disordered,REGION:Receptor binding site,
PSD	pleckstrin and Sec7 domain containing(PSD)	Homo sapiens			GO:0007165~signal transduction,GO:0031175~neuron projection development,GO:0032012~regulation of ARF protein signal transduction,	GO:0032154~cleavage furrow,GO:0032587~ruffle membrane,GO:0043197~dendritic spine,GO:0098999~extrinsic component of postsynaptic endosome membrane,GO:0099092~postsynaptic density, intracellular component,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005543~phospholipid binding,	IPR000904:SEC7-like,IPR001605:Pleckstrin homology domain, spectrin-type,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR023394:SEC7-like, alpha orthogonal bundle,	hsa04144:Endocytosis,			SM00222:Sec7,SM00233:PH,		KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->K: Loss of GEF activity, loss of ARF6 localization to the cleavage furrow and, later in cytokinesis, to the midbody ring.,MUTAGEN:RK->EE: Loss of localization to the plasma membrane during interphase and to the cleavage furrow during cytokinesis. No effect on ARF6 localization to the cleavage furrow and, later in cytokinesis, to the midbody ring.,REGION:Disordered,
PHLDA3	pleckstrin homology like domain family A member 3(PHLDA3)	Homo sapiens			GO:0009653~anatomical structure morphogenesis,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043065~positive regulation of apoptotic process,GO:0051898~negative regulation of protein kinase B signaling,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0010314~phosphatidylinositol-5-phosphate binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,	IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,					DOMAIN:PH,
PTN	pleiotrophin(PTN)	Homo sapiens			GO:0002232~leukocyte chemotaxis involved in inflammatory response,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0007185~transmembrane receptor protein tyrosine phosphatase signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007399~nervous system development,GO:0007406~negative regulation of neuroblast proliferation,GO:0007612~learning,GO:0007613~memory,GO:0008284~positive regulation of cell proliferation,GO:0010594~regulation of endothelial cell migration,GO:0010976~positive regulation of neuron projection development,GO:0010996~response to auditory stimulus,GO:0030282~bone mineralization,GO:0030501~positive regulation of bone mineralization,GO:0031104~dendrite regeneration,GO:0031641~regulation of myelination,GO:0042246~tissue regeneration,GO:0043113~receptor clustering,GO:0043932~ossification involved in bone remodeling,GO:0044849~estrous cycle,GO:0045778~positive regulation of ossification,GO:0046697~decidualization,GO:0048167~regulation of synaptic plasticity,GO:0048477~oogenesis,GO:0048680~positive regulation of axon regeneration,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0051781~positive regulation of cell division,GO:1900006~positive regulation of dendrite development,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1903706~regulation of hemopoiesis,GO:2000036~regulation of stem cell population maintenance,GO:2000347~positive regulation of hepatocyte proliferation,GO:2000738~positive regulation of stem cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0004864~protein phosphatase inhibitor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0019901~protein kinase binding,GO:0030246~carbohydrate binding,GO:0035374~chondroitin sulfate binding,	IPR000762:Midkine heparin-binding growth factor,IPR020089:Pleiotrophin/Midkine heparin-binding growth factor, N-terminal domain,IPR020090:Pleiotrophin/Midkine heparin-binding growth factor, C-terminal domain,IPR020091:Pleiotrophin/Midkine heparin-binding growth factor, disulphide-rich domain,IPR020092:Pleiotrophin/Midkine heparin-binding growth factor, conserved site,				SM00193:PTN,		KW-0964~Secreted,		KW-0732~Signal,		KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,	KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:Pleiotrophin/Midkine C-terminal,DOMAIN:Pleiotrophin/Midkine N-terminal,REGION:Chondroitin sulfate A binding,REGION:Chondroitin sulfate binding,REGION:Disordered,
PLXNA4	plexin A4(PLXNA4)	Homo sapiens			GO:0007162~negative regulation of cell adhesion,GO:0008360~regulation of cell shape,GO:0021612~facial nerve structural organization,GO:0021615~glossopharyngeal nerve morphogenesis,GO:0021637~trigeminal nerve structural organization,GO:0021644~vagus nerve morphogenesis,GO:0021784~postganglionic parasympathetic fiber development,GO:0021793~chemorepulsion of branchiomotor axon,GO:0021960~anterior commissure morphogenesis,GO:0030334~regulation of cell migration,GO:0035050~embryonic heart tube development,GO:0043087~regulation of GTPase activity,GO:0048485~sympathetic nervous system development,GO:0048841~regulation of axon extension involved in axon guidance,GO:0050772~positive regulation of axonogenesis,GO:0050923~regulation of negative chemotaxis,GO:0071526~semaphorin-plexin signaling pathway,GO:0097492~sympathetic neuron axon guidance,GO:0099558~maintenance of synapse structure,GO:1902287~semaphorin-plexin signaling pathway involved in axon guidance,	GO:0002116~semaphorin receptor complex,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0017154~semaphorin receptor activity,	IPR001627:Semaphorin/CD100 antigen,IPR002165:Plexin,IPR002909:Cell surface receptor IPT/TIG,IPR008936:Rho GTPase activation protein,IPR013548:Plexin, cytoplasmic RasGAP domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016201:Plexin-like fold,	hsa04360:Axon guidance,			SM00423:PSI,SM00429:IPT,SM00630:Sema,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IPT/TIG,DOMAIN:IPT/TIG 1,DOMAIN:IPT/TIG 2,DOMAIN:IPT/TIG 3,DOMAIN:IPT/TIG 4,DOMAIN:PSI,DOMAIN:PSI 1,DOMAIN:PSI 2,DOMAIN:PSI 3,DOMAIN:Sema,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PDPN	podoplanin(PDPN)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0001946~lymphangiogenesis,GO:0007266~Rho protein signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016477~cell migration,GO:0030168~platelet activation,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0043066~negative regulation of apoptotic process,GO:0044319~wound healing, spreading of cells,GO:0048535~lymph node development,GO:0051272~positive regulation of cellular component movement,GO:0055093~response to hyperoxia,GO:0060838~lymphatic endothelial cell fate commitment,GO:0070252~actin-mediated cell contraction,GO:0090091~positive regulation of extracellular matrix disassembly,GO:0098609~cell-cell adhesion,GO:1900024~regulation of substrate adhesion-dependent cell spreading,GO:1901731~positive regulation of platelet aggregation,GO:1904328~regulation of myofibroblast contraction,GO:2000392~regulation of lamellipodium morphogenesis,	GO:0001726~ruffle,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030175~filopodium,GO:0031258~lamellipodium membrane,GO:0031410~cytoplasmic vesicle,GO:0031527~filopodium membrane,GO:0031528~microvillus membrane,GO:0032587~ruffle membrane,GO:0042995~cell projection,GO:0045121~membrane raft,GO:0061851~leading edge of lamellipodium,GO:0070161~anchoring junction,GO:0097197~tetraspanin-enriched microdomain,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019956~chemokine binding,GO:0051087~chaperone binding,						KW-0133~Cell shape,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Pro residues,MUTAGEN:Missing: Prevents self-assembly and association to lipid rafts. Reduces the recruitment to invadopodium. Disrupts assembly into adhesion rings. Fails invadopodia-mediated ECM degradation.,MUTAGEN:R->N: Highly decreases interaction with the EZR and MSN. Induces an intermediate phenotype between epithelial and mesenchymal. Does not affect localization at cell surface protrusions. Induces reorganization of the actin cytoskeleton oncomitantly with the induced morphological changes. Increases cell migration individually. Increases invasiveness. Enhances RHOA activity. Colocalizes at cell-surface protrusions with RHOA and RAC1.,MUTAGEN:RK->QN: Impairs interaction with the EZR and MSN. Impairs epithelial to mesenchymal transition. Does not affect localization at cell surface protrusions. Does not induce reorganization of the actin cytoskeleton. Increases cell migration collectively.,MUTAGEN:RKMSGR->QNMGSN: Does not affect localization at cell surface protrusions. Does not induce reorganization of the actin cytoskeleton. Increases cell migration collectively. Does not significant change RHOA activation. No effect on interaction with CD44. Impairs interaction with the EZR and MSN. Impairs epithelial to mesenchymal transition. Does not change localization at invadopodium. Fails to assemble into rings. Fails invadopodia-mediated ECM degradation.,MUTAGEN:T->A: Eliminates induction of platelet aggregation.,PEPTIDE:29kDa cytosolic podoplanin intracellular domain,REGION:Disordered,REGION:Requires for dimerization and lipid rafts association,REGION:Requires for interaction with MSN and EZR,SITE:Cleavage; by gamma-secretase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PABPC1	poly(A) binding protein cytoplasmic 1(PABPC1)	Homo sapiens		h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,	GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000398~mRNA splicing, via spliceosome,GO:0006378~mRNA polyadenylation,GO:0031047~gene silencing by RNA,GO:0045070~positive regulation of viral genome replication,GO:0048255~mRNA stabilization,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0070934~CRD-mediated mRNA stabilization,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:2000623~negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0031252~cell leading edge,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0070062~extracellular exosome,GO:0071013~catalytic step 2 spliceosome,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0008143~poly(A) binding,GO:0008266~poly(U) RNA binding,GO:0008494~translation activator activity,	IPR000504:RNA recognition motif domain,IPR002004:Polyadenylate-binding protein/Hyperplastic disc protein,IPR003954:RNA recognition motif domain, eukaryote,IPR006515:Polyadenylate binding protein, human types 1, 2, 3, 4,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa03015:mRNA surveillance pathway,hsa03018:RNA degradation,			SM00360:RRM,SM00361:RRM_1,SM00517:PolyA,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0866~Nonsense-mediated mRNA decay,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PABC,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,MUTAGEN:R->A: Greatly reduces methylation by CARM1 (in vitro); when associated with A-455.,MUTAGEN:R->A: Greatly reduces methylation by CARM1 (in vitro); when associated with A-460.,REGION:(Microbial infection) Binding to HRSV M2-1 protein,REGION:CSDE1-binding,REGION:Disordered,
PKD2	polycystin 2, transient receptor potential cation channel(PKD2)	Homo sapiens			GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001889~liver development,GO:0001892~embryonic placenta development,GO:0001947~heart looping,GO:0003127~detection of nodal flow,GO:0006811~ion transport,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007259~JAK-STAT cascade,GO:0007368~determination of left/right symmetry,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0021510~spinal cord development,GO:0021915~neural tube development,GO:0031587~positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity,GO:0034614~cellular response to reactive oxygen species,GO:0035502~metanephric part of ureteric bud development,GO:0035725~sodium ion transmembrane transport,GO:0035904~aorta development,GO:0042127~regulation of cell proliferation,GO:0042994~cytoplasmic sequestering of transcription factor,GO:0044782~cilium organization,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050982~detection of mechanical stimulus,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051262~protein tetramerization,GO:0051289~protein homotetramerization,GO:0051290~protein heterotetramerization,GO:0051298~centrosome duplication,GO:0051649~establishment of localization in cell,GO:0051726~regulation of cell cycle,GO:0060315~negative regulation of ryanodine-sensitive calcium-release channel activity,GO:0060674~placenta blood vessel development,GO:0061333~renal tubule morphogenesis,GO:0061441~renal artery morphogenesis,GO:0070588~calcium ion transmembrane transport,GO:0071277~cellular response to calcium ion,GO:0071320~cellular response to cAMP,GO:0071464~cellular response to hydrostatic pressure,GO:0071470~cellular response to osmotic stress,GO:0071498~cellular response to fluid shear stress,GO:0071805~potassium ion transmembrane transport,GO:0071910~determination of liver left/right asymmetry,GO:0072075~metanephric mesenchyme development,GO:0072164~mesonephric tubule development,GO:0072177~mesonephric duct development,GO:0072208~metanephric smooth muscle tissue development,GO:0072214~metanephric cortex development,GO:0072218~metanephric ascending thin limb development,GO:0072219~metanephric cortical collecting duct development,GO:0072235~metanephric distal tubule development,GO:0072284~metanephric S-shaped body morphogenesis,GO:0090279~regulation of calcium ion import,GO:0098662~inorganic cation transmembrane transport,GO:0198738~cell-cell signaling by wnt,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0002133~polycystin complex,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005929~cilium,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030027~lamellipodium,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0031514~motile cilium,GO:0034703~cation channel complex,GO:0036064~ciliary basal body,GO:0042995~cell projection,GO:0045180~basal cortex,GO:0060170~ciliary membrane,GO:0070062~extracellular exosome,GO:0071458~integral component of cytoplasmic side of endoplasmic reticulum membrane,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,GO:0072686~mitotic spindle,GO:0097730~non-motile cilium,GO:0098553~lumenal side of endoplasmic reticulum membrane,GO:0098554~cytoplasmic side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005244~voltage-gated ion channel activity,GO:0005245~voltage-gated calcium channel activity,GO:0005248~voltage-gated sodium channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0005267~potassium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0015271~outward rectifier potassium channel activity,GO:0022843~voltage-gated cation channel activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042805~actinin binding,GO:0043398~HLH domain binding,GO:0044325~ion channel binding,GO:0048763~calcium-induced calcium release activity,GO:0051117~ATPase binding,GO:0051219~phosphoprotein binding,GO:0051371~muscle alpha-actinin binding,	IPR002048:EF-hand domain,IPR003915:Polycystic kidney disease type 2 protein,IPR011992:EF-hand-like domain,IPR013122:Polycystin cation channel, PKD1/PKD2,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,		613095~Polycystic kidney disease 2,			KW-0109~Calcium transport,KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,KW-0879~Wnt signaling pathway,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0630~Potassium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:Polycystin,DOMAIN:Polycystin cation channel PKD1/PKD2,INTRAMEM:Pore-forming,MOTIF:Selectivity filter,MUTAGEN:DDD->AAA: Strongly decreases interaction with PACS1 and enhances expression at the cell membrane.,MUTAGEN:E->A: Loss of calcium-binding site; when associated with A-771.,MUTAGEN:E->Q: Abolishes calcium binding via the EF-hand.,MUTAGEN:F->A,I: No effect on channel activation.,MUTAGEN:F->P: Gain-of-function mutation resulting in increased channel activity. Absence of gain of function; when associated with F-605 DEL; when associated with A-201; when associated with V-511; when associated with G-414; when associated with G-420; when associated with Y-684 DEL; when associated with A-684. Increased channel activity; when associated with 736-L-N-737 DEL.,MUTAGEN:I->A: Abolishes oligomerization and interaction with PKD1; when associated with A-842; A-846; A-849; A-863 and A-867.,MUTAGEN:I->K: Loss of protein solubility.,MUTAGEN:I->P: Loss of protein solubility.,MUTAGEN:K->A: Abolishes increased channel activity due to a gain of function mutation; when associated with P-604.,MUTAGEN:L->A: Abolishes oligomerization and interaction with PKD1; when associated with A-842; A-846; A-849; A-860 and A-863.,MUTAGEN:L->A: Abolishes oligomerization and interaction with PKD1; when associated with A-846; A-849; A-860; A-863 and A-867.,MUTAGEN:L->N: Gain of function mutation.,MUTAGEN:L->P: Loss of protein solubility.,MUTAGEN:M->A: Abolishes oligomerization and interaction with PKD1; when associated with A-842; A-846; A-860; A-863 and A-867.,MUTAGEN:M->K: Loss of protein solubility.,MUTAGEN:Missing: Abolishes increased channel activity due to a gain of function mutation; when associated with P-604.,MUTAGEN:Missing: Increased channel activity; when associated with P-604.,MUTAGEN:Q->G: Strongly increases calcium binding affinity.,MUTAGEN:S->A: Abolishes increased channel opening in response to cAMP and phosphorylation by PKA.,MUTAGEN:S->A: Abolishes phosphorylation of the N-terminal domain. Abolishes the ability to complement a pkd2-deficient zebrafish mutant; when associated with A-80.,MUTAGEN:S->A: Decreases interaction with PACS1 and enhances expression at the cell membrane. Decreases phosphorylation; when associated with A-721; A-801; A-831 and A-943.,MUTAGEN:S->A: Decreases phosphorylation of the N-terminal domain. Abolishes the ability to complement a pkd2-deficient zebrafish mutant; when associated with A-76.,MUTAGEN:S->A: Decreases phosphorylation; when associated with A-721; A-801; A-812 and A-831.,MUTAGEN:S->A: Decreases phosphorylation; when associated with A-721; A-801; A-812 and A-943.,MUTAGEN:S->A: Decreases phosphorylation; when associated with A-721; A-812; A-831 and A-943.,MUTAGEN:S->D: No effect on interaction with PACS1.,MUTAGEN:S->D: Phosphomimetic mutant. No effect on release of Ca(2+) stores from the endoplasmic reticulum.,MUTAGEN:S->G: Loss of phosphorylation at this site. Impairs release of Ca(2+) stores from the endoplasmic reticulum.,MUTAGEN:S->N: Loss of phosphorylation at Ser-801.,MUTAGEN:T->A: Decreases phosphorylation; when associated with A-801; A-812; A-831 and A-943.,MUTAGEN:T->A: Loss of calcium-binding site; when associated with A-774.,MUTAGEN:V->A: Abolishes oligomerization and interaction with PKD1; when associated with A-842; A-846; A-849; A-860 and A-867.,MUTAGEN:V->A: Abolishes oligomerization and interaction with PKD1; when associated with A-842; A-849; A-860; A-863 and A-867.,MUTAGEN:V->E: Loss of protein solubility.,MUTAGEN:V->E: Loss of protein solubility; when associated with K-849.,MUTAGEN:W->A: Abolishes increased channel activity due to a gain of function mutation; when associated with P-604.,MUTAGEN:Y->A: Abolishes increased channel activity due to a gain of function mutation; when associated with P-604.,REGION:Disordered,REGION:Important for interaction with PACS1 and PACS2,REGION:Linker,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=S1,TRANSMEM:Helical; Name=S2,TRANSMEM:Helical; Name=S3,TRANSMEM:Helical; Name=S4,TRANSMEM:Helical; Name=S6,
GALNT13	polypeptide N-acetylgalactosaminyltransferase 13(GALNT13)	Homo sapiens			GO:0006493~protein O-linked glycosylation,GO:0016266~O-glycan processing,GO:0018242~protein O-linked glycosylation via serine,GO:0018243~protein O-linked glycosylation via threonine,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0004653~polypeptide N-acetylgalactosaminyltransferase activity,GO:0016740~transferase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000772:Ricin B lectin domain,IPR001173:Glycosyl transferase, family 2,	hsa00512:Mucin type O-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,			SM00458:RICIN,		KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glycosyltransferase 2-like,DOMAIN:Ricin B lectin,DOMAIN:Ricin B-type lectin,REGION:Catalytic subdomain A,REGION:Catalytic subdomain B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GALNT5	polypeptide N-acetylgalactosaminyltransferase 5(GALNT5)	Homo sapiens			GO:0006024~glycosaminoglycan biosynthetic process,GO:0006493~protein O-linked glycosylation,GO:0016266~O-glycan processing,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0004653~polypeptide N-acetylgalactosaminyltransferase activity,GO:0016740~transferase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000772:Ricin B lectin domain,IPR001173:Glycosyl transferase, family 2,	hsa00512:Mucin type O-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,			SM00458:RICIN,		KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ricin B lectin,DOMAIN:Ricin B-type lectin,REGION:Catalytic subdomain A,REGION:Catalytic subdomain B,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
KCNMA1	potassium calcium-activated channel subfamily M alpha 1(KCNMA1)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006813~potassium ion transport,GO:0006970~response to osmotic stress,GO:0030007~cellular potassium ion homeostasis,GO:0034465~response to carbon monoxide,GO:0034765~regulation of ion transmembrane transport,GO:0042311~vasodilation,GO:0042391~regulation of membrane potential,GO:0043065~positive regulation of apoptotic process,GO:0045794~negative regulation of cell volume,GO:0051592~response to calcium ion,GO:0060073~micturition,GO:0060083~smooth muscle contraction involved in micturition,GO:0060087~relaxation of vascular smooth muscle,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005901~caveola,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0045211~postsynaptic membrane,	GO:0003779~actin binding,GO:0005249~voltage-gated potassium channel activity,GO:0005515~protein binding,GO:0015269~calcium-activated potassium channel activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0060072~large conductance calcium-activated potassium channel activity,	IPR003148:Regulator of K+ conductance, N-terminal,IPR003929:Potassium channel, calcium-activated, BK, alpha subunit,IPR005821:Ion transport domain,IPR013099:Ion transport 2,IPR024939:Calcium-activated potassium channel Slo,	hsa04022:cGMP-PKG signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04911:Insulin secretion,hsa04924:Renin secretion,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,	609446~Paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy,617643~Cerebellar atrophy, developmental delay, and seizures,618596~Epilepsy, idiopathic generalized, susceptibility to, 16,618729~Liang-Wang syndrome,			KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Calcium-activated potassium channel BK alpha subunit,DOMAIN:Ion transport,DOMAIN:Potassium channel,DOMAIN:RCK N-terminal,INTRAMEM:Pore-forming; Name=P region,LIPID:S-palmitoyl cysteine,MOTIF:Calcium bowl,MOTIF:Selectivity for potassium,MUTAGEN:A->S: Activated at more negative voltages. No effect on inhibition by HMIMP.,MUTAGEN:C->A: Decreased localization to the plasma membrane. Abolishes localization to the plasma membrane; when associated with A-118 and A-121.,MUTAGEN:C->A: Decreased localization to the plasma membrane. Abolishes localization to the plasma membrane; when associated with A-119 and A-121.,MUTAGEN:C->S: Loss of heme-induced channel inhibition.,MUTAGEN:E->K: No effect in the coupling between calcium and channel opening.,MUTAGEN:F->A: Loss of function.,MUTAGEN:GYG->AAA: Loss of function.,MUTAGEN:H->R: Loss of heme-induced channel inhibition.,MUTAGEN:L->R,H: No effect in the coupling between calcium and channel opening.,MUTAGEN:Q->R: No effect in the coupling between calcium and channel opening.,MUTAGEN:R->E: Induces reduction in the coupling between calcium and channel opening.,MUTAGEN:R->N: Induces reduction in the coupling between calcium and channel opening.,MUTAGEN:R->Q: Induces reduction in the coupling between calcium and channel opening.,MUTAGEN:T->S: Activated at more negative voltages. Slower rate of inactivation. Impaired inhibition by HMIMP. No effect on channel inhibition by Iberiotoxin.,MUTAGEN:V->I: No effect on activation voltage. No effect on inhibition by HMIMP.,REGION:Disordered,REGION:Heme-binding motif,REGION:Segment S10,REGION:Segment S7,REGION:Segment S8,REGION:Segment S9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S0,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S4,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,
KCNIP4	potassium voltage-gated channel interacting protein 4(KCNIP4)	Homo sapiens			GO:0071805~potassium ion transmembrane transport,GO:0072659~protein localization to plasma membrane,GO:1901379~regulation of potassium ion transmembrane transport,	GO:0005737~cytoplasm,GO:0005777~peroxisome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0030425~dendrite,GO:0043025~neuronal cell body,	GO:0005244~voltage-gated ion channel activity,GO:0005267~potassium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0576~Peroxisome,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1; degenerate,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,REGION:Disordered,REGION:Interaction with KCND2,REGION:KIS,
KCNS1	potassium voltage-gated channel modifier subfamily S member 1(KCNS1)	Homo sapiens			GO:0006813~potassium ion transport,GO:0051260~protein homooligomerization,GO:0071805~potassium ion transmembrane transport,GO:1902259~regulation of delayed rectifier potassium channel activity,	GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003971:Potassium channel, voltage dependent, Kv9,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,				SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,		COMPBIAS:Polar residues,DOMAIN:BTB,INTRAMEM:Helical; Name=Pore helix,MOTIF:Selectivity filter,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNA3	potassium voltage-gated channel subfamily A member 3(KCNA3)	Homo sapiens		h_bArr-mapkPathway:Role of -arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of -arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bArrestinPathway:-arrestins in GPCR Desensitization,	GO:0006813~potassium ion transport,GO:0021554~optic nerve development,GO:0022038~corpus callosum development,GO:0034765~regulation of ion transmembrane transport,GO:0051260~protein homooligomerization,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0042734~presynaptic membrane,GO:0044305~calyx of Held,GO:0045121~membrane raft,GO:0045211~postsynaptic membrane,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0005244~voltage-gated ion channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0015271~outward rectifier potassium channel activity,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003972:Potassium channel, voltage dependent, Kv1,IPR004050:Potassium channel, voltage dependent, Kv1.3,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,				SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BTB,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MOTIF:Selectivity filter,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNA5	potassium voltage-gated channel subfamily A member 5(KCNA5)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006813~potassium ion transport,GO:0007219~Notch signaling pathway,GO:0009612~response to mechanical stimulus,GO:0010033~response to organic substance,GO:0019229~regulation of vasoconstriction,GO:0034765~regulation of ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0042542~response to hydrogen peroxide,GO:0043266~regulation of potassium ion transport,GO:0050796~regulation of insulin secretion,GO:0051260~protein homooligomerization,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0055075~potassium ion homeostasis,GO:0055093~response to hyperoxia,GO:0060081~membrane hyperpolarization,GO:0060372~regulation of atrial cardiac muscle cell membrane repolarization,GO:0071805~potassium ion transmembrane transport,GO:0086014~atrial cardiac muscle cell action potential,GO:0086050~membrane repolarization during bundle of His cell action potential,GO:0086052~membrane repolarization during SA node cell action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:0097623~potassium ion export across plasma membrane,GO:0098914~membrane repolarization during atrial cardiac muscle cell action potential,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:2000288~positive regulation of myoblast proliferation,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0008076~voltage-gated potassium channel complex,GO:0009986~cell surface,GO:0014704~intercalated disc,GO:0016021~integral component of membrane,GO:0030018~Z disc,GO:0034705~potassium channel complex,GO:0045121~membrane raft,GO:0046691~intracellular canaliculus,GO:0048471~perinuclear region of cytoplasm,	GO:0005102~receptor binding,GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0015271~outward rectifier potassium channel activity,GO:0019901~protein kinase binding,GO:0051393~alpha-actinin binding,GO:0086087~voltage-gated potassium channel activity involved in bundle of His cell action potential repolarization,GO:0086089~voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization,GO:0086090~voltage-gated potassium channel activity involved in SA node cell action potential repolarization,GO:0097110~scaffold protein binding,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003972:Potassium channel, voltage dependent, Kv1,IPR004052:Potassium channel, voltage dependent, Kv1.5,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,		612240~Atrial fibrillation, familial, 7,		SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-1020~Atrial fibrillation,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),INTRAMEM:Helical; Name=Pore helix,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MOTIF:Selectivity filter,MUTAGEN:I->N: Reduces sumoylation; when associated with N-535.,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-221.,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-536.,MUTAGEN:L->N: Reduces sumoylation; when associated with N-220.,MUTAGEN:T->A: Loss of DLG1 effect on channel current.,REGION:2 X 11 AA tandem repeat of D-[SP]-G-V-R-P-L-P-P-L-P,REGION:Disordered,REGION:S4-S5 linker,REPEAT:1,REPEAT:2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNE3	potassium voltage-gated channel subfamily E regulatory subunit 3(KCNE3)	Homo sapiens			GO:0006814~sodium ion transport,GO:0030644~cellular chloride ion homeostasis,GO:0060307~regulation of ventricular cardiac muscle cell membrane repolarization,GO:0086005~ventricular cardiac muscle cell action potential,GO:0086011~membrane repolarization during action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:0097623~potassium ion export across plasma membrane,GO:0098915~membrane repolarization during ventricular cardiac muscle cell action potential,GO:1902260~negative regulation of delayed rectifier potassium channel activity,GO:1903765~negative regulation of potassium ion export across plasma membrane,GO:1903817~negative regulation of voltage-gated potassium channel activity,GO:1905025~negative regulation of membrane repolarization during ventricular cardiac muscle cell action potential,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0031982~vesicle,GO:0032809~neuronal cell body membrane,GO:0043204~perikaryon,GO:0045121~membrane raft,GO:1990794~basolateral part of cell,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0044325~ion channel binding,GO:1902282~voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization,	IPR000369:Potassium channel, voltage-dependent, beta subunit, KCNE,IPR005426:Potassium channel, voltage-dependent, beta subunit, KCNE3,	hsa04974:Protein digestion and absorption,	613119~Brugada syndrome 6,			KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0992~Brugada syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->N: Decreases current 4-fold in KCNH2/KCNE3 channel.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
KCNH5	potassium voltage-gated channel subfamily H member 5(KCNH5)	Homo sapiens			GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0034765~regulation of ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0005249~voltage-gated potassium channel activity,GO:0005516~calmodulin binding,GO:0044325~ion channel binding,GO:0044877~macromolecular complex binding,	IPR000014:PAS domain,IPR000595:Cyclic nucleotide-binding domain,IPR000700:PAS-associated, C-terminal,IPR001610:PAC motif,IPR003938:Potassium channel, voltage-dependent, EAG/ELK/ERG,IPR003949:Potassium channel, voltage-dependent, EAG,IPR005821:Ion transport domain,IPR014710:RmlC-like jelly roll fold,IPR018490:Cyclic nucleotide-binding-like,				SM00086:PAC,SM00100:cNMP,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0112~Calmodulin-binding,KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:PAC,DOMAIN:PAS,INTRAMEM:Pore-forming; Name=Segment H5,MOTIF:Selectivity filter,REGION:CAD (involved in subunit assembly),REGION:Calmodulin-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNH8	potassium voltage-gated channel subfamily H member 8(KCNH8)	Homo sapiens			GO:0034765~regulation of ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005249~voltage-gated potassium channel activity,	IPR000014:PAS domain,IPR000595:Cyclic nucleotide-binding domain,IPR000700:PAS-associated, C-terminal,IPR001610:PAC motif,IPR003938:Potassium channel, voltage-dependent, EAG/ELK/ERG,IPR003950:Potassium channel, voltage-dependent, ELK,IPR005821:Ion transport domain,IPR014710:RmlC-like jelly roll fold,IPR018490:Cyclic nucleotide-binding-like,				SM00086:PAC,SM00100:cNMP,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:PAC,DOMAIN:PAS,INTRAMEM:Pore-forming; Name=Segment H5,MOTIF:Selectivity filter,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
PFDN4	prefoldin subunit 4(PFDN4)	Homo sapiens			GO:0006457~protein folding,GO:0061077~chaperone-mediated protein folding,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0016272~prefoldin complex,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR002777:Prefoldin beta-like,IPR009053:Prefoldin,IPR016661:Prefoldin, subunit 4,			PIRSF016477:prefoldin, subunit 4,			KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
PENK	proenkephalin(PENK)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0001662~behavioral fear response,GO:0001666~response to hypoxia,GO:0001964~startle response,GO:0002118~aggressive behavior,GO:0007165~signal transduction,GO:0007218~neuropeptide signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0007600~sensory perception,GO:0009314~response to radiation,GO:0009636~response to toxic substance,GO:0014009~glial cell proliferation,GO:0019233~sensory perception of pain,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0034599~cellular response to oxidative stress,GO:0035094~response to nicotine,GO:0035641~locomotory exploration behavior,GO:0043278~response to morphine,GO:0045471~response to ethanol,GO:0051592~response to calcium ion,GO:0051867~general adaptation syndrome, behavioral process,GO:0071305~cellular response to vitamin D,GO:0071320~cellular response to cAMP,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071871~response to epinephrine,GO:0098586~cellular response to virus,GO:0099538~synaptic signaling via neuropeptide,GO:2000987~positive regulation of behavioral fear response,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0030425~dendrite,GO:0032280~symmetric synapse,GO:0034466~chromaffin granule lumen,GO:0034592~synaptic vesicle lumen,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0043679~axon terminus,GO:0070852~cell body fiber,GO:0099013~neuronal dense core vesicle lumen,	GO:0001515~opioid peptide activity,GO:0005184~neuropeptide hormone activity,GO:0031628~opioid receptor binding,	IPR000703:Proenkephalin A,IPR006024:Opioid neuropeptide precursor,	hsa04080:Neuroactive ligand-receptor interaction,					KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0257~Endorphin,KW-0527~Neuropeptide,KW-0555~Opioid peptide,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,PEPTIDE:Leu-enkephalin,PEPTIDE:Met-enkephalin,PEPTIDE:Met-enkephalin-Arg-Gly-Leu,PEPTIDE:Met-enkephalin-Arg-Phe,PEPTIDE:PENK(114-133),PEPTIDE:PENK(143-183),PEPTIDE:PENK(237-258),PEPTIDE:Synenkephalin,REGION:Disordered,SITE:Cleavage; by CTSL,
PDCD1	programmed cell death 1(PDCD1)	Homo sapiens			GO:0001783~B cell apoptotic process,GO:0002250~adaptive immune response,GO:0002644~negative regulation of tolerance induction,GO:0002903~negative regulation of B cell apoptotic process,GO:0006915~apoptotic process,GO:0006959~humoral immune response,GO:0007275~multicellular organism development,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0050776~regulation of immune response,GO:0050777~negative regulation of immune response,GO:0070234~positive regulation of T cell apoptotic process,GO:1902482~regulatory T cell apoptotic process,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,hsa04660:T cell receptor signaling pathway,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	126200~Multiple sclerosis, disease progression, modifier of,605218~Systemic lupus erythematosus, susceptibility to, 2,		SM00406:IGv,SM00409:IG,	KW-0053~Apoptosis,KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0772~Systemic lupus erythematosus,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ig-like,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,MOTIF:ITIM motif,MOTIF:ITSM motif,MUTAGEN:K->R: Abolishes ubiquitination by the SCF(FBXO38) complex.,MUTAGEN:K->R: Does not affect ubiquitination by the SCF(FBXO38) complex.,MUTAGEN:N->A: Decreased N-glycosylation without affecting binding to binding to nivolumab drug.,REGION:Disordered,REGION:Interaction with CD274/PDCD1L1,REGION:Nivolumab binding,REGION:Pembrolizumab binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PROKR2	prokineticin receptor 2(PROKR2)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007623~circadian rhythm,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004983~neuropeptide Y receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000611:Neuropeptide Y receptor family,IPR017452:GPCR, rhodopsin-like, 7TM,		244200~Hypogonadotropic hypogonadism 3 with or without anosmia,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1016~Hypogonadotropic hypogonadism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PRLR	prolactin receptor(PRLR)	Homo sapiens			GO:0006694~steroid biosynthetic process,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007259~JAK-STAT cascade,GO:0007566~embryo implantation,GO:0007595~lactation,GO:0008284~positive regulation of cell proliferation,GO:0009617~response to bacterium,GO:0019221~cytokine-mediated signaling pathway,GO:0030155~regulation of cell adhesion,GO:0030856~regulation of epithelial cell differentiation,GO:0030890~positive regulation of B cell proliferation,GO:0031954~positive regulation of protein autophosphorylation,GO:0038161~prolactin signaling pathway,GO:0038165~oncostatin-M-mediated signaling pathway,GO:0042976~activation of Janus kinase activity,GO:0043066~negative regulation of apoptotic process,GO:0060644~mammary gland epithelial cell differentiation,GO:0060736~prostate gland growth,GO:0060749~mammary gland alveolus development,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031904~endosome lumen,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004923~leukemia inhibitory factor receptor activity,GO:0004925~prolactin receptor activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0017046~peptide hormone binding,GO:0019901~protein kinase binding,GO:0019955~cytokine binding,GO:0046872~metal ion binding,	IPR003528:Long hematopoietin receptor, single chain, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015152:Growth hormone/erythropoietin receptor, ligand binding,	hsa04060:Cytokine-cytokine receptor interaction,hsa04080:Neuroactive ligand-receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04917:Prolactin signaling pathway,	615554~Multiple fibroadenomas of the breast,615555~Hyperprolactinemia,		SM00060:FN3,		KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Growth hormone/erythropoietin receptor ligand binding,MOTIF:Box 1 motif,MOTIF:WSXWS motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PRLHR	prolactin releasing hormone receptor(PRLHR)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007565~female pregnancy,GO:0007631~feeding behavior,GO:0042445~hormone metabolic process,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005929~cilium,GO:0016021~integral component of membrane,GO:0043005~neuron projection,	GO:0004930~G-protein coupled receptor activity,GO:0004983~neuropeptide Y receptor activity,GO:0005515~protein binding,GO:0008188~neuropeptide receptor activity,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001402:Prolactin-releasing peptide receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:I->A: Abolishes binding to GRIP1.,MUTAGEN:Missing: Abolishes binding to GRIP1 and PICK1.,MUTAGEN:S->A: Abolishes binding to GRIP1.,MUTAGEN:T->A: No effect on binding to GRIP1.,MUTAGEN:V->A: Abolishes binding to GRIP1.,MUTAGEN:V->A: No effect on binding to GRIP1.,REGION:Required for interaction with GRIP1, GRIP2 and PICK1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PRR14	proline rich 14(PRR14)	Homo sapiens			GO:0007517~muscle organ development,	GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005694~chromosome,	GO:0005515~protein binding,	IPR026320:Proline-rich protein 14,					KW-0517~Myogenesis,	KW-0158~Chromosome,KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Tantalus-like,MUTAGEN:E->K: Increased binding to GRB2 and enhanced cell proliferation.,MUTAGEN:S->C: Increased binding to GRB2 and enhanced cell proliferation.,MUTAGEN:VV->AA: Loss of heterochromatin association. Loss of interaction with CBX5.,MUTAGEN:VV->EE: Loss of heterochromatin association during interphase and loss of chromatin association during anaphase.,REGION:Disordered,REGION:Required for nuclear lamina association,REGION:Required for nuclear localization,REGION:Required for the interaction with GRB2 and sufficient to promote the phosphorylation of AKT and cell proliferation,REGION:Sufficient for heterochromatin association in interphase and chromatin association in anaphase,
PRAP1	proline rich acidic protein 1(PRAP1)	Homo sapiens			GO:0006974~cellular response to DNA damage stimulus,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0043066~negative regulation of apoptotic process,GO:0071481~cellular response to X-ray,GO:1902426~deactivation of mitotic spindle assembly checkpoint,GO:1904731~positive regulation of intestinal lipid absorption,GO:1905885~positive regulation of triglyceride transport,GO:2001140~positive regulation of phospholipid transport,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,GO:0017129~triglyceride binding,		hsa04140:Autophagy - animal,					KW-0256~Endoplasmic reticulum,KW-0964~Secreted,		KW-0732~Signal,	KW-0446~Lipid-binding,			COMPBIAS:Basic and acidic residues,REGION:Disordered,
P4HA3	prolyl 4-hydroxylase subunit alpha 3(P4HA3)	Homo sapiens			GO:0018401~peptidyl-proline hydroxylation to 4-hydroxy-L-proline,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,	GO:0004656~procollagen-proline 4-dioxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0031418~L-ascorbic acid binding,	IPR005123:Oxoglutarate/iron-dependent dioxygenase,IPR006620:Prolyl 4-hydroxylase, alpha subunit,IPR011990:Tetratricopeptide-like helical,IPR013547:Prolyl 4-hydroxylase alpha-subunit, N-terminal,	hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,			SM00702:P4Hc,		KW-0256~Endoplasmic reticulum,		KW-0175~Coiled coil,KW-0732~Signal,KW-0802~TPR repeat,	KW-0408~Iron,KW-0479~Metal-binding,KW-0847~Vitamin C,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fe2OG dioxygenase,DOMAIN:Prolyl 4-hydroxylase alpha-subunit N-terminal,REPEAT:TPR,
PROM1	prominin 1(PROM1)	Homo sapiens			GO:0010842~retina layer formation,GO:0045494~photoreceptor cell maintenance,GO:0060042~retina morphogenesis in camera-type eye,GO:0060219~camera-type eye photoreceptor cell differentiation,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0072139~glomerular parietal epithelial cell differentiation,GO:2000768~positive regulation of nephron tubule epithelial cell differentiation,	GO:0001750~photoreceptor outer segment,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005902~microvillus,GO:0005929~cilium,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031528~microvillus membrane,GO:0031982~vesicle,GO:0042622~photoreceptor outer segment membrane,GO:0070062~extracellular exosome,GO:0071914~prominosome,	GO:0005515~protein binding,GO:0015485~cholesterol binding,GO:0042805~actinin binding,GO:0045296~cadherin binding,	IPR008795:Prominin,	hsa05202:Transcriptional misregulation in cancer,	603786~Stargardt disease 4,608051~Macular dystrophy, retinal, 2,612095~Retinitis pigmentosa 41,612657~Cone-rod dystrophy 12,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,KW-0751~Stargardt disease,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:K->Q: Loss of acetylation; when associated with Q-225 and Q-257.,MUTAGEN:K->Q: Loss of acetylation; when associated with Q-225 and Q-264.,MUTAGEN:K->Q: Loss of acetylation; when associated with Q-257 and Q-264.,MUTAGEN:K->R: Loss of expression of the protein in part due to proteasomal degradation; when associated with Q-225 and Q-257.,MUTAGEN:K->R: Loss of expression of the protein in part due to proteasomal degradation; when associated with Q-225 and Q-264.,MUTAGEN:K->R: Loss of expression of the protein in part due to proteasomal degradation; when associated with Q-257 and Q-264.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
POMC	proopiomelanocortin(POMC)	Homo sapiens	110.CRHandLC-NA,		GO:0006091~generation of precursor metabolites and energy,GO:0007165~signal transduction,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0008217~regulation of blood pressure,GO:0019722~calcium-mediated signaling,GO:0031640~killing of cells of other organism,GO:0032098~regulation of appetite,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033059~cellular pigmentation,GO:0035821~modification of morphology or physiology of other organism,GO:0042593~glucose homeostasis,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070873~regulation of glycogen metabolic process,GO:0070965~positive regulation of neutrophil mediated killing of fungus,GO:1990680~response to melanocyte-stimulating hormone,GO:2000852~regulation of corticosterone secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005782~peroxisomal matrix,GO:0030141~secretory granule,GO:0034774~secretory granule lumen,	GO:0001664~G-protein coupled receptor binding,GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0031781~type 3 melanocortin receptor binding,GO:0031782~type 4 melanocortin receptor binding,GO:0070996~type 1 melanocortin receptor binding,	IPR001941:Pro-opiomelanocortin/corticotropin, ACTH,IPR013531:Pro-opiomelanocortin/corticotropin, ACTH, central region,IPR013532:Opiodes neuropeptide,IPR013593:Pro-opiomelanocortin N-terminal,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04920:Adipocytokine signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04934:Cushing syndrome,	601665~Obesity, early-onset, susceptibility to,609734~Obesity, adrenal insufficiency, and red hair due to POMC deficiency,		SM01363:SM01363,SM01364:SM01364,SM01365:SM01365,		KW-0964~Secreted,	KW-0550~Obesity,	KW-0732~Signal,		KW-0257~Endorphin,KW-0372~Hormone,	KW-0007~Acetylation,KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (HexNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Opiodes neuropeptide,DOMAIN:Pro-opiomelanocortin N-terminal,DOMAIN:Pro-opiomelanocortin/corticotropin ACTH central region,PEPTIDE:Beta-endorphin,PEPTIDE:Corticotropin,PEPTIDE:Corticotropin-like intermediary peptide,PEPTIDE:Lipotropin beta,PEPTIDE:Lipotropin gamma,PEPTIDE:Melanocyte-stimulating hormone alpha,PEPTIDE:Melanocyte-stimulating hormone beta,PEPTIDE:Melanotropin gamma,PEPTIDE:Met-enkephalin,PEPTIDE:NPP,PEPTIDE:Potential peptide,REGION:Disordered,
PCSK1	proprotein convertase subtilisin/kexin type 1(PCSK1)	Homo sapiens			GO:0006508~proteolysis,GO:0007267~cell-cell signaling,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0010157~response to chlorate,GO:0016485~protein processing,GO:0016486~peptide hormone processing,GO:0016540~protein autoprocessing,GO:0021983~pituitary gland development,GO:0022008~neurogenesis,GO:0030070~insulin processing,GO:0031016~pancreas development,GO:0031667~response to nutrient levels,GO:0032496~response to lipopolysaccharide,GO:0043043~peptide biosynthetic process,GO:0043278~response to morphine,GO:0043434~response to peptide hormone,GO:0048678~response to axon injury,GO:0050714~positive regulation of protein secretion,GO:0051384~response to glucocorticoid,GO:0051592~response to calcium ion,GO:0070542~response to fatty acid,GO:0070555~response to interleukin-1,	GO:0005615~extracellular space,GO:0005791~rough endoplasmic reticulum,GO:0005802~trans-Golgi network,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030425~dendrite,GO:0034774~secretory granule lumen,GO:0043005~neuron projection,GO:0043204~perikaryon,GO:0043679~axon terminus,GO:0048471~perinuclear region of cytoplasm,	GO:0004252~serine-type endopeptidase activity,GO:0042802~identical protein binding,	IPR000209:Peptidase S8/S53 domain,IPR002884:Proprotein convertase, P,IPR008979:Galactose-binding domain-like,IPR015500:Peptidase S8, subtilisin-related,IPR022005:Prohormone convertase enzyme,IPR022398:Peptidase S8, subtilisin, His-active site,IPR023827:Peptidase S8, subtilisin,  Asp-active site,IPR023828:Peptidase S8, subtilisin, Ser-active site,		600955~Endocrinopathy due to proprotein convertase 1/3 deficiency,612362~Obesity, susceptibility to, BMIQ12,				KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0550~Obesity,	KW-0732~Signal,	KW-0106~Calcium,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:P/Homo B,DOMAIN:Peptidase S8,DOMAIN:Peptidase S8 pro-domain,REGION:Disordered,
PTGDR	prostaglandin D2 receptor(PTGDR)	Homo sapiens			GO:0006954~inflammatory response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0030238~male sex determination,GO:0030431~sleep,GO:0043303~mast cell degranulation,GO:0046085~adenosine metabolic process,GO:0071799~cellular response to prostaglandin D stimulus,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0001785~prostaglandin J receptor activity,GO:0004956~prostaglandin D receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000376:Prostaglandin D receptor,IPR008365:Prostanoid receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,	607277~Asthma, susceptibility to, 1,			KW-0467~Mast cell degranulation,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-1058~Asthma,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PTGS2	prostaglandin-endoperoxide synthase 2(PTGS2)	Homo sapiens		h_acetaminophenPathway:Mechanism of Acetaminophen Activity and Toxicity,h_eicosanoidPathway:Eicosanoid Metabolism,	GO:0001516~prostaglandin biosynthetic process,GO:0001525~angiogenesis,GO:0006954~inflammatory response,GO:0006979~response to oxidative stress,GO:0007566~embryo implantation,GO:0007568~aging,GO:0007612~learning,GO:0007613~memory,GO:0008217~regulation of blood pressure,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009624~response to nematode,GO:0009750~response to fructose,GO:0010042~response to manganese ion,GO:0010226~response to lithium ion,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0019233~sensory perception of pain,GO:0019371~cyclooxygenase pathway,GO:0030282~bone mineralization,GO:0030728~ovulation,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0031622~positive regulation of fever generation,GO:0031915~positive regulation of synaptic plasticity,GO:0032227~negative regulation of synaptic transmission, dopaminergic,GO:0032310~prostaglandin secretion,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033280~response to vitamin D,GO:0034605~cellular response to heat,GO:0034612~response to tumor necrosis factor,GO:0034644~cellular response to UV,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042307~positive regulation of protein import into nucleus,GO:0042633~hair cycle,GO:0043065~positive regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045786~negative regulation of cell cycle,GO:0045907~positive regulation of vasoconstriction,GO:0045986~negative regulation of smooth muscle contraction,GO:0045987~positive regulation of smooth muscle contraction,GO:0046697~decidualization,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050727~regulation of inflammatory response,GO:0050873~brown fat cell differentiation,GO:0051384~response to glucocorticoid,GO:0051926~negative regulation of calcium ion transport,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0070542~response to fatty acid,GO:0071260~cellular response to mechanical stimulus,GO:0071284~cellular response to lead ion,GO:0071318~cellular response to ATP,GO:0071456~cellular response to hypoxia,GO:0071471~cellular response to non-ionic osmotic stress,GO:0071498~cellular response to fluid shear stress,GO:0071636~positive regulation of transforming growth factor beta production,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090271~positive regulation of fibroblast growth factor production,GO:0090336~positive regulation of brown fat cell differentiation,GO:0090362~positive regulation of platelet-derived growth factor production,GO:0098869~cellular oxidant detoxification,GO:1902219~negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress,GO:1990776~response to angiotensin,	GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005901~caveola,GO:0032991~macromolecular complex,GO:0043005~neuron projection,	GO:0004601~peroxidase activity,GO:0004666~prostaglandin-endoperoxide synthase activity,GO:0005515~protein binding,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0051213~dioxygenase activity,	IPR000742:Epidermal growth factor-like domain,IPR010255:Haem peroxidase,IPR019791:Haem peroxidase, animal, subgroup,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,hsa04064:NF-kappa B signaling pathway,hsa04370:VEGF signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04723:Retrograde endocannabinoid signaling,hsa04726:Serotonergic synapse,hsa04913:Ovarian steroidogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05140:Leishmaniasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05206:MicroRNAs in cancer,hsa05222:Small cell lung cancer,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0643~Prostaglandin biosynthesis,KW-0644~Prostaglandin metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0539~Nucleus,		KW-0245~EGF-like domain,KW-0732~Signal,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	ACT_SITE:For cyclooxygenase activity,ACT_SITE:Proton acceptor,BINDING:axial binding residue,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,MUTAGEN:C->S: Abolishes enzyme activity.,MUTAGEN:C->S: Does not affect activation by nitric oxid (NO).,MUTAGEN:C->S: Prevents activation by nitric oxid (NO).,MUTAGEN:G->V: Loss of cyclooxygenase activity. Loss of cyclooxygenase activity; when associated with T-516.,MUTAGEN:H->A: Reduces two-electron hydroperoxide reduction and cyclooxygenase activity. Catalyzes predominantly one-electron hydroperoxide reduction.,MUTAGEN:Q->N: Increases two-electron hydroperoxide reduction. Has no effect on cyclooxygenase activity.,MUTAGEN:Q->R: Impairs two-electron hydroperoxide reduction and cyclooxygenase activity.,MUTAGEN:Q->V: Impairs two-electron hydroperoxide reduction.,MUTAGEN:S->A: No effect on protein stability. Increased decrease of protein stability; when associated with A-371.,MUTAGEN:S->T: Decreased enzyme activity with arachidonic acid. Loss of cyclooxygenase activity; when associated with V-519.,MUTAGEN:Y->A: Decreased protein stability. Increased decrease of protein stability; when associated with A-516.,SITE:Aspirin-acetylated serine,
PSCA	prostate stem cell antigen(PSCA)	Homo sapiens			GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0099601~regulation of neurotransmitter receptor activity,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0031225~anchored component of membrane,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0033130~acetylcholine receptor binding,	IPR016054:Ly-6 antigen / uPA receptor -like,				SM00134:LU,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:UPAR/Ly6,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,
PMEPA1	prostate transmembrane protein, androgen induced 1(PMEPA1)	Homo sapiens			GO:0010991~negative regulation of SMAD protein complex assembly,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030521~androgen receptor signaling pathway,GO:0060392~negative regulation of SMAD protein import into nucleus,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,	GO:0000139~Golgi membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0050699~WW domain binding,GO:0070412~R-SMAD binding,						KW-0833~Ubl conjugation pathway,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0734~Signal transduction inhibitor,		COMPBIAS:Polar residues,MOTIF:PPxY motif 1,MOTIF:PPxY motif 2,MOTIF:SMAD interaction motif (SIM),MUTAGEN:Y->A: Impairs interaction with NEDD4. Impairs polyubiquitination of AR; when associated with A-232.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
PRM3	protamine 3(PRM3)	Homo sapiens			GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0030261~chromosome condensation,GO:0030317~flagellated sperm motility,	GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003677~DNA binding,	IPR026077:Protamine-P3,					KW-0221~Differentiation,KW-0226~DNA condensation,KW-0744~Spermatogenesis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0544~Nucleosome core,				KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PROC	protein C, inactivator of coagulation factors Va and VIIIa(PROC)	Homo sapiens		h_amiPathway:Acute Myocardial Infarction,h_extrinsicPathway:Extrinsic Prothrombin Activation Pathway,h_intrinsicPathway:Intrinsic Prothrombin Activation Pathway,	GO:0006508~proteolysis,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007596~blood coagulation,GO:0030195~negative regulation of blood coagulation,GO:0043066~negative regulation of apoptotic process,GO:0050728~negative regulation of inflammatory response,GO:0050819~negative regulation of coagulation,GO:1903142~positive regulation of establishment of endothelial barrier,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005796~Golgi lumen,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000294:Gamma-carboxyglutamic acid-rich (GLA) domain,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR001881:EGF-like calcium-binding,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR012224:Peptidase S1A, coagulation factor VII/IX/X/C/Z,IPR013032:EGF-like, conserved site,IPR017857:Coagulation factor, subgroup, Gla domain,IPR018097:EGF-like calcium-binding, conserved site,IPR018114:Peptidase S1, trypsin family, active site,	hsa04610:Complement and coagulation cascades,	176860~Thrombophilia 3 due to protein C deficiency, autosomal dominant,612304~Thrombophilia 3 due to protein C deficiency, autosomal recessive,	PIRSF001143:coagulation factor X,	SM00020:Tryp_SPc,SM00069:GLA,SM00179:EGF_CA,SM00181:EGF,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0964~Secreted,	KW-0225~Disease variant,KW-0792~Thrombophilia,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0301~Gamma-carboxyglutamic acid,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical; partial,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain (between light and heavy chains),DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:Gla,DOMAIN:Peptidase S1,PEPTIDE:Activation peptide,REGION:Disordered,SITE:Cleavage; by thrombin,
PRKCB	protein kinase C beta(PRKCB)	Homo sapiens		h_agpcrPathway:Attenuation of GPCR Signaling,h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_crebPathway:Transcription factor CREB and its extracellular signals,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_edg1Pathway:Phospholipids as signalling intermediaries,h_egfPathway:EGF Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erbb4Pathway:g-Secretase mediated ErbB4 Signaling Pathway ,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ghPathway:Growth Hormone Signaling Pathway,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_ionPathway:Ion Channel and Phorbal Esters Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_nos1Pathway:Nitric Oxide Signaling Pathway,h_par1pathway:Thrombin signaling and protease-activated receptors,h_pdgfPathway:PDGF Signaling Pathway,h_pkcPathway:Activation of PKC through G protein coupled receptor,h_plcdPathway:Phospholipase C d1 in phospholipid associated cell signaling,h_plcPathway:Phospholipase C Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0002250~adaptive immune response,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006915~apoptotic process,GO:0007077~mitotic nuclear envelope disassembly,GO:0007165~signal transduction,GO:0007207~phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0010827~regulation of glucose transport,GO:0010829~negative regulation of glucose transport,GO:0014059~regulation of dopamine secretion,GO:0018105~peptidyl-serine phosphorylation,GO:0018894~dibenzo-p-dioxin metabolic process,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032024~positive regulation of insulin secretion,GO:0033280~response to vitamin D,GO:0035408~histone H3-T6 phosphorylation,GO:0035556~intracellular signal transduction,GO:0040008~regulation of growth,GO:0042113~B cell activation,GO:0042488~positive regulation of odontogenesis of dentin-containing tooth,GO:0042953~lipoprotein transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043687~post-translational protein modification,GO:0045471~response to ethanol,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050861~positive regulation of B cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0071322~cellular response to carbohydrate stimulus,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008091~spectrin,GO:0031526~brush border membrane,GO:0044305~calyx of Held,GO:0070062~extracellular exosome,GO:0099523~presynaptic cytosol,	GO:0003682~chromatin binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005080~protein kinase C binding,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0035403~histone kinase activity (H3-T6 specific),GO:0042393~histone binding,GO:0050681~androgen receptor binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014375:Protein kinase C, alpha/beta/gamma types,IPR015727:Protein kinase C mu-related,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04150:mTOR signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04662:B cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05140:Leishmaniasis,hsa05143:African trypanosomiasis,hsa05146:Amoebiasis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05214:Glioma,hsa05223:Non-small cell lung cancer,hsa05225:Hepatocellular carcinoma,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,		PIRSF000550:protein kinase C, alpha/beta/gamma types,	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,SM00239:C2,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Protein kinase,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKG2	protein kinase cGMP-dependent 2(PRKG2)	Homo sapiens		h_no1Pathway:Actions of Nitric Oxide in the Heart,h_raccPathway:Ion Channels and Their Functional Role in Vascular Endothelium,	GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0032332~positive regulation of chondrocyte differentiation,GO:0036289~peptidyl-serine autophosphorylation,GO:0046146~tetrahydrobiopterin metabolic process,GO:0072659~protein localization to plasma membrane,GO:1903829~positive regulation of cellular protein localization,GO:2001226~negative regulation of chloride transport,	GO:0005829~cytosol,GO:0016324~apical plasma membrane,GO:0031965~nuclear membrane,	GO:0004672~protein kinase activity,GO:0004692~cGMP-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005524~ATP binding,GO:0030553~cGMP binding,GO:0042802~identical protein binding,GO:0051019~mitogen-activated protein kinase binding,	IPR000595:Cyclic nucleotide-binding domain,IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002374:cGMP-dependent kinase,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014710:RmlC-like jelly roll fold,IPR017441:Protein kinase, ATP binding site,IPR018488:Cyclic nucleotide-binding, conserved site,IPR018490:Cyclic nucleotide-binding-like,	hsa04022:cGMP-PKG signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04730:Long-term depression,hsa04740:Olfactory transduction,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04970:Salivary secretion,	619636~Acromesomelic dysplasia 4,619638~Spondylometaphyseal dysplasia, Pagnamenta type,	PIRSF000559:cGMP-dependent protein kinase,	SM00100:cNMP,SM00133:S_TK_X,SM00220:S_TKc,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0140~cGMP,KW-0142~cGMP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:AGC-kinase C-terminal,DOMAIN:Cyclic nucleotide-binding,DOMAIN:Protein kinase,LIPID:N-myristoyl glycine,MUTAGEN:D->A: Reduces cGMP binding affinity; when associated with A-415.,MUTAGEN:R->A: Reduces cGMP binding affinity; when associated with A-412.,REGION:Disordered,REGION:cGMP-binding, high affinity; cAMP-binding, low affinity,REGION:cGMP-binding, high affinity; cAMP-binding, moderate affinity,
PPP1R14A	protein phosphatase 1 regulatory inhibitor subunit 14A(PPP1R14A)	Homo sapiens			GO:0042325~regulation of phosphorylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004864~protein phosphatase inhibitor activity,GO:0004865~protein serine/threonine phosphatase inhibitor activity,	IPR008025:PKC-activated phosphatase-1 inhibitor,	hsa04270:Vascular smooth muscle contraction,					KW-0963~Cytoplasm,				KW-0650~Protein phosphatase inhibitor,	KW-0597~Phosphoprotein,	REGION:Disordered,REGION:Inhibitory,
PPP1R14C	protein phosphatase 1 regulatory inhibitor subunit 14C(PPP1R14C)	Homo sapiens			GO:0042325~regulation of phosphorylation,	GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004865~protein serine/threonine phosphatase inhibitor activity,	IPR008025:PKC-activated phosphatase-1 inhibitor,						KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0650~Protein phosphatase inhibitor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
PPP1R1B	protein phosphatase 1 regulatory inhibitor subunit 1B(PPP1R1B)	Homo sapiens		h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_fosbPathway:FOSB gene expression and drug abuse,	GO:0001975~response to amphetamine,GO:0006351~transcription, DNA-templated,GO:0007165~signal transduction,GO:0007621~negative regulation of female receptivity,GO:0007626~locomotory behavior,GO:0008542~visual learning,GO:0032515~negative regulation of phosphoprotein phosphatase activity,GO:0035556~intracellular signal transduction,GO:0043278~response to morphine,GO:0048148~behavioral response to cocaine,GO:0071314~cellular response to cocaine,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043025~neuronal cell body,	GO:0004860~protein kinase inhibitor activity,GO:0004862~cAMP-dependent protein kinase inhibitor activity,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,	IPR008466:Protein phosphatase inhibitor, 1DARPP-32,IPR015670:Dopamine/cAMP-regulated neuronal phosphoprotein,	hsa04024:cAMP signaling pathway,hsa04728:Dopaminergic synapse,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,					KW-0963~Cytoplasm,				KW-0650~Protein phosphatase inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PPP2R5A	protein phosphatase 2 regulatory subunit B'alpha(PPP2R5A)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0035307~positive regulation of protein dephosphorylation,GO:0090219~negative regulation of lipid kinase activity,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0000159~protein phosphatase type 2A complex,GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030018~Z disc,GO:0031430~M band,	GO:0004721~phosphoprotein phosphatase activity,GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0019900~kinase binding,GO:0072542~protein phosphatase activator activity,	IPR002554:Protein phosphatase 2A, regulatory B subunit, B56,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,		PIRSF028043:serine/threonine-protein phosphatase 2A, subunit B56,			KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
PPP2R2C	protein phosphatase 2 regulatory subunit Bgamma(PPP2R2C)	Homo sapiens			GO:0070262~peptidyl-serine dephosphorylation,	GO:0000159~protein phosphatase type 2A complex,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,	IPR000009:Protein phosphatase 2A, regulatory subunit PR55,IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR018067:Protein phosphatase 2A, regulatory subunit PR55, conserved site,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,		PIRSF037309:serine/threonine-protein phosphatase 2A, subunit B55,	SM00320:WD40,				KW-0677~Repeat,KW-0853~WD repeat,				REGION:Disordered,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PTK6	protein tyrosine kinase 6(PTK6)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0010976~positive regulation of neuron projection development,GO:0016477~cell migration,GO:0030154~cell differentiation,GO:0038128~ERBB2 signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0045087~innate immune response,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045787~positive regulation of cell cycle,GO:0045926~negative regulation of growth,GO:0046777~protein autophosphorylation,GO:0060575~intestinal epithelial cell differentiation,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0071300~cellular response to retinoic acid,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016604~nuclear body,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,				SM00219:TyrKc,SM00252:SH2,SM00326:SH3,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,MUTAGEN:K->M: Abolishes kinase activity and cell transformation, and phosphorylation of STAP2.,MUTAGEN:K->R: Abolishes kinase activity.,MUTAGEN:R->L: Decrease in STAP2 phosphorylation.,MUTAGEN:W->A: Abrogates interaction between PTK6-domain kinase and PTK6-linker. Abrogates autophosphorylation and phosphorylation of KHDRBS1.,MUTAGEN:W->A: Strong decrease in STAP2 phosphorylation. Markedly decreased interaction between SH3 domain the linker region.,MUTAGEN:Y->A: 3-fold lower specific kinase activity. Decreased, but still significant, autophosphorylation. Decreased, but still significant, autophosphorylation; when associated with A-447.,MUTAGEN:Y->A: Decrease in STAP2 phosphorylation.,MUTAGEN:Y->F: Decrease in transforming potential and increase in the kinase activity level. Decreased, but still significant, autophosphorylation; when associated with A-342.,REGION:Linker,
PTP4A2	protein tyrosine phosphatase 4A2(PTP4A2)	Homo sapiens			GO:0016311~dephosphorylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0004727~prenylated protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,				SM00404:PTPc_motif,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,ACT_SITE:Proton donor,DOMAIN:Tyrosine-protein phosphatase,LIPID:S-farnesyl cysteine,MUTAGEN:C->S: No effect on interaction with RABGGTB.,MUTAGEN:Missing: Locates in the nucleus and cytosol. No interaction with RABGGTB.,PROPEP:Removed in mature form,
PTPN5	protein tyrosine phosphatase non-receptor type 5(PTPN5)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0035335~peptidyl-tyrosine dephosphorylation,	GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,	GO:0001784~phosphotyrosine binding,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR008356:Protein-tyrosine phosphatase, KIM-containing,IPR016130:Protein-tyrosine phosphatase, active site,IPR016334:Protein-tyrosine phosphatase, receptor type R/non-receptor type 5,	hsa04010:MAPK signaling pathway,		PIRSF001997:receptor tyrosine-protein phosphatase, types R/5,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,TRANSMEM:Helical,
PTPN6	protein tyrosine phosphatase non-receptor type 6(PTPN6)	Homo sapiens		h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,	GO:0000165~MAPK cascade,GO:0000278~mitotic cell cycle,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002924~negative regulation of humoral immune response mediated by circulating immunoglobulin,GO:0006470~protein dephosphorylation,GO:0006950~response to stress,GO:0007186~G-protein coupled receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030220~platelet formation,GO:0031295~T cell costimulation,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033007~negative regulation of mast cell activation involved in immune response,GO:0033277~abortive mitotic cell cycle,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035556~intracellular signal transduction,GO:0035855~megakaryocyte development,GO:0042098~T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042981~regulation of apoptotic process,GO:0043407~negative regulation of MAP kinase activity,GO:0043409~negative regulation of MAPK cascade,GO:0045577~regulation of B cell differentiation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0051897~positive regulation of protein kinase B signaling,GO:0060338~regulation of type I interferon-mediated signaling pathway,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070527~platelet aggregation,GO:1905867~epididymis development,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0035580~specific granule lumen,GO:0042105~alpha-beta T cell receptor complex,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0001784~phosphotyrosine binding,GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0042169~SH2 domain binding,GO:0050839~cell adhesion molecule binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR000980:SH2 domain,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR012152:Protein-tyrosine phosphatase, non-receptor type-6, -11,IPR016130:Protein-tyrosine phosphatase, active site,	hsa04520:Adherens junction,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05140:Leishmaniasis,hsa05205:Proteoglycans in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,		PIRSF000929:non-receptor tyrosine-protein phosphatase, 6/11 types,	SM00194:PTPc,SM00252:SH2,SM00404:PTPc_motif,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0727~SH2 domain,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,
PTPRH	protein tyrosine phosphatase receptor type H(PTPRH)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0006915~apoptotic process,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016324~apical plasma membrane,GO:0016607~nuclear speck,GO:0031528~microvillus membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,				SM00060:FN3,SM00194:PTPc,SM00404:PTPc_motif,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Loss of activity. No induction of apoptosis.,MUTAGEN:D->A: Loss of activity. Acts as a dominant negative mutant.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPRO	protein tyrosine phosphatase receptor type O(PTPRO)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0002548~monocyte chemotaxis,GO:0003093~regulation of glomerular filtration,GO:0003105~negative regulation of glomerular filtration,GO:0006470~protein dephosphorylation,GO:0007411~axon guidance,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010977~negative regulation of neuron projection development,GO:0030032~lamellipodium assembly,GO:0032835~glomerulus development,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0036060~slit diaphragm assembly,GO:0050807~regulation of synapse organization,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090260~negative regulation of retinal ganglion cell axon guidance,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0030027~lamellipodium,GO:0030424~axon,GO:0030426~growth cone,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0070062~extracellular exosome,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:0099061~integral component of postsynaptic density membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0017147~Wnt-protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,		614196~Nephrotic syndrome, type 6,		SM00060:FN3,SM00194:PTPc,SM00404:PTPc_motif,		KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPRR	protein tyrosine phosphatase receptor type R(PTPRR)	Homo sapiens		h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,	GO:0001701~in utero embryonic development,GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0010633~negative regulation of epithelial cell migration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0038128~ERBB2 signaling pathway,GO:0070373~negative regulation of ERK1 and ERK2 cascade,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0048471~perinuclear region of cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR008356:Protein-tyrosine phosphatase, KIM-containing,IPR016130:Protein-tyrosine phosphatase, active site,IPR016334:Protein-tyrosine phosphatase, receptor type R/non-receptor type 5,	hsa04010:MAPK signaling pathway,		PIRSF001997:receptor tyrosine-protein phosphatase, types R/5,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PRG2	proteoglycan 2, pro eosinophil major basic protein(PRG2)	Homo sapiens			GO:0002215~defense response to nematode,GO:0006955~immune response,GO:0010936~negative regulation of macrophage cytokine production,GO:0032693~negative regulation of interleukin-10 production,GO:0032753~positive regulation of interleukin-4 production,GO:0042742~defense response to bacterium,	GO:0005576~extracellular region,GO:0030133~transport vesicle,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030021~extracellular matrix structural constituent conferring compression resistance,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR002352:Eosinophil major basic protein,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,	hsa05310:Asthma,			SM00034:CLECT,	KW-0391~Immunity,	KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,	KW-0430~Lectin,	KW-0044~Antibiotic,KW-0358~Heparin-binding,KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-0944~Nitration,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (GalNAc...) threonine; partial,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Acidic residues,DISULFID:Interchain (with C-461 in PAPPA),DISULFID:Interchain (with C-732 in PAPPA),DOMAIN:C-type lectin,PROPEP:Acidic,REGION:Disordered,
PCDH10	protocadherin 10(PCDH10)	Homo sapiens			GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin cytoplasmic C-terminal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDH8	protocadherin 8(PCDH8)	Homo sapiens			GO:0001756~somitogenesis,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007267~cell-cell signaling,GO:0007268~chemical synaptic transmission,GO:0016331~morphogenesis of embryonic epithelium,GO:0050804~modulation of synaptic transmission,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0042734~presynaptic membrane,GO:0045211~postsynaptic membrane,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
P2RX5	purinergic receptor P2X 5(P2RX5)	Homo sapiens			GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0033198~response to ATP,GO:0035590~purinergic nucleotide receptor signaling pathway,GO:0050850~positive regulation of calcium-mediated signaling,GO:0060079~excitatory postsynaptic potential,GO:0070588~calcium ion transmembrane transport,	GO:0005639~integral component of nuclear inner membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0098794~postsynapse,	GO:0001614~purinergic nucleotide receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0004931~extracellular ATP-gated cation channel activity,GO:0005216~ion channel activity,GO:0005524~ATP binding,	IPR001429:P2X purinoreceptor,IPR003048:P2X5 purinoceptor,IPR027309:P2X purinoreceptor extracellular domain,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,		PIRSF005713:ATP-gated ion channel P2X4 receptor,		KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,
P2RX7	purinergic receptor P2X 7(P2RX7)	Homo sapiens			GO:0000165~MAPK cascade,GO:0000902~cell morphogenesis,GO:0001845~phagolysosome assembly,GO:0001913~T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0001934~positive regulation of protein phosphorylation,GO:0002028~regulation of sodium ion transport,GO:0002931~response to ischemia,GO:0006468~protein phosphorylation,GO:0006509~membrane protein ectodomain proteolysis,GO:0006649~phospholipid transfer to membrane,GO:0006900~membrane budding,GO:0006954~inflammatory response,GO:0007005~mitochondrion organization,GO:0007166~cell surface receptor signaling pathway,GO:0009306~protein secretion,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010043~response to zinc ion,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0010628~positive regulation of gene expression,GO:0014047~glutamate secretion,GO:0014049~positive regulation of glutamate secretion,GO:0014051~gamma-aminobutyric acid secretion,GO:0014054~positive regulation of gamma-aminobutyric acid secretion,GO:0016079~synaptic vesicle exocytosis,GO:0016485~protein processing,GO:0017121~phospholipid scrambling,GO:0019233~sensory perception of pain,GO:0030163~protein catabolic process,GO:0030501~positive regulation of bone mineralization,GO:0031668~cellular response to extracellular stimulus,GO:0032060~bleb assembly,GO:0032308~positive regulation of prostaglandin secretion,GO:0032310~prostaglandin secretion,GO:0032496~response to lipopolysaccharide,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032963~collagen metabolic process,GO:0033198~response to ATP,GO:0034405~response to fluid shear stress,GO:0034767~positive regulation of ion transmembrane transport,GO:0035585~calcium-mediated signaling using extracellular calcium source,GO:0035590~purinergic nucleotide receptor signaling pathway,GO:0042098~T cell proliferation,GO:0043029~T cell homeostasis,GO:0043132~NAD transport,GO:0043406~positive regulation of MAP kinase activity,GO:0043409~negative regulation of MAPK cascade,GO:0043410~positive regulation of MAPK cascade,GO:0045779~negative regulation of bone resorption,GO:0045794~negative regulation of cell volume,GO:0045821~positive regulation of glycolytic process,GO:0046513~ceramide biosynthetic process,GO:0046931~pore complex assembly,GO:0048705~skeletal system morphogenesis,GO:0048873~homeostasis of number of cells within a tissue,GO:0050714~positive regulation of protein secretion,GO:0050830~defense response to Gram-positive bacterium,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051495~positive regulation of cytoskeleton organization,GO:0051592~response to calcium ion,GO:0051602~response to electrical stimulus,GO:0051709~regulation of killing of cells of other organism,GO:0051882~mitochondrial depolarization,GO:0051899~membrane depolarization,GO:0051901~positive regulation of mitochondrial depolarization,GO:0060079~excitatory postsynaptic potential,GO:0060907~positive regulation of macrophage cytokine production,GO:0070230~positive regulation of lymphocyte apoptotic process,GO:0070231~T cell apoptotic process,GO:0070234~positive regulation of T cell apoptotic process,GO:0070588~calcium ion transmembrane transport,GO:0071318~cellular response to ATP,GO:0071359~cellular response to dsRNA,GO:0072593~reactive oxygen species metabolic process,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:1904172~positive regulation of bleb assembly,GO:1905114~cell surface receptor signaling pathway involved in cell-cell signaling,	GO:0005639~integral component of nuclear inner membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031594~neuromuscular junction,GO:0032059~bleb,GO:0043025~neuronal cell body,GO:0098793~presynapse,GO:0098794~postsynapse,	GO:0001530~lipopolysaccharide binding,GO:0001614~purinergic nucleotide receptor activity,GO:0004931~extracellular ATP-gated cation channel activity,GO:0005102~receptor binding,GO:0005216~ion channel activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR001429:P2X purinoreceptor,IPR003050:P2X7 purinoceptor,IPR027309:P2X purinoreceptor extracellular domain,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04621:NOD-like receptor signaling pathway,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:P2X purinoreceptor 7 intracellular,MUTAGEN:N->A: Alters cell surface expression.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,
PDK4	pyruvate dehydrogenase kinase 4(PDK4)	Homo sapiens			GO:0006006~glucose metabolic process,GO:0006468~protein phosphorylation,GO:0006885~regulation of pH,GO:0008286~insulin receptor signaling pathway,GO:0009267~cellular response to starvation,GO:0010510~regulation of acetyl-CoA biosynthetic process from pyruvate,GO:0010565~regulation of cellular ketone metabolic process,GO:0010906~regulation of glucose metabolic process,GO:0016310~phosphorylation,GO:0042304~regulation of fatty acid biosynthetic process,GO:0042593~glucose homeostasis,GO:0042594~response to starvation,GO:0045124~regulation of bone resorption,GO:0046320~regulation of fatty acid oxidation,GO:0071398~cellular response to fatty acid,GO:0072593~reactive oxygen species metabolic process,GO:2000811~negative regulation of anoikis,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004672~protein kinase activity,GO:0004740~pyruvate dehydrogenase (acetyl-transferring) kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR003594:Histidine kinase-like ATPase, ATP-binding domain,IPR005467:Signal transduction histidine kinase, core,IPR018955:Branched-chain alpha-ketoacid dehydrogenase kinase/Pyruvate dehydrogenase kinase, N-terminal,	hsa05415:Diabetic cardiomyopathy,			SM00387:HATPase_c,	KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,KW-0670~Pyruvate,	KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:Histidine kinase,MUTAGEN:D->A: Loss of activity; when associated with A-395.,MUTAGEN:R->A: Loss of activity.,MUTAGEN:W->A: Loss of activity; when associated with A-394.,MUTAGEN:Y->F: Loss of activity.,SITE:Interaction with the other subunit in the homodimer,TRANSIT:Mitochondrion,
QSOX1	quiescin sulfhydryl oxidase 1(QSOX1)	Homo sapiens			GO:0006457~protein folding,GO:0008285~negative regulation of cell proliferation,GO:0016242~negative regulation of macroautophagy,GO:0085029~extracellular matrix assembly,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0030173~integral component of Golgi membrane,GO:0031093~platelet alpha granule lumen,GO:0035580~specific granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0045171~intercellular bridge,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0003756~protein disulfide isomerase activity,GO:0016971~flavin-linked sulfhydryl oxidase activity,GO:0071949~FAD binding,	IPR013766:Thioredoxin domain,IPR017905:ERV/ALR sulphydryl oxidase,						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Redox-active,DOMAIN:ERV/ALR sulfhydryl oxidase,DOMAIN:Thioredoxin,MUTAGEN:C->S: Loss of activity.,MUTAGEN:C->S: No effect. Reduces activity by 70%; when associated with S-512.,MUTAGEN:C->S: Reduces activity by 40%. Reduces activity by 70%; when associated with S-509.,MUTAGEN:C->S: Reduces activity by 93%.,MUTAGEN:C->S: Reduces activity by 96%.,MUTAGEN:CGHC->AGHA: Loss of catalytic activity. Cannot prevent cell detachment after depletion of the endogenous protein.,MUTAGEN:H->A: Decreased protein stability and catalytic activity; when associated with S-119 or T-119.,MUTAGEN:N->Q: Loss of glycosylation site.,MUTAGEN:N->Q: Loss of glycosylation site. Abolishes secretion. No effect on catalytic activity.,MUTAGEN:P->S,T: Loss of catalytic activity. Decreased protein stability and catalytic activity; when associated with A-72.,MUTAGEN:TTVAPTT->ANVAPVA: Decreased O-glycosylation.,REGION:Disordered,TRANSMEM:Helical,
RHOD	ras homolog family member D(RHOD)	Homo sapiens			GO:0007015~actin filament organization,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0008360~regulation of cell shape,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030335~positive regulation of cell migration,GO:0030865~cortical cytoskeleton organization,GO:0032956~regulation of actin cytoskeleton organization,GO:0045785~positive regulation of cell adhesion,GO:0048041~focal adhesion assembly,GO:0051017~actin filament bundle assembly,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0000139~Golgi membrane,GO:0005741~mitochondrial outer membrane,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0010008~endosome membrane,GO:0031410~cytoplasmic vesicle,GO:0042995~cell projection,	GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005525~GTP binding,GO:0019901~protein kinase binding,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04360:Axon guidance,					KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:C->S: Abolishes endosomal localization.,PROPEP:Removed in mature form,
RIPK3	receptor interacting serine/threonine kinase 3(RIPK3)	Homo sapiens			GO:0001914~regulation of T cell mediated cytotoxicity,GO:0002819~regulation of adaptive immune response,GO:0006464~cellular protein modification process,GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010922~positive regulation of phosphatase activity,GO:0012501~programmed cell death,GO:0032147~activation of protein kinase activity,GO:0032649~regulation of interferon-gamma production,GO:0033077~T cell differentiation in thymus,GO:0036211~protein modification process,GO:0038061~NIK/NF-kappaB signaling,GO:0042981~regulation of apoptotic process,GO:0043029~T cell homeostasis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046006~regulation of activated T cell proliferation,GO:0046777~protein autophosphorylation,GO:0048535~lymph node development,GO:0048536~spleen development,GO:0048538~thymus development,GO:0050896~response to stimulus,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051351~positive regulation of ligase activity,GO:0051353~positive regulation of oxidoreductase activity,GO:0051607~defense response to virus,GO:0060545~positive regulation of necroptotic process,GO:0070235~regulation of activation-induced cell death of T cells,GO:0070266~necroptotic process,GO:0070301~cellular response to hydrogen peroxide,GO:0072593~reactive oxygen species metabolic process,GO:0097190~apoptotic signaling pathway,GO:0097300~programmed necrotic cell death,GO:0097527~necroptotic signaling pathway,GO:0097528~execution phase of necroptosis,GO:1990000~amyloid fibril formation,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000452~regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0003713~transcription coactivator activity,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004704~NF-kappaB-inducing kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR025735:RHIM domain,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04668:TNF signaling pathway,hsa05132:Salmonella infection,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,KW-1210~Necrosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,MOTIF:RIP homotypic interaction motif (RHIM),MUTAGEN:D->N: Abolishes kinase activity and ability to mediate necroptosis.,MUTAGEN:K->A: Abolishes kinase activity. Loss of PGAM5- and MLKL-binding. No effect on RIPK1-binding. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of STUB1-mediated ubiquitination.,MUTAGEN:K->D: Abolishes kinase activity.,MUTAGEN:K->R: Loss of PELI1-mediated ubiquitination. No loss of interaction with PELI1.,MUTAGEN:S->A: Abolishes ability to mediate necroptosis. Partial loss of kinase activity. No loss of PELI1-mediated degradation.,MUTAGEN:S->D: No loss of PELI1-mediated degradation.,MUTAGEN:T->A: Abolishes kinase activity. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with STUB1 and STUB1-mediated ubiquitination. No loss of interaction with RIPK1. Loss of ability to mediate TNF-induced necroptosis. Loss of autophosphorylation at Ser-227.,MUTAGEN:T->S: No loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with RIPK1 and MLKL.,MUTAGEN:VQVG->AAAA: Abolished cleavage by S.flexneri OspD3.,MUTAGEN:Y->A,F: Loss of interaction with PELI1 and PELI1-mediated ubiquitination.,REGION:Disordered,
REG1A	regenerating family member 1 alpha(REG1A)	Homo sapiens			GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0043434~response to peptide hormone,GO:0044278~cell wall disruption in other organism,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0008083~growth factor activity,GO:0030246~carbohydrate binding,GO:0038023~signaling receptor activity,GO:0042834~peptidoglycan binding,GO:0070492~oligosaccharide binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,				SM00034:CLECT,		KW-0964~Secreted,		KW-0732~Signal,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc) threonine,DOMAIN:C-type lectin,
REG3A	regenerating family member 3 alpha(REG3A)	Homo sapiens			GO:0006953~acute-phase response,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0009609~response to symbiotic bacterium,GO:0009611~response to wounding,GO:0010838~positive regulation of keratinocyte proliferation,GO:0043434~response to peptide hormone,GO:0044278~cell wall disruption in other organism,GO:0045617~negative regulation of keratinocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0090303~positive regulation of wound healing,GO:2000972~positive regulation of detection of glucose,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016021~integral component of membrane,	GO:0005179~hormone activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0042834~peptidoglycan binding,GO:0070492~oligosaccharide binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,				SM00034:CLECT,	KW-0011~Acute phase,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0929~Antimicrobial,	KW-1015~Disulfide bond,	DOMAIN:C-type lectin,MOTIF:EPN,MUTAGEN:E->Q: Reduces antibacterial activity but no effect on peptidoglycan binding.,MUTAGEN:E->Q: Reduces peptidoglycan binding and antibacterial activity. No effect on binding to phospholipids and membrane toxicity. No effect on filament formation.,MUTAGEN:K->A: Reduces binding to phospholipids and membrane toxicity. Loss of filament formation.,MUTAGEN:K->Q,H: No effect on binding to phospholipids and membrane toxicity.,MUTAGEN:R->A: Reduces membrane toxicity.,REGION:Sufficient to activate EXTL3,TRANSMEM:Helical,
RGS12	regulator of G protein signaling 12(RGS12)	Homo sapiens			GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009966~regulation of signal transduction,GO:0009968~negative regulation of signal transduction,	GO:0000794~condensed nuclear chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016363~nuclear matrix,GO:0030425~dendrite,GO:0045202~synapse,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0030695~GTPase regulator activity,	IPR001478:PDZ domain,IPR003109:GoLoco motif,IPR003116:Raf-like Ras-binding,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,				SM00228:PDZ,SM00315:RGS,SM00390:GoLoco,SM00455:RBD,SM00462:PTB,	KW-0804~Transcription,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,		KW-0343~GTPase activation,KW-0678~Repressor,KW-0734~Signal transduction inhibitor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GoLoco,DOMAIN:PDZ,DOMAIN:PID,DOMAIN:RBD,DOMAIN:RBD 1,DOMAIN:RBD 2,DOMAIN:RGS,REGION:Disordered,
RGS17	regulator of G protein signaling 17(RGS17)	Homo sapiens			GO:0001975~response to amphetamine,GO:0007186~G-protein coupled receptor signaling pathway,GO:0009968~negative regulation of signal transduction,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0043005~neuron projection,GO:0045202~synapse,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR016137:Regulator of G protein signalling superfamily,				SM00315:RGS,		KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:RGS,REGION:Disordered,
RGS22	regulator of G protein signaling 22(RGS22)	Homo sapiens			GO:0009966~regulation of signal transduction,GO:0009968~negative regulation of signal transduction,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015629~actin cytoskeleton,	GO:0001965~G-protein alpha-subunit binding,	IPR016137:Regulator of G protein signalling superfamily,				SM00315:RGS,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0734~Signal transduction inhibitor,		COMPBIAS:Polar residues,DOMAIN:RGS,DOMAIN:RGS 1,DOMAIN:RGS 2,REGION:Disordered,
RGS4	regulator of G protein signaling 4(RGS4)	Homo sapiens			GO:0001975~response to amphetamine,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007420~brain development,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010460~positive regulation of heart rate,GO:0042220~response to cocaine,GO:0043278~response to morphine,GO:0043547~positive regulation of GTPase activity,GO:0045471~response to ethanol,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:0051924~regulation of calcium ion transport,GO:0060160~negative regulation of dopamine receptor signaling pathway,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:1900924~negative regulation of glycine import,GO:1901380~negative regulation of potassium ion transmembrane transport,GO:1990791~dorsal root ganglion development,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005516~calmodulin binding,GO:0019901~protein kinase binding,	IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,				SM00315:RGS,			KW-1211~Schizophrenia,			KW-0734~Signal transduction inhibitor,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:RGS,LIPID:S-palmitoyl cysteine,
RGS7	regulator of G protein signaling 7(RGS7)	Homo sapiens			GO:0001975~response to amphetamine,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007420~brain development,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009409~response to cold,GO:0009968~negative regulation of signal transduction,GO:0035556~intracellular signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0045471~response to ethanol,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:1901381~positive regulation of potassium ion transmembrane transport,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0043005~neuron projection,GO:0045121~membrane raft,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0031681~G-protein beta-subunit binding,	IPR000591:DEP domain,IPR015898:G-protein gamma-like domain,IPR016137:Regulator of G protein signalling superfamily,				SM00049:DEP,SM00224:GGL,SM00315:RGS,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:DEP,DOMAIN:G protein gamma,DOMAIN:RGS,DOMAIN:Regulator of G-protein signalling DHEX,MUTAGEN:W->F: Diminishes interaction with GNB5.,REGION:Disordered,
RETNLB	resistin like beta(RETNLB)	Homo sapiens			GO:0007165~signal transduction,GO:0050673~epithelial cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005179~hormone activity,	IPR009714:Resistin,						KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-1015~Disulfide bond,	DISULFID:Interchain,
RTN3	reticulon 3(RTN3)	Homo sapiens			GO:0006915~apoptotic process,GO:0007420~brain development,GO:0016192~vesicle-mediated transport,GO:0030182~neuron differentiation,GO:0071786~endoplasmic reticulum tubular network organization,GO:0071787~endoplasmic reticulum tubular network formation,GO:1902430~negative regulation of beta-amyloid formation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0045202~synapse,	GO:0005515~protein binding,	IPR003388:Reticulon,	hsa05010:Alzheimer disease,				KW-0053~Apoptosis,KW-0346~Stress response,KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Reticulon,INTRAMEM:Helical,REGION:Disordered,REGION:Interaction with BACE1,REGION:Interaction with FADD,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
RAET1E	retinoic acid early transcript 1E(RAET1E)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,GO:0042267~natural killer cell mediated cytotoxicity,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0046703~natural killer cell lectin-like receptor binding,	IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,	hsa04650:Natural killer cell mediated cytotoxicity,				KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MHC class I-like antigen recognition-like,REGION:Disordered,REGION:MHC class I alpha-1 like; down-regulates the cell surface expression of KLRK1,REGION:MHC class I alpha-2 like; down-regulates the cell surface expression of KLRK1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
RARRES2	retinoic acid receptor responder 2(RARRES2)	Homo sapiens			GO:0001523~retinoid metabolic process,GO:0001934~positive regulation of protein phosphorylation,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0008286~insulin receptor signaling pathway,GO:0010759~positive regulation of macrophage chemotaxis,GO:0019732~antifungal humoral response,GO:0030154~cell differentiation,GO:0045087~innate immune response,GO:0045600~positive regulation of fat cell differentiation,GO:0048566~embryonic digestive tract development,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050921~positive regulation of chemotaxis,GO:0050994~regulation of lipid catabolic process,GO:0061760~antifungal innate immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0031089~platelet dense granule lumen,	GO:0005102~receptor binding,GO:0005515~protein binding,						KW-0145~Chemotaxis,KW-0221~Differentiation,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0675~Receptor,	KW-1015~Disulfide bond,	REGION:Disordered,
RPL22	ribosomal protein L22(RPL22)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0046632~alpha-beta T cell differentiation,GO:0099577~regulation of translation at presynapse, modulating synaptic transmission,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0042802~identical protein binding,GO:0045182~translation regulator activity,	IPR002671:Ribosomal protein L22e,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0358~Heparin-binding,KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	REGION:Disordered,
RING1	ring finger protein 1(RING1)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,	GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0009952~anterior/posterior pattern specification,GO:0016567~protein ubiquitination,GO:0035518~histone H2A monoubiquitination,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048593~camera-type eye morphogenesis,	GO:0000151~ubiquitin ligase complex,GO:0001739~sex chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0031519~PcG protein complex,GO:0035102~PRC1 complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,GO:0097027~ubiquitin-protein transferase activator activity,	IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,	hsa03083:Polycomb repressive complex,			SM00184:RING,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0678~Repressor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:RING-type,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Necessary for interaction with CBX2,REGION:Necessary for transcriptional repression,ZN_FING:RING-type,
RNF144A	ring finger protein 144A(RNF144A)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,	GO:0000151~ubiquitin ligase complex,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR002867:Zinc finger, C6HC-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,				SM00647:IBR,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:RING-type,REGION:TRIAD supradomain,TRANSMEM:Helical,ZN_FING:IBR-type,ZN_FING:RING-type 1,ZN_FING:RING-type 2; atypical,
ROBO4	roundabout guidance receptor 4(ROBO4)	Homo sapiens			GO:0001525~angiogenesis,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007411~axon guidance,GO:0030334~regulation of cell migration,GO:0061028~establishment of endothelial barrier,GO:0070593~dendrite self-avoidance,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0098632~protein binding involved in cell-cell adhesion,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,		618496~Aortic valve disease 3,		SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0037~Angiogenesis,KW-0221~Differentiation,		KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,
RYR2	ryanodine receptor 2(RYR2)	Homo sapiens		h_no1Pathway:Actions of Nitric Oxide in the Heart,	GO:0001666~response to hypoxia,GO:0002027~regulation of heart rate,GO:0003143~embryonic heart tube morphogenesis,GO:0003220~left ventricular cardiac muscle tissue morphogenesis,GO:0003300~cardiac muscle hypertrophy,GO:0005513~detection of calcium ion,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006941~striated muscle contraction,GO:0010460~positive regulation of heart rate,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0010882~regulation of cardiac muscle contraction by calcium ion signaling,GO:0014808~release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0014850~response to muscle activity,GO:0019722~calcium-mediated signaling,GO:0031000~response to caffeine,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0035994~response to muscle stretch,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051284~positive regulation of sequestering of calcium ion,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051649~establishment of localization in cell,GO:0051775~response to redox state,GO:0055117~regulation of cardiac muscle contraction,GO:0060048~cardiac muscle contraction,GO:0060402~calcium ion transport into cytosol,GO:0070296~sarcoplasmic reticulum calcium ion transport,GO:0071313~cellular response to caffeine,GO:0071872~cellular response to epinephrine stimulus,GO:0072599~establishment of protein localization to endoplasmic reticulum,GO:0086005~ventricular cardiac muscle cell action potential,GO:0086029~Purkinje myocyte to ventricular cardiac muscle cell signaling,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0097050~type B pancreatic cell apoptotic process,GO:0098735~positive regulation of the force of heart contraction,GO:0098904~regulation of AV node cell action potential,GO:0098907~regulation of SA node cell action potential,GO:0098910~regulation of atrial cardiac muscle cell action potential,GO:0098911~regulation of ventricular cardiac muscle cell action potential,GO:1901896~positive regulation of calcium-transporting ATPase activity,	GO:0005790~smooth endoplasmic reticulum,GO:0005886~plasma membrane,GO:0014701~junctional sarcoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0030659~cytoplasmic vesicle membrane,GO:0032991~macromolecular complex,GO:0033017~sarcoplasmic reticulum membrane,GO:0034704~calcium channel complex,GO:0042383~sarcolemma,	GO:0005219~ryanodine-sensitive calcium-release channel activity,GO:0005262~calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0015278~calcium-release channel activity,GO:0019899~enzyme binding,GO:0034236~protein kinase A catalytic subunit binding,GO:0034237~protein kinase A regulatory subunit binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0043924~suramin binding,GO:0044325~ion channel binding,GO:0048763~calcium-induced calcium release activity,	IPR000699:Intracellular calcium-release channel,IPR001870:B30.2/SPRY domain,IPR002048:EF-hand domain,IPR003032:Ryanodine receptor Ryr,IPR003877:SPla/RYanodine receptor SPRY,IPR005821:Ion transport domain,IPR009460:Ryanodine Receptor TM 4-6,IPR011992:EF-hand-like domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013333:Ryanodine receptor,IPR013662:RyR/IP3R Homology associated domain,IPR014821:Inositol 1,4,5-trisphosphate/ryanodine receptor,IPR016093:MIR motif,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04911:Insulin secretion,hsa04921:Oxytocin signaling pathway,hsa04972:Pancreatic secretion,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05415:Diabetic cardiomyopathy,	115000~Ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome,604772~Ventricular tachycardia, catecholaminergic polymorphic, 1,		SM00449:SPRY,SM00472:MIR,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0112~Calmodulin-binding,KW-0217~Developmental protein,KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:B30.2/SPRY 1,DOMAIN:B30.2/SPRY 2,DOMAIN:B30.2/SPRY 3,DOMAIN:EF-hand,DOMAIN:MIR 1,DOMAIN:MIR 2,DOMAIN:MIR 3,DOMAIN:MIR 4,DOMAIN:MIR 5,INTRAMEM:Pore-forming,MUTAGEN:D->N: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:G->A: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:H->N: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:H->Q: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:I->M: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:I->V: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:M->I: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:Q->H: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:S->A: Abolishes phosphorylation by PKA.,REGION:4 X approximate repeats,REGION:Disordered,REGION:Interaction with CALM,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
SCARA3	scavenger receptor class A member 3(SCARA3)	Homo sapiens			GO:0006897~endocytosis,GO:0006979~response to oxidative stress,GO:0009650~UV protection,	GO:0000139~Golgi membrane,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0005044~scavenger receptor activity,GO:0005515~protein binding,	IPR008160:Collagen triple helix repeat,						KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0176~Collagen,KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
SOSTDC1	sclerostin domain containing 1(SOSTDC1)	Homo sapiens			GO:0007389~pattern specification process,GO:0010454~negative regulation of cell fate commitment,GO:0016055~Wnt signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030509~BMP signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0031069~hair follicle morphogenesis,GO:0042475~odontogenesis of dentin-containing tooth,GO:0045662~negative regulation of myoblast differentiation,GO:0060070~canonical Wnt signaling pathway,GO:0060648~mammary gland bud morphogenesis,GO:0072148~epithelial cell fate commitment,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:2000016~negative regulation of determination of dorsal identity,	GO:0005615~extracellular space,	GO:0036122~BMP binding,GO:0098821~BMP receptor activity,	IPR006207:Cystine knot, C-terminal,IPR008835:Sclerostin/Sclerostin domain-containing protein 1,					KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DOMAIN:CTCK,REGION:Disordered,
SFRP2	secreted frizzled related protein 2(SFRP2)	Homo sapiens			GO:0001569~branching involved in blood vessel morphogenesis,GO:0002063~chondrocyte development,GO:0003151~outflow tract morphogenesis,GO:0003214~cardiac left ventricle morphogenesis,GO:0003402~planar cell polarity pathway involved in axis elongation,GO:0006915~apoptotic process,GO:0007267~cell-cell signaling,GO:0007501~mesodermal cell fate specification,GO:0007584~response to nutrient,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0010629~negative regulation of gene expression,GO:0010659~cardiac muscle cell apoptotic process,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010975~regulation of neuron projection development,GO:0016055~Wnt signaling pathway,GO:0030154~cell differentiation,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030199~collagen fibril organization,GO:0030307~positive regulation of cell growth,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0030509~BMP signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0031668~cellular response to extracellular stimulus,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035567~non-canonical Wnt signaling pathway,GO:0036342~post-anal tail morphogenesis,GO:0042662~negative regulation of mesodermal cell fate specification,GO:0042733~embryonic digit morphogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043508~negative regulation of JUN kinase activity,GO:0045600~positive regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048546~digestive tract morphogenesis,GO:0048856~anatomical structure development,GO:0048866~stem cell fate specification,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0060028~convergent extension involved in axis elongation,GO:0060070~canonical Wnt signaling pathway,GO:0060349~bone morphogenesis,GO:0061056~sclerotome development,GO:0061185~negative regulation of dermatome development,GO:0071425~hematopoietic stem cell proliferation,GO:0071481~cellular response to X-ray,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090179~planar cell polarity pathway involved in neural tube closure,GO:0090244~Wnt signaling pathway involved in somitogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:1904956~regulation of midbrain dopaminergic neuron differentiation,GO:2000035~regulation of stem cell division,GO:2000041~negative regulation of planar cell polarity pathway involved in axis elongation,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0001968~fibronectin binding,GO:0005178~integrin binding,GO:0017147~Wnt-protein binding,GO:0048018~receptor agonist activity,GO:0061133~endopeptidase activator activity,	IPR001134:Netrin domain,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015526:Frizzled/secreted frizzled-related protein,IPR018933:Netrin module, non-TIMP type,IPR020067:Frizzled domain,IPR026558:Secreted frizzled-related protein 2,	hsa04310:Wnt signaling pathway,			SM00063:FRI,SM00643:C345C,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	DOMAIN:FZ,DOMAIN:NTR,
SFRP5	secreted frizzled related protein 5(SFRP5)	Homo sapiens			GO:0006915~apoptotic process,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007601~visual perception,GO:0008285~negative regulation of cell proliferation,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030510~regulation of BMP signaling pathway,GO:0035567~non-canonical Wnt signaling pathway,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0051898~negative regulation of protein kinase B signaling,GO:0060070~canonical Wnt signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:2000057~negative regulation of Wnt signaling pathway involved in digestive tract morphogenesis,	GO:0005615~extracellular space,	GO:0017147~Wnt-protein binding,	IPR001134:Netrin domain,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015526:Frizzled/secreted frizzled-related protein,IPR018933:Netrin module, non-TIMP type,IPR020067:Frizzled domain,	hsa04310:Wnt signaling pathway,			SM00063:FRI,SM00643:C345C,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	DOMAIN:FZ,DOMAIN:NTR,
SPP2	secreted phosphoprotein 2(SPP2)	Homo sapiens			GO:0001501~skeletal system development,GO:0046849~bone remodeling,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0031089~platelet dense granule lumen,	GO:0004866~endopeptidase inhibitor activity,	IPR010892:Secreted phosphoprotein 24,						KW-0964~Secreted,		KW-0732~Signal,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,
SCTR	secretin receptor(SCTR)	Homo sapiens			GO:0002024~diet induced thermogenesis,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007420~brain development,GO:0009992~cellular water homeostasis,GO:0031667~response to nutrient levels,GO:0032098~regulation of appetite,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0048167~regulation of synaptic plasticity,	GO:0005881~cytoplasmic microtubule,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0008528~G-protein coupled peptide receptor activity,GO:0015055~secretin receptor activity,GO:0017046~peptide hormone binding,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR002144:GPCR, family 2, secretin receptor,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04972:Pancreatic secretion,hsa04976:Bile secretion,			SM00008:HormR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
SEMA3C	semaphorin 3C(SEMA3C)	Homo sapiens			GO:0001755~neural crest cell migration,GO:0001756~somitogenesis,GO:0001974~blood vessel remodeling,GO:0003148~outflow tract septum morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003350~pulmonary myocardium development,GO:0006955~immune response,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0009410~response to xenobiotic stimulus,GO:0009791~post-embryonic development,GO:0021915~neural tube development,GO:0030335~positive regulation of cell migration,GO:0048843~negative regulation of axon extension involved in axon guidance,GO:0050919~negative chemotaxis,GO:0060174~limb bud formation,GO:0060666~dichotomous subdivision of terminal units involved in salivary gland branching,GO:0071526~semaphorin-plexin signaling pathway,GO:1905312~positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005887~integral component of plasma membrane,GO:0070062~extracellular exosome,	GO:0030215~semaphorin receptor binding,GO:0045499~chemorepellent activity,	IPR001627:Semaphorin/CD100 antigen,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016201:Plexin-like fold,IPR027231:Semaphorin,	hsa04360:Axon guidance,			SM00409:IG,SM00423:PSI,SM00630:Sema,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Sema,REGION:Disordered,
SEMA4A	semaphorin 4A(SEMA4A)	Homo sapiens			GO:0001525~angiogenesis,GO:0001755~neural crest cell migration,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0008360~regulation of cell shape,GO:0010594~regulation of endothelial cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030154~cell differentiation,GO:0030335~positive regulation of cell migration,GO:0045063~T-helper 1 cell differentiation,GO:0048843~negative regulation of axon extension involved in axon guidance,GO:0050919~negative chemotaxis,GO:0071526~semaphorin-plexin signaling pathway,GO:1904891~positive regulation of excitatory synapse assembly,GO:1905704~positive regulation of inhibitory synapse assembly,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0030215~semaphorin receptor binding,GO:0045499~chemorepellent activity,	IPR001627:Semaphorin/CD100 antigen,IPR002165:Plexin,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016201:Plexin-like fold,IPR027231:Semaphorin,	hsa04360:Axon guidance,	610282~Retinitis pigmentosa 35,610283~Cone-rod dystrophy 10,		SM00423:PSI,SM00630:Sema,	KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0391~Immunity,KW-0524~Neurogenesis,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:PSI,DOMAIN:Sema,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SERINC2	serine incorporator 2(SERINC2)	Homo sapiens			GO:0006658~phosphatidylserine metabolic process,GO:0006665~sphingolipid metabolic process,GO:1904219~positive regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity,GO:1904222~positive regulation of serine C-palmitoyltransferase activity,	GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,		IPR005016:TMS membrane protein/tumour differentially expressed protein,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
SRRM4	serine/arginine repetitive matrix 4(SRRM4)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0007605~sensory perception of sound,GO:0008380~RNA splicing,GO:0030154~cell differentiation,GO:0042551~neuron maturation,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,	GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,						KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Serine/arginine repetitive matrix protein C-terminal,REGION:Disordered,
STK19	serine/threonine kinase 19(STK19)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0046579~positive regulation of Ras protein signal transduction,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,	IPR018865:Serine-threonine protein kinase 19,						KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0464~Manganese,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,REGION:Disordered,
STK40	serine/threonine kinase 40(STK40)	Homo sapiens			GO:0003016~respiratory system process,GO:0005977~glycogen metabolic process,GO:0010468~regulation of gene expression,GO:0016310~phosphorylation,GO:0035264~multicellular organism growth,GO:0043066~negative regulation of apoptotic process,GO:0043408~regulation of MAPK cascade,GO:0048286~lung alveolus development,GO:0060425~lung morphogenesis,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR024104:Pseudokinase tribbles family/serine-threonine-protein kinase 40,IPR024236:Serine/threonine-protein kinase 40,				SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,REGION:Disordered,
SERPINA6	serpin family A member 6(SERPINA6)	Homo sapiens			GO:0008211~glucocorticoid metabolic process,GO:0010951~negative regulation of endopeptidase activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005496~steroid binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,		611489~Corticosteroid-binding globulin deficiency,		SM00093:SERPIN,	KW-0813~Transport,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0446~Lipid-binding,KW-0754~Steroid-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Serpin,SITE:Conserved cysteine within steroid binding domain,
SERPING1	serpin family G member 1(SERPING1)	Homo sapiens		h_intrinsicPathway:Intrinsic Prothrombin Activation Pathway,	GO:0001869~negative regulation of complement activation, lectin pathway,GO:0006958~complement activation, classical pathway,GO:0007568~aging,GO:0007596~blood coagulation,GO:0008015~blood circulation,GO:0010951~negative regulation of endopeptidase activity,GO:0030193~regulation of blood coagulation,GO:0042730~fibrinolysis,GO:0045087~innate immune response,GO:0045916~negative regulation of complement activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,	IPR000215:Serpin family,IPR015553:Protease inhibitor I4, serpin C1,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04610:Complement and coagulation cascades,hsa05133:Pertussis,	106100~Angioedema, hereditary, 1 and 2,120790~Complement component 4, partial deficiency of,		SM00093:SERPIN,	KW-0094~Blood coagulation,KW-0180~Complement pathway,KW-0280~Fibrinolysis,KW-0356~Hemostasis,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; in variant TA,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Serpin,REGION:7 X 4 AA tandem repeats of [QE]-P-T-[TQ],REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,SITE:Reactive bond,SITE:Reactive bond for chymotrypsin,
SESN2	sestrin 2(SESN2)	Homo sapiens			GO:0001932~regulation of protein phosphorylation,GO:0006111~regulation of gluconeogenesis,GO:0006635~fatty acid beta-oxidation,GO:0009749~response to glucose,GO:0016239~positive regulation of macroautophagy,GO:0030308~negative regulation of cell growth,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0032042~mitochondrial DNA metabolic process,GO:0032868~response to insulin,GO:0034198~cellular response to amino acid starvation,GO:0034599~cellular response to oxidative stress,GO:0036091~positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0042149~cellular response to glucose starvation,GO:0042593~glucose homeostasis,GO:0043491~protein kinase B signaling,GO:0046323~glucose import,GO:0070328~triglyceride homeostasis,GO:0071230~cellular response to amino acid stimulus,GO:0071233~cellular response to leucine,GO:0072593~reactive oxygen species metabolic process,GO:0098869~cellular oxidant detoxification,GO:1900182~positive regulation of protein localization to nucleus,GO:1901031~regulation of response to reactive oxygen species,GO:1902010~negative regulation of translation in response to endoplasmic reticulum stress,GO:1903432~regulation of TORC1 signaling,GO:1904262~negative regulation of TORC1 signaling,GO:1904263~positive regulation of TORC1 signaling,GO:1904504~positive regulation of lipophagy,GO:1990253~cellular response to leucine starvation,GO:2000479~regulation of cAMP-dependent protein kinase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0031588~nucleotide-activated protein kinase complex,GO:0031932~TORC2 complex,GO:1990316~ATG1/ULK1 kinase complex,	GO:0004601~peroxidase activity,GO:0005092~GDP-dissociation inhibitor activity,GO:0005515~protein binding,GO:0016684~oxidoreductase activity, acting on peroxide as acceptor,GO:0032542~sulfiredoxin activity,GO:0042731~PH domain binding,GO:0044877~macromolecular complex binding,GO:0070728~leucine binding,	IPR006730:PA26 p53-induced protein (sestrin),	hsa04115:p53 signaling pathway,hsa04150:mTOR signaling pathway,hsa04211:Longevity regulating pathway,					KW-0963~Cytoplasm,				KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:C->S: Decreased alkylhydroperoxide reductase activity and loss of the ability to decrease intracellular reactive oxygen species. No effect on interaction with the GATOR2 complex. No effect on inhibition of TOR signaling.,MUTAGEN:C->S: No effect on ability to decrease intracellular reactive oxygen species.,MUTAGEN:C->S: No effect on alkylhydroperoxide reductase activity.,MUTAGEN:C->S: No effect on alkylhydroperoxide reductase activity. Altered ability to decrease intracellular reactive oxygen species. No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:C->S: No effect on alkylhydroperoxide reductase activity. No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:D->A: No effect on alkylhydroperoxide reductase activity. Loss of interaction with the GATOR2 complex. Unable to inhibit the TORC1 signaling pathway.,MUTAGEN:D->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-387.,MUTAGEN:D->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-411 and A-415.,MUTAGEN:DD->AA: Loss of interaction with the GATOR2 complex. No effect on leucine-binding.,MUTAGEN:E->A: Decreased leucine-binding.,MUTAGEN:E->L: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with R-258 and R-261.,MUTAGEN:E->Q: Loss of leucine-binding. Constitutively interacts with the GATOR2 complex.,MUTAGEN:G->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-409 and A-415.,MUTAGEN:H->A: Decreased alkylhydroperoxide reductase activity. No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:H->A: Loss of leucine-binding.,MUTAGEN:H->E: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with C-128.,MUTAGEN:K->A: Abolished 'Lys-63'-linked ubiquitination by RNF167.,MUTAGEN:K->A: About two-fold prolonged half-life in cycloheximide/CHX time course.,MUTAGEN:K->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-419 and A-422.,MUTAGEN:K->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-419 and A-426.,MUTAGEN:L->A: Decreased leucine-binding. Promotes interaction with RNF167.,MUTAGEN:L->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-376.,MUTAGEN:L->C: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with E-113.,MUTAGEN:L->R: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with R-258 and L-259.,MUTAGEN:MER->LMM: No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:N->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-373.,MUTAGEN:P->S: No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:Q->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-409 and A-411.,MUTAGEN:QD->AA: No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:R->A: Loss of leucine-binding. Promotes interaction with RNF167. Constitutively interacts with the GATOR2 complex.,MUTAGEN:R->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-422 and A-426.,MUTAGEN:R->P: No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:S->A: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with A-385.,MUTAGEN:S->W: Loss of interaction with GATOR2. No effect on leucine-binding. Unable to mediate leucine-induced inhibition of the TORC1 signaling pathway.,MUTAGEN:T->A: Loss of leucine-binding. Constitutively interacts with the GATOR2 complex.,MUTAGEN:TF->AA: No effect on the ability to inhibit the TORC1 signaling pathway.,MUTAGEN:V->R: No effect on the ability to inhibit the TORC1 signaling pathway; when associated with L-259 and R-261.,MUTAGEN:W->E: Loss of leucine-binding.,MUTAGEN:W->L: Decreased affinity for leucine. Requires increased leucine concentration to dissociate from GATOR2 and activate TORC1 signaling.,MUTAGEN:Y->A: Loss of leucine-binding.,MUTAGEN:Y->F: Decreased alkylhydroperoxide reductase activity. No effect on the ability to inhibit the TORC1 signaling pathway.,REGION:C-terminal domain; mediates TORC1 regulation,REGION:Disordered,REGION:N-terminal domain; mediates the alkylhydroperoxide reductase activity,
SHISA3	shisa family member 3(SHISA3)	Homo sapiens			GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR026910:Shisa family,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,		REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SIGLEC9	sialic acid binding Ig like lectin 9(SIGLEC9)	Homo sapiens			GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0033691~sialic acid binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04613:Neutrophil extracellular trap formation,			SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,MOTIF:ITIM motif,MOTIF:SLAM-like motif,MUTAGEN:R->K: Loss of sialic acid binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SIRPB1	signal regulatory protein beta 1(SIRPB1)	Homo sapiens			GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0050766~positive regulation of phagocytosis,GO:0050870~positive regulation of T cell activation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0005515~protein binding,	IPR003597:Immunoglobulin C1-set,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04380:Osteoclast differentiation,			SM00406:IGv,SM00407:IGc1,SM00409:IG,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type 1,DOMAIN:Ig-like C1-type 2,DOMAIN:Ig-like V-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SIRPD	signal regulatory protein delta(SIRPD)	Homo sapiens				GO:0005576~extracellular region,GO:0005886~plasma membrane,		IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,		KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,REGION:Disordered,
STAT5A	signal transducer and activator of transcription 5A(STAT5A)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tpoPathway:TPO Signaling Pathway,	GO:0001553~luteinization,GO:0001779~natural killer cell differentiation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007259~JAK-STAT cascade,GO:0007565~female pregnancy,GO:0007595~lactation,GO:0019218~regulation of steroid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0019915~lipid storage,GO:0030222~eosinophil differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0032355~response to estradiol,GO:0032743~positive regulation of interleukin-2 production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0032870~cellular response to hormone stimulus,GO:0033077~T cell differentiation in thymus,GO:0035723~interleukin-15-mediated signaling pathway,GO:0035771~interleukin-4-mediated signaling pathway,GO:0038026~reelin-mediated signaling pathway,GO:0038043~interleukin-5-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038156~interleukin-3-mediated signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042448~progesterone metabolic process,GO:0043029~T cell homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043434~response to peptide hormone,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046543~development of secondary female sexual characteristics,GO:0046544~development of secondary male sexual characteristics,GO:0048541~Peyer's patch development,GO:0050729~positive regulation of inflammatory response,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097531~mast cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,	IPR000980:SH2 domain,IPR001217:STAT transcription factor, core,IPR008967:p53-like transcription factor, DNA-binding,IPR012345:STAT transcription factor, DNA-binding, subdomain,IPR013799:STAT transcription factor, protein interaction,IPR013800:STAT transcription factor, all-alpha,IPR013801:STAT transcription factor, DNA-binding,IPR015988:STAT transcription factor, coiled coil,	hsa04012:ErbB signaling pathway,hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,			SM00252:SH2,SM00964:SM00964,	KW-0421~Lactation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MUTAGEN:T->A: Abolishes interaction with INSR.,MUTAGEN:Y->F: Abolishes phosphorylation by HCK.,REGION:Disordered,REGION:Required for interaction with NMI,
STAT5B	signal transducer and activator of transcription 5B(STAT5B)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tpoPathway:TPO Signaling Pathway,	GO:0000278~mitotic cell cycle,GO:0001553~luteinization,GO:0001779~natural killer cell differentiation,GO:0001787~natural killer cell proliferation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007259~JAK-STAT cascade,GO:0007565~female pregnancy,GO:0007595~lactation,GO:0019218~regulation of steroid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0019915~lipid storage,GO:0030183~B cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0032355~response to estradiol,GO:0032743~positive regulation of interleukin-2 production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0032870~cellular response to hormone stimulus,GO:0033028~myeloid cell apoptotic process,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0033077~T cell differentiation in thymus,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042448~progesterone metabolic process,GO:0042492~gamma-delta T cell differentiation,GO:0043029~T cell homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043434~response to peptide hormone,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046543~development of secondary female sexual characteristics,GO:0046544~development of secondary male sexual characteristics,GO:0048541~Peyer's patch development,GO:0050729~positive regulation of inflammatory response,GO:0050798~activated T cell proliferation,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097531~mast cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,	IPR000980:SH2 domain,IPR001217:STAT transcription factor, core,IPR008967:p53-like transcription factor, DNA-binding,IPR012345:STAT transcription factor, DNA-binding, subdomain,IPR013799:STAT transcription factor, protein interaction,IPR013800:STAT transcription factor, all-alpha,IPR013801:STAT transcription factor, DNA-binding,IPR015988:STAT transcription factor, coiled coil,	hsa04012:ErbB signaling pathway,hsa04062:Chemokine signaling pathway,hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,	102578~Leukemia, acute promyelocytic, somatic,245590~Growth hormone insensitivity with immune dysregulation 1, autosomal recessive,618985~Growth hormone insensitivity with immune dysregulation 2, autosomal dominant,		SM00252:SH2,SM00964:SM00964,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MUTAGEN:T->A: Abolishes interaction with INSR.,MUTAGEN:Y->F: Abolishes phosphorylation by HCK.,REGION:Required for interaction with NMI,
SSH1	slingshot protein phosphatase 1(SSH1)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0006470~protein dephosphorylation,GO:0030036~actin cytoskeleton organization,GO:0030837~negative regulation of actin filament polymerization,GO:0031915~positive regulation of synaptic plasticity,GO:0032268~regulation of cellular protein metabolic process,GO:0051246~regulation of protein metabolic process,GO:0071318~cellular response to ATP,GO:0098976~excitatory chemical synaptic transmission,GO:1904719~positive regulation of AMPA glutamate receptor clustering,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030027~lamellipodium,GO:0030426~growth cone,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0045202~synapse,	GO:0003779~actin binding,GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0016791~phosphatase activity,GO:0017018~myosin phosphatase activity,	IPR000340:Dual specificity phosphatase, catalytic domain,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR014876:DEK, C-terminal,IPR016130:Protein-tyrosine phosphatase, active site,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,IPR027233:Protein phosphatase Slingshot homologue 1,	hsa04360:Axon guidance,hsa04810:Regulation of actin cytoskeleton,			SM00195:DSPc,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DEK-C,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Abrogates phosphatase activity.,MUTAGEN:S->A: Reduces binding to YWHAB, YWHAG, YWHAQ and YWHAZ. Abolishes binding to YWHAB, YWHAG, YWHAQ and YWHAZ and increases association with F-actin; when associated with A-937.,MUTAGEN:S->A: Reduces binding to YWHAB, YWHAG, YWHAQ and YWHAZ. Abolishes binding to YWHAB, YWHAG, YWHAQ and YWHAZ and increases association with F-actin; when associated with A-978.,MUTAGEN:W->A: Impairs stimulation of phosphatase activity by actin but does not affect basal activity.,REGION:Disordered,REGION:Interaction with YWHAG,TRANSMEM:Helical,
SLIT2	slit guidance ligand 2(SLIT2)	Homo sapiens			GO:0001657~ureteric bud development,GO:0001933~negative regulation of protein phosphorylation,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002689~negative regulation of leukocyte chemotaxis,GO:0003180~aortic valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0007411~axon guidance,GO:0008045~motor neuron axon guidance,GO:0010593~negative regulation of lamellipodium assembly,GO:0010596~negative regulation of endothelial cell migration,GO:0014912~negative regulation of smooth muscle cell migration,GO:0016043~cellular component organization,GO:0021836~chemorepulsion involved in postnatal olfactory bulb interneuron migration,GO:0021972~corticospinal neuron axon guidance through spinal cord,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0030837~negative regulation of actin filament polymerization,GO:0031290~retinal ganglion cell axon guidance,GO:0032870~cellular response to hormone stimulus,GO:0035385~Roundabout signaling pathway,GO:0043065~positive regulation of apoptotic process,GO:0043116~negative regulation of vascular permeability,GO:0048699~generation of neurons,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048846~axon extension involved in axon guidance,GO:0050772~positive regulation of axonogenesis,GO:0050919~negative chemotaxis,GO:0050929~induction of negative chemotaxis,GO:0051058~negative regulation of small GTPase mediated signal transduction,GO:0051414~response to cortisol,GO:0060412~ventricular septum morphogenesis,GO:0061364~apoptotic process involved in luteolysis,GO:0070100~negative regulation of chemokine-mediated signaling pathway,GO:0071504~cellular response to heparin,GO:0071672~negative regulation of smooth muscle cell chemotaxis,GO:0071676~negative regulation of mononuclear cell migration,GO:0090024~negative regulation of neutrophil chemotaxis,GO:0090027~negative regulation of monocyte chemotaxis,GO:0090260~negative regulation of retinal ganglion cell axon guidance,GO:0090288~negative regulation of cellular response to growth factor stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009986~cell surface,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005095~GTPase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043237~laminin-1 binding,GO:0043394~proteoglycan binding,GO:0048495~Roundabout binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,IPR000742:Epidermal growth factor-like domain,IPR001611:Leucine-rich repeat,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR003591:Leucine-rich repeat, typical subtype,IPR003645:Follistatin-like, N-terminal,IPR006207:Cystine knot, C-terminal,IPR013032:EGF-like, conserved site,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR018097:EGF-like calcium-binding, conserved site,	hsa04360:Axon guidance,			SM00013:LRRNT,SM00041:CT,SM00082:LRRCT,SM00179:EGF_CA,SM00181:EGF,SM00274:FOLN,SM00282:LamG,SM00369:LRR_TYP,	KW-0145~Chemotaxis,KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-0358~Heparin-binding,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CTCK,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:LRRCT 1,DOMAIN:LRRCT 2,DOMAIN:LRRCT 3,DOMAIN:LRRCT 4,DOMAIN:LRRNT,DOMAIN:LRRNT 2,DOMAIN:LRRNT 3,DOMAIN:LRRNT 4,DOMAIN:Laminin G,DOMAIN:Laminin G-like,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,SITE:Cleavage,
SNORD47	small nucleolar RNA, C/D box 47(SNORD47)	Homo sapiens			GO:0006396~RNA processing,	GO:0005730~nucleolus,
SPRR1B	small proline rich protein 1B(SPRR1B)	Homo sapiens			GO:0008544~epidermis development,GO:0018149~peptide cross-linking,GO:0030216~keratinocyte differentiation,GO:0031424~keratinization,	GO:0001533~cornified envelope,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005198~structural molecule activity,	IPR003302:Cornifin (SPRR1),					KW-0417~Keratinization,	KW-0963~Cytoplasm,		KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:2 X 12 AA approximate repeats,REGION:6 X 8 AA approximate tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,
SPRR2A	small proline rich protein 2A(SPRR2A)	Homo sapiens			GO:0008544~epidermis development,GO:0008585~female gonad development,GO:0019731~antibacterial humoral response,GO:0030216~keratinocyte differentiation,GO:0031424~keratinization,GO:0032355~response to estradiol,GO:0048874~homeostasis of number of cells in a free-living population,GO:0050830~defense response to Gram-positive bacterium,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030133~transport vesicle,GO:0030141~secretory granule,	GO:0005515~protein binding,GO:0008289~lipid binding,							KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0446~Lipid-binding,	KW-0044~Antibiotic,KW-0929~Antimicrobial,	KW-1015~Disulfide bond,	REGION:3 X 9 AA tandem repeats of P-K-C-P-[EQ]-P-C-P-P,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
SCNN1B	sodium channel epithelial 1 subunit beta(SCNN1B)	Homo sapiens			GO:0002269~leukocyte activation involved in inflammatory response,GO:0002283~neutrophil activation involved in immune response,GO:0003014~renal system process,GO:0006814~sodium ion transport,GO:0006883~cellular sodium ion homeostasis,GO:0007588~excretion,GO:0008217~regulation of blood pressure,GO:0009410~response to xenobiotic stimulus,GO:0010467~gene expression,GO:0014824~artery smooth muscle contraction,GO:0032094~response to food,GO:0032341~aldosterone metabolic process,GO:0034101~erythrocyte homeostasis,GO:0035264~multicellular organism growth,GO:0035725~sodium ion transmembrane transport,GO:0036254~cellular response to amiloride,GO:0042045~epithelial fluid transport,GO:0050891~multicellular organismal water homeostasis,GO:0050909~sensory perception of taste,GO:0050914~sensory perception of salty taste,GO:0050915~sensory perception of sour taste,GO:0055075~potassium ion homeostasis,GO:0055078~sodium ion homeostasis,GO:0070254~mucus secretion,GO:0070944~neutrophil mediated killing of bacterium,GO:0071468~cellular response to acidic pH,GO:0097274~urea homeostasis,GO:0098719~sodium ion import across plasma membrane,GO:1904045~cellular response to aldosterone,GO:1904117~cellular response to vasopressin,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0034706~sodium channel complex,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0005272~sodium channel activity,GO:0005515~protein binding,GO:0015280~ligand-gated sodium channel activity,GO:0050699~WW domain binding,	IPR001873:Na+ channel, amiloride-sensitive,IPR004724:Epithelial sodium channel,IPR020903:Na+ channel, amiloride-sensitive, conserved site,	hsa04742:Taste transduction,hsa04960:Aldosterone-regulated sodium reabsorption,	177200~Liddle syndrome 1,211400~Bronchiectasis with or without elevated sweat chloride 1,620125~Pseudohypoaldosteronism, type IB2, autosomal recessive,			KW-0406~Ion transport,KW-0716~Sensory transduction,KW-0739~Sodium transport,KW-0813~Transport,KW-0919~Taste,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,	KW-0407~Ion channel,KW-0894~Sodium channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,
SLC12A5	solute carrier family 12 member 5(SLC12A5)	Homo sapiens			GO:0006811~ion transport,GO:0006873~cellular ion homeostasis,GO:0006884~cell volume homeostasis,GO:0006971~hypotonic response,GO:0007268~chemical synaptic transmission,GO:0007612~learning,GO:0009410~response to xenobiotic stimulus,GO:0030644~cellular chloride ion homeostasis,GO:0035264~multicellular organism growth,GO:0040040~thermosensory behavior,GO:0051452~intracellular pH reduction,GO:0055064~chloride ion homeostasis,GO:0055075~potassium ion homeostasis,GO:0060996~dendritic spine development,GO:0072488~ammonium transmembrane transport,GO:1902476~chloride transmembrane transport,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032590~dendrite membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0045202~synapse,GO:0071944~cell periphery,	GO:0008519~ammonium transmembrane transporter activity,GO:0015108~chloride transmembrane transporter activity,GO:0015379~potassium:chloride symporter activity,GO:0019901~protein kinase binding,GO:0046872~metal ion binding,	IPR000076:K-Cl co-transporter,IPR004841:Amino acid permease domain,IPR004842:Na/K/Cl co-transporter superfamily,IPR018491:K/Cl co-transporter, type 1/type 3,	hsa04727:GABAergic synapse,	616645~Developmental and epileptic encephalopathy 34,616685~Epilepsy, idiopathic generalized, susceptibility to, 14,			KW-0406~Ion transport,KW-0633~Potassium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0630~Potassium,KW-0868~Chloride,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Amino acid permease/ SLC12A,DOMAIN:SLC12A transporter C-terminal,MUTAGEN:T->A: Decreased phosphorylation by WNK kinases, leading to increased potassium-chloride cotransport activity; when associated with A-1030.,MUTAGEN:T->A: Decreased phosphorylation by WNK kinases, leading to increased potassium-chloride cotransport activity; when associated with A-929.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Discontinuously helical,TRANSMEM:Helical,
SLC13A5	solute carrier family 13 member 5(SLC13A5)	Homo sapiens			GO:0006814~sodium ion transport,GO:0015729~oxaloacetate transport,GO:0015741~fumarate transport,GO:0015742~alpha-ketoglutarate transport,GO:0015744~succinate transport,GO:0015746~citrate transport,GO:0035674~tricarboxylic acid transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0071285~cellular response to lithium ion,GO:0071422~succinate transmembrane transport,GO:0098656~anion transmembrane transport,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005343~organic acid:sodium symporter activity,GO:0005515~protein binding,GO:0015137~citrate transmembrane transporter activity,GO:0015141~succinate transmembrane transporter activity,GO:0017153~sodium:dicarboxylate symporter activity,GO:0022857~transmembrane transporter activity,GO:0042802~identical protein binding,	IPR001898:Sodium/sulphate symporter,		615905~Developmental and epileptic encephalopathy 25, with amelogenesis imperfecta,			KW-0406~Ion transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0986~Amelogenesis imperfecta,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:G->Q: No effect on its function in citrate transport.,MUTAGEN:I->A,F: Significant loss of function in citrate transport.,MUTAGEN:I->V: No effect on its function in citrate transport.,TRANSMEM:Helical,
SLC19A1	solute carrier family 19 member 1(SLC19A1)	Homo sapiens			GO:0006855~drug transmembrane transport,GO:0007565~female pregnancy,GO:0015711~organic anion transport,GO:0015884~folic acid transport,GO:0046655~folic acid metabolic process,GO:0051958~methotrexate transport,GO:0055085~transmembrane transport,GO:0098656~anion transmembrane transport,GO:0098838~reduced folate transmembrane transport,GO:1904447~folic acid import into cell,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031526~brush border membrane,	GO:0005542~folic acid binding,GO:0008514~organic anion transmembrane transporter activity,GO:0008517~folic acid transporter activity,GO:0008518~reduced folate carrier activity,GO:0015297~antiporter activity,GO:0015350~methotrexate transporter activity,GO:0042910~xenobiotic transporter activity,GO:0061507~cyclic-GMP-AMP binding,	IPR002666:Reduced folate carrier,	hsa01523:Antifolate resistance,hsa04977:Vitamin digestion and absorption,	601775~Megaloblastic anemia, folate-responsive,	PIRSF028739:folate/thiamine transporter,PIRSF500793:folate transporter 1 [Parent=PIRSF028739],		KW-0050~Antiport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0290~Folate-binding,		KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:N->Q: Completely abolishes N-glycosylation without affecting subcellular location or folate:anion antiporter activity.,REGION:Disordered,REGION:Required for substrate-binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC2A10	solute carrier family 2 member 10(SLC2A10)	Homo sapiens			GO:0008643~carbohydrate transport,GO:0008645~hexose transport,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0015757~galactose transport,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0032683~negative regulation of connective tissue growth factor production,GO:0043588~skin development,GO:0045454~cell redox homeostasis,GO:0060392~negative regulation of SMAD protein import into nucleus,GO:0060840~artery development,GO:0070837~dehydroascorbic acid transport,GO:0072359~circulatory system development,GO:0072498~embryonic skeletal joint development,GO:0098708~glucose import across plasma membrane,GO:1902600~hydrogen ion transmembrane transport,GO:1902729~negative regulation of proteoglycan biosynthetic process,GO:1902730~positive regulation of proteoglycan biosynthetic process,GO:1903053~regulation of extracellular matrix organization,GO:1904659~glucose transmembrane transport,GO:2001045~negative regulation of integrin-mediated signaling pathway,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005351~sugar:proton symporter activity,GO:0015293~symporter activity,GO:0022857~transmembrane transporter activity,GO:0033300~dehydroascorbic acid transporter activity,GO:0055056~D-glucose transmembrane transporter activity,	IPR003663:Sugar/inositol transporter,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR020846:Major facilitator superfamily domain,		208050~Arterial tortuosity syndrome,			KW-0762~Sugar transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Major facilitator superfamily (MFS) profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC2A2	solute carrier family 2 member 2(SLC2A2)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0008643~carbohydrate transport,GO:0015755~fructose transport,GO:0015757~galactose transport,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0046323~glucose import,GO:0070837~dehydroascorbic acid transport,GO:1904659~glucose transmembrane transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005903~brush border,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,	GO:0005353~fructose transmembrane transporter activity,GO:0005354~galactose transmembrane transporter activity,GO:0005355~glucose transmembrane transporter activity,GO:0015149~hexose transmembrane transporter activity,GO:0022857~transmembrane transporter activity,GO:0033300~dehydroascorbic acid transporter activity,GO:0055056~D-glucose transmembrane transporter activity,	IPR002440:Glucose transporter, type 2 (GLUT2),IPR003663:Sugar/inositol transporter,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR020846:Major facilitator superfamily domain,	hsa04911:Insulin secretion,hsa04917:Prolactin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04950:Maturity onset diabetes of the young,hsa04973:Carbohydrate digestion and absorption,hsa05230:Central carbon metabolism in cancer,	125853~Diabetes mellitus, noninsulin-dependent,227810~Fanconi-Bickel syndrome,			KW-0762~Sugar transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:I->V: Reduced fructose transport.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC2A9	solute carrier family 2 member 9(SLC2A9)	Homo sapiens			GO:0008643~carbohydrate transport,GO:0008645~hexose transport,GO:0015747~urate transport,GO:0015749~monosaccharide transport,GO:0015755~fructose transport,GO:0046415~urate metabolic process,GO:1902600~hydrogen ion transmembrane transport,GO:1904659~glucose transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,	GO:0005351~sugar:proton symporter activity,GO:0005353~fructose transmembrane transporter activity,GO:0005355~glucose transmembrane transporter activity,GO:0015143~urate transmembrane transporter activity,GO:0015149~hexose transmembrane transporter activity,GO:0022857~transmembrane transporter activity,	IPR003663:Sugar/inositol transporter,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR020846:Major facilitator superfamily domain,		612076~Hypouricemia, renal, 2,612076~Uric acid concentration, serum, QTL 2,			KW-0762~Sugar transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:C->A: No effect on fructose transport. Higher affinity and lower transport capacity for urate.,MUTAGEN:C->F: Decreased urate uptake. Decreased Vmax for urate transport. Has no effect on glucose transport.,MUTAGEN:C->G: No effect on urate and fructose transport.,MUTAGEN:C->L: No effect on fructose transport. Highly reduced urate transport.,MUTAGEN:C->S: Increased fructose transport. Highly reduced urate transport.,MUTAGEN:C->S: No effect on urate and fructose transport.,MUTAGEN:C->T: Decreased fructose transport. Higher affinity and lower transport capacity for urate.,MUTAGEN:C->V: No effect on fructose transport. Increased urate binding affinity and decreased urate transport capacity.,MUTAGEN:L->V: Increased fructose binding affinity and decreased fructose transport capacity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC22A11	solute carrier family 22 member 11(SLC22A11)	Homo sapiens			GO:0006811~ion transport,GO:0015698~inorganic anion transport,GO:0015711~organic anion transport,GO:0015732~prostaglandin transport,GO:0046415~urate metabolic process,GO:0055085~transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0070062~extracellular exosome,	GO:0005452~inorganic anion exchanger activity,GO:0005515~protein binding,GO:0008514~organic anion transmembrane transporter activity,GO:0015132~prostaglandin transmembrane transporter activity,GO:0015347~sodium-independent organic anion transmembrane transporter activity,GO:0022857~transmembrane transporter activity,	IPR005828:General substrate transporter,IPR020846:Major facilitator superfamily domain,					KW-0039~Anion exchange,KW-0050~Antiport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:G->L,S,V: Strongly reduced cell surface expression and estrone 3-sulfate transport.,MUTAGEN:H->A: Reduced cell surface expression and estrone 3-sulfate transport. Reduced cell surface expression and estrone 3-sulfate transport; when associated with A-52; A-83; A-305 and A-469.,MUTAGEN:H->A: Reduced cell surface expression and estrone 3-sulfate transport; when associated with A-47; A-52; A-305 and A-469.,MUTAGEN:H->A: Reduced cell surface expression and estrone 3-sulfate transport; when associated with A-47; A-52; A-83 and A-469.,MUTAGEN:H->A: Slightly reduced estrone 3-sulfate transport. Reduced cell surface expression and estrone 3-sulfate transport; when associated with A-47; A-52; A-83 and A-305.,MUTAGEN:H->A: Slightly reduced estrone 3-sulfate transport. Reduced cell surface expression and estrone 3-sulfate transport; when associated with A-47; A-83; A-305 and A-469.,MUTAGEN:N->Q: No visible effect on N-glycosylation. Loss of N-glycosylation and of cell surface expression; when associated with Q-39; Q-56 and Q-63.,MUTAGEN:N->Q: No visible effect on N-glycosylation. Loss of N-glycosylation and of cell surface expression; when associated with Q-39; Q-56 and Q-99.,MUTAGEN:N->Q: No visible effect on N-glycosylation. Loss of N-glycosylation and of cell surface expression; when associated with Q-39; Q-63 and Q-99.,MUTAGEN:N->Q: No visible effect on N-glycosylation. Loss of N-glycosylation and of cell surface location; when associated with Q-56; Q-63 and Q-99.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC22A2	solute carrier family 22 member 2(SLC22A2)	Homo sapiens			GO:0006812~cation transport,GO:0006836~neurotransmitter transport,GO:0006837~serotonin transport,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007589~body fluid secretion,GO:0010628~positive regulation of gene expression,GO:0015695~organic cation transport,GO:0015732~prostaglandin transport,GO:0015837~amine transport,GO:0015847~putrescine transport,GO:0015848~spermidine transport,GO:0015870~acetylcholine transport,GO:0015871~choline transport,GO:0015872~dopamine transport,GO:0015874~norepinephrine transport,GO:0042908~xenobiotic transport,GO:0048241~epinephrine transport,GO:0051608~histamine transport,GO:0051610~serotonin uptake,GO:0051615~histamine uptake,GO:0051620~norepinephrine uptake,GO:0071934~thiamine transmembrane transport,GO:0072530~purine-containing compound transmembrane transport,GO:0089718~amino acid import across plasma membrane,GO:0090494~dopamine uptake,GO:0097638~L-arginine import across plasma membrane,GO:1901998~toxin transport,GO:1902475~L-alpha-amino acid transmembrane transport,GO:1903711~spermidine transmembrane transport,GO:1903826~arginine transmembrane transport,GO:1990962~drug transport across blood-brain barrier,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0070062~extracellular exosome,GO:0098793~presynapse,	GO:0005275~amine transmembrane transporter activity,GO:0005277~acetylcholine transmembrane transporter activity,GO:0005326~neurotransmitter transporter activity,GO:0008504~monoamine transmembrane transporter activity,GO:0008514~organic anion transmembrane transporter activity,GO:0015101~organic cation transmembrane transporter activity,GO:0015132~prostaglandin transmembrane transporter activity,GO:0015179~L-amino acid transmembrane transporter activity,GO:0015214~pyrimidine nucleoside transmembrane transporter activity,GO:0015220~choline transmembrane transporter activity,GO:0015234~thiamine transmembrane transporter activity,GO:0015489~putrescine transmembrane transporter activity,GO:0015562~efflux transmembrane transporter activity,GO:0015606~spermidine transmembrane transporter activity,GO:0015651~quaternary ammonium group transmembrane transporter activity,GO:0019534~toxin transporter activity,GO:0022857~transmembrane transporter activity,GO:0042910~xenobiotic transporter activity,GO:0061459~L-arginine transmembrane transporter activity,	IPR004749:Organic cation transport protein,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR020846:Major facilitator superfamily domain,	hsa05231:Choline metabolism in cancer,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,MOTIF:Proline-rich sequence,MUTAGEN:P->A: Decreased TEA and metformin uptake. Decreased tyrosine phosphorylation.,MUTAGEN:S->A: No change in TEA and metformin uptake. No change in tyrosine phosphorylation.,MUTAGEN:Y->F: Decreased TEA uptake and YES1-mediated tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-241. Strong decrease in TEA uptake; when associated with F-377. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-241 and F-377.,MUTAGEN:Y->F: No change in TEA uptake.,MUTAGEN:Y->F: Slight decrease in TEA uptake. No change in tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-362. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-241 and F-362.,MUTAGEN:Y->F: Slight decrease in TEA uptake. No change in tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-362. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-362 and F-377.,SITE:Involved in recognition of organic cations and participates in structural changes that occur during translocation of organic cations,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC25A10	solute carrier family 25 member 10(SLC25A10)	Homo sapiens			GO:0006094~gluconeogenesis,GO:0006811~ion transport,GO:0006835~dicarboxylic acid transport,GO:0006839~mitochondrial transport,GO:0006869~lipid transport,GO:0008272~sulfate transport,GO:0015709~thiosulfate transport,GO:0015729~oxaloacetate transport,GO:0035435~phosphate ion transmembrane transport,GO:0070221~sulfide oxidation, using sulfide:quinone oxidoreductase,GO:0071422~succinate transmembrane transport,GO:0071423~malate transmembrane transport,GO:1902356~oxaloacetate(2-) transmembrane transport,GO:1902358~sulfate transmembrane transport,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,	GO:0005310~dicarboxylic acid transmembrane transporter activity,GO:0005515~protein binding,GO:0015114~phosphate ion transmembrane transporter activity,GO:0015116~sulfate transmembrane transporter activity,GO:0015117~thiosulfate transmembrane transporter activity,GO:0015131~oxaloacetate transmembrane transporter activity,GO:0015140~malate transmembrane transporter activity,GO:0015141~succinate transmembrane transporter activity,GO:0015297~antiporter activity,	IPR002030:Mitochondrial brown fat uncoupling protein,IPR018108:Mitochondrial substrate/solute carrier,IPR023395:Mitochondrial carrier domain,	hsa04964:Proximal tubule bicarbonate reclamation,	618972~Mitochondrial DNA depletion syndrome 19,			KW-0050~Antiport,KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC27A3	solute carrier family 27 member 3(SLC27A3)	Homo sapiens			GO:0001676~long-chain fatty acid metabolic process,GO:0015908~fatty acid transport,GO:0015909~long-chain fatty acid transport,	GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,	GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005324~long-chain fatty acid transporter activity,GO:0005524~ATP binding,GO:0031957~very long-chain fatty acid-CoA ligase activity,GO:0047676~arachidonate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa04931:Insulin resistance,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,		COMPBIAS:Basic and acidic residues,DOMAIN:AMP-binding enzyme C-terminal,DOMAIN:AMP-dependent synthetase/ligase,REGION:Disordered,TRANSMEM:Helical,
SLC27A4	solute carrier family 27 member 4(SLC27A4)	Homo sapiens			GO:0001579~medium-chain fatty acid transport,GO:0001676~long-chain fatty acid metabolic process,GO:0006631~fatty acid metabolic process,GO:0007584~response to nutrient,GO:0015908~fatty acid transport,GO:0015909~long-chain fatty acid transport,GO:0042760~very long-chain fatty acid catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043588~skin development,GO:0044381~glucose import in response to insulin stimulus,GO:0044539~long-chain fatty acid import,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0051649~establishment of localization in cell,GO:0090630~activation of GTPase activity,GO:1990379~lipid transport across blood brain barrier,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031526~brush border membrane,	GO:0000166~nucleotide binding,GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005324~long-chain fatty acid transporter activity,GO:0015245~fatty acid transporter activity,GO:0031957~very long-chain fatty acid-CoA ligase activity,GO:0047676~arachidonate-CoA ligase activity,GO:0090433~palmitoyl-CoA ligase activity,GO:0090434~oleoyl-CoA ligase activity,GO:1901480~oleate transporter activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR022272:Lipocalin conserved site,IPR025110:Domain of unknown function DUF4009,	hsa03320:PPAR signaling pathway,hsa04931:Insulin resistance,hsa04975:Fat digestion and absorption,	608649~Ichthyosis prematurity syndrome,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0977~Ichthyosis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0547~Nucleotide-binding,	KW-0436~Ligase,		DOMAIN:AMP-binding enzyme C-terminal,DOMAIN:AMP-dependent synthetase/ligase,TRANSMEM:Helical,
SLC4A11	solute carrier family 4 member 11(SLC4A11)	Homo sapiens			GO:0006814~sodium ion transport,GO:0006820~anion transport,GO:0006833~water transport,GO:0015701~bicarbonate transport,GO:0030003~cellular cation homeostasis,GO:0034599~cellular response to oxidative stress,GO:0035445~borate transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0042044~fluid transport,GO:0046713~borate transport,GO:0050801~ion homeostasis,GO:0051881~regulation of mitochondrial membrane potential,GO:0055085~transmembrane transport,GO:0071476~cellular hypotonic response,GO:1902600~hydrogen ion transmembrane transport,GO:2000739~regulation of mesenchymal stem cell differentiation,	GO:0005886~plasma membrane,GO:0012506~vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,	GO:0005272~sodium channel activity,GO:0005372~water transmembrane transporter activity,GO:0005452~inorganic anion exchanger activity,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0015106~bicarbonate transmembrane transporter activity,GO:0015252~hydrogen ion channel activity,GO:0015293~symporter activity,GO:0015301~anion:anion antiporter activity,GO:0022857~transmembrane transporter activity,GO:0046715~borate transmembrane transporter activity,GO:0046983~protein dimerization activity,	IPR003020:Bicarbonate transporter, eukaryotic,IPR011531:Bicarbonate transporter, C-terminal,IPR016152:Phosphotransferase/anion transporter,		217400~Corneal endothelial dystrophy and perceptive deafness,217700~Corneal endothelial dystrophy, autosomal recessive,613268~Corneal dystrophy, Fuchs endothelial, 4,			KW-0039~Anion exchange,KW-0406~Ion transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Bicarbonate transporter-like transmembrane,MUTAGEN:N->A: Decreases the water flux across the plasma membrane.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC40A1	solute carrier family 40 member 1(SLC40A1)	Homo sapiens			GO:0002260~lymphocyte homeostasis,GO:0003158~endothelium development,GO:0006366~transcription from RNA polymerase II promoter,GO:0006879~cellular iron ion homeostasis,GO:0006915~apoptotic process,GO:0034395~regulation of transcription from RNA polymerase II promoter in response to iron,GO:0034755~iron ion transmembrane transport,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051649~establishment of localization in cell,GO:0055072~iron ion homeostasis,GO:0060345~spleen trabecula formation,GO:0060586~multicellular organismal iron ion homeostasis,GO:1903988~ferrous iron export across plasma membrane,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,	GO:0005381~iron ion transmembrane transporter activity,GO:0005515~protein binding,GO:0015093~ferrous iron transmembrane transporter activity,GO:0017046~peptide hormone binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR009716:Ferroporti-1,	hsa04216:Ferroptosis,hsa04978:Mineral absorption,	606069~Hemochromatosis, type 4,			KW-0406~Ion transport,KW-0410~Iron transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:A->D: Loss of iron export function.,MUTAGEN:C->S: Complete loss of HAMP-dependent ubiquitination. Does not affect protein stability. Does not affect cell surface localization.,MUTAGEN:D->N: About 95% loss of HAMP binding.,MUTAGEN:D->Y: Loss of iron export activity. Loss of cell surface localization. Increases intracellular manganese.,MUTAGEN:K->E: Loss of HAMP-induced endocytosis.,MUTAGEN:K->R: No loss of ubiquitination; when associated with R-236.,MUTAGEN:K->R: No loss of ubiquitination; when associated with R-253.,MUTAGEN:L->F: Loss of iron export activity.,MUTAGEN:N->D: Complete loss of HAMP-binding.,MUTAGEN:R->G: Reduces protein stability. Loss of cell surface localization. Loss of iron export activity. Increases intracellular manganese.,MUTAGEN:S->R: Reduces protein stability.,MUTAGEN:Y->C: About 90% loss of HAMP binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC44A4	solute carrier family 44 member 4(SLC44A4)	Homo sapiens			GO:0006656~phosphatidylcholine biosynthetic process,GO:0008292~acetylcholine biosynthetic process,GO:0015871~choline transport,GO:0030307~positive regulation of cell growth,GO:0030974~thiamine pyrophosphate transport,GO:0032475~otolith formation,GO:0035675~neuromast hair cell development,GO:0055085~transmembrane transport,GO:0061526~acetylcholine secretion,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0070062~extracellular exosome,	GO:0015220~choline transmembrane transporter activity,GO:0015297~antiporter activity,GO:0022857~transmembrane transporter activity,GO:0090422~thiamine pyrophosphate transporter activity,	IPR007603:Choline transporter-like,	hsa05231:Choline metabolism in cancer,	617606~Deafness, autosomal dominant 72,			KW-0050~Antiport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:N->D: Decreases glycosylation levels. Decreases thiamine pyrophosphate uptake.,MUTAGEN:N->D: Decreases glycosylation levels. No effect on thiamine pyrophosphate uptake.,MUTAGEN:N->D: No effect on glycosylation.,SITE:Breakpoint for translocation with NEU1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC5A7	solute carrier family 5 member 7(SLC5A7)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0006814~sodium ion transport,GO:0006836~neurotransmitter transport,GO:0007271~synaptic transmission, cholinergic,GO:0007274~neuromuscular synaptic transmission,GO:0008292~acetylcholine biosynthetic process,GO:0015871~choline transport,GO:0055085~transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,GO:0031901~early endosome membrane,GO:0042734~presynaptic membrane,GO:0043204~perikaryon,GO:0045202~synapse,	GO:0005307~choline:sodium symporter activity,GO:0015220~choline transmembrane transporter activity,GO:0022857~transmembrane transporter activity,GO:0033265~choline binding,	IPR001734:Sodium/solute symporter,	hsa04725:Cholinergic synapse,hsa05231:Choline metabolism in cancer,	158580~Neuronopathy, distal hereditary motor, type VIIA,617143~Myasthenic syndrome, congenital, 20, presynaptic,			KW-0406~Ion transport,KW-0530~Neurotransmitter biosynthesis,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-1004~Congenital myasthenic syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MOTIF:Dileucine-like motif,MUTAGEN:E->Q: Decreased choline transmembrane transporter activity, only 5% of wild-type choline uptake activity.,MUTAGEN:I->A: Decreased choline transmembrane transporter activity, only 20% of wild-type choline uptake activity.,MUTAGEN:I->A: No change in protein internalization. No change in choline transmembrane transporter activity.,MUTAGEN:K->V: Decreased protein internalization; when associated with 531-L-V-532. Increased choline transmembrane transporter activity; when associated with 531-L-V-532.,MUTAGEN:L->A: Loss of protein internalization to vesicular structures in neurons. Increased choline transmembrane transporter activity.,MUTAGEN:LV->AA: Decreased protein internalization; when associated with V-538. Increased choline transmembrane transporter activity; when associated with V-538.,MUTAGEN:V->A: Decreased protein internalization. Increased choline transmembrane transporter activity.,REGION:Mediates interaction with SEC14L1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC5A9	solute carrier family 5 member 9(SLC5A9)	Homo sapiens			GO:0006814~sodium ion transport,GO:0008645~hexose transport,GO:1904659~glucose transmembrane transport,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005362~low-affinity glucose:sodium symporter activity,GO:0005412~glucose:sodium symporter activity,GO:0022857~transmembrane transporter activity,	IPR001734:Sodium/solute symporter,IPR018212:Sodium/solute symporter, conserved site,					KW-0406~Ion transport,KW-0739~Sodium transport,KW-0762~Sugar transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC6A2	solute carrier family 6 member 2(SLC6A2)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0007268~chemical synaptic transmission,GO:0009410~response to xenobiotic stimulus,GO:0015844~monoamine transport,GO:0015874~norepinephrine transport,GO:0035725~sodium ion transmembrane transport,GO:0048265~response to pain,GO:0051583~dopamine uptake involved in synaptic transmission,GO:0051620~norepinephrine uptake,GO:0070050~neuron cellular homeostasis,GO:0071702~organic substance transport,GO:0071705~nitrogen compound transport,GO:0098810~neurotransmitter reuptake,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032809~neuronal cell body membrane,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0045121~membrane raft,GO:0098793~presynapse,	GO:0003779~actin binding,GO:0005326~neurotransmitter transporter activity,GO:0005328~neurotransmitter:sodium symporter activity,GO:0005330~dopamine:sodium symporter activity,GO:0005334~norepinephrine:sodium symporter activity,GO:0005515~protein binding,GO:0008504~monoamine transmembrane transporter activity,GO:0015293~symporter activity,GO:0043014~alpha-tubulin binding,GO:0046872~metal ion binding,GO:0048487~beta-tubulin binding,	IPR000175:Sodium:neurotransmitter symporter,IPR002435:Sodium:neurotransmitter symporter, noradrenaline,	hsa04721:Synaptic vesicle cycle,	604715~Orthostatic intolerance,			KW-0532~Neurotransmitter transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0915~Sodium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC6A3	solute carrier family 6 member 3(SLC6A3)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0007568~aging,GO:0007595~lactation,GO:0007608~sensory perception of smell,GO:0007626~locomotory behavior,GO:0009410~response to xenobiotic stimulus,GO:0010039~response to iron ion,GO:0015844~monoamine transport,GO:0015872~dopamine transport,GO:0015874~norepinephrine transport,GO:0021984~adenohypophysis development,GO:0035094~response to nicotine,GO:0035725~sodium ion transmembrane transport,GO:0040018~positive regulation of multicellular organism growth,GO:0042053~regulation of dopamine metabolic process,GO:0042220~response to cocaine,GO:0042416~dopamine biosynthetic process,GO:0042420~dopamine catabolic process,GO:0045471~response to ethanol,GO:0051583~dopamine uptake involved in synaptic transmission,GO:0051591~response to cAMP,GO:0051620~norepinephrine uptake,GO:0060134~prepulse inhibition,GO:0090494~dopamine uptake,GO:1990384~hyaloid vascular plexus regression,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016600~flotillin complex,GO:0030424~axon,GO:0032809~neuronal cell body membrane,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043679~axon terminus,GO:0045121~membrane raft,GO:0045211~postsynaptic membrane,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0002020~protease binding,GO:0005102~receptor binding,GO:0005326~neurotransmitter transporter activity,GO:0005330~dopamine:sodium symporter activity,GO:0005334~norepinephrine:sodium symporter activity,GO:0005515~protein binding,GO:0008504~monoamine transmembrane transporter activity,GO:0035240~dopamine binding,GO:0043176~amine binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0051721~protein phosphatase 2A binding,GO:1901363~heterocyclic compound binding,	IPR000175:Sodium:neurotransmitter symporter,IPR002436:Sodium:neurotransmitter symporter, dopamine,	hsa04721:Synaptic vesicle cycle,hsa04728:Dopaminergic synapse,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,	188890~Nicotine dependence, protection against,613135~Parkinsonism-dystonia, infantile, 1,			KW-0532~Neurotransmitter transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0908~Parkinsonism,KW-1023~Dystonia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0915~Sodium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,REGION:Interaction with TGFB1I1,SITE:Contributes to high-affinity binding to cocaine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC6A5	solute carrier family 6 member 5(SLC6A5)	Homo sapiens			GO:0001504~neurotransmitter uptake,GO:0006836~neurotransmitter transport,GO:0007268~chemical synaptic transmission,GO:0035725~sodium ion transmembrane transport,GO:0060012~synaptic transmission, glycinergic,GO:0071702~organic substance transport,GO:0071705~nitrogen compound transport,GO:1903804~glycine import into cell,	GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031045~dense core granule,GO:0042734~presynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0015293~symporter activity,GO:0015375~glycine:sodium symporter activity,GO:0046872~metal ion binding,	IPR000175:Sodium:neurotransmitter symporter,	hsa04721:Synaptic vesicle cycle,	614618~Hyperekplexia 3,			KW-0532~Neurotransmitter transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:Y->A: Decreased surface expression. Decreased glycine transport.,MUTAGEN:Y->E: Decreased glycine transport.,MUTAGEN:Y->F: No effect on glycine transport.,MUTAGEN:Y->K: No effect on glycine transport.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC6A6	solute carrier family 6 member 6(SLC6A6)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0006865~amino acid transport,GO:0010940~positive regulation of necrotic cell death,GO:0015734~taurine transport,GO:0032328~alanine transport,GO:0035725~sodium ion transmembrane transport,GO:0045597~positive regulation of cell differentiation,GO:0050804~modulation of synaptic transmission,GO:0051939~gamma-aminobutyric acid import,GO:0071702~organic substance transport,GO:0071705~nitrogen compound transport,GO:0089718~amino acid import across plasma membrane,GO:0098739~import across plasma membrane,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030425~dendrite,GO:0031528~microvillus membrane,GO:0043025~neuronal cell body,GO:0045211~postsynaptic membrane,GO:0098797~plasma membrane protein complex,GO:0098982~GABA-ergic synapse,GO:0099055~integral component of postsynaptic membrane,	GO:0005283~sodium:amino acid symporter activity,GO:0005332~gamma-aminobutyric acid:sodium symporter activity,GO:0005368~taurine transmembrane transporter activity,GO:0005369~taurine:sodium symporter activity,GO:0015171~amino acid transmembrane transporter activity,GO:0015185~gamma-aminobutyric acid transmembrane transporter activity,GO:0015293~symporter activity,GO:0022858~alanine transmembrane transporter activity,	IPR000175:Sodium:neurotransmitter symporter,IPR002434:Sodium:neurotransmitter symporter, taurine,		145350~Hypotaurinemic retinal degeneration and cardiomyopathy,			KW-0532~Neurotransmitter transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC7A4	solute carrier family 7 member 4(SLC7A4)	Homo sapiens			GO:0006865~amino acid transport,GO:1990822~basic amino acid transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0015171~amino acid transmembrane transporter activity,GO:0015174~basic amino acid transmembrane transporter activity,	IPR002293:Amino acid/polyamine transporter I,					KW-0029~Amino-acid transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cationic amino acid transporter C-terminal,TRANSMEM:Helical,
SLC8A1	solute carrier family 8 member A1(SLC8A1)	Homo sapiens			GO:0002026~regulation of the force of heart contraction,GO:0002027~regulation of heart rate,GO:0002028~regulation of sodium ion transport,GO:0006811~ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006883~cellular sodium ion homeostasis,GO:0006936~muscle contraction,GO:0007154~cell communication,GO:0007584~response to nutrient,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0010468~regulation of gene expression,GO:0010649~regulation of cell communication by electrical coupling,GO:0010763~positive regulation of fibroblast migration,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0010882~regulation of cardiac muscle contraction by calcium ion signaling,GO:0014829~vascular smooth muscle contraction,GO:0021537~telencephalon development,GO:0030001~metal ion transport,GO:0030501~positive regulation of bone mineralization,GO:0033198~response to ATP,GO:0034614~cellular response to reactive oxygen species,GO:0035725~sodium ion transmembrane transport,GO:0035902~response to immobilization stress,GO:0035994~response to muscle stretch,GO:0036376~sodium ion export from cell,GO:0042542~response to hydrogen peroxide,GO:0044557~relaxation of smooth muscle,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0055013~cardiac muscle cell development,GO:0055074~calcium ion homeostasis,GO:0055119~relaxation of cardiac muscle,GO:0060048~cardiac muscle contraction,GO:0060401~cytosolic calcium ion transport,GO:0060402~calcium ion transport into cytosol,GO:0070509~calcium ion import,GO:0070588~calcium ion transmembrane transport,GO:0071313~cellular response to caffeine,GO:0071320~cellular response to cAMP,GO:0071456~cellular response to hypoxia,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0086012~membrane depolarization during cardiac muscle cell action potential,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0097553~calcium ion transmembrane import into cytosol,GO:0098703~calcium ion import across plasma membrane,GO:0098719~sodium ion import across plasma membrane,GO:0098735~positive regulation of the force of heart contraction,GO:1901660~calcium ion export,GO:1903779~regulation of cardiac conduction,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0014069~postsynaptic density,GO:0014704~intercalated disc,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030018~Z disc,GO:0030054~cell junction,GO:0030315~T-tubule,GO:0030424~axon,GO:0030425~dendrite,GO:0042383~sarcolemma,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0043679~axon terminus,GO:0045202~synapse,GO:0071944~cell periphery,GO:0098794~postsynapse,GO:0099055~integral component of postsynaptic membrane,	GO:0005432~calcium:sodium antiporter activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008092~cytoskeletal protein binding,GO:0015491~cation:cation antiporter activity,GO:0030506~ankyrin binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,GO:0099580~ion antiporter activity involved in regulation of postsynaptic membrane potential,GO:1905060~calcium:cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration,	IPR001623:DnaJ domain,IPR002987:Sodium/calcium exchanger, isoform 1,IPR003644:Na-Ca exchanger/integrin-beta4,IPR004836:Sodium/calcium exchanger protein,IPR004837:Sodium/calcium exchanger membrane region,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04371:Apelin signaling pathway,hsa04740:Olfactory transduction,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04974:Protein digestion and absorption,hsa04978:Mineral absorption,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,			SM00237:Calx_beta,	KW-0050~Antiport,KW-0109~Calcium transport,KW-0406~Ion transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0915~Sodium,	KW-0112~Calmodulin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Calx-beta,DOMAIN:Calx-beta 1,DOMAIN:Calx-beta 2,DOMAIN:J,DOMAIN:Sodium/calcium exchanger membrane region,REGION:Putative calmodulin-binding region,REPEAT:Alpha-1,REPEAT:Alpha-2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLCO2B1	solute carrier organic anion transporter family member 2B1(SLCO2B1)	Homo sapiens			GO:0006805~xenobiotic metabolic process,GO:0006811~ion transport,GO:0015711~organic anion transport,GO:0015721~bile acid and bile salt transport,GO:0015732~prostaglandin transport,GO:0042167~heme catabolic process,GO:0043252~sodium-independent organic anion transport,GO:0055085~transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,	GO:0008514~organic anion transmembrane transporter activity,GO:0015125~bile acid transmembrane transporter activity,GO:0015132~prostaglandin transmembrane transporter activity,GO:0015347~sodium-independent organic anion transmembrane transporter activity,GO:0022857~transmembrane transporter activity,	IPR002350:Kazal domain,IPR004156:Organic anion transporter polypeptide OATP,					KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Kazal-like,MUTAGEN:A->V: Decreased E1S transport, no change in cell surface expression, increased Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:C->A: No change in E1S transport.,MUTAGEN:F->A: Decreased E1S transport; decreased cell surface expression; no change in Km and Vmax values. Decreased taurocholate transport.,MUTAGEN:F->Y: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:G->A: Decreased E1S transport.,MUTAGEN:H->A: Decreased E1S transport, decreased cell surface expression; no change in Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:H->K: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:H->Q: Decreased high-affinity transport of E1S; no change in low-affinity transport of E1S.,MUTAGEN:H->Q: Decreased low- and high-affinity transport of E1S.,MUTAGEN:H->Q: Decreased low-affinity transport of E1S; no change in high affinity transport of E1S.,MUTAGEN:H->Q: Decreased low-affinity transport of E1S; no change in high-affinity transport of E1S.,MUTAGEN:H->Q: Increased high-affinity transport of E1S; decreased low-affinity transport of E1S.,MUTAGEN:H->Q: Increased low- and high-affinity transport of E1S.,MUTAGEN:H->Q: No change in low- and high-affinity transport of E1S.,MUTAGEN:H->Q: Strong decrease in high-affinity transport of E1S and lower Vmax/Km value; no change in low-affinity transport of E1S and higher Vmax/Km value. No change in PGE2 transport. Decreased in low- and high-affinity transport of E1S and lower Vmax/Km values; when associated with Q-579.,MUTAGEN:H->Q: Strong decrease in low-affinity and decreased in high-affinity transport of E1S; undetectable kinetic parameter for low-affinity and no change in Vmax/Km value for high-affinity transort. Increased PGE2 transport. Decreased in low- and high-affinity transport of E1S and lower Vmax/Km values; when associated with Q-618.,MUTAGEN:I->A: Decreased E1S transport, no change in cell surface expression.,MUTAGEN:K->A: Decreased E1S transport, no change in cell surface expression.,MUTAGEN:L->A: Decreased E1S transport, no change in cell surface expression; increased Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:L->A: Decreased E1S transport, no change in cell surface expression; no change in Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:L->A: Decreased E1S transport.,MUTAGEN:L->A: No change in E1S transport.,MUTAGEN:L->I: Decreased E1S transport.,MUTAGEN:M->A: No change in E1S transport.,MUTAGEN:Q->A: Decreased E1S transport, no change in cell surface expression; no change in Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:Q->N: Decreased E1S transport.,MUTAGEN:Q->N: Decreased E1S transport; no change in cell surface expression.,MUTAGEN:R->A: Loss of E1S transport; small decrease in cell surface expression. Strong decrease in low-affinity transport of E1S and loss of high-affinity transport of E1S. Decreased PGE2 transport.,MUTAGEN:S->A: Decreased E1S transport, no change in cell surface expression, increased Km value and decreased Vmax value for E1S transport activity. Decreased taurocholate transport.,MUTAGEN:S->A: Decreased E1S transport.,MUTAGEN:S->T: Decreased E1S transport.,MUTAGEN:V->A: Decreased E1S transport, decreased cell surface expression; no change in Km value and decreased Vmax value. Decreased taurocholate transport.,MUTAGEN:V->I: Decreased E1S transport.,MUTAGEN:W->A: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:W->A: Decreased E1S transport; decreased cell surface expression. Strong decrease in cell surface expression; when associated with A-272 and A-276.,MUTAGEN:W->A: Decreased E1S transport; decreased cell surface expression. Strong decrease in cell surface expression; when associated with A-272 and A-277.,MUTAGEN:W->A: Decreased E1S transport; decreased cell surface expression. Strong decrease in cell surface expression; when associated with A-276 and A-277.,MUTAGEN:W->A: No change in E1S transport; decreased cell surface expression.,MUTAGEN:W->A: No change in E1S transport; no change in cell surface expression.,MUTAGEN:W->F: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:W->F: No change in E1S transport; decreased cell surface expression.,MUTAGEN:W->H: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:W->S: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:W->Y: Decreased E1S transport; decreased cell surface expression.,MUTAGEN:Y->A: No change in E1S transport.,REGION:Disordered,REGION:Required for E1S and taurocholate transport; required for transporter stability,SITE:Essential for E1S and PGE2 transport activity and may interact with these substrates,SITE:Essential for E1S transport activity and may interact with this substrate,SITE:Implicated in high-affinity site for E1S transport,SITE:Implicated in low-affinity site for E1S transport,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SSTR4	somatostatin receptor 4(SSTR4)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007218~neuropeptide signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0016477~cell migration,GO:0030900~forebrain development,GO:0038170~somatostatin signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071385~cellular response to glucocorticoid stimulus,GO:0090238~positive regulation of arachidonic acid secretion,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0043005~neuron projection,	GO:0004930~G-protein coupled receptor activity,GO:0004994~somatostatin receptor activity,GO:0005515~protein binding,GO:0042277~peptide binding,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000586:Somatostatin receptor family,IPR001512:Somatostatin receptor 4,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
SSTR5	somatostatin receptor 5(SSTR5)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007218~neuropeptide signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0032467~positive regulation of cytokinesis,GO:0038170~somatostatin signaling pathway,GO:0042593~glucose homeostasis,GO:0050796~regulation of insulin secretion,GO:0071385~cellular response to glucocorticoid stimulus,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0043005~neuron projection,	GO:0004930~G-protein coupled receptor activity,GO:0004994~somatostatin receptor activity,GO:0005515~protein binding,GO:0042277~peptide binding,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000586:Somatostatin receptor family,IPR001184:Somatostatin receptor 5,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04935:Growth hormone synthesis, secretion and action,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine; by ZDHHC5,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
SNX9	sorting nexin 9(SNX9)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0006898~receptor-mediated endocytosis,GO:0016197~endosomal transport,GO:0030838~positive regulation of actin filament polymerization,GO:0036089~cleavage furrow formation,GO:0043547~positive regulation of GTPase activity,GO:0045860~positive regulation of protein kinase activity,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0060988~lipid tube assembly,GO:0065003~macromolecular complex assembly,GO:0097320~plasma membrane tubulation,GO:1900242~regulation of synaptic vesicle endocytosis,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0030136~clathrin-coated vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0032437~cuticular plate,GO:0070062~extracellular exosome,GO:0098793~presynapse,	GO:0005515~protein binding,GO:0005545~1-phosphatidylinositol binding,GO:0031625~ubiquitin protein ligase binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0071933~Arp2/3 complex binding,	IPR001452:Src homology-3 domain,IPR001683:Phox homologous domain,IPR014536:Sorting nexin, Snx9 type,IPR019497:Sorting nexin protein, WASP-binding domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa05132:Salmonella infection,		PIRSF027744:sorting nexin, Snx9 type,	SM00312:PX,SM00326:SH3,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0254~Endocytosis,KW-0498~Mitosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:PX,DOMAIN:SH3,DOMAIN:Sorting nexin protein WASP-binding,MUTAGEN:K->A: Abolishes binding to phosphatidylinositol 3-phosphate, but not to phosphatidylinositol 4,5-bisphosphate; when associated with A-287.,MUTAGEN:K->E: Abolishes membrane tubulation activity; when associated with E-522.,MUTAGEN:K->E: Abolishes membrane tubulation activity; when associated with E-528.,MUTAGEN:K->E: Strongly reduced membrane binding.,MUTAGEN:KR->EE: Loss of membrane binding.,MUTAGEN:Y->A: Abolishes membrane tubulation activity. Abolishes binding to phosphatidylinositol 3-phosphate, but not to phosphatidylinositol 4,5-bisphosphate; when associated with A-313.,REGION:Critical for tubulation activity,REGION:Disordered,
SALL1	spalt like transcription factor 1(SALL1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001657~ureteric bud development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001822~kidney development,GO:0003281~ventricular septum development,GO:0003337~mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007507~heart development,GO:0008406~gonad development,GO:0021553~olfactory nerve development,GO:0021889~olfactory bulb interneuron differentiation,GO:0021983~pituitary gland development,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030325~adrenal gland development,GO:0031129~inductive cell-cell signaling,GO:0042733~embryonic digit morphogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048566~embryonic digestive tract development,GO:0060173~limb development,GO:0061034~olfactory bulb mitral cell layer development,GO:0072073~kidney epithelium development,GO:0072092~ureteric bud invasion,	GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0010369~chromocenter,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		107480~Townes-Brocks branchiootorenal-like syndrome,107480~Townes-Brocks syndrome 1,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
SALL2	spalt like transcription factor 2(SALL2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001654~eye development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0021915~neural tube development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		216820~Coloboma, ocular, autosomal recessive,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,
SALL3	spalt like transcription factor 3(SALL3)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR022755:Zinc finger, double-stranded RNA binding,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
SPACA3	sperm acrosome associated 3(SPACA3)	Homo sapiens			GO:0007342~fusion of sperm to egg plasma membrane,GO:0009566~fertilization,GO:0035036~sperm-egg recognition,GO:0042117~monocyte activation,GO:0043032~positive regulation of macrophage activation,GO:0050766~positive regulation of phagocytosis,	GO:0001669~acrosomal vesicle,GO:0002080~acrosomal membrane,GO:0005576~extracellular region,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0036126~sperm flagellum,GO:0043159~acrosomal matrix,	GO:0003796~lysozyme activity,GO:0005515~protein binding,	IPR000974:Glycoside hydrolase, family 22, lysozyme,IPR001916:Glycoside hydrolase, family 22,IPR019799:Glycoside hydrolase, family 22, conserved site,IPR023346:Lysozyme-like domain,				SM00263:LYZ1,		KW-0472~Membrane,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-1015~Disulfide bond,	DOMAIN:C-type lysozyme,DOMAIN:Glycosyl hydrolases family 22 (GH22),SITE:Cleavage; to produce processed form,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
SPAG6	sperm associated antigen 6(SPAG6)	Homo sapiens			GO:0003351~epithelial cilium movement,GO:0007288~sperm axoneme assembly,GO:0030030~cell projection organization,GO:0046847~filopodium assembly,GO:1990138~neuron projection extension,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005874~microtubule,GO:0005930~axoneme,GO:0015630~microtubule cytoskeleton,GO:0097228~sperm principal piece,	GO:0008017~microtubule binding,	IPR000225:Armadillo,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,				SM00185:ARM,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0677~Repeat,				REPEAT:ARM 1,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,
SGPP2	sphingosine-1-phosphate phosphatase 2(SGPP2)	Homo sapiens			GO:0006670~sphingosine metabolic process,GO:0030148~sphingolipid biosynthetic process,GO:0046839~phospholipid dephosphorylation,GO:0061469~regulation of type B pancreatic cell proliferation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0042392~sphingosine-1-phosphate phosphatase activity,GO:0070780~dihydrosphingosine-1-phosphate phosphatase activity,	IPR000326:Phosphatidic acid phosphatase type 2/haloperoxidase,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04071:Sphingolipid signaling pathway,			SM00014:acidPPc,	KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,		ACT_SITE:Nucleophile,ACT_SITE:Proton donor,DOMAIN:Phosphatidic acid phosphatase type 2/haloperoxidase,REGION:Disordered,REGION:Phosphatase sequence motif I,REGION:Phosphatase sequence motif II,REGION:Phosphatase sequence motif III,SITE:Stabilizes the active site histidine for nucleophilic attack,TRANSMEM:Helical,
SPSB1	splA/ryanodine receptor domain and SOCS box containing 1(SPSB1)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001496:SOCS protein, C-terminal,IPR001870:B30.2/SPRY domain,IPR003877:SPla/RYanodine receptor SPRY,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00449:SPRY,SM00969:SM00969,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,				KW-0675~Receptor,	KW-0597~Phosphoprotein,	DOMAIN:B30.2/SPRY,DOMAIN:SOCS box,MUTAGEN:LPLP->AAAA: Abolishes interaction with RNF7 and CUL5.,MUTAGEN:Y->F: Loss of phosphorylation.,
SPRED2	sprouty related EVH1 domain containing 2(SPRED2)	Homo sapiens			GO:0001933~negative regulation of protein phosphorylation,GO:0009966~regulation of signal transduction,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0043409~negative regulation of MAPK cascade,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0090311~regulation of protein deacetylation,GO:1902747~negative regulation of lens fiber cell differentiation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,	GO:0005173~stem cell factor receptor binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030291~protein serine/threonine kinase inhibitor activity,	IPR000697:EVH1,IPR007875:Sprouty,IPR011993:Pleckstrin homology-like domain,IPR023337:c-Kit-binding domain,		619745~Noonan syndrome 14,		SM00461:WH1,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:KBD,DOMAIN:SPR,DOMAIN:WH1,MUTAGEN:Y->F: No effect on phosphorylation or ubiquitination.,MUTAGEN:Y->F: No effect on phosphorylation or ubiquitination; when associated with F-264.,MUTAGEN:Y->F: No effect on phosphorylation or ubiquitination; when associated with F-266.,MUTAGEN:Y->F: Reduces ubiquitination and CBL-induced phosphorylation; when associated with F-228.,MUTAGEN:Y->F: Reduces ubiquitination and CBL-induced phosphorylation; when associated with F-231.,REGION:Disordered,
STAB1	stabilin 1(STAB1)	Homo sapiens			GO:0006898~receptor-mediated endocytosis,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007267~cell-cell signaling,GO:0016525~negative regulation of angiogenesis,GO:0042742~defense response to bacterium,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,	GO:0005041~low-density lipoprotein receptor activity,GO:0005044~scavenger receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005540~hyaluronic acid binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0030169~low-density lipoprotein particle binding,	IPR000538:Link,IPR000742:Epidermal growth factor-like domain,IPR000782:FAS1 domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR024731:EGF domain, merozoite surface protein 1-like,				SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00445:LINK,SM00554:FAS1,	KW-0395~Inflammatory response,	KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11,DOMAIN:EGF-like 12,DOMAIN:EGF-like 13,DOMAIN:EGF-like 14,DOMAIN:EGF-like 15,DOMAIN:EGF-like 16,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8,DOMAIN:EGF-like 9,DOMAIN:FAS1,DOMAIN:FAS1 1,DOMAIN:FAS1 2,DOMAIN:FAS1 3,DOMAIN:FAS1 4,DOMAIN:FAS1 5,DOMAIN:FAS1 6,DOMAIN:FAS1 7,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Link,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
STAR	steroidogenic acute regulatory protein(STAR)	Homo sapiens			GO:0006694~steroid biosynthetic process,GO:0008203~cholesterol metabolic process,GO:0008211~glucocorticoid metabolic process,GO:0032367~intracellular cholesterol transport,GO:0044255~cellular lipid metabolic process,GO:0050810~regulation of steroid biosynthetic process,GO:0070859~positive regulation of bile acid biosynthetic process,	GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,	GO:0005515~protein binding,GO:0015485~cholesterol binding,	IPR000799:Steroidogenic acute regulatory protein,IPR002913:START domain,IPR023393:START-like domain,	hsa04913:Ovarian steroidogenesis,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04934:Cushing syndrome,hsa04979:Cholesterol metabolism,	201710~Lipoid adrenal hyperplasia,		SM00234:START,	KW-0445~Lipid transport,KW-0755~Steroidogenesis,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0954~Congenital adrenal hyperplasia,	KW-0809~Transit peptide,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:START,REGION:Disordered,TRANSIT:Mitochondrion,
STIM2	stromal interaction molecule 2(STIM2)	Homo sapiens			GO:0002115~store-operated calcium entry,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0032237~activation of store-operated calcium channel activity,GO:0051928~positive regulation of calcium ion transport,GO:0070588~calcium ion transmembrane transport,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043229~intracellular organelle,	GO:0005246~calcium channel regulator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0015279~store-operated calcium channel activity,GO:0046872~metal ion binding,	IPR001660:Sterile alpha motif domain,IPR013761:Sterile alpha motif/pointed domain,	hsa04020:Calcium signaling pathway,				KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:SAM,DOMAIN:Stromal interaction molecule Orai1-activating region,MUTAGEN:D->A: No effect on inhibitory activity; when associated with A-91.,MUTAGEN:E->A: No effect on inhibitory activity; when associated with A-80.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SULF1	sulfatase 1(SULF1)	Homo sapiens			GO:0001822~kidney development,GO:0001937~negative regulation of endothelial cell proliferation,GO:0002063~chondrocyte development,GO:0003094~glomerular filtration,GO:0006915~apoptotic process,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0014846~esophagus smooth muscle contraction,GO:0016525~negative regulation of angiogenesis,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030201~heparan sulfate proteoglycan metabolic process,GO:0030336~negative regulation of cell migration,GO:0030513~positive regulation of BMP signaling pathway,GO:0032836~glomerular basement membrane development,GO:0035860~glial cell-derived neurotrophic factor receptor signaling pathway,GO:0040036~regulation of fibroblast growth factor receptor signaling pathway,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048706~embryonic skeletal system development,GO:0051216~cartilage development,GO:0060348~bone development,GO:0060384~innervation,GO:0060686~negative regulation of prostatic bud formation,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0045121~membrane raft,	GO:0004065~arylsulfatase activity,GO:0005509~calcium ion binding,GO:0005539~glycosaminoglycan binding,GO:0008449~N-acetylglucosamine-6-sulfatase activity,GO:0008484~sulfuric ester hydrolase activity,	IPR000917:Sulfatase,IPR014615:Extracellular sulfatase,IPR017850:Alkaline-phosphatase-like, core domain,IPR024607:Sulfatase, conserved site,IPR024609:Extracellular sulfatase, C-terminal,			PIRSF036665:extracellular sulfatase,		KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Nucleophile,BINDING:via 3-oxoalanine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Extracellular sulfatase C-terminal,DOMAIN:Sulfatase N-terminal,MUTAGEN:CC->AA: Loss of arylsulfatase activity and loss of ability to modulate apoptosis.,REGION:Catalytic domain; necessary for arylsulfatase activity,REGION:Disordered,REGION:Hydrophilic domain; necessary for endoglucosamine-6-sulfatase activity,SITE:Cleavage; by furin,
SULF2	sulfatase 2(SULF2)	Homo sapiens			GO:0001822~kidney development,GO:0002063~chondrocyte development,GO:0003094~glomerular filtration,GO:0009611~response to wounding,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0014846~esophagus smooth muscle contraction,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030201~heparan sulfate proteoglycan metabolic process,GO:0032836~glomerular basement membrane development,GO:0035860~glial cell-derived neurotrophic factor receptor signaling pathway,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0048706~embryonic skeletal system development,GO:0051216~cartilage development,GO:0060348~bone development,GO:0060384~innervation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097421~liver regeneration,GO:2000345~regulation of hepatocyte proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005795~Golgi stack,GO:0005886~plasma membrane,GO:0009986~cell surface,	GO:0003824~catalytic activity,GO:0004065~arylsulfatase activity,GO:0005509~calcium ion binding,GO:0005539~glycosaminoglycan binding,GO:0008449~N-acetylglucosamine-6-sulfatase activity,GO:0008484~sulfuric ester hydrolase activity,	IPR000917:Sulfatase,IPR014615:Extracellular sulfatase,IPR017850:Alkaline-phosphatase-like, core domain,IPR024607:Sulfatase, conserved site,IPR024609:Extracellular sulfatase, C-terminal,			PIRSF036665:extracellular sulfatase,			KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0654~Proteoglycan,	ACT_SITE:Nucleophile,BINDING:via 3-oxoalanine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,DOMAIN:Extracellular sulfatase C-terminal,DOMAIN:Sulfatase N-terminal,MUTAGEN:CC->AA: Loss of arylsulfatase activity.,MUTAGEN:KEK->AEA: No effect on N-acetylglucosamine-6-sulfatase activity. Significant loss of N-acetylglucosamine-6-sulfatase activity; when associated with 402-A--A-404.,MUTAGEN:KKK->AAA: No effect on N-acetylglucosamine-6-sulfatase activity. Significant loss of N-acetylglucosamine-6-sulfatase activity; when associated with 180-A--A-182.,REGION:Catalytic domain; necessary for arylsulfatase activity,REGION:Disordered,REGION:Hydrophilic domain; necessary for endoglucosamine-6-sulfatase activity,SITE:Cleavage; by furin,
SOD3	superoxide dismutase 3(SOD3)	Homo sapiens		h_longevityPathway:The IGF-1 Receptor and Longevity,	GO:0001666~response to hypoxia,GO:0019430~removal of superoxide radicals,GO:0046688~response to copper ion,GO:0097746~regulation of blood vessel diameter,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005796~Golgi lumen,GO:0070062~extracellular exosome,	GO:0004784~superoxide dismutase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0060090~binding, bridging,	IPR001424:Superoxide dismutase, copper/zinc binding domain,IPR018152:Superoxide dismutase, copper/zinc, binding site,IPR024134:Superoxide dismutase (Cu/Zn) / chaperones,IPR024141:Superoxide dismutase (Cu/Zn), extracellular,		Superoxide dismutase, elevated extracellular~Superoxide dismutase, elevated extracellular,				KW-0333~Golgi apparatus,KW-0964~Secreted,		KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0049~Antioxidant,KW-0358~Heparin-binding,KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0971~Glycation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (Glc) (glycation) lysine; in vitro,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Superoxide dismutase copper/zinc binding,SITE:Not glycated,
SVIL	supervillin(SVIL)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0007519~skeletal muscle tissue development,GO:0008154~actin polymerization or depolymerization,GO:0032467~positive regulation of cytokinesis,GO:0051014~actin filament severing,GO:0051016~barbed-end actin filament capping,	GO:0002102~podosome,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0036449~microtubule minus-end,GO:0042995~cell projection,GO:0043034~costamere,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0051015~actin filament binding,	IPR003128:Villin headpiece,IPR007122:Villin/Gelsolin,IPR007123:Gelsolin domain,IPR015628:Supervillin,		619040~Myofibrillar myopathy 10,		SM00153:VHP,SM00262:GEL,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0911~Desmin-related myopathy,KW-1060~Myofibrillar myopathy,	KW-0677~Repeat,	KW-0106~Calcium,	KW-0009~Actin-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Gelsolin-like,DOMAIN:HP,MUTAGEN:L->K: Strongly increased affinity for F-actin.,REGION:Disordered,REGION:Interaction with MYLK,REGION:Interaction with NEB,REPEAT:Gelsolin-like 1,REPEAT:Gelsolin-like 2,REPEAT:Gelsolin-like 3,REPEAT:Gelsolin-like 4,REPEAT:Gelsolin-like 5,
SFTPB	surfactant protein B(SFTPB)	Homo sapiens			GO:0006665~sphingolipid metabolic process,GO:0007585~respiratory gaseous exchange,GO:0009887~animal organ morphogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005771~multivesicular body,GO:0005789~endoplasmic reticulum membrane,GO:0042599~lamellar body,GO:0045334~clathrin-coated endocytic vesicle,GO:0097208~alveolar lamellar body,GO:0097486~multivesicular body lumen,	GO:0005515~protein binding,	IPR003119:Saposin type A,IPR007856:Saposin-like type B, 1,IPR008138:Saposin-like type B, 2,IPR008139:Saposin B,IPR008373:Saposin,IPR011001:Saposin-like,		265120~Surfactant metabolism dysfunction, pulmonary, 1,		SM00162:SAPA,SM00741:SapB,	KW-0305~Gaseous exchange,	KW-0767~Surface film,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Saposin A-type,DOMAIN:Saposin B-type,DOMAIN:Saposin B-type 1,DOMAIN:Saposin B-type 2,DOMAIN:Saposin B-type 3,
SNED1	sushi, nidogen and EGF like domains 1(SNED1)	Homo sapiens			GO:0007160~cell-matrix adhesion,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0005112~Notch binding,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000436:Sushi/SCR/CCP,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR003886:Nidogen, extracellular domain,IPR003961:Fibronectin, type III,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013032:EGF-like, conserved site,IPR013783:Immunoglobulin-like fold,IPR018097:EGF-like calcium-binding, conserved site,				SM00032:CCP,SM00060:FN3,SM00179:EGF_CA,SM00181:EGF,SM00539:NIDO,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13,DOMAIN:EGF-like 14,DOMAIN:EGF-like 15,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8,DOMAIN:EGF-like 9,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Follistatin-like 1,DOMAIN:Follistatin-like 2,DOMAIN:NIDO,DOMAIN:Sushi,REGION:Disordered,
SYN2	synapsin II(SYN2)	Homo sapiens			GO:0007268~chemical synaptic transmission,GO:0007269~neurotransmitter secretion,GO:0017156~calcium ion regulated exocytosis,GO:0097091~synaptic vesicle clustering,	GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0030672~synaptic vesicle membrane,GO:0031201~SNARE complex,GO:0045202~synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR001359:Synapsin,IPR013815:ATP-grasp fold, subdomain 1,IPR016185:Pre-ATP-grasp domain,IPR019735:Synapsin, conserved site,IPR019736:Synapsin, phosphorylation site,IPR020897:Synapsin, pre-ATP-grasp domain,IPR020898:Synapsin, ATP-binding domain,		181500~Schizophrenia, susceptibility to,				KW-0770~Synapse,	KW-1211~Schizophrenia,				KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Synapsin ATP-binding,DOMAIN:Synapsin pre-ATP-grasp,REGION:A,REGION:B; linker,REGION:C; actin-binding and synaptic-vesicle binding,REGION:Disordered,REGION:E,REGION:G; Pro-rich linker,REGION:H; Pro/Ser-rich linker,
SV2A	synaptic vesicle glycoprotein 2A(SV2A)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0006874~cellular calcium ion homeostasis,GO:0007268~chemical synaptic transmission,GO:0014052~regulation of gamma-aminobutyric acid secretion,GO:0016082~synaptic vesicle priming,GO:0055085~transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0030285~integral component of synaptic vesicle membrane,GO:0030425~dendrite,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0048786~presynaptic active zone,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0019901~protein kinase binding,GO:0022857~transmembrane transporter activity,	IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,IPR022308:Synaptic vesicle protein SV2,	hsa04512:ECM-receptor interaction,				KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Major facilitator superfamily (MFS) profile,REGION:Disordered,REGION:Interaction with SYT1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SV2C	synaptic vesicle glycoprotein 2C(SV2C)	Homo sapiens			GO:0006836~neurotransmitter transport,GO:0007268~chemical synaptic transmission,GO:0055085~transmembrane transport,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0030285~integral component of synaptic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0043005~neuron projection,	GO:0005515~protein binding,GO:0022857~transmembrane transporter activity,	IPR001646:Pentapeptide repeat,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,IPR022308:Synaptic vesicle protein SV2,	hsa04512:ECM-receptor interaction,				KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:F->A: No longer interacts with BoNT/A HC.,MUTAGEN:N->A: No change in interaction with C.botulinum neurotoxin type A heavy chain (botA, BoNT/A HC). Decreased molecular weight probably due to glycosylation loss, decreased interaction with BoNT/A HC.,MUTAGEN:N->Q: Decreased molecular weight probably due to glycosylation loss, decreased binding to BoNT/A HC. Greater reduction in weight; when associated with Q-565.,MUTAGEN:N->Q: Decreased molecular weight probably due to glycosylation loss, no change in binding to BoNT/A heavy chain. Greater reduction in weight; when associated with Q-559.,MUTAGEN:S->A: Decreased molecular weight probably due to glycosylation loss, decreased binding to BoNT/A HC.,REGION:(Microbial infection) C.botulinum neurotoxin type A-binding,REGION:Disordered,REGION:Interaction with SYT1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SYCP2	synaptonemal complex protein 2(SYCP2)	Homo sapiens			GO:0000080~mitotic G1 phase,GO:0006915~apoptotic process,GO:0007130~synaptonemal complex assembly,GO:0007140~male meiosis,GO:0007143~female meiotic division,GO:0009566~fertilization,GO:0035234~ectopic germ cell programmed cell death,GO:0043066~negative regulation of apoptotic process,GO:0048808~male genitalia morphogenesis,GO:0051093~negative regulation of developmental process,GO:0051301~cell division,GO:2000242~negative regulation of reproductive process,	GO:0000795~synaptonemal complex,GO:0000800~lateral element,GO:0005634~nucleus,GO:0005694~chromosome,	GO:0003677~DNA binding,	IPR024832:Synaptonemal complex protein 2,IPR024835:Synaptonemal complex protein 2/protein 2-like,		258150~Spermatogenic failure 1,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0469~Meiosis,	KW-0158~Chromosome,KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Synaptonemal complex protein 2 Spt16M-like,DOMAIN:Synaptonemal complex protein 2 armadillo-repeat-like,REGION:Disordered,
SYTL1	synaptotagmin like 1(SYTL1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006887~exocytosis,	GO:0005886~plasma membrane,GO:0019897~extrinsic component of plasma membrane,GO:0031528~microvillus membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0070382~exocytic vesicle,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042043~neurexin family protein binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR010911:Rab-binding domain,				SM00239:C2,	KW-0268~Exocytosis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:RabBD,REGION:Disordered,
SYTL2	synaptotagmin like 2(SYTL2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006904~vesicle docking involved in exocytosis,GO:0016192~vesicle-mediated transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0019897~extrinsic component of plasma membrane,GO:0042470~melanosome,GO:0070382~exocytic vesicle,	GO:0001786~phosphatidylserine binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0019902~phosphatase binding,GO:0031267~small GTPase binding,GO:0042043~neurexin family protein binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR001565:Synaptotagmin,IPR010911:Rab-binding domain,IPR027006:Synaptotagmin-like protein 2,				SM00239:C2,	KW-0268~Exocytosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:RabBD,MUTAGEN:E->A: Abolishes interaction with RAB27A.,MUTAGEN:R->A: Abolishes interaction with RAB27A.,REGION:Disordered,
SDCBP2	syndecan binding protein 2(SDCBP2)	Homo sapiens			GO:0007399~nervous system development,GO:0008283~cell proliferation,GO:0035556~intracellular signal transduction,GO:0046907~intracellular transport,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016607~nuclear speck,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0008022~protein C-terminus binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,	IPR001478:PDZ domain,				SM00228:PDZ,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0446~Lipid-binding,			DOMAIN:PDZ 1,DOMAIN:PDZ 2,MUTAGEN:K->A: Abolishes phosphatidylinositol 4,5-bisphosphate binding and targeting to plasma membrane, speckles and nucleoli; when associated with A-113; A-167 and A-197. Reduces phosphatidylinositol 4,5-bisphosphate binding and does not change subcellular localization; when associated with A-197.,MUTAGEN:K->A: Abolishes phosphatidylinositol 4,5-bisphosphate binding and targeting to plasma membrane, speckles and nucleoli; when associated with A-113; A-167 and A-244. Reduces phosphatidylinositol 4,5-bisphosphate binding and does not change subcellular localization; when associated with A-244.,MUTAGEN:K->A: Abolishes phosphatidylinositol 4,5-bisphosphate binding and targeting to plasma membrane, speckles and nucleoli; when associated with A-113; A-197 and A-244. Reduces phosphatidylinositol 4,5-bisphosphate binding and does not change subcellular localization; when associated with A-113.,MUTAGEN:K->A: Abolishes phosphatidylinositol 4,5-bisphosphate binding and targeting to plasma membrane, speckles and nucleoli; when associated with A-167; A-197 and A-244. Reduces phosphatidylinositol 4,5-bisphosphate binding and does not change subcellular localization; when associated with A-167.,
TAC1	tachykinin precursor 1(TAC1)	Homo sapiens			GO:0001878~response to yeast,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0006954~inflammatory response,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007217~tachykinin receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0007268~chemical synaptic transmission,GO:0007320~insemination,GO:0009582~detection of abiotic stimulus,GO:0019233~sensory perception of pain,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0031640~killing of cells of other organism,GO:0045087~innate immune response,GO:0048265~response to pain,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0051930~regulation of sensory perception of pain,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:1901215~negative regulation of neuron death,GO:1901216~positive regulation of neuron death,GO:1902093~positive regulation of flagellated sperm motility,GO:1904058~positive regulation of sensory perception of pain,GO:1990090~cellular response to nerve growth factor stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0031835~substance P receptor binding,GO:0031836~neuromedin K receptor binding,GO:0031837~substance K receptor binding,GO:0048018~receptor agonist activity,	IPR008215:Tachykinin,IPR008216:Protachykinin,IPR013055:Tachykinin/Neurokinin-like, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,			SM00203:TK,		KW-0964~Secreted,		KW-0732~Signal,		KW-0527~Neuropeptide,KW-0529~Neurotransmitter,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	DOMAIN:Tachykinin,PEPTIDE:C-terminal-flanking peptide,PEPTIDE:Neurokinin A,PEPTIDE:Neuropeptide K,PEPTIDE:Neuropeptide gamma, 1st part,PEPTIDE:Neuropeptide gamma, 2nd part,PEPTIDE:Substance P,SITE:Cleavage; by ACE,SITE:Cleavage; by ACE and MME,SITE:Cleavage; by FAP,SITE:Cleavage; by MME,
TAC4	tachykinin precursor 4(TAC4)	Homo sapiens			GO:0003085~negative regulation of systemic arterial blood pressure,GO:0006954~inflammatory response,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007217~tachykinin receptor signaling pathway,GO:0008217~regulation of blood pressure,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0051930~regulation of sensory perception of pain,GO:1902093~positive regulation of flagellated sperm motility,GO:1904057~negative regulation of sensory perception of pain,GO:1904058~positive regulation of sensory perception of pain,	GO:0005615~extracellular space,	GO:0031835~substance P receptor binding,GO:0031837~substance K receptor binding,GO:0048018~receptor agonist activity,	IPR013055:Tachykinin/Neurokinin-like, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,					KW-0964~Secreted,		KW-0732~Signal,		KW-0382~Hypotensive agent,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	PEPTIDE:Endokinin-A,PEPTIDE:Endokinin-A/B,PEPTIDE:Endokinin-C,
TSHZ2	teashirt zinc finger homeobox 2(TSHZ2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010468~regulation of gene expression,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR010294:ADAM-TS Spacer 1,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR027008:Teashirt family,IPR027010:Teashirt homologue 2,				SM00355:ZnF_C2H2,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0371~Homeobox,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Homeobox; atypical,DOMAIN:ADAMTS/ADAMTS-like Spacer 1,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3; atypical,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
TCTN1	tectonic family member 1(TCTN1)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0001841~neural tube formation,GO:0008589~regulation of smoothened signaling pathway,GO:0021523~somatic motor neuron differentiation,GO:0021537~telencephalon development,GO:0021904~dorsal/ventral neural tube patterning,GO:0021956~central nervous system interneuron axonogenesis,GO:0030030~cell projection organization,GO:0060271~cilium assembly,GO:1904491~protein localization to ciliary transition zone,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0036038~MKS complex,		IPR011677:Domain of unknown function DUF1619,		614173~Joubert syndrome 13,			KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,	KW-0979~Joubert syndrome,KW-1186~Ciliopathy,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Tectonic,REGION:Disordered,
TERT	telomerase reverse transcriptase(TERT)	Homo sapiens		h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0000723~telomere maintenance,GO:0001172~transcription, RNA-templated,GO:0006278~RNA-dependent DNA biosynthetic process,GO:0007004~telomere maintenance via telomerase,GO:0007005~mitochondrion organization,GO:0010629~negative regulation of gene expression,GO:0022616~DNA strand elongation,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030422~production of siRNA involved in RNA interference,GO:0031647~regulation of protein stability,GO:0032092~positive regulation of protein binding,GO:0042635~positive regulation of hair cycle,GO:0043524~negative regulation of neuron apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0046326~positive regulation of glucose import,GO:0046686~response to cadmium ion,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0070200~establishment of protein localization to telomere,GO:0071456~cellular response to hypoxia,GO:0071897~DNA biosynthetic process,GO:0090399~replicative senescence,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903620~positive regulation of transdifferentiation,GO:1903704~negative regulation of production of siRNA involved in RNA interference,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904751~positive regulation of protein localization to nucleolus,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000648~positive regulation of stem cell proliferation,GO:2000773~negative regulation of cellular senescence,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0000333~telomerase catalytic core complex,GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016605~PML body,GO:0016607~nuclear speck,GO:0031379~RNA-directed RNA polymerase complex,GO:0042645~mitochondrial nucleoid,GO:1990572~TERT-RMRP complex,	GO:0000049~tRNA binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003720~telomerase activity,GO:0003721~telomerase RNA reverse transcriptase activity,GO:0003723~RNA binding,GO:0003964~RNA-directed DNA polymerase activity,GO:0003968~RNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0042162~telomeric DNA binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0051087~chaperone binding,GO:0070034~telomerase RNA binding,GO:0098680~template-free RNA nucleotidyltransferase,	IPR000477:Reverse transcriptase,IPR003545:Telomere reverse transcriptase,IPR021891:Telomerase ribonucleoprotein complex - RNA-binding domain,	hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	601626~Leukemia, acute myeloid,613989~Dyskeratosis congenita, autosomal dominant 2,613989~Dyskeratosis congenita, autosomal recessive 4,614742~Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1,615134~Melanoma, cutaneous malignant, 9,		SM00975:SM00975,		KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,	KW-0732~Signal,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0238~DNA-binding,KW-0548~Nucleotidyltransferase,KW-0687~Ribonucleoprotein,KW-0695~RNA-directed DNA polymerase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Reverse transcriptase,DOMAIN:Telomerase ribonucleoprotein complex - RNA-binding,MOTIF:Bipartite nuclear localization signal,MOTIF:TFLY; involved in RNA binding,MUTAGEN:D->A: Loss of telomerase activity.,MUTAGEN:D->A: Loss of telomerase activity. In the absence of TR, no loss of binding to telomeric primers.,MUTAGEN:DD->AA: Loss of telomerase activity.,MUTAGEN:L->Y: Moderate reduction in telomerase activity, no change in repeat extension rate nor on nucleotide incorporation fidelity. Little further reduction in activity but 13.5-fold increase in nucleotide incorporation fidelity; when associated with M-867.,MUTAGEN:Q->A: About 80% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. Little effect on repeat addition processivity, nor on TR interaction nor on protein levels.,MUTAGEN:Q->N: About 85% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction.,MUTAGEN:Q->T: About 90% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction.,MUTAGEN:R->A: Abolishes telomerase catalytic activity.,MUTAGEN:S->A: Abolishes phosphorylation by DYRK2.,MUTAGEN:V->A: About 75% reduction in telomerase activity, about 80% reduction in repeat reduction rate and 3.9-fold increase in nucleotide incorporation fidelity.,MUTAGEN:V->M: About 75% reduction in telomerase activity, about 50% reduction in repeat extension rate and 5.2-fold increase in nucleotide incorporation fidelity. Little further reduction in activity and 13.5-fold increase in nucleotide incorporation fidelity; when associated with Y-866.,MUTAGEN:V->T: Severe reduction in telomerase activity, about 50% reduction in repeat extension rate and 2.2-fold increase in nucleotide incorporation fidelity. No further reduction in activity but 2.8-fold increase in nucleotide incorporation fidelity; when associated with Y-866.,MUTAGEN:W->A: Defective in high-affinity TERC interactions.,MUTAGEN:WCGLL->AAAAA: Completely abolishes telomerase-mediated primer extension and reduced binding to short telomeric primers. Complete loss of catalytic activity but no further loss of binding to telomeric primers; when associated with 137-A--A-141.,MUTAGEN:WGLLL->AAAAA: Reduced catalytic activity and repeat addition processivity. Complete loss of catalytic activity but no loss of binding to telomeric primers; when associated with 930-A--A-934.,MUTAGEN:Y->F: Abolishes oxidative stress-induced phosphorylation and RAN binding. Impaired nuclear export and enhanced antiapoptotic activity against ROS-dependent apoptosis induction. Impaired interaction with PTPN11. No dephosphorylation by PTPN11.,REGION:CP motif,REGION:CTE,REGION:Disordered,REGION:GQ motif,REGION:Linker,REGION:Primer grip sequence,REGION:QFP motif,REGION:RNA-interacting domain 1,REGION:RNA-interacting domain 2,REGION:Required for oligomerization,REGION:Required for regulating specificity for telomeric DNA and for processivity for primer elongation,SITE:Required for nucleotide incorporation and primer extension rate,SITE:Required for optimal binding of telomeric ssDNA and incorporation of nucleotides at the second position of the template,
TNN	tenascin N(TNN)	Homo sapiens			GO:0002076~osteoblast development,GO:0007160~cell-matrix adhesion,GO:0007409~axonogenesis,GO:0010976~positive regulation of neuron projection development,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0033689~negative regulation of osteoblast proliferation,GO:0045668~negative regulation of osteoblast differentiation,GO:0070593~dendrite self-avoidance,GO:1903010~regulation of bone development,GO:1903672~positive regulation of sprouting angiogenesis,GO:1905240~negative regulation of canonical Wnt signaling pathway involved in osteoblast differentiation,GO:1905899~regulation of smooth muscle tissue development,GO:1990138~neuron projection extension,GO:2001223~negative regulation of neuron migration,	GO:0005615~extracellular space,GO:0009986~cell surface,GO:0043025~neuronal cell body,GO:0090733~tenascin complex,GO:0097442~CA3 pyramidal cell dendrite,GO:1990026~hippocampal mossy fiber expansion,	GO:0005178~integrin binding,GO:0042802~identical protein binding,	IPR000742:Epidermal growth factor-like domain,IPR002049:EGF-like, laminin,IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,IPR020837:Fibrinogen, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05165:Human papillomavirus infection,hsa05206:MicroRNAs in cancer,			SM00060:FN3,SM00181:EGF,SM00186:FBG,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:Fibrinogen C-terminal,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Fibronectin type-III 9,REGION:Disordered,
TSPAN8	tetraspanin 8(TSPAN8)	Homo sapiens			GO:0007283~spermatogenesis,GO:0010468~regulation of gene expression,GO:0030195~negative regulation of blood coagulation,	GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005515~protein binding,	IPR000301:Tetraspanin,IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin, conserved site,			PIRSF002419:tetraspanin,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TTC7B	tetratricopeptide repeat domain 7B(TTC7B)	Homo sapiens			GO:0046854~phosphatidylinositol phosphorylation,GO:0072659~protein localization to plasma membrane,	GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR011990:Tetratricopeptide-like helical,IPR019734:Tetratricopeptide repeat,				SM00028:TPR,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0802~TPR repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Tetratricopeptide repeat protein 7 N-terminal,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 10,REPEAT:TPR 11,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
TMT1A	thiol methyltransferase 1A(TMT1A)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0006306~DNA methylation,GO:0032259~methylation,GO:0042476~odontogenesis,GO:0080009~mRNA methylation,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:1904724~tertiary granule lumen,	GO:0001734~mRNA (N6-adenosine)-methyltransferase activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,	IPR013216:Methyltransferase type 11,					KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0489~Methyltransferase,KW-0808~Transferase,		DOMAIN:Methyltransferase type 11,REGION:Targeting to lipid droplets,TRANSMEM:Helical,
TXNRD1	thioredoxin reductase 1(TXNRD1)	Homo sapiens			GO:0001707~mesoderm formation,GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0045454~cell redox homeostasis,GO:0098869~cellular oxidant detoxification,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004791~thioredoxin-disulfide reductase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016668~oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor,GO:0042802~identical protein binding,GO:0050137~NADPH peroxidase activity,GO:0050660~flavin adenine dinucleotide binding,GO:0071949~FAD binding,GO:0097573~glutathione oxidoreductase activity,	IPR002109:Glutaredoxin,IPR003953:FAD binding domain,IPR004099:Pyridine nucleotide-disulphide oxidoreductase, dimerisation,IPR006338:Thioredoxin/glutathione reductase selenoprotein,IPR012999:Pyridine nucleotide-disulphide oxidoreductase, class I, active site,IPR016156:FAD/NAD-linked reductase, dimerisation,IPR023753:Pyridine nucleotide-disulphide oxidoreductase, FAD/NAD(P)-binding domain,	hsa00450:Selenocompound metabolism,hsa05200:Pathways in cancer,hsa05225:Hepatocellular carcinoma,		PIRSF000350:mercury(II) reductase, MerA type,		KW-0249~Electron transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0676~Redox-active center,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,KW-0521~NADP,KW-0547~Nucleotide-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Cysteinyl-selenocysteine (Cys-Sec),DISULFID:Redox-active,DOMAIN:FAD-dependent oxidoreductase 2 FAD binding,DOMAIN:FAD/NAD(P)-binding,DOMAIN:Glutaredoxin,DOMAIN:Pyridine nucleotide-disulphide oxidoreductase dimerisation,NON_STD:Selenocysteine,REGION:Disordered,REGION:Required for interaction with ESR1 and ESR2,
THBS4	thrombospondin 4(THBS4)	Homo sapiens			GO:0001938~positive regulation of endothelial cell proliferation,GO:0006986~response to unfolded protein,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0016525~negative regulation of angiogenesis,GO:0034103~regulation of tissue remodeling,GO:0034976~response to endoplasmic reticulum stress,GO:0048266~behavioral response to pain,GO:0048771~tissue remodeling,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0051451~myoblast migration,GO:0051781~positive regulation of cell division,GO:0071603~endothelial cell-cell adhesion,GO:0090023~positive regulation of neutrophil chemotaxis,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0016529~sarcoplasmic reticulum,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,	IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR003367:Thrombospondin, type 3-like repeat,IPR008859:Thrombospondin, C-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR017897:Thrombospondin, type 3 repeat,IPR018097:EGF-like calcium-binding, conserved site,IPR024665:Thrombospondin/cartilage oligomeric matrix protein, coiled-coil domain,	hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05144:Malaria,hsa05165:Human papillomavirus infection,			SM00179:EGF_CA,SM00181:EGF,SM00210:TSPN,	KW-0130~Cell adhesion,KW-0797~Tissue remodeling,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0703~Sarcoplasmic reticulum,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0339~Growth factor,KW-0497~Mitogen,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:Laminin G-like,DOMAIN:TSP C-terminal,MOTIF:Cell attachment site,REGION:Disordered,REPEAT:TSP type-3,REPEAT:TSP type-3 1,REPEAT:TSP type-3 2,REPEAT:TSP type-3 3,REPEAT:TSP type-3 4,REPEAT:TSP type-3 5,REPEAT:TSP type-3 6,REPEAT:TSP type-3 7,REPEAT:TSP type-3 8,
TOX	thymocyte selection associated high mobility group box(TOX)	Homo sapiens			GO:0001779~natural killer cell differentiation,GO:0002362~CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment,GO:0002364~NK T cell lineage commitment,GO:0002521~leukocyte differentiation,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010976~positive regulation of neuron projection development,GO:0021895~cerebral cortex neuron differentiation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0043373~CD4-positive, alpha-beta T cell lineage commitment,GO:0043375~CD8-positive, alpha-beta T cell lineage commitment,GO:0048535~lymph node development,GO:0048541~Peyer's patch development,GO:1901537~positive regulation of DNA demethylation,GO:1902232~regulation of positive thymic T cell selection,GO:2000179~positive regulation of neural precursor cell proliferation,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,	IPR009071:High mobility group (HMG) box domain,				SM00398:HMG,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:HMG box,DOMAIN:HMG box,MOTIF:Nuclear localization signal,REGION:Disordered,
TPO	thyroid peroxidase(TPO)	Homo sapiens			GO:0006590~thyroid hormone generation,GO:0006979~response to oxidative stress,GO:0035162~embryonic hemopoiesis,GO:0042446~hormone biosynthetic process,GO:0042744~hydrogen peroxide catabolic process,GO:0098869~cellular oxidant detoxification,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0004447~iodide peroxidase activity,GO:0004601~peroxidase activity,GO:0005509~calcium ion binding,GO:0020037~heme binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000436:Sushi/SCR/CCP,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR010255:Haem peroxidase,IPR018097:EGF-like calcium-binding, conserved site,IPR019791:Haem peroxidase, animal, subgroup,	hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,hsa04918:Thyroid hormone synthesis,hsa05320:Autoimmune thyroid disease,	274500~Thyroid dyshormonogenesis 2A,		SM00032:CCP,SM00179:EGF_CA,SM00181:EGF,	KW-0376~Hydrogen peroxide,KW-0893~Thyroid hormones biosynthesis,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0984~Congenital hypothyroidism,	KW-0245~EGF-like domain,KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:axial binding residue,BINDING:covalent,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:EGF-like,DOMAIN:EGF-like; calcium-binding,DOMAIN:Sushi,REGION:Disordered,SITE:Transition state stabilizer,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TLR2	toll like receptor 2(TLR2)	Homo sapiens		h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_tollPathway:Toll-Like Receptor Pathway,	GO:0001666~response to hypoxia,GO:0001774~microglial cell activation,GO:0001775~cell activation,GO:0001817~regulation of cytokine production,GO:0002224~toll-like receptor signaling pathway,GO:0002237~response to molecule of bacterial origin,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0006691~leukotriene metabolic process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007252~I-kappaB phosphorylation,GO:0007612~learning,GO:0008285~negative regulation of cell proliferation,GO:0009636~response to toxic substance,GO:0010628~positive regulation of gene expression,GO:0014005~microglia development,GO:0030177~positive regulation of Wnt signaling pathway,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032289~central nervous system myelin formation,GO:0032493~response to bacterial lipoprotein,GO:0032496~response to lipopolysaccharide,GO:0032570~response to progesterone,GO:0032722~positive regulation of chemokine production,GO:0032728~positive regulation of interferon-beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032741~positive regulation of interleukin-18 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032868~response to insulin,GO:0034123~positive regulation of toll-like receptor signaling pathway,GO:0034134~toll-like receptor 2 signaling pathway,GO:0038124~toll-like receptor TLR6:TLR2 signaling pathway,GO:0042495~detection of triacyl bacterial lipopeptide,GO:0042496~detection of diacyl bacterial lipopeptide,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046209~nitric oxide metabolic process,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050729~positive regulation of inflammatory response,GO:0050765~negative regulation of phagocytosis,GO:0050830~defense response to Gram-positive bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0051964~negative regulation of synapse assembly,GO:0070542~response to fatty acid,GO:0071221~cellular response to bacterial lipopeptide,GO:0071223~cellular response to lipoteichoic acid,GO:0071346~cellular response to interferon-gamma,GO:0071726~cellular response to diacyl bacterial lipopeptide,GO:0071727~cellular response to triacyl bacterial lipopeptide,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1903974~positive regulation of cellular response to macrophage colony-stimulating factor stimulus,GO:1904466~positive regulation of matrix metallopeptidase secretion,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031226~intrinsic component of plasma membrane,GO:0035354~Toll-like receptor 1-Toll-like receptor 2 protein complex,GO:0035355~Toll-like receptor 2-Toll-like receptor 6 protein complex,GO:0042995~cell projection,GO:0043235~receptor complex,GO:0044297~cell body,GO:0045121~membrane raft,	GO:0001530~lipopolysaccharide binding,GO:0001540~beta-amyloid binding,GO:0001875~lipopolysaccharide receptor activity,GO:0003953~NAD+ nucleosidase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0035325~Toll-like receptor binding,GO:0038023~signaling receptor activity,GO:0038187~pattern recognition receptor activity,GO:0042497~triacyl lipopeptide binding,GO:0042802~identical protein binding,GO:0042834~peptidoglycan binding,GO:0044877~macromolecular complex binding,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,GO:0071723~lipopeptide binding,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR017241:Toll-like receptor,IPR027185:Toll-like receptor 2,	hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05205:Proteoglycans in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,	114500~Colorectal cancer, susceptibility to,246300~Leprosy, susceptibility to,607948~Mycobacterium tuberculosis, susceptibility to,	PIRSF037595:toll-like receptor, 1/2/4/6/10 types [Parent=PIRSF800008],	SM00082:LRRCT,SM00255:TIR,SM00369:LRR_TYP,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:LRRCT,DOMAIN:TIR,MOTIF:ATG16L1-binding motif,MUTAGEN:K->R: Loss of PPP1R11-mediated ubiquitination and degradation.,MUTAGEN:K->R: Reduced protein stability.,MUTAGEN:KK->RR: Reduced protein stability.,MUTAGEN:N->D: Prevents addition of N-glycans. Prevents secretion of the N-terminal ectodomain.,MUTAGEN:N->D: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain.,MUTAGEN:N->S: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain.,MUTAGEN:P->F: Abolishes the interaction with MYD88. No effect on oligomerization or on the structure of the TIR domain.,MUTAGEN:T->A: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain.,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,SITE:Interaction with bacterial lipopeptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TCN1	transcobalamin 1(TCN1)	Homo sapiens			GO:0006824~cobalt ion transport,GO:0015889~cobalamin transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0035580~specific granule lumen,GO:1904724~tertiary granule lumen,	GO:0005515~protein binding,GO:0031419~cobalamin binding,	IPR002157:Cobalamin (vitamin B12)-binding transporter, eukaryotic,					KW-0171~Cobalt transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0964~Secreted,		KW-0732~Signal,	KW-0170~Cobalt,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Flexible linker,REGION:Globular C-terminal beta domain,REGION:Globular N-terminal alpha domain,
TCERG1L	transcription elongation regulator 1 like(TCERG1L)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,	GO:0005634~nucleus,	GO:0003712~transcription cofactor activity,GO:0070063~RNA polymerase binding,	IPR001202:WW domain,IPR002713:FF domain,				SM00441:FF,SM00456:WW,				KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,DOMAIN:FF 1,DOMAIN:FF 2,DOMAIN:WW 1,DOMAIN:WW 2,REGION:Disordered,
TF	transferrin(TF)	Homo sapiens	98.Dietary_Fat_and_Gene_Transcription,	h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,	GO:0001895~retina homeostasis,GO:0006826~iron ion transport,GO:0006879~cellular iron ion homeostasis,GO:0007015~actin filament organization,GO:0019731~antibacterial humoral response,GO:0030316~osteoclast differentiation,GO:0031647~regulation of protein stability,GO:0034755~iron ion transmembrane transport,GO:0034756~regulation of iron ion transport,GO:0042327~positive regulation of phosphorylation,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0055072~iron ion homeostasis,GO:0060395~SMAD protein signal transduction,GO:0070371~ERK1 and ERK2 cascade,GO:0071281~cellular response to iron ion,GO:2000147~positive regulation of cell motility,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016324~apical plasma membrane,GO:0030120~vesicle coat,GO:0030139~endocytic vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031232~extrinsic component of external side of plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0031982~vesicle,GO:0034774~secretory granule lumen,GO:0045178~basal part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0097433~dense body,GO:1990712~HFE-transferrin receptor complex,	GO:0005515~protein binding,GO:0008198~ferrous iron binding,GO:0008199~ferric iron binding,GO:0034986~iron chaperone activity,GO:1990459~transferrin receptor binding,	IPR001156:Transferrin family,IPR016357:Transferrin,IPR018195:Transferrin family, iron binding site,	hsa04066:HIF-1 signaling pathway,hsa04216:Ferroptosis,hsa04350:TGF-beta signaling pathway,hsa04978:Mineral absorption,	209300~Atransferrinemia,	PIRSF002549:transferrin,PIRSF500682:serotransferrin  [Parent=PIRSF002549],	SM00094:TR_FER,	KW-0406~Ion transport,KW-0410~Iron transport,KW-0813~Transport,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,	KW-0408~Iron,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical; partial,CARBOHYD:O-linked (GalNAc...) serine,DOMAIN:Transferrin-like,DOMAIN:Transferrin-like 1,DOMAIN:Transferrin-like 2,REGION:Disordered,
TRRAP	transformation/transcription domain associated protein(TRRAP)	Homo sapiens		h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,	GO:0006281~DNA repair,GO:0006282~regulation of DNA repair,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016573~histone acetylation,GO:0016578~histone deubiquitination,GO:0035521~monoubiquitinated histone deubiquitination,GO:0035522~monoubiquitinated histone H2A deubiquitination,GO:0042981~regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0043966~histone H3 acetylation,GO:0043967~histone H4 acetylation,GO:0043968~histone H2A acetylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051726~regulation of cell cycle,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000112~regulation of cellular macromolecule biosynthetic process,GO:2000779~regulation of double-strand break repair,	GO:0000123~histone acetyltransferase complex,GO:0000124~SAGA complex,GO:0000786~nucleosome,GO:0000812~Swr1 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0033276~transcription factor TFTC complex,GO:0035267~NuA4 histone acetyltransferase complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR000403:Phosphatidylinositol 3-/4-kinase, catalytic domain,IPR003151:PIK-related kinase, FAT,IPR003152:PIK-related kinase, FATC,IPR011009:Protein kinase-like domain,IPR011989:Armadillo-like helical,IPR014009:PIK-related kinase,IPR016024:Armadillo-type fold,	hsa03082:ATP-dependent chromatin remodeling,hsa05166:Human T-cell leukemia virus 1 infection,	618454~Developmental delay with or without dysmorphic facies and autism,618778~Deafness, autosomal dominant 75,		SM00146:PI3Kc,SM01343:SM01343,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1010~Non-syndromic deafness,KW-1268~Autism spectrum disorder,			KW-0010~Activator,KW-0156~Chromatin regulator,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FAT,DOMAIN:FATC,DOMAIN:PI3K/PI4K catalytic,DOMAIN:PIK-related kinase FAT,MOTIF:Bipartite nuclear localization signal,REGION:Activation loop,REGION:Catalytic loop,REGION:Disordered,REGION:G-loop,REGION:Interaction with TP53,
TACC2	transforming acidic coiled-coil containing protein 2(TACC2)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0007052~mitotic spindle organization,GO:0008283~cell proliferation,GO:0021987~cerebral cortex development,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0016922~ligand-dependent nuclear receptor binding,	IPR007707:Transforming acidic coiled-coil,						KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SPAZ,DOMAIN:Transforming acidic coiled-coil-containing protein C-terminal,REGION:Disordered,
TGFB1I1	transforming growth factor beta 1 induced transcript 1(TGFB1I1)	Homo sapiens			GO:0007155~cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016055~Wnt signaling pathway,GO:0016331~morphogenesis of embryonic epithelium,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030579~ubiquitin-dependent SMAD protein catabolic process,GO:0030855~epithelial cell differentiation,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016363~nuclear matrix,GO:0043231~intracellular membrane-bounded organelle,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0048495~Roundabout binding,GO:0050681~androgen receptor binding,GO:0070411~I-SMAD binding,	IPR001781:Zinc finger, LIM-type,IPR017305:Leupaxin,			PIRSF037881:leupaxin ,	SM00132:LIM,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,MOTIF:LD motif 1,MOTIF:LD motif 2,MOTIF:LD motif 3,MOTIF:LD motif 4,MUTAGEN:C->A: Abolishes interaction with CBLC and enhancement of CBLC E3 ubiquitin-protein ligase activity.,MUTAGEN:C->A: No effect on interaction with CBLC.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-369.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-372.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-428.,MUTAGEN:FLKLF->ALKAA: Loss of interaction with AR; when associated with 338-A--A-342.,MUTAGEN:FLQLF->ALQAA: Loss of interaction with AR; when associated with 456-A--A-460.,MUTAGEN:H->S: Loss of AR coactivation; when associated with S-431.,MUTAGEN:Y->F: Prevents phosphorylation by FAK2 and FYN. Prevents interaction with CSK.,REGION:Disordered,REGION:Interaction with PTK2/FAK1,REGION:Interaction with PTK2B/PYK2,REGION:Transcription activation,
TGFBI	transforming growth factor beta induced(TGFBI)	Homo sapiens			GO:0001525~angiogenesis,GO:0002062~chondrocyte differentiation,GO:0007155~cell adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007601~visual perception,GO:0008283~cell proliferation,GO:0030198~extracellular matrix organization,GO:0050896~response to stimulus,GO:0051179~localization,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0042802~identical protein binding,GO:0050839~cell adhesion molecule binding,GO:0050840~extracellular matrix binding,	IPR000782:FAS1 domain,IPR011489:EMI domain,IPR016666:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,		121820~Corneal dystrophy, epithelial basement membrane,121900~Corneal dystrophy, Groenouw type I,122200~Corneal dystrophy, lattice type I,602082~Corneal dystrophy, Thiel-Behnke type,607541~Corneal dystrophy, Avellino type,608470~Corneal dystrophy, Reis-Bucklers type,608471~Corneal dystrophy, lattice type IIIA,	PIRSF016553:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,	SM00554:FAS1,	KW-0130~Cell adhesion,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0034~Amyloid,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-1008~Amyloidosis,KW-1212~Corneal dystrophy,	KW-0677~Repeat,KW-0732~Signal,			KW-0301~Gamma-carboxyglutamic acid,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:EMI,DOMAIN:FAS1,DOMAIN:FAS1 1,DOMAIN:FAS1 2,DOMAIN:FAS1 3,DOMAIN:FAS1 4,MOTIF:Cell attachment site,
TGFBR1	transforming growth factor beta receptor 1(TGFBR1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_mapkPathway:MAPKinase Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_slrp2Pathway:Function of SLRP in Bone: An Integrated View,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0001501~skeletal system development,GO:0001701~in utero embryonic development,GO:0001822~kidney development,GO:0001824~blastocyst development,GO:0001837~epithelial to mesenchymal transition,GO:0001935~endothelial cell proliferation,GO:0001937~negative regulation of endothelial cell proliferation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002088~lens development in camera-type eye,GO:0003222~ventricular trabecula myocardium morphogenesis,GO:0003223~ventricular compact myocardium morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007399~nervous system development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008354~germ cell migration,GO:0008584~male gonad development,GO:0009791~post-embryonic development,GO:0009952~anterior/posterior pattern specification,GO:0010468~regulation of gene expression,GO:0010604~positive regulation of macromolecule metabolic process,GO:0010628~positive regulation of gene expression,GO:0010717~regulation of epithelial to mesenchymal transition,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030199~collagen fibril organization,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0031396~regulation of protein ubiquitination,GO:0032331~negative regulation of chondrocyte differentiation,GO:0032924~activin receptor signaling pathway,GO:0035556~intracellular signal transduction,GO:0036446~myofibroblast differentiation,GO:0042060~wound healing,GO:0042118~endothelial cell activation,GO:0043062~extracellular structure organization,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043393~regulation of protein binding,GO:0043410~positive regulation of MAPK cascade,GO:0043542~endothelial cell migration,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046847~filopodium assembly,GO:0048538~thymus development,GO:0048663~neuron fate commitment,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048705~skeletal system morphogenesis,GO:0048762~mesenchymal cell differentiation,GO:0048844~artery morphogenesis,GO:0048870~cell motility,GO:0051173~positive regulation of nitrogen compound metabolic process,GO:0051239~regulation of multicellular organismal process,GO:0051272~positive regulation of cellular component movement,GO:0051491~positive regulation of filopodium assembly,GO:0051496~positive regulation of stress fiber assembly,GO:0051726~regulation of cell cycle,GO:0051897~positive regulation of protein kinase B signaling,GO:0060017~parathyroid gland development,GO:0060021~palate development,GO:0060037~pharyngeal system development,GO:0060043~regulation of cardiac muscle cell proliferation,GO:0060317~cardiac epithelial to mesenchymal transition,GO:0060389~pathway-restricted SMAD protein phosphorylation,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060412~ventricular septum morphogenesis,GO:0060978~angiogenesis involved in coronary vascular morphogenesis,GO:0060982~coronary artery morphogenesis,GO:0070723~response to cholesterol,GO:0071363~cellular response to growth factor stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0080090~regulation of primary metabolic process,GO:1901203~positive regulation of extracellular matrix assembly,GO:1902462~positive regulation of mesenchymal stem cell proliferation,GO:1905007~positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,GO:1905075~positive regulation of occluding junction disassembly,GO:1905223~epicardium morphogenesis,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0048179~activin receptor complex,GO:0070021~transforming growth factor beta1-type II receptor-type I receptor complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004675~transmembrane receptor protein serine/threonine kinase activity,GO:0005024~transforming growth factor beta-activated receptor activity,GO:0005025~transforming growth factor beta receptor activity, type I,GO:0005102~receptor binding,GO:0005114~type II transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016361~activin receptor activity, type I,GO:0019838~growth factor binding,GO:0031625~ubiquitin protein ligase binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048185~activin binding,GO:0050431~transforming growth factor beta binding,GO:0070411~I-SMAD binding,	IPR000333:Activin type II/Transforming growth factor-beta II receptor,IPR000472:TGF-beta receptor/activin receptor, type I/II,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003605:TGF beta receptor, GS motif,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04068:FoxO signaling pathway,hsa04144:Endocytosis,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04390:Hippo signaling pathway,hsa04520:Adherens junction,hsa04659:Th17 cell differentiation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05415:Diabetic cardiomyopathy,	132800~Multiple self-healing squamous epithelioma, susceptibility to,609192~Loeys-Dietz syndrome 1,		SM00220:S_TKc,SM00467:GS,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0341~Growth regulation,	KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0989~Craniosynostosis,KW-0993~Aortic aneurysm,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:Activin types I and II receptor,DOMAIN:GS,DOMAIN:Protein kinase,MOTIF:FKBP1A-binding,MUTAGEN:L->G: Loss of interaction with FKBP1A.,MUTAGEN:P->K: Loss of interaction with FKBP1A.,MUTAGEN:S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-189.,MUTAGEN:S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-191.,MUTAGEN:S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-189 and A-191.,MUTAGEN:T->D: Constitutive activation.,MUTAGEN:T->D: Loss of response to TGF-beta.,MUTAGEN:T->V: Loss of phosphorylation. Loss of response to TGF-beta.,MUTAGEN:T->V: Reduced phosphorylation. Reduced response to TGF-beta.,MUTAGEN:TT->VV: Loss of phosphorylation on threonine residues. Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with A-187; A-189 and A-191.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TAGLN	transgelin(TAGLN)	Homo sapiens			GO:0007517~muscle organ development,GO:0030855~epithelial cell differentiation,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR000557:Calponin repeat,IPR001715:Calponin homology domain,IPR003096:Smooth muscle protein/calponin,				SM00033:CH,		KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),REPEAT:Calponin-like,
TGM2	transglutaminase 2(TGM2)	Homo sapiens		h_plcdPathway:Phospholipase C d1 in phospholipid associated cell signaling,	GO:0006338~chromatin remodeling,GO:0006508~proteolysis,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0010467~gene expression,GO:0012501~programmed cell death,GO:0014046~dopamine secretion,GO:0018149~peptide cross-linking,GO:0018153~isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine,GO:0018277~protein deamination,GO:0019221~cytokine-mediated signaling pathway,GO:0019933~cAMP-mediated signaling,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043277~apoptotic cell clearance,GO:0043547~positive regulation of GTPase activity,GO:0045785~positive regulation of cell adhesion,GO:0050769~positive regulation of neurogenesis,GO:0051057~positive regulation of small GTPase mediated signal transduction,GO:0051260~protein homooligomerization,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0060348~bone development,GO:0060445~branching involved in salivary gland morphogenesis,GO:0060662~salivary gland cavitation,GO:0071314~cellular response to cocaine,GO:1903351~cellular response to dopamine,GO:1904015~cellular response to serotonin,GO:2000425~regulation of apoptotic cell clearance,	GO:0000785~chromatin,GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0031012~extracellular matrix,GO:0031226~intrinsic component of plasma membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003810~protein-glutamine gamma-glutamyltransferase activity,GO:0003924~GTPase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0008233~peptidase activity,GO:0046872~metal ion binding,GO:0050568~protein-glutamine glutaminase activity,	IPR001102:Transglutaminase, N-terminal,IPR002931:Transglutaminase-like,IPR008958:Transglutaminase, C-terminal,IPR013783:Immunoglobulin-like fold,IPR013808:Transglutaminase, conserved site,IPR014756:Immunoglobulin E-set,IPR023608:Protein-glutamine gamma-glutamyltransferase, eukaryota,	hsa05016:Huntington disease,		PIRSF000459:protein-glutamine gamma-glutamyltransferase/erythrocyte membrane protein band 4.2,	SM00460:TGc,		KW-0158~Chromosome,KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,			KW-0106~Calcium,KW-0342~GTP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0012~Acyltransferase,KW-0378~Hydrolase,KW-0645~Protease,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-?),DISULFID:Alternate,DOMAIN:Transglutaminase C-terminal,DOMAIN:Transglutaminase N-terminal,DOMAIN:Transglutaminase-like,MUTAGEN:C->A: Does not affect the protein-glutamine deamidase activity.,MUTAGEN:C->A: Impaired substrate recognition for the protein-glutamine deamidase activity.,MUTAGEN:C->S: Abolished protein-glutamine gamma-glutamyltransferase activity without affecting alpha-1 adrenergic receptor signaling. Abolished isopeptidase activity.,MUTAGEN:C->V: Abolished protein-glutamine gamma-glutamyltransferase activity without affecting cytotoxic activity.,MUTAGEN:C->V: Dominant negative mutant. Abolishes WDR54 cross-linking.,MUTAGEN:E->R: Impaired Ca(2+)-binding leading to reduced transglutaminase activity.,MUTAGEN:F->L: Abolished isopeptidase and transamidase activities.,MUTAGEN:S->E: Abolishes GTP-binding and transglutaminase activities. Does not have cytotoxic activity when overexpressed.,MUTAGEN:V->G: Displays lower Ca(2+)-binding affinity and reduced transglutaminase activity.,MUTAGEN:VVNFESDK->IASMSSDS: Substitution with F13A1 sequence. Abolished interaction with phospholipase C and ability to promote alpha-1 adrenergic receptor signaling.,MUTAGEN:W->F,L: Abolished isopeptidase and transamidase activities.,MUTAGEN:W->F: Abolished isopeptidase activity and reduced transamidase activity.,MUTAGEN:W->F: In TG2-I; strongly reduced transamidase activity without affecting the isopeptidase activity.,MUTAGEN:W->F: In TG2-T; strongly reduced isopeptidase activity without affecting the transamidase activity.,MUTAGEN:W->F: Reduced isopeptidase and transamidase activities.,MUTAGEN:W->L: Abolished isopeptidase and transamidase activities.,MUTAGEN:Y->L: No effect on isopeptidase and transamidase activities.,SITE:Important for catalytic activity,
TRPM2	transient receptor potential cation channel subfamily M member 2(TRPM2)	Homo sapiens			GO:0001659~temperature homeostasis,GO:0002407~dendritic cell chemotaxis,GO:0006816~calcium ion transport,GO:0006979~response to oxidative stress,GO:0009408~response to heat,GO:0014074~response to purine-containing compound,GO:0032024~positive regulation of insulin secretion,GO:0032956~regulation of actin cytoskeleton organization,GO:0033194~response to hydroperoxide,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0035725~sodium ion transmembrane transport,GO:0044849~estrous cycle,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051289~protein homotetramerization,GO:0051489~regulation of filopodium assembly,GO:0070301~cellular response to hydrogen peroxide,GO:0070588~calcium ion transmembrane transport,GO:0071277~cellular response to calcium ion,GO:0071415~cellular response to purine-containing compound,GO:0071421~manganese ion transmembrane transport,GO:0071502~cellular response to temperature stimulus,GO:0071577~zinc II ion transmembrane transport,GO:0097028~dendritic cell differentiation,GO:0097553~calcium ion transmembrane import into cytosol,GO:0098655~cation transmembrane transport,GO:0098703~calcium ion import across plasma membrane,GO:1903223~positive regulation of oxidative stress-induced neuron death,GO:2000249~regulation of actin cytoskeleton reorganization,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0035579~specific granule membrane,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0043204~perikaryon,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0005272~sodium channel activity,GO:0005384~manganese ion transmembrane transporter activity,GO:0005509~calcium ion binding,GO:0015278~calcium-release channel activity,GO:0047631~ADP-ribose diphosphatase activity,GO:0072571~mono-ADP-D-ribose binding,GO:0099604~ligand-gated calcium channel activity,	IPR000086:NUDIX hydrolase domain,IPR005821:Ion transport domain,IPR015797:NUDIX hydrolase domain-like,	hsa04621:NOD-like receptor signaling pathway,hsa04921:Oxytocin signaling pathway,				KW-0109~Calcium transport,KW-0406~Ion transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0915~Sodium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,KW-0894~Sodium channel,	KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:Nudix hydrolase,INTRAMEM:Pore-forming,MOTIF:Nudix box,MUTAGEN:D->A: Strongly increased residual channel activity after exposure to pH 5.5.,MUTAGEN:GY->LDE: Prevents fast inactivation of the channel.,MUTAGEN:H->A: Moderately decreases channel activity.,MUTAGEN:H->A: No effect on channel activity.,MUTAGEN:ILRQ->EFRE: Decreased channel activity in response to ADP-ribose.,MUTAGEN:K->A: Decreases channel activity.,MUTAGEN:K->A: Nearly abolishes channel activity.,MUTAGEN:K->A: Strongly reduces channel activity at ph 7.3. Increased residual channel activity after exposure to pH 5.5.,MUTAGEN:M->A: Abolishes lowering of temperature threshold for activation in response to reactive oxygen species.,MUTAGEN:M->I: Only slight effect on activity.,MUTAGEN:Missing: Loss of channel activity.,MUTAGEN:Q->E: Decreased channel activity.,MUTAGEN:QE->KK: Expected to abolish the initially proposed hydrolase activity. Does not abolish channel activity in response to ADP-ribose.,MUTAGEN:R->A: Abolishes channel activity.,MUTAGEN:R->A: Mildly decreases channel activity.,MUTAGEN:R->A: No significant effect on channel activity; when associated with A-302.,MUTAGEN:R->A: No significant effect on channel activity; when associated with A-358.,MUTAGEN:R->G: No effect on channel activity; when associated with Q-1400.,MUTAGEN:R->Q: Abolishes channel activity.,MUTAGEN:R->Q: No effect on channel activity; when associated with G-1407.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRPM3	transient receptor potential cation channel subfamily M member 3(TRPM3)	Homo sapiens			GO:0006812~cation transport,GO:0016048~detection of temperature stimulus,GO:0050951~sensory perception of temperature stimulus,GO:0051262~protein tetramerization,GO:0070588~calcium ion transmembrane transport,GO:0098655~cation transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005227~calcium activated cation channel activity,GO:0005261~cation channel activity,GO:0005262~calcium channel activity,	IPR005821:Ion transport domain,		620224~Neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures,620253~Cataract 50 with or without glaucoma,			KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0898~Cataract,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ion transport,DOMAIN:TRPM SLOG,DOMAIN:TRPM tetramerisation,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRPM8	transient receptor potential cation channel subfamily M member 8(TRPM8)	Homo sapiens			GO:0006812~cation transport,GO:0006874~cellular calcium ion homeostasis,GO:0009409~response to cold,GO:0016048~detection of temperature stimulus,GO:0019722~calcium-mediated signaling,GO:0050951~sensory perception of temperature stimulus,GO:0050955~thermoception,GO:0070588~calcium ion transmembrane transport,GO:0098655~cation transmembrane transport,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,	GO:0005216~ion channel activity,GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0099604~ligand-gated calcium channel activity,	IPR005821:Ion transport domain,	hsa04750:Inflammatory mediator regulation of TRP channels,				KW-0406~Ion transport,KW-0716~Sensory transduction,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ion transport,DOMAIN:TRPM SLOG,MUTAGEN:H->N: No effect on glycosylation or channel activity.,MUTAGEN:L->P: Abolishes multimerization and channel activity. Reduces cell surface expression.,MUTAGEN:N->Q: Abolishes glycosylation.,MUTAGEN:N->Q: No effect on glycosylation or ability to form functional channels.,REGION:Disordered,REGION:Epitope; activates specific cytotoxic T lymphocytes,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
TOMM34	translocase of outer mitochondrial membrane 34(TOMM34)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0031072~heat shock protein binding,	IPR001440:Tetratricopeptide TPR-1,IPR011990:Tetratricopeptide-like helical,IPR019734:Tetratricopeptide repeat,				SM00028:TPR,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,
TM4SF18	transmembrane 4 L six family member 18(TM4SF18)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR008661:L6 membrane,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TM4SF4	transmembrane 4 L six family member 4(TM4SF4)	Homo sapiens			GO:0042246~tissue regeneration,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR008661:L6 membrane,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TM9SF4	transmembrane 9 superfamily member 4(TM9SF4)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006909~phagocytosis,GO:0007155~cell adhesion,GO:0051453~regulation of intracellular pH,GO:0070072~vacuolar proton-transporting V-type ATPase complex assembly,GO:0070863~positive regulation of protein exit from endoplasmic reticulum,GO:0072657~protein localization to membrane,GO:2000010~positive regulation of protein localization to cell surface,	GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR004240:Nonaspanin (TM9SF),						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM100	transmembrane protein 100(TMEM100)	Homo sapiens			GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0007219~Notch signaling pathway,GO:0030509~BMP signaling pathway,GO:0043491~protein kinase B signaling,GO:0045603~positive regulation of endothelial cell differentiation,GO:0050848~regulation of calcium-mediated signaling,GO:0051930~regulation of sensory perception of pain,GO:0060842~arterial endothelial cell differentiation,GO:0071773~cellular response to BMP stimulus,GO:2001214~positive regulation of vasculogenesis,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,						KW-0221~Differentiation,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	TRANSMEM:Helical,
TMEM119	transmembrane protein 119(TMEM119)	Homo sapiens			GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0001934~positive regulation of protein phosphorylation,GO:0001958~endochondral ossification,GO:0007283~spermatogenesis,GO:0010628~positive regulation of gene expression,GO:0010832~negative regulation of myotube differentiation,GO:0030501~positive regulation of bone mineralization,GO:0031214~biomineral tissue development,GO:0033690~positive regulation of osteoblast proliferation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045779~negative regulation of bone resorption,GO:0048515~spermatid differentiation,GO:1903012~positive regulation of bone development,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,							KW-0091~Biomineralization,KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0892~Osteogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GalNAc...) serine,COMPBIAS:Basic and acidic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM132D	transmembrane protein 132D(TMEM132D)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR026307:Transmembrane protein 132,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM135	transmembrane protein 135(TMEM135)	Homo sapiens		h_prionPathway:Prion Pathway,	GO:0002082~regulation of oxidative phosphorylation,GO:0003406~retinal pigment epithelium development,GO:0007031~peroxisome organization,GO:0009409~response to cold,GO:0032094~response to food,GO:0070584~mitochondrion morphogenesis,GO:0090140~regulation of mitochondrial fission,	GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005811~lipid particle,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,		IPR026749:Transmembrane protein 135,						KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Transmembrane protein 135 N-terminal,TRANSMEM:Helical,
TMEM158	transmembrane protein 158(TMEM158)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0042277~peptide binding,							KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
TMEM196	transmembrane protein 196(TMEM196)	Homo sapiens				GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
TMPRSS6	transmembrane serine protease 6(TMPRSS6)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006879~cellular iron ion homeostasis,GO:0022617~extracellular matrix disassembly,GO:0030509~BMP signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030574~collagen catabolic process,GO:0033619~membrane protein proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0055072~iron ion homeostasis,GO:0060586~multicellular organismal iron ion homeostasis,GO:0097264~self proteolysis,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,	IPR000082:SEA domain,IPR000859:CUB domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR017118:Peptidase S1A, matriptase-2,IPR018114:Peptidase S1, trypsin family, active site,		206200~Iron-refractory iron deficiency anemia,	PIRSF037135:matriptase-2,	SM00020:Tryp_SPc,SM00192:LDLa,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:Peptidase S1,DOMAIN:SEA,MUTAGEN:R->A: Does not undergo proteolytic processing.,MUTAGEN:S->A: Does not undergo proteolytic processing.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
TNPO2	transportin 2(TNPO2)	Homo sapiens			GO:0006606~protein import into nucleus,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0031267~small GTPase binding,GO:0061608~nuclear import signal receptor activity,	IPR001494:Importin-beta, N-terminal,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa03013:Nucleocytoplasmic transport,	619556~Intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies,		SM00913:SM00913,	KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Importin N-terminal,REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 16,REPEAT:HEAT 17,REPEAT:HEAT 18,REPEAT:HEAT 19,REPEAT:HEAT 2,REPEAT:HEAT 20,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
TFF1	trefoil factor 1(TFF1)	Homo sapiens		h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,	GO:0005975~carbohydrate metabolic process,GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010039~response to iron ion,GO:0030154~cell differentiation,GO:0030277~maintenance of gastrointestinal epithelium,GO:0035902~response to immobilization stress,GO:0043434~response to peptide hormone,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR000519:P-type trefoil,IPR017957:P-type trefoil, conserved site,IPR017994:P-type trefoil, chordata,	hsa04915:Estrogen signaling pathway,			SM00018:PD,		KW-0964~Secreted,		KW-0732~Signal,		KW-0339~Growth factor,	KW-1015~Disulfide bond,	DOMAIN:P-type,MUTAGEN:C->S: Abolishes inhibition of gastric cancer cell growth.,
TCHH	trichohyalin(TCHH)	Homo sapiens			GO:0031424~keratinization,GO:0045109~intermediate filament organization,	GO:0001533~cornified envelope,GO:0005829~cytosol,GO:0005856~cytoskeleton,	GO:0005509~calcium ion binding,GO:0046914~transition metal ion binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,		617252~Uncombable hair syndrome 3,		SM01394:SM01394,	KW-0417~Keratinization,			KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0164~Citrullination,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:10 X 30 AA tandem repeats,REGION:23 X 26 AA approximate tandem repeats,REGION:5 X 13 AA tandem repeats of R-R-E-Q-E-E-E-R-R-E-Q-Q-L,REGION:8 X 6 AA tandem repeats of R-R-E-Q-Q-L,REGION:9 X 28 AA approximate tandem repeats,REGION:Disordered,REGION:S-100-like,REPEAT:1-1; approximate,REPEAT:1-2; approximate,REPEAT:1-3; approximate,REPEAT:1-4,REPEAT:1-5,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,REPEAT:2-4,REPEAT:2-5,REPEAT:2-6,REPEAT:2-7,REPEAT:2-8,REPEAT:4-1,REPEAT:4-10,REPEAT:4-2,REPEAT:4-3,REPEAT:4-4,REPEAT:4-5,REPEAT:4-6,REPEAT:4-7,REPEAT:4-8,REPEAT:4-9,
TREM2	triggering receptor expressed on myeloid cells 2(TREM2)	Homo sapiens			GO:0001774~microglial cell activation,GO:0001934~positive regulation of protein phosphorylation,GO:0002282~microglial cell activation involved in immune response,GO:0002588~positive regulation of antigen processing and presentation of peptide antigen via MHC class II,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0002931~response to ischemia,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006959~humoral immune response,GO:0007613~memory,GO:0010468~regulation of gene expression,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0010822~positive regulation of mitochondrion organization,GO:0010875~positive regulation of cholesterol efflux,GO:0010887~negative regulation of cholesterol storage,GO:0010891~negative regulation of sequestering of triglyceride,GO:0010983~positive regulation of high-density lipoprotein particle clearance,GO:0014067~negative regulation of phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0019216~regulation of lipid metabolic process,GO:0030316~osteoclast differentiation,GO:0032006~regulation of TOR signaling,GO:0032008~positive regulation of TOR signaling,GO:0032497~detection of lipopolysaccharide,GO:0032499~detection of peptidoglycan,GO:0032675~regulation of interleukin-6 production,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032733~positive regulation of interleukin-10 production,GO:0033674~positive regulation of kinase activity,GO:0034136~negative regulation of toll-like receptor 2 signaling pathway,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0034151~regulation of toll-like receptor 6 signaling pathway,GO:0034241~positive regulation of macrophage fusion,GO:0034351~negative regulation of glial cell apoptotic process,GO:0035176~social behavior,GO:0038160~CXCL12-activated CXCR4 signaling pathway,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043277~apoptotic cell clearance,GO:0045088~regulation of innate immune response,GO:0045672~positive regulation of osteoclast differentiation,GO:0045728~respiratory burst after phagocytosis,GO:0045960~positive regulation of complement activation, classical pathway,GO:0048143~astrocyte activation,GO:0048678~response to axon injury,GO:0050714~positive regulation of protein secretion,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050766~positive regulation of phagocytosis,GO:0050829~defense response to Gram-negative bacterium,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050866~negative regulation of cell activation,GO:0050921~positive regulation of chemotaxis,GO:0051897~positive regulation of protein kinase B signaling,GO:0051898~negative regulation of protein kinase B signaling,GO:0055088~lipid homeostasis,GO:0060075~regulation of resting membrane potential,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0061518~microglial cell proliferation,GO:0070269~pyroptosis,GO:0070345~negative regulation of fat cell proliferation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070392~detection of lipoteichoic acid,GO:0071223~cellular response to lipoteichoic acid,GO:0071224~cellular response to peptidoglycan,GO:0071333~cellular response to glucose stimulus,GO:0071396~cellular response to lipid,GO:0071456~cellular response to hypoxia,GO:0071640~regulation of macrophage inflammatory protein 1 alpha production,GO:0097028~dendritic cell differentiation,GO:0097062~dendritic spine maintenance,GO:0098657~import into cell,GO:1900015~regulation of cytokine production involved in inflammatory response,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1900223~positive regulation of beta-amyloid clearance,GO:1900226~negative regulation of NLRP3 inflammasome complex assembly,GO:1901076~positive regulation of engulfment of apoptotic cell,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1901800~positive regulation of proteasomal protein catabolic process,GO:1901980~positive regulation of inward rectifier potassium channel activity,GO:1902227~negative regulation of macrophage colony-stimulating factor signaling pathway,GO:1902531~regulation of intracellular signal transduction,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903082~positive regulation of C-C chemokine receptor CCR7 signaling pathway,GO:1903376~regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903753~negative regulation of p38MAPK cascade,GO:1903980~positive regulation of microglial cell activation,GO:1904093~negative regulation of autophagic cell death,GO:1904141~positive regulation of microglial cell migration,GO:1904646~cellular response to beta-amyloid,GO:1904951~positive regulation of establishment of protein localization,GO:1905291~positive regulation of CAMKK-AMPK signaling cascade,GO:1905581~positive regulation of low-density lipoprotein particle clearance,GO:1905805~excitatory synapse disassembly,GO:1905808~positive regulation of synapse disassembly,GO:1905907~negative regulation of amyloid fibril formation,GO:2000350~positive regulation of CD40 signaling pathway,GO:2001171~positive regulation of ATP biosynthetic process,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031226~intrinsic component of plasma membrane,GO:0044853~plasma membrane raft,	GO:0001530~lipopolysaccharide binding,GO:0001540~beta-amyloid binding,GO:0001786~phosphatidylserine binding,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008035~high-density lipoprotein particle binding,GO:0008289~lipid binding,GO:0008429~phosphatidylethanolamine binding,GO:0019209~kinase activator activity,GO:0030169~low-density lipoprotein particle binding,GO:0034185~apolipoprotein binding,GO:0034186~apolipoprotein A-I binding,GO:0034189~very-low-density lipoprotein particle binding,GO:0038023~signaling receptor activity,GO:0042834~peptidoglycan binding,GO:0044877~macromolecular complex binding,GO:0070891~lipoteichoic acid binding,GO:0071813~lipoprotein particle binding,GO:0097110~scaffold protein binding,GO:1990782~protein tyrosine kinase binding,	IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04380:Osteoclast differentiation,	618193~Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2,				KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,MUTAGEN:C->A: Loss of proteolytic cleavage by ADAM10 and ectodomain shedding. Decreases protein maturation and cell membrane localization.,MUTAGEN:K->M: Loss of LDL, CLU and APOE binding.,MUTAGEN:N->D: Loss of glycosylation.,MUTAGEN:N->K: No effect on cell membrane localization.,MUTAGEN:R->D: Decreases binding to THP-1 cells.,REGION:Disordered,SITE:Cleavage of ectodomain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRIM59	tripartite motif containing 59(TRIM59)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0046597~negative regulation of viral entry into host cell,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,IPR027370:RING-type zinc-finger, LisH dimerisation motif,				SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,		DOMAIN:B box-type,DOMAIN:RING-type,TRANSMEM:Helical,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM62	tripartite motif containing 62(TRIM62)	Homo sapiens			GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0016567~protein ubiquitination,GO:0019076~viral release from host cell,GO:0032897~negative regulation of viral transcription,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044314~protein K27-linked ubiquitination,GO:0045087~innate immune response,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046596~regulation of viral entry into host cell,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:1905036~positive regulation of antifungal innate immune response,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR001870:B30.2/SPRY domain,IPR003877:SPla/RYanodine receptor SPRY,IPR003879:Butyrophylin-like,IPR006574:SPRY-associated,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR017907:Zinc finger, RING-type, conserved site,				SM00184:RING,SM00449:SPRY,SM00589:PRY,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:B30.2/SPRY,MUTAGEN:CSIC->ASIA: Abolished E3 ubiquitin ligase activity.,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM67	tripartite motif containing 67(TRIM67)	Homo sapiens			GO:0010976~positive regulation of neuron projection development,GO:0032880~regulation of protein localization,GO:0046580~negative regulation of Ras protein signal transduction,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,	GO:0008270~zinc ion binding,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR001870:B30.2/SPRY domain,IPR003649:B-box, C-terminal,IPR003877:SPla/RYanodine receptor SPRY,IPR003961:Fibronectin, type III,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR017903:COS domain,IPR017907:Zinc finger, RING-type, conserved site,IPR018957:Zinc finger, C3HC4 RING-type,				SM00060:FN3,SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00502:BBC,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:COS,DOMAIN:Fibronectin type-III,REGION:Disordered,ZN_FING:B box-type 1; degenerate,ZN_FING:B box-type 2,ZN_FING:RING-type; degenerate,
TRIM71	tripartite motif containing 71(TRIM71)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0000209~protein polyubiquitination,GO:0001843~neural tube closure,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010586~miRNA metabolic process,GO:0010608~posttranscriptional regulation of gene expression,GO:0017148~negative regulation of translation,GO:0021915~neural tube development,GO:0035196~production of miRNAs involved in gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051865~protein autoubiquitination,GO:0060964~regulation of gene silencing by miRNA,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0071310~cellular response to organic substance,GO:0072089~stem cell proliferation,GO:2000177~regulation of neural precursor cell proliferation,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0000932~P-body,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030371~translation repressor activity,GO:0035198~miRNA binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001258:NHL repeat,IPR001298:Filamin/ABP280 repeat,IPR001841:Zinc finger, RING-type,IPR011042:Six-bladed beta-propeller, TolB-like,IPR013017:NHL repeat, subgroup,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR017868:Filamin/ABP280 repeat-like,IPR017907:Zinc finger, RING-type, conserved site,	hsa05206:MicroRNAs in cancer,	618667~Hydrocephalus, congenital, 4,		SM00184:RING,SM00336:BBOX,SM00557:IG_FLMN,	KW-0833~Ubl conjugation pathway,KW-0943~RNA-mediated gene silencing,	KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0694~RNA-binding,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MUTAGEN:G->D: Strongly decreases repression on mRNA.,MUTAGEN:H->L: Abolishes repression on mRNA. Abolishes interaction with AGO2, PABPC1 and PUM2. Increases interaction with HSP90AA1.,MUTAGEN:R->A: Decreases repression on mRNA. Abolishes interaction with AGO2, HSP90AA1, PABPC1 and PUM2.,MUTAGEN:Y->A: Decreases repression on mRNA. Decreases interaction with HSP90AA1. Abolishes interaction with PABPC1 and PUM2. Increases interaction with AGO2.,REGION:Disordered,REPEAT:Filamin,REPEAT:NHL 1,REPEAT:NHL 2,REPEAT:NHL 3,REPEAT:NHL 4,REPEAT:NHL 5,REPEAT:NHL 6,ZN_FING:B box-type 1; atypical,ZN_FING:B box-type 2,ZN_FING:RING-type,
TPM3	tropomyosin 3(TPM3)	Homo sapiens			GO:0006936~muscle contraction,GO:0007015~actin filament organization,	GO:0001725~stress fiber,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005862~muscle thin filament tropomyosin,GO:0005884~actin filament,GO:0015629~actin cytoskeleton,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR000533:Tropomyosin,IPR014751:DNA repair protein XRCC4, C-terminal,	hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04814:Motor proteins,hsa05200:Pathways in cancer,hsa05216:Thyroid cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,	255310~Congenital myopathy 4A, autosomal dominant,609284~Congenital myopathy 4B, autosomal recessive,				KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-1057~Nemaline myopathy,	KW-0175~Coiled coil,		KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
TP53AIP1	tumor protein p53 regulated apoptosis inducing protein 1(TP53AIP1)	Homo sapiens			GO:0006915~apoptotic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,			hsa04115:p53 signaling pathway,hsa04210:Apoptosis,				KW-0053~Apoptosis,	KW-0496~Mitochondrion,						COMPBIAS:Polar residues,REGION:Disordered,
TTYH1	tweety family member 1(TTYH1)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0006821~chloride transport,GO:0006826~iron ion transport,GO:0031589~cell-substrate adhesion,GO:0034220~ion transmembrane transport,GO:0034755~iron ion transmembrane transport,GO:0046847~filopodium assembly,GO:0098609~cell-cell adhesion,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030868~smooth endoplasmic reticulum membrane,GO:0031527~filopodium membrane,GO:0032433~filopodium tip,GO:0034707~chloride channel complex,GO:0045202~synapse,	GO:0005229~intracellular calcium activated chloride channel activity,GO:0005254~chloride channel activity,GO:0005381~iron ion transmembrane transporter activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0072320~volume-sensitive chloride channel activity,	IPR006990:Tweety,					KW-0130~Cell adhesion,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0869~Chloride channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,
TWIST1	twist family bHLH transcription factor 1(TWIST1)	Homo sapiens		h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001764~neuron migration,GO:0001843~neural tube closure,GO:0003180~aortic valve morphogenesis,GO:0003183~mitral valve morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010936~negative regulation of macrophage cytokine production,GO:0014067~negative regulation of phosphatidylinositol 3-kinase signaling,GO:0030335~positive regulation of cell migration,GO:0030500~regulation of bone mineralization,GO:0032000~positive regulation of fatty acid beta-oxidation,GO:0032502~developmental process,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033128~negative regulation of histone phosphorylation,GO:0035067~negative regulation of histone acetylation,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035359~negative regulation of peroxisome proliferator activated receptor signaling pathway,GO:0042473~outer ear morphogenesis,GO:0042476~odontogenesis,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045668~negative regulation of osteoblast differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045843~negative regulation of striated muscle tissue development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048642~negative regulation of skeletal muscle tissue development,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051898~negative regulation of protein kinase B signaling,GO:0060021~palate development,GO:0060363~cranial suture morphogenesis,GO:0060900~embryonic camera-type eye formation,GO:0061029~eyelid development in camera-type eye,GO:0071363~cellular response to growth factor stimulus,GO:0071456~cellular response to hypoxia,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:0097009~energy homeostasis,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000144~positive regulation of DNA-templated transcription, initiation,GO:2000147~positive regulation of cell motility,GO:2000276~negative regulation of oxidative phosphorylation uncoupler activity,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2000773~negative regulation of cellular senescence,GO:2000780~negative regulation of double-strand break repair,GO:2000793~cell proliferation involved in heart valve development,GO:2000802~positive regulation of endocardial cushion to mesenchymal transition involved in heart valve formation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043425~bHLH transcription factor binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR015789:Twist-related,	hsa05205:Proteoglycans in cancer,	101400~Saethre-Chotzen syndrome with or without eyelid anomalies,123100~Craniosynostosis 1,180750~Robinow-Sorauf syndrome,617746~Sweeney-Cox syndrome,		SM00353:HLH,	KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0989~Craniosynostosis,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,REGION:Sufficient for transactivation activity,
TYR	tyrosinase(TYR)	Homo sapiens			GO:0006583~melanin biosynthetic process from tyrosine,GO:0006726~eye pigment biosynthetic process,GO:0007601~visual perception,GO:0008283~cell proliferation,GO:0009411~response to UV,GO:0009637~response to blue light,GO:0033280~response to vitamin D,GO:0042438~melanin biosynthetic process,GO:0043473~pigmentation,GO:0048538~thymus development,GO:0051591~response to cAMP,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005798~Golgi-associated vesicle,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0033162~melanosome membrane,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0004503~monophenol monooxygenase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR002227:Tyrosinase,IPR008922:Uncharacterised domain, di-copper centre,	hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,hsa04916:Melanogenesis,	203100~Albinism, oculocutaneous, type IA,601800~Melanoma, cutaneous malignant, susceptibility to, 8,601800~Skin/hair/eye pigmentation 3, blue/green eyes,601800~Skin/hair/eye pigmentation 3, light/dark/freckling skin,606952~Albinism, oculocutaneous, type IB,			KW-0470~Melanin biosynthesis,	KW-0472~Membrane,	KW-0015~Albinism,KW-0209~Deafness,KW-0225~Disease variant,KW-0897~Waardenburg syndrome,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,KW-0825~Tumor antigen,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Tyrosinase copper-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal, melanosome,TRANSMEM:Helical,
TIE1	tyrosine kinase with immunoglobulin like and EGF like domains 1(TIE1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0001936~regulation of endothelial cell proliferation,GO:0003180~aortic valve morphogenesis,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007498~mesoderm development,GO:0016310~phosphorylation,GO:0016525~negative regulation of angiogenesis,GO:0030336~negative regulation of cell migration,GO:0032526~response to retinoic acid,GO:0033674~positive regulation of kinase activity,GO:0045026~plasma membrane fusion,GO:0045766~positive regulation of angiogenesis,GO:0048771~tissue remodeling,GO:0060836~lymphatic endothelial cell differentiation,GO:0060854~branching involved in lymph vessel morphogenesis,GO:1901201~regulation of extracellular matrix assembly,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR000742:Epidermal growth factor-like domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,		619401~Lymphatic malformation 11,		SM00060:FN3,SM00181:EGF,SM00219:TyrKc,SM00409:IG,	KW-0037~Angiogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Protein kinase,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
UCHL1	ubiquitin C-terminal hydrolase L1(UCHL1)	Homo sapiens			GO:0002176~male germ cell proliferation,GO:0002931~response to ischemia,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007412~axon target recognition,GO:0007628~adult walking behavior,GO:0008283~cell proliferation,GO:0016241~regulation of macroautophagy,GO:0016579~protein deubiquitination,GO:0019233~sensory perception of pain,GO:0019896~axonal transport of mitochondrion,GO:0021762~substantia nigra development,GO:0042755~eating behavior,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043407~negative regulation of MAP kinase activity,GO:0050905~neuromuscular process,GO:0055001~muscle cell development,GO:0071466~cellular response to xenobiotic stimulus,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0043025~neuronal cell body,GO:0044306~neuron projection terminus,GO:1904115~axon cytoplasm,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008242~omega peptidase activity,GO:0016874~ligase activity,GO:0031625~ubiquitin protein ligase binding,GO:0031694~alpha-2A adrenergic receptor binding,GO:0043130~ubiquitin binding,	IPR001578:Peptidase C12, ubiquitin carboxyl-terminal hydrolase 1,	hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	613643~Parkinson disease 5, susceptibility to,615491~Spastic paraplegia 79B, autosomal recessive,620221~Spastic paraplegia 79A, autosomal dominant,			KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,KW-0907~Parkinson disease,KW-0908~Parkinsonism,			KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,DOMAIN:Ubiquitin carboxyl-terminal hydrolase family 1 cysteine active-site,LIPID:S-farnesyl cysteine,MUTAGEN:C->S: Abolishes enzymatic activity.,MUTAGEN:D->N: 6-fold decrease in affinity for ubiquitin ethyl ester; 97.5% decrease in enzymatic activity.,MUTAGEN:F->A: Almost complete loss of activity.,MUTAGEN:H->D: 10000-fold decrease in enzymatic activity; no change in affinity for ubiquitin ethyl ester.,MUTAGEN:H->K,Q,N,Y: Abolishes enzymatic activity.,MUTAGEN:H->Q,N: 2-fold increase in affinity for ubiquitin ethyl ester, slight reduction in enzymatic activity.,MUTAGEN:Q->R: No effect on enzymatic parameters.,PROPEP:Removed in mature form,REGION:Interaction with ubiquitin,SITE:Important for enzyme activity,SITE:Susceptible to oxidation,
UBD	ubiquitin D(UBD)	Homo sapiens			GO:0006508~proteolysis,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032446~protein modification by small protein conjugation,GO:0034341~response to interferon-gamma,GO:0034612~response to tumor necrosis factor,GO:0043011~myeloid dendritic cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0070842~aggresome assembly,GO:1901990~regulation of mitotic cell cycle phase transition,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016235~aggresome,	GO:0005515~protein binding,GO:0070628~proteasome binding,	IPR000626:Ubiquitin,IPR019956:Ubiquitin subgroup,				SM00213:UBQ,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,	DOMAIN:Ubiquitin-like,DOMAIN:Ubiquitin-like 1,DOMAIN:Ubiquitin-like 2,MUTAGEN:GG->AA: Impaired thioester formation-mediated activation by UBA6. Loss of interaction with UBA6 and SQSTM1. No effect on its interaction with MAD2L1, HDAC6 and NUB1.,MUTAGEN:H->D: Decreases interaction with MAD2L1, no effect on the interaction with HDAC6, UBA6, NUB1 and SQSTM1 and moderately attenuates UBD-induced tumor formation in vivo; when associated with D-77 and Q-79. Complete loss of interaction with MAD2L1, no effect on the interaction with TP53/p53, HDAC6, UBA6, NUB1 and SQSTM1 and significantly attenuates UBD-induced tumor formation in vivo; when associated with D-11; Q-13; D-77 and Q-79.,MUTAGEN:H->D: Decreases interaction with MAD2L1, no effect on the interaction with HDAC6, UBA6, NUB1 and SQSTM1 and moderately attenuates UBD-induced tumor formation in vivo; when associated with Q-13. Complete loss of interaction with MAD2L1, no effect on the interaction with TP53/p53, HDAC6, UBA6, NUB1 and SQSTM1 and significantly attenuates UBD-induced tumor formation in vivo; when associated with Q-13; D-75; D-77 and Q-79.,MUTAGEN:K->Q: Decreases interaction with MAD2L1, no effect on the interaction with HDAC6, UBA6, NUB1 and SQSTM1 and moderately attenuates UBD-induced tumor formation in vivo; when associated with D-75 and D-77. Complete loss of interaction with MAD2L1, no effect on the interaction with TP53/p53, HDAC6, UBA6, NUB1 and SQSTM1 and significantly attenuates UBD-induced tumor formation in vivo; when associated with D-11; Q-13; D-75 and D-77.,MUTAGEN:R->Q: Decreases interaction with MAD2L1, no effect on the interaction with HDAC6, UBA6, NUB1 and SQSTM1 and moderately attenuates UBD-induced tumor formation in vivo; when associated with D-11. Complete loss of interaction with MAD2L1, no effect on the interaction with TP53/p53, HDAC6, UBA6, NUB1 and SQSTM1 and significantly attenuates UBD-induced tumor formation in vivo; when associated with D-11; D-75; D-77 and Q-79.,MUTAGEN:T->D: Decreases interaction with MAD2L1, no effect on the interaction with HDAC6, UBA6, NUB1 and SQSTM1 and moderately attenuates UBD-induced tumor formation in vivo; when associated with D-75 and Q-79. Complete loss of interaction with MAD2L1, no effect on the interaction with TP53/p53, HDAC6, UBA6, NUB1 and SQSTM1 and significantly attenuates UBD-induced tumor formation in vivo; when associated with D-11; Q-13; D-75 and Q-79.,SITE:Activation by thioester intermediate formation with UBA6,
USP21	ubiquitin specific peptidase 21(USP21)	Homo sapiens			GO:0006325~chromatin organization,GO:0006508~proteolysis,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016578~histone deubiquitination,GO:0016579~protein deubiquitination,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003713~transcription coactivator activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0019784~NEDD8-specific protease activity,GO:0046872~metal ion binding,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,	hsa04217:Necroptosis,				KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,		ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:USP,MOTIF:Nuclear export signal,MUTAGEN:C->A,S: Abolishes ubiquitin thioesterase activity.,REGION:Disordered,
USP44	ubiquitin specific peptidase 44(USP44)	Homo sapiens			GO:0006289~nucleotide-excision repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007049~cell cycle,GO:0007059~chromosome segregation,GO:0016579~protein deubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045066~regulatory T cell differentiation,GO:0045841~negative regulation of mitotic metaphase/anaphase transition,GO:0051301~cell division,GO:0090266~regulation of mitotic cell cycle spindle assembly checkpoint,GO:1904667~negative regulation of ubiquitin protein ligase activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0072686~mitotic spindle,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0101005~ubiquitinyl hydrolase activity,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR001607:Zinc finger, UBP-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,				SM00290:ZnF_UBP,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0391~Immunity,KW-0399~Innate immunity,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:UBP-type,DOMAIN:USP,MUTAGEN:C->S,A: Abolishes deubiquitinase activity.,REGION:Disordered,ZN_FING:UBP-type,
USP5	ubiquitin specific peptidase 5(USP5)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0071108~protein K48-linked deubiquitination,	GO:0005634~nucleus,GO:0005764~lysosome,GO:0005829~cytosol,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0043130~ubiquitin binding,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR001607:Zinc finger, UBP-type,IPR009060:UBA-like,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR016652:Ubiquitinyl hydrolase,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,			PIRSF016308:ubiquitin-specific protease (ubiquitin carboxyl-terminal hydrolase),	SM00165:UBA,SM00290:ZnF_UBP,	KW-0833~Ubl conjugation pathway,			KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:UBA,DOMAIN:UBA 1,DOMAIN:UBA 2,DOMAIN:UBP-type,DOMAIN:USP,DOMAIN:Ubiquitinyl hydrolase variant UBP zinc finger,MUTAGEN:C->A: Decreased rate of activity and decreased zinc binding.,MUTAGEN:C->A: Decreased rate of activity.,MUTAGEN:C->A: Loss of activity. Loss of ubiquitin binding; when associated with A-221. Lower affinity for triubiquitin and tetraubiquitin, but no effect on affinity for diubiquitin; when associated with E-666. Lower affinity for diubiquitin, triubiquitin and tetraubiquitin; when associated with E-734.,MUTAGEN:D->A: Loss of polyubiquitin binding and hydrolysis.,MUTAGEN:H->A: Decreased rate of activity.,MUTAGEN:M->E: Lower affinity for diubiquitin, triubiquitin and tetraubiquitin; when associated with A-335. No effect on activity; when associated with E-666.,MUTAGEN:M->E: Lower affinity for triubiquitin and tetraubiquitin, but no effect on affinity for diubiquitin; when associated with A-335. No effect on activity; when associated with E-734.,MUTAGEN:R->A: Loss of polyubiquitin hydrolysis. Loss of ubiquitin binding; when associated with A-335.,MUTAGEN:RRY->KWF: Loss of polyubiquitin binding and subsequent activation.,MUTAGEN:Y->F: Loss of polyubiquitin binding.,REGION:Disordered,ZN_FING:UBP-type; degenerate,
UBE4B	ubiquitination factor E4B(UBE4B)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0008626~granzyme-mediated apoptotic signaling pathway,GO:0009411~response to UV,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0019899~enzyme binding,GO:0034450~ubiquitin-ubiquitin ligase activity,	IPR003613:U box domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR019474:Ubiquitin conjugation factor E4, core,	hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,			SM00504:Ubox,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:U-box,DOMAIN:Ubiquitin conjugation factor E4 core,MUTAGEN:D->A: Abolishes cleavage by caspase-3 and caspase-7.,MUTAGEN:D->A: Abolishes cleavage by caspase-6 and granzyme B.,MUTAGEN:D->A: Abolishes cleavage by caspase-6. No effect on cleavage by granzyme B.,REGION:Disordered,SITE:Cleavage; by caspase-3 and caspase-7,SITE:Cleavage; by caspase-6 and granzyme B,
UNC5D	unc-5 netrin receptor D(UNC5D)	Homo sapiens			GO:0006915~apoptotic process,GO:0007411~axon guidance,GO:0021859~pyramidal neuron differentiation,GO:0038007~netrin-activated signaling pathway,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,GO:2001222~regulation of neuron migration,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0005042~netrin receptor activity,	IPR000488:Death domain,IPR000884:Thrombospondin, type 1 repeat,IPR000906:ZU5,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR011029:Death-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,	hsa04360:Axon guidance,			SM00005:DEATH,SM00209:TSP1,SM00218:ZU5,SM00408:IGc2,SM00409:IG,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Death,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:ZU5,REGION:Important for interaction with FLRT2,SITE:Cleavage; by caspase-3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
UTF1	undifferentiated embryonic cell transcription factor 1(UTF1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008584~male gonad development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,						KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,MUTAGEN:L->P: Abolishes coactivation activity; when associated with P-296.,MUTAGEN:L->P: Abolishes coactivation activity; when associated with P-303.,REGION:Disordered,REGION:Leucine-zipper,
UNG	uracil DNA glycosylase(UNG)	Homo sapiens			GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0016446~somatic hypermutation of immunoglobulin genes,GO:0043066~negative regulation of apoptotic process,GO:0045008~depyrimidination,GO:0045190~isotype switching,GO:0097510~base-excision repair, AP site formation via deaminated base removal,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,	GO:0003684~damaged DNA binding,GO:0004844~uracil DNA N-glycosylase activity,GO:0005515~protein binding,GO:0043024~ribosomal small subunit binding,	IPR002043:Uracil-DNA glycosylase,IPR005122:Uracil-DNA glycosylase-like,IPR018085:Uracil-DNA glycosylase, active site,	hsa03410:Base excision repair,hsa05340:Primary immunodeficiency,	608106~Immunodeficiency with hyper IgM, type 5,		SM00986:SM00986,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Uracil-DNA glycosylase-like,MUTAGEN:D->E,N: Loss of activity.,MUTAGEN:N->D: Cytosine-DNA glycosylase activity.,MUTAGEN:Y->A,C,S: Thymine-DNA glycosylase activity.,REGION:Disordered,REGION:FAM72A-binding,
UCN	urocortin(UCN)	Homo sapiens			GO:0001964~startle response,GO:0006954~inflammatory response,GO:0006979~response to oxidative stress,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007565~female pregnancy,GO:0007605~sensory perception of sound,GO:0008306~associative learning,GO:0009060~aerobic respiration,GO:0010629~negative regulation of gene expression,GO:0010996~response to auditory stimulus,GO:0030157~pancreatic juice secretion,GO:0030307~positive regulation of cell growth,GO:0031175~neuron projection development,GO:0032099~negative regulation of appetite,GO:0032355~response to estradiol,GO:0032755~positive regulation of interleukin-6 production,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034199~activation of protein kinase A activity,GO:0035176~social behavior,GO:0035483~gastric emptying,GO:0042311~vasodilation,GO:0042756~drinking behavior,GO:0043066~negative regulation of apoptotic process,GO:0043117~positive regulation of vascular permeability,GO:0043524~negative regulation of neuron apoptotic process,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0045727~positive regulation of translation,GO:0045740~positive regulation of DNA replication,GO:0045776~negative regulation of blood pressure,GO:0045792~negative regulation of cell size,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046888~negative regulation of hormone secretion,GO:0048265~response to pain,GO:0051384~response to glucocorticoid,GO:0051461~positive regulation of corticotropin secretion,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060452~positive regulation of cardiac muscle contraction,GO:0060455~negative regulation of gastric acid secretion,GO:0060547~negative regulation of necrotic cell death,GO:0090280~positive regulation of calcium ion import,GO:1901215~negative regulation of neuron death,GO:2000252~negative regulation of feeding behavior,GO:2000987~positive regulation of behavioral fear response,	GO:0005576~extracellular region,GO:0030425~dendrite,GO:0043196~varicosity,GO:0043204~perikaryon,GO:0043679~axon terminus,	GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0046811~histone deacetylase inhibitor activity,GO:0051430~corticotropin-releasing hormone receptor 1 binding,GO:0051431~corticotropin-releasing hormone receptor 2 binding,	IPR000187:Corticotropin-releasing factor, CRF,IPR003620:Urocortin/corticotropin-releasing factor,IPR018446:Corticotropin-releasing factor conserved site,	hsa04080:Neuroactive ligand-receptor interaction,			SM00039:CRF,	KW-1009~Hearing,	KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	MUTAGEN:F->A: Strongly reduced affinity for CRHR2.,MUTAGEN:I->A: Reduced affinity for CRHR2.,MUTAGEN:R->A: Reduced affinity for CRHR1.,MUTAGEN:V->A: Reduced affinity for CRHR2.,PEPTIDE:Urocortin,REGION:Disordered,
VEGFA	vascular endothelial growth factor A(VEGFA)	Homo sapiens		h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_no1Pathway:Actions of Nitric Oxide in the Heart,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001570~vasculogenesis,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001822~kidney development,GO:0001934~positive regulation of protein phosphorylation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002040~sprouting angiogenesis,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002052~positive regulation of neuroblast proliferation,GO:0002092~positive regulation of receptor internalization,GO:0002575~basophil chemotaxis,GO:0002687~positive regulation of leukocyte migration,GO:0003007~heart morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003169~coronary vein morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0007498~mesoderm development,GO:0007595~lactation,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010749~regulation of nitric oxide mediated signal transduction,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0030154~cell differentiation,GO:0030224~monocyte differentiation,GO:0030225~macrophage differentiation,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0030855~epithelial cell differentiation,GO:0031077~post-embryonic camera-type eye development,GO:0031334~positive regulation of protein complex assembly,GO:0031954~positive regulation of protein autophosphorylation,GO:0032147~activation of protein kinase activity,GO:0032793~positive regulation of CREB transcription factor activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035148~tube formation,GO:0035767~endothelial cell chemotaxis,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036303~lymph vessel morphogenesis,GO:0036324~vascular endothelial growth factor receptor-2 signaling pathway,GO:0038033~positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway,GO:0038084~vascular endothelial growth factor signaling pathway,GO:0038089~positive regulation of cell migration by vascular endothelial growth factor signaling pathway,GO:0038091~positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,GO:0038190~VEGF-activated neuropilin signaling pathway,GO:0042327~positive regulation of phosphorylation,GO:0042462~eye photoreceptor cell development,GO:0043066~negative regulation of apoptotic process,GO:0043117~positive regulation of vascular permeability,GO:0043129~surfactant homeostasis,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0045785~positive regulation of cell adhesion,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048469~cell maturation,GO:0048593~camera-type eye morphogenesis,GO:0048842~positive regulation of axon extension involved in axon guidance,GO:0048844~artery morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050918~positive chemotaxis,GO:0050927~positive regulation of positive chemotaxis,GO:0050930~induction of positive chemotaxis,GO:0051272~positive regulation of cellular component movement,GO:0051781~positive regulation of cell division,GO:0051894~positive regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0055013~cardiac muscle cell development,GO:0060319~primitive erythrocyte differentiation,GO:0060749~mammary gland alveolus development,GO:0060754~positive regulation of mast cell chemotaxis,GO:0060948~cardiac vascular smooth muscle cell development,GO:0060982~coronary artery morphogenesis,GO:0061042~vascular wound healing,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071456~cellular response to hypoxia,GO:0071542~dopaminergic neuron differentiation,GO:0071679~commissural neuron axon guidance,GO:0090037~positive regulation of protein kinase C signaling,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0090259~regulation of retinal ganglion cell axon guidance,GO:0097475~motor neuron migration,GO:0097533~cellular stress response to acid chemical,GO:1900086~positive regulation of peptidyl-tyrosine autophosphorylation,GO:1900745~positive regulation of p38MAPK cascade,GO:1900748~positive regulation of vascular endothelial growth factor signaling pathway,GO:1901165~positive regulation of trophoblast cell migration,GO:1901727~positive regulation of histone deacetylase activity,GO:1902336~positive regulation of retinal ganglion cell axon guidance,GO:1902966~positive regulation of protein localization to early endosome,GO:1903141~negative regulation of establishment of endothelial barrier,GO:1903392~negative regulation of adherens junction organization,GO:1903572~positive regulation of protein kinase D signaling,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903672~positive regulation of sprouting angiogenesis,GO:1905278~positive regulation of epithelial tube formation,GO:1905604~negative regulation of maintenance of permeability of blood-brain barrier,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,GO:2000573~positive regulation of DNA biosynthetic process,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005912~adherens junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0030141~secretory granule,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:1990150~VEGF-A complex,	GO:0001968~fibronectin binding,GO:0005125~cytokine activity,GO:0005161~platelet-derived growth factor receptor binding,GO:0005172~vascular endothelial growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0038191~neuropilin binding,GO:0042056~chemoattractant activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043183~vascular endothelial growth factor receptor 1 binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0048018~receptor agonist activity,GO:0050840~extracellular matrix binding,	IPR000072:Platelet-derived growth factor (PDGF),IPR023581:Platelet-derived growth factor, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05219:Bladder cancer,hsa05323:Rheumatoid arthritis,hsa05418:Fluid shear stress and atherosclerosis,	603933~Microvascular complications of diabetes 1,		SM00141:PDGF,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0333~Golgi apparatus,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DISULFID:Interchain,DOMAIN:Platelet-derived growth factor (PDGF) family profile,REGION:Disordered,
VIPR2	vasoactive intestinal peptide receptor 2(VIPR2)	Homo sapiens		h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007267~cell-cell signaling,GO:0048662~negative regulation of smooth muscle cell proliferation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004999~vasoactive intestinal polypeptide receptor activity,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,	IPR000832:GPCR, family 2, secretin-like,IPR001571:GPCR, family 2, vasoactive intestinal peptide receptor,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR002284:GPCR, family 2, vasoactive intestinal peptide receptor 2,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,			SM00008:HormR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 2 profile 1,DOMAIN:G-protein coupled receptors family 2 profile 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
VASH1	vasohibin 1(VASH1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001937~negative regulation of endothelial cell proliferation,GO:0006508~proteolysis,GO:0007049~cell cycle,GO:0009611~response to wounding,GO:0010596~negative regulation of endothelial cell migration,GO:0016525~negative regulation of angiogenesis,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045765~regulation of angiogenesis,GO:0051726~regulation of cell cycle,GO:0060716~labyrinthine layer blood vessel development,GO:1901491~negative regulation of lymphangiogenesis,GO:2000772~regulation of cellular senescence,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0045177~apical part of cell,	GO:0003779~actin binding,GO:0004181~metallocarboxypeptidase activity,GO:0005515~protein binding,						KW-0131~Cell cycle,KW-0338~Growth arrest,	KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0732~Signal,		KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:C->A,S: Abolished tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:F->R: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-77. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-81. Abolished tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-77 and R-81.,MUTAGEN:H->A: Abolished tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:K->A,E: Abolished tyrosine carboxypeptidase activity on alpha-tubulin. Abolished tyrosine carboxypeptidase activity on alpha-tubulin; when associated with A-222.,MUTAGEN:K->A,E: Reduced tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:K->E: Abolished tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:K->E: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-194. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-203.,MUTAGEN:K->E: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-194. Strognly reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-203.,MUTAGEN:K->E: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-256. No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-258. No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-276.,MUTAGEN:K->E: No effect on tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-194. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-203.,MUTAGEN:L->A: Slightly reduced tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:LP->EE: Almost abolished interaction with VASH1.,MUTAGEN:M->R: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-141. Abolished tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-81 and R-141.,MUTAGEN:MWKHV->RWKHR: No effect on tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:R->A,E: Abolished tyrosine carboxypeptidase activity on alpha-tubulin. Abolished tyrosine carboxypeptidase activity on alpha-tubulin; when associated with A-146.,MUTAGEN:R->A: Disappearance of 36, 32 and 27 kDa processed forms.,MUTAGEN:R->A: Disappearance of 42 kDa processed form.,MUTAGEN:R->E: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. Strongly reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-258. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-258. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-256. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with E-276.,MUTAGEN:R->E: Slightly reduced tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:R->Q: Reduced tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:S->A: Abolished tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:V->R: No effect on tyrosine carboxypeptidase activity on alpha-tubulin. Reduced tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-141. Abolished tyrosine carboxypeptidase activity on alpha-tubulin; when associated with R-77 and R-141.,MUTAGEN:WERMW->AERMA: Strongly reduced interaction with SVBP.,MUTAGEN:Y->A,F: Abolished tyrosine carboxypeptidase activity on alpha-tubulin.,MUTAGEN:Y->F: Slightly reduced tyrosine carboxypeptidase activity on alpha-tubulin.,REGION:Disordered,REGION:Involved in heparin-binding and antiangiogenic activity,SITE:Cleavage,
VCAN	versican(VCAN)	Homo sapiens			GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0002052~positive regulation of neuroblast proliferation,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006027~glycosaminoglycan catabolic process,GO:0007155~cell adhesion,GO:0007275~multicellular organism development,GO:0007417~central nervous system development,GO:0008037~cell recognition,GO:0008347~glial cell migration,GO:0010001~glial cell differentiation,	GO:0001750~photoreceptor outer segment,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0033165~interphotoreceptor matrix,GO:0043202~lysosomal lumen,GO:0045202~synapse,GO:0072534~perineuronal net,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005539~glycosaminoglycan binding,GO:0005540~hyaluronic acid binding,GO:0030021~extracellular matrix structural constituent conferring compression resistance,GO:0030246~carbohydrate binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000436:Sushi/SCR/CCP,IPR000538:Link,IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR001881:EGF-like calcium-binding,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018097:EGF-like calcium-binding, conserved site,IPR018378:C-type lectin, conserved site,	hsa04514:Cell adhesion molecules,	143200~Wagner syndrome 1,		SM00032:CCP,SM00034:CLECT,SM00179:EGF_CA,SM00181:EGF,SM00409:IG,SM00445:LINK,		KW-0272~Extracellular matrix,KW-0964~Secreted,KW-0966~Cell projection,	KW-0898~Cataract,	KW-0245~EGF-like domain,KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,	KW-0106~Calcium,KW-0373~Hyaluronic acid,KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C-type lectin,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,DOMAIN:Link,DOMAIN:Link 1,DOMAIN:Link 2,DOMAIN:Sushi,REGION:Disordered,REGION:GAG-alpha (glucosaminoglycan attachment domain),REGION:GAG-beta,SITE:Cleavage; by ADAMTS15,
VSX1	visual system homeobox 1(VSX1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007601~visual perception,GO:0042551~neuron maturation,GO:0048666~neuron development,GO:0050896~response to stimulus,GO:0060040~retinal bipolar neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR023339:CVC domain,		148300~Keratoconus 1,614195~Craniofacial anomalies and anterior segment dysgenesis syndrome,		SM00389:HOX,	KW-0716~Sensory transduction,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0844~Vision,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:CVC,MOTIF:Nuclear localization signal,MOTIF:Octapeptide motif,REGION:Disordered,
VWF	von Willebrand factor(VWF)	Homo sapiens			GO:0007155~cell adhesion,GO:0007596~blood coagulation,GO:0007599~hemostasis,GO:0009611~response to wounding,GO:0030168~platelet activation,GO:0031589~cell-substrate adhesion,GO:1902533~positive regulation of intracellular signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0031012~extracellular matrix,GO:0031091~platelet alpha granule,GO:0031093~platelet alpha granule lumen,GO:0033093~Weibel-Palade body,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0019865~immunoglobulin binding,GO:0042802~identical protein binding,GO:0047485~protein N-terminus binding,GO:0051087~chaperone binding,	IPR001007:von Willebrand factor, type C,IPR001846:von Willebrand factor, type D domain,IPR002035:von Willebrand factor, type A,IPR002919:Trypsin Inhibitor-like, cysteine rich domain,IPR006207:Cystine knot, C-terminal,IPR014853:Uncharacterised domain, cysteine-rich,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04610:Complement and coagulation cascades,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa05165:Human papillomavirus infection,hsa05171:Coronavirus disease - COVID-19,	193400~von Willebrand disease, type 1,277480~von Willebrand disease, type 3,613554~von Willebrand disease, types 2A, 2B, 2M, and 2N,	PIRSF002495:von Willebrand factor,	SM00041:CT,SM00214:VWC,SM00215:VWC_out,SM00216:VWD,SM00327:VWA,SM00832:SM00832,	KW-0094~Blood coagulation,KW-0130~Cell adhesion,KW-0356~Hemostasis,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0852~von Willebrand disease,	KW-0677~Repeat,KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,DISULFID:Or C-1899 with C-1942,DOMAIN:CTCK,DOMAIN:TIL 1,DOMAIN:TIL 2,DOMAIN:TIL 3,DOMAIN:TIL 4,DOMAIN:VWFA,DOMAIN:VWFA 1; binding site for platelet glycoprotein Ib,DOMAIN:VWFA 2,DOMAIN:VWFA 3; main binding site for collagens type I and III,DOMAIN:VWFC,DOMAIN:VWFC 1,DOMAIN:VWFC 2,DOMAIN:VWFC 3,DOMAIN:VWFD,DOMAIN:VWFD 1,DOMAIN:VWFD 2,DOMAIN:VWFD 3,DOMAIN:VWFD 4,MOTIF:Cell attachment site,MUTAGEN:C->R: Reduced secretion and increased intracellular retention. Similar phenotype; when associated with S-1169.,MUTAGEN:C->S: Reduced secretion and increased intracellular retention. Similar phenotype; when associated with R-1149.,REGION:Amino-terminal,REGION:CX,REGION:E1,REGION:E2,
XDH	xanthine dehydrogenase(XDH)	Homo sapiens		h_freePathway:Free Radical Induced Apoptosis,	GO:0000255~allantoin metabolic process,GO:0001933~negative regulation of protein phosphorylation,GO:0001937~negative regulation of endothelial cell proliferation,GO:0006147~guanine catabolic process,GO:0006148~inosine catabolic process,GO:0006149~deoxyinosine catabolic process,GO:0006154~adenosine catabolic process,GO:0006157~deoxyadenosine catabolic process,GO:0006161~deoxyguanosine catabolic process,GO:0006196~AMP catabolic process,GO:0006204~IMP catabolic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007595~lactation,GO:0009114~hypoxanthine catabolic process,GO:0009115~xanthine catabolic process,GO:0010629~negative regulation of gene expression,GO:0016226~iron-sulfur cluster assembly,GO:0043605~cellular amide catabolic process,GO:0045602~negative regulation of endothelial cell differentiation,GO:0046038~GMP catabolic process,GO:0046055~dGMP catabolic process,GO:0046059~dAMP catabolic process,GO:0051898~negative regulation of protein kinase B signaling,GO:1900745~positive regulation of p38MAPK cascade,GO:1900747~negative regulation of vascular endothelial growth factor signaling pathway,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2001213~negative regulation of vasculogenesis,	GO:0005615~extracellular space,GO:0005777~peroxisome,GO:0005829~cytosol,GO:0016529~sarcoplasmic reticulum,	GO:0004854~xanthine dehydrogenase activity,GO:0004855~xanthine oxidase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0042803~protein homodimerization activity,GO:0043546~molybdopterin cofactor binding,GO:0050660~flavin adenine dinucleotide binding,GO:0051537~2 iron, 2 sulfur cluster binding,GO:0070674~hypoxanthine dehydrogenase activity,GO:0070675~hypoxanthine oxidase activity,GO:0071949~FAD binding,	IPR000674:Aldehyde oxidase/xanthine dehydrogenase, a/b hammerhead,IPR001041:2Fe-2S ferredoxin-type domain,IPR002346:Molybdopterin dehydrogenase, FAD-binding,IPR002888:[2Fe-2S]-binding,IPR005107:CO dehydrogenase flavoprotein, C-terminal,IPR006058:2Fe-2S ferredoxin, iron-sulphur binding site,IPR008274:Aldehyde oxidase/xanthine dehydrogenase, molybdopterin binding,IPR012675:Beta-grasp domain,IPR014307:Xanthine dehydrogenase, small subunit,IPR016166:FAD-binding, type 2,IPR016167:FAD-binding, type 2, subdomain 1,IPR016169:CO dehydrogenase flavoprotein-like, FAD-binding, subdomain 2,IPR016208:Aldehyde oxidase/xanthine dehydrogenase,IPR022407:Oxidoreductase, molybdopterin binding site,	hsa00230:Purine metabolism,hsa00232:Caffeine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa04146:Peroxisome,	278300~Xanthinuria, type I,	PIRSF000127:xanthine dehydrogenase,	SM01008:SM01008,SM01092:SM01092,		KW-0576~Peroxisome,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,		KW-0001~2Fe-2S,KW-0274~FAD,KW-0285~Flavoprotein,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0500~Molybdenum,KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,DISULFID:In oxidase form,DOMAIN:2Fe-2S ferredoxin-type,DOMAIN:FAD-binding PCMH-type,DOMAIN:Molybdopterin dehydrogenase FAD-binding,MUTAGEN:E->V: Strongly decreased activity towards xanthine and hypoxanthine. Increased affinity and activity towards aromatic aldehydes.,MUTAGEN:R->M: Abolishes xanthine oxidase activity.,
YPEL4	yippee like 4(YPEL4)	Homo sapiens				GO:0005634~nucleus,GO:0005730~nucleolus,	GO:0046872~metal ion binding,	IPR004910:Yippee-like protein,						KW-0539~Nucleus,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	DOMAIN:Yippee,
ZC3H12D	zinc finger CCCH-type containing 12D(ZC3H12D)	Homo sapiens			GO:0006402~mRNA catabolic process,GO:0030308~negative regulation of cell growth,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003729~mRNA binding,GO:0004521~endoribonuclease activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR000571:Zinc finger, CCCH-type,IPR021869:Ribonuclease Zc3h12a-like,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,		COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:RNase NYN,DOMAIN:Rege-1 UBA-like,MUTAGEN:D->N: Inhibits interleukin IL6 mRNA instability.,REGION:Disordered,REGION:Necessary for interaction with ZC3H12A,ZN_FING:C3H1-type,
ZNHIT1	zinc finger HIT-type containing 1(ZNHIT1)	Homo sapiens			GO:0003015~heart process,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0036335~intestinal stem cell homeostasis,GO:0042692~muscle cell differentiation,GO:0043486~histone exchange,GO:0055074~calcium ion homeostasis,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:1902164~positive regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:1905458~positive regulation of lymphoid progenitor cell differentiation,	GO:0000786~nucleosome,GO:0000812~Swr1 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0005515~protein binding,GO:0031491~nucleosome binding,GO:0042393~histone binding,GO:0046872~metal ion binding,	IPR007529:Zinc finger, HIT-type,	hsa03082:ATP-dependent chromatin remodeling,					KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:HIT-type,MOTIF:Nuclear localization signal,MUTAGEN:S->A: No change in the in vitro MAPK14/MAPK11-induced phosphorylation level of ZNHIT1.,MUTAGEN:T->A: Impairs the p38 MAPK-mediated phosphorylation of ZNHIT1.,REGION:Disordered,REGION:Interaction with NR1D2,ZN_FING:HIT-type,
ZSCAN18	zinc finger and SCAN domain containing 18(ZSCAN18)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR003309:Transcription regulator SCAN,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,SM00431:SCAN,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:SCAN box,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,
ZNF132	zinc finger protein 132(ZNF132)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		DOMAIN:C2H2-type,DOMAIN:KRAB,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 13,ZN_FING:C2H2-type 14,ZN_FING:C2H2-type 15,ZN_FING:C2H2-type 16,ZN_FING:C2H2-type 17,ZN_FING:C2H2-type 18,ZN_FING:C2H2-type 1; degenerate,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF154	zinc finger protein 154(ZNF154)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 1; degenerate,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF296	zinc finger protein 296(ZNF296)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2000171~negative regulation of dendrite development,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
ZNF300	zinc finger protein 300(ZNF300)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016604~nuclear body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF652	zinc finger protein 652(ZNF652)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,REGION:Mediates interaction with CBFA2T3,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9; degenerate,
ZNF677	zinc finger protein 677(ZNF677)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Basic residues,DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZFPM2	zinc finger protein, FOG family member 2(ZFPM2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0003148~outflow tract septum morphogenesis,GO:0003221~right ventricular cardiac muscle tissue morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007506~gonadal mesoderm development,GO:0007507~heart development,GO:0009653~anatomical structure morphogenesis,GO:0010604~positive regulation of macromolecule metabolic process,GO:0030154~cell differentiation,GO:0030324~lung development,GO:0045444~fat cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048513~animal organ development,GO:0048568~embryonic organ development,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060412~ventricular septum morphogenesis,GO:0060548~negative regulation of cell death,GO:2000020~positive regulation of male gonad development,GO:2000195~negative regulation of female gonad development,	GO:0000785~chromatin,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05206:MicroRNAs in cancer,	187500~Tetralogy of Fallot,610187~Diaphragmatic hernia 3,616067~46XY sex reversal 9,		SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0334~Gonadal differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,DOMAIN:CCHC FOG-type,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with CTBP2,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:CCHC FOG-type 1,ZN_FING:CCHC FOG-type 2,ZN_FING:CCHC FOG-type 3,ZN_FING:CCHC FOG-type 4,ZN_FING:CCHC FOG-type 5,
